Sort code,Jurisdiction,Drug class code,Drug class,Age group,Sex ," TPS
($ 000) ","Proportion 
of TPS (%)","Rate of 
use (%)",Number of active beneficiaries,Rank
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"1,105,266.00",8.2,0.5,"57,741",1
1,Canada,J05AP,Antivirals for treatment of HCV infections,Total,Total,"673,721.00",5.0,0.1,"12,019",2
1,Canada,S01LA,Antineovascularization agents,Total,Total,"615,215.90",4.6,0.5,"67,055",3
1,Canada,C10AA,HMG-CoA reductase inhibitors,Total,Total,"380,677.40",2.8,28.3,"3,476,989",4
1,Canada,N05AX,Other antipsychotics,Total,Total,"328,804.60",2.4,2.2,"267,339",5
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"311,728.20",2.3,4.5,"557,992",6
1,Canada,L01XE,Protein kinase inhibitors,Total,Total,"305,765.30",2.3,0.1,"10,046",7
1,Canada,L04AA,Selective immunosuppressants,Total,Total,"298,639.20",2.2,0.4,"44,622",8
1,Canada,A02BC,Proton pump inhibitors,Total,Total,"288,247.20",2.1,21.0,"2,579,405",9
1,Canada,B01AF,Direct factor Xa inhibitors,Total,Total,"272,265.40",2.0,3.0,"372,314",10
1,Canada,L04AX,Other immunosuppressants,Total,Total,"254,558.20",1.9,0.3,"33,508",11
1,Canada,C09AA,"ACE inhibitors, plain",Total,Total,"253,426.80",1.9,14.7,"1,805,740",12
1,Canada,N03AX,Other antiepileptics,Total,Total,"217,363.20",1.6,7.0,"855,604",13
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"213,721.30",1.6,4.3,"526,419",14
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"206,738.20",1.5,2.1,"261,637",15
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"201,329.30",1.5,2.1,"262,558",16
1,Canada,N06AX,Other antidepressants,Total,Total,"196,429.80",1.5,9.9,"1,212,754",17
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"191,858.30",1.4,0.2,"22,189",18
1,Canada,C08CA,Dihydropyridine derivatives,Total,Total,"189,630.40",1.4,12.5,"1,533,890",19
1,Canada,N02AA,Natural opium alkaloids,Total,Total,"186,701.50",1.4,6.3,"777,036",20
1,Canada,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"182,141.30",1.3,10.9,"1,337,637",21
1,Canada,N07BC,Drugs used in opioid dependence,Total,Total,"180,241.30",1.3,0.8,"97,514",22
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"175,905.50",1.3,1.7,"212,759",23
1,Canada,R03BB,Anticholinergics,Total,Total,"153,618.50",1.1,3.9,"480,659",24
1,Canada,C09CA,"Angiotensin II antagonists, plain",Total,Total,"127,185.40",0.9,8.7,"1,075,535",25
1,Canada,L04AC,Interleukin inhibitors,Total,Total,"120,172.30",0.9,0.1,"8,166",26
1,Canada,C07AB,"Beta-blocking agents, selective",Total,Total,"118,230.00",0.9,12.7,"1,558,599",27
1,Canada,N06BA,Centrally acting sympathomimetics,Total,Total,"110,844.60",0.8,1.8,"223,903",28
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"105,924.80",0.8,1.3,"154,722",29
1,Canada,R03BA,Glucocorticoids,Total,Total,"103,404.70",0.8,5.9,"728,345",30
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"94,780.15",0.7,1.8,"222,143",31
1,Canada,H03AA,Thyroid hormones,Total,Total,"94,354.82",0.7,12.2,"1,504,848",32
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"93,881.37",0.7,1.1,"135,178",33
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"93,092.39",0.7,0.2,"30,723",34
1,Canada,B01AB,Heparin group,Total,Total,"88,552.92",0.7,0.6,"77,421",35
1,Canada,M05BA,Bisphosphonates,Total,Total,"85,023.86",0.6,3.7,"454,972",36
1,Canada,A10BA,Biguanides,Total,Total,"82,602.99",0.6,9.6,"1,182,460",37
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"81,562.82",0.6,3.2,"390,606",38
1,Canada,B03XA,Other antianemic preparations,Total,Total,"78,933.80",0.6,0.1,"17,170",39
1,Canada,L03AA,Colony-stimulating factors,Total,Total,"77,084.46",0.6,0.1,"14,814",40
1,Canada,N05BA,Benzodiazepine derivatives,Total,Total,"66,456.18",0.5,9.4,"1,155,617",41
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"64,082.62",0.5,12.9,"1,580,019",42
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"63,261.58",0.5,5.1,"621,302",43
1,Canada,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"61,929.19",0.5,2.0,"246,036",44
1,Canada,H01CB,Somatostatin and analogues,Total,Total,"61,560.60",0.5,0.0,"4,306",45
1,Canada,C09BA,ACE inhibitors and diuretics,Total,Total,"61,057.66",0.5,2.5,"311,584",46
1,Canada,L02BX,Other hormone antagonists and related agents,Total,Total,"59,518.12",0.4,0.0,"3,868",47
1,Canada,S01EE,Prostaglandin analogues,Total,Total,"57,193.79",0.4,2.4,"298,950",48
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"56,884.27",0.4,10.3,"1,261,292",49
1,Canada,L04AD,Calcineurin inhibitors,Total,Total,"56,770.35",0.4,0.1,"18,419",50
1,Canada,C08DB,Benzothiazepine derivatives,Total,Total,"56,166.32",0.4,1.9,"239,168",51
1,Canada,N06DA,Anticholinesterases,Total,Total,"55,533.43",0.4,1.1,"141,243",52
1,Canada,C09DA,Angiotensin II antagonists and diuretics,Total,Total,"55,468.65",0.4,3.9,"473,781",53
1,Canada,S01ED,Beta-blocking agents,Total,Total,"54,090.78",0.4,2.3,"278,758",54
1,Canada,A11CC,Vitamin D and analogues,Total,Total,"54,035.47",0.4,5.6,"683,289",55
1,Canada,B01AE,Direct thrombin inhibitors,Total,Total,"52,701.21",0.4,0.4,"55,094",56
1,Canada,C03CA,"Sulfonamides, plain",Total,Total,"51,519.59",0.4,5.2,"633,825",57
1,Canada,L03AB,Interferons,Total,Total,"50,676.03",0.4,0.0,"3,406",58
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"49,017.09",0.4,0.2,"24,259",59
1,Canada,N07XX,Other nervous system drugs,Total,Total,"48,468.69",0.4,0.0,"5,067",60
1,Canada,A07EC,Aminosalicylic acid and similar agents,Total,Total,"46,476.41",0.3,0.7,"85,156",61
1,Canada,L02BB,Antiandrogens,Total,Total,"46,305.69",0.3,0.1,"17,084",62
1,Canada,N02BA,Salicylic acid and derivatives,Total,Total,"46,259.04",0.3,4.5,"551,447",63
1,Canada,N04BA,Dopa and dopa derivatives,Total,Total,"44,578.67",0.3,0.6,"79,346",64
1,Canada,A10BB,Sulfonylureas,Total,Total,"44,510.37",0.3,3.9,"475,362",65
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"44,254.95",0.3,0.0,"2,987",66
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,"42,716.93",0.3,0.1,"12,614",67
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"40,384.58",0.3,3.5,"433,060",68
1,Canada,J05AX,Other antivirals,Total,Total,"39,548.41",0.3,0.1,"6,527",69
1,Canada,R01AD,Corticosteroids,Total,Total,"38,510.20",0.3,7.0,"861,180",70
1,Canada,L03AX,Other immunostimulants,Total,Total,"38,246.98",0.3,0.0,"3,588",71
1,Canada,A16AB,Enzymes,Total,Total,"37,842.03",0.3,0.0,75,72
1,Canada,N07BA,Drugs used in nicotine dependence,Total,Total,"37,715.54",0.3,1.9,"237,344",73
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"37,629.26",0.3,3.0,"372,169",74
1,Canada,L01XC,Monoclonal antibodies,Total,Total,"36,923.89",0.3,0.0,"3,395",75
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"35,766.26",0.3,2.0,"249,815",76
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"35,558.39",0.3,0.5,"58,798",77
1,Canada,J05AE,Protease inhibitors,Total,Total,"35,462.70",0.3,0.0,"5,273",78
1,Canada,N03AE,Benzodiazepine derivatives,Total,Total,"34,921.30",0.3,2.9,"352,905",79
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,Total,"34,853.95",0.3,0.2,"22,390",80
1,Canada,N02BE,Anilides,Total,Total,"34,041.04",0.3,7.0,"854,863",81
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,Total,"33,437.34",0.2,2.8,"340,294",82
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"32,328.74",0.2,0.7,"81,565",83
1,Canada,N03AG,Fatty acid derivatives,Total,Total,"31,073.47",0.2,0.8,"97,648",84
1,Canada,A02BA,H2-receptor antagonists,Total,Total,"30,774.17",0.2,3.5,"426,124",85
1,Canada,C10AX,Other lipid-modifying agents,Total,Total,"30,533.32",0.2,1.9,"227,894",86
1,Canada,A04AD,Other antiemetics,Total,Total,"30,524.87",0.2,0.4,"52,232",87
1,Canada,C01DA,Organic nitrates,Total,Total,"29,816.00",0.2,3.1,"386,982",88
1,Canada,M01AE,Propionic acid derivatives,Total,Total,"28,224.30",0.2,9.8,"1,209,312",89
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"27,762.71",0.2,0.8,"95,125",90
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"27,167.92",0.2,0.0,"1,286",91
1,Canada,N02AB,Phenylpiperidine derivatives,Total,Total,"26,933.61",0.2,0.3,"42,247",92
1,Canada,M03BX,Other centrally acting agents,Total,Total,"26,874.15",0.2,3.8,"467,000",93
1,Canada,D07AC,"Corticosteroids, potent (group III)",Total,Total,"26,866.44",0.2,8.6,"1,052,812",94
1,Canada,H02AB,Glucocorticoids,Total,Total,"25,885.46",0.2,8.6,"1,062,005",95
1,Canada,B01AA,Vitamin K antagonists,Total,Total,"25,352.24",0.2,2.1,"256,166",96
1,Canada,B03AA,"Iron bivalent, oral preparations",Total,Total,"25,072.36",0.2,3.3,"405,800",97
1,Canada,C03AA,"Thiazides, plain",Total,Total,"25,011.01",0.2,6.3,"769,060",98
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,"23,344.60",0.2,0.3,"35,006",99
1,Canada,J01CA,Penicillins with extended spectrum,Total,Total,"22,932.60",0.2,14.9,"1,828,553",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"534,790.00",8.1,0.5,"25,974",1
1,Canada,J05AP,Antivirals for treatment of HCV infections,Total,M,"430,018.10",6.5,0.1,"7,661",2
1,Canada,S01LA,Antineovascularization agents,Total,M,"259,900.60",3.9,0.5,"28,863",3
1,Canada,N05AX,Other antipsychotics,Total,M,"193,798.60",2.9,2.4,"130,311",4
1,Canada,C10AA,HMG-CoA reductase inhibitors,Total,M,"192,767.50",2.9,34.0,"1,857,773",5
1,Canada,L01XE,Protein kinase inhibitors,Total,M,"173,159.20",2.6,0.1,"5,453",6
1,Canada,L04AX,Other immunosuppressants,Total,M,"150,622.10",2.3,0.3,"14,861",7
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"145,805.30",2.2,0.3,"16,644",8
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"137,019.20",2.1,4.3,"237,337",9
1,Canada,B01AF,Direct factor Xa inhibitors,Total,M,"136,902.10",2.1,3.4,"187,069",10
1,Canada,C09AA,"ACE inhibitors, plain",Total,M,"132,053.30",2.0,18.1,"988,793",11
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"122,351.50",1.9,4.4,"242,892",12
1,Canada,A02BC,Proton pump inhibitors,Total,M,"115,153.90",1.7,19.7,"1,075,972",13
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"109,835.00",1.7,2.6,"140,027",14
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"105,807.90",1.6,2.5,"135,559",15
1,Canada,N07BC,Drugs used in opioid dependence,Total,M,"103,550.40",1.6,1.0,"56,517",16
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"99,946.74",1.5,2.2,"121,437",17
1,Canada,L04AA,Selective immunosuppressants,Total,M,"99,286.25",1.5,0.3,"17,065",18
1,Canada,N03AX,Other antiepileptics,Total,M,"91,862.44",1.4,6.2,"338,366",19
1,Canada,N02AA,Natural opium alkaloids,Total,M,"87,905.79",1.3,6.1,"335,886",20
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"86,708.94",1.3,0.5,"27,187",21
1,Canada,C08CA,Dihydropyridine derivatives,Total,M,"82,906.45",1.3,13.1,"718,207",22
1,Canada,R03BB,Anticholinergics,Total,M,"74,706.66",1.1,4.2,"231,212",23
1,Canada,N06AX,Other antidepressants,Total,M,"69,336.27",1.1,7.9,"433,984",24
1,Canada,N06BA,Centrally acting sympathomimetics,Total,M,"69,158.33",1.1,2.4,"132,565",25
1,Canada,N06AB,Selective serotonin reuptake inhibitors,Total,M,"63,932.95",1.0,8.2,"445,857",26
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"60,683.80",0.9,1.6,"88,296",27
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"60,580.55",0.9,10.8,"591,413",28
1,Canada,L02BX,Other hormone antagonists and related agents,Total,M,"59,493.90",0.9,0.1,"3,865",29
1,Canada,C07AB,"Beta-blocking agents, selective",Total,M,"55,463.75",0.8,14.6,"799,704",30
1,Canada,L04AC,Interleukin inhibitors,Total,M,"54,266.64",0.8,0.1,"3,444",31
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"52,377.30",0.8,2.1,"117,149",32
1,Canada,C09CA,"Angiotensin II antagonists, plain",Total,M,"50,215.03",0.8,8.4,"457,183",33
1,Canada,L02BB,Antiandrogens,Total,M,"46,280.27",0.7,0.3,"17,025",34
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"43,375.64",0.7,4.1,"224,227",35
1,Canada,B01AB,Heparin group,Total,M,"42,338.86",0.6,0.6,"34,263",36
1,Canada,R03BA,Glucocorticoids,Total,M,"42,018.08",0.6,5.5,"300,057",37
1,Canada,B03XA,Other antianemic preparations,Total,M,"41,746.81",0.6,0.2,"8,831",38
1,Canada,A10BA,Biguanides,Total,M,"41,530.57",0.6,11.5,"627,842",39
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"35,661.24",0.5,4.5,"248,577",40
1,Canada,L04AD,Calcineurin inhibitors,Total,M,"34,535.03",0.5,0.2,"11,118",41
1,Canada,C09BA,ACE inhibitors and diuretics,Total,M,"31,504.73",0.5,3.0,"163,285",42
1,Canada,H01CB,Somatostatin and analogues,Total,M,"31,043.48",0.5,0.0,"1,941",43
1,Canada,J05AX,Other antivirals,Total,M,"30,522.95",0.5,0.1,"4,820",44
1,Canada,B01AE,Direct thrombin inhibitors,Total,M,"29,292.96",0.4,0.6,"31,265",45
1,Canada,L03AA,Colony-stimulating factors,Total,M,"29,004.38",0.4,0.1,"5,430",46
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"28,364.94",0.4,12.3,"670,594",47
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"27,888.54",0.4,0.1,"8,155",48
1,Canada,J05AE,Protease inhibitors,Total,M,"26,805.95",0.4,0.1,"3,858",49
1,Canada,N04BA,Dopa and dopa derivatives,Total,M,"25,565.31",0.4,0.8,"43,368",50
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"25,212.42",0.4,10.7,"583,076",51
1,Canada,N05BA,Benzodiazepine derivatives,Total,M,"24,828.11",0.4,7.2,"394,574",52
1,Canada,S01ED,Beta-blocking agents,Total,M,"23,970.51",0.4,2.3,"128,104",53
1,Canada,S01EE,Prostaglandin analogues,Total,M,"23,962.00",0.4,2.4,"130,822",54
1,Canada,N02BA,Salicylic acid and derivatives,Total,M,"23,761.17",0.4,5.5,"299,650",55
1,Canada,H03AA,Thyroid hormones,Total,M,"23,443.65",0.4,6.7,"364,686",56
1,Canada,A10BB,Sulfonylureas,Total,M,"23,258.85",0.4,4.8,"263,604",57
1,Canada,C09DA,Angiotensin II antagonists and diuretics,Total,M,"22,826.81",0.3,3.8,"205,215",58
1,Canada,A16AB,Enzymes,Total,M,"22,819.39",0.3,0.0,43,59
1,Canada,C08DB,Benzothiazepine derivatives,Total,M,"22,683.05",0.3,1.8,"100,538",60
1,Canada,A07EC,Aminosalicylic acid and similar agents,Total,M,"22,134.95",0.3,0.7,"37,903",61
1,Canada,C03CA,"Sulfonamides, plain",Total,M,"21,566.06",0.3,5.2,"282,008",62
1,Canada,G04BD,Drugs for urinary frequency and incontinence,Total,M,"20,724.93",0.3,1.5,"79,603",63
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,M,"20,299.71",0.3,0.2,"12,451",64
1,Canada,N06DA,Anticholinesterases,Total,M,"19,887.24",0.3,1.0,"53,788",65
1,Canada,N07BA,Drugs used in nicotine dependence,Total,M,"19,190.93",0.3,2.2,"121,044",66
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"18,274.36",0.3,0.1,"8,006",67
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"18,143.94",0.3,0.0,"1,144",68
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,"17,955.53",0.3,0.5,"29,428",69
1,Canada,A11CC,Vitamin D and analogues,Total,M,"17,813.32",0.3,3.5,"194,055",70
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"17,456.02",0.3,0.8,"42,245",71
1,Canada,G03BA,3-oxoandrosten (4) derivatives,Total,M,"17,446.67",0.3,0.8,"43,103",72
1,Canada,N03AG,Fatty acid derivatives,Total,M,"17,117.33",0.3,0.9,"50,300",73
1,Canada,M05BA,Bisphosphonates,Total,M,"16,887.88",0.3,1.5,"80,202",74
1,Canada,R01AD,Corticosteroids,Total,M,"16,463.16",0.3,6.4,"349,289",75
1,Canada,C10AX,Other lipid-modifying agents,Total,M,"16,191.95",0.2,2.3,"125,528",76
1,Canada,N07XX,Other nervous system drugs,Total,M,"16,183.51",0.2,0.0,"1,946",77
1,Canada,M04AA,Preparations inhibiting uric acid production,Total,M,"14,925.16",0.2,4.2,"230,850",78
1,Canada,N03AE,Benzodiazepine derivatives,Total,M,"14,677.18",0.2,2.4,"131,160",79
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,"14,391.96",0.2,0.9,"48,674",80
1,Canada,C01DA,Organic nitrates,Total,M,"14,143.66",0.2,3.9,"211,716",81
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,"13,915.17",0.2,0.4,"20,665",82
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,"13,770.05",0.2,2.5,"135,320",83
1,Canada,A04AD,Other antiemetics,Total,M,"13,480.82",0.2,0.4,"21,168",84
1,Canada,L03AB,Interferons,Total,M,"13,108.23",0.2,0.0,917,85
1,Canada,D07AC,"Corticosteroids, potent (group III)",Total,M,"12,784.92",0.2,8.5,"463,346",86
1,Canada,A02BA,H2-receptor antagonists,Total,M,"12,513.21",0.2,3.0,"163,020",87
1,Canada,B01AA,Vitamin K antagonists,Total,M,"12,277.04",0.2,2.6,"139,532",88
1,Canada,M01AE,Propionic acid derivatives,Total,M,"12,115.22",0.2,9.5,"522,338",89
1,Canada,N02BE,Anilides,Total,M,"11,634.09",0.2,6.0,"327,815",90
1,Canada,H01AC,Somatropin and somatropin agonists,Total,M,"11,346.06",0.2,0.0,"1,032",91
1,Canada,V03AC,Iron-chelating agents,Total,M,"11,271.60",0.2,0.0,540,92
1,Canada,M03BX,Other centrally acting agents,Total,M,"11,073.88",0.2,3.6,"194,442",93
1,Canada,L03AX,Other immunostimulants,Total,M,"10,648.06",0.2,0.0,942,94
1,Canada,H02AB,Glucocorticoids,Total,M,"10,582.50",0.2,8.3,"451,314",95
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,Total,M,"10,575.19",0.2,0.1,"5,029",96
1,Canada,A09AA,Enzyme preparations,Total,M,"10,570.37",0.2,0.2,"12,138",97
1,Canada,N02AB,Phenylpiperidine derivatives,Total,M,"10,128.68",0.2,0.3,"15,294",98
1,Canada,L01XC,Monoclonal antibodies,Total,M,"10,089.38",0.2,0.0,984,99
1,Canada,J01CA,Penicillins with extended spectrum,Total,M,"10,012.35",0.2,14.8,"811,203",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"570,418.80",8.2,0.5,"31,763",1
1,Canada,S01LA,Antineovascularization agents,Total,F,"355,267.40",5.1,0.6,"38,187",2
1,Canada,J05AP,Antivirals for treatment of HCV infections,Total,F,"243,030.40",3.5,0.1,"4,347",3
1,Canada,L04AA,Selective immunosuppressants,Total,F,"199,307.60",2.9,0.4,"27,532",4
1,Canada,C10AA,HMG-CoA reductase inhibitors,Total,F,"187,729.20",2.7,23.8,"1,617,507",5
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"174,587.80",2.5,4.7,"320,356",6
1,Canada,A02BC,Proton pump inhibitors,Total,F,"172,932.00",2.5,22.1,"1,500,974",7
1,Canada,B01AF,Direct factor Xa inhibitors,Total,F,"135,319.30",2.0,2.7,"185,176",8
1,Canada,N05AX,Other antipsychotics,Total,F,"134,731.40",1.9,2.0,"136,784",9
1,Canada,L01XE,Protein kinase inhibitors,Total,F,"132,592.10",1.9,0.1,"4,590",10
1,Canada,N06AX,Other antidepressants,Total,F,"126,988.50",1.8,11.4,"777,857",11
1,Canada,N03AX,Other antiepileptics,Total,F,"125,381.00",1.8,7.6,"516,626",12
1,Canada,C09AA,"ACE inhibitors, plain",Total,F,"121,236.40",1.8,12.0,"815,985",13
1,Canada,N06AB,Selective serotonin reuptake inhibitors,Total,F,"118,089.90",1.7,13.1,"890,631",14
1,Canada,C08CA,Dihydropyridine derivatives,Total,F,"106,614.90",1.5,12.0,"814,702",15
1,Canada,L04AX,Other immunosuppressants,Total,F,"103,934.90",1.5,0.3,"18,635",16
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"100,776.70",1.5,1.9,"125,862",17
1,Canada,N02AA,Natural opium alkaloids,Total,F,"98,763.02",1.4,6.5,"440,798",18
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"91,370.00",1.3,1.8,"122,296",19
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"91,287.36",1.3,4.2,"283,135",20
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"83,291.69",1.2,1.9,"130,127",21
1,Canada,R03BB,Anticholinergics,Total,F,"78,879.44",1.1,3.7,"249,291",22
1,Canada,C09CA,"Angiotensin II antagonists, plain",Total,F,"76,902.68",1.1,9.1,"617,778",23
1,Canada,N07BC,Drugs used in opioid dependence,Total,F,"76,585.14",1.1,0.6,"40,898",24
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"75,706.98",1.1,1.3,"90,966",25
1,Canada,H03AA,Thyroid hormones,Total,F,"70,875.16",1.0,16.8,"1,139,552",26
1,Canada,M05BA,Bisphosphonates,Total,F,"68,101.65",1.0,5.5,"374,608",27
1,Canada,L04AC,Interleukin inhibitors,Total,F,"65,905.67",1.0,0.1,"4,722",28
1,Canada,C07AB,"Beta-blocking agents, selective",Total,F,"62,713.26",0.9,11.2,"758,145",29
1,Canada,R03BA,Glucocorticoids,Total,F,"61,236.00",0.9,6.3,"426,528",30
1,Canada,L03AA,Colony-stimulating factors,Total,F,"48,052.29",0.7,0.1,"9,381",31
1,Canada,B01AB,Heparin group,Total,F,"46,163.12",0.7,0.6,"43,114",32
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"45,140.61",0.7,1.0,"66,252",33
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"43,997.60",0.6,0.1,"5,326",34
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"42,344.19",0.6,1.5,"104,831",35
1,Canada,N06BA,Centrally acting sympathomimetics,Total,F,"41,630.01",0.6,1.3,"91,190",36
1,Canada,N05BA,Benzodiazepine derivatives,Total,F,"41,608.01",0.6,11.2,"760,505",37
1,Canada,G04BD,Drugs for urinary frequency and incontinence,Total,F,"41,189.09",0.6,2.4,"166,342",38
1,Canada,A10BA,Biguanides,Total,F,"41,014.55",0.6,8.2,"553,707",39
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"38,153.59",0.6,2.4,"166,223",40
1,Canada,L03AB,Interferons,Total,F,"37,567.80",0.5,0.0,"2,489",41
1,Canada,B03XA,Other antianemic preparations,Total,F,"37,183.71",0.5,0.1,"8,336",42
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"37,140.34",0.5,5.4,"369,443",43
1,Canada,A11CC,Vitamin D and analogues,Total,F,"36,125.16",0.5,7.1,"485,543",44
1,Canada,N06DA,Anticholinesterases,Total,F,"35,638.08",0.5,1.3,"87,424",45
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"35,626.46",0.5,13.3,"905,680",46
1,Canada,C08DB,Benzothiazepine derivatives,Total,F,"33,474.84",0.5,2.0,"138,588",47
1,Canada,S01EE,Prostaglandin analogues,Total,F,"33,215.27",0.5,2.5,"168,059",48
1,Canada,C09DA,Angiotensin II antagonists and diuretics,Total,F,"32,608.03",0.5,3.9,"268,340",49
1,Canada,N07XX,Other nervous system drugs,Total,F,"32,285.18",0.5,0.0,"3,121",50
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"31,640.20",0.5,10.0,"676,995",51
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"30,730.76",0.4,0.2,"16,246",52
1,Canada,H01CB,Somatostatin and analogues,Total,F,"30,511.83",0.4,0.0,"2,364",53
1,Canada,S01ED,Beta-blocking agents,Total,F,"30,102.51",0.4,2.2,"150,541",54
1,Canada,C03CA,"Sulfonamides, plain",Total,F,"29,939.73",0.4,5.2,"351,559",55
1,Canada,C09BA,ACE inhibitors and diuretics,Total,F,"29,501.28",0.4,2.2,"148,046",56
1,Canada,L03AX,Other immunostimulants,Total,F,"27,598.92",0.4,0.0,"2,646",57
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,F,"27,439.70",0.4,4.2,"283,610",58
1,Canada,L01XC,Monoclonal antibodies,Total,F,"26,834.51",0.4,0.0,"2,411",59
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"26,594.95",0.4,4.4,"297,369",60
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"26,111.01",0.4,0.0,"1,843",61
1,Canada,A07EC,Aminosalicylic acid and similar agents,Total,F,"24,333.52",0.4,0.7,"47,232",62
1,Canada,B01AE,Direct thrombin inhibitors,Total,F,"23,402.45",0.3,0.4,"23,823",63
1,Canada,N02BA,Salicylic acid and derivatives,Total,F,"22,493.42",0.3,3.7,"251,698",64
1,Canada,N02BE,Anilides,Total,F,"22,253.08",0.3,7.7,"520,300",65
1,Canada,L04AD,Calcineurin inhibitors,Total,F,"22,219.75",0.3,0.1,"7,291",66
1,Canada,R01AD,Corticosteroids,Total,F,"21,993.62",0.3,7.5,"510,637",67
1,Canada,A10BB,Sulfonylureas,Total,F,"21,217.10",0.3,3.1,"211,359",68
1,Canada,N03AE,Benzodiazepine derivatives,Total,F,"20,228.16",0.3,3.3,"221,481",69
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"19,250.04",0.3,0.0,879,70
1,Canada,N04BA,Dopa and dopa derivatives,Total,F,"19,004.18",0.3,0.5,"35,956",71
1,Canada,N07BA,Drugs used in nicotine dependence,Total,F,"18,514.04",0.3,1.7,"116,243",72
1,Canada,A02BA,H2-receptor antagonists,Total,F,"18,224.73",0.3,3.9,"262,227",73
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,"17,570.71",0.3,0.4,"29,298",74
1,Canada,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"17,333.93",0.3,5.5,"373,075",75
1,Canada,A04AD,Other antiemetics,Total,F,"17,031.48",0.2,0.5,"31,042",76
1,Canada,N02AB,Phenylpiperidine derivatives,Total,F,"16,799.88",0.2,0.4,"26,945",77
1,Canada,M01AE,Propionic acid derivatives,Total,F,"16,022.92",0.2,10.0,"682,482",78
1,Canada,B03AA,"Iron bivalent, oral preparations",Total,F,"15,952.30",0.2,3.9,"264,622",79
1,Canada,C03AA,"Thiazides, plain",Total,F,"15,843.51",0.2,6.9,"465,435",80
1,Canada,L02BG,Aromatase inhibitors,Total,F,"15,834.49",0.2,0.7,"45,079",81
1,Canada,M03BX,Other centrally acting agents,Total,F,"15,785.64",0.2,4.0,"272,066",82
1,Canada,C01DA,Organic nitrates,Total,F,"15,663.66",0.2,2.6,"175,109",83
1,Canada,A12AA,Calcium,Total,F,"15,617.12",0.2,3.1,"210,716",84
1,Canada,N02CC,Selective serotonin (5HT1) agonists,Total,F,"15,613.07",0.2,1.2,"83,497",85
1,Canada,H02AB,Glucocorticoids,Total,F,"15,277.94",0.2,9.0,"609,453",86
1,Canada,A16AB,Enzymes,Total,F,"15,022.63",0.2,0.0,32,87
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"14,867.30",0.2,0.6,"39,301",88
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,F,"14,766.82",0.2,0.1,"4,433",89
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,F,"14,474.03",0.2,0.1,"9,878",90
1,Canada,C10AX,Other lipid-modifying agents,Total,F,"14,334.66",0.2,1.5,"102,306",91
1,Canada,D07AC,"Corticosteroids, potent (group III)",Total,F,"14,027.79",0.2,8.6,"587,662",92
1,Canada,N03AG,Fatty acid derivatives,Total,F,"13,938.29",0.2,0.7,"47,245",93
1,Canada,A06AA,"Softeners, emollients",Total,F,"13,621.26",0.2,3.0,"200,518",94
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,"13,359.96",0.2,0.7,"46,417",95
1,Canada,B01AA,Vitamin K antagonists,Total,F,"13,069.53",0.2,1.7,"116,577",96
1,Canada,J01CA,Penicillins with extended spectrum,Total,F,"12,729.21",0.2,14.9,"1,009,022",97
1,Canada,L01BA,Folic acid analogues,Total,F,"12,348.73",0.2,1.1,"73,724",98
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"12,301.32",0.2,3.6,"243,425",99
1,Canada,J01FA,Macrolides,Total,F,"12,224.96",0.2,9.7,"657,653",100
1,Canada,S01LA,Antineovascularization agents,65+,Total,"580,204.30",7.5,1.1,"62,599",1
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"340,159.90",4.4,0.3,"18,363",2
1,Canada,C10AA,HMG-CoA reductase inhibitors,65+,Total,"309,645.10",4.0,48.7,"2,710,331",3
1,Canada,B01AF,Direct factor Xa inhibitors,65+,Total,"254,868.70",3.3,6.0,"336,226",4
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"234,571.80",3.0,6.9,"386,233",5
1,Canada,L01XE,Protein kinase inhibitors,65+,Total,"224,822.40",2.9,0.1,"7,387",6
1,Canada,A02BC,Proton pump inhibitors,65+,Total,"207,794.00",2.7,31.5,"1,756,496",7
1,Canada,C09AA,"ACE inhibitors, plain",65+,Total,"202,475.50",2.6,24.2,"1,347,126",8
1,Canada,L04AX,Other immunosuppressants,65+,Total,"201,325.00",2.6,0.3,"16,154",9
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"166,828.60",2.2,3.7,"204,229",10
1,Canada,C08CA,Dihydropyridine derivatives,65+,Total,"161,044.70",2.1,22.2,"1,237,190",11
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"133,420.20",1.7,3.0,"169,668",12
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"132,262.20",1.7,2.7,"153,068",13
1,Canada,J05AP,Antivirals for treatment of HCV infections,65+,Total,"130,129.80",1.7,0.0,"2,272",14
1,Canada,R03BB,Anticholinergics,65+,Total,"124,403.60",1.6,6.7,"374,953",15
1,Canada,C09CA,"Angiotensin II antagonists, plain",65+,Total,"108,933.50",1.4,15.9,"884,152",16
1,Canada,C07AB,"Beta-blocking agents, selective",65+,Total,"99,645.92",1.3,23.1,"1,287,557",17
1,Canada,N03AX,Other antiepileptics,65+,Total,"98,168.65",1.3,8.5,"474,075",18
1,Canada,L04AA,Selective immunosuppressants,65+,Total,"95,136.50",1.2,0.4,"20,969",19
1,Canada,N06AX,Other antidepressants,65+,Total,"93,206.83",1.2,10.6,"588,869",20
1,Canada,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"90,344.07",1.2,10.6,"589,683",21
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"88,101.86",1.1,2.3,"127,423",22
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"81,930.86",1.1,0.5,"25,588",23
1,Canada,N02AA,Natural opium alkaloids,65+,Total,"81,596.99",1.1,8.0,"447,413",24
1,Canada,M05BA,Bisphosphonates,65+,Total,"77,236.23",1.0,7.4,"411,049",25
1,Canada,H03AA,Thyroid hormones,65+,Total,"71,564.50",0.9,18.9,"1,052,050",26
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"71,382.19",0.9,1.8,"100,019",27
1,Canada,B03XA,Other antianemic preparations,65+,Total,"64,558.52",0.8,0.2,"13,457",28
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"62,197.64",0.8,5.6,"311,426",29
1,Canada,B01AB,Heparin group,65+,Total,"59,819.88",0.8,1.0,"54,821",30
1,Canada,A10BA,Biguanides,65+,Total,"58,707.81",0.8,14.6,"812,831",31
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"57,337.62",0.7,9.6,"533,735",32
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"56,302.95",0.7,2.2,"124,570",33
1,Canada,L02BX,Other hormone antagonists and related agents,65+,Total,"56,053.35",0.7,0.1,"3,608",34
1,Canada,R03BA,Glucocorticoids,65+,Total,"55,774.41",0.7,5.5,"308,101",35
1,Canada,N06DA,Anticholinesterases,65+,Total,"54,605.20",0.7,2.5,"138,856",36
1,Canada,N05AX,Other antipsychotics,65+,Total,"53,855.13",0.7,1.7,"94,109",37
1,Canada,S01EE,Prostaglandin analogues,65+,Total,"53,165.38",0.7,4.8,"268,786",38
1,Canada,B01AE,Direct thrombin inhibitors,65+,Total,"50,698.09",0.7,0.9,"52,459",39
1,Canada,S01ED,Beta-blocking agents,65+,Total,"49,901.04",0.6,4.4,"247,248",40
1,Canada,C08DB,Benzothiazepine derivatives,65+,Total,"49,801.94",0.6,3.7,"203,966",41
1,Canada,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"49,650.17",0.6,3.4,"190,500",42
1,Canada,C09BA,ACE inhibitors and diuretics,65+,Total,"48,384.16",0.6,4.1,"228,060",43
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"47,891.46",0.6,3.5,"196,583",44
1,Canada,C09DA,Angiotensin II antagonists and diuretics,65+,Total,"46,506.36",0.6,6.8,"379,951",45
1,Canada,L04AC,Interleukin inhibitors,65+,Total,"45,877.35",0.6,0.1,"3,084",46
1,Canada,C03CA,"Sulfonamides, plain",65+,Total,"44,940.39",0.6,9.8,"547,937",47
1,Canada,L03AA,Colony-stimulating factors,65+,Total,"44,526.14",0.6,0.2,"8,453",48
1,Canada,H01CB,Somatostatin and analogues,65+,Total,"43,851.70",0.6,0.1,"2,973",49
1,Canada,L02BB,Antiandrogens,65+,Total,"43,610.00",0.6,0.3,"16,312",50
1,Canada,N04BA,Dopa and dopa derivatives,65+,Total,"40,055.88",0.5,1.3,"70,160",51
1,Canada,A11CC,Vitamin D and analogues,65+,Total,"39,274.86",0.5,8.2,"454,343",52
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"37,527.97",0.5,13.4,"744,669",53
1,Canada,N02BA,Salicylic acid and derivatives,65+,Total,"37,466.15",0.5,8.0,"443,900",54
1,Canada,N05BA,Benzodiazepine derivatives,65+,Total,"36,552.14",0.5,12.1,"672,546",55
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"33,947.86",0.4,4.1,"230,811",56
1,Canada,A10BB,Sulfonylureas,65+,Total,"32,069.40",0.4,6.0,"335,897",57
1,Canada,A07EC,Aminosalicylic acid and similar agents,65+,Total,"29,865.37",0.4,0.8,"44,857",58
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"28,070.81",0.4,0.8,"45,610",59
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,Total,"27,466.44",0.4,4.9,"271,169",60
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"27,152.30",0.4,1.2,"65,091",61
1,Canada,C01DA,Organic nitrates,65+,Total,"27,114.07",0.3,5.9,"329,058",62
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"26,822.86",0.3,4.2,"233,697",63
1,Canada,C10AX,Other lipid-modifying agents,65+,Total,"25,001.93",0.3,3.4,"191,177",64
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"24,849.70",0.3,0.2,"12,944",65
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"23,963.60",0.3,10.5,"585,874",66
1,Canada,N02BE,Anilides,65+,Total,"23,393.29",0.3,9.2,"511,341",67
1,Canada,R01AD,Corticosteroids,65+,Total,"22,839.94",0.3,7.9,"437,477",68
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,"22,388.52",0.3,0.0,"2,442",69
1,Canada,B01AA,Vitamin K antagonists,65+,Total,"22,201.86",0.3,4.0,"221,881",70
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"20,340.44",0.3,3.9,"219,292",71
1,Canada,L04AD,Calcineurin inhibitors,65+,Total,"20,044.31",0.3,0.1,"7,186",72
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"20,036.67",0.3,0.0,"1,438",73
1,Canada,L01XC,Monoclonal antibodies,65+,Total,"19,476.42",0.3,0.0,"1,794",74
1,Canada,M04AA,Preparations inhibiting uric acid production,65+,Total,"19,456.76",0.3,4.6,"257,205",75
1,Canada,C03AA,"Thiazides, plain",65+,Total,"19,364.04",0.2,10.5,"587,032",76
1,Canada,A02BA,H2-receptor antagonists,65+,Total,"18,437.61",0.2,4.1,"228,339",77
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"18,070.02",0.2,1.0,"58,226",78
1,Canada,B03AA,"Iron bivalent, oral preparations",65+,Total,"17,506.22",0.2,4.6,"257,756",79
1,Canada,H02AB,Glucocorticoids,65+,Total,"17,332.59",0.2,10.9,"609,217",80
1,Canada,D07AC,"Corticosteroids, potent (group III)",65+,Total,"17,100.48",0.2,10.1,"562,914",81
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,Total,"16,177.94",0.2,0.1,"4,496",82
1,Canada,A12AA,Calcium,65+,Total,"16,094.76",0.2,3.5,"197,342",83
1,Canada,A06AA,"Softeners, emollients",65+,Total,"15,518.17",0.2,4.6,"255,778",84
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,"15,214.55",0.2,0.5,"26,812",85
1,Canada,N02AB,Phenylpiperidine derivatives,65+,Total,"14,792.94",0.2,0.5,"26,764",86
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"14,626.20",0.2,0.0,683,87
1,Canada,A06AB,Contact laxatives,65+,Total,"13,793.27",0.2,5.3,"295,795",88
1,Canada,C07AG,Alpha- and beta-blocking agents,65+,Total,"13,434.78",0.2,0.9,"52,287",89
1,Canada,L02BG,Aromatase inhibitors,65+,Total,"13,297.59",0.2,0.6,"34,381",90
1,Canada,J01MA,Fluoroquinolones,65+,Total,"12,875.66",0.2,10.7,"593,943",91
1,Canada,S01XA,Other ophthalmologicals,65+,Total,"12,768.39",0.2,1.3,"71,545",92
1,Canada,M01AH,Coxibs,65+,Total,"12,760.64",0.2,3.8,"210,053",93
1,Canada,L01BA,Folic acid analogues,65+,Total,"12,439.08",0.2,1.2,"68,599",94
1,Canada,C10AC,Bile acid sequestrants,65+,Total,"12,193.39",0.2,0.7,"38,002",95
1,Canada,A06AD,Osmotically acting laxatives,65+,Total,"12,005.75",0.2,4.0,"220,522",96
1,Canada,C03DA,Aldosterone antagonists,65+,Total,"11,938.28",0.2,2.4,"135,566",97
1,Canada,N03AE,Benzodiazepine derivatives,65+,Total,"11,300.76",0.1,2.8,"156,755",98
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,Total,"11,257.73",0.1,0.2,"10,964",99
1,Canada,C10AB,Fibrates,65+,Total,"11,253.52",0.1,1.2,"68,863",100
1,Canada,S01LA,Antineovascularization agents,65+,M,"240,768.90",6.6,1.1,"26,390",1
1,Canada,C10AA,HMG-CoA reductase inhibitors,65+,M,"154,591.10",4.2,56.7,"1,418,802",2
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"143,431.80",3.9,0.3,"7,178",3
1,Canada,B01AF,Direct factor Xa inhibitors,65+,M,"126,508.10",3.5,6.7,"167,000",4
1,Canada,L01XE,Protein kinase inhibitors,65+,M,"125,982.30",3.5,0.2,"4,010",5
1,Canada,L04AX,Other immunosuppressants,65+,M,"120,085.60",3.3,0.3,"7,510",6
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"105,011.60",2.9,6.7,"167,770",7
1,Canada,C09AA,"ACE inhibitors, plain",65+,M,"103,562.70",2.8,28.9,"723,298",8
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"86,245.98",2.4,4.3,"106,551",9
1,Canada,J05AP,Antivirals for treatment of HCV infections,65+,M,"84,402.68",2.3,0.1,"1,474",10
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"81,870.26",2.2,1.0,"25,566",11
1,Canada,A02BC,Proton pump inhibitors,65+,M,"80,531.56",2.2,29.0,"726,004",12
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"76,644.01",2.1,3.6,"88,938",13
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"75,272.70",2.1,3.7,"92,430",14
1,Canada,C08CA,Dihydropyridine derivatives,65+,M,"67,716.08",1.9,22.2,"555,987",15
1,Canada,R03BB,Anticholinergics,65+,M,"61,042.85",1.7,7.3,"183,091",16
1,Canada,L02BX,Other hormone antagonists and related agents,65+,M,"56,049.58",1.5,0.1,"3,607",17
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"55,090.79",1.5,20.5,"513,810",18
1,Canada,C07AB,"Beta-blocking agents, selective",65+,M,"44,758.00",1.2,25.7,"643,740",19
1,Canada,L02BB,Antiandrogens,65+,M,"43,593.55",1.2,0.7,"16,291",20
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"42,918.26",1.2,2.4,"59,728",21
1,Canada,C09CA,"Angiotensin II antagonists, plain",65+,M,"41,983.12",1.2,14.7,"367,537",22
1,Canada,N03AX,Other antiepileptics,65+,M,"38,340.04",1.1,7.3,"182,131",23
1,Canada,L04AA,Selective immunosuppressants,65+,M,"35,066.22",1.0,0.3,"8,385",24
1,Canada,B03XA,Other antianemic preparations,65+,M,"34,505.94",0.9,0.3,"6,882",25
1,Canada,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"33,888.26",0.9,9.2,"230,108",26
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"33,571.49",0.9,7.0,"175,321",27
1,Canada,N02AA,Natural opium alkaloids,65+,M,"33,358.45",0.9,7.4,"185,823",28
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"32,289.81",0.9,2.7,"67,473",29
1,Canada,B01AB,Heparin group,65+,M,"30,110.08",0.8,1.0,"24,891",30
1,Canada,A10BA,Biguanides,65+,M,"29,649.15",0.8,17.5,"437,294",31
1,Canada,N06AX,Other antidepressants,65+,M,"29,176.47",0.8,8.0,"200,847",32
1,Canada,B01AE,Direct thrombin inhibitors,65+,M,"27,946.76",0.8,1.2,"29,463",33
1,Canada,N06AB,Selective serotonin reuptake inhibitors,65+,M,"27,320.08",0.7,7.4,"184,281",34
1,Canada,C09BA,ACE inhibitors and diuretics,65+,M,"24,651.34",0.7,4.7,"116,673",35
1,Canada,N04BA,Dopa and dopa derivatives,65+,M,"22,909.44",0.6,1.5,"38,740",36
1,Canada,H01CB,Somatostatin and analogues,65+,M,"22,207.38",0.6,0.1,"1,364",37
1,Canada,S01EE,Prostaglandin analogues,65+,M,"22,108.46",0.6,4.7,"116,455",38
1,Canada,R03BA,Glucocorticoids,65+,M,"21,969.77",0.6,4.7,"117,662",39
1,Canada,S01ED,Beta-blocking agents,65+,M,"21,766.50",0.6,4.5,"111,546",40
1,Canada,N05AX,Other antipsychotics,65+,M,"20,237.04",0.6,1.4,"33,990",41
1,Canada,L04AC,Interleukin inhibitors,65+,M,"19,928.39",0.5,0.0,"1,227",42
1,Canada,L03AA,Colony-stimulating factors,65+,M,"19,712.32",0.5,0.1,"3,618",43
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,"19,643.71",0.5,0.1,"2,124",44
1,Canada,C08DB,Benzothiazepine derivatives,65+,M,"19,599.45",0.5,3.3,"82,971",45
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"19,458.22",0.5,3.1,"78,607",46
1,Canada,N06DA,Anticholinesterases,65+,M,"19,443.57",0.5,2.1,"52,641",47
1,Canada,C09DA,Angiotensin II antagonists and diuretics,65+,M,"18,720.68",0.5,6.4,"159,860",48
1,Canada,N02BA,Salicylic acid and derivatives,65+,M,"18,597.58",0.5,9.4,"236,425",49
1,Canada,C03CA,"Sulfonamides, plain",65+,M,"18,283.85",0.5,9.6,"241,635",50
1,Canada,H03AA,Thyroid hormones,65+,M,"17,586.51",0.5,10.8,"270,224",51
1,Canada,G04BD,Drugs for urinary frequency and incontinence,65+,M,"17,358.64",0.5,2.6,"64,489",52
1,Canada,A10BB,Sulfonylureas,65+,M,"16,771.04",0.5,7.5,"187,010",53
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"16,669.61",0.5,12.3,"308,908",54
1,Canada,M05BA,Bisphosphonates,65+,M,"14,795.51",0.4,2.8,"70,685",55
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"14,677.43",0.4,1.4,"34,009",56
1,Canada,A07EC,Aminosalicylic acid and similar agents,65+,M,"14,396.98",0.4,0.8,"20,412",57
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,"14,243.02",0.4,0.9,"22,671",58
1,Canada,C10AX,Other lipid-modifying agents,65+,M,"12,961.17",0.4,4.2,"104,436",59
1,Canada,M04AA,Preparations inhibiting uric acid production,65+,M,"12,676.33",0.3,7.2,"180,250",60
1,Canada,A11CC,Vitamin D and analogues,65+,M,"12,653.63",0.3,5.4,"134,139",61
1,Canada,L04AD,Calcineurin inhibitors,65+,M,"12,590.59",0.3,0.2,"4,493",62
1,Canada,C01DA,Organic nitrates,65+,M,"12,550.20",0.3,7.0,"176,184",63
1,Canada,N05BA,Benzodiazepine derivatives,65+,M,"11,332.20",0.3,8.7,"217,560",64
1,Canada,B01AA,Vitamin K antagonists,65+,M,"10,490.46",0.3,4.8,"119,178",65
1,Canada,G03BA,3-oxoandrosten (4) derivatives,65+,M,"10,391.11",0.3,0.9,"21,792",66
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,"10,372.01",0.3,0.1,"2,888",67
1,Canada,R01AD,Corticosteroids,65+,M,"10,178.58",0.3,7.3,"183,915",68
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"10,137.03",0.3,10.8,"270,816",69
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,65+,M,"9,745.80",0.3,0.2,"4,585",70
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,"9,590.51",0.3,1.2,"31,214",71
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"9,343.20",0.3,0.0,633,72
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,"8,970.11",0.2,0.6,"15,612",73
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,"8,778.21",0.2,0.2,"4,159",74
1,Canada,D07AC,"Corticosteroids, potent (group III)",65+,M,"8,498.12",0.2,10.4,"259,256",75
1,Canada,C07AG,Alpha- and beta-blocking agents,65+,M,"7,679.37",0.2,1.2,"30,696",76
1,Canada,N02BE,Anilides,65+,M,"7,199.87",0.2,7.4,"185,741",77
1,Canada,C09DX,"Angiotensin II antagonists, other combinations",65+,M,"7,068.65",0.2,0.2,"5,644",78
1,Canada,H02AB,Glucocorticoids,65+,M,"7,026.98",0.2,10.4,"260,301",79
1,Canada,A02BA,H2-receptor antagonists,65+,M,"7,001.68",0.2,3.5,"88,644",80
1,Canada,B03AA,"Iron bivalent, oral preparations",65+,M,"6,856.15",0.2,4.3,"108,558",81
1,Canada,C03AA,"Thiazides, plain",65+,M,"6,687.42",0.2,9.0,"225,031",82
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,M,"6,558.91",0.2,0.2,"5,911",83
1,Canada,J05AX,Other antivirals,65+,M,"6,531.72",0.2,0.0,830,84
1,Canada,C03DA,Aldosterone antagonists,65+,M,"6,323.00",0.2,2.7,"67,089",85
1,Canada,L01XC,Monoclonal antibodies,65+,M,"5,990.41",0.2,0.0,574,86
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,"5,861.87",0.2,2.6,"65,172",87
1,Canada,J01MA,Fluoroquinolones,65+,M,"5,803.05",0.2,10.2,"255,262",88
1,Canada,C10AB,Fibrates,65+,M,"5,780.59",0.2,1.4,"36,266",89
1,Canada,A06AA,"Softeners, emollients",65+,M,"5,658.76",0.2,4.2,"104,186",90
1,Canada,C10AC,Bile acid sequestrants,65+,M,"5,580.78",0.2,0.5,"13,389",91
1,Canada,L01XX,Other antineoplastic agents,65+,M,"5,445.94",0.1,0.1,"3,511",92
1,Canada,A06AB,Contact laxatives,65+,M,"5,441.42",0.1,5.1,"127,739",93
1,Canada,D05AX,Other antipsoriatics for topical use,65+,M,"5,211.26",0.1,0.8,"20,190",94
1,Canada,V03AC,Iron-chelating agents,65+,M,"5,011.47",0.1,0.0,277,95
1,Canada,J05AE,Protease inhibitors,65+,M,"4,961.19",0.1,0.0,637,96
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,M,"4,938.40",0.1,1.9,"47,493",97
1,Canada,N02AB,Phenylpiperidine derivatives,65+,M,"4,796.74",0.1,0.4,"9,052",98
1,Canada,A06AD,Osmotically acting laxatives,65+,M,"4,786.13",0.1,3.7,"91,731",99
1,Canada,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,"4,734.28",0.1,0.1,"3,019",100
1,Canada,S01LA,Antineovascularization agents,65+,F,"339,433.80",8.3,1.2,"36,208",1
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"196,728.10",4.8,0.4,"11,185",2
1,Canada,C10AA,HMG-CoA reductase inhibitors,65+,F,"155,014.50",3.8,42.1,"1,291,248",3
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"129,540.40",3.2,7.1,"218,424",4
1,Canada,B01AF,Direct factor Xa inhibitors,65+,F,"128,344.40",3.1,5.5,"169,204",5
1,Canada,A02BC,Proton pump inhibitors,65+,F,"127,239.20",3.1,33.6,"1,030,295",6
1,Canada,C09AA,"ACE inhibitors, plain",65+,F,"98,883.87",2.4,20.4,"623,687",7
1,Canada,L01XE,Protein kinase inhibitors,65+,F,"98,827.87",2.4,0.1,"3,375",8
1,Canada,C08CA,Dihydropyridine derivatives,65+,F,"93,300.55",2.3,22.2,"681,044",9
1,Canada,L04AX,Other immunosuppressants,65+,F,"81,239.15",2.0,0.3,"8,643",10
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"80,550.35",2.0,3.2,"97,643",11
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"78,349.25",1.9,4.0,"122,828",12
1,Canada,C09CA,"Angiotensin II antagonists, plain",65+,F,"66,933.17",1.6,16.9,"516,512",13
1,Canada,N06AX,Other antidepressants,65+,F,"64,024.72",1.6,12.7,"387,980",14
1,Canada,R03BB,Anticholinergics,65+,F,"63,356.30",1.5,6.3,"191,845",15
1,Canada,N06AB,Selective serotonin reuptake inhibitors,65+,F,"63,015.55",1.5,13.2,"405,357",16
1,Canada,M05BA,Bisphosphonates,65+,F,"62,425.84",1.5,11.1,"340,304",17
1,Canada,L04AA,Selective immunosuppressants,65+,F,"60,070.28",1.5,0.4,"12,584",18
1,Canada,N03AX,Other antiepileptics,65+,F,"59,822.02",1.5,9.5,"291,896",19
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"58,132.13",1.4,2.5,"77,210",20
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"55,569.30",1.4,2.1,"64,079",21
1,Canada,C07AB,"Beta-blocking agents, selective",65+,F,"54,875.32",1.3,21.0,"643,684",22
1,Canada,H03AA,Thyroid hormones,65+,F,"53,971.54",1.3,25.5,"781,762",23
1,Canada,N02AA,Natural opium alkaloids,65+,F,"48,238.00",1.2,8.5,"261,569",24
1,Canada,J05AP,Antivirals for treatment of HCV infections,65+,F,"45,600.77",1.1,0.0,796,25
1,Canada,N06DA,Anticholinesterases,65+,F,"35,156.83",0.9,2.8,"86,201",26
1,Canada,R03BA,Glucocorticoids,65+,F,"33,797.64",0.8,6.2,"190,407",27
1,Canada,N05AX,Other antipsychotics,65+,F,"33,614.76",0.8,2.0,"60,111",28
1,Canada,G04BD,Drugs for urinary frequency and incontinence,65+,F,"32,287.21",0.8,4.1,"125,993",29
1,Canada,S01EE,Prostaglandin analogues,65+,F,"31,052.29",0.8,5.0,"152,316",30
1,Canada,C08DB,Benzothiazepine derivatives,65+,F,"30,200.43",0.7,3.9,"120,987",31
1,Canada,B03XA,Other antianemic preparations,65+,F,"30,050.87",0.7,0.2,"6,574",32
1,Canada,B01AB,Heparin group,65+,F,"29,708.18",0.7,1.0,"29,928",33
1,Canada,A10BA,Biguanides,65+,F,"29,047.51",0.7,12.3,"375,425",34
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"28,620.07",0.7,4.4,"136,078",35
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"28,450.26",0.7,1.3,"40,269",36
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"28,430.20",0.7,3.8,"117,961",37
1,Canada,S01ED,Beta-blocking agents,65+,F,"28,129.25",0.7,4.4,"135,679",38
1,Canada,C09DA,Angiotensin II antagonists and diuretics,65+,F,"27,778.04",0.7,7.2,"220,053",39
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"26,765.88",0.7,7.6,"233,225",40
1,Canada,C03CA,"Sulfonamides, plain",65+,F,"26,653.33",0.6,10.0,"306,254",41
1,Canada,A11CC,Vitamin D and analogues,65+,F,"26,617.72",0.6,10.4,"320,195",42
1,Canada,L04AC,Interleukin inhibitors,65+,F,"25,948.96",0.6,0.1,"1,857",43
1,Canada,N05BA,Benzodiazepine derivatives,65+,F,"25,218.34",0.6,14.8,"454,958",44
1,Canada,L03AA,Colony-stimulating factors,65+,F,"24,813.82",0.6,0.2,"4,835",45
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"24,008.37",0.6,1.9,"57,083",46
1,Canada,C09BA,ACE inhibitors and diuretics,65+,F,"23,721.91",0.6,3.6,"111,351",47
1,Canada,B01AE,Direct thrombin inhibitors,65+,F,"22,746.88",0.6,0.8,"22,992",48
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,F,"22,528.05",0.5,7.3,"223,676",49
1,Canada,H01CB,Somatostatin and analogues,65+,F,"21,644.32",0.5,0.1,"1,609",50
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"20,855.08",0.5,14.2,"435,688",51
1,Canada,N02BA,Salicylic acid and derivatives,65+,F,"18,867.58",0.5,6.8,"207,458",52
1,Canada,N04BA,Dopa and dopa derivatives,65+,F,"17,142.50",0.4,1.0,"31,417",53
1,Canada,N02BE,Anilides,65+,F,"16,188.31",0.4,10.6,"325,453",54
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"16,071.49",0.4,0.3,"8,785",55
1,Canada,A07EC,Aminosalicylic acid and similar agents,65+,F,"15,466.60",0.4,0.8,"24,443",56
1,Canada,A10BB,Sulfonylureas,65+,F,"15,290.41",0.4,4.9,"148,823",57
1,Canada,C01DA,Organic nitrates,65+,F,"14,561.08",0.4,5.0,"152,844",58
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"14,475.95",0.4,5.0,"154,100",59
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"13,825.21",0.3,10.3,"315,001",60
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,"13,821.38",0.3,0.7,"22,929",61
1,Canada,L01XC,Monoclonal antibodies,65+,F,"13,486.01",0.3,0.0,"1,220",62
1,Canada,L02BG,Aromatase inhibitors,65+,F,"13,262.87",0.3,1.1,"34,244",63
1,Canada,C03AA,"Thiazides, plain",65+,F,"12,674.69",0.3,11.8,"361,960",64
1,Canada,R01AD,Corticosteroids,65+,F,"12,658.52",0.3,8.3,"253,507",65
1,Canada,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"12,474.35",0.3,1.0,"31,079",66
1,Canada,A12AA,Calcium,65+,F,"12,440.21",0.3,5.1,"155,552",67
1,Canada,C10AX,Other lipid-modifying agents,65+,F,"12,039.75",0.3,2.8,"86,736",68
1,Canada,B01AA,Vitamin K antagonists,65+,F,"11,709.68",0.3,3.4,"102,690",69
1,Canada,A02BA,H2-receptor antagonists,65+,F,"11,431.80",0.3,4.6,"139,662",70
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"10,693.48",0.3,0.0,805,71
1,Canada,B03AA,"Iron bivalent, oral preparations",65+,F,"10,645.89",0.3,4.9,"149,151",72
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"10,380.35",0.3,0.0,469,73
1,Canada,H02AB,Glucocorticoids,65+,F,"10,304.62",0.3,11.4,"348,878",74
1,Canada,N02AB,Phenylpiperidine derivatives,65+,F,"9,995.99",0.2,0.6,"17,710",75
1,Canada,S01XA,Other ophthalmologicals,65+,F,"9,889.71",0.2,1.6,"49,718",76
1,Canada,A06AA,"Softeners, emollients",65+,F,"9,856.97",0.2,4.9,"151,547",77
1,Canada,D07AC,"Corticosteroids, potent (group III)",65+,F,"8,600.25",0.2,9.9,"303,609",78
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,"8,478.84",0.2,0.9,"27,009",79
1,Canada,L01BA,Folic acid analogues,65+,F,"8,363.72",0.2,1.5,"45,269",80
1,Canada,A06AB,Contact laxatives,65+,F,"8,347.66",0.2,5.5,"167,993",81
1,Canada,M01AH,Coxibs,65+,F,"8,257.04",0.2,4.3,"132,803",82
1,Canada,N03AE,Benzodiazepine derivatives,65+,F,"7,551.36",0.2,3.3,"102,474",83
1,Canada,L04AD,Calcineurin inhibitors,65+,F,"7,453.71",0.2,0.1,"2,693",84
1,Canada,A03FA,Propulsives,65+,F,"7,220.03",0.2,3.5,"105,938",85
1,Canada,A06AD,Osmotically acting laxatives,65+,F,"7,218.84",0.2,4.2,"128,770",86
1,Canada,A12BA,Potassium,65+,F,"7,103.26",0.2,2.5,"75,508",87
1,Canada,J01MA,Fluoroquinolones,65+,F,"7,071.42",0.2,11.1,"338,636",88
1,Canada,M04AA,Preparations inhibiting uric acid production,65+,F,"6,778.93",0.2,2.5,"76,939",89
1,Canada,N04BC,Dopamine agonists,65+,F,"6,624.35",0.2,0.9,"28,193",90
1,Canada,C10AC,Bile acid sequestrants,65+,F,"6,611.23",0.2,0.8,"24,611",91
1,Canada,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,"6,471.42",0.2,4.0,"123,761",92
1,Canada,N05CF,Benzodiazepine-related drugs,65+,F,"6,393.80",0.2,2.7,"81,719",93
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,"6,242.05",0.2,0.4,"11,196",94
1,Canada,S01EC,Carbonic anhydrase inhibitors,65+,F,"5,997.70",0.1,1.2,"37,522",95
1,Canada,C07AA,"Beta-blocking agents, non-selective",65+,F,"5,967.41",0.1,1.7,"52,334",96
1,Canada,L03AB,Interferons,65+,F,"5,825.64",0.1,0.0,375,97
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,F,"5,803.85",0.1,0.1,"1,607",98
1,Canada,C01AA,Digitalis glycosides,65+,F,"5,791.63",0.1,1.5,"46,132",99
1,Canada,M05BB,"Bisphosphonates, combinations",65+,F,"5,757.66",0.1,2.2,"66,952",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"765,083.40",13.3,0.6,"39,377",1
1,Canada,J05AP,Antivirals for treatment of HCV infections,<65,Total,"543,179.70",9.4,0.1,"9,740",2
1,Canada,N05AX,Other antipsychotics,<65,Total,"274,851.70",4.8,2.6,"173,077",3
1,Canada,L04AA,Selective immunosuppressants,<65,Total,"203,477.20",3.5,0.4,"23,635",4
1,Canada,N07BC,Drugs used in opioid dependence,<65,Total,"174,683.40",3.0,1.4,"91,659",5
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"168,480.10",2.9,0.3,"19,622",6
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"165,802.70",2.9,4.9,"329,599",7
1,Canada,N03AX,Other antiepileptics,<65,Total,"119,134.80",2.1,5.7,"381,159",8
1,Canada,N06BA,Centrally acting sympathomimetics,<65,Total,"107,178.00",1.9,3.2,"212,322",9
1,Canada,N02AA,Natural opium alkaloids,<65,Total,"105,082.30",1.8,4.9,"329,417",10
1,Canada,N06AX,Other antidepressants,<65,Total,"103,169.50",1.8,9.3,"623,299",11
1,Canada,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"91,735.04",1.6,11.1,"747,183",12
1,Canada,L01XE,Protein kinase inhibitors,<65,Total,"80,941.02",1.4,0.0,"2,658",13
1,Canada,A02BC,Proton pump inhibitors,<65,Total,"80,377.67",1.4,12.2,"821,370",14
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"77,101.07",1.3,2.6,"171,595",15
1,Canada,L04AC,Interleukin inhibitors,<65,Total,"74,294.96",1.3,0.1,"5,082",16
1,Canada,C10AA,HMG-CoA reductase inhibitors,<65,Total,"70,944.23",1.2,11.4,"765,638",17
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"67,844.79",1.2,1.4,"92,746",18
1,Canada,L04AX,Other immunosuppressants,<65,Total,"53,232.72",0.9,0.3,"17,348",19
1,Canada,C09AA,"ACE inhibitors, plain",<65,Total,"50,882.55",0.9,6.8,"458,033",20
1,Canada,R03BA,Glucocorticoids,<65,Total,"47,569.27",0.8,6.3,"419,607",21
1,Canada,N07XX,Other nervous system drugs,<65,Total,"43,917.27",0.8,0.1,"3,772",22
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"43,513.05",0.8,0.9,"59,471",23
1,Canada,L03AB,Interferons,<65,Total,"43,008.59",0.7,0.0,"2,884",24
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"39,838.27",0.7,0.9,"57,289",25
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"38,442.13",0.7,1.5,"97,464",26
1,Canada,L04AD,Calcineurin inhibitors,<65,Total,"36,715.01",0.6,0.2,"11,225",27
1,Canada,S01LA,Antineovascularization agents,<65,Total,"34,965.38",0.6,0.1,"4,452",28
1,Canada,L03AX,Other immunostimulants,<65,Total,"34,560.17",0.6,0.0,"3,278",29
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"34,496.51",0.6,0.8,"54,603",30
1,Canada,A16AB,Enzymes,<65,Total,"33,995.22",0.6,0.0,68,31
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"32,905.86",0.6,10.1,"674,577",32
1,Canada,L03AA,Colony-stimulating factors,<65,Total,"32,537.90",0.6,0.1,"6,359",33
1,Canada,J05AX,Other antivirals,<65,Total,"31,929.30",0.6,0.1,"5,539",34
1,Canada,N05BA,Benzodiazepine derivatives,<65,Total,"29,895.15",0.5,7.2,"482,741",35
1,Canada,J05AE,Protease inhibitors,<65,Total,"29,806.21",0.5,0.1,"4,532",36
1,Canada,N07BA,Drugs used in nicotine dependence,<65,Total,"29,324.46",0.5,2.8,"187,378",37
1,Canada,R03BB,Anticholinergics,<65,Total,"29,198.07",0.5,1.6,"105,635",38
1,Canada,B01AB,Heparin group,<65,Total,"28,713.86",0.5,0.3,"22,587",39
1,Canada,C08CA,Dihydropyridine derivatives,<65,Total,"28,536.67",0.5,4.4,"296,107",40
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"26,527.90",0.5,12.4,"834,179",41
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"26,521.74",0.5,0.1,"8,109",42
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"24,218.28",0.4,0.0,"1,549",43
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"24,161.36",0.4,0.2,"11,312",44
1,Canada,N03AG,Fatty acid derivatives,<65,Total,"24,138.70",0.4,1.1,"71,908",45
1,Canada,A10BA,Biguanides,<65,Total,"23,864.59",0.4,5.5,"369,036",46
1,Canada,N03AE,Benzodiazepine derivatives,<65,Total,"23,613.06",0.4,2.9,"195,971",47
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,Total,"23,552.04",0.4,0.2,"11,397",48
1,Canada,H03AA,Thyroid hormones,<65,Total,"22,770.82",0.4,6.7,"452,402",49
1,Canada,A04AD,Other antiemetics,<65,Total,"21,709.74",0.4,0.5,"30,760",50
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"20,034.77",0.3,3.2,"213,538",51
1,Canada,M01AE,Propionic acid derivatives,<65,Total,"19,924.09",0.3,13.1,"877,532",52
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"19,345.44",0.3,1.2,"79,090",53
1,Canada,M03BX,Other centrally acting agents,<65,Total,"18,897.91",0.3,4.8,"319,321",54
1,Canada,C07AB,"Beta-blocking agents, selective",<65,Total,"18,558.93",0.3,4.0,"270,594",55
1,Canada,C09CA,"Angiotensin II antagonists, plain",<65,Total,"18,217.69",0.3,2.8,"191,029",56
1,Canada,H01CB,Somatostatin and analogues,<65,Total,"17,708.90",0.3,0.0,"1,333",57
1,Canada,H01AC,Somatropin and somatropin agonists,<65,Total,"17,479.02",0.3,0.0,"1,683",58
1,Canada,R07AX,Other respiratory system products,<65,Total,"17,455.95",0.3,0.0,74,59
1,Canada,L01XC,Monoclonal antibodies,<65,Total,"17,447.47",0.3,0.0,"1,601",60
1,Canada,B01AF,Direct factor Xa inhibitors,<65,Total,"17,376.27",0.3,0.5,"36,053",61
1,Canada,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"17,339.79",0.3,5.6,"373,234",62
1,Canada,N05AE,Indole derivatives,<65,Total,"16,734.85",0.3,0.2,"13,892",63
1,Canada,A07EC,Aminosalicylic acid and similar agents,<65,Total,"16,607.21",0.3,0.6,"40,285",64
1,Canada,R01AD,Corticosteroids,<65,Total,"15,637.90",0.3,6.3,"422,844",65
1,Canada,A11CC,Vitamin D and analogues,<65,Total,"14,755.12",0.3,3.4,"228,910",66
1,Canada,J01CA,Penicillins with extended spectrum,<65,Total,"14,549.02",0.3,17.9,"1,198,582",67
1,Canada,B03XA,Other antianemic preparations,<65,Total,"14,375.28",0.2,0.1,"3,713",68
1,Canada,N02CC,Selective serotonin (5HT1) agonists,<65,Total,"14,093.80",0.2,1.2,"83,388",69
1,Canada,V03AC,Iron-chelating agents,<65,Total,"12,918.86",0.2,0.0,569,70
1,Canada,N03AF,Carboxamide derivatives,<65,Total,"12,739.68",0.2,0.6,"39,659",71
1,Canada,C09BA,ACE inhibitors and diuretics,<65,Total,"12,649.68",0.2,1.2,"83,376",72
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"12,541.72",0.2,0.0,603,73
1,Canada,A10BB,Sulfonylureas,<65,Total,"12,423.47",0.2,2.1,"139,221",74
1,Canada,A02BA,H2-receptor antagonists,<65,Total,"12,320.54",0.2,2.9,"197,352",75
1,Canada,G04BD,Drugs for urinary frequency and incontinence,<65,Total,"12,274.69",0.2,0.8,"55,495",76
1,Canada,N02AB,Phenylpiperidine derivatives,<65,Total,"12,140.14",0.2,0.2,"15,480",77
1,Canada,V06C,Infant formulas,<65,Total,"11,643.41",0.2,0.1,"9,241",78
1,Canada,G02BA,Intrauterine contraceptives,<65,Total,"11,392.06",0.2,0.9,"60,399",79
1,Canada,C02AC,Imidazoline receptor agonists,<65,Total,"11,260.89",0.2,0.8,"56,702",80
1,Canada,A09AA,Enzyme preparations,<65,Total,"11,251.90",0.2,0.2,"13,171",81
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"11,160.43",0.2,3.4,"229,570",82
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,"11,153.27",0.2,0.1,"5,128",83
1,Canada,J01FA,Macrolides,<65,Total,"11,133.39",0.2,10.1,"675,535",84
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,"10,804.45",0.2,2.1,"138,452",85
1,Canada,N02BE,Anilides,<65,Total,"10,626.16",0.2,5.1,"342,290",86
1,Canada,C01CA,Adrenergic and dopaminergic agents,<65,Total,"10,599.44",0.2,1.6,"107,480",87
1,Canada,J01DB,First-generation cephalosporins,<65,Total,"10,322.62",0.2,6.7,"447,314",88
1,Canada,D07AC,"Corticosteroids, potent (group III)",<65,Total,"9,742.34",0.2,7.3,"488,969",89
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,"9,686.13",0.2,0.5,"36,874",90
1,Canada,C09DA,Angiotensin II antagonists and diuretics,<65,Total,"8,943.86",0.2,1.4,"93,683",91
1,Canada,J02AC,Triazole derivatives,<65,Total,"8,830.82",0.2,1.4,"95,871",92
1,Canada,N02BA,Salicylic acid and derivatives,<65,Total,"8,791.54",0.2,1.6,"107,509",93
1,Canada,H02AB,Glucocorticoids,<65,Total,"8,544.37",0.1,6.7,"452,335",94
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,"8,129.37",0.1,0.1,"8,188",95
1,Canada,M05BA,Bisphosphonates,<65,Total,"7,775.70",0.1,0.7,"43,849",96
1,Canada,R05CB,Mucolytics,<65,Total,"7,694.57",0.1,0.0,"1,534",97
1,Canada,A04AA,Serotonin (5HT3) antagonists,<65,Total,"7,664.07",0.1,0.4,"27,622",98
1,Canada,B03AA,"Iron bivalent, oral preparations",<65,Total,"7,549.65",0.1,2.2,"147,450",99
1,Canada,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,Total,"7,473.87",0.1,0.0,"2,032",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"391,358.20",13.3,0.6,"18,796",1
1,Canada,J05AP,Antivirals for treatment of HCV infections,<65,M,"345,615.40",11.8,0.2,"6,187",2
1,Canada,N05AX,Other antipsychotics,<65,M,"173,561.60",5.9,3.2,"96,321",3
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"126,161.60",4.3,0.5,"14,520",4
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"102,893.30",3.5,5.5,"164,285",5
1,Canada,N07BC,Drugs used in opioid dependence,<65,M,"99,968.60",3.4,1.8,"53,162",6
1,Canada,N06BA,Centrally acting sympathomimetics,<65,M,"67,398.36",2.3,4.3,"127,085",7
1,Canada,L04AA,Selective immunosuppressants,<65,M,"64,220.03",2.2,0.3,"8,680",8
1,Canada,N02AA,Natural opium alkaloids,<65,M,"54,547.34",1.9,5.1,"150,063",9
1,Canada,N03AX,Other antiepileptics,<65,M,"53,521.93",1.8,5.3,"156,234",10
1,Canada,L01XE,Protein kinase inhibitors,<65,M,"47,176.85",1.6,0.0,"1,443",11
1,Canada,N06AX,Other antidepressants,<65,M,"40,159.80",1.4,7.9,"233,137",12
1,Canada,C10AA,HMG-CoA reductase inhibitors,<65,M,"38,176.24",1.3,14.8,"438,970",13
1,Canada,N06AB,Selective serotonin reuptake inhibitors,<65,M,"36,612.86",1.2,8.8,"261,576",14
1,Canada,A02BC,Proton pump inhibitors,<65,M,"34,622.29",1.2,11.8,"349,968",15
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"34,562.26",1.2,1.6,"47,597",16
1,Canada,L04AC,Interleukin inhibitors,<65,M,"34,338.25",1.2,0.1,"2,217",17
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"32,007.60",1.1,2.3,"69,567",18
1,Canada,L04AX,Other immunosuppressants,<65,M,"30,536.51",1.0,0.2,"7,351",19
1,Canada,C09AA,"ACE inhibitors, plain",<65,M,"28,490.51",1.0,9.0,"265,494",20
1,Canada,J05AX,Other antivirals,<65,M,"23,991.23",0.8,0.1,"3,990",21
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"23,302.73",0.8,1.1,"32,499",22
1,Canada,L04AD,Calcineurin inhibitors,<65,M,"21,944.43",0.7,0.2,"6,625",23
1,Canada,J05AE,Protease inhibitors,<65,M,"21,844.76",0.7,0.1,"3,221",24
1,Canada,A16AB,Enzymes,<65,M,"21,445.37",0.7,0.0,40,25
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"20,087.49",0.7,1.7,"49,676",26
1,Canada,R03BA,Glucocorticoids,<65,M,"20,048.31",0.7,6.2,"182,395",27
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,"19,561.89",0.7,1.0,"29,008",28
1,Canada,S01LA,Antineovascularization agents,<65,M,"19,131.75",0.7,0.1,"2,473",29
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"17,765.53",0.6,1.0,"28,568",30
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"17,516.53",0.6,0.2,"5,267",31
1,Canada,C08CA,Dihydropyridine derivatives,<65,M,"15,190.37",0.5,5.5,"162,220",32
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"15,075.39",0.5,10.5,"312,260",33
1,Canada,N07BA,Drugs used in nicotine dependence,<65,M,"15,001.36",0.5,3.2,"95,992",34
1,Canada,N07XX,Other nervous system drugs,<65,M,"14,450.37",0.5,0.0,"1,412",35
1,Canada,N03AG,Fatty acid derivatives,<65,M,"14,017.57",0.5,1.3,"39,123",36
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,M,"13,740.80",0.5,0.2,"6,540",37
1,Canada,R03BB,Anticholinergics,<65,M,"13,663.82",0.5,1.6,"48,121",38
1,Canada,N05BA,Benzodiazepine derivatives,<65,M,"13,495.92",0.5,6.0,"177,014",39
1,Canada,B01AB,Heparin group,<65,M,"12,228.79",0.4,0.3,"9,372",40
1,Canada,A10BA,Biguanides,<65,M,"11,881.42",0.4,6.4,"190,548",41
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"11,695.33",0.4,12.2,"361,686",42
1,Canada,L03AB,Interferons,<65,M,"11,266.43",0.4,0.0,770,43
1,Canada,H01AC,Somatropin and somatropin agonists,<65,M,"11,227.44",0.4,0.0,998,44
1,Canada,N03AE,Benzodiazepine derivatives,<65,M,"10,927.91",0.4,2.6,"76,883",45
1,Canada,C07AB,"Beta-blocking agents, selective",<65,M,"10,705.72",0.4,5.3,"155,963",46
1,Canada,B01AF,Direct factor Xa inhibitors,<65,M,"10,392.61",0.4,0.7,"20,068",47
1,Canada,A04AD,Other antiemetics,<65,M,"9,841.35",0.3,0.4,"12,399",48
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"9,804.14",0.3,1.6,"48,906",49
1,Canada,R07AX,Other respiratory system products,<65,M,"9,538.95",0.3,0.0,37,50
1,Canada,L03AX,Other immunostimulants,<65,M,"9,536.79",0.3,0.0,852,51
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"9,496.15",0.3,0.1,"3,847",52
1,Canada,L03AA,Colony-stimulating factors,<65,M,"9,292.06",0.3,0.1,"1,812",53
1,Canada,H01CB,Somatostatin and analogues,<65,M,"8,836.10",0.3,0.0,577,54
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"8,800.75",0.3,0.0,511,55
1,Canada,M01AE,Propionic acid derivatives,<65,M,"8,595.19",0.3,12.6,"374,346",56
1,Canada,C09CA,"Angiotensin II antagonists, plain",<65,M,"8,231.91",0.3,3.0,"89,646",57
1,Canada,M03BX,Other centrally acting agents,<65,M,"7,980.67",0.3,4.5,"133,678",58
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"7,908.18",0.3,2.4,"70,148",59
1,Canada,A07EC,Aminosalicylic acid and similar agents,<65,M,"7,737.97",0.3,0.6,"17,491",60
1,Canada,B03XA,Other antianemic preparations,<65,M,"7,240.87",0.2,0.1,"1,949",61
1,Canada,N05AE,Indole derivatives,<65,M,"7,122.11",0.2,0.2,"5,626",62
1,Canada,G03BA,3-oxoandrosten (4) derivatives,<65,M,"7,055.55",0.2,0.7,"21,311",63
1,Canada,N03AF,Carboxamide derivatives,<65,M,"6,918.20",0.2,0.7,"20,028",64
1,Canada,C02AC,Imidazoline receptor agonists,<65,M,"6,898.60",0.2,0.9,"26,464",65
1,Canada,C09BA,ACE inhibitors and diuretics,<65,M,"6,853.40",0.2,1.6,"46,612",66
1,Canada,A09AA,Enzyme preparations,<65,M,"6,544.58",0.2,0.2,"5,706",67
1,Canada,A10BB,Sulfonylureas,<65,M,"6,487.80",0.2,2.6,"76,594",68
1,Canada,J01CA,Penicillins with extended spectrum,<65,M,"6,300.28",0.2,17.9,"530,344",69
1,Canada,R01AD,Corticosteroids,<65,M,"6,284.58",0.2,5.6,"165,374",70
1,Canada,V03AC,Iron-chelating agents,<65,M,"6,260.14",0.2,0.0,263,71
1,Canada,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,"6,220.49",0.2,0.1,"1,641",72
1,Canada,H03AA,Thyroid hormones,<65,M,"5,857.14",0.2,3.2,"94,462",73
1,Canada,V06C,Infant formulas,<65,M,"5,618.47",0.2,0.1,"4,079",74
1,Canada,A02BA,H2-receptor antagonists,<65,M,"5,511.53",0.2,2.5,"74,376",75
1,Canada,G04CA,Alpha-adrenoreceptor antagonists,<65,M,"5,489.61",0.2,2.6,"77,602",76
1,Canada,N02AB,Phenylpiperidine derivatives,<65,M,"5,331.94",0.2,0.2,"6,242",77
1,Canada,N02BA,Salicylic acid and derivatives,<65,M,"5,163.59",0.2,2.1,"63,225",78
1,Canada,A11CC,Vitamin D and analogues,<65,M,"5,159.68",0.2,2.0,"59,916",79
1,Canada,B02AB,Proteinase inhibitors,<65,M,"5,059.73",0.2,0.0,47,80
1,Canada,J01DB,First-generation cephalosporins,<65,M,"4,994.00",0.2,7.1,"210,130",81
1,Canada,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,"4,945.06",0.2,0.2,"5,053",82
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,<65,M,"4,838.68",0.2,0.1,"1,621",83
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,"4,801.44",0.2,0.6,"17,460",84
1,Canada,C01CA,Adrenergic and dopaminergic agents,<65,M,"4,778.58",0.2,1.5,"45,845",85
1,Canada,J01FA,Macrolides,<65,M,"4,622.59",0.2,9.5,"282,452",86
1,Canada,N02BE,Anilides,<65,M,"4,434.22",0.2,4.8,"142,074",87
1,Canada,D07AC,"Corticosteroids, potent (group III)",<65,M,"4,286.80",0.1,6.9,"204,090",88
1,Canada,N05AF,Thioxanthene derivatives,<65,M,"4,263.59",0.1,0.2,"6,598",89
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,"4,244.97",0.1,2.4,"71,533",90
1,Canada,J01GB,Other aminoglycosides,<65,M,"4,228.82",0.1,0.0,832,91
1,Canada,J02AC,Triazole derivatives,<65,M,"4,147.73",0.1,0.3,"9,838",92
1,Canada,C09DA,Angiotensin II antagonists and diuretics,<65,M,"4,106.14",0.1,1.5,"45,355",93
1,Canada,L01XC,Monoclonal antibodies,<65,M,"4,098.97",0.1,0.0,410,94
1,Canada,R05CB,Mucolytics,<65,M,"4,079.51",0.1,0.0,804,95
1,Canada,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,"3,711.45",0.1,0.2,"6,756",96
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,"3,672.03",0.1,0.0,193,97
1,Canada,H02AB,Glucocorticoids,<65,M,"3,555.52",0.1,6.4,"191,013",98
1,Canada,L02BX,Other hormone antagonists and related agents,<65,M,"3,444.32",0.1,0.0,258,99
1,Canada,G04BD,Drugs for urinary frequency and incontinence,<65,M,"3,366.29",0.1,0.5,"15,114",100
1,Canada,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"373,690.70",13.3,0.6,"20,578",1
1,Canada,J05AP,Antivirals for treatment of HCV infections,<65,F,"197,429.60",7.0,0.1,"3,551",2
1,Canada,L04AA,Selective immunosuppressants,<65,F,"139,237.30",5.0,0.4,"14,948",3
1,Canada,N05AX,Other antipsychotics,<65,F,"101,116.60",3.6,2.1,"76,673",4
1,Canada,N07BC,Drugs used in opioid dependence,<65,F,"74,681.92",2.7,1.0,"38,475",5
1,Canada,N03AX,Other antiepileptics,<65,F,"65,558.96",2.3,6.0,"224,730",6
1,Canada,N06AX,Other antidepressants,<65,F,"62,963.80",2.2,10.5,"389,877",7
1,Canada,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"62,857.16",2.2,4.4,"165,174",8
1,Canada,N06AB,Selective serotonin reuptake inhibitors,<65,F,"55,074.40",2.0,13.0,"485,274",9
1,Canada,N02AA,Natural opium alkaloids,<65,F,"50,525.02",1.8,4.8,"179,229",10
1,Canada,A02BC,Proton pump inhibitors,<65,F,"45,692.82",1.6,12.6,"470,679",11
1,Canada,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"45,047.36",1.6,2.7,"101,932",12
1,Canada,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"41,276.58",1.5,0.1,"5,011",13
1,Canada,L04AC,Interleukin inhibitors,<65,F,"39,956.70",1.4,0.1,"2,865",14
1,Canada,N06BA,Centrally acting sympathomimetics,<65,F,"39,764.01",1.4,2.3,"85,201",15
1,Canada,L01XE,Protein kinase inhibitors,<65,F,"33,764.18",1.2,0.0,"1,215",16
1,Canada,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"33,237.88",1.2,1.2,"45,086",17
1,Canada,C10AA,HMG-CoA reductase inhibitors,<65,F,"32,714.53",1.2,8.7,"326,257",18
1,Canada,L03AB,Interferons,<65,F,"31,742.16",1.1,0.1,"2,114",19
1,Canada,N07XX,Other nervous system drugs,<65,F,"29,466.90",1.0,0.1,"2,360",20
1,Canada,R03BA,Glucocorticoids,<65,F,"27,438.36",1.0,6.3,"236,121",21
1,Canada,L03AX,Other immunostimulants,<65,F,"25,023.38",0.9,0.1,"2,426",22
1,Canada,L03AA,Colony-stimulating factors,<65,F,"23,238.47",0.8,0.1,"4,546",23
1,Canada,L04AX,Other immunosuppressants,<65,F,"22,695.70",0.8,0.3,"9,992",24
1,Canada,C09AA,"ACE inhibitors, plain",<65,F,"22,352.35",0.8,5.2,"192,297",25
1,Canada,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,"20,226.36",0.7,0.8,"28,219",26
1,Canada,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"20,137.69",0.7,0.7,"26,887",27
1,Canada,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"18,335.82",0.7,1.3,"47,748",28
1,Canada,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"17,814.99",0.6,9.7,"361,994",29
1,Canada,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"17,324.19",0.6,10.0,"372,980",30
1,Canada,H03AA,Thyroid hormones,<65,F,"16,903.56",0.6,9.6,"357,789",31
1,Canada,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"16,690.36",0.6,0.7,"25,983",32
1,Canada,B01AB,Heparin group,<65,F,"16,454.94",0.6,0.4,"13,186",33
1,Canada,N05BA,Benzodiazepine derivatives,<65,F,"16,389.67",0.6,8.2,"305,547",34
1,Canada,S01LA,Antineovascularization agents,<65,F,"15,833.63",0.6,0.1,"1,979",35
1,Canada,R03BB,Anticholinergics,<65,F,"15,523.14",0.6,1.5,"57,446",36
1,Canada,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"15,417.53",0.5,0.0,"1,038",37
1,Canada,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"14,771.37",0.5,12.6,"469,992",38
1,Canada,L04AD,Calcineurin inhibitors,<65,F,"14,766.04",0.5,0.1,"4,598",39
1,Canada,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"14,659.27",0.5,0.2,"7,461",40
1,Canada,N07BA,Drugs used in nicotine dependence,<65,F,"14,320.18",0.5,2.4,"91,370",41
1,Canada,L01XC,Monoclonal antibodies,<65,F,"13,348.50",0.5,0.0,"1,191",42
1,Canada,C08CA,Dihydropyridine derivatives,<65,F,"13,314.16",0.5,3.6,"133,657",43
1,Canada,N03AE,Benzodiazepine derivatives,<65,F,"12,676.81",0.5,3.2,"119,007",44
1,Canada,A16AB,Enzymes,<65,F,"12,549.85",0.4,0.0,28,45
1,Canada,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"12,119.00",0.4,3.8,"143,269",46
1,Canada,A10BA,Biguanides,<65,F,"11,967.05",0.4,4.8,"178,282",47
1,Canada,A04AD,Other antiemetics,<65,F,"11,860.29",0.4,0.5,"18,352",48
1,Canada,G02BA,Intrauterine contraceptives,<65,F,"11,382.02",0.4,1.6,"60,366",49
1,Canada,M01AE,Propionic acid derivatives,<65,F,"11,282.41",0.4,13.4,"500,842",50
1,Canada,N02CC,Selective serotonin (5HT1) agonists,<65,F,"11,170.84",0.4,1.8,"68,504",51
1,Canada,M03BX,Other centrally acting agents,<65,F,"10,910.98",0.4,5.0,"185,500",52
1,Canada,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,"10,374.47",0.4,3.7,"136,218",53
1,Canada,N03AG,Fatty acid derivatives,<65,F,"10,110.72",0.4,0.9,"32,743",54
1,Canada,C09CA,"Angiotensin II antagonists, plain",<65,F,"9,969.47",0.4,2.7,"101,265",55
1,Canada,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,F,"9,780.18",0.3,0.1,"4,830",56
1,Canada,N05AE,Indole derivatives,<65,F,"9,600.50",0.3,0.2,"8,256",57
1,Canada,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"9,533.51",0.3,0.8,"30,145",58
1,Canada,A11CC,Vitamin D and analogues,<65,F,"9,507.44",0.3,4.4,"165,348",59
1,Canada,R01AD,Corticosteroids,<65,F,"9,335.11",0.3,6.9,"257,130",60
1,Canada,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,"8,962.97",0.3,0.1,"2,826",61
1,Canada,G04BD,Drugs for urinary frequency and incontinence,<65,F,"8,901.87",0.3,1.1,"40,349",62
1,Canada,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"8,869.69",0.3,0.0,410,63
1,Canada,H01CB,Somatostatin and analogues,<65,F,"8,867.51",0.3,0.0,755,64
1,Canada,A07EC,Aminosalicylic acid and similar agents,<65,F,"8,866.93",0.3,0.6,"22,789",65
1,Canada,J01CA,Penicillins with extended spectrum,<65,F,"8,125.73",0.3,17.8,"663,189",66
1,Canada,R07AX,Other respiratory system products,<65,F,"7,917.00",0.3,0.0,37,67
1,Canada,J05AE,Protease inhibitors,<65,F,"7,872.73",0.3,0.0,"1,296",68
1,Canada,C07AB,"Beta-blocking agents, selective",<65,F,"7,837.87",0.3,3.1,"114,460",69
1,Canada,J05AX,Other antivirals,<65,F,"7,827.49",0.3,0.0,"1,538",70
1,Canada,B03XA,Other antianemic preparations,<65,F,"7,132.85",0.3,0.0,"1,762",71
1,Canada,B01AF,Direct factor Xa inhibitors,<65,F,"6,974.94",0.2,0.4,"15,972",72
1,Canada,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"6,900.03",0.2,4.2,"157,955",73
1,Canada,N02AB,Phenylpiperidine derivatives,<65,F,"6,803.89",0.2,0.2,"9,235",74
1,Canada,A02BA,H2-receptor antagonists,<65,F,"6,792.76",0.2,3.3,"122,564",75
1,Canada,V03AC,Iron-chelating agents,<65,F,"6,658.72",0.2,0.0,306,76
1,Canada,J01FA,Macrolides,<65,F,"6,470.92",0.2,10.5,"391,621",77
1,Canada,L02AE,Gonadotropin-releasing hormone analogues,<65,F,"6,308.20",0.2,0.1,"3,503",78
1,Canada,H01AC,Somatropin and somatropin agonists,<65,F,"6,251.06",0.2,0.0,684,79
1,Canada,N02BE,Anilides,<65,F,"6,064.77",0.2,5.2,"194,847",80
1,Canada,A10BB,Sulfonylureas,<65,F,"5,926.69",0.2,1.7,"62,536",81
1,Canada,N03AF,Carboxamide derivatives,<65,F,"5,816.07",0.2,0.5,"19,603",82
1,Canada,C01CA,Adrenergic and dopaminergic agents,<65,F,"5,811.29",0.2,1.7,"61,581",83
1,Canada,C09BA,ACE inhibitors and diuretics,<65,F,"5,779.37",0.2,1.0,"36,695",84
1,Canada,V06C,Infant formulas,<65,F,"5,753.17",0.2,0.1,"4,911",85
1,Canada,R06AA,Aminoalkyl ethers,<65,F,"5,743.35",0.2,2.0,"73,018",86
1,Canada,M05BA,Bisphosphonates,<65,F,"5,675.81",0.2,0.9,"34,304",87
1,Canada,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,"5,664.32",0.2,2.7,"99,691",88
1,Canada,G03AC,Progestogens,<65,F,"5,570.45",0.2,2.6,"97,572",89
1,Canada,D07AC,"Corticosteroids, potent (group III)",<65,F,"5,427.53",0.2,7.6,"284,053",90
1,Canada,B03AA,"Iron bivalent, oral preparations",<65,F,"5,306.41",0.2,3.1,"115,471",91
1,Canada,J01DB,First-generation cephalosporins,<65,F,"5,252.99",0.2,6.3,"235,996",92
1,Canada,A04AA,Serotonin (5HT3) antagonists,<65,F,"5,252.94",0.2,0.5,"17,992",93
1,Canada,H02AB,Glucocorticoids,<65,F,"4,973.32",0.2,7.0,"260,575",94
1,Canada,M05BX,Other drugs affecting bone structure and mineralization,<65,F,"4,942.44",0.2,0.2,"7,299",95
1,Canada,A12AX,"Calcium, combinations with vitamin D and/or other drugs",<65,F,"4,911.65",0.2,1.6,"59,934",96
1,Canada,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,"4,881.12",0.2,0.5,"19,408",97
1,Canada,C09DA,Angiotensin II antagonists and diuretics,<65,F,"4,829.99",0.2,1.3,"48,287",98
1,Canada,A09AA,Enzyme preparations,<65,F,"4,704.30",0.2,0.2,"7,457",99
1,Canada,J02AC,Triazole derivatives,<65,F,"4,675.91",0.2,2.3,"85,938",100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"11,544.09",8.0,0.7,707,1
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,Total,Total,"5,287.82",3.7,1.7,"1,728",2
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,Total,Total,"5,262.09",3.6,0.4,397,3
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,Total,Total,"5,112.01",3.5,38.0,"38,623",4
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,Total,Total,"4,315.22",3.0,35.3,"35,915",5
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",Total,Total,"3,939.44",2.7,22.9,"23,270",6
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,Total,Total,"3,751.71",2.6,0.1,145,7
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,Total,Total,"3,550.54",2.5,13.7,"13,967",8
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"3,276.09",2.3,16.4,"16,626",9
2,Newfoundland and Labrador,R03BA,Glucocorticoids,Total,Total,"2,790.14",1.9,10.0,"10,199",10
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"2,590.21",1.8,2.6,"2,660",11
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"2,561.73",1.8,4.3,"4,355",12
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,Total,Total,"2,468.20",1.7,0.4,413,13
2,Newfoundland and Labrador,N06AX,Other antidepressants,Total,Total,"2,454.31",1.7,11.8,"11,953",14
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"2,372.31",1.6,5.1,"5,159",15
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,Total,Total,"2,321.12",1.6,0.2,178,16
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",Total,Total,"2,151.35",1.5,22.6,"22,951",17
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,Total,Total,"2,141.22",1.5,5.4,"5,465",18
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"1,973.14",1.4,4.7,"4,815",19
2,Newfoundland and Labrador,N05AX,Other antipsychotics,Total,Total,"1,770.14",1.2,2.4,"2,440",20
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,Total,Total,"1,543.61",1.1,17.1,"17,348",21
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,Total,Total,"1,538.88",1.1,10.8,"11,017",22
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,Total,Total,"1,498.48",1.0,0.0,32,23
2,Newfoundland and Labrador,R03BB,Anticholinergics,Total,Total,"1,466.28",1.0,6.4,"6,526",24
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,Total,Total,"1,341.80",0.9,5.8,"5,932",25
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,Total,Total,"1,341.46",0.9,11.0,"11,213",26
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"1,237.68",0.9,11.1,"11,251",27
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,232.32",0.9,21.0,"21,351",28
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,Total,Total,"1,221.80",0.8,0.4,444,29
2,Newfoundland and Labrador,N07XX,Other nervous system drugs,Total,Total,"1,196.85",0.8,0.1,81,30
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,Total,Total,"1,191.01",0.8,2.8,"2,804",31
2,Newfoundland and Labrador,A10BA,Biguanides,Total,Total,"1,183.69",0.8,14.3,"14,555",32
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"1,181.93",0.8,1.7,"1,773",33
2,Newfoundland and Labrador,C09CA,"Angiotensin II antagonists, plain",Total,Total,"1,126.19",0.8,8.6,"8,759",34
2,Newfoundland and Labrador,H03AA,Thyroid hormones,Total,Total,959.85,0.7,11.6,"11,829",35
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,945.66,0.7,7.5,"7,603",36
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,941.07,0.7,0.3,323,37
2,Newfoundland and Labrador,N03AX,Other antiepileptics,Total,Total,932.04,0.6,2.2,"2,198",38
2,Newfoundland and Labrador,L03AB,Interferons,Total,Total,890.96,0.6,0.1,51,39
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,Total,Total,879.15,0.6,0.2,176,40
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,Total,Total,857.34,0.6,0.1,132,41
2,Newfoundland and Labrador,A10BB,Sulfonylureas,Total,Total,840.01,0.6,8.1,"8,190",42
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,Total,Total,816.63,0.6,13.5,"13,748",43
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,Total,Total,793.41,0.5,5.7,"5,761",44
2,Newfoundland and Labrador,L02BB,Antiandrogens,Total,Total,747.33,0.5,0.2,227,45
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,Total,Total,730.50,0.5,0.0,35,46
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",Total,Total,704.03,0.5,9.2,"9,346",47
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,688.89,0.5,5.8,"5,892",48
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,685.83,0.5,0.1,94,49
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,Total,Total,676.08,0.5,2.1,"2,141",50
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,Total,Total,672.98,0.5,0.8,823,51
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,Total,Total,618.98,0.4,0.0,22,52
2,Newfoundland and Labrador,C01DA,Organic nitrates,Total,Total,606.93,0.4,4.7,"4,787",53
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,Total,Total,605.91,0.4,7.2,"7,367",54
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,598.38,0.4,3.7,"3,754",55
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,Total,Total,596.26,0.4,2.4,"2,436",56
2,Newfoundland and Labrador,A16AB,Enzymes,Total,Total,**,**,**,*,57
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,Total,Total,565.03,0.4,1.5,"1,517",58
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,Total,Total,558.38,0.4,20.6,"20,895",59
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,Total,Total,537.85,0.4,0.8,809,60
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,Total,Total,537.47,0.4,4.5,"4,548",61
2,Newfoundland and Labrador,H02AB,Glucocorticoids,Total,Total,522.49,0.4,14.1,"14,302",62
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,Total,Total,519.87,0.4,2.0,"2,027",63
2,Newfoundland and Labrador,A12BA,Potassium,Total,Total,514.58,0.4,4.1,"4,176",64
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",Total,Total,512.35,0.4,11.8,"12,009",65
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,Total,Total,511.18,0.4,2.9,"2,969",66
2,Newfoundland and Labrador,L03AX,Other immunostimulants,Total,Total,498.59,0.3,0.0,49,67
2,Newfoundland and Labrador,J01FA,Macrolides,Total,Total,498.24,0.3,13.0,"13,236",68
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,Total,Total,477.36,0.3,8.5,"8,645",69
2,Newfoundland and Labrador,R01AD,Corticosteroids,Total,Total,462.91,0.3,8.7,"8,804",70
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,433.10,0.3,0.7,673,71
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,Total,Total,423.00,0.3,3.2,"3,276",72
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,413.55,0.3,3.1,"3,171",73
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,Total,Total,374.08,0.3,10.5,"10,653",74
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,Total,Total,372.85,0.3,0.0,22,75
2,Newfoundland and Labrador,C09DA,Angiotensin II antagonists and diuretics,Total,Total,369.65,0.3,3.0,"3,021",76
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,Total,Total,366.16,0.3,1.3,"1,283",77
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,Total,Total,355.79,0.2,4.5,"4,591",78
2,Newfoundland and Labrador,M05BA,Bisphosphonates,Total,Total,340.57,0.2,2.7,"2,711",79
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",Total,Total,338.10,0.2,6.9,"6,999",80
2,Newfoundland and Labrador,J05AE,Protease inhibitors,Total,Total,331.69,0.2,0.0,42,81
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,Total,Total,313.34,0.2,8.4,"8,545",82
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,Total,Total,304.89,0.2,0.7,752,83
2,Newfoundland and Labrador,A09AA,Enzyme preparations,Total,Total,287.32,0.2,0.1,141,84
2,Newfoundland and Labrador,R05CB,Mucolytics,Total,Total,274.58,0.2,0.0,50,85
2,Newfoundland and Labrador,R07AX,Other respiratory system products,Total,Total,**, ** , ** ,*,86
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",Total,Total,266.96,0.2,1.6,"1,591",87
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,Total,Total,264.99,0.2,0.7,718,88
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",Total,Total,263.04,0.2,1.6,"1,597",89
2,Newfoundland and Labrador,C10AB,Fibrates,Total,Total,262.43,0.2,1.9,"1,941",90
2,Newfoundland and Labrador,A03FA,Propulsives,Total,Total,259.20,0.2,4.1,"4,117",91
2,Newfoundland and Labrador,J05AX,Other antivirals,Total,Total,256.88,0.2,0.0,26,92
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,251.87,0.2,2.2,"2,192",93
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,Total,251.84,0.2,7.8,"7,882",94
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,Total,Total,251.58,0.2,1.8,"1,814",95
2,Newfoundland and Labrador,D06BB,Antivirals,Total,Total,250.65,0.2,1.3,"1,322",96
2,Newfoundland and Labrador,N06DA,Anticholinesterases,Total,Total,248.76,0.2,0.9,897,97
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,Total,Total,232.51,0.2,4.0,"4,038",98
2,Newfoundland and Labrador,V03AC,Iron-chelating agents,Total,Total,231.93,0.2,0.0,12,99
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,Total,Total,230.92,0.2,1.2,"1,223",100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"5,194.18",8.0,0.7,297,1
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,Total,M,"3,199.28",4.9,2.5,"1,062",2
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,Total,M,"2,844.48",4.4,0.4,179,3
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,Total,M,"2,391.78",3.7,0.2,84,4
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,Total,M,"2,345.50",3.6,40.9,"17,604",5
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",Total,M,"1,818.10",2.8,25.5,"10,977",6
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,Total,M,"1,689.38",2.6,32.8,"14,128",7
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,Total,M,"1,517.99",2.3,13.9,"5,971",8
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"1,473.58",2.3,5.7,"2,444",9
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"1,176.83",1.8,2.8,"1,196",10
2,Newfoundland and Labrador,R03BA,Glucocorticoids,Total,M,"1,168.38",1.8,9.4,"4,026",11
2,Newfoundland and Labrador,N05AX,Other antipsychotics,Total,M,"1,146.94",1.8,3.1,"1,337",12
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,138.75",1.7,4.4,"1,910",13
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,Total,M,"1,118.21",1.7,0.1,22,14
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,074.87",1.6,12.3,"5,281",15
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,Total,M,"1,061.17",1.6,0.2,74,16
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,Total,M,"1,033.24",1.6,0.4,173,17
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,Total,M,"1,015.04",1.6,5.5,"2,387",18
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",Total,M,938.18,1.4,24.2,"10,414",19
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,Total,M,848.04,1.3,0.6,278,20
2,Newfoundland and Labrador,N06AX,Other antidepressants,Total,M,842.51,1.3,9.6,"4,149",21
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,833.12,1.3,4.8,"2,072",22
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,Total,M,763.00,1.2,4.1,"1,773",23
2,Newfoundland and Labrador,L02BB,Antiandrogens,Total,M,747.33,1.1,0.5,227,24
2,Newfoundland and Labrador,R03BB,Anticholinergics,Total,M,725.88,1.1,7.3,"3,126",25
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,Total,M,677.77,1.0,10.2,"4,393",26
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,Total,M,610.51,0.9,6.1,"2,614",27
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,Total,M,605.62,0.9,12.2,"5,229",28
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,Total,M,599.93,0.9,0.0,21,29
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,590.00,0.9,11.5,"4,930",30
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,Total,M,543.97,0.8,13.1,"5,652",31
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,541.16,0.8,0.2,74,32
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,Total,M,539.64,0.8,0.5,206,33
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,Total,M,535.73,0.8,9.9,"4,252",34
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,533.38,0.8,20.1,"8,658",35
2,Newfoundland and Labrador,A10BA,Biguanides,Total,M,523.85,0.8,15.0,"6,433",36
2,Newfoundland and Labrador,N07XX,Other nervous system drugs,Total,M,506.51,0.8,0.1,39,37
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,466.59,0.7,1.6,707,38
2,Newfoundland and Labrador,C09CA,"Angiotensin II antagonists, plain",Total,M,385.61,0.6,7.2,"3,106",39
2,Newfoundland and Labrador,N03AX,Other antiepileptics,Total,M,381.33,0.6,2.0,865,40
2,Newfoundland and Labrador,A10BB,Sulfonylureas,Total,M,356.25,0.5,8.2,"3,531",41
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,Total,M,350.13,0.5,13.1,"5,647",42
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,Total,M,340.11,0.5,5.2,"2,216",43
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,Total,M,317.59,0.5,0.8,357,44
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,316.92,0.5,5.9,"2,518",45
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,Total,M,308.68,0.5,1.8,768,46
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,306.58,0.5,4.6,"1,967",47
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,Total,M,291.43,0.4,0.1,41,48
2,Newfoundland and Labrador,R07AX,Other respiratory system products,Total,M,**, ** , ** ,*,49
2,Newfoundland and Labrador,C01DA,Organic nitrates,Total,M,273.83,0.4,5.6,"2,430",50
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,Total,M,270.66,0.4,5.5,"2,378",51
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,Total,M,270.34,0.4,2.0,866,52
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,Total,M,266.26,0.4,6.8,"2,917",53
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",Total,M,262.24,0.4,8.6,"3,706",54
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,Total,M,248.26,0.4,0.0,10,55
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,Total,M,236.63,0.4,2.2,966,56
2,Newfoundland and Labrador,J05AE,Protease inhibitors,Total,M,235.38,0.4,0.1,32,57
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,Total,M,230.36,0.4,0.0,13,58
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,Total,M,229.21,0.4,0.1,41,59
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,Total,M,227.61,0.3,0.8,352,60
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,Total,M,223.70,0.3,18.7,"8,061",61
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,Total,M,216.33,0.3,6.4,"2,771",62
2,Newfoundland and Labrador,H02AB,Glucocorticoids,Total,M,208.96,0.3,13.5,"5,788",63
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,206.46,0.3,2.9,"1,258",64
2,Newfoundland and Labrador,H03AA,Thyroid hormones,Total,M,205.30,0.3,6.0,"2,561",65
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,Total,M,193.59,0.3,1.8,770,66
2,Newfoundland and Labrador,J01FA,Macrolides,Total,M,188.07,0.3,11.1,"4,784",67
2,Newfoundland and Labrador,R01AD,Corticosteroids,Total,M,179.11,0.3,7.1,"3,067",68
2,Newfoundland and Labrador,A09AA,Enzyme preparations,Total,M,178.42,0.3,0.2,78,69
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,Total,M,176.92,0.3,1.4,588,70
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,Total,M,171.87,0.3,3.1,"1,326",71
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,Total,M,170.60,0.3,0.9,378,72
2,Newfoundland and Labrador,R05CB,Mucolytics,Total,M,169.83,0.3,0.1,30,73
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",Total,M,169.56,0.3,9.6,"4,151",74
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",Total,M,168.87,0.3,0.7,284,75
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,Total,M,168.67,0.3,7.2,"3,101",76
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,Total,M,154.02,0.2,8.4,"3,610",77
2,Newfoundland and Labrador,A12BA,Potassium,Total,M,152.48,0.2,3.0,"1,286",78
2,Newfoundland and Labrador,L03AB,Interferons,Total,M,152.43,0.2,0.0,9,79
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,Total,M,146.05,0.2,8.7,"3,722",80
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",Total,M,143.09,0.2,6.4,"2,753",81
2,Newfoundland and Labrador,J05AX,Other antivirals,Total,M,141.89,0.2,0.0,16,82
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,Total,M,131.46,0.2,1.6,697,83
2,Newfoundland and Labrador,C09DA,Angiotensin II antagonists and diuretics,Total,M,123.94,0.2,2.5,"1,060",84
2,Newfoundland and Labrador,N05AF,Thioxanthene derivatives,Total,M,117.28,0.2,0.4,178,85
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,Total,M,116.49,0.2,2.0,849,86
2,Newfoundland and Labrador,C10AB,Fibrates,Total,M,115.98,0.2,2.0,844,87
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,115.60,0.2,0.5,217,88
2,Newfoundland and Labrador,L03AX,Other immunostimulants,Total,M,114.64,0.2,0.0,12,89
2,Newfoundland and Labrador,M05BX,Other drugs affecting bone structure and mineralization,Total,M,111.89,0.2,0.1,25,90
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,Total,M,106.42,0.2,0.5,215,91
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,M,104.92,0.2,7.5,"3,209",92
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",Total,M,101.26,0.2,1.4,587,93
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,Total,M,99.84,0.2,1.6,709,94
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,Total,M,98.08,0.2,2.7,"1,162",95
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",Total,M,88.13,0.1,2.3,984,96
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,Total,M,88.13,0.1,4.1,"1,758",97
2,Newfoundland and Labrador,A03FA,Propulsives,Total,M,87.82,0.1,3.3,"1,432",98
2,Newfoundland and Labrador,N02AB,Phenylpiperidine derivatives,Total,M,86.43,0.1,0.9,397,99
2,Newfoundland and Labrador,N06DA,Anticholinesterases,Total,M,84.48,0.1,0.7,317,100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"6,349.92",8.0,0.7,410,1
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,764.23",3.5,35.8,"21,000",2
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,Total,F,"2,624.58",3.3,37.2,"21,774",3
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,Total,F,"2,417.62",3.1,0.4,218,4
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,200.88",2.8,19.4,"11,342",5
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",Total,F,"2,119.08",2.7,21.0,"12,281",6
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,Total,F,"2,088.54",2.6,1.1,666,7
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,Total,F,"2,031.74",2.6,13.6,"7,990",8
2,Newfoundland and Labrador,R03BA,Glucocorticoids,Total,F,"1,621.23",2.0,10.5,"6,170",9
2,Newfoundland and Labrador,N06AX,Other antidepressants,Total,F,"1,611.61",2.0,13.3,"7,802",10
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,Total,F,"1,434.96",1.8,0.4,240,11
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,422.86",1.8,4.2,"2,444",12
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"1,413.38",1.8,2.5,"1,464",13
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,Total,F,"1,359.92",1.7,0.1,61,14
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,Total,F,"1,259.95",1.6,0.2,104,15
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",Total,F,"1,212.17",1.5,21.4,"12,522",16
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,"1,139.64",1.4,4.7,"2,742",17
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,Total,F,"1,126.18",1.4,5.3,"3,078",18
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,Total,F,999.18,1.3,20.0,"11,689",19
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,898.70,1.1,4.6,"2,714",20
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,Total,F,860.39,1.1,11.3,"6,617",21
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,Total,F,805.50,1.0,11.9,"6,957",22
2,Newfoundland and Labrador,H03AA,Thyroid hormones,Total,F,754.20,1.0,15.8,"9,264",23
2,Newfoundland and Labrador,C09CA,"Angiotensin II antagonists, plain",Total,F,739.79,0.9,9.6,"5,647",24
2,Newfoundland and Labrador,R03BB,Anticholinergics,Total,F,739.43,0.9,5.8,"3,398",25
2,Newfoundland and Labrador,L03AB,Interferons,Total,F,738.54,0.9,0.1,42,26
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,Total,F,731.00,0.9,5.7,"3,316",27
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,715.33,0.9,1.8,"1,066",28
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,698.80,0.9,21.7,"12,688",29
2,Newfoundland and Labrador,N07XX,Other nervous system drugs,Total,F,690.34,0.9,0.1,42,30
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,Total,F,682.16,0.9,0.4,238,31
2,Newfoundland and Labrador,A10BA,Biguanides,Total,F,659.36,0.8,13.9,"8,117",32
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,Total,F,649.94,0.8,0.2,135,33
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,647.63,0.8,10.8,"6,317",34
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,628.23,0.8,8.7,"5,083",35
2,Newfoundland and Labrador,N05AX,Other antipsychotics,Total,F,622.80,0.8,1.9,"1,102",36
2,Newfoundland and Labrador,A16AB,Enzymes,Total,F,**,**,**,*,37
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,Total,F,565.91,0.7,0.2,91,38
2,Newfoundland and Labrador,N03AX,Other antiepileptics,Total,F,550.71,0.7,2.3,"1,333",39
2,Newfoundland and Labrador,A10BB,Sulfonylureas,Total,F,483.76,0.6,8.0,"4,659",40
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,Total,F,482.24,0.6,0.0,25,41
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,Total,F,466.49,0.6,13.8,"8,099",42
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,Total,F,453.30,0.6,6.1,"3,545",43
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",Total,F,441.74,0.6,9.6,"5,638",44
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,Total,F,428.01,0.5,1.8,"1,031",45
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,Total,F,411.34,0.5,3.9,"2,260",46
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,407.71,0.5,5.4,"3,153",47
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,Total,F,405.75,0.5,2.2,"1,275",48
2,Newfoundland and Labrador,L03AX,Other immunostimulants,Total,F,383.94,0.5,0.1,37,49
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,Total,F,380.27,0.5,0.0,10,50
2,Newfoundland and Labrador,A12BA,Potassium,Total,F,362.10,0.5,4.9,"2,890",51
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,Total,F,358.81,0.5,2.5,"1,466",52
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,Total,F,355.39,0.4,0.8,466,53
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",Total,F,342.58,0.4,13.4,"7,850",54
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,Total,F,339.59,0.4,7.6,"4,447",55
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,Total,F,334.54,0.4,21.9,"12,828",56
2,Newfoundland and Labrador,C01DA,Organic nitrates,Total,F,333.03,0.4,4.0,"2,355",57
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,Total,F,326.28,0.4,2.1,"1,257",58
2,Newfoundland and Labrador,H02AB,Glucocorticoids,Total,F,313.48,0.4,14.5,"8,510",59
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,Total,F,310.24,0.4,0.8,457,60
2,Newfoundland and Labrador,J01FA,Macrolides,Total,F,310.14,0.4,14.4,"8,450",61
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,Total,F,308.66,0.4,9.5,"5,541",62
2,Newfoundland and Labrador,M05BA,Bisphosphonates,Total,F,306.22,0.4,4.2,"2,440",63
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,291.40,0.4,3.0,"1,784",64
2,Newfoundland and Labrador,R01AD,Corticosteroids,Total,F,283.80,0.4,9.8,"5,737",65
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",Total,F,266.90,0.3,2.7,"1,590",66
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,Total,F,266.45,0.3,3.7,"2,166",67
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",Total,F,264.22,0.3,0.7,389,68
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,Total,F,256.21,0.3,1.3,748,69
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,251.87,0.3,3.7,"2,192",70
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,Total,F,250.88,0.3,3.3,"1,947",71
2,Newfoundland and Labrador,C09DA,Angiotensin II antagonists and diuretics,Total,F,245.40,0.3,3.3,"1,958",72
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,Total,F,226.88,0.3,0.8,495,73
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,Total,F,219.98,0.3,12.0,"7,039",74
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",Total,F,194.71,0.2,7.2,"4,244",75
2,Newfoundland and Labrador,D06BB,Antivirals,Total,F,190.66,0.2,1.7,993,76
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,Total,F,189.09,0.2,1.2,694,77
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,Total,F,174.57,0.2,1.5,895,78
2,Newfoundland and Labrador,A03FA,Propulsives,Total,F,171.38,0.2,4.6,"2,684",79
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,Total,F,170.35,0.2,8.2,"4,791",80
2,Newfoundland and Labrador,V03AC,Iron-chelating agents,Total,F,167.51,0.2,0.0,6,81
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,Total,F,167.23,0.2,8.2,"4,821",82
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,Total,F,164.59,0.2,4.8,"2,799",83
2,Newfoundland and Labrador,N06DA,Anticholinesterases,Total,F,164.27,0.2,1.0,580,84
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",Total,F,161.78,0.2,1.7,"1,010",85
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,Total,F,158.58,0.2,0.9,503,86
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,F,146.89,0.2,8.0,"4,672",87
2,Newfoundland and Labrador,C10AB,Fibrates,Total,F,146.27,0.2,1.9,"1,096",88
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,146.17,0.2,2.7,"1,564",89
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,144.67,0.2,0.0,20,90
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,Total,F,142.50,0.2,0.0,9,91
2,Newfoundland and Labrador,G03AC,Progestogens,Total,F,140.16,0.2,2.3,"1,335",92
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,Total,F,139.26,0.2,3.1,"1,816",93
2,Newfoundland and Labrador,L01BA,Folic acid analogues,Total,F,137.56,0.2,1.2,722,94
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,Total,F,135.08,0.2,1.6,965,95
2,Newfoundland and Labrador,G02BA,Intrauterine contraceptives,Total,F,134.31,0.2,0.7,386,96
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,Total,F,134.28,0.2,0.6,374,97
2,Newfoundland and Labrador,A03AX,Other drugs for functional gastrointestinal disorders,Total,F,131.06,0.2,1.0,603,98
2,Newfoundland and Labrador,M01AH,Coxibs,Total,F,130.52,0.2,3.1,"1,832",99
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,Total,F,129.38,0.2,0.0,18,100
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,65+,Total,"3,798.87",5.2,0.4,198,1
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,65+,Total,"3,721.15",5.1,56.4,"29,293",2
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,65+,Total,"2,898.44",4.0,22.0,"11,429",3
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",65+,Total,"2,840.61",3.9,33.7,"17,480",4
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"2,836.64",3.9,0.3,176,5
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,65+,Total,"2,666.42",3.7,44.0,"22,850",6
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,65+,Total,"2,465.98",3.4,0.2,93,7
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,65+,Total,"2,067.98",2.8,0.7,351,8
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"1,853.02",2.5,3.6,"1,886",9
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",65+,Total,"1,685.41",2.3,36.1,"18,722",10
2,Newfoundland and Labrador,R03BA,Glucocorticoids,65+,Total,"1,445.30",2.0,9.3,"4,833",11
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"1,382.03",1.9,4.7,"2,463",12
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,341.29",1.8,14.4,"7,481",13
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"1,180.88",1.6,5.9,"3,050",14
2,Newfoundland and Labrador,R03BB,Anticholinergics,65+,Total,"1,049.05",1.4,9.1,"4,735",15
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,952.21,1.3,2.8,"1,446",16
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,65+,Total,950.59,1.3,8.4,"4,368",17
2,Newfoundland and Labrador,C09CA,"Angiotensin II antagonists, plain",65+,Total,897.41,1.2,13.6,"7,076",18
2,Newfoundland and Labrador,N06AX,Other antidepressants,65+,Total,895.19,1.2,9.7,"5,057",19
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,65+,Total,814.78,1.1,0.6,296,20
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,801.52,1.1,0.5,259,21
2,Newfoundland and Labrador,A10BA,Biguanides,65+,Total,747.60,1.0,19.7,"10,220",22
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,65+,Total,729.34,1.0,12.5,"6,473",23
2,Newfoundland and Labrador,L02BB,Antiandrogens,65+,Total,712.45,1.0,0.4,216,24
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,65+,Total,703.02,1.0,18.1,"9,370",25
2,Newfoundland and Labrador,H03AA,Thyroid hormones,65+,Total,629.68,0.9,16.6,"8,625",26
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,65+,Total,613.39,0.8,0.1,46,27
2,Newfoundland and Labrador,A10BB,Sulfonylureas,65+,Total,598.00,0.8,11.8,"6,118",28
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,593.39,0.8,9.8,"5,063",29
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,65+,Total,591.34,0.8,0.0,20,30
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,587.66,0.8,20.9,"10,859",31
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,65+,Total,574.07,0.8,11.1,"5,746",32
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,65+,Total,570.15,0.8,5.6,"2,890",33
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",65+,Total,558.56,0.8,14.8,"7,662",34
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,65+,Total,557.60,0.8,3.5,"1,795",35
2,Newfoundland and Labrador,C01DA,Organic nitrates,65+,Total,549.53,0.8,8.0,"4,135",36
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,65+,Total,546.59,0.7,0.1,77,37
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,65+,Total,518.05,0.7,4.1,"2,144",38
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,491.53,0.7,3.9,"2,044",39
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,482.24,0.7,6.1,"3,143",40
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,65+,Total,464.42,0.6,1.3,682,41
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,65+,Total,455.05,0.6,3.5,"1,817",42
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,444.92,0.6,7.9,"4,110",43
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,65+,Total,431.93,0.6,7.5,"3,887",44
2,Newfoundland and Labrador,A12BA,Potassium,65+,Total,421.02,0.6,6.7,"3,475",45
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,65+,Total,400.33,0.5,0.9,487,46
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,65+,Total,373.72,0.5,0.0,18,47
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,363.25,0.5,10.3,"5,353",48
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",65+,Total,354.08,0.5,17.8,"9,257",49
2,Newfoundland and Labrador,H02AB,Glucocorticoids,65+,Total,333.93,0.5,18.0,"9,325",50
2,Newfoundland and Labrador,M05BA,Bisphosphonates,65+,Total,310.22,0.4,4.8,"2,515",51
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,65+,Total,300.18,0.4,3.5,"1,813",52
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,65+,Total,291.76,0.4,10.2,"5,302",53
2,Newfoundland and Labrador,C09DA,Angiotensin II antagonists and diuretics,65+,Total,287.93,0.4,4.6,"2,370",54
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,274.24,0.4,4.3,"2,227",55
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,65+,Total,271.38,0.4,7.1,"3,660",56
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,65+,Total,256.45,0.4,1.2,642,57
2,Newfoundland and Labrador,J01FA,Macrolides,65+,Total,248.00,0.3,12.6,"6,520",58
2,Newfoundland and Labrador,N06DA,Anticholinesterases,65+,Total,240.70,0.3,1.7,873,59
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,65+,Total,239.05,0.3,13.5,"7,033",60
2,Newfoundland and Labrador,N03AX,Other antiepileptics,65+,Total,237.50,0.3,1.6,837,61
2,Newfoundland and Labrador,R01AD,Corticosteroids,65+,Total,228.58,0.3,8.7,"4,532",62
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,223.47,0.3,0.7,367,63
2,Newfoundland and Labrador,N05AX,Other antipsychotics,65+,Total,216.56,0.3,1.4,728,64
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,65+,Total,202.62,0.3,0.9,491,65
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,65+,Total,200.78,0.3,4.2,"2,164",66
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,65+,Total,196.29,0.3,0.1,66,67
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,190.80,0.3,2.2,"1,163",68
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,65+,Total,187.50,0.3,2.7,"1,427",69
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,65+,Total,186.31,0.3,15.6,"8,123",70
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,65+,Total,185.87,0.3,0.8,397,71
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",65+,Total,185.32,0.3,7.7,"3,971",72
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,65+,Total,175.88,0.2,3.3,"1,725",73
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,65+,Total,175.75,0.2,5.9,"3,049",74
2,Newfoundland and Labrador,C10AB,Fibrates,65+,Total,165.15,0.2,2.6,"1,328",75
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",65+,Total,155.10,0.2,1.8,955,76
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,65+,Total,**, ** , ** ,*,77
2,Newfoundland and Labrador,A03FA,Propulsives,65+,Total,152.92,0.2,5.0,"2,587",78
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,65+,Total,143.51,0.2,3.5,"1,808",79
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,65+,Total,143.07,0.2,5.4,"2,806",80
2,Newfoundland and Labrador,C01AA,Digitalis glycosides,65+,Total,142.30,0.2,2.1,"1,110",81
2,Newfoundland and Labrador,M01AH,Coxibs,65+,Total,135.86,0.2,3.8,"1,952",82
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,65+,Total,133.09,0.2,8.5,"4,404",83
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,65+,Total,129.50,0.2,6.5,"3,385",84
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,65+,Total,128.35,0.2,5.4,"2,812",85
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,Total,126.28,0.2,8.1,"4,205",86
2,Newfoundland and Labrador,J01DC,Second-generation cephalosporins,65+,Total,125.20,0.2,5.6,"2,929",87
2,Newfoundland and Labrador,V03AC,Iron-chelating agents,65+,Total,119.17,0.2,0.0,6,88
2,Newfoundland and Labrador,L01BA,Folic acid analogues,65+,Total,117.91,0.2,1.2,627,89
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,112.84,0.2,2.1,"1,114",90
2,Newfoundland and Labrador,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,111.77,0.2,0.2,125,91
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,65+,Total,111.16,0.2,4.5,"2,343",92
2,Newfoundland and Labrador,D06BB,Antivirals,65+,Total,110.48,0.2,1.1,581,93
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,108.99,0.1,0.6,293,94
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",65+,Total,108.67,0.1,2.6,"1,340",95
2,Newfoundland and Labrador,B01AB,Heparin group,65+,Total,107.76,0.1,0.4,193,96
2,Newfoundland and Labrador,C03BA,"Sulfonamides, plain",65+,Total,106.56,0.1,3.5,"1,842",97
2,Newfoundland and Labrador,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,106.50,0.1,0.1,31,98
2,Newfoundland and Labrador,S01EC,Carbonic anhydrase inhibitors,65+,Total,104.78,0.1,0.9,486,99
2,Newfoundland and Labrador,B01AE,Direct thrombin inhibitors,65+,Total,104.57,0.1,0.2,98,100
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,65+,M,"2,021.59",6.3,0.4,94,1
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,668.69",5.2,60.8,"13,225",2
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,65+,M,"1,388.74",4.3,0.2,51,3
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",65+,M,"1,294.38",4.0,37.6,"8,192",4
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"1,226.29",3.8,0.3,70,5
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,65+,M,"1,185.59",3.7,21.5,"4,683",6
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,65+,M,"1,011.00",3.2,41.3,"8,988",7
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,885.44,2.8,4.1,901,8
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,65+,M,831.42,2.6,0.6,141,9
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,65+,M,801.52,2.5,1.2,259,10
2,Newfoundland and Labrador,L02BB,Antiandrogens,65+,M,712.45,2.2,1.0,216,11
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",65+,M,701.00,2.2,38.3,"8,346",12
2,Newfoundland and Labrador,R03BA,Glucocorticoids,65+,M,627.84,2.0,8.9,"1,927",13
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,613.11,1.9,5.0,"1,084",14
2,Newfoundland and Labrador,L02BX,Other hormone antagonists and related agents,65+,M,591.34,1.8,0.1,20,15
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,65+,M,520.37,1.6,21.0,"4,562",16
2,Newfoundland and Labrador,R03BB,Anticholinergics,65+,M,520.33,1.6,10.7,"2,319",17
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,506.52,1.6,6.1,"1,327",18
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,65+,M,421.52,1.3,8.8,"1,913",19
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,65+,M,387.44,1.2,0.6,138,20
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,372.65,1.2,2.6,571,21
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,65+,M,372.14,1.2,10.0,"2,171",22
2,Newfoundland and Labrador,A10BA,Biguanides,65+,M,333.14,1.0,21.2,"4,621",23
2,Newfoundland and Labrador,C09CA,"Angiotensin II antagonists, plain",65+,M,292.63,0.9,11.3,"2,459",24
2,Newfoundland and Labrador,N06AX,Other antidepressants,65+,M,278.55,0.9,7.6,"1,653",25
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,65+,M,276.22,0.9,11.1,"2,423",26
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,65+,M,275.23,0.9,5.7,"1,236",27
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,260.89,0.8,21.0,"4,566",28
2,Newfoundland and Labrador,A10BB,Sulfonylureas,65+,M,250.38,0.8,12.2,"2,658",29
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,247.07,0.8,7.4,"1,613",30
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,65+,M,240.78,0.8,0.1,15,31
2,Newfoundland and Labrador,C01DA,Organic nitrates,65+,M,240.47,0.8,9.5,"2,062",32
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,229.90,0.7,3.8,826,33
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,65+,M,216.37,0.7,3.3,713,34
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,65+,M,213.23,0.7,0.1,25,35
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,65+,M,210.72,0.7,9.2,"2,013",36
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,65+,M,208.13,0.7,13.0,"2,835",37
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,65+,M,202.63,0.6,9.8,"2,123",38
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",65+,M,202.27,0.6,14.1,"3,061",39
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,65+,M,197.75,0.6,3.8,823,40
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,65+,M,191.76,0.6,1.3,288,41
2,Newfoundland and Labrador,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,190.56,0.6,5.3,"1,160",42
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,65+,M,182.01,0.6,1.0,213,43
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,172.72,0.5,11.0,"2,389",44
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,65+,M,**, ** , ** ,**,45
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,65+,M,161.42,0.5,3.1,674,46
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,65+,M,154.80,0.5,9.8,"2,127",47
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,65+,M,140.20,0.4,1.5,322,48
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,65+,M,138.48,0.4,11.1,"2,426",49
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,65+,M,**, ** , ** ,*,50
2,Newfoundland and Labrador,H03AA,Thyroid hormones,65+,M,131.71,0.4,8.6,"1,876",51
2,Newfoundland and Labrador,H02AB,Glucocorticoids,65+,M,130.44,0.4,17.8,"3,878",52
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,126.41,0.4,6.0,"1,299",53
2,Newfoundland and Labrador,A12BA,Potassium,65+,M,122.97,0.4,4.9,"1,066",54
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",65+,M,115.79,0.4,15.0,"3,267",55
2,Newfoundland and Labrador,N05AX,Other antipsychotics,65+,M,100.68,0.3,1.4,310,56
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,65+,M,100.32,0.3,11.5,"2,507",57
2,Newfoundland and Labrador,M05BX,Other drugs affecting bone structure and mineralization,65+,M,99.98,0.3,0.1,22,58
2,Newfoundland and Labrador,J01FA,Macrolides,65+,M,99.32,0.3,11.6,"2,536",59
2,Newfoundland and Labrador,N03AX,Other antiepileptics,65+,M,96.21,0.3,1.6,339,60
2,Newfoundland and Labrador,C09DA,Angiotensin II antagonists and diuretics,65+,M,93.89,0.3,3.8,821,61
2,Newfoundland and Labrador,R01AD,Corticosteroids,65+,M,91.50,0.3,7.7,"1,667",62
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,65+,M,85.64,0.3,0.7,154,63
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,65+,M,85.32,0.3,3.1,668,64
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",65+,M,83.04,0.3,7.7,"1,673",65
2,Newfoundland and Labrador,N06DA,Anticholinesterases,65+,M,81.95,0.3,1.4,308,66
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,65+,M,71.38,0.2,14.0,"3,042",67
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,65+,M,71.38,0.2,3.4,743,68
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",65+,M,71.24,0.2,0.6,141,69
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,65+,M,67.24,0.2,4.1,895,70
2,Newfoundland and Labrador,C10AB,Fibrates,65+,M,64.26,0.2,2.5,536,71
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,65+,M,64.06,0.2,3.0,660,72
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,65+,M,63.17,0.2,9.1,"1,975",73
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,65+,M,61.02,0.2,5.4,"1,176",74
2,Newfoundland and Labrador,C01AA,Digitalis glycosides,65+,M,58.29,0.2,2.3,505,75
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,65+,M,57.01,0.2,1.9,416,76
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,65+,M,54.68,0.2,5.3,"1,163",77
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,M,54.63,0.2,8.4,"1,819",78
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",65+,M,54.25,0.2,1.6,338,79
2,Newfoundland and Labrador,C01BD,"Antiarrhythmics, class III",65+,M,54.17,0.2,1.5,317,80
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,65+,M,53.54,0.2,4.5,984,81
2,Newfoundland and Labrador,B01AB,Heparin group,65+,M,53.09,0.2,0.4,97,82
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",65+,M,53.06,0.2,2.5,552,83
2,Newfoundland and Labrador,J01DC,Second-generation cephalosporins,65+,M,51.33,0.2,5.4,"1,183",84
2,Newfoundland and Labrador,S01EC,Carbonic anhydrase inhibitors,65+,M,50.66,0.2,1.0,228,85
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,49.99,0.2,0.0,7,86
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,65+,M,49.96,0.2,0.7,160,87
2,Newfoundland and Labrador,A03FA,Propulsives,65+,M,49.79,0.2,4.4,954,88
2,Newfoundland and Labrador,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,**,**,**,*,89
2,Newfoundland and Labrador,M01AH,Coxibs,65+,M,49.12,0.2,3.4,732,90
2,Newfoundland and Labrador,C04AD,Purine derivatives,65+,M,48.55,0.2,0.6,126,91
2,Newfoundland and Labrador,B01AE,Direct thrombin inhibitors,65+,M,47.50,0.1,0.2,41,92
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,65+,M,47.25,0.1,1.4,306,93
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,65+,M,46.75,0.1,4.4,961,94
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,45.98,0.1,0.7,142,95
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,44.68,0.1,1.8,392,96
2,Newfoundland and Labrador,M04AC,Preparations with no effect on uric acid metabolism,65+,M,44.58,0.1,3.8,827,97
2,Newfoundland and Labrador,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,43.14,0.1,0.2,53,98
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,65+,M,39.44,0.1,0.9,203,99
2,Newfoundland and Labrador,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,38.51,0.1,0.5,113,100
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,65+,F,"2,050.81",5.0,53.3,"16,055",1
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,65+,F,"1,777.28",4.3,0.3,104,2
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,65+,F,"1,712.75",4.2,22.4,"6,745",3
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,65+,F,"1,654.64",4.0,46.0,"13,855",4
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"1,610.35",3.9,0.4,106,5
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",65+,F,"1,544.38",3.8,30.8,"9,280",6
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,65+,F,"1,236.57",3.0,0.7,210,7
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,65+,F,"1,077.24",2.6,0.1,42,8
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",65+,F,983.88,2.4,34.4,"10,369",9
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,65+,F,968.94,2.4,17.6,"5,308",10
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,967.57,2.4,3.3,985,11
2,Newfoundland and Labrador,R03BA,Glucocorticoids,65+,F,817.22,2.0,9.6,"2,904",12
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,768.80,1.9,4.6,"1,378",13
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,673.98,1.6,5.7,"1,722",14
2,Newfoundland and Labrador,N06AX,Other antidepressants,65+,F,616.45,1.5,11.3,"3,402",15
2,Newfoundland and Labrador,C09CA,"Angiotensin II antagonists, plain",65+,F,604.35,1.5,15.3,"4,614",16
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,579.56,1.4,2.9,875,17
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,65+,F,528.79,1.3,8.1,"2,453",18
2,Newfoundland and Labrador,R03BB,Anticholinergics,65+,F,528.45,1.3,8.0,"2,415",19
2,Newfoundland and Labrador,H03AA,Thyroid hormones,65+,F,497.71,1.2,22.4,"6,747",20
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,65+,F,494.51,1.2,21.7,"6,529",21
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,65+,F,452.90,1.1,13.4,"4,047",22
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,65+,F,427.34,1.0,0.5,158,23
2,Newfoundland and Labrador,A10BA,Biguanides,65+,F,413.98,1.0,18.6,"5,594",24
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,65+,F,372.62,0.9,0.1,31,25
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,65+,F,371.01,0.9,12.0,"3,619",26
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",65+,F,356.29,0.9,15.3,"4,601",27
2,Newfoundland and Labrador,A10BB,Sulfonylureas,65+,F,347.62,0.8,11.5,"3,460",28
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,65+,F,341.23,0.8,3.6,"1,082",29
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,65+,F,333.36,0.8,0.2,52,30
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,326.72,0.8,20.9,"6,291",31
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,65+,F,320.13,0.8,4.4,"1,319",32
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,318.41,0.8,9.3,"2,810",33
2,Newfoundland and Labrador,C01DA,Organic nitrates,65+,F,309.02,0.8,6.9,"2,072",34
2,Newfoundland and Labrador,A12BA,Potassium,65+,F,298.04,0.7,8.0,"2,409",35
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,65+,F,294.91,0.7,5.5,"1,654",36
2,Newfoundland and Labrador,S01EE,Prostaglandin analogues,65+,F,293.63,0.7,3.8,"1,143",37
2,Newfoundland and Labrador,M05BA,Bisphosphonates,65+,F,283.99,0.7,7.6,"2,297",38
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,272.72,0.7,7.4,"2,225",39
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,65+,F,272.66,0.7,1.3,394,40
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,261.59,0.6,4.0,"1,217",41
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,65+,F,243.17,0.6,4.6,"1,397",42
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",65+,F,238.17,0.6,19.9,"5,986",43
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,235.13,0.6,5.1,"1,529",44
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,65+,F,220.91,0.5,6.2,"1,871",45
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,65+,F,218.33,0.5,0.9,274,46
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,65+,F,**, ** , ** ,**,47
2,Newfoundland and Labrador,H02AB,Glucocorticoids,65+,F,203.47,0.5,18.1,"5,446",48
2,Newfoundland and Labrador,C09DA,Angiotensin II antagonists and diuretics,65+,F,193.74,0.5,5.1,"1,546",49
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,190.51,0.5,9.8,"2,961",50
2,Newfoundland and Labrador,L02BG,Aromatase inhibitors,65+,F,184.96,0.5,1.3,395,51
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,65+,F,162.62,0.4,0.2,49,52
2,Newfoundland and Labrador,N06DA,Anticholinesterases,65+,F,158.75,0.4,1.9,565,53
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,65+,F,153.26,0.4,9.5,"2,874",54
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",65+,F,152.23,0.4,0.8,226,55
2,Newfoundland and Labrador,J01FA,Macrolides,65+,F,148.68,0.4,13.2,"3,984",56
2,Newfoundland and Labrador,N03AX,Other antiepileptics,65+,F,141.30,0.3,1.7,498,57
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,65+,F,138.68,0.3,15.0,"4,523",58
2,Newfoundland and Labrador,R01AD,Corticosteroids,65+,F,137.09,0.3,9.5,"2,865",59
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,65+,F,129.40,0.3,4.7,"1,421",60
2,Newfoundland and Labrador,N07CA,Antivertigo preparations,65+,F,122.17,0.3,6.9,"2,063",61
2,Newfoundland and Labrador,C10AC,Bile acid sequestrants,65+,F,116.98,0.3,1.1,337,62
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,65+,F,116.49,0.3,5.1,"1,532",63
2,Newfoundland and Labrador,N04BA,Dopa and dopa derivatives,65+,F,116.25,0.3,1.1,320,64
2,Newfoundland and Labrador,N05AX,Other antipsychotics,65+,F,115.48,0.3,1.4,417,65
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,65+,F,114.86,0.3,16.9,"5,077",66
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,65+,F,111.56,0.3,3.5,"1,062",67
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,65+,F,110.63,0.3,9.8,"2,943",68
2,Newfoundland and Labrador,V03AC,Iron-chelating agents,65+,F,**, ** , ** ,*,69
2,Newfoundland and Labrador,A03FA,Propulsives,65+,F,103.11,0.3,5.4,"1,632",70
2,Newfoundland and Labrador,C10AX,Other lipid-modifying agents,65+,F,102.18,0.2,2.5,759,71
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",65+,F,101.99,0.2,7.6,"2,296",72
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",65+,F,100.85,0.2,2.0,617,73
2,Newfoundland and Labrador,C10AB,Fibrates,65+,F,100.72,0.2,2.6,791,74
2,Newfoundland and Labrador,M05BB,"Bisphosphonates, combinations",65+,F,86.94,0.2,2.7,828,75
2,Newfoundland and Labrador,M01AH,Coxibs,65+,F,86.65,0.2,4.0,"1,219",76
2,Newfoundland and Labrador,D06BB,Antivirals,65+,F,84.35,0.2,1.4,417,77
2,Newfoundland and Labrador,C01AA,Digitalis glycosides,65+,F,83.91,0.2,2.0,604,78
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,65+,F,81.98,0.2,5.4,"1,627",79
2,Newfoundland and Labrador,L01BA,Folic acid analogues,65+,F,81.70,0.2,1.4,430,80
2,Newfoundland and Labrador,C03DA,Aldosterone antagonists,65+,F,76.20,0.2,3.0,912,81
2,Newfoundland and Labrador,A05AA,Bile acids and derivatives,65+,F,76.02,0.2,0.3,78,82
2,Newfoundland and Labrador,A03AX,Other drugs for functional gastrointestinal disorders,65+,F,75.40,0.2,1.1,330,83
2,Newfoundland and Labrador,J01DC,Second-generation cephalosporins,65+,F,73.87,0.2,5.8,"1,746",84
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,65+,F,73.65,0.2,5.5,"1,647",85
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,65+,F,73.01,0.2,1.7,501,86
2,Newfoundland and Labrador,C03BA,"Sulfonamides, plain",65+,F,72.39,0.2,3.9,"1,188",87
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,F,71.62,0.2,7.9,"2,385",88
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,65+,F,69.86,0.2,8.1,"2,427",89
2,Newfoundland and Labrador,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,68.64,0.2,0.2,72,90
2,Newfoundland and Labrador,C05AA,Corticosteroids,65+,F,68.45,0.2,3.7,"1,123",91
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,68.16,0.2,2.4,722,92
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,65+,F,64.42,0.2,4.6,"1,382",93
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,63.02,0.2,0.5,151,94
2,Newfoundland and Labrador,S01BA,"Corticosteroids, plain",65+,F,58.92,0.1,4.1,"1,248",95
2,Newfoundland and Labrador,C03EA,Low-ceiling diuretics and potassium-sparing agents,65+,F,57.77,0.1,3.5,"1,066",96
2,Newfoundland and Labrador,B01AE,Direct thrombin inhibitors,65+,F,57.07,0.1,0.2,57,97
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",65+,F,55.61,0.1,2.6,788,98
2,Newfoundland and Labrador,B01AB,Heparin group,65+,F,54.68,0.1,0.3,96,99
2,Newfoundland and Labrador,S01EC,Carbonic anhydrase inhibitors,65+,F,54.12,0.1,0.9,258,100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"8,707.45",12.2,1.1,531,1
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,<65,Total,"5,258.63",7.4,3.4,"1,712",2
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"1,934.68",2.7,18.4,"9,144",3
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"1,880.78",2.6,6.3,"3,115",4
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,<65,Total,"1,707.72",2.4,0.3,132,5
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,<65,Total,"1,648.32",2.3,26.3,"13,059",6
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,<65,Total,"1,571.07",2.2,5.2,"2,575",7
2,Newfoundland and Labrador,N06AX,Other antidepressants,<65,Total,"1,559.12",2.2,13.9,"6,896",8
2,Newfoundland and Labrador,N05AX,Other antipsychotics,<65,Total,"1,553.58",2.2,3.4,"1,712",9
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,<65,Total,"1,463.23",2.0,0.4,199,10
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,389.85",1.9,18.7,"9,321",11
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,<65,Total,**, ** , ** ,**,12
2,Newfoundland and Labrador,R03BA,Glucocorticoids,<65,Total,"1,344.55",1.9,10.8,"5,365",13
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,<65,Total,"1,285.73",1.8,0.1,52,14
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,179.70",1.6,3.8,"1,892",15
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,<65,Total,"1,178.35",1.6,5.6,"2,761",16
2,Newfoundland and Labrador,N07XX,Other nervous system drugs,<65,Total,"1,166.22",1.6,0.1,74,17
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",<65,Total,"1,098.11",1.5,11.6,"5,784",18
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,<65,Total,964.37,1.3,10.6,"5,267",19
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,874.40,1.2,11.9,"5,897",20
2,Newfoundland and Labrador,L03AB,Interferons,<65,Total,850.03,1.2,0.1,49,21
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,<65,Total,840.51,1.2,16.0,"7,977",22
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,792.26,1.1,3.5,"1,765",23
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,737.19,1.0,1.6,774,24
2,Newfoundland and Labrador,N03AX,Other antiepileptics,<65,Total,694.07,1.0,2.7,"1,360",25
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,<65,Total,682.87,1.0,0.2,110,26
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,<65,Total,651.23,0.9,5.1,"2,532",27
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,644.57,0.9,21.1,"10,489",28
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,635.84,0.9,0.2,87,29
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,<65,Total,611.94,0.9,9.5,"4,738",30
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,<65,Total,592.64,0.8,7.2,"3,597",31
2,Newfoundland and Labrador,A16AB,Enzymes,<65,Total,**,**,**,*,32
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,<65,Total,524.87,0.7,17.0,"8,446",33
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,500.33,0.7,7.0,"3,492",34
2,Newfoundland and Labrador,L03AX,Other immunostimulants,<65,Total,478.49,0.7,0.1,47,35
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",<65,Total,465.37,0.7,8.5,"4,219",36
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,<65,Total,462.84,0.6,9.2,"4,561",37
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,<65,Total,462.80,0.6,2.4,"1,194",38
2,Newfoundland and Labrador,A10BA,Biguanides,<65,Total,436.09,0.6,8.7,"4,335",39
2,Newfoundland and Labrador,R03BB,Anticholinergics,<65,Total,416.53,0.6,3.6,"1,790",40
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,<65,Total,407.02,0.6,0.3,148,41
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,<65,Total,400.21,0.6,0.1,62,42
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,<65,Total,391.21,0.5,3.1,"1,564",43
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,<65,Total,372.85,0.5,0.0,22,44
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,<65,Total,372.00,0.5,25.7,"12,770",45
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,<65,Total,356.78,0.5,0.0,17,46
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,<65,Total,349.00,0.5,11.7,"5,832",47
2,Newfoundland and Labrador,H03AA,Thyroid hormones,<65,Total,330.03,0.5,6.4,"3,201",48
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,<65,Total,310.75,0.4,0.1,55,49
2,Newfoundland and Labrador,J05AE,Protease inhibitors,<65,Total,303.66,0.4,0.1,38,50
2,Newfoundland and Labrador,R07AX,Other respiratory system products,<65,Total,**, ** , ** ,*,51
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,<65,Total,274.34,0.4,1.6,791,52
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,<65,Total,272.65,0.4,0.7,336,53
2,Newfoundland and Labrador,R05CB,Mucolytics,<65,Total,270.31,0.4,0.1,42,54
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,266.96,0.4,3.2,"1,591",55
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,251.87,0.4,4.4,"2,192",56
2,Newfoundland and Labrador,J01FA,Macrolides,<65,Total,250.21,0.3,13.5,"6,714",57
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,<65,Total,247.13,0.3,3.1,"1,551",58
2,Newfoundland and Labrador,A10BB,Sulfonylureas,<65,Total,242.02,0.3,4.2,"2,072",59
2,Newfoundland and Labrador,J05AX,Other antivirals,<65,Total,237.32,0.3,0.0,24,60
2,Newfoundland and Labrador,R01AD,Corticosteroids,<65,Total,234.33,0.3,8.6,"4,272",61
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,228.65,0.3,0.7,326,62
2,Newfoundland and Labrador,C09CA,"Angiotensin II antagonists, plain",<65,Total,228.38,0.3,3.4,"1,679",63
2,Newfoundland and Labrador,A09AA,Enzyme preparations,<65,Total,224.66,0.3,0.2,97,64
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,<65,Total,211.01,0.3,2.3,"1,156",65
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,209.62,0.3,0.6,306,66
2,Newfoundland and Labrador,H02AB,Glucocorticoids,<65,Total,188.54,0.3,10.0,"4,974",67
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,<65,Total,181.45,0.3,2.0,"1,005",68
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,<65,Total,180.25,0.3,8.3,"4,141",69
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",<65,Total,158.18,0.2,5.5,"2,748",70
2,Newfoundland and Labrador,A04AD,Other antiemetics,<65,Total,155.32,0.2,0.5,268,71
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",<65,Total,152.78,0.2,6.1,"3,028",72
2,Newfoundland and Labrador,G03AC,Progestogens,<65,Total,145.94,0.2,2.7,"1,339",73
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",<65,Total,145.32,0.2,3.4,"1,680",74
2,Newfoundland and Labrador,N05AF,Thioxanthene derivatives,<65,Total,142.14,0.2,0.5,225,75
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,<65,Total,140.01,0.2,1.3,634,76
2,Newfoundland and Labrador,D06BB,Antivirals,<65,Total,139.71,0.2,1.5,740,77
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,139.55,0.2,0.1,64,78
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,139.31,0.2,1.9,944,79
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,<65,Total,134.99,0.2,7.3,"3,618",80
2,Newfoundland and Labrador,G02BA,Intrauterine contraceptives,<65,Total,132.66,0.2,0.8,382,81
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,125.57,0.2,7.4,"3,677",82
2,Newfoundland and Labrador,N05BE,Azaspirodecanedione derivatives,<65,Total,123.99,0.2,0.8,422,83
2,Newfoundland and Labrador,N02AB,Phenylpiperidine derivatives,<65,Total,121.47,0.2,1.1,527,84
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,<65,Total,118.49,0.2,0.7,346,85
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,115.77,0.2,1.2,609,86
2,Newfoundland and Labrador,V03AC,Iron-chelating agents,<65,Total,112.76,0.2,0.0,6,87
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,111.55,0.2,2.2,"1,097",88
2,Newfoundland and Labrador,N07BA,Drugs used in nicotine dependence,<65,Total,110.77,0.2,1.4,672,89
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",<65,Total,107.95,0.2,1.3,642,90
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,107.29,0.2,0.3,128,91
2,Newfoundland and Labrador,A03FA,Propulsives,<65,Total,106.29,0.1,3.1,"1,530",92
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,<65,Total,105.47,0.1,1.3,660,93
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,<65,Total,97.66,0.1,4.1,"2,048",94
2,Newfoundland and Labrador,C10AB,Fibrates,<65,Total,97.28,0.1,1.2,613,95
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,<65,Total,95.36,0.1,1.7,828,96
2,Newfoundland and Labrador,A12BA,Potassium,<65,Total,93.57,0.1,1.4,701,97
2,Newfoundland and Labrador,A07AA,Antibiotics,<65,Total,91.96,0.1,1.3,659,98
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,<65,Total,91.65,0.1,0.0,13,99
2,Newfoundland and Labrador,N05AN,Lithium,<65,Total,89.64,0.1,0.8,373,100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"3,967.88",11.9,1.1,227,1
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,<65,M,"3,176.60",9.5,4.9,"1,051",2
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"1,243.67",3.7,7.6,"1,618",3
2,Newfoundland and Labrador,N05AX,Other antipsychotics,<65,M,"1,046.26",3.1,4.8,"1,027",4
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,<65,M,"1,003.05",3.0,0.2,33,5
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,<65,M,**, ** , ** ,**,6
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,<65,M,822.89,2.5,0.4,85,7
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,<65,M,820.39,2.5,0.3,59,8
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,<65,M,756.52,2.3,8.2,"1,753",9
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,<65,M,739.80,2.2,5.4,"1,151",10
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,<65,M,702.74,2.1,14.6,"3,110",11
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,<65,M,678.38,2.0,24.2,"5,140",12
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,<65,M,676.62,2.0,20.6,"4,378",13
2,Newfoundland and Labrador,N06AX,Other antidepressants,<65,M,563.96,1.7,11.7,"2,496",14
2,Newfoundland and Labrador,R03BA,Glucocorticoids,<65,M,540.54,1.6,9.9,"2,099",15
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,525.65,1.6,3.9,826,16
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",<65,M,523.62,1.6,13.1,"2,784",17
2,Newfoundland and Labrador,N07XX,Other nervous system drugs,<65,M,494.45,1.5,0.2,34,18
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,491.17,1.5,0.3,67,19
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,<65,M,474.99,1.4,10.7,"2,269",20
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,417.28,1.3,12.0,"2,541",21
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,<65,M,335.84,1.0,13.3,"2,817",22
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,<65,M,332.39,1.0,6.1,"1,288",23
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,326.60,1.0,3.5,745,24
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,291.38,0.9,1.4,295,25
2,Newfoundland and Labrador,N03AX,Other antiepileptics,<65,M,284.66,0.9,2.5,525,26
2,Newfoundland and Labrador,R07AX,Other respiratory system products,<65,M,**, ** , ** ,*,27
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,272.49,0.8,19.2,"4,092",28
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,<65,M,268.74,0.8,6.9,"1,473",29
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,<65,M,259.51,0.8,8.6,"1,829",30
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,<65,M,258.71,0.8,2.9,608,31
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",<65,M,237.15,0.7,9.7,"2,067",32
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,<65,M,230.36,0.7,0.1,13,33
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,<65,M,211.65,0.6,15.2,"3,221",34
2,Newfoundland and Labrador,J05AE,Protease inhibitors,<65,M,207.35,0.6,0.1,28,35
2,Newfoundland and Labrador,R03BB,Anticholinergics,<65,M,205.55,0.6,3.8,807,36
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,<65,M,205.24,0.6,8.2,"1,741",37
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,<65,M,201.82,0.6,0.2,32,38
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,<65,M,195.55,0.6,0.1,24,39
2,Newfoundland and Labrador,A10BA,Biguanides,<65,M,190.71,0.6,8.5,"1,812",40
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,190.51,0.6,5.7,"1,219",41
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,<65,M,188.99,0.6,3.3,701,42
2,Newfoundland and Labrador,R05CB,Mucolytics,<65,M,168.40,0.5,0.1,23,43
2,Newfoundland and Labrador,L03AB,Interferons,<65,M,152.43,0.5,0.0,9,44
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,<65,M,152.32,0.5,23.6,"5,019",45
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,<65,M,152.20,0.5,0.3,68,46
2,Newfoundland and Labrador,A09AA,Enzyme preparations,<65,M,143.55,0.4,0.2,53,47
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,<65,M,137.48,0.4,1.8,385,48
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,<65,M,135.58,0.4,0.7,144,49
2,Newfoundland and Labrador,J05AX,Other antivirals,<65,M,122.32,0.4,0.1,14,50
2,Newfoundland and Labrador,L03AX,Other immunostimulants,<65,M,114.64,0.3,0.1,12,51
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,<65,M,113.99,0.3,9.1,"1,938",52
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,<65,M,107.81,0.3,3.1,666,53
2,Newfoundland and Labrador,A10BB,Sulfonylureas,<65,M,105.87,0.3,4.1,873,54
2,Newfoundland and Labrador,N05AF,Thioxanthene derivatives,<65,M,102.81,0.3,0.7,152,55
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",<65,M,97.63,0.3,0.7,143,56
2,Newfoundland and Labrador,C09CA,"Angiotensin II antagonists, plain",<65,M,92.98,0.3,3.0,647,57
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,92.88,0.3,0.6,135,58
2,Newfoundland and Labrador,J01FA,Macrolides,<65,M,88.75,0.3,10.6,"2,248",59
2,Newfoundland and Labrador,R01AD,Corticosteroids,<65,M,87.62,0.3,6.6,"1,400",60
2,Newfoundland and Labrador,G04CA,Alpha-adrenoreceptor antagonists,<65,M,85.10,0.3,3.1,666,61
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,<65,M,84.21,0.3,1.8,391,62
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,<65,M,82.88,0.2,8.2,"1,747",63
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,<65,M,**, ** , ** ,*,64
2,Newfoundland and Labrador,H02AB,Glucocorticoids,<65,M,78.52,0.2,9.0,"1,910",65
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,<65,M,78.20,0.2,0.1,16,66
2,Newfoundland and Labrador,H03AA,Thyroid hormones,<65,M,73.59,0.2,3.2,685,67
2,Newfoundland and Labrador,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,69.63,0.2,0.4,75,68
2,Newfoundland and Labrador,M04AA,Preparations inhibiting uric acid production,<65,M,61.53,0.2,3.0,644,69
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",<65,M,60.05,0.2,5.1,"1,080",70
2,Newfoundland and Labrador,N02AB,Phenylpiperidine derivatives,<65,M,60.01,0.2,0.9,182,71
2,Newfoundland and Labrador,B01AA,Vitamin K antagonists,<65,M,59.93,0.2,1.7,365,72
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",<65,M,59.91,0.2,3.0,644,73
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,59.50,0.2,1.7,354,74
2,Newfoundland and Labrador,N05AD,Butyrophenone derivatives,<65,M,58.48,0.2,0.5,111,75
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,<65,M,53.97,0.2,0.7,153,76
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",<65,M,53.78,0.2,4.2,884,77
2,Newfoundland and Labrador,N05BE,Azaspirodecanedione derivatives,<65,M,53.75,0.2,0.8,161,78
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,<65,M,53.70,0.2,5.2,"1,103",79
2,Newfoundland and Labrador,A04AD,Other antiemetics,<65,M,51.79,0.2,0.5,99,80
2,Newfoundland and Labrador,C10AB,Fibrates,<65,M,51.73,0.2,1.4,308,81
2,Newfoundland and Labrador,V03AC,Iron-chelating agents,<65,M,**, ** , ** ,*,82
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,<65,M,50.75,0.2,1.7,352,83
2,Newfoundland and Labrador,N03AA,Barbiturates and derivatives,<65,M,50.41,0.2,0.7,142,84
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,50.29,0.2,6.5,"1,390",85
2,Newfoundland and Labrador,N05AA,Phenothiazines with aliphatic side-chain,<65,M,48.85,0.1,0.7,151,86
2,Newfoundland and Labrador,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,47.66,0.1,0.1,11,87
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",<65,M,47.01,0.1,1.2,249,88
2,Newfoundland and Labrador,N05AN,Lithium,<65,M,46.95,0.1,0.8,179,89
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,<65,M,46.51,0.1,0.1,19,90
2,Newfoundland and Labrador,N07BA,Drugs used in nicotine dependence,<65,M,46.14,0.1,1.3,283,91
2,Newfoundland and Labrador,J01GB,Other aminoglycosides,<65,M,44.51,0.1,0.1,12,92
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,<65,M,42.83,0.1,1.4,293,93
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,<65,M,41.38,0.1,3.7,797,94
2,Newfoundland and Labrador,N04AC,Ethers of tropine or tropine derivatives,<65,M,40.00,0.1,1.0,208,95
2,Newfoundland and Labrador,S01ED,Beta-blocking agents,<65,M,38.89,0.1,0.7,143,96
2,Newfoundland and Labrador,A03FA,Propulsives,<65,M,38.02,0.1,2.2,478,97
2,Newfoundland and Labrador,D07CA,"Corticosteroids, weak, combinations with antibiotics",<65,M,35.07,0.1,2.0,432,98
2,Newfoundland and Labrador,L02BB,Antiandrogens,<65,M,34.87,0.1,0.1,11,99
2,Newfoundland and Labrador,B01AF,Direct factor Xa inhibitors,<65,M,34.48,0.1,0.3,63,100
2,Newfoundland and Labrador,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"4,739.57",12.4,1.1,304,1
2,Newfoundland and Labrador,N07BC,Drugs used in opioid dependence,<65,F,"2,082.03",5.4,2.3,661,2
2,Newfoundland and Labrador,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,231.94",3.2,21.2,"6,034",3
2,Newfoundland and Labrador,N06AX,Other antidepressants,<65,F,995.16,2.6,15.5,"4,400",4
2,Newfoundland and Labrador,A02BC,Proton pump inhibitors,<65,F,969.94,2.5,27.8,"7,919",5
2,Newfoundland and Labrador,L04AC,Interleukin inhibitors,<65,F,887.33,2.3,0.3,73,6
2,Newfoundland and Labrador,N02AA,Natural opium alkaloids,<65,F,831.27,2.2,5.0,"1,424",7
2,Newfoundland and Labrador,R03BA,Glucocorticoids,<65,F,804.01,2.1,11.5,"3,266",8
2,Newfoundland and Labrador,C10AA,HMG-CoA reductase inhibitors,<65,F,713.23,1.9,17.4,"4,943",9
2,Newfoundland and Labrador,L03AB,Interferons,<65,F,697.60,1.8,0.1,40,10
2,Newfoundland and Labrador,N07XX,Other nervous system drugs,<65,F,671.77,1.8,0.1,40,11
2,Newfoundland and Labrador,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,654.06,1.7,3.7,"1,066",12
2,Newfoundland and Labrador,L04AX,Other immunosuppressants,<65,F,640.34,1.7,0.4,114,13
2,Newfoundland and Labrador,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,637.11,1.7,5.3,"1,497",14
2,Newfoundland and Labrador,C09AA,"ACE inhibitors, plain",<65,F,574.50,1.5,10.5,"3,000",15
2,Newfoundland and Labrador,A16AB,Enzymes,<65,F,**,**,**,*,16
2,Newfoundland and Labrador,N05AX,Other antipsychotics,<65,F,507.32,1.3,2.4,685,17
2,Newfoundland and Labrador,N05BA,Benzodiazepine derivatives,<65,F,504.67,1.3,18.1,"5,160",18
2,Newfoundland and Labrador,N05CF,Benzodiazepine-related drugs,<65,F,489.38,1.3,10.5,"2,998",19
2,Newfoundland and Labrador,L04AA,Selective immunosuppressants,<65,F,487.32,1.3,0.3,86,20
2,Newfoundland and Labrador,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,465.66,1.2,3.6,"1,020",21
2,Newfoundland and Labrador,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,457.12,1.2,11.8,"3,356",22
2,Newfoundland and Labrador,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,445.81,1.2,1.7,479,23
2,Newfoundland and Labrador,N06BA,Centrally acting sympathomimetics,<65,F,421.83,1.1,3.5,"1,008",24
2,Newfoundland and Labrador,N03AX,Other antiepileptics,<65,F,409.41,1.1,2.9,835,25
2,Newfoundland and Labrador,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,372.08,1.0,22.5,"6,397",26
2,Newfoundland and Labrador,L03AX,Other immunostimulants,<65,F,363.85,1.0,0.1,35,27
2,Newfoundland and Labrador,J05AP,Antivirals for treatment of HCV infections,<65,F,**, ** , ** ,**,28
2,Newfoundland and Labrador,A02BA,H2-receptor antagonists,<65,F,352.43,0.9,10.2,"2,909",29
2,Newfoundland and Labrador,N03AE,Benzodiazepine derivatives,<65,F,323.90,0.8,7.5,"2,124",30
2,Newfoundland and Labrador,C08CA,Dihydropyridine derivatives,<65,F,318.83,0.8,4.4,"1,244",31
2,Newfoundland and Labrador,M01AB,Acetic acid derivatives and related substances,<65,F,313.22,0.8,18.4,"5,225",32
2,Newfoundland and Labrador,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,309.82,0.8,8.0,"2,273",33
2,Newfoundland and Labrador,L01XE,Protein kinase inhibitors,<65,F,282.68,0.7,0.1,19,34
2,Newfoundland and Labrador,H01CB,Somatostatin and analogues,<65,F,**, ** , ** ,**,35
2,Newfoundland and Labrador,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,266.90,0.7,5.6,"1,590",36
2,Newfoundland and Labrador,M03BX,Other centrally acting agents,<65,F,257.61,0.7,9.9,"2,820",37
2,Newfoundland and Labrador,H03AA,Thyroid hormones,<65,F,256.44,0.7,8.8,"2,516",38
2,Newfoundland and Labrador,B03XA,Other antianemic preparations,<65,F,254.83,0.7,0.3,80,39
2,Newfoundland and Labrador,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,251.87,0.7,7.7,"2,192",40
2,Newfoundland and Labrador,A10BA,Biguanides,<65,F,245.38,0.6,8.9,"2,523",41
2,Newfoundland and Labrador,M01AE,Propionic acid derivatives,<65,F,235.01,0.6,13.7,"3,894",42
2,Newfoundland and Labrador,L03AA,Colony-stimulating factors,<65,F,232.55,0.6,0.1,39,43
2,Newfoundland and Labrador,C07AB,"Beta-blocking agents, selective",<65,F,228.22,0.6,7.6,"2,152",44
2,Newfoundland and Labrador,J01CA,Penicillins with extended spectrum,<65,F,219.69,0.6,27.2,"7,751",45
2,Newfoundland and Labrador,R03BB,Anticholinergics,<65,F,210.98,0.6,3.5,983,46
2,Newfoundland and Labrador,N03AG,Fatty acid derivatives,<65,F,204.09,0.5,2.1,586,47
2,Newfoundland and Labrador,C09BA,ACE inhibitors and diuretics,<65,F,202.22,0.5,3.0,863,48
2,Newfoundland and Labrador,S01LA,Antineovascularization agents,<65,F,198.39,0.5,0.1,30,49
2,Newfoundland and Labrador,G04BD,Drugs for urinary frequency and incontinence,<65,F,168.17,0.4,3.0,863,50
2,Newfoundland and Labrador,J01FA,Macrolides,<65,F,161.46,0.4,15.7,"4,466",51
2,Newfoundland and Labrador,R01AD,Corticosteroids,<65,F,146.71,0.4,10.1,"2,872",52
2,Newfoundland and Labrador,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,144.67,0.4,0.1,20,53
2,Newfoundland and Labrador,H01AC,Somatropin and somatropin agonists,<65,F,142.50,0.4,0.0,9,54
2,Newfoundland and Labrador,G03AC,Progestogens,<65,F,139.66,0.4,4.7,"1,332",55
2,Newfoundland and Labrador,N05CD,Benzodiazepine derivatives,<65,F,139.32,0.4,3.1,885,56
2,Newfoundland and Labrador,A07EC,Aminosalicylic acid and similar agents,<65,F,137.06,0.4,0.7,192,57
2,Newfoundland and Labrador,N03AF,Carboxamide derivatives,<65,F,136.86,0.4,1.4,406,58
2,Newfoundland and Labrador,A10BB,Sulfonylureas,<65,F,136.15,0.4,4.2,"1,199",59
2,Newfoundland and Labrador,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,135.77,0.4,0.7,191,60
2,Newfoundland and Labrador,C09CA,"Angiotensin II antagonists, plain",<65,F,135.40,0.4,3.6,"1,032",61
2,Newfoundland and Labrador,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,134.99,0.4,3.3,928,62
2,Newfoundland and Labrador,G02BA,Intrauterine contraceptives,<65,F,132.66,0.3,1.3,382,63
2,Newfoundland and Labrador,C02AC,Imidazoline receptor agonists,<65,F,130.70,0.3,2.3,653,64
2,Newfoundland and Labrador,J05AX,Other antivirals,<65,F,114.99,0.3,0.0,10,65
2,Newfoundland and Labrador,A10AE,"Insulins and analogues for injection, long-acting",<65,F,111.99,0.3,0.6,163,66
2,Newfoundland and Labrador,H02AB,Glucocorticoids,<65,F,110.01,0.3,10.8,"3,064",67
2,Newfoundland and Labrador,D06BB,Antivirals,<65,F,106.31,0.3,2.0,576,68
2,Newfoundland and Labrador,C03AA,"Thiazides, plain",<65,F,104.40,0.3,6.5,"1,864",69
2,Newfoundland and Labrador,A04AD,Other antiemetics,<65,F,103.53,0.3,0.6,169,70
2,Newfoundland and Labrador,R05CB,Mucolytics,<65,F,101.91,0.3,0.1,19,71
2,Newfoundland and Labrador,J01DB,First-generation cephalosporins,<65,F,97.37,0.3,8.4,"2,394",72
2,Newfoundland and Labrador,J05AE,Protease inhibitors,<65,F,96.31,0.3,0.0,10,73
2,Newfoundland and Labrador,L02AE,Gonadotropin-releasing hormone analogues,<65,F,93.04,0.2,0.2,45,74
2,Newfoundland and Labrador,D07AC,"Corticosteroids, potent (group III)",<65,F,92.72,0.2,6.8,"1,948",75
2,Newfoundland and Labrador,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,*,76
2,Newfoundland and Labrador,C03CA,"Sulfonamides, plain",<65,F,85.41,0.2,3.6,"1,036",77
2,Newfoundland and Labrador,J01MA,Fluoroquinolones,<65,F,81.29,0.2,8.8,"2,515",78
2,Newfoundland and Labrador,A09AA,Enzyme preparations,<65,F,81.11,0.2,0.2,44,79
2,Newfoundland and Labrador,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,78.02,0.2,3.0,842,80
2,Newfoundland and Labrador,L01XC,Monoclonal antibodies,<65,F,77.98,0.2,0.0,12,81
2,Newfoundland and Labrador,A07AA,Antibiotics,<65,F,75.98,0.2,1.6,446,82
2,Newfoundland and Labrador,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,75.27,0.2,8.0,"2,287",83
2,Newfoundland and Labrador,B01AB,Heparin group,<65,F,72.34,0.2,0.2,54,84
2,Newfoundland and Labrador,J02AC,Triazole derivatives,<65,F,72.11,0.2,7.7,"2,181",85
2,Newfoundland and Labrador,N05BE,Azaspirodecanedione derivatives,<65,F,70.24,0.2,0.9,261,86
2,Newfoundland and Labrador,A03FA,Propulsives,<65,F,68.26,0.2,3.7,"1,052",87
2,Newfoundland and Labrador,R06AA,Aminoalkyl ethers,<65,F,67.34,0.2,1.1,319,88
2,Newfoundland and Labrador,N07BA,Drugs used in nicotine dependence,<65,F,64.64,0.2,1.4,389,89
2,Newfoundland and Labrador,C08DB,Benzothiazepine derivatives,<65,F,64.52,0.2,0.7,193,90
2,Newfoundland and Labrador,A12BA,Potassium,<65,F,64.06,0.2,1.7,481,91
2,Newfoundland and Labrador,V03AC,Iron-chelating agents,<65,F,**, ** , ** ,*,92
2,Newfoundland and Labrador,N02AB,Phenylpiperidine derivatives,<65,F,61.46,0.2,1.2,345,93
2,Newfoundland and Labrador,C07AA,"Beta-blocking agents, non-selective",<65,F,60.94,0.2,1.4,393,94
2,Newfoundland and Labrador,J01XE,Nitrofuran derivatives,<65,F,59.72,0.2,6.5,"1,848",95
2,Newfoundland and Labrador,D06AX,Other antibiotics for topical use,<65,F,56.27,0.1,4.4,"1,251",96
2,Newfoundland and Labrador,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,56.26,0.1,0.9,255,97
2,Newfoundland and Labrador,L01BA,Folic acid analogues,<65,F,55.86,0.1,1.0,292,98
2,Newfoundland and Labrador,N03AB,Hydantoin derivatives,<65,F,55.80,0.1,0.9,243,99
2,Newfoundland and Labrador,A03AX,Other drugs for functional gastrointestinal disorders,<65,F,55.66,0.1,1.0,273,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"4,044.65",13.3,0.6,337,1
3,Prince Edward Island,L04AX,Other immunosuppressants,Total,Total,"1,471.89",4.8,0.3,177,2
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,Total,Total,"1,326.26",4.4,1.5,809,3
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,Total,Total,994.38,3.3,24.8,"13,833",4
3,Prince Edward Island,A02BC,Proton pump inhibitors,Total,Total,725.50,2.4,20.4,"11,356",5
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,686.76,2.3,2.1,"1,164",6
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",Total,Total,672.96,2.2,13.7,"7,646",7
3,Prince Edward Island,S01LA,Antineovascularization agents,Total,Total,625.11,2.1,0.1,72,8
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,Total,Total,597.96,2.0,11.2,"6,258",9
3,Prince Edward Island,N05AX,Other antipsychotics,Total,Total,587.50,1.9,1.5,811,10
3,Prince Edward Island,L01XE,Protein kinase inhibitors,Total,Total,575.15,1.9,0.1,48,11
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,544.05,1.8,4.1,"2,289",12
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,Total,Total,523.63,1.7,11.0,"6,137",13
3,Prince Edward Island,N03AX,Other antiepileptics,Total,Total,495.89,1.6,4.6,"2,580",14
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,491.59,1.6,1.2,672,15
3,Prince Edward Island,L04AA,Selective immunosuppressants,Total,Total,478.84,1.6,0.1,69,16
3,Prince Edward Island,R03BB,Anticholinergics,Total,Total,460.36,1.5,4.5,"2,486",17
3,Prince Edward Island,R03BA,Glucocorticoids,Total,Total,452.08,1.5,3.7,"2,068",18
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,437.13,1.4,0.3,174,19
3,Prince Edward Island,N02AA,Natural opium alkaloids,Total,Total,424.14,1.4,3.9,"2,151",20
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,413.73,1.4,2.7,"1,494",21
3,Prince Edward Island,C09CA,"Angiotensin II antagonists, plain",Total,Total,364.34,1.2,8.8,"4,877",22
3,Prince Edward Island,N06AX,Other antidepressants,Total,Total,360.81,1.2,7.7,"4,306",23
3,Prince Edward Island,J07BB,Influenza vaccines,Total,Total,310.95,1.0,45.8,"25,535",24
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,290.88,1.0,1.3,727,25
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,Total,Total,283.46,0.9,0.9,520,26
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,Total,Total,276.87,0.9,0.7,417,27
3,Prince Edward Island,L02BB,Antiandrogens,Total,Total,269.66,0.9,0.2,115,28
3,Prince Edward Island,L04AC,Interleukin inhibitors,Total,Total,266.10,0.9,0.0,16,29
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",Total,Total,263.52,0.9,13.4,"7,466",30
3,Prince Edward Island,L03AB,Interferons,Total,Total,253.35,0.8,0.1,30,31
3,Prince Edward Island,A10BA,Biguanides,Total,Total,239.86,0.8,12.1,"6,726",32
3,Prince Edward Island,H03AA,Thyroid hormones,Total,Total,210.79,0.7,12.2,"6,796",33
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,202.27,0.7,10.5,"5,823",34
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,Total,Total,197.48,0.6,6.3,"3,486",35
3,Prince Edward Island,S01EE,Prostaglandin analogues,Total,Total,192.68,0.6,2.7,"1,480",36
3,Prince Edward Island,R01AD,Corticosteroids,Total,Total,183.74,0.6,9.2,"5,137",37
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,Total,Total,180.45,0.6,1.8,"1,023",38
3,Prince Edward Island,A02BA,H2-receptor antagonists,Total,Total,180.24,0.6,4.3,"2,411",39
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,174.51,0.6,4.2,"2,334",40
3,Prince Edward Island,A10BB,Sulfonylureas,Total,Total,166.23,0.5,5.7,"3,149",41
3,Prince Edward Island,S01ED,Beta-blocking agents,Total,Total,153.80,0.5,2.1,"1,163",42
3,Prince Edward Island,L03AX,Other immunostimulants,Total,Total,152.49,0.5,0.0,23,43
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,151.81,0.5,3.2,"1,779",44
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,Total,Total,148.91,0.5,1.7,936,45
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,Total,Total,147.35,0.5,0.5,303,46
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,146.69,0.5,6.2,"3,442",47
3,Prince Edward Island,C01DA,Organic nitrates,Total,Total,141.58,0.5,2.4,"1,334",48
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,Total,Total,137.69,0.5,1.9,"1,045",49
3,Prince Edward Island,N03AG,Fatty acid derivatives,Total,Total,126.16,0.4,0.8,471,50
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,121.62,0.4,2.5,"1,380",51
3,Prince Edward Island,N06DA,Anticholinesterases,Total,Total,115.64,0.4,1.0,535,52
3,Prince Edward Island,C09DA,Angiotensin II antagonists and diuretics,Total,Total,112.51,0.4,2.5,"1,410",53
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,107.70,0.4,0.4,243,54
3,Prince Edward Island,C03CA,"Sulfonamides, plain",Total,Total,99.35,0.3,5.6,"3,102",55
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",Total,Total,98.63,0.3,1.4,768,56
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,Total,Total,95.32,0.3,0.0,10,57
3,Prince Edward Island,B01AA,Vitamin K antagonists,Total,Total,88.78,0.3,3.3,"1,847",58
3,Prince Edward Island,M01AE,Propionic acid derivatives,Total,Total,88.36,0.3,5.8,"3,224",59
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,Total,Total,88.35,0.3,1.5,854,60
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,Total,Total,87.75,0.3,0.7,409,61
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,86.12,0.3,3.9,"2,181",62
3,Prince Edward Island,H02AB,Glucocorticoids,Total,Total,85.95,0.3,8.9,"4,940",63
3,Prince Edward Island,N07XX,Other nervous system drugs,Total,Total,83.87,0.3,0.0,9,64
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,Total,Total,80.53,0.3,0.6,348,65
3,Prince Edward Island,L02BG,Aromatase inhibitors,Total,Total,72.54,0.2,0.5,252,66
3,Prince Edward Island,M05BA,Bisphosphonates,Total,Total,70.34,0.2,2.4,"1,326",67
3,Prince Edward Island,C03AA,"Thiazides, plain",Total,Total,69.98,0.2,8.2,"4,561",68
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,Total,Total,69.41,0.2,11.5,"6,380",69
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,68.22,0.2,1.9,"1,037",70
3,Prince Edward Island,B01AB,Heparin group,Total,Total,67.02,0.2,0.3,191,71
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,Total,Total,66.95,0.2,1.7,928,72
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",Total,Total,66.43,0.2,4.9,"2,752",73
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,Total,Total,60.33,0.2,0.1,76,74
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,59.63,0.2,0.3,150,75
3,Prince Edward Island,N02BE,Anilides,Total,Total,55.80,0.2,1.4,752,76
3,Prince Edward Island,C10AC,Bile acid sequestrants,Total,Total,55.47,0.2,0.4,200,77
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,54.18,0.2,1.3,700,78
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,Total,Total,53.37,0.2,0.7,402,79
3,Prince Edward Island,A09AA,Enzyme preparations,Total,Total,51.49,0.2,0.1,75,80
3,Prince Edward Island,J01DB,First-generation cephalosporins,Total,Total,49.01,0.2,4.7,"2,623",81
3,Prince Edward Island,L01BA,Folic acid analogues,Total,Total,49.01,0.2,0.8,466,82
3,Prince Edward Island,J01FA,Macrolides,Total,Total,47.41,0.2,3.0,"1,648",83
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,46.81,0.2,0.2,99,84
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,Total,46.58,0.2,4.8,"2,655",85
3,Prince Edward Island,J01AA,Tetracyclines,Total,Total,46.24,0.2,6.1,"3,404",86
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,45.06,0.1,1.2,694,87
3,Prince Edward Island,A03FA,Propulsives,Total,Total,44.33,0.1,2.2,"1,241",88
3,Prince Edward Island,L01XC,Monoclonal antibodies,Total,Total,44.18,0.1,0.0,6,89
3,Prince Edward Island,A06AB,Contact laxatives,Total,Total,43.06,0.1,1.1,612,90
3,Prince Edward Island,N03AF,Carboxamide derivatives,Total,Total,42.77,0.1,0.6,320,91
3,Prince Edward Island,R06AE,Piperazine derivatives,Total,Total,39.89,0.1,0.4,223,92
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,39.45,0.1,0.0,6,93
3,Prince Edward Island,A06AD,Osmotically acting laxatives,Total,Total,38.80,0.1,0.6,353,94
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,Total,Total,38.60,0.1,1.7,946,95
3,Prince Edward Island,S01BA,"Corticosteroids, plain",Total,Total,38.59,0.1,3.1,"1,702",96
3,Prince Edward Island,M03BX,Other centrally acting agents,Total,Total,37.59,0.1,0.7,370,97
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,Total,Total,36.50,0.1,0.4,233,98
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,Total,Total,35.86,0.1,1.1,630,99
3,Prince Edward Island,N02AB,Phenylpiperidine derivatives,Total,Total,35.41,0.1,0.1,31,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"1,939.26",13.1,0.6,152,1
3,Prince Edward Island,L04AX,Other immunosuppressants,Total,M,"1,057.59",7.2,0.3,88,2
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,Total,M,705.37,4.8,1.8,447,3
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,Total,M,533.10,3.6,30.1,"7,600",4
3,Prince Edward Island,L01XE,Protein kinase inhibitors,Total,M,444.77,3.0,0.1,28,5
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,Total,M,**, ** , ** ,**,6
3,Prince Edward Island,N05AX,Other antipsychotics,Total,M,427.12,2.9,1.7,437,7
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,423.23,2.9,2.3,580,8
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",Total,M,352.42,2.4,16.4,"4,140",9
3,Prince Edward Island,A02BC,Proton pump inhibitors,Total,M,311.65,2.1,19.5,"4,917",10
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,304.41,2.1,5.0,"1,273",11
3,Prince Edward Island,L02BB,Antiandrogens,Total,M,269.66,1.8,0.5,115,12
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,Total,M,246.07,1.7,11.8,"2,991",13
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,Total,M,224.77,1.5,8.7,"2,205",14
3,Prince Edward Island,R03BB,Anticholinergics,Total,M,220.10,1.5,4.8,"1,210",15
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,216.64,1.5,3.2,815,16
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,213.71,1.4,1.2,301,17
3,Prince Edward Island,N03AX,Other antiepileptics,Total,M,203.71,1.4,4.0,"1,019",18
3,Prince Edward Island,N02AA,Natural opium alkaloids,Total,M,188.20,1.3,3.6,913,19
3,Prince Edward Island,S01LA,Antineovascularization agents,Total,M,185.15,1.3,0.1,23,20
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,Total,M,183.16,1.2,1.2,314,21
3,Prince Edward Island,R03BA,Glucocorticoids,Total,M,175.84,1.2,3.2,813,22
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",Total,M,156.00,1.1,1.6,394,23
3,Prince Edward Island,C09CA,"Angiotensin II antagonists, plain",Total,M,151.70,1.0,8.3,"2,090",24
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,Total,M,148.46,1.0,0.8,212,25
3,Prince Edward Island,N06AX,Other antidepressants,Total,M,140.72,1.0,6.2,"1,554",26
3,Prince Edward Island,J07BB,Influenza vaccines,Total,M,137.13,0.9,44.6,"11,257",27
3,Prince Edward Island,A10BA,Biguanides,Total,M,135.83,0.9,15.1,"3,825",28
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",Total,M,124.96,0.8,15.3,"3,860",29
3,Prince Edward Island,L04AC,Interleukin inhibitors,Total,M,98.14,0.7,0.0,6,30
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,Total,M,**, ** , ** ,**,31
3,Prince Edward Island,A10BB,Sulfonylureas,Total,M,94.49,0.6,7.5,"1,883",32
3,Prince Edward Island,L04AA,Selective immunosuppressants,Total,M,94.30,0.6,0.1,13,33
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,89.53,0.6,9.7,"2,449",34
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,Total,M,86.82,0.6,4.9,"1,240",35
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,Total,M,84.44,0.6,8.4,"2,130",36
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,Total,M,82.26,0.6,2.0,498,37
3,Prince Edward Island,N03AG,Fatty acid derivatives,Total,M,78.62,0.5,1.0,254,38
3,Prince Edward Island,A02BA,H2-receptor antagonists,Total,M,76.14,0.5,3.9,985,39
3,Prince Edward Island,R01AD,Corticosteroids,Total,M,75.66,0.5,8.3,"2,091",40
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,75.42,0.5,3.6,914,41
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,Total,M,74.65,0.5,1.6,416,42
3,Prince Edward Island,S01EE,Prostaglandin analogues,Total,M,69.30,0.5,2.2,561,43
3,Prince Edward Island,C01DA,Organic nitrates,Total,M,65.95,0.4,2.7,690,44
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,64.61,0.4,6.3,"1,600",45
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,Total,M,64.15,0.4,1.7,437,46
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,Total,M,61.28,0.4,0.5,123,47
3,Prince Edward Island,S01ED,Beta-blocking agents,Total,M,61.00,0.4,1.8,467,48
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,58.22,0.4,2.9,729,49
3,Prince Edward Island,H03AA,Thyroid hormones,Total,M,53.61,0.4,7.0,"1,759",50
3,Prince Edward Island,C09DA,Angiotensin II antagonists and diuretics,Total,M,51.23,0.3,2.5,624,51
3,Prince Edward Island,B01AA,Vitamin K antagonists,Total,M,49.28,0.3,4.0,"1,019",52
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,Total,M,49.21,0.3,0.8,198,53
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,48.69,0.3,0.5,115,54
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,45.06,0.3,2.7,694,55
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,Total,M,43.17,0.3,1.4,348,56
3,Prince Edward Island,L03AB,Interferons,Total,M,41.25,0.3,0.0,6,57
3,Prince Edward Island,L03AX,Other immunostimulants,Total,M,40.46,0.3,0.0,5,58
3,Prince Edward Island,C03CA,"Sulfonamides, plain",Total,M,40.39,0.3,5.3,"1,346",59
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",Total,M,40.24,0.3,1.2,313,60
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,Total,M,38.68,0.3,0.7,175,61
3,Prince Edward Island,M01AE,Propionic acid derivatives,Total,M,37.24,0.3,5.4,"1,355",62
3,Prince Edward Island,N06DA,Anticholinesterases,Total,M,36.24,0.2,0.7,184,63
3,Prince Edward Island,H02AB,Glucocorticoids,Total,M,35.75,0.2,8.4,"2,129",64
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,Total,M,35.25,0.2,0.2,43,65
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",Total,M,34.72,0.2,5.0,"1,255",66
3,Prince Edward Island,B01AB,Heparin group,Total,M,32.01,0.2,0.4,92,67
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,Total,M,29.43,0.2,10.6,"2,683",68
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,28.76,0.2,0.3,66,69
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,28.25,0.2,1.4,344,70
3,Prince Edward Island,C03AA,"Thiazides, plain",Total,M,24.18,0.2,6.6,"1,675",71
3,Prince Edward Island,N03AF,Carboxamide derivatives,Total,M,24.02,0.2,0.6,152,72
3,Prince Edward Island,A09AA,Enzyme preparations,Total,M,23.60,0.2,0.1,34,73
3,Prince Edward Island,J01DB,First-generation cephalosporins,Total,M,22.70,0.2,5.0,"1,257",74
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,Total,M,21.98,0.1,0.6,140,75
3,Prince Edward Island,N02BE,Anilides,Total,M,21.94,0.1,1.0,255,76
3,Prince Edward Island,N07XX,Other nervous system drugs,Total,M,**, ** , ** ,*,77
3,Prince Edward Island,J01AA,Tetracyclines,Total,M,20.82,0.1,5.9,"1,493",78
3,Prince Edward Island,A06AB,Contact laxatives,Total,M,20.38,0.1,0.9,221,79
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,20.00,0.1,0.3,64,80
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,Total,M,19.87,0.1,2.1,518,81
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,Total,M,18.16,0.1,3.4,853,82
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,Total,M,17.96,0.1,1.0,257,83
3,Prince Edward Island,L04AD,Calcineurin inhibitors,Total,M,17.92,0.1,0.0,8,84
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,M,17.41,0.1,4.3,"1,088",85
3,Prince Edward Island,L01BA,Folic acid analogues,Total,M,17.27,0.1,0.6,161,86
3,Prince Edward Island,J01FA,Macrolides,Total,M,17.26,0.1,2.4,614,87
3,Prince Edward Island,A06AD,Osmotically acting laxatives,Total,M,16.99,0.1,0.6,141,88
3,Prince Edward Island,N03AB,Hydantoin derivatives,Total,M,16.95,0.1,0.6,157,89
3,Prince Edward Island,M03BX,Other centrally acting agents,Total,M,16.76,0.1,0.6,159,90
3,Prince Edward Island,C10AC,Bile acid sequestrants,Total,M,16.13,0.1,0.3,74,91
3,Prince Edward Island,C09DB,Angiotensin II antagonists and calcium channel blockers,Total,M,15.18,0.1,0.3,72,92
3,Prince Edward Island,A03FA,Propulsives,Total,M,15.14,0.1,1.6,410,93
3,Prince Edward Island,C01AA,Digitalis glycosides,Total,M,15.10,0.1,1.0,241,94
3,Prince Edward Island,S01BA,"Corticosteroids, plain",Total,M,15.03,0.1,2.7,684,95
3,Prince Edward Island,R06AE,Piperazine derivatives,Total,M,13.71,0.1,0.3,73,96
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,13.31,0.1,0.1,19,97
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,Total,M,12.87,0.1,1.0,244,98
3,Prince Edward Island,C03DA,Aldosterone antagonists,Total,M,12.76,0.1,1.4,358,99
3,Prince Edward Island,N05AA,Phenothiazines with aliphatic side-chain,Total,M,12.67,0.1,0.4,100,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"2,105.40",13.5,0.6,185,1
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,Total,F,620.88,4.0,1.2,362,2
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,Total,F,461.27,3.0,20.5,"6,233",3
3,Prince Edward Island,S01LA,Antineovascularization agents,Total,F,439.97,2.8,0.2,49,4
3,Prince Edward Island,L04AX,Other immunosuppressants,Total,F,414.30,2.7,0.3,89,5
3,Prince Edward Island,A02BC,Proton pump inhibitors,Total,F,413.85,2.7,21.1,"6,439",6
3,Prince Edward Island,L04AA,Selective immunosuppressants,Total,F,384.54,2.5,0.2,56,7
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,Total,F,373.19,2.4,13.3,"4,053",8
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",Total,F,320.54,2.1,11.5,"3,506",9
3,Prince Edward Island,N03AX,Other antiepileptics,Total,F,292.18,1.9,5.1,"1,561",10
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,277.88,1.8,1.2,371,11
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,Total,F,277.56,1.8,10.3,"3,146",12
3,Prince Edward Island,R03BA,Glucocorticoids,Total,F,276.24,1.8,4.1,"1,255",13
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,263.53,1.7,1.9,584,14
3,Prince Edward Island,R03BB,Anticholinergics,Total,F,240.26,1.5,4.2,"1,276",15
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,239.64,1.5,3.3,"1,016",16
3,Prince Edward Island,N02AA,Natural opium alkaloids,Total,F,235.94,1.5,4.1,"1,238",17
3,Prince Edward Island,N06AX,Other antidepressants,Total,F,220.09,1.4,9.0,"2,752",18
3,Prince Edward Island,C09CA,"Angiotensin II antagonists, plain",Total,F,212.64,1.4,9.2,"2,787",19
3,Prince Edward Island,L03AB,Interferons,Total,F,212.09,1.4,0.1,24,20
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,197.09,1.3,2.2,679,21
3,Prince Edward Island,J07BB,Influenza vaccines,Total,F,173.83,1.1,46.9,"14,278",22
3,Prince Edward Island,L04AC,Interleukin inhibitors,Total,F,167.96,1.1,0.0,10,23
3,Prince Edward Island,N05AX,Other antipsychotics,Total,F,160.38,1.0,1.2,374,24
3,Prince Edward Island,H03AA,Thyroid hormones,Total,F,157.19,1.0,16.5,"5,037",25
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",Total,F,138.56,0.9,11.8,"3,606",26
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",Total,F,134.88,0.9,1.1,333,27
3,Prince Edward Island,L01XE,Protein kinase inhibitors,Total,F,130.38,0.8,0.1,20,28
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,Total,F,128.40,0.8,0.7,205,29
3,Prince Edward Island,S01EE,Prostaglandin analogues,Total,F,123.38,0.8,3.0,919,30
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,120.24,0.8,4.5,"1,374",31
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,116.29,0.7,5.3,"1,605",32
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,112.74,0.7,11.1,"3,374",33
3,Prince Edward Island,L03AX,Other immunostimulants,Total,F,112.02,0.7,0.1,18,34
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,Total,F,110.66,0.7,7.4,"2,246",35
3,Prince Edward Island,R01AD,Corticosteroids,Total,F,108.07,0.7,10.0,"3,046",36
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,Total,F,105.80,0.7,2.0,607,37
3,Prince Edward Island,A02BA,H2-receptor antagonists,Total,F,104.10,0.7,4.7,"1,426",38
3,Prince Edward Island,A10BA,Biguanides,Total,F,104.03,0.7,9.5,"2,901",39
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,Total,F,100.30,0.6,0.7,206,40
3,Prince Edward Island,S01ED,Beta-blocking agents,Total,F,92.80,0.6,2.3,696,41
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,Total,F,86.07,0.6,0.6,180,42
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,82.08,0.5,6.0,"1,842",43
3,Prince Edward Island,N06DA,Anticholinesterases,Total,F,79.40,0.5,1.2,351,44
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,76.39,0.5,2.8,865,45
3,Prince Edward Island,C01DA,Organic nitrates,Total,F,75.63,0.5,2.1,644,46
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,Total,F,73.53,0.5,2.0,608,47
3,Prince Edward Island,L02BG,Aromatase inhibitors,Total,F,72.42,0.5,0.8,248,48
3,Prince Edward Island,A10BB,Sulfonylureas,Total,F,71.74,0.5,4.2,"1,266",49
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,Total,F,66.66,0.4,1.4,438,50
3,Prince Edward Island,N07XX,Other nervous system drugs,Total,F,**, ** , ** ,**,51
3,Prince Edward Island,C09DA,Angiotensin II antagonists and diuretics,Total,F,61.28,0.4,2.6,786,52
3,Prince Edward Island,M05BA,Bisphosphonates,Total,F,59.79,0.4,3.7,"1,137",53
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,59.01,0.4,0.4,128,54
3,Prince Edward Island,C03CA,"Sulfonamides, plain",Total,F,58.96,0.4,5.8,"1,756",55
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",Total,F,58.39,0.4,1.5,455,56
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,54.18,0.3,2.3,700,57
3,Prince Edward Island,M01AE,Propionic acid derivatives,Total,F,51.12,0.3,6.1,"1,869",58
3,Prince Edward Island,H02AB,Glucocorticoids,Total,F,50.20,0.3,9.2,"2,811",59
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,Total,F,49.08,0.3,0.8,234,60
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,Total,F,48.99,0.3,2.2,671,61
3,Prince Edward Island,N03AG,Fatty acid derivatives,Total,F,47.54,0.3,0.7,217,62
3,Prince Edward Island,C03AA,"Thiazides, plain",Total,F,45.79,0.3,9.5,"2,886",63
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,Total,F,45.18,0.3,1.7,506,64
3,Prince Edward Island,L01XC,Monoclonal antibodies,Total,F,44.18,0.3,0.0,6,65
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,Total,F,39.98,0.3,12.1,"3,697",66
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,39.97,0.3,2.3,693,67
3,Prince Edward Island,B01AA,Vitamin K antagonists,Total,F,39.49,0.3,2.7,828,68
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,39.45,0.3,0.0,5,69
3,Prince Edward Island,C10AC,Bile acid sequestrants,Total,F,39.34,0.3,0.4,126,70
3,Prince Edward Island,B02BX,Other systemic hemostatics,Total,F,**, ** , ** ,*,71
3,Prince Edward Island,B01AB,Heparin group,Total,F,35.01,0.2,0.3,99,72
3,Prince Edward Island,N02BE,Anilides,Total,F,33.86,0.2,1.6,497,73
3,Prince Edward Island,L01BA,Folic acid analogues,Total,F,31.74,0.2,1.0,305,74
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",Total,F,31.72,0.2,4.9,"1,497",75
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,Total,F,31.39,0.2,0.9,262,76
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,Total,F,31.33,0.2,0.5,150,77
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,30.86,0.2,0.3,84,78
3,Prince Edward Island,J01FA,Macrolides,Total,F,30.14,0.2,3.4,"1,034",79
3,Prince Edward Island,A03FA,Propulsives,Total,F,29.19,0.2,2.7,831,80
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,F,29.17,0.2,5.1,"1,567",81
3,Prince Edward Island,A09AA,Enzyme preparations,Total,F,27.88,0.2,0.1,41,82
3,Prince Edward Island,G03AB,"Progestogens and estrogens, sequential preparations",Total,F,27.81,0.2,1.0,312,83
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,26.81,0.2,0.1,35,84
3,Prince Edward Island,J01DB,First-generation cephalosporins,Total,F,26.31,0.2,4.5,"1,366",85
3,Prince Edward Island,R06AE,Piperazine derivatives,Total,F,26.18,0.2,0.5,150,86
3,Prince Edward Island,J01AA,Tetracyclines,Total,F,25.42,0.2,6.3,"1,911",87
3,Prince Edward Island,L03AA,Colony-stimulating factors,Total,F,25.28,0.2,0.0,12,88
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,Total,F,25.08,0.2,0.1,33,89
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,Total,F,24.71,0.2,0.5,151,90
3,Prince Edward Island,N02CC,Selective serotonin (5HT1) agonists,Total,F,24.60,0.2,0.4,131,91
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,Total,F,24.30,0.2,0.5,149,92
3,Prince Edward Island,N02AB,Phenylpiperidine derivatives,Total,F,23.93,0.2,0.1,20,93
3,Prince Edward Island,S01BA,"Corticosteroids, plain",Total,F,23.56,0.2,3.3,"1,018",94
3,Prince Edward Island,A05AA,Bile acids and derivatives,Total,F,23.43,0.2,0.1,26,95
3,Prince Edward Island,J01XE,Nitrofuran derivatives,Total,F,23.23,0.1,4.7,"1,421",96
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,Total,F,22.99,0.1,1.3,386,97
3,Prince Edward Island,A06AB,Contact laxatives,Total,F,22.68,0.1,1.3,391,98
3,Prince Edward Island,L01AX,Other alkylating agents,Total,F,**, ** , ** ,*,99
3,Prince Edward Island,A06AD,Osmotically acting laxatives,Total,F,21.81,0.1,0.7,212,100
3,Prince Edward Island,L04AX,Other immunosuppressants,65+,Total,"1,246.39",7.6,0.4,108,1
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"1,165.03",7.1,0.3,86,2
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,65+,Total,794.10,4.8,42.5,"11,690",3
3,Prince Edward Island,S01LA,Antineovascularization agents,65+,Total,**, ** , ** ,**,4
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",65+,Total,570.84,3.5,23.1,"6,359",5
3,Prince Edward Island,A02BC,Proton pump inhibitors,65+,Total,467.39,2.8,30.7,"8,443",6
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,65+,Total,443.15,2.7,19.3,"5,307",7
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,417.80,2.5,2.1,585,8
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,401.69,2.4,0.6,158,9
3,Prince Edward Island,R03BB,Anticholinergics,65+,Total,371.33,2.3,7.7,"2,114",10
3,Prince Edward Island,C09CA,"Angiotensin II antagonists, plain",65+,Total,310.63,1.9,15.3,"4,212",11
3,Prince Edward Island,R03BA,Glucocorticoids,65+,Total,280.93,1.7,5.1,"1,404",12
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,65+,Total,257.52,1.6,1.4,390,13
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,239.65,1.5,3.3,909,14
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,233.34,1.4,3.1,861,15
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",65+,Total,216.72,1.3,23.7,"6,515",16
3,Prince Edward Island,L01XE,Protein kinase inhibitors,65+,Total,209.06,1.3,0.1,27,17
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,65+,Total,207.14,1.3,12.0,"3,302",18
3,Prince Edward Island,L02BB,Antiandrogens,65+,Total,201.07,1.2,0.4,105,19
3,Prince Edward Island,N03AX,Other antiepileptics,65+,Total,200.38,1.2,5.7,"1,570",20
3,Prince Edward Island,S01EE,Prostaglandin analogues,65+,Total,186.62,1.1,5.2,"1,431",21
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,65+,Total,160.73,1.0,3.4,932,22
3,Prince Edward Island,H03AA,Thyroid hormones,65+,Total,158.55,1.0,22.6,"6,202",23
3,Prince Edward Island,J07BB,Influenza vaccines,65+,Total,147.41,0.9,44.0,"12,087",24
3,Prince Edward Island,S01ED,Beta-blocking agents,65+,Total,142.01,0.9,4.1,"1,122",25
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,137.95,0.8,1.2,337,26
3,Prince Edward Island,L04AA,Selective immunosuppressants,65+,Total,137.48,0.8,0.1,31,27
3,Prince Edward Island,A10BA,Biguanides,65+,Total,137.36,0.8,14.2,"3,902",28
3,Prince Edward Island,N06AX,Other antidepressants,65+,Total,132.44,0.8,8.9,"2,440",29
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,65+,Total,127.28,0.8,2.8,766,30
3,Prince Edward Island,C01DA,Organic nitrates,65+,Total,126.01,0.8,4.3,"1,184",31
3,Prince Edward Island,N02AA,Natural opium alkaloids,65+,Total,121.57,0.7,5.9,"1,621",32
3,Prince Edward Island,R01AD,Corticosteroids,65+,Total,117.48,0.7,13.1,"3,592",33
3,Prince Edward Island,N06DA,Anticholinesterases,65+,Total,112.57,0.7,1.9,528,34
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,65+,Total,110.74,0.7,0.8,230,35
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,108.64,0.7,5.1,"1,395",36
3,Prince Edward Island,A02BA,H2-receptor antagonists,65+,Total,105.26,0.6,6.1,"1,683",37
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,104.26,0.6,0.9,259,38
3,Prince Edward Island,A10BB,Sulfonylureas,65+,Total,102.78,0.6,7.0,"1,936",39
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,101.95,0.6,4.3,"1,175",40
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,101.61,0.6,14.0,"3,837",41
3,Prince Edward Island,C09DA,Angiotensin II antagonists and diuretics,65+,Total,96.60,0.6,4.4,"1,208",42
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,92.46,0.6,5.8,"1,599",43
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,83.49,0.5,0.7,194,44
3,Prince Edward Island,C03CA,"Sulfonamides, plain",65+,Total,81.38,0.5,10.0,"2,747",45
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,76.71,0.5,7.3,"1,994",46
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,65+,Total,76.18,0.5,1.3,353,47
3,Prince Edward Island,B01AA,Vitamin K antagonists,65+,Total,75.87,0.5,6.1,"1,672",48
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",65+,Total,75.64,0.5,2.1,588,49
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,65+,Total,67.77,0.4,9.3,"2,561",50
3,Prince Edward Island,H02AB,Glucocorticoids,65+,Total,65.30,0.4,14.1,"3,888",51
3,Prince Edward Island,N05AX,Other antipsychotics,65+,Total,63.50,0.4,1.2,323,52
3,Prince Edward Island,L02BG,Aromatase inhibitors,65+,Total,62.87,0.4,0.8,219,53
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,65+,Total,60.57,0.4,1.0,283,54
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,65+,Total,59.61,0.4,0.3,75,55
3,Prince Edward Island,M05BA,Bisphosphonates,65+,Total,57.81,0.4,4.4,"1,218",56
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,56.57,0.3,9.5,"2,622",57
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,55.78,0.3,0.5,137,58
3,Prince Edward Island,C03AA,"Thiazides, plain",65+,Total,55.44,0.3,13.8,"3,789",59
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,65+,Total,**, ** , ** ,**,60
3,Prince Edward Island,B01AB,Heparin group,65+,Total,51.54,0.3,0.6,173,61
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,65+,Total,49.70,0.3,2.7,751,62
3,Prince Edward Island,A09AA,Enzyme preparations,65+,Total,49.18,0.3,0.2,65,63
3,Prince Edward Island,C10AC,Bile acid sequestrants,65+,Total,45.31,0.3,0.6,159,64
3,Prince Edward Island,L03AB,Interferons,65+,Total,**, ** , ** ,*,65
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",65+,Total,43.06,0.3,7.7,"2,128",66
3,Prince Edward Island,L04AC,Interleukin inhibitors,65+,Total,**, ** , ** ,*,67
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,40.75,0.2,2.4,654,68
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,39.57,0.2,2.4,671,69
3,Prince Edward Island,L03AX,Other immunostimulants,65+,Total,39.28,0.2,0.0,5,70
3,Prince Edward Island,B02BX,Other systemic hemostatics,65+,Total,**, ** , ** ,*,71
3,Prince Edward Island,S01BA,"Corticosteroids, plain",65+,Total,34.05,0.2,5.7,"1,573",72
3,Prince Edward Island,M01AE,Propionic acid derivatives,65+,Total,33.53,0.2,5.7,"1,559",73
3,Prince Edward Island,L01BA,Folic acid analogues,65+,Total,32.03,0.2,1.3,345,74
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,65+,Total,31.55,0.2,0.7,205,75
3,Prince Edward Island,N02BE,Anilides,65+,Total,30.61,0.2,1.8,492,76
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,65+,Total,28.23,0.2,12.6,"3,470",77
3,Prince Edward Island,C01AA,Digitalis glycosides,65+,Total,26.82,0.2,1.5,414,78
3,Prince Edward Island,J01AA,Tetracyclines,65+,Total,25.69,0.2,8.6,"2,358",79
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,Total,25.43,0.2,6.4,"1,749",80
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,65+,Total,25.09,0.2,2.4,655,81
3,Prince Edward Island,N03AG,Fatty acid derivatives,65+,Total,25.02,0.2,0.6,153,82
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,25.01,0.2,0.3,77,83
3,Prince Edward Island,C09DB,Angiotensin II antagonists and calcium channel blockers,65+,Total,24.01,0.1,0.5,124,84
3,Prince Edward Island,J01DB,First-generation cephalosporins,65+,Total,23.86,0.1,6.1,"1,675",85
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,**, ** , ** ,*,86
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,65+,Total,23.72,0.1,1.5,424,87
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,65+,Total,23.64,0.1,4.1,"1,119",88
3,Prince Edward Island,A03FA,Propulsives,65+,Total,23.52,0.1,3.2,886,89
3,Prince Edward Island,D06BB,Antivirals,65+,Total,23.11,0.1,0.8,229,90
3,Prince Edward Island,S01EC,Carbonic anhydrase inhibitors,65+,Total,21.58,0.1,0.8,225,91
3,Prince Edward Island,A06AB,Contact laxatives,65+,Total,20.43,0.1,1.5,406,92
3,Prince Edward Island,L01XX,Other antineoplastic agents,65+,Total,20.28,0.1,0.2,54,93
3,Prince Edward Island,J01FA,Macrolides,65+,Total,19.23,0.1,2.8,766,94
3,Prince Edward Island,A05AA,Bile acids and derivatives,65+,Total,19.21,0.1,0.1,22,95
3,Prince Edward Island,C05BA,Heparins or heparinoids for topical use,65+,Total,19.00,0.1,0.0,10,96
3,Prince Edward Island,C03DA,Aldosterone antagonists,65+,Total,18.51,0.1,2.1,570,97
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,18.32,0.1,0.1,25,98
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,65+,Total,18.32,0.1,1.8,490,99
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,65+,Total,17.88,0.1,0.5,145,100
3,Prince Edward Island,L04AX,Other immunosuppressants,65+,M,852.62,10.8,0.4,55,1
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,602.24,7.6,0.3,34,2
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,65+,M,421.03,5.3,50.6,"6,378",3
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,65+,M,**, ** , ** ,**,4
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",65+,M,294.74,3.7,26.9,"3,396",5
3,Prince Edward Island,L02BB,Antiandrogens,65+,M,201.07,2.5,0.8,105,6
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,65+,M,199.94,2.5,20.0,"2,525",7
3,Prince Edward Island,A02BC,Proton pump inhibitors,65+,M,191.94,2.4,28.9,"3,650",8
3,Prince Edward Island,R03BB,Anticholinergics,65+,M,181.70,2.3,8.4,"1,054",9
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,180.76,2.3,2.1,263,10
3,Prince Edward Island,S01LA,Antineovascularization agents,65+,M,**, ** , ** ,**,11
3,Prince Edward Island,L01XE,Protein kinase inhibitors,65+,M,169.74,2.1,0.1,15,12
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,65+,M,135.81,1.7,1.5,194,13
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,131.47,1.7,4.2,527,14
3,Prince Edward Island,C09CA,"Angiotensin II antagonists, plain",65+,M,128.14,1.6,14.2,"1,790",15
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,124.98,1.6,3.8,478,16
3,Prince Edward Island,R03BA,Glucocorticoids,65+,M,107.37,1.4,4.3,545,17
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",65+,M,99.06,1.3,26.2,"3,304",18
3,Prince Edward Island,N03AX,Other antiepileptics,65+,M,85.36,1.1,5.0,633,19
3,Prince Edward Island,A10BA,Biguanides,65+,M,77.49,1.0,17.6,"2,224",20
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",65+,M,77.36,1.0,1.5,183,21
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,65+,M,75.20,1.0,15.5,"1,958",22
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,65+,M,70.14,0.9,3.2,407,23
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,65+,M,69.90,0.9,9.2,"1,160",24
3,Prince Edward Island,J07BB,Influenza vaccines,65+,M,67.20,0.8,43.7,"5,513",25
3,Prince Edward Island,S01EE,Prostaglandin analogues,65+,M,66.64,0.8,4.3,537,26
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,65+,M,64.95,0.8,2.9,371,27
3,Prince Edward Island,A10BB,Sulfonylureas,65+,M,58.36,0.7,9.1,"1,154",28
3,Prince Edward Island,C01DA,Organic nitrates,65+,M,58.02,0.7,4.8,604,29
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,57.77,0.7,0.9,111,30
3,Prince Edward Island,N02AA,Natural opium alkaloids,65+,M,56.53,0.7,5.5,698,31
3,Prince Edward Island,S01ED,Beta-blocking agents,65+,M,52.32,0.7,3.5,446,32
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,65+,M,**, ** , ** ,**,33
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,49.73,0.6,5.3,674,34
3,Prince Edward Island,R01AD,Corticosteroids,65+,M,48.00,0.6,11.7,"1,481",35
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,45.98,0.6,13.0,"1,641",36
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,65+,M,45.42,0.6,0.7,94,37
3,Prince Edward Island,N06AX,Other antidepressants,65+,M,44.05,0.6,6.9,874,38
3,Prince Edward Island,C09DA,Angiotensin II antagonists and diuretics,65+,M,43.44,0.5,4.2,531,39
3,Prince Edward Island,A02BA,H2-receptor antagonists,65+,M,43.11,0.5,5.6,708,40
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,40.75,0.5,5.2,654,41
3,Prince Edward Island,B01AA,Vitamin K antagonists,65+,M,40.57,0.5,7.1,901,42
3,Prince Edward Island,H03AA,Thyroid hormones,65+,M,37.97,0.5,12.8,"1,617",43
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,36.88,0.5,0.7,89,44
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,65+,M,35.49,0.4,1.3,159,45
3,Prince Edward Island,N06DA,Anticholinesterases,65+,M,34.86,0.4,1.4,181,46
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,65+,M,34.53,0.4,0.3,42,47
3,Prince Edward Island,C03CA,"Sulfonamides, plain",65+,M,33.32,0.4,9.5,"1,197",48
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,65+,M,31.92,0.4,1.2,153,49
3,Prince Edward Island,B01AB,Heparin group,65+,M,30.18,0.4,0.7,86,50
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",65+,M,29.48,0.4,1.9,241,51
3,Prince Edward Island,L04AC,Interleukin inhibitors,65+,M,**, ** , ** ,*,52
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,27.96,0.4,10.0,"1,259",53
3,Prince Edward Island,H02AB,Glucocorticoids,65+,M,27.89,0.4,13.6,"1,715",54
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,27.86,0.4,0.5,61,55
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,27.19,0.3,3.9,486,56
3,Prince Edward Island,N05AX,Other antipsychotics,65+,M,26.44,0.3,0.9,119,57
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,65+,M,23.86,0.3,6.9,865,58
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",65+,M,22.31,0.3,8.0,"1,010",59
3,Prince Edward Island,A09AA,Enzyme preparations,65+,M,22.08,0.3,0.2,30,60
3,Prince Edward Island,C03AA,"Thiazides, plain",65+,M,18.64,0.2,10.8,"1,359",61
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,18.61,0.2,2.0,257,62
3,Prince Edward Island,M01AE,Propionic acid derivatives,65+,M,14.92,0.2,5.6,704,63
3,Prince Edward Island,C09DB,Angiotensin II antagonists and calcium channel blockers,65+,M,14.56,0.2,0.5,69,64
3,Prince Edward Island,C10AC,Bile acid sequestrants,65+,M,14.05,0.2,0.5,63,65
3,Prince Edward Island,L04AA,Selective immunosuppressants,65+,M,13.81,0.2,0.1,8,66
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,13.22,0.2,0.4,48,67
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,65+,M,13.03,0.2,5.9,740,68
3,Prince Edward Island,C01AA,Digitalis glycosides,65+,M,12.81,0.2,1.8,222,69
3,Prince Edward Island,J01AA,Tetracyclines,65+,M,12.79,0.2,8.8,"1,108",70
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,65+,M,12.54,0.2,1.6,207,71
3,Prince Edward Island,N03AG,Fatty acid derivatives,65+,M,12.32,0.2,0.6,76,72
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,65+,M,12.28,0.2,2.9,364,73
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,65+,M,12.21,0.2,11.9,"1,503",74
3,Prince Edward Island,L01BA,Folic acid analogues,65+,M,12.20,0.2,1.0,121,75
3,Prince Edward Island,S01BA,"Corticosteroids, plain",65+,M,12.06,0.2,4.9,619,76
3,Prince Edward Island,J01DB,First-generation cephalosporins,65+,M,11.43,0.1,6.6,829,77
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,65+,M,11.16,0.1,0.6,76,78
3,Prince Edward Island,L01XX,Other antineoplastic agents,65+,M,10.29,0.1,0.2,20,79
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,M,10.03,0.1,5.8,730,80
3,Prince Edward Island,C10AX,Other lipid-modifying agents,65+,M,9.53,0.1,1.2,154,81
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,65+,M,8.88,0.1,1.3,169,82
3,Prince Edward Island,N02BE,Anilides,65+,M,8.43,0.1,1.1,137,83
3,Prince Edward Island,S01EC,Carbonic anhydrase inhibitors,65+,M,8.34,0.1,0.7,89,84
3,Prince Edward Island,A03FA,Propulsives,65+,M,8.27,0.1,2.4,304,85
3,Prince Edward Island,D06BB,Antivirals,65+,M,8.19,0.1,0.6,77,86
3,Prince Edward Island,C01BD,"Antiarrhythmics, class III",65+,M,8.14,0.1,0.6,80,87
3,Prince Edward Island,M05BA,Bisphosphonates,65+,M,7.78,0.1,1.3,162,88
3,Prince Edward Island,C03DA,Aldosterone antagonists,65+,M,7.66,0.1,2.2,282,89
3,Prince Edward Island,A06AB,Contact laxatives,65+,M,7.48,0.1,1.0,126,90
3,Prince Edward Island,C10AB,Fibrates,65+,M,7.42,0.1,0.7,90,91
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,65+,M,7.33,0.1,1.5,190,92
3,Prince Edward Island,L04AD,Calcineurin inhibitors,65+,M,**, ** , ** ,**,93
3,Prince Edward Island,L01BC,Pyrimidine analogues,65+,M,7.21,0.1,0.9,117,94
3,Prince Edward Island,J01FA,Macrolides,65+,M,7.11,0.1,2.3,294,95
3,Prince Edward Island,N03AB,Hydantoin derivatives,65+,M,6.61,0.1,0.8,97,96
3,Prince Edward Island,A06AD,Osmotically acting laxatives,65+,M,6.59,0.1,0.5,64,97
3,Prince Edward Island,D07AA,"Corticosteroids, weak (group I)",65+,M,6.41,0.1,3.1,394,98
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,6.20,0.1,0.1,10,99
3,Prince Edward Island,D07XC,"Corticosteroids, potent, other combinations",65+,M,5.99,0.1,0.4,48,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,562.79,6.6,0.3,52,1
3,Prince Edward Island,S01LA,Antineovascularization agents,65+,F,**, ** , ** ,**,2
3,Prince Edward Island,L04AX,Other immunosuppressants,65+,F,393.77,4.6,0.4,53,3
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,65+,F,373.07,4.4,35.7,"5,312",4
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",65+,F,276.10,3.2,19.9,"2,963",5
3,Prince Edward Island,A02BC,Proton pump inhibitors,65+,F,275.45,3.2,32.2,"4,793",6
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,65+,F,243.21,2.9,18.7,"2,782",7
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,237.04,2.8,2.2,322,8
3,Prince Edward Island,R03BB,Anticholinergics,65+,F,189.63,2.2,7.1,"1,060",9
3,Prince Edward Island,C09CA,"Angiotensin II antagonists, plain",65+,F,182.49,2.1,16.3,"2,422",10
3,Prince Edward Island,R03BA,Glucocorticoids,65+,F,173.56,2.0,5.8,859,11
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,65+,F,137.24,1.6,14.4,"2,142",12
3,Prince Edward Island,L04AA,Selective immunosuppressants,65+,F,123.67,1.5,0.2,23,13
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,65+,F,121.70,1.4,1.3,196,14
3,Prince Edward Island,H03AA,Thyroid hormones,65+,F,120.58,1.4,30.8,"4,585",15
3,Prince Edward Island,S01EE,Prostaglandin analogues,65+,F,119.98,1.4,6.0,894,16
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",65+,F,117.66,1.4,21.6,"3,211",17
3,Prince Edward Island,N03AX,Other antiepileptics,65+,F,115.01,1.3,6.3,937,18
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,108.36,1.3,2.6,383,19
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,108.18,1.3,2.6,382,20
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,101.95,1.2,7.9,"1,175",21
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,65+,F,95.78,1.1,3.8,561,22
3,Prince Edward Island,S01ED,Beta-blocking agents,65+,F,89.69,1.1,4.5,676,23
3,Prince Edward Island,N06AX,Other antidepressants,65+,F,88.39,1.0,10.5,"1,566",24
3,Prince Edward Island,J07BB,Influenza vaccines,65+,F,80.22,0.9,44.2,"6,574",25
3,Prince Edward Island,N06DA,Anticholinesterases,65+,F,77.71,0.9,2.3,347,26
3,Prince Edward Island,R01AD,Corticosteroids,65+,F,69.49,0.8,14.2,"2,111",27
3,Prince Edward Island,C01DA,Organic nitrates,65+,F,67.99,0.8,3.9,580,28
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,65+,F,65.32,0.8,0.9,136,29
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,65.27,0.8,7.5,"1,113",30
3,Prince Edward Island,N02AA,Natural opium alkaloids,65+,F,65.04,0.8,6.2,923,31
3,Prince Edward Island,L02BG,Aromatase inhibitors,65+,F,62.81,0.7,1.5,216,32
3,Prince Edward Island,A02BA,H2-receptor antagonists,65+,F,62.15,0.7,6.6,975,33
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",65+,F,60.59,0.7,1.0,154,34
3,Prince Edward Island,A10BA,Biguanides,65+,F,59.87,0.7,11.3,"1,678",35
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,58.91,0.7,4.8,721,36
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,65+,F,57.13,0.7,2.4,359,37
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,55.63,0.7,14.8,"2,196",38
3,Prince Edward Island,C09DA,Angiotensin II antagonists and diuretics,65+,F,53.16,0.6,4.5,677,39
3,Prince Edward Island,M05BA,Bisphosphonates,65+,F,50.04,0.6,7.1,"1,056",40
3,Prince Edward Island,C03CA,"Sulfonamides, plain",65+,F,48.05,0.6,10.4,"1,550",41
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,46.62,0.5,0.7,105,42
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,46.49,0.5,1.0,148,43
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",65+,F,46.15,0.5,2.3,347,44
3,Prince Edward Island,L03AB,Interferons,65+,F,**, ** , ** ,*,45
3,Prince Edward Island,A10BB,Sulfonylureas,65+,F,44.43,0.5,5.3,782,46
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,65+,F,44.26,0.5,1.3,200,47
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,65+,F,43.92,0.5,11.4,"1,696",48
3,Prince Edward Island,L01XE,Protein kinase inhibitors,65+,F,39.32,0.5,0.1,12,49
3,Prince Edward Island,L03AX,Other immunostimulants,65+,F,39.28,0.5,0.0,5,50
3,Prince Edward Island,H02AB,Glucocorticoids,65+,F,37.40,0.4,14.6,"2,173",51
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,65+,F,37.16,0.4,3.7,544,52
3,Prince Edward Island,N05AX,Other antipsychotics,65+,F,37.07,0.4,1.4,204,53
3,Prince Edward Island,C03AA,"Thiazides, plain",65+,F,36.80,0.4,16.3,"2,430",54
3,Prince Edward Island,B01AA,Vitamin K antagonists,65+,F,35.30,0.4,5.2,771,55
3,Prince Edward Island,B02BX,Other systemic hemostatics,65+,F,**, ** , ** ,*,56
3,Prince Edward Island,C10AC,Bile acid sequestrants,65+,F,31.25,0.4,0.6,96,57
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,28.61,0.3,9.2,"1,363",58
3,Prince Edward Island,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,27.91,0.3,0.5,76,59
3,Prince Edward Island,A09AA,Enzyme preparations,65+,F,27.10,0.3,0.2,35,60
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,65+,F,25.08,0.3,0.8,124,61
3,Prince Edward Island,B01AE,Direct thrombin inhibitors,65+,F,25.08,0.3,0.2,33,62
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,**, ** , ** ,*,63
3,Prince Edward Island,N02BE,Anilides,65+,F,22.18,0.3,2.4,355,64
3,Prince Edward Island,S01BA,"Corticosteroids, plain",65+,F,21.99,0.3,6.4,954,65
3,Prince Edward Island,B01AB,Heparin group,65+,F,21.36,0.3,0.6,87,66
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,20.96,0.2,2.8,414,67
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",65+,F,20.75,0.2,7.5,"1,118",68
3,Prince Edward Island,C08DA,Phenylalkylamine derivatives,65+,F,20.39,0.2,0.9,129,69
3,Prince Edward Island,L01BA,Folic acid analogues,65+,F,19.83,0.2,1.5,224,70
3,Prince Edward Island,M01AE,Propionic acid derivatives,65+,F,18.61,0.2,5.7,855,71
3,Prince Edward Island,C05BA,Heparins or heparinoids for topical use,65+,F,18.44,0.2,0.1,9,72
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,65+,F,16.90,0.2,0.8,122,73
3,Prince Edward Island,A05AA,Bile acids and derivatives,65+,F,16.50,0.2,0.1,18,74
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,65+,F,16.02,0.2,13.2,"1,967",75
3,Prince Edward Island,J01XE,Nitrofuran derivatives,65+,F,15.70,0.2,8.0,"1,194",76
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,F,15.40,0.2,6.8,"1,019",77
3,Prince Edward Island,A03FA,Propulsives,65+,F,15.25,0.2,3.9,582,78
3,Prince Edward Island,D06BB,Antivirals,65+,F,14.91,0.2,1.0,152,79
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,65+,F,14.84,0.2,1.7,255,80
3,Prince Edward Island,L04AC,Interleukin inhibitors,65+,F,**, ** , ** ,*,81
3,Prince Edward Island,C01AA,Digitalis glycosides,65+,F,14.02,0.2,1.3,192,82
3,Prince Edward Island,S01EC,Carbonic anhydrase inhibitors,65+,F,13.25,0.2,0.9,136,83
3,Prince Edward Island,A06AB,Contact laxatives,65+,F,12.95,0.2,1.9,280,84
3,Prince Edward Island,J01AA,Tetracyclines,65+,F,12.90,0.2,8.4,"1,250",85
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,65+,F,12.81,0.2,2.0,291,86
3,Prince Edward Island,N03AG,Fatty acid derivatives,65+,F,12.69,0.1,0.5,77,87
3,Prince Edward Island,L03AA,Colony-stimulating factors,65+,F,12.54,0.1,0.0,6,88
3,Prince Edward Island,J01DB,First-generation cephalosporins,65+,F,12.44,0.1,5.7,846,89
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,12.12,0.1,0.1,15,90
3,Prince Edward Island,J01FA,Macrolides,65+,F,12.12,0.1,3.2,472,91
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",65+,F,12.01,0.1,0.6,95,92
3,Prince Edward Island,L01XC,Monoclonal antibodies,65+,F,**, ** , ** ,*,93
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,11.79,0.1,0.2,29,94
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,65+,F,10.99,0.1,2.0,300,95
3,Prince Edward Island,C03DA,Aldosterone antagonists,65+,F,10.85,0.1,1.9,288,96
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,65+,F,10.61,0.1,2.5,379,97
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,65+,F,10.38,0.1,2.1,310,98
3,Prince Edward Island,D07AA,"Corticosteroids, weak (group I)",65+,F,10.32,0.1,4.4,662,99
3,Prince Edward Island,L01XX,Other antineoplastic agents,65+,F,9.98,0.1,0.2,34,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"2,879.63",20.6,0.9,251,1
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,<65,Total,"1,320.83",9.5,2.8,803,2
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,582.50,4.2,3.2,905,3
3,Prince Edward Island,N05AX,Other antipsychotics,<65,Total,524.00,3.8,1.7,488,4
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,<65,Total,390.82,2.8,10.5,"2,956",5
3,Prince Edward Island,L01XE,Protein kinase inhibitors,<65,Total,366.09,2.6,0.1,21,6
3,Prince Edward Island,L04AA,Selective immunosuppressants,<65,Total,341.36,2.4,0.1,38,7
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,304.40,2.2,4.9,"1,380",8
3,Prince Edward Island,N02AA,Natural opium alkaloids,<65,Total,302.57,2.2,1.9,530,9
3,Prince Edward Island,N03AX,Other antiepileptics,<65,Total,295.52,2.1,3.6,"1,010",10
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,<65,Total,281.69,2.0,1.8,507,11
3,Prince Edward Island,A02BC,Proton pump inhibitors,<65,Total,258.11,1.8,10.3,"2,913",12
3,Prince Edward Island,N06AX,Other antidepressants,<65,Total,228.37,1.6,6.6,"1,866",13
3,Prince Edward Island,L04AX,Other immunosuppressants,<65,Total,225.51,1.6,0.2,69,14
3,Prince Edward Island,L04AC,Interleukin inhibitors,<65,Total,**, ** , ** ,**,15
3,Prince Edward Island,L03AB,Interferons,<65,Total,**, ** , ** ,**,16
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,<65,Total,200.28,1.4,7.6,"2,143",17
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,180.39,1.3,2.2,633,18
3,Prince Edward Island,R03BA,Glucocorticoids,<65,Total,171.15,1.2,2.4,664,19
3,Prince Edward Island,J07BB,Influenza vaccines,<65,Total,163.54,1.2,47.7,"13,448",20
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,152.93,1.1,1.4,390,21
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,<65,Total,129.70,0.9,3.3,925,22
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,<65,Total,113.96,0.8,2.2,621,23
3,Prince Edward Island,L03AX,Other immunostimulants,<65,Total,113.20,0.8,0.1,18,24
3,Prince Edward Island,A10BA,Biguanides,<65,Total,102.50,0.7,10.0,"2,824",25
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",<65,Total,102.12,0.7,4.6,"1,287",26
3,Prince Edward Island,N03AG,Fatty acid derivatives,<65,Total,101.15,0.7,1.1,318,27
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,100.66,0.7,7.0,"1,986",28
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,90.12,0.6,2.9,820,29
3,Prince Edward Island,R03BB,Anticholinergics,<65,Total,89.03,0.6,1.3,372,30
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,82.05,0.6,2.6,735,31
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,<65,Total,80.48,0.6,2.9,830,32
3,Prince Edward Island,N07XX,Other nervous system drugs,<65,Total,**, ** , ** ,**,33
3,Prince Edward Island,A02BA,H2-receptor antagonists,<65,Total,74.99,0.5,2.6,728,34
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,73.79,0.5,0.3,87,35
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,<65,Total,70.03,0.5,1.3,364,36
3,Prince Edward Island,L02BB,Antiandrogens,<65,Total,68.60,0.5,0.0,10,37
3,Prince Edward Island,R01AD,Corticosteroids,<65,Total,66.26,0.5,5.5,"1,545",38
3,Prince Edward Island,A10BB,Sulfonylureas,<65,Total,63.45,0.5,4.3,"1,213",39
3,Prince Edward Island,M01AE,Propionic acid derivatives,<65,Total,54.83,0.4,5.9,"1,665",40
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,54.18,0.4,2.5,700,41
3,Prince Edward Island,C09CA,"Angiotensin II antagonists, plain",<65,Total,53.72,0.4,2.4,665,42
3,Prince Edward Island,H03AA,Thyroid hormones,<65,Total,52.24,0.4,2.1,594,43
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",<65,Total,46.80,0.3,3.4,951,44
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,<65,Total,46.74,0.3,1.2,327,45
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,<65,Total,**, ** , ** ,*,46
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,43.17,0.3,1.4,384,47
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,<65,Total,41.18,0.3,10.3,"2,910",48
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,<65,Total,36.61,0.3,0.3,73,49
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,35.43,0.3,0.1,16,50
3,Prince Edward Island,N03AF,Carboxamide derivatives,<65,Total,32.69,0.2,0.6,174,51
3,Prince Edward Island,L01XC,Monoclonal antibodies,<65,Total,**, ** , ** ,*,52
3,Prince Edward Island,R06AE,Piperazine derivatives,<65,Total,30.47,0.2,0.6,159,53
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,28.65,0.2,1.3,366,54
3,Prince Edward Island,M03BX,Other centrally acting agents,<65,Total,28.53,0.2,0.7,208,55
3,Prince Edward Island,J01FA,Macrolides,<65,Total,28.18,0.2,3.1,882,56
3,Prince Edward Island,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,27.81,0.2,1.1,312,57
3,Prince Edward Island,S01LA,Antineovascularization agents,<65,Total,**, ** , ** ,*,58
3,Prince Edward Island,N02BE,Anilides,<65,Total,25.19,0.2,0.9,260,59
3,Prince Edward Island,A06AD,Osmotically acting laxatives,<65,Total,25.17,0.2,0.7,191,60
3,Prince Edward Island,J01DB,First-generation cephalosporins,<65,Total,25.14,0.2,3.4,948,61
3,Prince Edward Island,N02CC,Selective serotonin (5HT1) agonists,<65,Total,24.31,0.2,0.4,118,62
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,24.21,0.2,0.2,49,63
3,Prince Edward Island,L01AX,Other alkylating agents,<65,Total,24.14,0.2,0.0,5,64
3,Prince Edward Island,N02AB,Phenylpiperidine derivatives,<65,Total,23.59,0.2,0.1,16,65
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",<65,Total,23.37,0.2,2.2,624,66
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",<65,Total,22.99,0.2,0.6,180,67
3,Prince Edward Island,A06AB,Contact laxatives,<65,Total,22.64,0.2,0.7,206,68
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,21.80,0.2,0.1,22,69
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,<65,Total,21.64,0.2,0.6,170,70
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,21.14,0.2,3.2,906,71
3,Prince Edward Island,A03FA,Propulsives,<65,Total,20.81,0.1,1.3,355,72
3,Prince Edward Island,H02AB,Glucocorticoids,<65,Total,20.65,0.1,3.7,"1,052",73
3,Prince Edward Island,J01AA,Tetracyclines,<65,Total,20.55,0.1,3.7,"1,046",74
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,<65,Total,19.97,0.1,0.2,65,75
3,Prince Edward Island,R06AA,Aminoalkyl ethers,<65,Total,19.82,0.1,0.6,162,76
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,<65,Total,19.72,0.1,0.3,91,77
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,<65,Total,19.71,0.1,0.4,124,78
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,19.67,0.1,0.7,205,79
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,<65,Total,19.35,0.1,0.1,27,80
3,Prince Edward Island,G03AC,Progestogens,<65,Total,18.61,0.1,0.7,206,81
3,Prince Edward Island,C03CA,"Sulfonamides, plain",<65,Total,17.98,0.1,1.3,355,82
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,<65,Total,17.25,0.1,0.6,177,83
3,Prince Edward Island,L01BA,Folic acid analogues,<65,Total,16.97,0.1,0.4,121,84
3,Prince Edward Island,N05AA,Phenothiazines with aliphatic side-chain,<65,Total,16.92,0.1,0.4,104,85
3,Prince Edward Island,L04AD,Calcineurin inhibitors,<65,Total,16.10,0.1,0.0,7,86
3,Prince Edward Island,C09DA,Angiotensin II antagonists and diuretics,<65,Total,15.91,0.1,0.7,202,87
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,**, ** , ** ,*,88
3,Prince Edward Island,C01DA,Organic nitrates,<65,Total,15.57,0.1,0.5,150,89
3,Prince Edward Island,N03AB,Hydantoin derivatives,<65,Total,15.51,0.1,0.3,95,90
3,Prince Edward Island,B01AB,Heparin group,<65,Total,15.48,0.1,0.1,18,91
3,Prince Edward Island,G02BA,Intrauterine contraceptives,<65,Total,15.35,0.1,0.1,41,92
3,Prince Edward Island,L03AA,Colony-stimulating factors,<65,Total,14.92,0.1,0.0,8,93
3,Prince Edward Island,C03AA,"Thiazides, plain",<65,Total,14.54,0.1,2.7,772,94
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,<65,Total,13.51,0.1,1.0,291,95
3,Prince Edward Island,R06AX,Other antihistamines for systemic use,<65,Total,13.16,0.1,0.2,58,96
3,Prince Edward Island,N05AD,Butyrophenone derivatives,<65,Total,12.97,0.1,0.2,58,97
3,Prince Edward Island,B01AA,Vitamin K antagonists,<65,Total,12.91,0.1,0.6,175,98
3,Prince Edward Island,M05BA,Bisphosphonates,<65,Total,12.53,0.1,0.4,108,99
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,12.00,0.1,0.1,15,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"1,337.02",19.4,0.9,118,1
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,<65,M,703.54,10.2,3.5,445,2
3,Prince Edward Island,N05AX,Other antipsychotics,<65,M,400.69,5.8,2.5,318,3
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,365.46,5.3,3.7,469,4
3,Prince Edward Island,L01XE,Protein kinase inhibitors,<65,M,275.03,4.0,0.1,13,5
3,Prince Edward Island,L04AX,Other immunosuppressants,<65,M,204.97,3.0,0.3,33,6
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,<65,M,182.57,2.7,2.4,307,7
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,172.94,2.5,5.9,746,8
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,<65,M,154.87,2.3,8.3,"1,045",9
3,Prince Edward Island,N02AA,Natural opium alkaloids,<65,M,131.67,1.9,1.7,215,10
3,Prince Edward Island,A02BC,Proton pump inhibitors,<65,M,119.71,1.7,10.0,"1,267",11
3,Prince Edward Island,N03AX,Other antiepileptics,<65,M,118.35,1.7,3.1,386,12
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,<65,M,112.07,1.6,9.7,"1,222",13
3,Prince Edward Island,N06AX,Other antidepressants,<65,M,96.67,1.4,5.4,680,14
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,91.66,1.3,2.7,337,15
3,Prince Edward Island,L04AA,Selective immunosuppressants,<65,M,80.49,1.2,0.0,5,16
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",<65,M,78.64,1.1,1.7,211,17
3,Prince Edward Island,J07BB,Influenza vaccines,<65,M,69.93,1.0,45.4,"5,744",18
3,Prince Edward Island,L04AC,Interleukin inhibitors,<65,M,**, ** , ** ,*,19
3,Prince Edward Island,L02BB,Antiandrogens,<65,M,68.60,1.0,0.1,10,20
3,Prince Edward Island,R03BA,Glucocorticoids,<65,M,68.47,1.0,2.1,268,21
3,Prince Edward Island,N03AG,Fatty acid derivatives,<65,M,66.30,1.0,1.4,178,22
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,<65,M,62.96,0.9,3.0,375,23
3,Prince Edward Island,A10BA,Biguanides,<65,M,58.34,0.8,12.7,"1,601",24
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",<65,M,57.68,0.8,5.9,744,25
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,<65,M,55.27,0.8,2.1,268,26
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,<65,M,46.12,0.7,3.7,466,27
3,Prince Edward Island,L02BX,Other hormone antagonists and related agents,<65,M,**, ** , ** ,*,28
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,43.55,0.6,6.4,808,29
3,Prince Edward Island,L03AB,Interferons,<65,M,**, ** , ** ,**,30
3,Prince Edward Island,L03AX,Other immunostimulants,<65,M,40.46,0.6,0.0,5,31
3,Prince Edward Island,R03BB,Anticholinergics,<65,M,38.40,0.6,1.2,156,32
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,36.65,0.5,2.7,341,33
3,Prince Edward Island,A10BB,Sulfonylureas,<65,M,36.13,0.5,5.8,729,34
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,<65,M,35.84,0.5,1.3,158,35
3,Prince Edward Island,A02BA,H2-receptor antagonists,<65,M,33.03,0.5,2.2,277,36
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,32.94,0.5,0.3,38,37
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,31.03,0.5,1.9,243,38
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,<65,M,**, ** , ** ,**,39
3,Prince Edward Island,R01AD,Corticosteroids,<65,M,27.67,0.4,4.8,610,40
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",<65,M,25.89,0.4,4.4,556,41
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,25.70,0.4,1.9,240,42
3,Prince Edward Island,C09CA,"Angiotensin II antagonists, plain",<65,M,23.56,0.3,2.4,300,43
3,Prince Edward Island,M01AE,Propionic acid derivatives,<65,M,22.33,0.3,5.2,651,44
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,<65,M,21.35,0.3,1.0,125,45
3,Prince Edward Island,N07XX,Other nervous system drugs,<65,M,**, ** , ** ,*,46
3,Prince Edward Island,N03AF,Carboxamide derivatives,<65,M,18.93,0.3,0.7,88,47
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,<65,M,17.22,0.3,9.3,"1,180",48
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,<65,M,15.86,0.2,0.2,29,49
3,Prince Edward Island,H03AA,Thyroid hormones,<65,M,15.63,0.2,1.1,142,50
3,Prince Edward Island,C07AG,Alpha- and beta-blocking agents,<65,M,13.72,0.2,0.3,39,51
3,Prince Edward Island,N02BE,Anilides,<65,M,13.51,0.2,0.9,118,52
3,Prince Edward Island,A06AB,Contact laxatives,<65,M,12.90,0.2,0.8,95,53
3,Prince Edward Island,M03BX,Other centrally acting agents,<65,M,12.77,0.2,0.6,82,54
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,<65,M,12.65,0.2,0.1,18,55
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",<65,M,12.40,0.2,1.9,245,56
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,<65,M,12.11,0.2,0.7,91,57
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,11.82,0.2,0.2,26,58
3,Prince Edward Island,J01DB,First-generation cephalosporins,<65,M,11.27,0.2,3.4,428,59
3,Prince Edward Island,R06AE,Piperazine derivatives,<65,M,11.22,0.2,0.4,56,60
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",<65,M,10.76,0.2,0.6,72,61
3,Prince Edward Island,L04AD,Calcineurin inhibitors,<65,M,**, ** , ** ,*,62
3,Prince Edward Island,A06AD,Osmotically acting laxatives,<65,M,10.40,0.2,0.6,77,63
3,Prince Edward Island,N03AB,Hydantoin derivatives,<65,M,10.35,0.2,0.5,60,64
3,Prince Edward Island,J01FA,Macrolides,<65,M,10.15,0.1,2.5,320,65
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,<65,M,9.70,0.1,0.4,45,66
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,9.64,0.1,0.7,87,67
3,Prince Edward Island,G03HA,"Antiandrogens, plain",<65,M,9.53,0.1,0.1,10,68
3,Prince Edward Island,N05AA,Phenothiazines with aliphatic side-chain,<65,M,9.25,0.1,0.4,50,69
3,Prince Edward Island,G04CA,Alpha-adrenoreceptor antagonists,<65,M,9.24,0.1,1.4,172,70
3,Prince Edward Island,B01AA,Vitamin K antagonists,<65,M,8.72,0.1,0.9,118,71
3,Prince Edward Island,S01ED,Beta-blocking agents,<65,M,8.68,0.1,0.2,21,72
3,Prince Edward Island,N05AD,Butyrophenone derivatives,<65,M,8.44,0.1,0.2,28,73
3,Prince Edward Island,N02AB,Phenylpiperidine derivatives,<65,M,8.24,0.1,0.0,5,74
3,Prince Edward Island,H01BA,Vasopressin and analogues,<65,M,8.23,0.1,0.1,10,75
3,Prince Edward Island,J01AA,Tetracyclines,<65,M,8.03,0.1,3.0,385,76
3,Prince Edward Island,C01DA,Organic nitrates,<65,M,7.93,0.1,0.7,86,77
3,Prince Edward Island,H02AB,Glucocorticoids,<65,M,7.86,0.1,3.3,414,78
3,Prince Edward Island,C09DA,Angiotensin II antagonists and diuretics,<65,M,7.79,0.1,0.7,93,79
3,Prince Edward Island,M01AB,Acetic acid derivatives and related substances,<65,M,7.58,0.1,1.2,154,80
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,7.38,0.1,2.8,358,81
3,Prince Edward Island,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,7.11,0.1,0.1,9,82
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,<65,M,7.09,0.1,0.4,48,83
3,Prince Edward Island,C03CA,"Sulfonamides, plain",<65,M,7.07,0.1,1.2,149,84
3,Prince Edward Island,A03FA,Propulsives,<65,M,6.87,0.1,0.8,106,85
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,6.78,0.1,0.1,16,86
3,Prince Edward Island,N04BA,Dopa and dopa derivatives,<65,M,6.76,0.1,0.2,22,87
3,Prince Edward Island,S01LA,Antineovascularization agents,<65,M,**, ** , ** ,*,88
3,Prince Edward Island,N04AC,Ethers of tropine or tropine derivatives,<65,M,6.37,0.1,0.4,49,89
3,Prince Edward Island,N07BA,Drugs used in nicotine dependence,<65,M,5.60,0.1,0.5,57,90
3,Prince Edward Island,C03AA,"Thiazides, plain",<65,M,5.55,0.1,2.5,316,91
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,<65,M,5.42,0.1,0.4,50,92
3,Prince Edward Island,N05BE,Azaspirodecanedione derivatives,<65,M,5.26,0.1,0.2,27,93
3,Prince Edward Island,M04AA,Preparations inhibiting uric acid production,<65,M,5.13,0.1,0.9,113,94
3,Prince Edward Island,C03DA,Aldosterone antagonists,<65,M,5.10,0.1,0.6,76,95
3,Prince Edward Island,L01BA,Folic acid analogues,<65,M,5.06,0.1,0.3,40,96
3,Prince Edward Island,R06AX,Other antihistamines for systemic use,<65,M,4.76,0.1,0.2,22,97
3,Prince Edward Island,N03AD,Succinimide derivatives,<65,M,**, ** , ** ,*,98
3,Prince Edward Island,N05AB,Phenothiazines with piperazine structure,<65,M,4.33,0.1,0.2,22,99
3,Prince Edward Island,G04CB,Testosterone-5-alpha reductase inhibitors,<65,M,4.31,0.1,0.3,40,100
3,Prince Edward Island,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"1,542.61",21.8,0.9,133,1
3,Prince Edward Island,N07BC,Drugs used in opioid dependence,<65,F,617.30,8.7,2.3,358,2
3,Prince Edward Island,L04AA,Selective immunosuppressants,<65,F,260.87,3.7,0.2,33,3
3,Prince Edward Island,N06AB,Selective serotonin reuptake inhibitors,<65,F,235.95,3.3,12.3,"1,911",4
3,Prince Edward Island,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,217.04,3.1,2.8,436,5
3,Prince Edward Island,N03AX,Other antiepileptics,<65,F,177.17,2.5,4.0,624,6
3,Prince Edward Island,N02AA,Natural opium alkaloids,<65,F,170.90,2.4,2.0,315,7
3,Prince Edward Island,L03AB,Interferons,<65,F,**, ** , ** ,**,8
3,Prince Edward Island,L04AC,Interleukin inhibitors,<65,F,**, ** , ** ,**,9
3,Prince Edward Island,A02BC,Proton pump inhibitors,<65,F,138.40,2.0,10.6,"1,646",10
3,Prince Edward Island,N06AX,Other antidepressants,<65,F,131.70,1.9,7.6,"1,186",11
3,Prince Edward Island,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,131.46,1.9,4.1,634,12
3,Prince Edward Island,N05AX,Other antipsychotics,<65,F,123.31,1.7,1.1,170,13
3,Prince Edward Island,R03BA,Glucocorticoids,<65,F,102.68,1.5,2.5,396,14
3,Prince Edward Island,N06BA,Centrally acting sympathomimetics,<65,F,99.12,1.4,1.3,200,15
3,Prince Edward Island,J07BB,Influenza vaccines,<65,F,93.61,1.3,49.5,"7,704",16
3,Prince Edward Island,L01XE,Protein kinase inhibitors,<65,F,91.06,1.3,0.1,8,17
3,Prince Edward Island,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,88.73,1.3,1.9,296,18
3,Prince Edward Island,C10AA,HMG-CoA reductase inhibitors,<65,F,88.21,1.2,5.9,921,19
3,Prince Edward Island,A10AE,"Insulins and analogues for injection, long-acting",<65,F,74.29,1.1,1.1,179,20
3,Prince Edward Island,L03AX,Other immunostimulants,<65,F,72.74,1.0,0.1,13,21
3,Prince Edward Island,N05BA,Benzodiazepine derivatives,<65,F,66.74,0.9,3.5,550,22
3,Prince Edward Island,N05CF,Benzodiazepine-related drugs,<65,F,58.69,0.8,2.3,353,23
3,Prince Edward Island,N07XX,Other nervous system drugs,<65,F,**, ** , ** ,**,24
3,Prince Edward Island,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,57.11,0.8,7.6,"1,178",25
3,Prince Edward Island,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,54.18,0.8,4.5,700,26
3,Prince Edward Island,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,53.47,0.8,3.1,479,27
3,Prince Edward Island,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,51.02,0.7,3.2,492,28
3,Prince Edward Island,R03BB,Anticholinergics,<65,F,50.63,0.7,1.4,216,29
3,Prince Edward Island,C09AA,"ACE inhibitors, plain",<65,F,44.43,0.6,3.5,543,30
3,Prince Edward Island,A10BA,Biguanides,<65,F,44.17,0.6,7.9,"1,223",31
3,Prince Edward Island,A02BA,H2-receptor antagonists,<65,F,41.95,0.6,2.9,451,32
3,Prince Edward Island,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,40.84,0.6,0.3,49,33
3,Prince Edward Island,R01AD,Corticosteroids,<65,F,38.59,0.5,6.0,935,34
3,Prince Edward Island,H03AA,Thyroid hormones,<65,F,36.61,0.5,2.9,452,35
3,Prince Edward Island,N03AG,Fatty acid derivatives,<65,F,34.84,0.5,0.9,140,36
3,Prince Edward Island,C08CA,Dihydropyridine derivatives,<65,F,34.36,0.5,2.3,364,37
3,Prince Edward Island,N03AE,Benzodiazepine derivatives,<65,F,34.19,0.5,1.3,206,38
3,Prince Edward Island,M01AE,Propionic acid derivatives,<65,F,32.51,0.5,6.5,"1,014",39
3,Prince Edward Island,L01XC,Monoclonal antibodies,<65,F,**, ** , ** ,*,40
3,Prince Edward Island,C09CA,"Angiotensin II antagonists, plain",<65,F,30.15,0.4,2.3,365,41
3,Prince Edward Island,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,27.81,0.4,2.0,312,42
3,Prince Edward Island,A10BB,Sulfonylureas,<65,F,27.31,0.4,3.1,484,43
3,Prince Edward Island,C02AC,Imidazoline receptor agonists,<65,F,25.39,0.4,1.3,202,44
3,Prince Edward Island,J01CA,Penicillins with extended spectrum,<65,F,23.96,0.3,11.1,"1,730",45
3,Prince Edward Island,L01AX,Other alkylating agents,<65,F,**, ** , ** ,*,46
3,Prince Edward Island,C07AB,"Beta-blocking agents, selective",<65,F,20.90,0.3,2.5,395,47
3,Prince Edward Island,A07EC,Aminosalicylic acid and similar agents,<65,F,20.74,0.3,0.3,44,48
3,Prince Edward Island,N02CC,Selective serotonin (5HT1) agonists,<65,F,20.70,0.3,0.6,92,49
3,Prince Edward Island,L04AX,Other immunosuppressants,<65,F,20.54,0.3,0.2,36,50
3,Prince Edward Island,R06AE,Piperazine derivatives,<65,F,19.26,0.3,0.7,103,51
3,Prince Edward Island,S01LA,Antineovascularization agents,<65,F,**, ** , ** ,*,52
3,Prince Edward Island,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,19.00,0.3,1.8,279,53
3,Prince Edward Island,G03AC,Progestogens,<65,F,18.43,0.3,1.3,204,54
3,Prince Edward Island,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,18.28,0.3,1.3,199,55
3,Prince Edward Island,J01FA,Macrolides,<65,F,18.02,0.3,3.6,562,56
3,Prince Edward Island,R06AA,Aminoalkyl ethers,<65,F,17.72,0.3,0.8,129,57
3,Prince Edward Island,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,17.47,0.2,0.9,144,58
3,Prince Edward Island,M03BX,Other centrally acting agents,<65,F,15.76,0.2,0.8,126,59
3,Prince Edward Island,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**, ** , ** ,*,60
3,Prince Edward Island,G02BA,Intrauterine contraceptives,<65,F,15.35,0.2,0.3,41,61
3,Prince Edward Island,N02AB,Phenylpiperidine derivatives,<65,F,15.35,0.2,0.1,11,62
3,Prince Edward Island,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,15.02,0.2,0.0,6,63
3,Prince Edward Island,A06AD,Osmotically acting laxatives,<65,F,14.77,0.2,0.7,114,64
3,Prince Edward Island,A03FA,Propulsives,<65,F,13.94,0.2,1.6,249,65
3,Prince Edward Island,J01DB,First-generation cephalosporins,<65,F,13.87,0.2,3.3,520,66
3,Prince Edward Island,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,13.77,0.2,3.5,548,67
3,Prince Edward Island,N03AF,Carboxamide derivatives,<65,F,13.76,0.2,0.6,86,68
3,Prince Edward Island,B01AB,Heparin group,<65,F,13.65,0.2,0.1,12,69
3,Prince Edward Island,H02AB,Glucocorticoids,<65,F,12.80,0.2,4.1,638,70
3,Prince Edward Island,L03AA,Colony-stimulating factors,<65,F,12.73,0.2,0.0,6,71
3,Prince Edward Island,N05CD,Benzodiazepine derivatives,<65,F,12.62,0.2,0.5,76,72
3,Prince Edward Island,J01AA,Tetracyclines,<65,F,12.52,0.2,4.2,661,73
3,Prince Edward Island,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,12.39,0.2,0.1,23,74
3,Prince Edward Island,C07AA,"Beta-blocking agents, non-selective",<65,F,12.23,0.2,0.7,108,75
3,Prince Edward Island,L01BA,Folic acid analogues,<65,F,11.91,0.2,0.5,81,76
3,Prince Edward Island,G04BD,Drugs for urinary frequency and incontinence,<65,F,11.83,0.2,0.8,127,77
3,Prince Edward Island,N02BE,Anilides,<65,F,11.68,0.2,0.9,142,78
3,Prince Edward Island,D07AC,"Corticosteroids, potent (group III)",<65,F,10.97,0.2,2.4,379,79
3,Prince Edward Island,C03CA,"Sulfonamides, plain",<65,F,10.91,0.2,1.3,206,80
3,Prince Edward Island,C08DB,Benzothiazepine derivatives,<65,F,10.02,0.1,0.3,46,81
3,Prince Edward Island,M05BA,Bisphosphonates,<65,F,9.75,0.1,0.5,81,82
3,Prince Edward Island,A06AB,Contact laxatives,<65,F,9.73,0.1,0.7,111,83
3,Prince Edward Island,L02BG,Aromatase inhibitors,<65,F,9.61,0.1,0.2,32,84
3,Prince Edward Island,C09BA,ACE inhibitors and diuretics,<65,F,9.52,0.1,0.5,79,85
3,Prince Edward Island,A03AA,"Synthetic anticholinergics, esters with tertiary amino group",<65,F,9.41,0.1,0.3,44,86
3,Prince Edward Island,C03AA,"Thiazides, plain",<65,F,8.99,0.1,2.9,456,87
3,Prince Edward Island,R06AX,Other antihistamines for systemic use,<65,F,8.40,0.1,0.2,36,88
3,Prince Edward Island,C09DA,Angiotensin II antagonists and diuretics,<65,F,8.12,0.1,0.7,109,89
3,Prince Edward Island,C10AC,Bile acid sequestrants,<65,F,8.08,0.1,0.2,30,90
3,Prince Edward Island,B03AA,"Iron bivalent, oral preparations",<65,F,8.01,0.1,0.4,67,91
3,Prince Edward Island,A03AX,Other drugs for functional gastrointestinal disorders,<65,F,7.81,0.1,0.2,29,92
3,Prince Edward Island,N05AA,Phenothiazines with aliphatic side-chain,<65,F,7.67,0.1,0.3,54,93
3,Prince Edward Island,C01DA,Organic nitrates,<65,F,7.64,0.1,0.4,64,94
3,Prince Edward Island,J01XE,Nitrofuran derivatives,<65,F,7.53,0.1,1.5,227,95
3,Prince Edward Island,A12AA,Calcium,<65,F,7.53,0.1,0.3,50,96
3,Prince Edward Island,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**, ** , ** ,*,97
3,Prince Edward Island,N05AE,Indole derivatives,<65,F,**, ** , ** ,*,98
3,Prince Edward Island,A05AA,Bile acids and derivatives,<65,F,6.93,0.1,0.1,8,99
3,Prince Edward Island,B01AF,Direct factor Xa inhibitors,<65,F,6.70,0.1,0.1,9,100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"23,915.36",11.5,1.0,"1,469",1
4,Nova Scotia,L04AX,Other immunosuppressants,Total,Total,"8,700.24",4.2,0.4,679,2
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,Total,Total,"8,075.40",3.9,44.2,"66,901",3
4,Nova Scotia,A02BC,Proton pump inhibitors,Total,Total,"6,411.98",3.1,34.8,"52,774",4
4,Nova Scotia,C09AA,"ACE inhibitors, plain",Total,Total,"5,791.19",2.8,22.6,"34,288",5
4,Nova Scotia,L01XE,Protein kinase inhibitors,Total,Total,"5,761.43",2.8,0.1,224,6
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"5,272.51",2.5,4.4,"6,621",7
4,Nova Scotia,L04AA,Selective immunosuppressants,Total,Total,"4,867.40",2.3,0.4,587,8
4,Nova Scotia,C08CA,Dihydropyridine derivatives,Total,Total,"4,501.51",2.2,18.3,"27,767",9
4,Nova Scotia,R03BB,Anticholinergics,Total,Total,"3,438.67",1.6,8.6,"13,087",10
4,Nova Scotia,N02AA,Natural opium alkaloids,Total,Total,"3,399.79",1.6,8.0,"12,061",11
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"3,393.78",1.6,15.5,"23,448",12
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,Total,Total,"3,296.34",1.6,0.1,84,13
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",Total,Total,"3,205.04",1.5,24.2,"36,688",14
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"3,079.75",1.5,4.5,"6,825",15
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"3,043.03",1.5,2.0,"3,073",16
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"2,577.17",1.2,0.5,825,17
4,Nova Scotia,C09CA,"Angiotensin II antagonists, plain",Total,Total,"2,563.89",1.2,13.0,"19,744",18
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"2,554.40",1.2,3.5,"5,276",19
4,Nova Scotia,L04AC,Interleukin inhibitors,Total,Total,"2,552.79",1.2,0.1,160,20
4,Nova Scotia,H03AA,Thyroid hormones,Total,Total,"2,524.78",1.2,21.7,"32,920",21
4,Nova Scotia,N06AX,Other antidepressants,Total,Total,"2,504.23",1.2,11.8,"17,911",22
4,Nova Scotia,R03BA,Glucocorticoids,Total,Total,"2,343.80",1.1,6.7,"10,173",23
4,Nova Scotia,L02BB,Antiandrogens,Total,Total,"2,246.73",1.1,0.3,500,24
4,Nova Scotia,N03AX,Other antiepileptics,Total,Total,"2,168.13",1.0,5.2,"7,933",25
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,Total,Total,"1,997.99",1.0,1.9,"2,942",26
4,Nova Scotia,A10BA,Biguanides,Total,Total,"1,772.03",0.8,15.2,"22,967",27
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,Total,Total,"1,745.97",0.8,5.3,"8,034",28
4,Nova Scotia,R07AX,Other respiratory system products,Total,Total,"1,583.82",0.8,0.0,7,29
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,534.61",0.7,16.7,"25,298",30
4,Nova Scotia,N05AX,Other antipsychotics,Total,Total,"1,490.46",0.7,1.8,"2,777",31
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"1,376.74",0.7,3.4,"5,215",32
4,Nova Scotia,N05BA,Benzodiazepine derivatives,Total,Total,"1,326.91",0.6,12.3,"18,602",33
4,Nova Scotia,B01AB,Heparin group,Total,Total,"1,316.29",0.6,0.9,"1,424",34
4,Nova Scotia,H01CB,Somatostatin and analogues,Total,Total,"1,313.13",0.6,0.1,113,35
4,Nova Scotia,A02BA,H2-receptor antagonists,Total,Total,"1,305.15",0.6,8.6,"12,953",36
4,Nova Scotia,N07XX,Other nervous system drugs,Total,Total,"1,290.72",0.6,0.1,122,37
4,Nova Scotia,S01EE,Prostaglandin analogues,Total,Total,"1,263.78",0.6,3.7,"5,602",38
4,Nova Scotia,C09DA,Angiotensin II antagonists and diuretics,Total,Total,"1,235.35",0.6,6.3,"9,525",39
4,Nova Scotia,S01ED,Beta-blocking agents,Total,Total,"1,230.95",0.6,3.4,"5,133",40
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,216.54",0.6,7.6,"11,535",41
4,Nova Scotia,A10BB,Sulfonylureas,Total,Total,"1,214.41",0.6,7.9,"12,026",42
4,Nova Scotia,C03CA,"Sulfonamides, plain",Total,Total,"1,207.22",0.6,10.6,"16,049",43
4,Nova Scotia,C01DA,Organic nitrates,Total,Total,"1,114.81",0.5,6.8,"10,348",44
4,Nova Scotia,C08DB,Benzothiazepine derivatives,Total,Total,"1,112.66",0.5,2.9,"4,418",45
4,Nova Scotia,M05BA,Bisphosphonates,Total,Total,"1,111.96",0.5,5.4,"8,184",46
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"1,093.22",0.5,4.1,"6,251",47
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,Total,Total,"1,092.61",0.5,8.1,"12,197",48
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,Total,Total,"1,006.27",0.5,0.1,118,49
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,Total,Total,979.44,0.5,0.9,"1,395",50
4,Nova Scotia,N07BC,Drugs used in opioid dependence,Total,Total,937.36,0.4,0.6,920,51
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,Total,Total,925.41,0.4,3.4,"5,180",52
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,886.01,0.4,4.1,"6,214",53
4,Nova Scotia,B01AA,Vitamin K antagonists,Total,Total,884.62,0.4,5.6,"8,532",54
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,Total,884.22,0.4,8.6,"12,973",55
4,Nova Scotia,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,875.24,0.4,5.8,"8,833",56
4,Nova Scotia,C03AA,"Thiazides, plain",Total,Total,829.87,0.4,12.8,"19,432",57
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,813.55,0.4,0.9,"1,288",58
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,800.38,0.4,0.2,310,59
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,797.07,0.4,0.6,839,60
4,Nova Scotia,H02AB,Glucocorticoids,Total,Total,794.05,0.4,12.9,"19,518",61
4,Nova Scotia,L01XC,Monoclonal antibodies,Total,Total,792.47,0.4,0.0,67,62
4,Nova Scotia,N04BA,Dopa and dopa derivatives,Total,Total,776.33,0.4,1.1,"1,682",63
4,Nova Scotia,N06DA,Anticholinesterases,Total,Total,769.79,0.4,1.8,"2,736",64
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,752.09,0.4,7.0,"10,627",65
4,Nova Scotia,A12BA,Potassium,Total,Total,744.57,0.4,4.1,"6,172",66
4,Nova Scotia,A16AB,Enzymes,Total,Total,**, ** , ** ,*,67
4,Nova Scotia,B03XA,Other antianemic preparations,Total,Total,668.96,0.3,0.0,34,68
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,Total,Total,653.90,0.3,1.4,"2,072",69
4,Nova Scotia,B01AE,Direct thrombin inhibitors,Total,Total,631.27,0.3,0.4,651,70
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,Total,Total,605.40,0.3,4.8,"7,280",71
4,Nova Scotia,N03AE,Benzodiazepine derivatives,Total,Total,572.88,0.3,4.1,"6,179",72
4,Nova Scotia,R01AD,Corticosteroids,Total,Total,561.93,0.3,7.4,"11,213",73
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",Total,Total,533.03,0.3,2.0,"3,037",74
4,Nova Scotia,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,511.44,0.2,2.1,"3,244",75
4,Nova Scotia,S01XA,Other ophthalmologicals,Total,Total,499.25,0.2,4.5,"6,830",76
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",Total,Total,465.89,0.2,8.0,"12,187",77
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,454.95,0.2,0.0,27,78
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,Total,Total,454.56,0.2,0.8,"1,249",79
4,Nova Scotia,A03FA,Propulsives,Total,Total,454.51,0.2,4.2,"6,290",80
4,Nova Scotia,C10AX,Other lipid-modifying agents,Total,Total,435.89,0.2,2.2,"3,360",81
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,425.43,0.2,1.0,"1,546",82
4,Nova Scotia,L01AX,Other alkylating agents,Total,Total,411.11,0.2,0.1,78,83
4,Nova Scotia,M03BX,Other centrally acting agents,Total,Total,398.21,0.2,3.4,"5,131",84
4,Nova Scotia,J01DB,First-generation cephalosporins,Total,Total,390.88,0.2,8.5,"12,931",85
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,Total,Total,384.63,0.2,4.1,"6,158",86
4,Nova Scotia,A04AD,Other antiemetics,Total,Total,381.53,0.2,0.6,892,87
4,Nova Scotia,M01AE,Propionic acid derivatives,Total,Total,379.83,0.2,6.2,"9,377",88
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,376.43,0.2,0.0,28,89
4,Nova Scotia,L02BG,Aromatase inhibitors,Total,Total,372.17,0.2,0.7,"1,014",90
4,Nova Scotia,L01BA,Folic acid analogues,Total,Total,364.69,0.2,1.4,"2,061",91
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,Total,Total,358.83,0.2,0.1,195,92
4,Nova Scotia,M01AH,Coxibs,Total,Total,357.59,0.2,2.8,"4,173",93
4,Nova Scotia,J01AA,Tetracyclines,Total,Total,346.23,0.2,8.9,"13,438",94
4,Nova Scotia,S01BA,"Corticosteroids, plain",Total,Total,339.24,0.2,4.6,"6,925",95
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,334.31,0.2,2.7,"4,059",96
4,Nova Scotia,J01CA,Penicillins with extended spectrum,Total,Total,333.87,0.2,11.6,"17,584",97
4,Nova Scotia,M01AB,Acetic acid derivatives and related substances,Total,Total,331.24,0.2,2.7,"4,164",98
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,312.19,0.1,0.4,637,99
4,Nova Scotia,N02AB,Phenylpiperidine derivatives,Total,Total,290.67,0.1,0.3,454,100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"10,651.61",10.9,1.0,613,1
4,Nova Scotia,L04AX,Other immunosuppressants,Total,M,"5,302.27",5.4,0.5,314,2
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,Total,M,"4,027.79",4.1,51.8,"33,432",3
4,Nova Scotia,L01XE,Protein kinase inhibitors,Total,M,"3,348.38",3.4,0.2,124,4
4,Nova Scotia,C09AA,"ACE inhibitors, plain",Total,M,"2,901.81",3.0,26.8,"17,294",5
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"2,537.43",2.6,1.3,807,6
4,Nova Scotia,A02BC,Proton pump inhibitors,Total,M,"2,472.57",2.5,32.3,"20,826",7
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,418.00",2.5,4.6,"2,973",8
4,Nova Scotia,L02BB,Antiandrogens,Total,M,"2,246.73",2.3,0.8,500,9
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,Total,M,"2,185.98",2.2,0.1,58,10
4,Nova Scotia,C08CA,Dihydropyridine derivatives,Total,M,"1,941.15",2.0,18.9,"12,200",11
4,Nova Scotia,R03BB,Anticholinergics,Total,M,"1,663.89",1.7,9.4,"6,086",12
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"1,662.08",1.7,2.5,"1,582",13
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,"1,577.00",1.6,5.3,"3,414",14
4,Nova Scotia,N02AA,Natural opium alkaloids,Total,M,"1,553.74",1.6,7.8,"5,011",15
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",Total,M,"1,460.77",1.5,27.2,"17,574",16
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,391.33",1.4,4.2,"2,686",17
4,Nova Scotia,L04AC,Interleukin inhibitors,Total,M,"1,330.85",1.4,0.1,68,18
4,Nova Scotia,L04AA,Selective immunosuppressants,Total,M,"1,209.55",1.2,0.2,150,19
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,052.51",1.1,11.2,"7,217",20
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,Total,M,"1,006.27",1.0,0.2,118,21
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,Total,M,983.97,1.0,2.2,"1,394",22
4,Nova Scotia,C09CA,"Angiotensin II antagonists, plain",Total,M,980.08,1.0,12.1,"7,800",23
4,Nova Scotia,A10BA,Biguanides,Total,M,925.26,0.9,18.5,"11,962",24
4,Nova Scotia,N03AX,Other antiepileptics,Total,M,906.61,0.9,4.7,"3,051",25
4,Nova Scotia,R03BA,Glucocorticoids,Total,M,892.83,0.9,5.7,"3,702",26
4,Nova Scotia,R07AX,Other respiratory system products,Total,M,**, ** , ** ,*,27
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,Total,M,863.34,0.9,6.0,"3,882",28
4,Nova Scotia,N06AX,Other antidepressants,Total,M,839.89,0.9,9.1,"5,889",29
4,Nova Scotia,G04CA,Alpha-adrenoreceptor antagonists,Total,M,835.31,0.9,13.1,"8,446",30
4,Nova Scotia,N05AX,Other antipsychotics,Total,M,725.63,0.7,1.7,"1,121",31
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,665.61,0.7,15.8,"10,174",32
4,Nova Scotia,H01CB,Somatostatin and analogues,Total,M,661.92,0.7,0.1,56,33
4,Nova Scotia,H03AA,Thyroid hormones,Total,M,642.20,0.7,12.5,"8,092",34
4,Nova Scotia,A10BB,Sulfonylureas,Total,M,628.87,0.6,9.8,"6,332",35
4,Nova Scotia,B01AB,Heparin group,Total,M,617.23,0.6,1.0,627,36
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,603.95,0.6,3.3,"2,108",37
4,Nova Scotia,N07BC,Drugs used in opioid dependence,Total,M,591.13,0.6,0.9,581,38
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,539.89,0.6,4.9,"3,176",39
4,Nova Scotia,C01DA,Organic nitrates,Total,M,526.86,0.5,8.4,"5,419",40
4,Nova Scotia,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,510.80,0.5,5.0,"3,235",41
4,Nova Scotia,C03CA,"Sulfonamides, plain",Total,M,494.32,0.5,10.4,"6,704",42
4,Nova Scotia,S01ED,Beta-blocking agents,Total,M,490.80,0.5,3.3,"2,099",43
4,Nova Scotia,A02BA,H2-receptor antagonists,Total,M,489.21,0.5,7.3,"4,733",44
4,Nova Scotia,C09DA,Angiotensin II antagonists and diuretics,Total,M,474.20,0.5,5.8,"3,734",45
4,Nova Scotia,N04BA,Dopa and dopa derivatives,Total,M,467.17,0.5,1.4,907,46
4,Nova Scotia,N05BA,Benzodiazepine derivatives,Total,M,461.20,0.5,9.4,"6,059",47
4,Nova Scotia,S01EE,Prostaglandin analogues,Total,M,457.07,0.5,3.4,"2,180",48
4,Nova Scotia,C08DB,Benzothiazepine derivatives,Total,M,455.54,0.5,2.8,"1,788",49
4,Nova Scotia,B01AA,Vitamin K antagonists,Total,M,454.30,0.5,7.0,"4,543",50
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,Total,M,445.81,0.5,0.9,596,51
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,426.71,0.4,0.7,454,52
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,409.67,0.4,0.9,612,53
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,400.19,0.4,5.7,"3,690",54
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,Total,M,387.67,0.4,6.7,"4,329",55
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,Total,M,379.75,0.4,1.9,"1,214",56
4,Nova Scotia,B03XA,Other antianemic preparations,Total,M,378.39,0.4,0.0,19,57
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,Total,M,371.00,0.4,7.1,"4,602",58
4,Nova Scotia,N07XX,Other nervous system drugs,Total,M,354.43,0.4,0.1,43,59
4,Nova Scotia,B01AE,Direct thrombin inhibitors,Total,M,341.13,0.4,0.5,352,60
4,Nova Scotia,H02AB,Glucocorticoids,Total,M,333.93,0.3,12.6,"8,118",61
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,M,331.88,0.3,7.8,"5,028",62
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,322.44,0.3,7.2,"4,637",63
4,Nova Scotia,N06DA,Anticholinesterases,Total,M,285.72,0.3,1.6,"1,028",64
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,284.26,0.3,0.2,112,65
4,Nova Scotia,C03AA,"Thiazides, plain",Total,M,282.89,0.3,10.7,"6,883",66
4,Nova Scotia,L01AX,Other alkylating agents,Total,M,259.72,0.3,0.1,47,67
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,Total,M,255.63,0.3,1.1,710,68
4,Nova Scotia,R01AD,Corticosteroids,Total,M,248.16,0.3,7.0,"4,498",69
4,Nova Scotia,A12BA,Potassium,Total,M,242.01,0.2,3.1,"2,027",70
4,Nova Scotia,C10AX,Other lipid-modifying agents,Total,M,228.09,0.2,2.8,"1,784",71
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,Total,M,219.29,0.2,2.0,"1,315",72
4,Nova Scotia,N03AE,Benzodiazepine derivatives,Total,M,218.39,0.2,3.4,"2,195",73
4,Nova Scotia,L01XC,Monoclonal antibodies,Total,M,218.04,0.2,0.0,20,74
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",Total,M,216.64,0.2,2.0,"1,283",75
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",Total,M,215.58,0.2,8.1,"5,210",76
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,206.53,0.2,1.1,726,77
4,Nova Scotia,C02CA,Alpha-adrenoreceptor antagonists,Total,M,203.12,0.2,3.0,"1,913",78
4,Nova Scotia,A04AD,Other antiemetics,Total,M,175.19,0.2,0.6,395,79
4,Nova Scotia,L01XX,Other antineoplastic agents,Total,M,173.36,0.2,0.2,105,80
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,166.18,0.2,0.6,362,81
4,Nova Scotia,J01DB,First-generation cephalosporins,Total,M,162.28,0.2,8.4,"5,435",82
4,Nova Scotia,J01AA,Tetracyclines,Total,M,161.80,0.2,8.9,"5,713",83
4,Nova Scotia,A03FA,Propulsives,Total,M,159.49,0.2,3.6,"2,299",84
4,Nova Scotia,M01AE,Propionic acid derivatives,Total,M,157.52,0.2,5.9,"3,829",85
4,Nova Scotia,M03BX,Other centrally acting agents,Total,M,151.72,0.2,3.1,"2,030",86
4,Nova Scotia,M01AB,Acetic acid derivatives and related substances,Total,M,151.69,0.2,3.2,"2,066",87
4,Nova Scotia,M05BA,Bisphosphonates,Total,M,146.95,0.2,1.8,"1,152",88
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,Total,M,141.37,0.1,3.5,"2,282",89
4,Nova Scotia,M05BX,Other drugs affecting bone structure and mineralization,Total,M,140.74,0.1,0.1,48,90
4,Nova Scotia,C01AA,Digitalis glycosides,Total,M,138.90,0.1,1.6,"1,036",91
4,Nova Scotia,C03DA,Aldosterone antagonists,Total,M,138.06,0.1,2.4,"1,521",92
4,Nova Scotia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,137.92,0.1,0.2,146,93
4,Nova Scotia,N05CD,Benzodiazepine derivatives,Total,M,137.48,0.1,1.5,947,94
4,Nova Scotia,J01CA,Penicillins with extended spectrum,Total,M,133.90,0.1,10.8,"6,968",95
4,Nova Scotia,S01BA,"Corticosteroids, plain",Total,M,132.23,0.1,4.2,"2,721",96
4,Nova Scotia,C10AB,Fibrates,Total,M,129.33,0.1,1.5,968,97
4,Nova Scotia,M01AH,Coxibs,Total,M,127.53,0.1,2.4,"1,526",98
4,Nova Scotia,J01MA,Fluoroquinolones,Total,M,127.27,0.1,6.3,"4,035",99
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,124.69,0.1,2.0,"1,291",100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"13,263.75",11.9,1.0,856,1
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,Total,F,"4,047.62",3.6,38.5,"33,469",2
4,Nova Scotia,A02BC,Proton pump inhibitors,Total,F,"3,939.42",3.5,36.7,"31,948",3
4,Nova Scotia,L04AA,Selective immunosuppressants,Total,F,"3,657.85",3.3,0.5,437,4
4,Nova Scotia,L04AX,Other immunosuppressants,Total,F,"3,397.98",3.1,0.4,365,5
4,Nova Scotia,C09AA,"ACE inhibitors, plain",Total,F,"2,889.38",2.6,19.5,"16,994",6
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"2,854.51",2.6,4.2,"3,648",7
4,Nova Scotia,C08CA,Dihydropyridine derivatives,Total,F,"2,560.36",2.3,17.9,"15,567",8
4,Nova Scotia,L01XE,Protein kinase inhibitors,Total,F,"2,413.05",2.2,0.1,100,9
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,341.27",2.1,18.7,"16,231",10
4,Nova Scotia,H03AA,Thyroid hormones,Total,F,"1,882.57",1.7,28.5,"24,828",11
4,Nova Scotia,N02AA,Natural opium alkaloids,Total,F,"1,846.06",1.7,8.1,"7,050",12
4,Nova Scotia,R03BB,Anticholinergics,Total,F,"1,774.78",1.6,8.0,"7,001",13
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",Total,F,"1,744.27",1.6,22.0,"19,114",14
4,Nova Scotia,N06AX,Other antidepressants,Total,F,"1,664.34",1.5,13.8,"12,022",15
4,Nova Scotia,C09CA,"Angiotensin II antagonists, plain",Total,F,"1,583.80",1.4,13.7,"11,944",16
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,"1,502.75",1.4,3.9,"3,411",17
4,Nova Scotia,R03BA,Glucocorticoids,Total,F,"1,450.96",1.3,7.4,"6,471",18
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"1,380.94",1.2,1.7,"1,491",19
4,Nova Scotia,N03AX,Other antiepileptics,Total,F,"1,261.52",1.1,5.6,"4,882",20
4,Nova Scotia,L04AC,Interleukin inhibitors,Total,F,"1,221.94",1.1,0.1,92,21
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,163.07",1.0,3.0,"2,590",22
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,Total,F,"1,110.35",1.0,0.0,26,23
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,Total,F,"1,014.02",0.9,1.8,"1,548",24
4,Nova Scotia,M05BA,Bisphosphonates,Total,F,965.01,0.9,8.1,"7,032",25
4,Nova Scotia,N07XX,Other nervous system drugs,Total,F,936.29,0.8,0.1,79,26
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,884.11,0.8,7.1,"6,197",27
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,Total,F,882.64,0.8,4.8,"4,152",28
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,869.00,0.8,17.4,"15,124",29
4,Nova Scotia,N05BA,Benzodiazepine derivatives,Total,F,865.71,0.8,14.4,"12,543",30
4,Nova Scotia,A10BA,Biguanides,Total,F,846.77,0.8,12.7,"11,005",31
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,816.35,0.7,9.0,"7,845",32
4,Nova Scotia,A02BA,H2-receptor antagonists,Total,F,815.94,0.7,9.4,"8,220",33
4,Nova Scotia,S01EE,Prostaglandin analogues,Total,F,806.71,0.7,3.9,"3,422",34
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,772.78,0.7,3.6,"3,107",35
4,Nova Scotia,N05AX,Other antipsychotics,Total,F,764.83,0.7,1.9,"1,656",36
4,Nova Scotia,C09DA,Angiotensin II antagonists and diuretics,Total,F,761.15,0.7,6.7,"5,791",37
4,Nova Scotia,S01ED,Beta-blocking agents,Total,F,740.15,0.7,3.5,"3,034",38
4,Nova Scotia,C03CA,"Sulfonamides, plain",Total,F,712.90,0.6,10.7,"9,345",39
4,Nova Scotia,R07AX,Other respiratory system products,Total,F,**, ** , ** ,*,40
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,Total,F,706.11,0.6,4.4,"3,865",41
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,Total,F,704.94,0.6,9.0,"7,868",42
4,Nova Scotia,A16AB,Enzymes,Total,F,**, ** , ** ,*,43
4,Nova Scotia,B01AB,Heparin group,Total,F,699.06,0.6,0.9,797,44
4,Nova Scotia,C08DB,Benzothiazepine derivatives,Total,F,657.12,0.6,3.0,"2,630",45
4,Nova Scotia,H01CB,Somatostatin and analogues,Total,F,651.22,0.6,0.1,57,46
4,Nova Scotia,C01DA,Organic nitrates,Total,F,587.95,0.5,5.7,"4,929",47
4,Nova Scotia,A10BB,Sulfonylureas,Total,F,585.53,0.5,6.5,"5,694",48
4,Nova Scotia,L01XC,Monoclonal antibodies,Total,F,574.43,0.5,0.1,47,49
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,553.34,0.5,3.5,"3,075",50
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,F,552.34,0.5,9.1,"7,945",51
4,Nova Scotia,C03AA,"Thiazides, plain",Total,F,546.98,0.5,14.4,"12,549",52
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,Total,F,533.63,0.5,0.9,799,53
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,516.12,0.5,0.2,198,54
4,Nova Scotia,A12BA,Potassium,Total,F,502.56,0.5,4.8,"4,145",55
4,Nova Scotia,N06DA,Anticholinesterases,Total,F,484.07,0.4,2.0,"1,708",56
4,Nova Scotia,H02AB,Glucocorticoids,Total,F,460.12,0.4,13.1,"11,400",57
4,Nova Scotia,B01AA,Vitamin K antagonists,Total,F,430.33,0.4,4.6,"3,989",58
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,429.65,0.4,6.9,"5,990",59
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,403.88,0.4,0.8,676,60
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,380.15,0.3,0.0,23,61
4,Nova Scotia,S01XA,Other ophthalmologicals,Total,F,377.07,0.3,5.6,"4,875",62
4,Nova Scotia,L02BG,Aromatase inhibitors,Total,F,370.64,0.3,1.2,"1,008",63
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,370.36,0.3,0.4,385,64
4,Nova Scotia,N03AE,Benzodiazepine derivatives,Total,F,354.48,0.3,4.6,"3,984",65
4,Nova Scotia,N07BC,Drugs used in opioid dependence,Total,F,346.24,0.3,0.4,339,66
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",Total,F,316.40,0.3,2.0,"1,754",67
4,Nova Scotia,R01AD,Corticosteroids,Total,F,313.77,0.3,7.7,"6,715",68
4,Nova Scotia,N04BA,Dopa and dopa derivatives,Total,F,309.16,0.3,0.9,775,69
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,308.61,0.3,0.0,23,70
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,Total,F,300.45,0.3,0.2,166,71
4,Nova Scotia,A03FA,Propulsives,Total,F,295.02,0.3,4.6,"3,991",72
4,Nova Scotia,B03XA,Other antianemic preparations,Total,F,290.57,0.3,0.0,15,73
4,Nova Scotia,B01AE,Direct thrombin inhibitors,Total,F,290.14,0.3,0.3,299,74
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,Total,F,274.15,0.2,1.0,858,75
4,Nova Scotia,L01BA,Folic acid analogues,Total,F,251.82,0.2,1.6,"1,416",76
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",Total,F,250.31,0.2,8.0,"6,977",77
4,Nova Scotia,M03BX,Other centrally acting agents,Total,F,246.49,0.2,3.6,"3,101",78
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,Total,F,243.25,0.2,4.5,"3,876",79
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,Total,F,234.40,0.2,3.1,"2,678",80
4,Nova Scotia,J01XE,Nitrofuran derivatives,Total,F,232.84,0.2,8.1,"7,068",81
4,Nova Scotia,M01AH,Coxibs,Total,F,230.07,0.2,3.0,"2,647",82
4,Nova Scotia,J01DB,First-generation cephalosporins,Total,F,228.60,0.2,8.6,"7,496",83
4,Nova Scotia,M01AE,Propionic acid derivatives,Total,F,222.30,0.2,6.4,"5,548",84
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,218.90,0.2,0.9,820,85
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,209.62,0.2,3.2,"2,768",86
4,Nova Scotia,C10AX,Other lipid-modifying agents,Total,F,207.80,0.2,1.8,"1,576",87
4,Nova Scotia,S01BA,"Corticosteroids, plain",Total,F,207.01,0.2,4.8,"4,204",88
4,Nova Scotia,A04AD,Other antiemetics,Total,F,206.34,0.2,0.6,497,89
4,Nova Scotia,J01CA,Penicillins with extended spectrum,Total,F,199.97,0.2,12.2,"10,616",90
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,Total,F,198.93,0.2,0.6,539,91
4,Nova Scotia,J01AA,Tetracyclines,Total,F,184.43,0.2,8.9,"7,725",92
4,Nova Scotia,M01AB,Acetic acid derivatives and related substances,Total,F,179.55,0.2,2.4,"2,098",93
4,Nova Scotia,N02AB,Phenylpiperidine derivatives,Total,F,169.00,0.2,0.3,257,94
4,Nova Scotia,C10AC,Bile acid sequestrants,Total,F,159.41,0.1,0.9,769,95
4,Nova Scotia,N04BC,Dopamine agonists,Total,F,158.94,0.1,1.0,873,96
4,Nova Scotia,R03DC,Leukotriene receptor antagonists,Total,F,151.66,0.1,0.6,564,97
4,Nova Scotia,L01AX,Other alkylating agents,Total,F,151.39,0.1,0.0,31,98
4,Nova Scotia,C01AA,Digitalis glycosides,Total,F,149.04,0.1,1.2,"1,060",99
4,Nova Scotia,J01MA,Fluoroquinolones,Total,F,148.38,0.1,6.2,"5,398",100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"11,798.17",7.1,0.5,626,1
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,65+,Total,"7,687.49",4.6,49.0,"60,932",2
4,Nova Scotia,L04AX,Other immunosuppressants,65+,Total,"7,084.52",4.3,0.4,460,3
4,Nova Scotia,A02BC,Proton pump inhibitors,65+,Total,"5,943.23",3.6,37.4,"46,535",4
4,Nova Scotia,C09AA,"ACE inhibitors, plain",65+,Total,"5,469.41",3.3,24.9,"30,940",5
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"4,976.91",3.0,4.9,"6,038",6
4,Nova Scotia,L01XE,Protein kinase inhibitors,65+,Total,"4,575.63",2.7,0.1,176,7
4,Nova Scotia,C08CA,Dihydropyridine derivatives,65+,Total,"4,336.35",2.6,20.7,"25,787",8
4,Nova Scotia,R03BB,Anticholinergics,65+,Total,"3,248.91",1.9,9.6,"11,966",9
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",65+,Total,"3,075.83",1.8,27.3,"33,897",10
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"2,883.31",1.7,14.8,"18,407",11
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"2,694.44",1.6,4.6,"5,662",12
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"2,679.77",1.6,2.0,"2,527",13
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"2,491.37",1.5,0.6,781,14
4,Nova Scotia,C09CA,"Angiotensin II antagonists, plain",65+,Total,"2,468.02",1.5,14.7,"18,322",15
4,Nova Scotia,N02AA,Natural opium alkaloids,65+,Total,"2,428.38",1.5,7.9,"9,812",16
4,Nova Scotia,H03AA,Thyroid hormones,65+,Total,"2,381.43",1.4,23.9,"29,669",17
4,Nova Scotia,L02BB,Antiandrogens,65+,Total,"2,225.81",1.3,0.4,487,18
4,Nova Scotia,L04AA,Selective immunosuppressants,65+,Total,"2,212.06",1.3,0.3,327,19
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"2,161.86",1.3,3.3,"4,132",20
4,Nova Scotia,R03BA,Glucocorticoids,65+,Total,"2,144.21",1.3,6.9,"8,588",21
4,Nova Scotia,N06AX,Other antidepressants,65+,Total,"2,072.61",1.2,11.3,"14,069",22
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,65+,Total,"1,950.45",1.2,2.3,"2,818",23
4,Nova Scotia,N03AX,Other antiepileptics,65+,Total,"1,636.21",1.0,4.8,"6,014",24
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,65+,Total,"1,629.31",1.0,5.7,"7,141",25
4,Nova Scotia,A10BA,Biguanides,65+,Total,"1,628.75",1.0,15.9,"19,768",26
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"1,380.88",0.8,17.1,"21,237",27
4,Nova Scotia,L04AC,Interleukin inhibitors,65+,Total,"1,315.88",0.8,0.1,84,28
4,Nova Scotia,S01EE,Prostaglandin analogues,65+,Total,"1,247.17",0.7,4.4,"5,458",29
4,Nova Scotia,S01ED,Beta-blocking agents,65+,Total,"1,214.32",0.7,4.0,"5,003",30
4,Nova Scotia,A02BA,H2-receptor antagonists,65+,Total,"1,206.46",0.7,9.2,"11,392",31
4,Nova Scotia,C09DA,Angiotensin II antagonists and diuretics,65+,Total,"1,181.45",0.7,7.0,"8,721",32
4,Nova Scotia,C03CA,"Sulfonamides, plain",65+,Total,"1,151.75",0.7,11.9,"14,834",33
4,Nova Scotia,N05BA,Benzodiazepine derivatives,65+,Total,"1,149.85",0.7,12.6,"15,609",34
4,Nova Scotia,A10BB,Sulfonylureas,65+,Total,"1,136.71",0.7,8.5,"10,582",35
4,Nova Scotia,H01CB,Somatostatin and analogues,65+,Total,"1,106.66",0.7,0.1,83,36
4,Nova Scotia,C01DA,Organic nitrates,65+,Total,"1,082.10",0.6,7.8,"9,734",37
4,Nova Scotia,M05BA,Bisphosphonates,65+,Total,"1,081.27",0.6,6.3,"7,881",38
4,Nova Scotia,C08DB,Benzothiazepine derivatives,65+,Total,"1,078.55",0.6,3.3,"4,165",39
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"1,069.44",0.6,3.1,"3,896",40
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"1,052.17",0.6,4.7,"5,885",41
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"1,042.41",0.6,7.6,"9,419",42
4,Nova Scotia,B01AB,Heparin group,65+,Total,"1,034.67",0.6,1.0,"1,224",43
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,65+,Total,960.17,0.6,8.2,"10,250",44
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,65+,Total,955.75,0.6,0.1,110,45
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,65+,Total,880.05,0.5,0.9,"1,149",46
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,878.28,0.5,10.3,"12,868",47
4,Nova Scotia,N05AX,Other antipsychotics,65+,Total,868.06,0.5,1.7,"2,090",48
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,65+,Total,856.50,0.5,3.7,"4,625",49
4,Nova Scotia,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,853.11,0.5,6.8,"8,406",50
4,Nova Scotia,B01AA,Vitamin K antagonists,65+,Total,849.42,0.5,6.5,"8,074",51
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,831.32,0.5,4.4,"5,476",52
4,Nova Scotia,C03AA,"Thiazides, plain",65+,Total,792.93,0.5,14.3,"17,760",53
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,65+,Total,779.53,0.5,0.0,20,54
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,765.12,0.5,0.6,790,55
4,Nova Scotia,N06DA,Anticholinesterases,65+,Total,762.40,0.5,2.2,"2,716",56
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,761.96,0.5,0.9,"1,174",57
4,Nova Scotia,N04BA,Dopa and dopa derivatives,65+,Total,745.55,0.4,1.3,"1,595",58
4,Nova Scotia,A12BA,Potassium,65+,Total,707.87,0.4,4.6,"5,698",59
4,Nova Scotia,H02AB,Glucocorticoids,65+,Total,704.74,0.4,13.4,"16,727",60
4,Nova Scotia,B03XA,Other antianemic preparations,65+,Total,663.72,0.4,0.0,33,61
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,630.46,0.4,7.0,"8,695",62
4,Nova Scotia,B01AE,Direct thrombin inhibitors,65+,Total,624.25,0.4,0.5,642,63
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,65+,Total,596.04,0.4,1.4,"1,801",64
4,Nova Scotia,L01XC,Monoclonal antibodies,65+,Total,594.71,0.4,0.0,48,65
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,65+,Total,585.91,0.4,5.5,"6,843",66
4,Nova Scotia,R01AD,Corticosteroids,65+,Total,522.00,0.3,8.0,"9,932",67
4,Nova Scotia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,505.60,0.3,2.5,"3,171",68
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",65+,Total,499.10,0.3,2.1,"2,642",69
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,494.83,0.3,0.2,208,70
4,Nova Scotia,S01XA,Other ophthalmologicals,65+,Total,485.80,0.3,5.3,"6,628",71
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",65+,Total,429.64,0.3,8.6,"10,727",72
4,Nova Scotia,C10AX,Other lipid-modifying agents,65+,Total,420.58,0.3,2.5,"3,167",73
4,Nova Scotia,N03AE,Benzodiazepine derivatives,65+,Total,419.12,0.3,3.6,"4,452",74
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,397.00,0.2,1.1,"1,406",75
4,Nova Scotia,A03FA,Propulsives,65+,Total,394.26,0.2,4.3,"5,347",76
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,392.28,0.2,0.0,20,77
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,65+,Total,350.65,0.2,4.4,"5,502",78
4,Nova Scotia,L02BG,Aromatase inhibitors,65+,Total,348.70,0.2,0.7,893,79
4,Nova Scotia,J01DB,First-generation cephalosporins,65+,Total,348.61,0.2,8.9,"11,123",80
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,65+,Total,327.77,0.2,0.1,168,81
4,Nova Scotia,S01BA,"Corticosteroids, plain",65+,Total,327.35,0.2,5.3,"6,580",82
4,Nova Scotia,M01AH,Coxibs,65+,Total,326.33,0.2,2.9,"3,648",83
4,Nova Scotia,L01BA,Folic acid analogues,65+,Total,317.99,0.2,1.3,"1,637",84
4,Nova Scotia,M01AE,Propionic acid derivatives,65+,Total,314.80,0.2,5.7,"7,056",85
4,Nova Scotia,J01AA,Tetracyclines,65+,Total,309.78,0.2,9.4,"11,650",86
4,Nova Scotia,M01AB,Acetic acid derivatives and related substances,65+,Total,301.86,0.2,2.9,"3,573",87
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,292.28,0.2,2.7,"3,353",88
4,Nova Scotia,J01CA,Penicillins with extended spectrum,65+,Total,283.92,0.2,11.1,"13,861",89
4,Nova Scotia,C01AA,Digitalis glycosides,65+,Total,278.74,0.2,1.6,"1,990",90
4,Nova Scotia,L01XX,Other antineoplastic agents,65+,Total,276.24,0.2,0.2,233,91
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,274.48,0.2,0.0,19,92
4,Nova Scotia,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,272.73,0.2,0.2,266,93
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,266.33,0.2,0.5,560,94
4,Nova Scotia,C03DA,Aldosterone antagonists,65+,Total,258.04,0.2,2.3,"2,825",95
4,Nova Scotia,J01XE,Nitrofuran derivatives,65+,Total,257.13,0.2,5.9,"7,297",96
4,Nova Scotia,C10AC,Bile acid sequestrants,65+,Total,254.70,0.2,0.8,"1,041",97
4,Nova Scotia,J01MA,Fluoroquinolones,65+,Total,253.25,0.2,6.9,"8,623",98
4,Nova Scotia,M03BX,Other centrally acting agents,65+,Total,252.88,0.2,2.9,"3,643",99
4,Nova Scotia,N04BC,Dopamine agonists,65+,Total,251.81,0.2,1.0,"1,200",100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"4,597.04",5.9,0.4,226,1
4,Nova Scotia,L04AX,Other immunosuppressants,65+,M,"4,328.65",5.6,0.4,220,2
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,65+,M,"3,830.04",4.9,57.2,"30,417",3
4,Nova Scotia,C09AA,"ACE inhibitors, plain",65+,M,"2,729.26",3.5,29.2,"15,528",4
4,Nova Scotia,L01XE,Protein kinase inhibitors,65+,M,"2,546.12",3.3,0.2,100,5
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"2,491.37",3.2,1.5,781,6
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"2,283.69",2.9,5.1,"2,728",7
4,Nova Scotia,A02BC,Proton pump inhibitors,65+,M,"2,281.53",2.9,34.6,"18,408",8
4,Nova Scotia,L02BB,Antiandrogens,65+,M,"2,225.81",2.9,0.9,487,9
4,Nova Scotia,C08CA,Dihydropyridine derivatives,65+,M,"1,851.42",2.4,21.0,"11,170",10
4,Nova Scotia,R03BB,Anticholinergics,65+,M,"1,567.24",2.0,10.5,"5,589",11
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"1,509.71",1.9,2.5,"1,343",12
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",65+,M,"1,389.65",1.8,30.2,"16,089",13
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,"1,383.52",1.8,5.3,"2,833",14
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"1,190.33",1.5,4.0,"2,111",15
4,Nova Scotia,N02AA,Natural opium alkaloids,65+,M,"1,089.47",1.4,7.5,"3,980",16
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,65+,M,956.24,1.2,2.5,"1,337",17
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,65+,M,955.75,1.2,0.2,110,18
4,Nova Scotia,C09CA,"Angiotensin II antagonists, plain",65+,M,939.06,1.2,13.5,"7,203",19
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,65+,M,884.71,1.1,10.7,"5,708",20
4,Nova Scotia,A10BA,Biguanides,65+,M,854.77,1.1,19.6,"10,450",21
4,Nova Scotia,R03BA,Glucocorticoids,65+,M,821.30,1.1,5.8,"3,109",22
4,Nova Scotia,G04CA,Alpha-adrenoreceptor antagonists,65+,M,815.04,1.1,15.2,"8,085",23
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,65+,M,805.43,1.0,6.5,"3,441",24
4,Nova Scotia,N03AX,Other antiepileptics,65+,M,686.49,0.9,4.4,"2,318",25
4,Nova Scotia,N06AX,Other antidepressants,65+,M,677.73,0.9,8.7,"4,636",26
4,Nova Scotia,L04AC,Interleukin inhibitors,65+,M,667.11,0.9,0.1,38,27
4,Nova Scotia,L04AA,Selective immunosuppressants,65+,M,636.18,0.8,0.2,100,28
4,Nova Scotia,H03AA,Thyroid hormones,65+,M,611.09,0.8,13.9,"7,395",29
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,599.31,0.8,16.2,"8,620",30
4,Nova Scotia,A10BB,Sulfonylureas,65+,M,591.75,0.8,10.6,"5,623",31
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,65+,M,536.82,0.7,0.0,14,32
4,Nova Scotia,H01CB,Somatostatin and analogues,65+,M,535.06,0.7,0.1,40,33
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,518.06,0.7,5.5,"2,950",34
4,Nova Scotia,C01DA,Organic nitrates,65+,M,508.65,0.7,9.5,"5,064",35
4,Nova Scotia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,505.03,0.7,6.0,"3,165",36
4,Nova Scotia,B01AB,Heparin group,65+,M,497.17,0.6,1.0,541,37
4,Nova Scotia,S01ED,Beta-blocking agents,65+,M,483.10,0.6,3.8,"2,041",38
4,Nova Scotia,C03CA,"Sulfonamides, plain",65+,M,468.56,0.6,11.6,"6,162",39
4,Nova Scotia,C09DA,Angiotensin II antagonists and diuretics,65+,M,454.04,0.6,6.4,"3,422",40
4,Nova Scotia,S01EE,Prostaglandin analogues,65+,M,450.44,0.6,4.0,"2,125",41
4,Nova Scotia,N04BA,Dopa and dopa derivatives,65+,M,450.43,0.6,1.6,856,42
4,Nova Scotia,A02BA,H2-receptor antagonists,65+,M,449.75,0.6,7.9,"4,182",43
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,439.45,0.6,2.8,"1,512",44
4,Nova Scotia,C08DB,Benzothiazepine derivatives,65+,M,437.71,0.6,3.2,"1,679",45
4,Nova Scotia,B01AA,Vitamin K antagonists,65+,M,434.16,0.6,8.1,"4,300",46
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,413.25,0.5,0.8,431,47
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,65+,M,405.61,0.5,0.9,495,48
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,390.45,0.5,1.1,566,49
4,Nova Scotia,N05BA,Benzodiazepine derivatives,65+,M,381.46,0.5,9.5,"5,038",50
4,Nova Scotia,B03XA,Other antianemic preparations,65+,M,378.39,0.5,0.0,19,51
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,65+,M,356.15,0.5,8.1,"4,290",52
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,65+,M,349.42,0.5,2.0,"1,077",53
4,Nova Scotia,N05AX,Other antipsychotics,65+,M,345.06,0.4,1.4,738,54
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,338.02,0.4,5.7,"3,008",55
4,Nova Scotia,B01AE,Direct thrombin inhibitors,65+,M,335.00,0.4,0.6,344,56
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,65+,M,331.60,0.4,6.8,"3,625",57
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,329.48,0.4,9.4,"4,996",58
4,Nova Scotia,H02AB,Glucocorticoids,65+,M,292.75,0.4,13.2,"7,045",59
4,Nova Scotia,N06DA,Anticholinesterases,65+,M,282.56,0.4,1.9,"1,019",60
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,273.47,0.4,7.3,"3,864",61
4,Nova Scotia,C03AA,"Thiazides, plain",65+,M,267.73,0.3,11.8,"6,283",62
4,Nova Scotia,R01AD,Corticosteroids,65+,M,234.64,0.3,7.6,"4,068",63
4,Nova Scotia,A12BA,Potassium,65+,M,228.59,0.3,3.5,"1,850",64
4,Nova Scotia,C10AX,Other lipid-modifying agents,65+,M,219.67,0.3,3.1,"1,674",65
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",65+,M,204.63,0.3,2.1,"1,128",66
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,65+,M,203.84,0.3,2.2,"1,189",67
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",65+,M,201.10,0.3,8.8,"4,682",68
4,Nova Scotia,C02CA,Alpha-adrenoreceptor antagonists,65+,M,196.39,0.3,3.4,"1,824",69
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,192.31,0.2,1.2,660,70
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,179.04,0.2,0.2,81,71
4,Nova Scotia,L01XC,Monoclonal antibodies,65+,M,170.37,0.2,0.0,14,72
4,Nova Scotia,L01XX,Other antineoplastic agents,65+,M,163.26,0.2,0.2,100,73
4,Nova Scotia,J01AA,Tetracyclines,65+,M,147.05,0.2,9.6,"5,080",74
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,144.17,0.2,0.6,319,75
4,Nova Scotia,J01DB,First-generation cephalosporins,65+,M,143.71,0.2,8.8,"4,687",76
4,Nova Scotia,N03AE,Benzodiazepine derivatives,65+,M,140.72,0.2,2.9,"1,559",77
4,Nova Scotia,M01AB,Acetic acid derivatives and related substances,65+,M,140.12,0.2,3.4,"1,815",78
4,Nova Scotia,M05BA,Bisphosphonates,65+,M,139.44,0.2,2.0,"1,085",79
4,Nova Scotia,M05BX,Other drugs affecting bone structure and mineralization,65+,M,139.24,0.2,0.1,46,80
4,Nova Scotia,M01AE,Propionic acid derivatives,65+,M,134.48,0.2,5.6,"3,004",81
4,Nova Scotia,A03FA,Propulsives,65+,M,131.76,0.2,3.7,"1,953",82
4,Nova Scotia,C01AA,Digitalis glycosides,65+,M,131.47,0.2,1.8,959,83
4,Nova Scotia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,129.03,0.2,0.3,133,84
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,65+,M,128.04,0.2,3.8,"2,038",85
4,Nova Scotia,S01BA,"Corticosteroids, plain",65+,M,126.00,0.2,4.9,"2,582",86
4,Nova Scotia,C03DA,Aldosterone antagonists,65+,M,125.39,0.2,2.5,"1,318",87
4,Nova Scotia,C10AB,Fibrates,65+,M,118.49,0.2,1.6,828,88
4,Nova Scotia,S01XA,Other ophthalmologicals,65+,M,118.38,0.2,3.5,"1,886",89
4,Nova Scotia,M01AH,Coxibs,65+,M,117.74,0.2,2.5,"1,340",90
4,Nova Scotia,A04AD,Other antiemetics,65+,M,117.11,0.2,0.5,285,91
4,Nova Scotia,J01MA,Fluoroquinolones,65+,M,116.45,0.2,7.0,"3,732",92
4,Nova Scotia,J01CA,Penicillins with extended spectrum,65+,M,114.62,0.1,10.5,"5,568",93
4,Nova Scotia,N05CD,Benzodiazepine derivatives,65+,M,114.36,0.1,1.5,809,94
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,112.66,0.1,2.1,"1,116",95
4,Nova Scotia,C10AC,Bile acid sequestrants,65+,M,106.67,0.1,0.7,357,96
4,Nova Scotia,N04BC,Dopamine agonists,65+,M,105.73,0.1,0.9,462,97
4,Nova Scotia,G03BA,3-oxoandrosten (4) derivatives,65+,M,103.44,0.1,0.7,395,98
4,Nova Scotia,A09AA,Enzyme preparations,65+,M,98.69,0.1,0.2,112,99
4,Nova Scotia,L01BA,Folic acid analogues,65+,M,97.75,0.1,1.0,510,100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"7,201.13",8.1,0.6,400,1
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,65+,F,"3,857.45",4.3,42.9,"30,515",2
4,Nova Scotia,A02BC,Proton pump inhibitors,65+,F,"3,661.70",4.1,39.5,"28,127",3
4,Nova Scotia,L04AX,Other immunosuppressants,65+,F,"2,755.87",3.1,0.3,240,4
4,Nova Scotia,C09AA,"ACE inhibitors, plain",65+,F,"2,740.15",3.1,21.7,"15,412",5
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,693.22",3.0,4.7,"3,310",6
4,Nova Scotia,C08CA,Dihydropyridine derivatives,65+,F,"2,484.93",2.8,20.5,"14,617",7
4,Nova Scotia,L01XE,Protein kinase inhibitors,65+,F,"2,029.51",2.3,0.1,76,8
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,65+,F,"1,998.60",2.2,17.8,"12,699",9
4,Nova Scotia,H03AA,Thyroid hormones,65+,F,"1,770.34",2.0,31.3,"22,274",10
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",65+,F,"1,686.19",1.9,25.0,"17,808",11
4,Nova Scotia,R03BB,Anticholinergics,65+,F,"1,681.67",1.9,9.0,"6,377",12
4,Nova Scotia,L04AA,Selective immunosuppressants,65+,F,"1,575.87",1.8,0.3,227,13
4,Nova Scotia,C09CA,"Angiotensin II antagonists, plain",65+,F,"1,528.95",1.7,15.6,"11,119",14
4,Nova Scotia,N06AX,Other antidepressants,65+,F,"1,394.88",1.6,13.3,"9,433",15
4,Nova Scotia,N02AA,Natural opium alkaloids,65+,F,"1,338.92",1.5,8.2,"5,832",16
4,Nova Scotia,R03BA,Glucocorticoids,65+,F,"1,322.91",1.5,7.7,"5,479",17
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,"1,310.91",1.5,4.0,"2,829",18
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"1,170.06",1.3,1.7,"1,184",19
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,65+,F,994.21,1.1,2.1,"1,481",20
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,971.53,1.1,2.8,"2,021",21
4,Nova Scotia,N03AX,Other antiepileptics,65+,F,949.71,1.1,5.2,"3,696",22
4,Nova Scotia,M05BA,Bisphosphonates,65+,F,941.83,1.1,9.5,"6,796",23
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,830.80,0.9,7.7,"5,472",24
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,65+,F,823.88,0.9,5.2,"3,700",25
4,Nova Scotia,S01EE,Prostaglandin analogues,65+,F,796.74,0.9,4.7,"3,333",26
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,781.57,0.9,17.7,"12,617",27
4,Nova Scotia,A10BA,Biguanides,65+,F,773.97,0.9,13.1,"9,318",28
4,Nova Scotia,N05BA,Benzodiazepine derivatives,65+,F,768.38,0.9,14.9,"10,571",29
4,Nova Scotia,A02BA,H2-receptor antagonists,65+,F,756.72,0.8,10.1,"7,210",30
4,Nova Scotia,S01ED,Beta-blocking agents,65+,F,731.22,0.8,4.2,"2,962",31
4,Nova Scotia,C09DA,Angiotensin II antagonists and diuretics,65+,F,727.42,0.8,7.4,"5,299",32
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,704.38,0.8,9.0,"6,411",33
4,Nova Scotia,C03CA,"Sulfonamides, plain",65+,F,683.20,0.8,12.2,"8,672",34
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,65+,F,652.66,0.7,4.8,"3,436",35
4,Nova Scotia,L04AC,Interleukin inhibitors,65+,F,648.77,0.7,0.1,46,36
4,Nova Scotia,C08DB,Benzothiazepine derivatives,65+,F,640.83,0.7,3.5,"2,486",37
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,629.99,0.7,3.3,"2,384",38
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,65+,F,628.57,0.7,9.3,"6,625",39
4,Nova Scotia,C01DA,Organic nitrates,65+,F,573.45,0.6,6.6,"4,670",40
4,Nova Scotia,H01CB,Somatostatin and analogues,65+,F,571.61,0.6,0.1,43,41
4,Nova Scotia,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,548.79,0.6,11.1,"7,872",42
4,Nova Scotia,A10BB,Sulfonylureas,65+,F,544.96,0.6,7.0,"4,959",43
4,Nova Scotia,B01AB,Heparin group,65+,F,537.50,0.6,1.0,683,44
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,534.11,0.6,4.1,"2,935",45
4,Nova Scotia,C03AA,"Thiazides, plain",65+,F,525.20,0.6,16.1,"11,477",46
4,Nova Scotia,N05AX,Other antipsychotics,65+,F,523.00,0.6,1.9,"1,352",47
4,Nova Scotia,N06DA,Anticholinesterases,65+,F,479.84,0.5,2.4,"1,697",48
4,Nova Scotia,A12BA,Potassium,65+,F,479.28,0.5,5.4,"3,848",49
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,65+,F,474.43,0.5,0.9,654,50
4,Nova Scotia,L01XC,Monoclonal antibodies,65+,F,424.35,0.5,0.0,34,51
4,Nova Scotia,B01AA,Vitamin K antagonists,65+,F,415.26,0.5,5.3,"3,774",52
4,Nova Scotia,H02AB,Glucocorticoids,65+,F,411.99,0.5,13.6,"9,682",53
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,371.51,0.4,0.9,608,54
4,Nova Scotia,S01XA,Other ophthalmologicals,65+,F,367.42,0.4,6.7,"4,742",55
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,356.99,0.4,6.8,"4,831",56
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,351.86,0.4,0.5,359,57
4,Nova Scotia,L02BG,Aromatase inhibitors,65+,F,347.42,0.4,1.2,889,58
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,317.49,0.4,0.0,16,59
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,315.78,0.4,0.2,127,60
4,Nova Scotia,N04BA,Dopa and dopa derivatives,65+,F,295.12,0.3,1.0,739,61
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",65+,F,294.47,0.3,2.1,"1,514",62
4,Nova Scotia,B01AE,Direct thrombin inhibitors,65+,F,289.26,0.3,0.4,298,63
4,Nova Scotia,R01AD,Corticosteroids,65+,F,287.36,0.3,8.2,"5,864",64
4,Nova Scotia,B03XA,Other antianemic preparations,65+,F,285.34,0.3,0.0,14,65
4,Nova Scotia,N03AE,Benzodiazepine derivatives,65+,F,278.40,0.3,4.1,"2,893",66
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,65+,F,272.22,0.3,0.2,141,67
4,Nova Scotia,A03FA,Propulsives,65+,F,262.51,0.3,4.8,"3,394",68
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,65+,F,246.62,0.3,1.0,724,69
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,65+,F,242.72,0.3,0.0,6,70
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,65+,F,229.76,0.3,3.6,"2,553",71
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",65+,F,228.54,0.3,8.5,"6,045",72
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,65+,F,222.61,0.2,4.9,"3,464",73
4,Nova Scotia,L01BA,Folic acid analogues,65+,F,220.24,0.2,1.6,"1,127",74
4,Nova Scotia,J01XE,Nitrofuran derivatives,65+,F,214.93,0.2,8.7,"6,161",75
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,210.42,0.2,0.0,15,76
4,Nova Scotia,M01AH,Coxibs,65+,F,208.59,0.2,3.2,"2,308",77
4,Nova Scotia,J01DB,First-generation cephalosporins,65+,F,204.90,0.2,9.0,"6,436",78
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,204.69,0.2,1.0,746,79
4,Nova Scotia,S01BA,"Corticosteroids, plain",65+,F,201.35,0.2,5.6,"3,998",80
4,Nova Scotia,C10AX,Other lipid-modifying agents,65+,F,200.91,0.2,2.1,"1,493",81
4,Nova Scotia,M01AE,Propionic acid derivatives,65+,F,180.32,0.2,5.7,"4,052",82
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,179.62,0.2,3.1,"2,237",83
4,Nova Scotia,J01CA,Penicillins with extended spectrum,65+,F,169.30,0.2,11.7,"8,293",84
4,Nova Scotia,J01AA,Tetracyclines,65+,F,162.74,0.2,9.2,"6,570",85
4,Nova Scotia,M01AB,Acetic acid derivatives and related substances,65+,F,161.74,0.2,2.5,"1,758",86
4,Nova Scotia,M03BX,Other centrally acting agents,65+,F,157.32,0.2,3.0,"2,136",87
4,Nova Scotia,C10AC,Bile acid sequestrants,65+,F,148.03,0.2,1.0,684,88
4,Nova Scotia,C01AA,Digitalis glycosides,65+,F,147.27,0.2,1.4,"1,031",89
4,Nova Scotia,N04BC,Dopamine agonists,65+,F,146.08,0.2,1.0,738,90
4,Nova Scotia,R03DC,Leukotriene receptor antagonists,65+,F,138.00,0.2,0.7,466,91
4,Nova Scotia,J01MA,Fluoroquinolones,65+,F,136.80,0.2,6.9,"4,891",92
4,Nova Scotia,D07CA,"Corticosteroids, weak, combinations with antibiotics",65+,F,133.50,0.1,3.3,"2,375",93
4,Nova Scotia,M05BX,Other drugs affecting bone structure and mineralization,65+,F,133.48,0.1,0.3,220,94
4,Nova Scotia,C03DA,Aldosterone antagonists,65+,F,132.65,0.1,2.1,"1,507",95
4,Nova Scotia,N02AB,Phenylpiperidine derivatives,65+,F,131.32,0.1,0.3,202,96
4,Nova Scotia,D06AX,Other antibiotics for topical use,65+,F,129.04,0.1,4.8,"3,409",97
4,Nova Scotia,N05CD,Benzodiazepine derivatives,65+,F,127.00,0.1,1.9,"1,345",98
4,Nova Scotia,A04AD,Other antiemetics,65+,F,126.96,0.1,0.5,356,99
4,Nova Scotia,S01EC,Carbonic anhydrase inhibitors,65+,F,126.72,0.1,0.8,589,100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"12,117.19",28.9,3.1,843,1
4,Nova Scotia,L04AA,Selective immunosuppressants,<65,Total,"2,655.35",6.3,1.0,260,2
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,<65,Total,"2,516.80",6.0,0.2,64,3
4,Nova Scotia,L04AX,Other immunosuppressants,<65,Total,"1,615.72",3.9,0.8,219,4
4,Nova Scotia,R07AX,Other respiratory system products,<65,Total,"1,583.82",3.8,0.0,7,5
4,Nova Scotia,L04AC,Interleukin inhibitors,<65,Total,"1,236.91",2.9,0.3,76,6
4,Nova Scotia,L01XE,Protein kinase inhibitors,<65,Total,"1,185.80",2.8,0.2,48,7
4,Nova Scotia,N07XX,Other nervous system drugs,<65,Total,"1,179.26",2.8,0.4,95,8
4,Nova Scotia,N02AA,Natural opium alkaloids,<65,Total,971.41,2.3,8.3,"2,249",9
4,Nova Scotia,N07BC,Drugs used in opioid dependence,<65,Total,816.96,1.9,2.9,776,10
4,Nova Scotia,A16AB,Enzymes,<65,Total,**, ** , ** ,*,11
4,Nova Scotia,N05AX,Other antipsychotics,<65,Total,622.40,1.5,2.5,687,12
4,Nova Scotia,N03AX,Other antiepileptics,<65,Total,531.92,1.3,7.1,"1,919",13
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,<65,Total,510.47,1.2,18.6,"5,041",14
4,Nova Scotia,A02BC,Proton pump inhibitors,<65,Total,468.75,1.1,23.0,"6,239",15
4,Nova Scotia,N06AX,Other antidepressants,<65,Total,431.62,1.0,14.2,"3,842",16
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,<65,Total,394.38,0.9,3.8,"1,038",17
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,392.54,0.9,4.2,"1,144",18
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,<65,Total,387.91,0.9,22.0,"5,969",19
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,385.31,0.9,4.3,"1,163",20
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,363.25,0.9,2.0,546,21
4,Nova Scotia,C09AA,"ACE inhibitors, plain",<65,Total,321.78,0.8,12.4,"3,348",22
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,307.30,0.7,4.9,"1,319",23
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,305.55,0.7,0.4,102,24
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,295.59,0.7,2.2,583,25
4,Nova Scotia,B01AB,Heparin group,<65,Total,281.62,0.7,0.7,200,26
4,Nova Scotia,L01AX,Other alkylating agents,<65,Total,266.07,0.6,0.2,44,27
4,Nova Scotia,H01CB,Somatostatin and analogues,<65,Total,206.47,0.5,0.1,30,28
4,Nova Scotia,R03BA,Glucocorticoids,<65,Total,199.59,0.5,5.8,"1,585",29
4,Nova Scotia,L01XC,Monoclonal antibodies,<65,Total,197.75,0.5,0.1,19,30
4,Nova Scotia,R03BB,Anticholinergics,<65,Total,189.76,0.5,4.1,"1,121",31
4,Nova Scotia,N05BA,Benzodiazepine derivatives,<65,Total,177.06,0.4,11.0,"2,993",32
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,174.13,0.4,7.8,"2,116",33
4,Nova Scotia,C08CA,Dihydropyridine derivatives,<65,Total,165.16,0.4,7.3,"1,980",34
4,Nova Scotia,N03AE,Benzodiazepine derivatives,<65,Total,153.76,0.4,6.4,"1,727",35
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,153.73,0.4,15.0,"4,061",36
4,Nova Scotia,M03BX,Other centrally acting agents,<65,Total,145.33,0.3,5.5,"1,488",37
4,Nova Scotia,H03AA,Thyroid hormones,<65,Total,143.35,0.3,12.0,"3,251",38
4,Nova Scotia,A10BA,Biguanides,<65,Total,143.28,0.3,11.8,"3,199",39
4,Nova Scotia,A04AD,Other antiemetics,<65,Total,137.47,0.3,0.9,251,40
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,<65,Total,132.44,0.3,7.2,"1,947",41
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",<65,Total,129.21,0.3,10.3,"2,791",42
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,121.63,0.3,7.1,"1,932",43
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,<65,Total,116.66,0.3,3.3,893,44
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,101.95,0.2,0.0,9,45
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,<65,Total,99.39,0.2,0.9,246,46
4,Nova Scotia,A02BA,H2-receptor antagonists,<65,Total,98.69,0.2,5.8,"1,561",47
4,Nova Scotia,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,Total,97.34,0.2,0.3,87,48
4,Nova Scotia,C09CA,"Angiotensin II antagonists, plain",<65,Total,95.87,0.2,5.2,"1,422",49
4,Nova Scotia,H02AB,Glucocorticoids,<65,Total,89.31,0.2,10.3,"2,791",50
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,85.80,0.2,0.2,44,51
4,Nova Scotia,A10BB,Sulfonylureas,<65,Total,77.70,0.2,5.3,"1,444",52
4,Nova Scotia,N02AB,Phenylpiperidine derivatives,<65,Total,74.28,0.2,0.4,117,53
4,Nova Scotia,N03AG,Fatty acid derivatives,<65,Total,72.20,0.2,1.4,369,54
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,<65,Total,68.90,0.2,2.0,555,55
4,Nova Scotia,M01AE,Propionic acid derivatives,<65,Total,65.02,0.2,8.6,"2,321",56
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,62.66,0.1,0.0,7,57
4,Nova Scotia,A03FA,Propulsives,<65,Total,60.25,0.1,3.5,943,58
4,Nova Scotia,A04AA,Serotonin (5HT3) antagonists,<65,Total,59.04,0.1,1.0,267,59
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,<65,Total,57.86,0.1,1.0,271,60
4,Nova Scotia,C03CA,"Sulfonamides, plain",<65,Total,55.46,0.1,4.5,"1,215",61
4,Nova Scotia,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,54.96,0.1,3.5,961,62
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,54.69,0.1,2.7,738,63
4,Nova Scotia,C09DA,Angiotensin II antagonists and diuretics,<65,Total,53.90,0.1,3.0,804,64
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,51.59,0.1,0.4,114,65
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,<65,Total,50.51,0.1,0.0,8,66
4,Nova Scotia,J01CA,Penicillins with extended spectrum,<65,Total,49.95,0.1,13.7,"3,723",67
4,Nova Scotia,A07AA,Antibiotics,<65,Total,48.19,0.1,1.5,408,68
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,<65,Total,47.54,0.1,0.5,124,69
4,Nova Scotia,L01BA,Folic acid analogues,<65,Total,46.70,0.1,1.6,424,70
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,45.86,0.1,0.3,77,71
4,Nova Scotia,J02AC,Triazole derivatives,<65,Total,44.95,0.1,2.7,745,72
4,Nova Scotia,J01DB,First-generation cephalosporins,<65,Total,42.27,0.1,6.7,"1,808",73
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,42.03,0.1,2.6,706,74
4,Nova Scotia,N03AF,Carboxamide derivatives,<65,Total,41.59,0.1,0.9,242,75
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,41.05,0.1,1.4,366,76
4,Nova Scotia,R01AD,Corticosteroids,<65,Total,39.93,0.1,4.7,"1,281",77
4,Nova Scotia,C03AA,"Thiazides, plain",<65,Total,36.94,0.1,6.2,"1,672",78
4,Nova Scotia,A12BA,Potassium,<65,Total,36.70,0.1,1.7,474,79
4,Nova Scotia,J01AA,Tetracyclines,<65,Total,36.45,0.1,6.6,"1,788",80
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",<65,Total,36.25,0.1,5.4,"1,460",81
4,Nova Scotia,N05CD,Benzodiazepine derivatives,<65,Total,35.71,0.1,1.1,310,82
4,Nova Scotia,B01AA,Vitamin K antagonists,<65,Total,35.21,0.1,1.7,458,83
4,Nova Scotia,C08DB,Benzothiazepine derivatives,<65,Total,34.11,0.1,0.9,253,84
4,Nova Scotia,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,34.03,0.1,1.8,492,85
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,<65,Total,33.98,0.1,2.4,656,86
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",<65,Total,33.93,0.1,1.5,395,87
4,Nova Scotia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,33.78,0.1,0.1,17,88
4,Nova Scotia,C01DA,Organic nitrates,<65,Total,32.71,0.1,2.3,614,89
4,Nova Scotia,N05AA,Phenothiazines with aliphatic side-chain,<65,Total,32.27,0.1,0.8,217,90
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,31.95,0.1,0.2,49,91
4,Nova Scotia,M01AH,Coxibs,<65,Total,31.26,0.1,1.9,525,92
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,<65,Total,31.06,0.1,0.1,27,93
4,Nova Scotia,N04BA,Dopa and dopa derivatives,<65,Total,30.78,0.1,0.3,87,94
4,Nova Scotia,M05BA,Bisphosphonates,<65,Total,30.69,0.1,1.1,303,95
4,Nova Scotia,R05DA,Opium alkaloids and derivatives,<65,Total,30.02,0.1,0.6,166,96
4,Nova Scotia,M01AB,Acetic acid derivatives and related substances,<65,Total,29.38,0.1,2.2,591,97
4,Nova Scotia,C02AC,Imidazoline receptor agonists,<65,Total,29.06,0.1,1.1,291,98
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,28.43,0.1,0.5,140,99
4,Nova Scotia,J01FA,Macrolides,<65,Total,27.90,0.1,4.1,"1,116",100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"6,054.57",30.4,3.4,387,1
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,<65,M,"1,649.17",8.3,0.4,44,2
4,Nova Scotia,L04AX,Other immunosuppressants,<65,M,973.62,4.9,0.8,94,3
4,Nova Scotia,R07AX,Other respiratory system products,<65,M,**, ** , ** ,*,4
4,Nova Scotia,L01XE,Protein kinase inhibitors,<65,M,802.26,4.0,0.2,24,5
4,Nova Scotia,L04AC,Interleukin inhibitors,<65,M,663.74,3.3,0.3,30,6
4,Nova Scotia,L04AA,Selective immunosuppressants,<65,M,573.37,2.9,0.4,50,7
4,Nova Scotia,N07BC,Drugs used in opioid dependence,<65,M,514.95,2.6,4.3,490,8
4,Nova Scotia,N02AA,Natural opium alkaloids,<65,M,464.27,2.3,9.1,"1,031",9
4,Nova Scotia,N05AX,Other antipsychotics,<65,M,380.56,1.9,3.4,383,10
4,Nova Scotia,N07XX,Other nervous system drugs,<65,M,348.53,1.7,0.3,36,11
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,<65,M,227.63,1.1,5.3,594,12
4,Nova Scotia,N03AX,Other antiepileptics,<65,M,220.11,1.1,6.5,733,13
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,201.01,1.0,5.1,575,14
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,<65,M,197.75,1.0,26.7,"3,015",15
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,193.48,1.0,5.1,581,16
4,Nova Scotia,A02BC,Proton pump inhibitors,<65,M,191.03,1.0,21.4,"2,418",17
4,Nova Scotia,L01AX,Other alkylating agents,<65,M,172.85,0.9,0.2,28,18
4,Nova Scotia,C09AA,"ACE inhibitors, plain",<65,M,172.54,0.9,15.6,"1,766",19
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,<65,M,167.80,0.8,13.4,"1,509",20
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,164.50,0.8,5.3,596,21
4,Nova Scotia,N06AX,Other antidepressants,<65,M,162.16,0.8,11.1,"1,253",22
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",<65,M,152.37,0.8,2.1,239,23
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,134.31,0.7,2.2,245,24
4,Nova Scotia,H01CB,Somatostatin and analogues,<65,M,126.86,0.6,0.1,16,25
4,Nova Scotia,B01AB,Heparin group,<65,M,120.06,0.6,0.8,86,26
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,105.21,0.5,0.3,31,27
4,Nova Scotia,R03BB,Anticholinergics,<65,M,96.65,0.5,4.4,497,28
4,Nova Scotia,C08CA,Dihydropyridine derivatives,<65,M,89.73,0.5,9.1,"1,030",29
4,Nova Scotia,N05BA,Benzodiazepine derivatives,<65,M,79.73,0.4,9.0,"1,021",30
4,Nova Scotia,N03AE,Benzodiazepine derivatives,<65,M,77.68,0.4,5.6,636,31
4,Nova Scotia,R03BA,Glucocorticoids,<65,M,71.53,0.4,5.2,593,32
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",<65,M,71.13,0.4,13.1,"1,485",33
4,Nova Scotia,A10BA,Biguanides,<65,M,70.49,0.4,13.4,"1,512",34
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,66.30,0.3,13.7,"1,554",35
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,62.17,0.3,6.0,682,36
4,Nova Scotia,A04AD,Other antiemetics,<65,M,58.08,0.3,1.0,110,37
4,Nova Scotia,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,M,58.06,0.3,0.5,60,38
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,<65,M,57.90,0.3,3.9,441,39
4,Nova Scotia,M03BX,Other centrally acting agents,<65,M,56.16,0.3,4.6,523,40
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,<65,M,56.07,0.3,6.2,704,41
4,Nova Scotia,L02BX,Other hormone antagonists and related agents,<65,M,50.51,0.3,0.1,8,42
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,48.97,0.2,6.8,773,43
4,Nova Scotia,L01XC,Monoclonal antibodies,<65,M,47.68,0.2,0.1,6,44
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,<65,M,46.06,0.2,0.2,26,45
4,Nova Scotia,N03AG,Fatty acid derivatives,<65,M,41.18,0.2,1.6,179,46
4,Nova Scotia,H02AB,Glucocorticoids,<65,M,41.18,0.2,9.5,"1,073",47
4,Nova Scotia,C09CA,"Angiotensin II antagonists, plain",<65,M,41.02,0.2,5.3,597,48
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,<65,M,40.20,0.2,0.9,101,49
4,Nova Scotia,A02BA,H2-receptor antagonists,<65,M,39.47,0.2,4.9,551,50
4,Nova Scotia,A10BB,Sulfonylureas,<65,M,37.13,0.2,6.3,709,51
4,Nova Scotia,N02AB,Phenylpiperidine derivatives,<65,M,36.60,0.2,0.5,62,52
4,Nova Scotia,A07AA,Antibiotics,<65,M,34.34,0.2,1.2,130,53
4,Nova Scotia,H03AA,Thyroid hormones,<65,M,31.12,0.2,6.2,697,54
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,<65,M,30.33,0.2,1.2,137,55
4,Nova Scotia,A03FA,Propulsives,<65,M,27.74,0.1,3.1,346,56
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,<65,M,27.73,0.1,0.5,57,57
4,Nova Scotia,C03CA,"Sulfonamides, plain",<65,M,25.76,0.1,4.8,542,58
4,Nova Scotia,A04AA,Serotonin (5HT3) antagonists,<65,M,24.74,0.1,1.1,123,59
4,Nova Scotia,N05CD,Benzodiazepine derivatives,<65,M,23.12,0.1,1.2,138,60
4,Nova Scotia,M01AE,Propionic acid derivatives,<65,M,23.04,0.1,7.3,825,61
4,Nova Scotia,N05AA,Phenothiazines with aliphatic side-chain,<65,M,22.79,0.1,1.1,119,62
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,22.01,0.1,0.4,43,63
4,Nova Scotia,J02AC,Triazole derivatives,<65,M,21.86,0.1,0.8,90,64
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,21.82,0.1,2.0,226,65
4,Nova Scotia,L02BB,Antiandrogens,<65,M,20.92,0.1,0.1,13,66
4,Nova Scotia,G04CA,Alpha-adrenoreceptor antagonists,<65,M,20.27,0.1,3.2,361,67
4,Nova Scotia,C09DA,Angiotensin II antagonists and diuretics,<65,M,20.17,0.1,2.8,312,68
4,Nova Scotia,B01AA,Vitamin K antagonists,<65,M,20.14,0.1,2.2,243,69
4,Nova Scotia,J01CA,Penicillins with extended spectrum,<65,M,19.28,0.1,12.4,"1,400",70
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,19.23,0.1,0.4,46,71
4,Nova Scotia,J01DB,First-generation cephalosporins,<65,M,18.57,0.1,6.6,748,72
4,Nova Scotia,C01DA,Organic nitrates,<65,M,18.21,0.1,3.1,355,73
4,Nova Scotia,N03AB,Hydantoin derivatives,<65,M,17.92,0.1,1.1,128,74
4,Nova Scotia,C08DB,Benzothiazepine derivatives,<65,M,17.83,0.1,1.0,109,75
4,Nova Scotia,N04BA,Dopa and dopa derivatives,<65,M,16.74,0.1,0.5,51,76
4,Nova Scotia,B03AC,"Iron, parenteral preparations",<65,M,16.27,0.1,0.3,36,77
4,Nova Scotia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,16.10,0.1,0.1,10,78
4,Nova Scotia,N03AF,Carboxamide derivatives,<65,M,16.10,0.1,0.9,102,79
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,<65,M,15.45,0.1,1.1,126,80
4,Nova Scotia,C03AA,"Thiazides, plain",<65,M,15.17,0.1,5.3,600,81
4,Nova Scotia,L01BA,Folic acid analogues,<65,M,15.12,0.1,1.2,135,82
4,Nova Scotia,L03AX,Other immunostimulants,<65,M,**, ** , ** ,*,83
4,Nova Scotia,M04AA,Preparations inhibiting uric acid production,<65,M,14.84,0.1,2.8,312,84
4,Nova Scotia,J01AA,Tetracyclines,<65,M,14.75,0.1,5.6,633,85
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",<65,M,14.48,0.1,4.7,528,86
4,Nova Scotia,J01XA,Glycopeptide antibacterials,<65,M,14.22,0.1,0.1,7,87
4,Nova Scotia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,14.22,0.1,0.6,66,88
4,Nova Scotia,G03BA,3-oxoandrosten (4) derivatives,<65,M,14.20,0.1,1.0,115,89
4,Nova Scotia,R01AD,Corticosteroids,<65,M,13.52,0.1,3.8,430,90
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,13.46,0.1,0.2,23,91
4,Nova Scotia,A12BA,Potassium,<65,M,13.42,0.1,1.6,177,92
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,<65,M,13.33,0.1,2.2,244,93
4,Nova Scotia,C03DA,Aldosterone antagonists,<65,M,12.67,0.1,1.8,203,94
4,Nova Scotia,H05BX,Other anti-parathyroid agents,<65,M,12.58,0.1,0.0,5,95
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,12.03,0.1,1.5,175,96
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",<65,M,12.00,0.1,1.4,155,97
4,Nova Scotia,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,11.80,0.1,4.3,487,98
4,Nova Scotia,N05AE,Indole derivatives,<65,M,11.73,0.1,0.1,13,99
4,Nova Scotia,M01AB,Acetic acid derivatives and related substances,<65,M,11.57,0.1,2.2,251,100
4,Nova Scotia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"6,062.62",27.6,2.9,456,1
4,Nova Scotia,L04AA,Selective immunosuppressants,<65,F,"2,081.98",9.5,1.3,210,2
4,Nova Scotia,J05AP,Antivirals for treatment of HCV infections,<65,F,867.64,3.9,0.1,20,3
4,Nova Scotia,N07XX,Other nervous system drugs,<65,F,830.73,3.8,0.4,59,4
4,Nova Scotia,R07AX,Other respiratory system products,<65,F,**, ** , ** ,*,5
4,Nova Scotia,A16AB,Enzymes,<65,F,**, ** , ** ,*,6
4,Nova Scotia,L04AX,Other immunosuppressants,<65,F,642.10,2.9,0.8,125,7
4,Nova Scotia,L04AC,Interleukin inhibitors,<65,F,573.17,2.6,0.3,46,8
4,Nova Scotia,N02AA,Natural opium alkaloids,<65,F,507.14,2.3,7.7,"1,218",9
4,Nova Scotia,L01XE,Protein kinase inhibitors,<65,F,383.54,1.7,0.2,24,10
4,Nova Scotia,N06AB,Selective serotonin reuptake inhibitors,<65,F,342.68,1.6,22.3,"3,532",11
4,Nova Scotia,N03AX,Other antiepileptics,<65,F,311.81,1.4,7.5,"1,186",12
4,Nova Scotia,N07BC,Drugs used in opioid dependence,<65,F,302.01,1.4,1.8,286,13
4,Nova Scotia,A02BC,Proton pump inhibitors,<65,F,277.71,1.3,24.2,"3,821",14
4,Nova Scotia,N06AX,Other antidepressants,<65,F,269.46,1.2,16.4,"2,589",15
4,Nova Scotia,N05AX,Other antipsychotics,<65,F,241.83,1.1,1.9,304,16
4,Nova Scotia,A10AE,"Insulins and analogues for injection, long-acting",<65,F,210.88,1.0,1.9,307,17
4,Nova Scotia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,200.34,0.9,0.4,71,18
4,Nova Scotia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,191.83,0.9,3.7,582,19
4,Nova Scotia,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,191.54,0.9,3.6,569,20
4,Nova Scotia,C10AA,HMG-CoA reductase inhibitors,<65,F,190.16,0.9,18.7,"2,954",21
4,Nova Scotia,N06BA,Centrally acting sympathomimetics,<65,F,166.75,0.8,2.8,444,22
4,Nova Scotia,B01AB,Heparin group,<65,F,161.56,0.7,0.7,114,23
4,Nova Scotia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,161.28,0.7,2.1,338,24
4,Nova Scotia,L01XC,Monoclonal antibodies,<65,F,150.08,0.7,0.1,13,25
4,Nova Scotia,C09AA,"ACE inhibitors, plain",<65,F,149.23,0.7,10.0,"1,582",26
4,Nova Scotia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,142.80,0.6,4.6,723,27
4,Nova Scotia,R03BA,Glucocorticoids,<65,F,128.05,0.6,6.3,992,28
4,Nova Scotia,H03AA,Thyroid hormones,<65,F,112.23,0.5,16.2,"2,554",29
4,Nova Scotia,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,111.97,0.5,9.1,"1,434",30
4,Nova Scotia,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,98.19,0.4,0.1,8,31
4,Nova Scotia,N05BA,Benzodiazepine derivatives,<65,F,97.33,0.4,12.5,"1,972",32
4,Nova Scotia,L01AX,Other alkylating agents,<65,F,93.22,0.4,0.1,16,33
4,Nova Scotia,R03BB,Anticholinergics,<65,F,93.12,0.4,3.9,624,34
4,Nova Scotia,M03BX,Other centrally acting agents,<65,F,89.17,0.4,6.1,965,35
4,Nova Scotia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,87.43,0.4,15.9,"2,507",36
4,Nova Scotia,H01CB,Somatostatin and analogues,<65,F,79.61,0.4,0.1,14,37
4,Nova Scotia,A04AD,Other antiemetics,<65,F,79.38,0.4,0.9,141,38
4,Nova Scotia,N05CF,Benzodiazepine-related drugs,<65,F,76.37,0.3,7.9,"1,243",39
4,Nova Scotia,N03AE,Benzodiazepine derivatives,<65,F,76.08,0.3,6.9,"1,091",40
4,Nova Scotia,C08CA,Dihydropyridine derivatives,<65,F,75.43,0.3,6.0,950,41
4,Nova Scotia,A10BA,Biguanides,<65,F,72.80,0.3,10.7,"1,687",42
4,Nova Scotia,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,72.66,0.3,7.3,"1,159",43
4,Nova Scotia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,62.66,0.3,0.0,7,44
4,Nova Scotia,A02BA,H2-receptor antagonists,<65,F,59.23,0.3,6.4,"1,010",45
4,Nova Scotia,A07EC,Aminosalicylic acid and similar agents,<65,F,59.20,0.3,0.9,145,46
4,Nova Scotia,C09BA,ACE inhibitors and diuretics,<65,F,58.76,0.3,2.9,452,47
4,Nova Scotia,C07AB,"Beta-blocking agents, selective",<65,F,58.08,0.3,8.3,"1,306",48
4,Nova Scotia,C09CA,"Angiotensin II antagonists, plain",<65,F,54.85,0.2,5.2,825,49
4,Nova Scotia,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,54.84,0.2,6.1,960,50
4,Nova Scotia,G04BD,Drugs for urinary frequency and incontinence,<65,F,53.45,0.2,2.7,429,51
4,Nova Scotia,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,53.32,0.2,4.6,725,52
4,Nova Scotia,H02AB,Glucocorticoids,<65,F,48.13,0.2,10.9,"1,718",53
4,Nova Scotia,M01AE,Propionic acid derivatives,<65,F,41.98,0.2,9.5,"1,496",54
4,Nova Scotia,A10BB,Sulfonylureas,<65,F,40.57,0.2,4.7,735,55
4,Nova Scotia,L02AE,Gonadotropin-releasing hormone analogues,<65,F,39.74,0.2,0.1,18,56
4,Nova Scotia,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,F,39.28,0.2,0.2,27,57
4,Nova Scotia,N02AB,Phenylpiperidine derivatives,<65,F,37.68,0.2,0.3,55,58
4,Nova Scotia,A04AA,Serotonin (5HT3) antagonists,<65,F,34.30,0.2,0.9,144,59
4,Nova Scotia,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,34.03,0.2,3.1,491,60
4,Nova Scotia,C09DA,Angiotensin II antagonists and diuretics,<65,F,33.73,0.2,3.1,492,61
4,Nova Scotia,A03FA,Propulsives,<65,F,32.51,0.1,3.8,597,62
4,Nova Scotia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,32.37,0.1,0.4,68,63
4,Nova Scotia,L01BA,Folic acid analogues,<65,F,31.58,0.1,1.8,289,64
4,Nova Scotia,N03AG,Fatty acid derivatives,<65,F,31.02,0.1,1.2,190,65
4,Nova Scotia,J01CA,Penicillins with extended spectrum,<65,F,30.67,0.1,14.7,"2,323",66
4,Nova Scotia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,30.00,0.1,3.4,531,67
4,Nova Scotia,C03CA,"Sulfonamides, plain",<65,F,29.70,0.1,4.3,673,68
4,Nova Scotia,C05BA,Heparins or heparinoids for topical use,<65,F,28.22,0.1,0.2,25,69
4,Nova Scotia,C07AG,Alpha- and beta-blocking agents,<65,F,27.53,0.1,0.8,134,70
4,Nova Scotia,R01AD,Corticosteroids,<65,F,26.41,0.1,5.4,851,71
4,Nova Scotia,G02BA,Intrauterine contraceptives,<65,F,26.32,0.1,0.7,115,72
4,Nova Scotia,N03AF,Carboxamide derivatives,<65,F,25.49,0.1,0.9,140,73
4,Nova Scotia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,23.85,0.1,0.2,34,74
4,Nova Scotia,J01DB,First-generation cephalosporins,<65,F,23.69,0.1,6.7,"1,060",75
4,Nova Scotia,A12BA,Potassium,<65,F,23.28,0.1,1.9,297,76
4,Nova Scotia,L02BG,Aromatase inhibitors,<65,F,23.22,0.1,0.8,119,77
4,Nova Scotia,M05BA,Bisphosphonates,<65,F,23.18,0.1,1.5,236,78
4,Nova Scotia,J02AC,Triazole derivatives,<65,F,23.09,0.1,4.1,655,79
4,Nova Scotia,G03AC,Progestogens,<65,F,22.57,0.1,2.7,419,80
4,Nova Scotia,C07AA,"Beta-blocking agents, non-selective",<65,F,21.93,0.1,1.5,240,81
4,Nova Scotia,N02CC,Selective serotonin (5HT1) agonists,<65,F,21.89,0.1,1.3,206,82
4,Nova Scotia,C03AA,"Thiazides, plain",<65,F,21.77,0.1,6.8,"1,072",83
4,Nova Scotia,D07AC,"Corticosteroids, potent (group III)",<65,F,21.77,0.1,5.9,932,84
4,Nova Scotia,J01AA,Tetracyclines,<65,F,21.70,0.1,7.3,"1,155",85
4,Nova Scotia,M01AH,Coxibs,<65,F,21.48,0.1,2.1,339,86
4,Nova Scotia,R05DA,Opium alkaloids and derivatives,<65,F,21.38,0.1,0.7,111,87
4,Nova Scotia,D01AC,Imidazole and triazole derivatives,<65,F,20.64,0.1,2.6,412,88
4,Nova Scotia,B01AF,Direct factor Xa inhibitors,<65,F,19.81,0.1,0.4,67,89
4,Nova Scotia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,19.23,0.1,0.9,140,90
4,Nova Scotia,C02AC,Imidazoline receptor agonists,<65,F,18.93,0.1,1.2,197,91
4,Nova Scotia,J01FA,Macrolides,<65,F,18.57,0.1,4.6,726,92
4,Nova Scotia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,18.49,0.1,0.2,26,93
4,Nova Scotia,J01XE,Nitrofuran derivatives,<65,F,17.90,0.1,5.7,907,94
4,Nova Scotia,M01AB,Acetic acid derivatives and related substances,<65,F,17.81,0.1,2.2,340,95
4,Nova Scotia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,17.68,0.1,0.0,7,96
4,Nova Scotia,C08DB,Benzothiazepine derivatives,<65,F,16.29,0.1,0.9,144,97
4,Nova Scotia,N05AE,Indole derivatives,<65,F,16.06,0.1,0.1,15,98
4,Nova Scotia,D06AX,Other antibiotics for topical use,<65,F,15.31,0.1,3.4,543,99
4,Nova Scotia,B01AA,Vitamin K antagonists,<65,F,15.07,0.1,1.4,215,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"20,371.87",8.6,0.9,"1,097",1
5,New Brunswick,L01XE,Protein kinase inhibitors,Total,Total,"8,146.56",3.4,0.2,243,2
5,New Brunswick,S01LA,Antineovascularization agents,Total,Total,"8,061.44",3.4,0.7,933,3
5,New Brunswick,L04AX,Other immunosuppressants,Total,Total,"7,322.19",3.1,0.5,594,4
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,Total,Total,"6,997.36",2.9,0.1,157,5
5,New Brunswick,N07BC,Drugs used in opioid dependence,Total,Total,"6,866.32",2.9,2.1,"2,696",6
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"6,444.34",2.7,5.9,"7,543",7
5,New Brunswick,N05AX,Other antipsychotics,Total,Total,"6,331.88",2.7,5.0,"6,411",8
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,Total,Total,"6,034.82",2.5,38.6,"49,741",9
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"5,915.16",2.5,9.2,"11,875",10
5,New Brunswick,A02BC,Proton pump inhibitors,Total,Total,"5,898.94",2.5,37.4,"48,166",11
5,New Brunswick,C09AA,"ACE inhibitors, plain",Total,Total,"5,720.35",2.4,22.2,"28,572",12
5,New Brunswick,L04AA,Selective immunosuppressants,Total,Total,"5,582.36",2.3,0.7,893,13
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"4,736.02",2.0,18.9,"24,374",14
5,New Brunswick,N02AA,Natural opium alkaloids,Total,Total,"4,464.11",1.9,8.9,"11,522",15
5,New Brunswick,C08CA,Dihydropyridine derivatives,Total,Total,"3,872.16",1.6,16.1,"20,806",16
5,New Brunswick,N06AX,Other antidepressants,Total,Total,"3,698.69",1.6,13.3,"17,130",17
5,New Brunswick,N03AX,Other antiepileptics,Total,Total,"3,603.49",1.5,10.6,"13,636",18
5,New Brunswick,R03BB,Anticholinergics,Total,Total,"3,375.50",1.4,8.9,"11,442",19
5,New Brunswick,R03BA,Glucocorticoids,Total,Total,"3,091.04",1.3,9.8,"12,690",20
5,New Brunswick,B01AF,Direct factor Xa inhibitors,Total,Total,"3,036.19",1.3,3.2,"4,160",21
5,New Brunswick,L04AC,Interleukin inhibitors,Total,Total,"3,026.45",1.3,0.1,176,22
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"2,789.17",1.2,0.2,255,23
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"2,751.10",1.2,2.5,"3,260",24
5,New Brunswick,N05CF,Benzodiazepine-related drugs,Total,Total,"2,693.77",1.1,14.0,"18,093",25
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"2,496.64",1.0,2.5,"3,210",26
5,New Brunswick,N05BA,Benzodiazepine derivatives,Total,Total,"2,272.29",1.0,19.1,"24,663",27
5,New Brunswick,C09BA,ACE inhibitors and diuretics,Total,Total,"2,238.85",0.9,5.8,"7,471",28
5,New Brunswick,N07XX,Other nervous system drugs,Total,Total,"2,135.12",0.9,0.2,214,29
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"2,100.63",0.9,3.0,"3,845",30
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"2,046.69",0.9,5.3,"6,864",31
5,New Brunswick,B03XA,Other antianemic preparations,Total,Total,"1,953.88",0.8,0.3,353,32
5,New Brunswick,C07AB,"Beta-blocking agents, selective",Total,Total,"1,851.54",0.8,19.9,"25,682",33
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"1,778.91",0.7,0.4,520,34
5,New Brunswick,J05AH,Neuraminidase inhibitors,Total,Total,"1,700.94",0.7,9.4,"12,151",35
5,New Brunswick,L03AA,Colony-stimulating factors,Total,Total,"1,690.98",0.7,0.2,228,36
5,New Brunswick,C09CA,"Angiotensin II antagonists, plain",Total,Total,"1,687.28",0.7,9.6,"12,380",37
5,New Brunswick,L04AD,Calcineurin inhibitors,Total,Total,"1,686.17",0.7,0.4,552,38
5,New Brunswick,L03AB,Interferons,Total,Total,"1,674.60",0.7,0.1,114,39
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"1,583.06",0.7,2.9,"3,696",40
5,New Brunswick,N03AE,Benzodiazepine derivatives,Total,Total,"1,543.99",0.6,6.1,"7,861",41
5,New Brunswick,H03AA,Thyroid hormones,Total,Total,"1,496.73",0.6,17.8,"22,874",42
5,New Brunswick,C08DB,Benzothiazepine derivatives,Total,Total,"1,480.17",0.6,4.1,"5,266",43
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,476.42",0.6,3.6,"4,594",44
5,New Brunswick,L02BB,Antiandrogens,Total,Total,"1,467.58",0.6,0.2,299,45
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,350.32",0.6,20.2,"25,967",46
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"1,305.05",0.5,1.2,"1,539",47
5,New Brunswick,L02BX,Other hormone antagonists and related agents,Total,Total,"1,270.38",0.5,0.1,69,48
5,New Brunswick,A10BA,Biguanides,Total,Total,"1,242.83",0.5,14.1,"18,191",49
5,New Brunswick,N06BA,Centrally acting sympathomimetics,Total,Total,"1,237.62",0.5,2.1,"2,677",50
5,New Brunswick,H01CB,Somatostatin and analogues,Total,Total,"1,187.06",0.5,0.1,65,51
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"1,144.56",0.5,1.3,"1,644",52
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"1,115.69",0.5,10.6,"13,692",53
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,088.01",0.5,1.0,"1,291",54
5,New Brunswick,B01AB,Heparin group,Total,Total,"1,081.04",0.5,0.6,795,55
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,989.63,0.4,5.9,"7,616",56
5,New Brunswick,R07AX,Other respiratory system products,Total,Total,**,**,**,*,57
5,New Brunswick,S01ED,Beta-blocking agents,Total,Total,905.78,0.4,2.8,"3,639",58
5,New Brunswick,C03CA,"Sulfonamides, plain",Total,Total,887.69,0.4,10.1,"13,023",59
5,New Brunswick,M05BA,Bisphosphonates,Total,Total,865.12,0.4,5.1,"6,589",60
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,862.99,0.4,6.7,"8,645",61
5,New Brunswick,R01AD,Corticosteroids,Total,Total,825.09,0.3,10.7,"13,824",62
5,New Brunswick,B01AE,Direct thrombin inhibitors,Total,Total,814.28,0.3,0.6,774,63
5,New Brunswick,M03BX,Other centrally acting agents,Total,Total,798.60,0.3,5.7,"7,312",64
5,New Brunswick,A02BA,H2-receptor antagonists,Total,Total,780.21,0.3,5.3,"6,858",65
5,New Brunswick,N03AG,Fatty acid derivatives,Total,Total,773.95,0.3,1.9,"2,475",66
5,New Brunswick,N07BA,Drugs used in nicotine dependence,Total,Total,769.11,0.3,3.4,"4,348",67
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,744.66,0.3,0.7,955,68
5,New Brunswick,C01DA,Organic nitrates,Total,Total,732.61,0.3,5.7,"7,326",69
5,New Brunswick,S01EE,Prostaglandin analogues,Total,Total,729.11,0.3,2.5,"3,211",70
5,New Brunswick,A04AD,Other antiemetics,Total,Total,710.75,0.3,0.8,"1,049",71
5,New Brunswick,A10BB,Sulfonylureas,Total,Total,689.11,0.3,5.8,"7,527",72
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,680.92,0.3,3.4,"4,337",73
5,New Brunswick,C09DA,Angiotensin II antagonists and diuretics,Total,Total,677.30,0.3,3.2,"4,167",74
5,New Brunswick,A09AA,Enzyme preparations,Total,Total,649.96,0.3,0.2,297,75
5,New Brunswick,N06DA,Anticholinesterases,Total,Total,618.17,0.3,1.7,"2,177",76
5,New Brunswick,J05AE,Protease inhibitors,Total,Total,599.23,0.3,0.1,80,77
5,New Brunswick,C02AC,Imidazoline receptor agonists,Total,Total,573.15,0.2,1.2,"1,503",78
5,New Brunswick,N04BA,Dopa and dopa derivatives,Total,Total,567.93,0.2,1.0,"1,333",79
5,New Brunswick,J05AX,Other antivirals,Total,Total,532.33,0.2,0.1,70,80
5,New Brunswick,L03AX,Other immunostimulants,Total,Total,522.03,0.2,0.0,56,81
5,New Brunswick,M01AH,Coxibs,Total,Total,515.34,0.2,4.9,"6,315",82
5,New Brunswick,B01AA,Vitamin K antagonists,Total,Total,508.67,0.2,4.9,"6,277",83
5,New Brunswick,M01AE,Propionic acid derivatives,Total,Total,503.94,0.2,8.1,"10,386",84
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,Total,Total,493.39,0.2,1.3,"1,626",85
5,New Brunswick,N05CD,Benzodiazepine derivatives,Total,Total,414.71,0.2,3.1,"4,004",86
5,New Brunswick,C10AX,Other lipid-modifying agents,Total,Total,410.71,0.2,2.6,"3,345",87
5,New Brunswick,N05AE,Indole derivatives,Total,Total,409.01,0.2,0.3,382,88
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,405.57,0.2,2.0,"2,578",89
5,New Brunswick,A12BA,Potassium,Total,Total,400.78,0.2,3.9,"5,030",90
5,New Brunswick,H02AB,Glucocorticoids,Total,Total,383.21,0.2,10.6,"13,670",91
5,New Brunswick,A03FA,Propulsives,Total,Total,381.03,0.2,3.8,"4,953",92
5,New Brunswick,L01BA,Folic acid analogues,Total,Total,379.18,0.2,1.2,"1,591",93
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,373.82,0.2,0.1,183,94
5,New Brunswick,C10AC,Bile acid sequestrants,Total,Total,373.04,0.2,0.7,916,95
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,349.84,0.1,0.5,625,96
5,New Brunswick,V03AC,Iron-chelating agents,Total,Total,348.26,0.1,0.0,16,97
5,New Brunswick,N02AB,Phenylpiperidine derivatives,Total,Total,346.27,0.1,0.3,413,98
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",Total,Total,332.72,0.1,4.1,"5,326",99
5,New Brunswick,J01GB,Other aminoglycosides,Total,Total,330.89,0.1,0.1,85,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"8,928.65",7.7,0.9,480,1
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,Total,M,"5,241.33",4.5,0.2,117,2
5,New Brunswick,L04AX,Other immunosuppressants,Total,M,"5,031.55",4.3,0.5,281,3
5,New Brunswick,L01XE,Protein kinase inhibitors,Total,M,"4,440.58",3.8,0.2,118,4
5,New Brunswick,N05AX,Other antipsychotics,Total,M,"4,134.86",3.5,5.8,"3,276",5
5,New Brunswick,N07BC,Drugs used in opioid dependence,Total,M,"3,989.89",3.4,2.8,"1,565",6
5,New Brunswick,S01LA,Antineovascularization agents,Total,M,"3,511.54",3.0,0.7,398,7
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"3,423.36",2.9,9.8,"5,516",8
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,Total,M,"2,975.48",2.6,43.6,"24,589",9
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,889.49",2.5,5.8,"3,262",10
5,New Brunswick,C09AA,"ACE inhibitors, plain",Total,M,"2,769.18",2.4,24.9,"14,017",11
5,New Brunswick,N02AA,Natural opium alkaloids,Total,M,"2,419.68",2.1,8.6,"4,862",12
5,New Brunswick,A02BC,Proton pump inhibitors,Total,M,"2,360.50",2.0,34.6,"19,492",13
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"2,222.86",1.9,0.4,202,14
5,New Brunswick,L04AA,Selective immunosuppressants,Total,M,"2,056.11",1.8,0.7,407,15
5,New Brunswick,L04AC,Interleukin inhibitors,Total,M,"1,730.83",1.5,0.2,97,16
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"1,691.89",1.5,0.9,489,17
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,676.89",1.4,14.5,"8,182",18
5,New Brunswick,C08CA,Dihydropyridine derivatives,Total,M,"1,634.02",1.4,15.9,"8,954",19
5,New Brunswick,R03BB,Anticholinergics,Total,M,"1,615.73",1.4,9.5,"5,367",20
5,New Brunswick,N03AX,Other antiepileptics,Total,M,"1,520.39",1.3,9.4,"5,298",21
5,New Brunswick,N06AX,Other antidepressants,Total,M,"1,481.56",1.3,11.0,"6,224",22
5,New Brunswick,L02BB,Antiandrogens,Total,M,"1,466.53",1.3,0.5,297,23
5,New Brunswick,B01AF,Direct factor Xa inhibitors,Total,M,"1,452.75",1.2,3.4,"1,921",24
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"1,418.80",1.2,2.9,"1,649",25
5,New Brunswick,L02BX,Other hormone antagonists and related agents,Total,M,"1,270.38",1.1,0.1,69,26
5,New Brunswick,R03BA,Glucocorticoids,Total,M,"1,223.76",1.0,8.7,"4,883",27
5,New Brunswick,N05CF,Benzodiazepine-related drugs,Total,M,"1,210.35",1.0,12.9,"7,257",28
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"1,163.98",1.0,2.7,"1,510",29
5,New Brunswick,C09BA,ACE inhibitors and diuretics,Total,M,"1,072.84",0.9,6.3,"3,568",30
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,069.12",0.9,3.3,"1,861",31
5,New Brunswick,L04AD,Calcineurin inhibitors,Total,M,"1,057.30",0.9,0.6,343,32
5,New Brunswick,J05AH,Neuraminidase inhibitors,Total,M,921.38,0.8,8.1,"4,540",33
5,New Brunswick,N05BA,Benzodiazepine derivatives,Total,M,878.45,0.8,15.1,"8,492",34
5,New Brunswick,C07AB,"Beta-blocking agents, selective",Total,M,840.47,0.7,21.7,"12,238",35
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,Total,M,806.18,0.7,14.5,"8,189",36
5,New Brunswick,N06BA,Centrally acting sympathomimetics,Total,M,799.96,0.7,2.9,"1,643",37
5,New Brunswick,B03XA,Other antianemic preparations,Total,M,773.05,0.7,0.3,141,38
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,752.33,0.6,3.1,"1,756",39
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,736.44,0.6,6.1,"3,419",40
5,New Brunswick,H01CB,Somatostatin and analogues,Total,M,713.09,0.6,0.1,39,41
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,712.73,0.6,1.5,835,42
5,New Brunswick,N03AE,Benzodiazepine derivatives,Total,M,665.09,0.6,5.4,"3,037",43
5,New Brunswick,A10BA,Biguanides,Total,M,608.43,0.5,15.9,"8,953",44
5,New Brunswick,C08DB,Benzothiazepine derivatives,Total,M,600.06,0.5,3.8,"2,159",45
5,New Brunswick,C09CA,"Angiotensin II antagonists, plain",Total,M,593.29,0.5,8.1,"4,569",46
5,New Brunswick,R07AX,Other respiratory system products,Total,M,**,**,**,*,47
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,577.60,0.5,18.6,"10,488",48
5,New Brunswick,L03AA,Colony-stimulating factors,Total,M,567.04,0.5,0.1,83,49
5,New Brunswick,N07XX,Other nervous system drugs,Total,M,555.16,0.5,0.1,70,50
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,518.65,0.4,1.3,730,51
5,New Brunswick,J05AE,Protease inhibitors,Total,M,513.66,0.4,0.1,69,52
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,508.30,0.4,10.8,"6,075",53
5,New Brunswick,B01AB,Heparin group,Total,M,475.18,0.4,0.6,353,54
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,Total,M,448.30,0.4,2.3,"1,309",55
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,Total,M,441.03,0.4,0.9,520,56
5,New Brunswick,J05AX,Other antivirals,Total,M,436.53,0.4,0.1,54,57
5,New Brunswick,B01AE,Direct thrombin inhibitors,Total,M,412.28,0.4,0.7,401,58
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,404.79,0.3,4.6,"2,572",59
5,New Brunswick,N03AG,Fatty acid derivatives,Total,M,385.40,0.3,2.2,"1,230",60
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,385.32,0.3,0.9,486,61
5,New Brunswick,A09AA,Enzyme preparations,Total,M,377.64,0.3,0.3,150,62
5,New Brunswick,L03AB,Interferons,Total,M,374.23,0.3,0.0,26,63
5,New Brunswick,N07BA,Drugs used in nicotine dependence,Total,M,373.90,0.3,3.7,"2,105",64
5,New Brunswick,S01ED,Beta-blocking agents,Total,M,352.21,0.3,2.6,"1,460",65
5,New Brunswick,H03AA,Thyroid hormones,Total,M,345.52,0.3,9.9,"5,609",66
5,New Brunswick,C03CA,"Sulfonamides, plain",Total,M,341.67,0.3,9.2,"5,176",67
5,New Brunswick,A10BB,Sulfonylureas,Total,M,336.95,0.3,6.7,"3,788",68
5,New Brunswick,C01DA,Organic nitrates,Total,M,332.03,0.3,6.7,"3,783",69
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,328.69,0.3,4.3,"2,435",70
5,New Brunswick,A02BA,H2-receptor antagonists,Total,M,326.37,0.3,4.8,"2,723",71
5,New Brunswick,R01AD,Corticosteroids,Total,M,323.91,0.3,9.0,"5,051",72
5,New Brunswick,M03BX,Other centrally acting agents,Total,M,319.46,0.3,5.1,"2,881",73
5,New Brunswick,N04BA,Dopa and dopa derivatives,Total,M,304.16,0.3,1.2,650,74
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,Total,M,286.57,0.2,1.7,951,75
5,New Brunswick,A04AD,Other antiemetics,Total,M,282.75,0.2,0.8,424,76
5,New Brunswick,S01EE,Prostaglandin analogues,Total,M,264.72,0.2,2.2,"1,237",77
5,New Brunswick,C09DA,Angiotensin II antagonists and diuretics,Total,M,250.59,0.2,2.7,"1,542",78
5,New Brunswick,C02AC,Imidazoline receptor agonists,Total,M,239.59,0.2,1.0,577,79
5,New Brunswick,B01AA,Vitamin K antagonists,Total,M,238.59,0.2,5.5,"3,103",80
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,Total,M,217.94,0.2,0.1,62,81
5,New Brunswick,H01AC,Somatropin and somatropin agonists,Total,M,217.38,0.2,0.0,18,82
5,New Brunswick,N06DA,Anticholinesterases,Total,M,212.22,0.2,1.4,768,83
5,New Brunswick,C10AX,Other lipid-modifying agents,Total,M,210.34,0.2,3.1,"1,738",84
5,New Brunswick,M01AE,Propionic acid derivatives,Total,M,199.62,0.2,7.5,"4,222",85
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,196.78,0.2,0.6,340,86
5,New Brunswick,M01AH,Coxibs,Total,M,195.95,0.2,4.2,"2,374",87
5,New Brunswick,V03AC,Iron-chelating agents,Total,M,184.38,0.2,0.0,9,88
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,Total,M,174.67,0.1,4.8,"2,680",89
5,New Brunswick,J01GB,Other aminoglycosides,Total,M,172.29,0.1,0.1,38,90
5,New Brunswick,N05AE,Indole derivatives,Total,M,169.23,0.1,0.3,155,91
5,New Brunswick,N03AF,Carboxamide derivatives,Total,M,163.99,0.1,1.2,678,92
5,New Brunswick,N05CD,Benzodiazepine derivatives,Total,M,160.75,0.1,2.8,"1,570",93
5,New Brunswick,L01XX,Other antineoplastic agents,Total,M,156.99,0.1,0.1,73,94
5,New Brunswick,L03AX,Other immunostimulants,Total,M,155.61,0.1,0.0,14,95
5,New Brunswick,H02AB,Glucocorticoids,Total,M,153.64,0.1,9.9,"5,558",96
5,New Brunswick,C10AC,Bile acid sequestrants,Total,M,141.52,0.1,0.5,301,97
5,New Brunswick,J01DB,First-generation cephalosporins,Total,M,139.01,0.1,6.8,"3,851",98
5,New Brunswick,M05BA,Bisphosphonates,Total,M,138.64,0.1,1.9,"1,078",99
5,New Brunswick,D07AC,"Corticosteroids, potent (group III)",Total,M,137.37,0.1,6.3,"3,541",100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"11,443.22",9.4,0.9,617,1
5,New Brunswick,S01LA,Antineovascularization agents,Total,F,"4,549.91",3.7,0.7,535,2
5,New Brunswick,L01XE,Protein kinase inhibitors,Total,F,"3,705.98",3.1,0.2,125,3
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"3,554.84",2.9,5.9,"4,281",4
5,New Brunswick,A02BC,Proton pump inhibitors,Total,F,"3,538.34",2.9,39.6,"28,671",5
5,New Brunswick,L04AA,Selective immunosuppressants,Total,F,"3,526.25",2.9,0.7,486,6
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,Total,F,"3,059.29",2.5,34.7,"25,151",7
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,Total,F,"3,059.06",2.5,22.3,"16,191",8
5,New Brunswick,C09AA,"ACE inhibitors, plain",Total,F,"2,951.17",2.4,20.1,"14,555",9
5,New Brunswick,N07BC,Drugs used in opioid dependence,Total,F,"2,876.43",2.4,1.6,"1,131",10
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"2,491.80",2.1,8.8,"6,359",11
5,New Brunswick,L04AX,Other immunosuppressants,Total,F,"2,290.64",1.9,0.4,313,12
5,New Brunswick,C08CA,Dihydropyridine derivatives,Total,F,"2,238.14",1.8,16.4,"11,852",13
5,New Brunswick,N06AX,Other antidepressants,Total,F,"2,217.11",1.8,15.0,"10,905",14
5,New Brunswick,N05AX,Other antipsychotics,Total,F,"2,197.01",1.8,4.3,"3,135",15
5,New Brunswick,N03AX,Other antiepileptics,Total,F,"2,083.10",1.7,11.5,"8,338",16
5,New Brunswick,N02AA,Natural opium alkaloids,Total,F,"2,044.43",1.7,9.2,"6,660",17
5,New Brunswick,R03BA,Glucocorticoids,Total,F,"1,867.28",1.5,10.8,"7,807",18
5,New Brunswick,R03BB,Anticholinergics,Total,F,"1,759.76",1.4,8.4,"6,075",19
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,Total,F,"1,756.03",1.4,0.1,40,20
5,New Brunswick,B01AF,Direct factor Xa inhibitors,Total,F,"1,583.44",1.3,3.1,"2,239",21
5,New Brunswick,N07XX,Other nervous system drugs,Total,F,"1,579.95",1.3,0.2,144,22
5,New Brunswick,N05CF,Benzodiazepine-related drugs,Total,F,"1,483.41",1.2,15.0,"10,836",23
5,New Brunswick,N05BA,Benzodiazepine derivatives,Total,F,"1,393.84",1.1,22.3,"16,170",24
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"1,332.66",1.1,2.3,"1,700",25
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"1,332.30",1.1,2.2,"1,611",26
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"1,310.25",1.1,4.8,"3,445",27
5,New Brunswick,L03AB,Interferons,Total,F,"1,300.37",1.1,0.1,88,28
5,New Brunswick,L04AC,Interleukin inhibitors,Total,F,"1,295.62",1.1,0.1,79,29
5,New Brunswick,B03XA,Other antianemic preparations,Total,F,"1,180.83",1.0,0.3,212,30
5,New Brunswick,C09BA,ACE inhibitors and diuretics,Total,F,"1,166.02",1.0,5.4,"3,903",31
5,New Brunswick,H03AA,Thyroid hormones,Total,F,"1,151.17",0.9,23.8,"17,264",32
5,New Brunswick,L03AA,Colony-stimulating factors,Total,F,"1,123.93",0.9,0.2,145,33
5,New Brunswick,C09CA,"Angiotensin II antagonists, plain",Total,F,"1,093.98",0.9,10.8,"7,811",34
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,031.51",0.8,2.7,"1,984",35
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,Total,F,"1,028.13",0.8,4.5,"3,285",36
5,New Brunswick,C07AB,"Beta-blocking agents, selective",Total,F,"1,011.07",0.8,18.6,"13,444",37
5,New Brunswick,C08DB,Benzothiazepine derivatives,Total,F,880.11,0.7,4.3,"3,107",38
5,New Brunswick,N03AE,Benzodiazepine derivatives,Total,F,878.91,0.7,6.7,"4,824",39
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,830.73,0.7,2.7,"1,940",40
5,New Brunswick,J05AH,Neuraminidase inhibitors,Total,F,779.56,0.6,10.5,"7,611",41
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,772.72,0.6,21.4,"15,479",42
5,New Brunswick,M05BA,Bisphosphonates,Total,F,726.48,0.6,7.6,"5,511",43
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,670.10,0.6,5.9,"4,280",44
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,660.95,0.5,7.1,"5,181",45
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,Total,F,646.98,0.5,1.1,771,46
5,New Brunswick,A10BA,Biguanides,Total,F,634.40,0.5,12.7,"9,238",47
5,New Brunswick,L04AD,Calcineurin inhibitors,Total,F,628.87,0.5,0.3,209,48
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,625.90,0.5,1.3,914,49
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,607.40,0.5,10.5,"7,617",50
5,New Brunswick,B01AB,Heparin group,Total,F,605.86,0.5,0.6,442,51
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,592.33,0.5,1.0,704,52
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,566.31,0.5,0.1,53,53
5,New Brunswick,S01ED,Beta-blocking agents,Total,F,553.57,0.5,3.0,"2,179",54
5,New Brunswick,C03CA,"Sulfonamides, plain",Total,F,546.00,0.4,10.8,"7,846",55
5,New Brunswick,R01AD,Corticosteroids,Total,F,501.18,0.4,12.1,"8,773",56
5,New Brunswick,M03BX,Other centrally acting agents,Total,F,479.14,0.4,6.1,"4,431",57
5,New Brunswick,H01CB,Somatostatin and analogues,Total,F,473.97,0.4,0.0,26,58
5,New Brunswick,S01EE,Prostaglandin analogues,Total,F,464.38,0.4,2.7,"1,974",59
5,New Brunswick,A02BA,H2-receptor antagonists,Total,F,453.84,0.4,5.7,"4,135",60
5,New Brunswick,N06BA,Centrally acting sympathomimetics,Total,F,437.66,0.4,1.4,"1,034",61
5,New Brunswick,A04AD,Other antiemetics,Total,F,428.00,0.4,0.9,625,62
5,New Brunswick,C09DA,Angiotensin II antagonists and diuretics,Total,F,426.72,0.4,3.6,"2,625",63
5,New Brunswick,N06DA,Anticholinesterases,Total,F,405.95,0.3,1.9,"1,409",64
5,New Brunswick,B01AE,Direct thrombin inhibitors,Total,F,401.99,0.3,0.5,373,65
5,New Brunswick,C01DA,Organic nitrates,Total,F,400.59,0.3,4.9,"3,543",66
5,New Brunswick,N07BA,Drugs used in nicotine dependence,Total,F,395.21,0.3,3.1,"2,243",67
5,New Brunswick,N03AG,Fatty acid derivatives,Total,F,388.55,0.3,1.7,"1,245",68
5,New Brunswick,L03AX,Other immunostimulants,Total,F,366.42,0.3,0.1,42,69
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,359.34,0.3,0.6,469,70
5,New Brunswick,A10BB,Sulfonylureas,Total,F,352.16,0.3,5.2,"3,739",71
5,New Brunswick,C02AC,Imidazoline receptor agonists,Total,F,333.56,0.3,1.3,926,72
5,New Brunswick,R07AX,Other respiratory system products,Total,F,**,**,**,*,73
5,New Brunswick,L02BG,Aromatase inhibitors,Total,F,324.28,0.3,1.1,787,74
5,New Brunswick,M01AH,Coxibs,Total,F,319.39,0.3,5.4,"3,941",75
5,New Brunswick,M01AE,Propionic acid derivatives,Total,F,304.32,0.3,8.5,"6,164",76
5,New Brunswick,A12BA,Potassium,Total,F,280.82,0.2,4.7,"3,436",77
5,New Brunswick,A09AA,Enzyme preparations,Total,F,272.32,0.2,0.2,147,78
5,New Brunswick,B01AA,Vitamin K antagonists,Total,F,270.08,0.2,4.4,"3,174",79
5,New Brunswick,N04BA,Dopa and dopa derivatives,Total,F,263.77,0.2,0.9,683,80
5,New Brunswick,N05CD,Benzodiazepine derivatives,Total,F,253.96,0.2,3.4,"2,434",81
5,New Brunswick,A03FA,Propulsives,Total,F,253.71,0.2,4.5,"3,244",82
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,245.82,0.2,0.0,22,83
5,New Brunswick,L01BA,Folic acid analogues,Total,F,245.00,0.2,1.4,"1,000",84
5,New Brunswick,N05AE,Indole derivatives,Total,F,239.78,0.2,0.3,227,85
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,237.29,0.2,0.2,118,86
5,New Brunswick,C10AC,Bile acid sequestrants,Total,F,231.52,0.2,0.8,615,87
5,New Brunswick,H02AB,Glucocorticoids,Total,F,229.56,0.2,11.2,"8,112",88
5,New Brunswick,N02AB,Phenylpiperidine derivatives,Total,F,223.55,0.2,0.4,260,89
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",Total,F,216.65,0.2,4.8,"3,444",90
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,Total,F,206.82,0.2,0.9,675,91
5,New Brunswick,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,206.08,0.2,2.1,"1,525",92
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,205.94,0.2,2.8,"2,057",93
5,New Brunswick,C10AX,Other lipid-modifying agents,Total,F,200.37,0.2,2.2,"1,607",94
5,New Brunswick,C03AA,"Thiazides, plain",Total,F,193.54,0.2,8.7,"6,336",95
5,New Brunswick,J01FA,Macrolides,Total,F,183.06,0.2,8.6,"6,217",96
5,New Brunswick,R03DC,Leukotriene receptor antagonists,Total,F,182.62,0.2,0.9,656,97
5,New Brunswick,J01CA,Penicillins with extended spectrum,Total,F,177.66,0.1,12.1,"8,801",98
5,New Brunswick,C05BA,Heparins or heparinoids for topical use,Total,F,173.53,0.1,0.1,90,99
5,New Brunswick,D06BB,Antivirals,Total,F,171.64,0.1,0.9,643,100
5,New Brunswick,S01LA,Antineovascularization agents,65+,Total,"7,601.86",6.1,1.1,876,1
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"6,729.54",5.4,0.5,373,2
5,New Brunswick,L01XE,Protein kinase inhibitors,65+,Total,"5,901.05",4.7,0.2,174,3
5,New Brunswick,L04AX,Other immunosuppressants,65+,Total,"5,761.55",4.6,0.4,344,4
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"4,871.10",3.9,7.0,"5,656",5
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,65+,Total,"4,705.23",3.7,50.7,"40,799",6
5,New Brunswick,C09AA,"ACE inhibitors, plain",65+,Total,"4,541.45",3.6,28.9,"23,267",7
5,New Brunswick,A02BC,Proton pump inhibitors,65+,Total,"4,008.89",3.2,44.3,"35,657",8
5,New Brunswick,C08CA,Dihydropyridine derivatives,65+,Total,"3,328.96",2.7,22.6,"18,155",9
5,New Brunswick,B01AF,Direct factor Xa inhibitors,65+,Total,"2,797.03",2.2,4.7,"3,762",10
5,New Brunswick,R03BB,Anticholinergics,65+,Total,"2,615.10",2.1,10.8,"8,691",11
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"2,010.32",1.6,17.1,"13,794",12
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"1,958.63",1.6,3.1,"2,491",13
5,New Brunswick,R03BA,Glucocorticoids,65+,Total,"1,810.04",1.4,8.8,"7,118",14
5,New Brunswick,B03XA,Other antianemic preparations,65+,Total,"1,773.18",1.4,0.4,311,15
5,New Brunswick,C09BA,ACE inhibitors and diuretics,65+,Total,"1,756.12",1.4,7.3,"5,894",16
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"1,722.18",1.4,2.7,"2,191",17
5,New Brunswick,N02AA,Natural opium alkaloids,65+,Total,"1,680.57",1.3,9.3,"7,494",18
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"1,589.33",1.3,0.6,459,19
5,New Brunswick,C07AB,"Beta-blocking agents, selective",65+,Total,"1,476.19",1.2,27.4,"22,057",20
5,New Brunswick,C09CA,"Angiotensin II antagonists, plain",65+,Total,"1,429.12",1.1,13.3,"10,737",21
5,New Brunswick,N03AX,Other antiepileptics,65+,Total,"1,406.05",1.1,10.0,"8,032",22
5,New Brunswick,L02BB,Antiandrogens,65+,Total,"1,397.87",1.1,0.3,278,23
5,New Brunswick,C08DB,Benzothiazepine derivatives,65+,Total,"1,285.27",1.0,5.8,"4,640",24
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"1,279.73",1.0,6.2,"4,995",25
5,New Brunswick,N06AX,Other antidepressants,65+,Total,"1,243.74",1.0,10.8,"8,704",26
5,New Brunswick,L02BX,Other hormone antagonists and related agents,65+,Total,"1,218.54",1.0,0.1,66,27
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"1,213.29",1.0,3.0,"2,401",28
5,New Brunswick,N05BA,Benzodiazepine derivatives,65+,Total,"1,050.17",0.8,20.3,"16,360",29
5,New Brunswick,H03AA,Thyroid hormones,65+,Total,"1,048.40",0.8,23.0,"18,551",30
5,New Brunswick,L03AA,Colony-stimulating factors,65+,Total,"1,040.93",0.8,0.2,142,31
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"1,029.07",0.8,3.2,"2,608",32
5,New Brunswick,L04AA,Selective immunosuppressants,65+,Total,997.34,0.8,0.4,302,33
5,New Brunswick,N05CF,Benzodiazepine-related drugs,65+,Total,980.42,0.8,14.4,"11,575",34
5,New Brunswick,N05AX,Other antipsychotics,65+,Total,972.89,0.8,3.2,"2,609",35
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,969.51,0.8,7.5,"6,033",36
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,943.65,0.8,1.4,"1,115",37
5,New Brunswick,L04AC,Interleukin inhibitors,65+,Total,919.61,0.7,0.1,51,38
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,65+,Total,911.61,0.7,4.1,"3,306",39
5,New Brunswick,J05AH,Neuraminidase inhibitors,65+,Total,885.17,0.7,10.7,"8,605",40
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,877.00,0.7,1.6,"1,313",41
5,New Brunswick,H01CB,Somatostatin and analogues,65+,Total,844.14,0.7,0.1,47,42
5,New Brunswick,S01ED,Beta-blocking agents,65+,Total,841.33,0.7,4.2,"3,361",43
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,65+,Total,778.23,0.6,0.0,16,44
5,New Brunswick,B01AE,Direct thrombin inhibitors,65+,Total,776.37,0.6,0.9,733,45
5,New Brunswick,M05BA,Bisphosphonates,65+,Total,772.73,0.6,7.4,"5,970",46
5,New Brunswick,A10BA,Biguanides,65+,Total,762.52,0.6,17.0,"13,672",47
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,750.17,0.6,19.6,"15,762",48
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,749.57,0.6,9.6,"7,711",49
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,65+,Total,730.86,0.6,1.1,867,50
5,New Brunswick,C03CA,"Sulfonamides, plain",65+,Total,705.49,0.6,13.8,"11,080",51
5,New Brunswick,S01EE,Prostaglandin analogues,65+,Total,677.60,0.5,3.7,"2,989",52
5,New Brunswick,B01AB,Heparin group,65+,Total,672.87,0.5,0.7,564,53
5,New Brunswick,C01DA,Organic nitrates,65+,Total,658.56,0.5,8.0,"6,430",54
5,New Brunswick,N06DA,Anticholinesterases,65+,Total,605.87,0.5,2.7,"2,139",55
5,New Brunswick,C09DA,Angiotensin II antagonists and diuretics,65+,Total,570.89,0.5,4.5,"3,592",56
5,New Brunswick,R01AD,Corticosteroids,65+,Total,525.43,0.4,11.3,"9,136",57
5,New Brunswick,N04BA,Dopa and dopa derivatives,65+,Total,494.19,0.4,1.5,"1,173",58
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,470.46,0.4,3.9,"3,178",59
5,New Brunswick,A10BB,Sulfonylureas,65+,Total,469.39,0.4,7.1,"5,747",60
5,New Brunswick,L04AD,Calcineurin inhibitors,65+,Total,456.38,0.4,0.2,164,61
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,449.04,0.4,9.2,"7,367",62
5,New Brunswick,A02BA,H2-receptor antagonists,65+,Total,447.24,0.4,5.6,"4,494",63
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,445.89,0.4,0.7,569,64
5,New Brunswick,B01AA,Vitamin K antagonists,65+,Total,429.03,0.3,7.1,"5,685",65
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,414.82,0.3,5.5,"4,464",66
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,384.17,0.3,3.0,"2,453",67
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,65+,Total,381.00,0.3,1.6,"1,294",68
5,New Brunswick,M01AH,Coxibs,65+,Total,358.57,0.3,5.9,"4,775",69
5,New Brunswick,C10AX,Other lipid-modifying agents,65+,Total,336.40,0.3,3.6,"2,883",70
5,New Brunswick,A12BA,Potassium,65+,Total,327.81,0.3,5.3,"4,298",71
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,300.21,0.2,0.2,199,72
5,New Brunswick,L02BG,Aromatase inhibitors,65+,Total,288.55,0.2,0.9,686,73
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,284.52,0.2,0.6,499,74
5,New Brunswick,C10AC,Bile acid sequestrants,65+,Total,275.70,0.2,0.9,688,75
5,New Brunswick,L03AB,Interferons,65+,Total,267.32,0.2,0.0,20,76
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,266.95,0.2,0.0,27,77
5,New Brunswick,L01BA,Folic acid analogues,65+,Total,258.09,0.2,1.4,"1,111",78
5,New Brunswick,H02AB,Glucocorticoids,65+,Total,250.49,0.2,11.5,"9,266",79
5,New Brunswick,N03AE,Benzodiazepine derivatives,65+,Total,250.05,0.2,3.9,"3,173",80
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",65+,Total,240.17,0.2,5.2,"4,208",81
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,65+,Total,234.81,0.2,4.6,"3,680",82
5,New Brunswick,A04AD,Other antiemetics,65+,Total,234.25,0.2,0.6,506,83
5,New Brunswick,M03BX,Other centrally acting agents,65+,Total,225.84,0.2,4.1,"3,301",84
5,New Brunswick,N07BA,Drugs used in nicotine dependence,65+,Total,224.25,0.2,1.8,"1,419",85
5,New Brunswick,A03FA,Propulsives,65+,Total,223.58,0.2,4.3,"3,485",86
5,New Brunswick,N02AB,Phenylpiperidine derivatives,65+,Total,209.90,0.2,0.4,304,87
5,New Brunswick,N05CD,Benzodiazepine derivatives,65+,Total,209.72,0.2,3.3,"2,637",88
5,New Brunswick,C08DA,Phenylalkylamine derivatives,65+,Total,206.04,0.2,1.1,869,89
5,New Brunswick,N04BC,Dopamine agonists,65+,Total,205.53,0.2,1.1,846,90
5,New Brunswick,N07XX,Other nervous system drugs,65+,Total,198.38,0.2,0.0,33,91
5,New Brunswick,S01BA,"Corticosteroids, plain",65+,Total,185.58,0.1,5.3,"4,285",92
5,New Brunswick,C03AA,"Thiazides, plain",65+,Total,183.75,0.1,9.4,"7,541",93
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,183.12,0.1,2.6,"2,053",94
5,New Brunswick,L02AB,Progestogens,65+,Total,181.58,0.1,0.2,167,95
5,New Brunswick,D07AC,"Corticosteroids, potent (group III)",65+,Total,179.14,0.1,7.2,"5,769",96
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,177.53,0.1,0.0,16,97
5,New Brunswick,N03AG,Fatty acid derivatives,65+,Total,175.09,0.1,0.8,674,98
5,New Brunswick,C07AA,"Beta-blocking agents, non-selective",65+,Total,174.68,0.1,1.6,"1,325",99
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,172.44,0.1,0.1,98,100
5,New Brunswick,L04AX,Other immunosuppressants,65+,M,"3,806.05",6.5,0.5,166,1
5,New Brunswick,S01LA,Antineovascularization agents,65+,M,"3,303.25",5.7,1.1,370,2
5,New Brunswick,L01XE,Protein kinase inhibitors,65+,M,"3,019.08",5.2,0.2,84,3
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"2,746.11",4.7,0.4,150,4
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,65+,M,"2,287.82",3.9,59.0,"20,086",5
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"2,211.29",3.8,7.4,"2,507",6
5,New Brunswick,C09AA,"ACE inhibitors, plain",65+,M,"2,127.57",3.6,33.1,"11,250",7
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"1,583.53",2.7,1.3,457,8
5,New Brunswick,A02BC,Proton pump inhibitors,65+,M,"1,495.25",2.6,41.6,"14,168",9
5,New Brunswick,L02BB,Antiandrogens,65+,M,"1,396.82",2.4,0.8,276,10
5,New Brunswick,C08CA,Dihydropyridine derivatives,65+,M,"1,346.20",2.3,22.3,"7,582",11
5,New Brunswick,B01AF,Direct factor Xa inhibitors,65+,M,"1,312.12",2.3,5.1,"1,719",12
5,New Brunswick,R03BB,Anticholinergics,65+,M,"1,247.85",2.1,12.0,"4,085",13
5,New Brunswick,L02BX,Other hormone antagonists and related agents,65+,M,"1,218.54",2.1,0.2,66,14
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",65+,M,937.89,1.6,3.3,"1,135",15
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,923.50,1.6,3.5,"1,192",16
5,New Brunswick,C09BA,ACE inhibitors and diuretics,65+,M,832.47,1.4,8.2,"2,783",17
5,New Brunswick,N02AA,Natural opium alkaloids,65+,M,740.33,1.3,9.0,"3,074",18
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,65+,M,700.79,1.2,21.6,"7,341",19
5,New Brunswick,B03XA,Other antianemic preparations,65+,M,698.21,1.2,0.4,124,20
5,New Brunswick,R03BA,Glucocorticoids,65+,M,693.46,1.2,7.8,"2,659",21
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,654.56,1.1,3.5,"1,195",22
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,65+,M,**,**,**,**,23
5,New Brunswick,C07AB,"Beta-blocking agents, selective",65+,M,631.42,1.1,30.2,"10,291",24
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,65+,M,604.02,1.0,12.5,"4,241",25
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,568.08,1.0,5.8,"1,959",26
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,541.06,0.9,1.9,633,27
5,New Brunswick,H01CB,Somatostatin and analogues,65+,M,539.52,0.9,0.1,29,28
5,New Brunswick,N03AX,Other antiepileptics,65+,M,538.72,0.9,8.8,"3,003",29
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,505.67,0.9,3.7,"1,265",30
5,New Brunswick,C08DB,Benzothiazepine derivatives,65+,M,498.57,0.9,5.5,"1,860",31
5,New Brunswick,C09CA,"Angiotensin II antagonists, plain",65+,M,482.48,0.8,11.4,"3,870",32
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,459.02,0.8,8.6,"2,937",33
5,New Brunswick,L04AC,Interleukin inhibitors,65+,M,458.84,0.8,0.1,24,34
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,403.19,0.7,1.7,591,35
5,New Brunswick,N05AX,Other antipsychotics,65+,M,402.58,0.7,2.8,950,36
5,New Brunswick,L03AA,Colony-stimulating factors,65+,M,401.95,0.7,0.2,57,37
5,New Brunswick,N06AX,Other antidepressants,65+,M,400.79,0.7,8.7,"2,954",38
5,New Brunswick,J05AH,Neuraminidase inhibitors,65+,M,385.66,0.7,9.4,"3,187",39
5,New Brunswick,B01AE,Direct thrombin inhibitors,65+,M,385.65,0.7,1.1,371,40
5,New Brunswick,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,383.53,0.7,7.2,"2,448",41
5,New Brunswick,A10BA,Biguanides,65+,M,369.73,0.6,20.2,"6,859",42
5,New Brunswick,N05CF,Benzodiazepine-related drugs,65+,M,362.54,0.6,13.1,"4,443",43
5,New Brunswick,N05BA,Benzodiazepine derivatives,65+,M,332.73,0.6,15.3,"5,213",44
5,New Brunswick,B01AB,Heparin group,65+,M,323.92,0.6,0.8,258,45
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,318.51,0.5,18.6,"6,343",46
5,New Brunswick,S01ED,Beta-blocking agents,65+,M,316.47,0.5,3.8,"1,310",47
5,New Brunswick,L04AA,Selective immunosuppressants,65+,M,314.63,0.5,0.4,144,48
5,New Brunswick,L04AD,Calcineurin inhibitors,65+,M,307.83,0.5,0.3,108,49
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,65+,M,302.39,0.5,1.0,351,50
5,New Brunswick,C01DA,Organic nitrates,65+,M,286.61,0.5,9.5,"3,249",51
5,New Brunswick,C03CA,"Sulfonamides, plain",65+,M,260.36,0.4,12.8,"4,357",52
5,New Brunswick,N04BA,Dopa and dopa derivatives,65+,M,257.42,0.4,1.7,573,53
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,65+,M,255.91,0.4,2.8,937,54
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,249.57,0.4,0.9,309,55
5,New Brunswick,S01EE,Prostaglandin analogues,65+,M,240.94,0.4,3.3,"1,128",56
5,New Brunswick,H03AA,Thyroid hormones,65+,M,240.73,0.4,13.4,"4,550",57
5,New Brunswick,A10BB,Sulfonylureas,65+,M,224.67,0.4,8.6,"2,923",58
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,65+,M,221.23,0.4,2.3,776,59
5,New Brunswick,R01AD,Corticosteroids,65+,M,210.00,0.4,10.0,"3,420",60
5,New Brunswick,M05BX,Other drugs affecting bone structure and mineralization,65+,M,206.47,0.4,0.2,56,61
5,New Brunswick,N06DA,Anticholinesterases,65+,M,206.03,0.4,2.2,749,62
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,204.35,0.4,0.1,22,63
5,New Brunswick,C09DA,Angiotensin II antagonists and diuretics,65+,M,202.87,0.3,3.8,"1,305",64
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,200.98,0.3,9.7,"3,288",65
5,New Brunswick,B01AA,Vitamin K antagonists,65+,M,191.28,0.3,8.2,"2,784",66
5,New Brunswick,A02BA,H2-receptor antagonists,65+,M,173.38,0.3,5.1,"1,736",67
5,New Brunswick,C10AX,Other lipid-modifying agents,65+,M,169.40,0.3,4.4,"1,484",68
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,159.36,0.3,0.8,269,69
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,65+,M,139.43,0.2,6.7,"2,292",70
5,New Brunswick,M01AH,Coxibs,65+,M,129.17,0.2,5.2,"1,784",71
5,New Brunswick,N07BA,Drugs used in nicotine dependence,65+,M,115.48,0.2,2.1,713,72
5,New Brunswick,M05BA,Bisphosphonates,65+,M,109.43,0.2,2.6,882,73
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,107.91,0.2,3.9,"1,311",74
5,New Brunswick,C10AC,Bile acid sequestrants,65+,M,105.46,0.2,0.7,224,75
5,New Brunswick,A04AD,Other antiemetics,65+,M,99.97,0.2,0.6,207,76
5,New Brunswick,H02AB,Glucocorticoids,65+,M,98.88,0.2,11.1,"3,795",77
5,New Brunswick,L01BA,Folic acid analogues,65+,M,94.50,0.2,1.2,418,78
5,New Brunswick,A12BA,Potassium,65+,M,93.85,0.2,3.8,"1,303",79
5,New Brunswick,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,92.01,0.2,0.8,261,80
5,New Brunswick,D07AC,"Corticosteroids, potent (group III)",65+,M,88.03,0.2,7.6,"2,573",81
5,New Brunswick,M03BX,Other centrally acting agents,65+,M,85.79,0.1,4.0,"1,349",82
5,New Brunswick,N04BC,Dopamine agonists,65+,M,85.11,0.1,0.9,297,83
5,New Brunswick,N03AE,Benzodiazepine derivatives,65+,M,84.77,0.1,3.2,"1,102",84
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",65+,M,81.43,0.1,4.5,"1,530",85
5,New Brunswick,N03AG,Fatty acid derivatives,65+,M,81.34,0.1,0.8,289,86
5,New Brunswick,N05CD,Benzodiazepine derivatives,65+,M,77.92,0.1,2.9,985,87
5,New Brunswick,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",65+,M,77.77,0.1,7.4,"2,504",88
5,New Brunswick,C08DA,Phenylalkylamine derivatives,65+,M,76.66,0.1,1.0,324,89
5,New Brunswick,C03DA,Aldosterone antagonists,65+,M,74.21,0.1,3.1,"1,061",90
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,73.83,0.1,2.1,721,91
5,New Brunswick,A09AA,Enzyme preparations,65+,M,73.17,0.1,0.2,61,92
5,New Brunswick,J01DB,First-generation cephalosporins,65+,M,72.24,0.1,7.0,"2,389",93
5,New Brunswick,A03FA,Propulsives,65+,M,71.51,0.1,3.5,"1,201",94
5,New Brunswick,V03AC,Iron-chelating agents,65+,M,70.23,0.1,0.0,7,95
5,New Brunswick,C01BD,"Antiarrhythmics, class III",65+,M,69.13,0.1,1.2,425,96
5,New Brunswick,S01BA,"Corticosteroids, plain",65+,M,68.02,0.1,4.8,"1,649",97
5,New Brunswick,L02AB,Progestogens,65+,M,66.64,0.1,0.2,58,98
5,New Brunswick,G03BA,3-oxoandrosten (4) derivatives,65+,M,66.52,0.1,0.4,153,99
5,New Brunswick,N07BC,Drugs used in opioid dependence,65+,M,66.51,0.1,0.1,33,100
5,New Brunswick,S01LA,Antineovascularization agents,65+,F,"4,298.61",6.4,1.1,506,1
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"3,983.43",5.9,0.5,223,2
5,New Brunswick,L01XE,Protein kinase inhibitors,65+,F,"2,881.97",4.3,0.2,90,3
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,659.81",4.0,6.8,"3,149",4
5,New Brunswick,A02BC,Proton pump inhibitors,65+,F,"2,513.64",3.7,46.2,"21,489",5
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,65+,F,"2,417.42",3.6,44.6,"20,713",6
5,New Brunswick,C09AA,"ACE inhibitors, plain",65+,F,"2,413.87",3.6,25.9,"12,017",7
5,New Brunswick,C08CA,Dihydropyridine derivatives,65+,F,"1,982.76",2.9,22.8,"10,573",8
5,New Brunswick,L04AX,Other immunosuppressants,65+,F,"1,955.49",2.9,0.4,178,9
5,New Brunswick,B01AF,Direct factor Xa inhibitors,65+,F,"1,484.91",2.2,4.4,"2,043",10
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,65+,F,"1,406.30",2.1,20.6,"9,553",11
5,New Brunswick,R03BB,Anticholinergics,65+,F,"1,367.25",2.0,9.9,"4,606",12
5,New Brunswick,R03BA,Glucocorticoids,65+,F,"1,116.57",1.7,9.6,"4,459",13
5,New Brunswick,B03XA,Other antianemic preparations,65+,F,"1,074.97",1.6,0.4,187,14
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"1,035.13",1.5,2.8,"1,299",15
5,New Brunswick,C09CA,"Angiotensin II antagonists, plain",65+,F,946.63,1.4,14.8,"6,867",16
5,New Brunswick,N02AA,Natural opium alkaloids,65+,F,940.24,1.4,9.5,"4,420",17
5,New Brunswick,C09BA,ACE inhibitors and diuretics,65+,F,923.66,1.4,6.7,"3,111",18
5,New Brunswick,N03AX,Other antiepileptics,65+,F,867.34,1.3,10.8,"5,029",19
5,New Brunswick,C07AB,"Beta-blocking agents, selective",65+,F,844.77,1.3,25.3,"11,766",20
5,New Brunswick,N06AX,Other antidepressants,65+,F,842.95,1.3,12.4,"5,750",21
5,New Brunswick,H03AA,Thyroid hormones,65+,F,807.67,1.2,30.1,"14,001",22
5,New Brunswick,C08DB,Benzothiazepine derivatives,65+,F,786.70,1.2,6.0,"2,780",23
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",65+,F,784.29,1.2,2.3,"1,056",24
5,New Brunswick,N05BA,Benzodiazepine derivatives,65+,F,717.44,1.1,24.0,"11,147",25
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,711.65,1.1,6.5,"3,036",26
5,New Brunswick,L04AA,Selective immunosuppressants,65+,F,682.71,1.0,0.3,158,27
5,New Brunswick,M05BA,Bisphosphonates,65+,F,663.30,1.0,11.0,"5,088",28
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,65+,F,655.70,1.0,5.1,"2,369",29
5,New Brunswick,L03AA,Colony-stimulating factors,65+,F,638.98,0.9,0.2,85,30
5,New Brunswick,N05CF,Benzodiazepine-related drugs,65+,F,617.88,0.9,15.3,"7,132",31
5,New Brunswick,N05AX,Other antipsychotics,65+,F,570.31,0.8,3.6,"1,659",32
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,558.73,0.8,2.6,"1,206",33
5,New Brunswick,S01ED,Beta-blocking agents,65+,F,524.86,0.8,4.4,"2,051",34
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,523.41,0.8,2.9,"1,343",35
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,510.49,0.8,6.7,"3,096",36
5,New Brunswick,J05AH,Neuraminidase inhibitors,65+,F,499.51,0.7,11.7,"5,418",37
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,473.82,0.7,1.6,722,38
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,468.78,0.7,6.8,"3,163",39
5,New Brunswick,L04AC,Interleukin inhibitors,65+,F,460.77,0.7,0.1,27,40
5,New Brunswick,C03CA,"Sulfonamides, plain",65+,F,445.13,0.7,14.5,"6,723",41
5,New Brunswick,S01EE,Prostaglandin analogues,65+,F,436.66,0.6,4.0,"1,861",42
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,431.66,0.6,20.3,"9,419",43
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,65+,F,428.47,0.6,1.1,516,44
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,402.59,0.6,1.0,482,45
5,New Brunswick,N06DA,Anticholinesterases,65+,F,399.84,0.6,3.0,"1,390",46
5,New Brunswick,A10BA,Biguanides,65+,F,392.79,0.6,14.7,"6,813",47
5,New Brunswick,B01AE,Direct thrombin inhibitors,65+,F,390.72,0.6,0.8,362,48
5,New Brunswick,C01DA,Organic nitrates,65+,F,371.94,0.6,6.8,"3,181",49
5,New Brunswick,C09DA,Angiotensin II antagonists and diuretics,65+,F,368.02,0.5,4.9,"2,287",50
5,New Brunswick,B01AB,Heparin group,65+,F,348.95,0.5,0.7,306,51
5,New Brunswick,R01AD,Corticosteroids,65+,F,315.43,0.5,12.3,"5,716",52
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,306.91,0.5,6.8,"3,153",53
5,New Brunswick,H01CB,Somatostatin and analogues,65+,F,304.62,0.5,0.0,18,54
5,New Brunswick,L02BG,Aromatase inhibitors,65+,F,287.52,0.4,1.5,684,55
5,New Brunswick,A02BA,H2-receptor antagonists,65+,F,273.87,0.4,5.9,"2,758",56
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,248.06,0.4,8.8,"4,079",57
5,New Brunswick,A10BB,Sulfonylureas,65+,F,244.73,0.4,6.1,"2,824",58
5,New Brunswick,B01AA,Vitamin K antagonists,65+,F,237.75,0.4,6.2,"2,901",59
5,New Brunswick,N04BA,Dopa and dopa derivatives,65+,F,236.77,0.4,1.3,600,60
5,New Brunswick,A12BA,Potassium,65+,F,233.95,0.3,6.4,"2,995",61
5,New Brunswick,M01AH,Coxibs,65+,F,229.40,0.3,6.4,"2,991",62
5,New Brunswick,L03AB,Interferons,65+,F,226.88,0.3,0.0,17,63
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,196.32,0.3,0.6,260,64
5,New Brunswick,N07XX,Other nervous system drugs,65+,F,182.50,0.3,0.1,25,65
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,170.27,0.3,0.0,15,66
5,New Brunswick,C10AC,Bile acid sequestrants,65+,F,170.24,0.3,1.0,464,67
5,New Brunswick,C10AX,Other lipid-modifying agents,65+,F,167.01,0.2,3.0,"1,399",68
5,New Brunswick,N03AE,Benzodiazepine derivatives,65+,F,165.27,0.2,4.5,"2,071",69
5,New Brunswick,L01BA,Folic acid analogues,65+,F,163.59,0.2,1.5,693,70
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,65+,F,159.77,0.2,1.1,518,71
5,New Brunswick,B03AA,"Iron bivalent, oral preparations",65+,F,158.73,0.2,5.8,"2,678",72
5,New Brunswick,A03FA,Propulsives,65+,F,152.08,0.2,4.9,"2,284",73
5,New Brunswick,H02AB,Glucocorticoids,65+,F,151.61,0.2,11.8,"5,471",74
5,New Brunswick,B02BX,Other systemic hemostatics,65+,F,148.66,0.2,0.0,5,75
5,New Brunswick,L04AD,Calcineurin inhibitors,65+,F,148.55,0.2,0.1,56,76
5,New Brunswick,N02AB,Phenylpiperidine derivatives,65+,F,146.55,0.2,0.4,208,77
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,65+,F,**,**,**,*,78
5,New Brunswick,M03BX,Other centrally acting agents,65+,F,140.05,0.2,4.2,"1,952",79
5,New Brunswick,A04AD,Other antiemetics,65+,F,134.28,0.2,0.6,299,80
5,New Brunswick,N05CD,Benzodiazepine derivatives,65+,F,131.80,0.2,3.6,"1,652",81
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,131.46,0.2,0.2,73,82
5,New Brunswick,C08DA,Phenylalkylamine derivatives,65+,F,129.38,0.2,1.2,545,83
5,New Brunswick,C03AA,"Thiazides, plain",65+,F,128.00,0.2,11.2,"5,203",84
5,New Brunswick,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,125.15,0.2,0.5,230,85
5,New Brunswick,N04BC,Dopamine agonists,65+,F,120.42,0.2,1.2,549,86
5,New Brunswick,S01BA,"Corticosteroids, plain",65+,F,117.56,0.2,5.7,"2,636",87
5,New Brunswick,L02AB,Progestogens,65+,F,114.94,0.2,0.2,109,88
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,109.28,0.2,2.9,"1,332",89
5,New Brunswick,C07AA,"Beta-blocking agents, non-selective",65+,F,108.88,0.2,1.8,835,90
5,New Brunswick,N07BA,Drugs used in nicotine dependence,65+,F,108.77,0.2,1.5,706,91
5,New Brunswick,C05BA,Heparins or heparinoids for topical use,65+,F,106.95,0.2,0.1,52,92
5,New Brunswick,R03DC,Leukotriene receptor antagonists,65+,F,105.98,0.2,0.8,387,93
5,New Brunswick,J01XE,Nitrofuran derivatives,65+,F,102.51,0.2,7.3,"3,378",94
5,New Brunswick,D06BB,Antivirals,65+,F,100.11,0.1,0.9,401,95
5,New Brunswick,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,99.46,0.1,6.0,"2,807",96
5,New Brunswick,A02BX,Other drugs for peptic ulcer and gastroesophageal reflux disease (GERD),65+,F,98.62,0.1,1.4,653,97
5,New Brunswick,J01DC,Second-generation cephalosporins,65+,F,96.67,0.1,5.9,"2,733",98
5,New Brunswick,M04AA,Preparations inhibiting uric acid production,65+,F,95.38,0.1,3.0,"1,388",99
5,New Brunswick,J01FA,Macrolides,65+,F,95.28,0.1,7.5,"3,487",100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"13,642.34",12.1,1.5,724,1
5,New Brunswick,N07BC,Drugs used in opioid dependence,<65,Total,"6,784.31",6.0,5.5,"2,653",2
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,<65,Total,"6,219.13",5.5,0.3,141,3
5,New Brunswick,N05AX,Other antipsychotics,<65,Total,"5,358.98",4.8,7.9,"3,802",4
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"4,635.43",4.1,14.2,"6,880",5
5,New Brunswick,L04AA,Selective immunosuppressants,<65,Total,"4,585.02",4.1,1.2,591,6
5,New Brunswick,N02AA,Natural opium alkaloids,<65,Total,"2,783.54",2.5,8.3,"4,028",7
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"2,725.62",2.4,21.9,"10,579",8
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"2,522.22",2.2,0.5,228,9
5,New Brunswick,N06AX,Other antidepressants,<65,Total,"2,454.93",2.2,17.4,"8,425",10
5,New Brunswick,L01XE,Protein kinase inhibitors,<65,Total,"2,245.51",2.0,0.1,69,11
5,New Brunswick,N03AX,Other antiepileptics,<65,Total,"2,197.44",2.0,11.6,"5,604",12
5,New Brunswick,L04AC,Interleukin inhibitors,<65,Total,"2,106.84",1.9,0.3,125,13
5,New Brunswick,N07XX,Other nervous system drugs,<65,Total,"1,936.73",1.7,0.4,181,14
5,New Brunswick,A02BC,Proton pump inhibitors,<65,Total,"1,889.95",1.7,25.9,"12,506",15
5,New Brunswick,N05CF,Benzodiazepine-related drugs,<65,Total,"1,713.34",1.5,13.5,"6,518",16
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"1,573.23",1.4,3.9,"1,887",17
5,New Brunswick,L04AX,Other immunosuppressants,<65,Total,"1,560.64",1.4,0.5,250,18
5,New Brunswick,L03AB,Interferons,<65,Total,"1,407.28",1.3,0.2,94,19
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,329.53",1.2,18.5,"8,941",20
5,New Brunswick,N03AE,Benzodiazepine derivatives,<65,Total,"1,293.95",1.2,9.7,"4,688",21
5,New Brunswick,R03BA,Glucocorticoids,<65,Total,"1,281.00",1.1,11.5,"5,572",22
5,New Brunswick,L04AD,Calcineurin inhibitors,<65,Total,"1,229.79",1.1,0.8,388,23
5,New Brunswick,N05BA,Benzodiazepine derivatives,<65,Total,"1,222.12",1.1,17.2,"8,302",24
5,New Brunswick,N06BA,Centrally acting sympathomimetics,<65,Total,"1,189.49",1.1,5.2,"2,518",25
5,New Brunswick,C09AA,"ACE inhibitors, plain",<65,Total,"1,178.90",1.0,11.0,"5,305",26
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"1,077.18",1.0,1.7,831,27
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"1,028.92",0.9,2.2,"1,069",28
5,New Brunswick,R07AX,Other respiratory system products,<65,Total,**,**,**,*,29
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,887.34,0.8,3.0,"1,444",30
5,New Brunswick,J05AH,Neuraminidase inhibitors,<65,Total,815.77,0.7,7.3,"3,546",31
5,New Brunswick,R03BB,Anticholinergics,<65,Total,760.40,0.7,5.7,"2,751",32
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,666.65,0.6,13.1,"6,325",33
5,New Brunswick,L03AA,Colony-stimulating factors,<65,Total,650.04,0.6,0.2,86,34
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,600.15,0.5,21.1,"10,205",35
5,New Brunswick,N03AG,Fatty acid derivatives,<65,Total,598.85,0.5,3.7,"1,801",36
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,574.82,0.5,6.5,"3,152",37
5,New Brunswick,M03BX,Other centrally acting agents,<65,Total,572.76,0.5,8.3,"4,011",38
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,<65,Total,564.82,0.5,2.7,"1,288",39
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,553.98,0.5,2.3,"1,088",40
5,New Brunswick,N07BA,Drugs used in nicotine dependence,<65,Total,544.86,0.5,6.1,"2,929",41
5,New Brunswick,C08CA,Dihydropyridine derivatives,<65,Total,543.21,0.5,5.5,"2,651",42
5,New Brunswick,J05AE,Protease inhibitors,<65,Total,540.26,0.5,0.2,73,43
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,538.01,0.5,1.5,719,44
5,New Brunswick,C02AC,Imidazoline receptor agonists,<65,Total,506.22,0.5,2.1,996,45
5,New Brunswick,A09AA,Enzyme preparations,<65,Total,505.88,0.4,0.3,157,46
5,New Brunswick,C09BA,ACE inhibitors and diuretics,<65,Total,482.73,0.4,3.3,"1,577",47
5,New Brunswick,A10BA,Biguanides,<65,Total,480.30,0.4,9.3,"4,519",48
5,New Brunswick,A04AD,Other antiemetics,<65,Total,476.50,0.4,1.1,543,49
5,New Brunswick,J05AX,Other antivirals,<65,Total,471.78,0.4,0.1,62,50
5,New Brunswick,S01LA,Antineovascularization agents,<65,Total,459.58,0.4,0.1,57,51
5,New Brunswick,H03AA,Thyroid hormones,<65,Total,448.29,0.4,8.9,"4,322",52
5,New Brunswick,L03AX,Other immunostimulants,<65,Total,435.50,0.4,0.1,50,53
5,New Brunswick,B01AB,Heparin group,<65,Total,408.17,0.4,0.5,231,54
5,New Brunswick,C07AB,"Beta-blocking agents, selective",<65,Total,375.36,0.3,7.5,"3,625",55
5,New Brunswick,M01AE,Propionic acid derivatives,<65,Total,368.89,0.3,13.3,"6,424",56
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,361.40,0.3,0.9,424,57
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,<65,Total,357.15,0.3,0.9,424,58
5,New Brunswick,N05AE,Indole derivatives,<65,Total,343.83,0.3,0.7,330,59
5,New Brunswick,H01CB,Somatostatin and analogues,<65,Total,342.92,0.3,0.0,18,60
5,New Brunswick,A02BA,H2-receptor antagonists,<65,Total,332.97,0.3,4.9,"2,364",61
5,New Brunswick,R01AD,Corticosteroids,<65,Total,299.66,0.3,9.7,"4,688",62
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,298.77,0.3,0.8,386,63
5,New Brunswick,H01AC,Somatropin and somatropin agonists,<65,Total,286.76,0.3,0.1,29,64
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,267.55,0.2,0.7,331,65
5,New Brunswick,C09CA,"Angiotensin II antagonists, plain",<65,Total,258.16,0.2,3.4,"1,643",66
5,New Brunswick,J01GB,Other aminoglycosides,<65,Total,249.01,0.2,0.1,51,67
5,New Brunswick,B01AF,Direct factor Xa inhibitors,<65,Total,239.15,0.2,0.8,398,68
5,New Brunswick,N03AF,Carboxamide derivatives,<65,Total,227.34,0.2,1.7,799,69
5,New Brunswick,V03AC,Iron-chelating agents,<65,Total,221.60,0.2,0.0,6,70
5,New Brunswick,A10BB,Sulfonylureas,<65,Total,219.72,0.2,3.7,"1,780",71
5,New Brunswick,N05BE,Azaspirodecanedione derivatives,<65,Total,216.44,0.2,0.8,380,72
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,210.46,0.2,2.4,"1,159",73
5,New Brunswick,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,207.55,0.2,3.2,"1,537",74
5,New Brunswick,N05CD,Benzodiazepine derivatives,<65,Total,204.99,0.2,2.8,"1,367",75
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,201.38,0.2,0.2,85,76
5,New Brunswick,C08DB,Benzothiazepine derivatives,<65,Total,194.90,0.2,1.3,626,77
5,New Brunswick,J01CA,Penicillins with extended spectrum,<65,Total,190.52,0.2,15.6,"7,530",78
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,189.59,0.2,0.1,61,79
5,New Brunswick,C03CA,"Sulfonamides, plain",<65,Total,182.18,0.2,4.0,"1,942",80
5,New Brunswick,B03XA,Other antianemic preparations,<65,Total,180.70,0.2,0.1,42,81
5,New Brunswick,R05CB,Mucolytics,<65,Total,176.07,0.2,0.1,27,82
5,New Brunswick,A03FA,Propulsives,<65,Total,157.45,0.1,3.0,"1,468",83
5,New Brunswick,M01AH,Coxibs,<65,Total,156.77,0.1,3.2,"1,540",84
5,New Brunswick,G02BA,Intrauterine contraceptives,<65,Total,152.25,0.1,0.8,394,85
5,New Brunswick,N07BB,Drugs used in alcohol dependence,<65,Total,151.93,0.1,0.3,132,86
5,New Brunswick,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,147.35,0.1,1.9,903,87
5,New Brunswick,C01CA,Adrenergic and dopaminergic agents,<65,Total,145.19,0.1,1.5,717,88
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,144.37,0.1,2.0,985,89
5,New Brunswick,J01FA,Macrolides,<65,Total,141.97,0.1,8.7,"4,228",90
5,New Brunswick,N02AB,Phenylpiperidine derivatives,<65,Total,136.38,0.1,0.2,109,91
5,New Brunswick,J01DB,First-generation cephalosporins,<65,Total,134.44,0.1,6.6,"3,203",92
5,New Brunswick,L01XX,Other antineoplastic agents,<65,Total,133.52,0.1,0.0,19,93
5,New Brunswick,N05AF,Thioxanthene derivatives,<65,Total,132.73,0.1,0.5,228,94
5,New Brunswick,H02AB,Glucocorticoids,<65,Total,132.72,0.1,9.1,"4,404",95
5,New Brunswick,G03AC,Progestogens,<65,Total,128.93,0.1,2.4,"1,174",96
5,New Brunswick,M01AB,Acetic acid derivatives and related substances,<65,Total,128.70,0.1,2.2,"1,058",97
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,128.16,0.1,0.0,10,98
5,New Brunswick,N05AD,Butyrophenone derivatives,<65,Total,125.19,0.1,0.7,361,99
5,New Brunswick,L01BA,Folic acid analogues,<65,Total,121.09,0.1,1.0,480,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"6,182.55",10.6,1.5,330,1
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,<65,M,"4,605.93",7.9,0.5,104,2
5,New Brunswick,N07BC,Drugs used in opioid dependence,<65,M,"3,923.39",6.7,6.9,"1,532",3
5,New Brunswick,N05AX,Other antipsychotics,<65,M,"3,732.28",6.4,10.4,"2,326",4
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"2,855.28",4.9,15.9,"3,557",5
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"2,018.51",3.5,0.8,180,6
5,New Brunswick,L04AA,Selective immunosuppressants,<65,M,"1,741.49",3.0,1.2,263,7
5,New Brunswick,N02AA,Natural opium alkaloids,<65,M,"1,679.34",2.9,8.0,"1,788",8
5,New Brunswick,L01XE,Protein kinase inhibitors,<65,M,"1,421.51",2.4,0.2,34,9
5,New Brunswick,L04AC,Interleukin inhibitors,<65,M,"1,271.99",2.2,0.3,73,10
5,New Brunswick,L04AX,Other immunosuppressants,<65,M,"1,225.50",2.1,0.5,115,11
5,New Brunswick,N06AX,Other antidepressants,<65,M,"1,080.77",1.9,14.6,"3,270",12
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,<65,M,"1,072.86",1.8,17.6,"3,941",13
5,New Brunswick,N03AX,Other antiepileptics,<65,M,981.67,1.7,10.3,"2,295",14
5,New Brunswick,A02BC,Proton pump inhibitors,<65,M,865.25,1.5,23.8,"5,324",15
5,New Brunswick,N05CF,Benzodiazepine-related drugs,<65,M,847.81,1.5,12.6,"2,814",16
5,New Brunswick,N06BA,Centrally acting sympathomimetics,<65,M,777.98,1.3,7.1,"1,575",17
5,New Brunswick,L04AD,Calcineurin inhibitors,<65,M,749.47,1.3,1.1,235,18
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,<65,M,687.66,1.2,20.2,"4,503",19
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,678.21,1.2,3.4,755,20
5,New Brunswick,C09AA,"ACE inhibitors, plain",<65,M,641.61,1.1,12.4,"2,767",21
5,New Brunswick,R07AX,Other respiratory system products,<65,M,**,**,**,*,22
5,New Brunswick,N03AE,Benzodiazepine derivatives,<65,M,580.31,1.0,8.7,"1,935",23
5,New Brunswick,N05BA,Benzodiazepine derivatives,<65,M,545.72,0.9,14.7,"3,279",24
5,New Brunswick,N07XX,Other nervous system drugs,<65,M,539.29,0.9,0.3,62,25
5,New Brunswick,J05AH,Neuraminidase inhibitors,<65,M,535.72,0.9,6.1,"1,353",26
5,New Brunswick,R03BA,Glucocorticoids,<65,M,530.29,0.9,10.0,"2,224",27
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",<65,M,480.91,0.8,2.3,514,28
5,New Brunswick,J05AE,Protease inhibitors,<65,M,466.08,0.8,0.3,63,29
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,414.56,0.7,3.0,666,30
5,New Brunswick,J05AX,Other antivirals,<65,M,375.98,0.6,0.2,46,31
5,New Brunswick,R03BB,Anticholinergics,<65,M,367.89,0.6,5.7,"1,282",32
5,New Brunswick,L03AB,Interferons,<65,M,333.79,0.6,0.1,23,33
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,307.32,0.5,12.5,"2,787",34
5,New Brunswick,A09AA,Enzyme preparations,<65,M,304.47,0.5,0.4,89,35
5,New Brunswick,N03AG,Fatty acid derivatives,<65,M,304.06,0.5,4.2,941,36
5,New Brunswick,C08CA,Dihydropyridine derivatives,<65,M,287.82,0.5,6.1,"1,372",37
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,277.42,0.5,2.2,482,38
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,259.09,0.4,18.6,"4,145",39
5,New Brunswick,N07BA,Drugs used in nicotine dependence,<65,M,258.42,0.4,6.2,"1,392",40
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,246.66,0.4,2.2,491,41
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,240.48,0.4,1.4,318,42
5,New Brunswick,C09BA,ACE inhibitors and diuretics,<65,M,240.37,0.4,3.5,785,43
5,New Brunswick,A10BA,Biguanides,<65,M,238.69,0.4,9.4,"2,094",44
5,New Brunswick,M03BX,Other centrally acting agents,<65,M,233.67,0.4,6.9,"1,532",45
5,New Brunswick,C02AC,Imidazoline receptor agonists,<65,M,226.45,0.4,2.1,465,46
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,220.78,0.4,5.0,"1,124",47
5,New Brunswick,H01AC,Somatropin and somatropin agonists,<65,M,217.38,0.4,0.1,18,48
5,New Brunswick,C07AB,"Beta-blocking agents, selective",<65,M,209.05,0.4,8.7,"1,947",49
5,New Brunswick,S01LA,Antineovascularization agents,<65,M,208.28,0.4,0.1,28,50
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,<65,M,192.38,0.3,1.7,372,51
5,New Brunswick,A04AD,Other antiemetics,<65,M,182.78,0.3,1.0,217,52
5,New Brunswick,H01CB,Somatostatin and analogues,<65,M,173.57,0.3,0.0,10,53
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,171.67,0.3,0.9,202,54
5,New Brunswick,L03AA,Colony-stimulating factors,<65,M,165.09,0.3,0.1,26,55
5,New Brunswick,A02BA,H2-receptor antagonists,<65,M,153.00,0.3,4.4,987,56
5,New Brunswick,B01AB,Heparin group,<65,M,151.25,0.3,0.4,95,57
5,New Brunswick,M01AE,Propionic acid derivatives,<65,M,140.73,0.2,11.1,"2,472",58
5,New Brunswick,B01AF,Direct factor Xa inhibitors,<65,M,140.63,0.2,0.9,202,59
5,New Brunswick,N05AE,Indole derivatives,<65,M,140.59,0.2,0.6,134,60
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,<65,M,138.64,0.2,0.8,169,61
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,135.75,0.2,0.8,177,62
5,New Brunswick,J01GB,Other aminoglycosides,<65,M,127.41,0.2,0.1,23,63
5,New Brunswick,L03AX,Other immunostimulants,<65,M,125.51,0.2,0.1,12,64
5,New Brunswick,N03AF,Carboxamide derivatives,<65,M,125.32,0.2,1.9,433,65
5,New Brunswick,L01XX,Other antineoplastic agents,<65,M,123.30,0.2,0.0,9,66
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,115.47,0.2,0.6,139,67
5,New Brunswick,V03AC,Iron-chelating agents,<65,M,**,**,**,*,68
5,New Brunswick,R01AD,Corticosteroids,<65,M,113.91,0.2,7.3,"1,631",69
5,New Brunswick,A10BB,Sulfonylureas,<65,M,112.28,0.2,3.9,865,70
5,New Brunswick,C09CA,"Angiotensin II antagonists, plain",<65,M,110.81,0.2,3.1,699,71
5,New Brunswick,R05CB,Mucolytics,<65,M,109.91,0.2,0.1,15,72
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,<65,M,108.37,0.2,0.1,32,73
5,New Brunswick,G04CA,Alpha-adrenoreceptor antagonists,<65,M,105.40,0.2,3.8,848,74
5,New Brunswick,H03AA,Thyroid hormones,<65,M,104.79,0.2,4.7,"1,059",75
5,New Brunswick,C08DB,Benzothiazepine derivatives,<65,M,101.49,0.2,1.3,299,76
5,New Brunswick,N05BE,Azaspirodecanedione derivatives,<65,M,99.98,0.2,0.7,163,77
5,New Brunswick,N07BB,Drugs used in alcohol dependence,<65,M,98.55,0.2,0.4,87,78
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,95.55,0.2,0.2,40,79
5,New Brunswick,N05AF,Thioxanthene derivatives,<65,M,91.57,0.2,0.7,152,80
5,New Brunswick,N05CD,Benzodiazepine derivatives,<65,M,82.83,0.1,2.6,585,81
5,New Brunswick,J01CA,Penicillins with extended spectrum,<65,M,81.81,0.1,14.0,"3,131",82
5,New Brunswick,N05AD,Butyrophenone derivatives,<65,M,81.66,0.1,1.0,217,83
5,New Brunswick,C03CA,"Sulfonamides, plain",<65,M,81.30,0.1,3.7,819,84
5,New Brunswick,B03XA,Other antianemic preparations,<65,M,74.84,0.1,0.1,17,85
5,New Brunswick,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,74.63,0.1,0.1,14,86
5,New Brunswick,L02BB,Antiandrogens,<65,M,69.71,0.1,0.1,21,87
5,New Brunswick,M01AH,Coxibs,<65,M,66.78,0.1,2.6,590,88
5,New Brunswick,J01DB,First-generation cephalosporins,<65,M,66.77,0.1,6.5,"1,462",89
5,New Brunswick,C07AG,Alpha- and beta-blocking agents,<65,M,65.34,0.1,0.8,175,90
5,New Brunswick,M01AB,Acetic acid derivatives and related substances,<65,M,61.92,0.1,2.1,467,91
5,New Brunswick,N03AB,Hydantoin derivatives,<65,M,61.39,0.1,1.4,310,92
5,New Brunswick,N02AB,Phenylpiperidine derivatives,<65,M,59.37,0.1,0.3,57,93
5,New Brunswick,A03AB,"Synthetic anticholinergics, quaternary ammonium compounds",<65,M,57.23,0.1,0.1,20,94
5,New Brunswick,N05AA,Phenothiazines with aliphatic side-chain,<65,M,56.23,0.1,1.0,213,95
5,New Brunswick,A03FA,Propulsives,<65,M,55.81,0.1,2.3,508,96
5,New Brunswick,C01CA,Adrenergic and dopaminergic agents,<65,M,55.74,0.1,1.2,277,97
5,New Brunswick,H02AB,Glucocorticoids,<65,M,54.77,0.1,7.9,"1,763",98
5,New Brunswick,J01FA,Macrolides,<65,M,54.19,0.1,6.7,"1,498",99
5,New Brunswick,L01AX,Other alkylating agents,<65,M,53.29,0.1,0.0,7,100
5,New Brunswick,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"7,459.79",13.8,1.5,394,1
5,New Brunswick,N07BC,Drugs used in opioid dependence,<65,F,"2,860.92",5.3,4.3,"1,121",2
5,New Brunswick,L04AA,Selective immunosuppressants,<65,F,"2,843.53",5.2,1.3,328,3
5,New Brunswick,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"1,780.15",3.3,12.8,"3,323",4
5,New Brunswick,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,652.76",3.1,25.5,"6,638",5
5,New Brunswick,N05AX,Other antipsychotics,<65,F,"1,626.70",3.0,5.7,"1,476",6
5,New Brunswick,J05AP,Antivirals for treatment of HCV infections,<65,F,"1,613.21",3.0,0.1,37,7
5,New Brunswick,N07XX,Other nervous system drugs,<65,F,"1,397.45",2.6,0.5,119,8
5,New Brunswick,N06AX,Other antidepressants,<65,F,"1,374.16",2.5,19.8,"5,155",9
5,New Brunswick,N03AX,Other antiepileptics,<65,F,"1,215.77",2.2,12.7,"3,309",10
5,New Brunswick,N02AA,Natural opium alkaloids,<65,F,"1,104.19",2.0,8.6,"2,240",11
5,New Brunswick,L03AB,Interferons,<65,F,"1,073.49",2.0,0.3,71,12
5,New Brunswick,A02BC,Proton pump inhibitors,<65,F,"1,024.70",1.9,27.6,"7,182",13
5,New Brunswick,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,895.03,1.7,4.4,"1,132",14
5,New Brunswick,N05CF,Benzodiazepine-related drugs,<65,F,865.54,1.6,14.2,"3,704",15
5,New Brunswick,L04AC,Interleukin inhibitors,<65,F,834.85,1.5,0.2,52,16
5,New Brunswick,L01XE,Protein kinase inhibitors,<65,F,824.01,1.5,0.1,35,17
5,New Brunswick,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,799.76,1.5,1.3,349,18
5,New Brunswick,R03BA,Glucocorticoids,<65,F,750.70,1.4,12.9,"3,348",19
5,New Brunswick,N03AE,Benzodiazepine derivatives,<65,F,713.63,1.3,10.6,"2,753",20
5,New Brunswick,N05BA,Benzodiazepine derivatives,<65,F,676.40,1.2,19.3,"5,023",21
5,New Brunswick,C10AA,HMG-CoA reductase inhibitors,<65,F,641.87,1.2,17.1,"4,438",22
5,New Brunswick,A10AE,"Insulins and analogues for injection, long-acting",<65,F,548.01,1.0,2.1,555,23
5,New Brunswick,C09AA,"ACE inhibitors, plain",<65,F,537.29,1.0,9.8,"2,538",24
5,New Brunswick,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,503.71,0.9,0.2,48,25
5,New Brunswick,L03AA,Colony-stimulating factors,<65,F,484.95,0.9,0.2,60,26
5,New Brunswick,L04AD,Calcineurin inhibitors,<65,F,480.32,0.9,0.6,153,27
5,New Brunswick,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,472.78,0.9,3.0,778,28
5,New Brunswick,N06BA,Centrally acting sympathomimetics,<65,F,411.51,0.8,3.6,943,29
5,New Brunswick,R03BB,Anticholinergics,<65,F,392.51,0.7,5.6,"1,469",30
5,New Brunswick,G04BD,Drugs for urinary frequency and incontinence,<65,F,372.43,0.7,3.5,916,31
5,New Brunswick,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,359.34,0.7,13.6,"3,538",32
5,New Brunswick,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,354.04,0.7,7.8,"2,028",33
5,New Brunswick,H03AA,Thyroid hormones,<65,F,343.50,0.6,12.5,"3,263",34
5,New Brunswick,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,341.06,0.6,23.3,"6,060",35
5,New Brunswick,M03BX,Other centrally acting agents,<65,F,339.09,0.6,9.5,"2,479",36
5,New Brunswick,L04AX,Other immunosuppressants,<65,F,335.14,0.6,0.5,135,37
5,New Brunswick,R07AX,Other respiratory system products,<65,F,**,**,**,*,38
5,New Brunswick,L03AX,Other immunostimulants,<65,F,309.99,0.6,0.1,38,39
5,New Brunswick,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,307.32,0.6,2.3,597,40
5,New Brunswick,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,297.53,0.5,1.5,401,41
5,New Brunswick,N03AG,Fatty acid derivatives,<65,F,294.80,0.5,3.3,860,42
5,New Brunswick,A04AD,Other antiemetics,<65,F,293.72,0.5,1.3,326,43
5,New Brunswick,N07BA,Drugs used in nicotine dependence,<65,F,286.44,0.5,5.9,"1,537",44
5,New Brunswick,J05AH,Neuraminidase inhibitors,<65,F,280.05,0.5,8.4,"2,193",45
5,New Brunswick,C02AC,Imidazoline receptor agonists,<65,F,279.77,0.5,2.0,531,46
5,New Brunswick,B01AB,Heparin group,<65,F,256.91,0.5,0.5,136,47
5,New Brunswick,C08CA,Dihydropyridine derivatives,<65,F,255.38,0.5,4.9,"1,279",48
5,New Brunswick,S01LA,Antineovascularization agents,<65,F,251.29,0.5,0.1,29,49
5,New Brunswick,C09BA,ACE inhibitors and diuretics,<65,F,242.36,0.4,3.0,792,50
5,New Brunswick,A10BA,Biguanides,<65,F,241.61,0.4,9.3,"2,425",51
5,New Brunswick,M01AE,Propionic acid derivatives,<65,F,228.16,0.4,15.2,"3,952",52
5,New Brunswick,A07EC,Aminosalicylic acid and similar agents,<65,F,218.51,0.4,1.0,255,53
5,New Brunswick,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,206.08,0.4,5.9,"1,525",54
5,New Brunswick,N05AE,Indole derivatives,<65,F,203.24,0.4,0.8,196,55
5,New Brunswick,A09AA,Enzyme preparations,<65,F,201.41,0.4,0.3,68,56
5,New Brunswick,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,201.33,0.4,4.3,"1,117",57
5,New Brunswick,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,189.73,0.4,0.9,222,58
5,New Brunswick,R01AD,Corticosteroids,<65,F,185.75,0.3,11.8,"3,057",59
5,New Brunswick,A02BA,H2-receptor antagonists,<65,F,179.97,0.3,5.3,"1,377",60
5,New Brunswick,H01CB,Somatostatin and analogues,<65,F,169.35,0.3,0.0,8,61
5,New Brunswick,C07AB,"Beta-blocking agents, selective",<65,F,166.30,0.3,6.5,"1,678",62
5,New Brunswick,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,163.03,0.3,0.8,209,63
5,New Brunswick,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,152.09,0.3,0.7,192,64
5,New Brunswick,G02BA,Intrauterine contraceptives,<65,F,151.86,0.3,1.5,393,65
5,New Brunswick,C09CA,"Angiotensin II antagonists, plain",<65,F,147.35,0.3,3.6,944,66
5,New Brunswick,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,147.15,0.3,3.5,900,67
5,New Brunswick,G03AC,Progestogens,<65,F,128.86,0.2,4.5,"1,173",68
5,New Brunswick,N05CD,Benzodiazepine derivatives,<65,F,122.16,0.2,3.0,782,69
5,New Brunswick,J01GB,Other aminoglycosides,<65,F,121.60,0.2,0.1,28,70
5,New Brunswick,N05BE,Azaspirodecanedione derivatives,<65,F,116.46,0.2,0.8,217,71
5,New Brunswick,J01CA,Penicillins with extended spectrum,<65,F,108.71,0.2,16.9,"4,399",72
5,New Brunswick,V03AC,Iron-chelating agents,<65,F,**,**,**,*,73
5,New Brunswick,A10BB,Sulfonylureas,<65,F,107.44,0.2,3.5,915,74
5,New Brunswick,B03XA,Other antianemic preparations,<65,F,105.86,0.2,0.1,25,75
5,New Brunswick,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,105.83,0.2,0.2,45,76
5,New Brunswick,N03AF,Carboxamide derivatives,<65,F,102.01,0.2,1.4,366,77
5,New Brunswick,A03FA,Propulsives,<65,F,101.63,0.2,3.7,960,78
5,New Brunswick,C03CA,"Sulfonamides, plain",<65,F,100.87,0.2,4.3,"1,123",79
5,New Brunswick,B01AF,Direct factor Xa inhibitors,<65,F,98.53,0.2,0.8,196,80
5,New Brunswick,R06AA,Aminoalkyl ethers,<65,F,97.72,0.2,1.4,360,81
5,New Brunswick,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,96.65,0.2,2.8,725,82
5,New Brunswick,J05AX,Other antivirals,<65,F,95.80,0.2,0.1,16,83
5,New Brunswick,C08DB,Benzothiazepine derivatives,<65,F,93.41,0.2,1.3,327,84
5,New Brunswick,M01AH,Coxibs,<65,F,89.99,0.2,3.7,950,85
5,New Brunswick,C01CA,Adrenergic and dopaminergic agents,<65,F,89.45,0.2,1.7,440,86
5,New Brunswick,J01FA,Macrolides,<65,F,87.78,0.2,10.5,"2,730",87
5,New Brunswick,L01BA,Folic acid analogues,<65,F,81.41,0.2,1.2,307,88
5,New Brunswick,L02AE,Gonadotropin-releasing hormone analogues,<65,F,81.22,0.1,0.1,29,89
5,New Brunswick,H02AB,Glucocorticoids,<65,F,77.95,0.1,10.2,"2,641",90
5,New Brunswick,N02AB,Phenylpiperidine derivatives,<65,F,77.01,0.1,0.2,52,91
5,New Brunswick,R03DC,Leukotriene receptor antagonists,<65,F,76.65,0.1,1.0,269,92
5,New Brunswick,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,75.54,0.1,0.0,7,93
5,New Brunswick,J05AE,Protease inhibitors,<65,F,74.18,0.1,0.0,10,94
5,New Brunswick,N02CC,Selective serotonin (5HT1) agonists,<65,F,71.90,0.1,1.2,317,95
5,New Brunswick,D06BB,Antivirals,<65,F,71.53,0.1,0.9,242,96
5,New Brunswick,H01AC,Somatropin and somatropin agonists,<65,F,69.38,0.1,0.0,11,97
5,New Brunswick,J01DB,First-generation cephalosporins,<65,F,67.67,0.1,6.7,"1,741",98
5,New Brunswick,M01AB,Acetic acid derivatives and related substances,<65,F,66.78,0.1,2.3,591,99
5,New Brunswick,C05BA,Heparins or heparinoids for topical use,<65,F,66.58,0.1,0.1,38,100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"257,787.30",6.7,0.4,"12,888",1
6,Quebec,S01LA,Antineovascularization agents,Total,Total,"160,272.80",4.1,0.6,"16,892",2
6,Quebec,C10AA,HMG-CoA reductase inhibitors,Total,Total,"129,066.80",3.3,31.8,"926,932",3
6,Quebec,L01XE,Protein kinase inhibitors,Total,Total,"109,712.50",2.8,0.1,"3,545",4
6,Quebec,A02BC,Proton pump inhibitors,Total,Total,"108,072.80",2.8,29.0,"844,867",5
6,Quebec,L04AA,Selective immunosuppressants,Total,Total,"99,402.43",2.6,0.4,"11,053",6
6,Quebec,N05AX,Other antipsychotics,Total,Total,"89,468.25",2.3,2.7,"77,409",7
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"81,158.25",2.1,6.0,"173,591",8
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"79,463.61",2.1,4.8,"139,129",9
6,Quebec,B01AF,Direct factor Xa inhibitors,Total,Total,"75,134.15",1.9,3.6,"106,311",10
6,Quebec,J05AP,Antivirals for treatment of HCV infections,Total,Total,"72,731.83",1.9,0.0,"1,343",11
6,Quebec,N03AX,Other antiepileptics,Total,Total,"69,256.12",1.8,8.1,"236,349",12
6,Quebec,L04AX,Other immunosuppressants,Total,Total,"64,716.75",1.7,0.2,"6,498",13
6,Quebec,C08CA,Dihydropyridine derivatives,Total,Total,"61,150.62",1.6,14.4,"420,588",14
6,Quebec,C09AA,"ACE inhibitors, plain",Total,Total,"61,066.59",1.6,11.8,"342,474",15
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"61,063.31",1.6,0.3,"8,147",16
6,Quebec,N06AX,Other antidepressants,Total,Total,"51,806.18",1.3,10.5,"306,682",17
6,Quebec,N06BA,Centrally acting sympathomimetics,Total,Total,"51,330.93",1.3,3.1,"91,041",18
6,Quebec,R03BB,Anticholinergics,Total,Total,"50,866.46",1.3,4.8,"140,013",19
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"46,505.40",1.2,2.4,"69,292",20
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"45,948.30",1.2,2.3,"66,439",21
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"45,088.18",1.2,10.0,"292,311",22
6,Quebec,C07AB,"Beta-blocking agents, selective",Total,Total,"44,943.00",1.2,13.9,"406,134",23
6,Quebec,N02BA,Salicylic acid and derivatives,Total,Total,"44,766.66",1.2,17.8,"517,612",24
6,Quebec,A11CC,Vitamin D and analogues,Total,Total,"43,348.54",1.1,19.9,"580,142",25
6,Quebec,C09CA,"Angiotensin II antagonists, plain",Total,Total,"39,462.40",1.0,10.5,"304,710",26
6,Quebec,N02AA,Natural opium alkaloids,Total,Total,"37,340.86",1.0,10.2,"298,578",27
6,Quebec,B03XA,Other antianemic preparations,Total,Total,"37,040.81",1.0,0.3,"8,920",28
6,Quebec,H03AA,Thyroid hormones,Total,Total,"36,588.27",0.9,14.0,"407,987",29
6,Quebec,R03BA,Glucocorticoids,Total,Total,"35,015.88",0.9,8.3,"241,462",30
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"34,344.59",0.9,1.7,"49,345",31
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,Total,"33,151.11",0.9,11.6,"337,797",32
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"32,330.45",0.8,1.4,"40,210",33
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"30,914.08",0.8,0.4,"10,625",34
6,Quebec,L03AA,Colony-stimulating factors,Total,Total,"30,535.75",0.8,0.2,"5,299",35
6,Quebec,L04AC,Interleukin inhibitors,Total,Total,"30,018.35",0.8,0.1,"1,883",36
6,Quebec,B01AB,Heparin group,Total,Total,"28,908.05",0.7,1.1,"30,766",37
6,Quebec,A10BA,Biguanides,Total,Total,"28,791.92",0.7,9.8,"284,874",38
6,Quebec,N05BA,Benzodiazepine derivatives,Total,Total,"28,557.84",0.7,13.3,"387,987",39
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"25,267.09",0.7,13.0,"379,459",40
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"23,114.08",0.6,1.3,"36,624",41
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"22,701.10",0.6,3.2,"93,249",42
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"22,648.88",0.6,1.6,"47,947",43
6,Quebec,M05BA,Bisphosphonates,Total,Total,"22,339.28",0.6,5.3,"155,081",44
6,Quebec,C09DA,Angiotensin II antagonists and diuretics,Total,Total,"21,611.56",0.6,5.9,"172,981",45
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"20,857.06",0.5,0.1,"1,657",46
6,Quebec,N02BE,Anilides,Total,Total,"19,920.49",0.5,13.7,"398,374",47
6,Quebec,N06DA,Anticholinesterases,Total,Total,"19,483.86",0.5,1.4,"42,141",48
6,Quebec,H01CB,Somatostatin and analogues,Total,Total,"19,432.46",0.5,0.1,"1,598",49
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"18,832.27",0.5,5.7,"166,830",50
6,Quebec,A12AA,Calcium,Total,Total,"18,717.29",0.5,8.0,"234,339",51
6,Quebec,C03CA,"Sulfonamides, plain",Total,Total,"18,628.41",0.5,4.8,"140,648",52
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"17,250.87",0.4,2.4,"69,001",53
6,Quebec,J05AX,Other antivirals,Total,Total,"17,165.92",0.4,0.1,"3,021",54
6,Quebec,L02BX,Other hormone antagonists and related agents,Total,Total,"16,488.08",0.4,0.0,"1,173",55
6,Quebec,C08DB,Benzothiazepine derivatives,Total,Total,"16,232.27",0.4,2.2,"64,418",56
6,Quebec,L04AD,Calcineurin inhibitors,Total,Total,"16,211.32",0.4,0.2,"5,149",57
6,Quebec,S01ED,Beta-blocking agents,Total,Total,"15,461.39",0.4,2.6,"74,356",58
6,Quebec,A10BB,Sulfonylureas,Total,Total,"15,290.85",0.4,4.4,"128,320",59
6,Quebec,R01AD,Corticosteroids,Total,Total,"15,229.12",0.4,10.8,"315,252",60
6,Quebec,S01EE,Prostaglandin analogues,Total,Total,"15,093.13",0.4,2.5,"73,994",61
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,Total,"13,816.37",0.4,0.3,"9,141",62
6,Quebec,C09BA,ACE inhibitors and diuretics,Total,Total,"13,694.11",0.4,2.4,"69,410",63
6,Quebec,A06AA,"Softeners, emollients",Total,Total,"13,676.83",0.4,5.1,"149,971",64
6,Quebec,L02BB,Antiandrogens,Total,Total,"13,515.09",0.3,0.2,"5,690",65
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"13,279.76",0.3,3.0,"86,868",66
6,Quebec,B01AE,Direct thrombin inhibitors,Total,Total,"12,785.77",0.3,0.5,"14,365",67
6,Quebec,N07BA,Drugs used in nicotine dependence,Total,Total,"12,689.26",0.3,2.9,"84,588",68
6,Quebec,L03AB,Interferons,Total,Total,"12,542.59",0.3,0.0,917,69
6,Quebec,A07EC,Aminosalicylic acid and similar agents,Total,Total,"12,294.50",0.3,0.6,"18,880",70
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,"12,230.69",0.3,0.4,"10,400",71
6,Quebec,C10AX,Other lipid-modifying agents,Total,Total,"12,103.49",0.3,2.4,"68,924",72
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"11,983.43",0.3,4.7,"135,813",73
6,Quebec,S01XA,Other ophthalmologicals,Total,Total,"11,945.08",0.3,1.2,"35,460",74
6,Quebec,V06C,Infant formulas,Total,Total,"11,853.08",0.3,0.3,"9,887",75
6,Quebec,J05AE,Protease inhibitors,Total,Total,"11,553.77",0.3,0.1,"1,719",76
6,Quebec,C01DA,Organic nitrates,Total,Total,"11,390.76",0.3,4.1,"118,161",77
6,Quebec,N03AE,Benzodiazepine derivatives,Total,Total,"11,335.35",0.3,4.1,"118,818",78
6,Quebec,N04BA,Dopa and dopa derivatives,Total,Total,"11,015.50",0.3,0.5,"15,159",79
6,Quebec,A16AB,Enzymes,Total,Total,"10,686.55",0.3,0.0,16,80
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,Total,"10,184.30",0.3,3.7,"107,435",81
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"10,043.20",0.3,0.2,"4,679",82
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,Total,Total,"9,964.38",0.3,1.2,"36,259",83
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"9,735.31",0.3,1.2,"35,533",84
6,Quebec,N07BC,Drugs used in opioid dependence,Total,Total,"9,712.00",0.3,0.2,"6,517",85
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"9,354.01",0.2,3.3,"96,883",86
6,Quebec,C03AA,"Thiazides, plain",Total,Total,"9,214.96",0.2,5.1,"149,662",87
6,Quebec,B03AA,"Iron bivalent, oral preparations",Total,Total,"9,178.65",0.2,4.7,"136,020",88
6,Quebec,N07XX,Other nervous system drugs,Total,Total,"8,993.04",0.2,0.1,"1,578",89
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,"8,805.12",0.2,4.1,"118,800",90
6,Quebec,N02AB,Phenylpiperidine derivatives,Total,Total,"8,716.53",0.2,0.6,"17,749",91
6,Quebec,N03AG,Fatty acid derivatives,Total,Total,"8,655.09",0.2,0.9,"25,294",92
6,Quebec,L01XC,Monoclonal antibodies,Total,Total,"8,604.93",0.2,0.0,861,93
6,Quebec,M03BX,Other centrally acting agents,Total,Total,"8,504.93",0.2,4.7,"135,965",94
6,Quebec,B01AA,Vitamin K antagonists,Total,Total,"8,439.60",0.2,2.0,"58,396",95
6,Quebec,A06AB,Contact laxatives,Total,Total,"8,217.47",0.2,3.0,"86,518",96
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"8,214.61",0.2,0.6,"17,555",97
6,Quebec,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,"8,004.30",0.2,0.1,"2,387",98
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"7,790.87",0.2,3.6,"106,246",99
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"7,624.43",0.2,0.0,339,100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"124,741.70",6.7,0.5,"5,797",1
6,Quebec,S01LA,Antineovascularization agents,Total,M,"65,907.52",3.6,0.6,"7,044",2
6,Quebec,C10AA,HMG-CoA reductase inhibitors,Total,M,"65,649.18",3.6,39.3,"494,554",3
6,Quebec,L01XE,Protein kinase inhibitors,Total,M,"57,620.09",3.1,0.1,"1,829",4
6,Quebec,N05AX,Other antipsychotics,Total,M,"53,713.62",2.9,2.9,"36,955",5
6,Quebec,J05AP,Antivirals for treatment of HCV infections,Total,M,"49,900.40",2.7,0.1,924,6
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"49,241.77",2.7,0.5,"6,556",7
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"47,575.44",2.6,6.4,"80,044",8
6,Quebec,A02BC,Proton pump inhibitors,Total,M,"43,804.36",2.4,28.0,"353,004",9
6,Quebec,B01AF,Direct factor Xa inhibitors,Total,M,"38,201.34",2.1,4.3,"54,565",10
6,Quebec,L04AX,Other immunosuppressants,Total,M,"37,905.95",2.0,0.2,"2,991",11
6,Quebec,L04AA,Selective immunosuppressants,Total,M,"36,708.00",2.0,0.4,"4,612",12
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"34,585.06",1.9,4.6,"58,318",13
6,Quebec,C09AA,"ACE inhibitors, plain",Total,M,"33,308.69",1.8,15.2,"191,511",14
6,Quebec,N06BA,Centrally acting sympathomimetics,Total,M,"31,617.03",1.7,4.1,"51,255",15
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"28,818.08",1.6,0.7,"9,329",16
6,Quebec,N03AX,Other antiepileptics,Total,M,"28,565.66",1.5,7.3,"92,452",17
6,Quebec,C08CA,Dihydropyridine derivatives,Total,M,"27,164.57",1.5,15.6,"196,226",18
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"26,805.75",1.4,3.1,"39,445",19
6,Quebec,R03BB,Anticholinergics,Total,M,"24,176.84",1.3,5.3,"66,511",20
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"23,874.78",1.3,2.9,"36,502",21
6,Quebec,N02BA,Salicylic acid and derivatives,Total,M,"22,968.86",1.2,22.3,"280,987",22
6,Quebec,C07AB,"Beta-blocking agents, selective",Total,M,"21,479.68",1.2,16.2,"203,527",23
6,Quebec,B03XA,Other antianemic preparations,Total,M,"19,795.63",1.1,0.4,"4,740",24
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"18,440.84",1.0,1.8,"22,055",25
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"17,940.21",1.0,12.6,"159,009",26
6,Quebec,N06AX,Other antidepressants,Total,M,"17,580.72",1.0,8.5,"106,797",27
6,Quebec,N02AA,Natural opium alkaloids,Total,M,"17,476.05",0.9,10.5,"132,431",28
6,Quebec,L02BX,Other hormone antagonists and related agents,Total,M,"16,488.08",0.9,0.1,"1,173",29
6,Quebec,C09CA,"Angiotensin II antagonists, plain",Total,M,"15,868.69",0.9,10.5,"131,951",30
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,Total,M,"15,115.77",0.8,7.5,"94,725",31
6,Quebec,A10BA,Biguanides,Total,M,"14,877.94",0.8,12.2,"153,921",32
6,Quebec,R03BA,Glucocorticoids,Total,M,"14,224.57",0.8,7.6,"95,222",33
6,Quebec,B01AB,Heparin group,Total,M,"13,899.37",0.8,1.1,"13,705",34
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"13,623.31",0.7,1.7,"21,694",35
6,Quebec,J05AX,Other antivirals,Total,M,"13,522.31",0.7,0.2,"2,304",36
6,Quebec,L02BB,Antiandrogens,Total,M,"13,510.75",0.7,0.4,"5,659",37
6,Quebec,A11CC,Vitamin D and analogues,Total,M,"13,428.03",0.7,12.7,"159,422",38
6,Quebec,L03AA,Colony-stimulating factors,Total,M,"13,346.85",0.7,0.2,"2,185",39
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"13,234.84",0.7,6.9,"86,426",40
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"13,138.61",0.7,2.1,"26,052",41
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"12,377.52",0.7,4.3,"54,172",42
6,Quebec,L04AC,Interleukin inhibitors,Total,M,"12,336.15",0.7,0.1,764,43
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"11,413.06",0.6,12.6,"159,074",44
6,Quebec,N05BA,Benzodiazepine derivatives,Total,M,"10,218.57",0.6,10.6,"133,426",45
6,Quebec,L04AD,Calcineurin inhibitors,Total,M,"9,778.24",0.5,0.2,"3,117",46
6,Quebec,H03AA,Thyroid hormones,Total,M,"9,669.83",0.5,8.2,"103,790",47
6,Quebec,H01CB,Somatostatin and analogues,Total,M,"9,300.35",0.5,0.1,709,48
6,Quebec,J05AE,Protease inhibitors,Total,M,"9,242.48",0.5,0.1,"1,340",49
6,Quebec,C09DA,Angiotensin II antagonists and diuretics,Total,M,"8,962.95",0.5,6.0,"75,757",50
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"8,854.02",0.5,0.1,674,51
6,Quebec,A10BB,Sulfonylureas,Total,M,"8,291.42",0.4,5.8,"73,442",52
6,Quebec,C03CA,"Sulfonamides, plain",Total,M,"8,282.18",0.4,5.0,"63,375",53
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,M,"7,518.08",0.4,0.4,"4,933",54
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,"7,425.59",0.4,0.5,"6,076",55
6,Quebec,C09BA,ACE inhibitors and diuretics,Total,M,"7,279.69",0.4,3.0,"37,258",56
6,Quebec,B01AE,Direct thrombin inhibitors,Total,M,"6,949.71",0.4,0.7,"8,214",57
6,Quebec,N06DA,Anticholinesterases,Total,M,"6,878.47",0.4,1.2,"15,342",58
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,Total,M,"6,830.47",0.4,1.1,"13,917",59
6,Quebec,S01ED,Beta-blocking agents,Total,M,"6,753.72",0.4,2.7,"33,800",60
6,Quebec,N02BE,Anilides,Total,M,"6,746.88",0.4,12.3,"154,685",61
6,Quebec,C08DB,Benzothiazepine derivatives,Total,M,"6,394.05",0.3,2.1,"26,168",62
6,Quebec,C10AX,Other lipid-modifying agents,Total,M,"6,383.46",0.3,3.1,"38,581",63
6,Quebec,N07BA,Drugs used in nicotine dependence,Total,M,"6,297.73",0.3,3.3,"41,510",64
6,Quebec,R01AD,Corticosteroids,Total,M,"6,277.62",0.3,9.7,"122,548",65
6,Quebec,N07BC,Drugs used in opioid dependence,Total,M,"6,200.11",0.3,0.3,"3,895",66
6,Quebec,S01EE,Prostaglandin analogues,Total,M,"6,176.42",0.3,2.5,"31,859",67
6,Quebec,N04BA,Dopa and dopa derivatives,Total,M,"6,116.82",0.3,0.7,"8,322",68
6,Quebec,V06C,Infant formulas,Total,M,"6,061.17",0.3,0.4,"4,635",69
6,Quebec,A07EC,Aminosalicylic acid and similar agents,Total,M,"5,955.99",0.3,0.7,"8,575",70
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,M,"5,953.07",0.3,4.5,"56,272",71
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,Total,M,"5,657.35",0.3,1.9,"23,706",72
6,Quebec,C01DA,Organic nitrates,Total,M,"5,557.82",0.3,5.2,"65,142",73
6,Quebec,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"5,479.10",0.3,0.1,"1,611",74
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,Total,M,"5,359.73",0.3,0.2,"2,389",75
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,"5,322.93",0.3,1.5,"19,055",76
6,Quebec,A06AA,"Softeners, emollients",Total,M,"5,136.57",0.3,4.4,"55,980",77
6,Quebec,M04AA,Preparations inhibiting uric acid production,Total,M,"5,057.50",0.3,3.9,"48,619",78
6,Quebec,M05BA,Bisphosphonates,Total,M,"4,732.77",0.3,2.3,"29,513",79
6,Quebec,A16AB,Enzymes,Total,M,"4,662.17",0.3,0.0,8,80
6,Quebec,N03AG,Fatty acid derivatives,Total,M,"4,642.91",0.3,1.0,"12,969",81
6,Quebec,C02AC,Imidazoline receptor agonists,Total,M,"4,612.10",0.2,0.8,"10,034",82
6,Quebec,N03AE,Benzodiazepine derivatives,Total,M,"4,550.21",0.2,3.4,"42,884",83
6,Quebec,J01DH,Carbapenems,Total,M,"4,373.73",0.2,0.2,"2,233",84
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"4,346.40",0.2,0.7,"9,044",85
6,Quebec,A12AA,Calcium,Total,M,"4,320.83",0.2,3.7,"47,167",86
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,M,"4,244.92",0.2,3.6,"44,836",87
6,Quebec,B01AA,Vitamin K antagonists,Total,M,"3,957.34",0.2,2.4,"30,311",88
6,Quebec,B03AA,"Iron bivalent, oral preparations",Total,M,"3,560.52",0.2,3.9,"48,634",89
6,Quebec,C03AA,"Thiazides, plain",Total,M,"3,416.49",0.2,4.6,"58,098",90
6,Quebec,L03AB,Interferons,Total,M,"3,408.25",0.2,0.0,263,91
6,Quebec,C09DX,"Angiotensin II antagonists, other combinations",Total,M,"3,320.71",0.2,0.2,"2,773",92
6,Quebec,M03BX,Other centrally acting agents,Total,M,"3,239.59",0.2,4.3,"53,668",93
6,Quebec,D07AC,"Corticosteroids, potent (group III)",Total,M,"3,183.09",0.2,7.2,"90,917",94
6,Quebec,N07XX,Other nervous system drugs,Total,M,"3,179.59",0.2,0.1,637,95
6,Quebec,A06AB,Contact laxatives,Total,M,"3,173.83",0.2,2.6,"33,361",96
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"3,154.87",0.2,0.1,"1,299",97
6,Quebec,N02AB,Phenylpiperidine derivatives,Total,M,"3,150.06",0.2,0.5,"6,191",98
6,Quebec,H02AB,Glucocorticoids,Total,M,"3,069.57",0.2,8.2,"102,647",99
6,Quebec,V03AC,Iron-chelating agents,Total,M,"3,066.52",0.2,0.0,139,100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"133,045.60",6.6,0.4,"7,091",1
6,Quebec,S01LA,Antineovascularization agents,Total,F,"94,365.26",4.7,0.6,"9,848",2
6,Quebec,A02BC,Proton pump inhibitors,Total,F,"64,268.44",3.2,29.7,"491,863",3
6,Quebec,C10AA,HMG-CoA reductase inhibitors,Total,F,"63,417.62",3.1,26.1,"432,378",4
6,Quebec,L04AA,Selective immunosuppressants,Total,F,"62,694.43",3.1,0.4,"6,441",5
6,Quebec,L01XE,Protein kinase inhibitors,Total,F,"52,092.38",2.6,0.1,"1,716",6
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"44,878.55",2.2,4.9,"80,811",7
6,Quebec,N03AX,Other antiepileptics,Total,F,"40,690.46",2.0,8.7,"143,897",8
6,Quebec,B01AF,Direct factor Xa inhibitors,Total,F,"36,932.81",1.8,3.1,"51,746",9
6,Quebec,N05AX,Other antipsychotics,Total,F,"35,754.62",1.8,2.4,"40,454",10
6,Quebec,N06AX,Other antidepressants,Total,F,"34,225.37",1.7,12.1,"199,884",11
6,Quebec,C08CA,Dihydropyridine derivatives,Total,F,"33,986.04",1.7,13.6,"224,362",12
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"33,582.81",1.7,5.7,"93,547",13
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,Total,F,"29,972.42",1.5,11.9,"197,586",14
6,Quebec,A11CC,Vitamin D and analogues,Total,F,"29,920.50",1.5,25.4,"420,720",15
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"28,984.85",1.4,2.8,"46,956",16
6,Quebec,C09AA,"ACE inhibitors, plain",Total,F,"27,757.90",1.4,9.1,"150,963",17
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",Total,F,"27,198.04",1.3,17.0,"281,525",18
6,Quebec,H03AA,Thyroid hormones,Total,F,"26,918.44",1.3,18.4,"304,197",19
6,Quebec,L04AX,Other immunosuppressants,Total,F,"26,810.81",1.3,0.2,"3,507",20
6,Quebec,R03BB,Anticholinergics,Total,F,"26,689.62",1.3,4.4,"73,502",21
6,Quebec,C09CA,"Angiotensin II antagonists, plain",Total,F,"23,593.71",1.2,10.4,"172,759",22
6,Quebec,C07AB,"Beta-blocking agents, selective",Total,F,"23,463.31",1.2,12.3,"202,607",23
6,Quebec,J05AP,Antivirals for treatment of HCV infections,Total,F,"22,831.43",1.1,0.0,419,24
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"22,630.62",1.1,2.0,"32,790",25
6,Quebec,N02BA,Salicylic acid and derivatives,Total,F,"21,797.80",1.1,14.3,"236,625",26
6,Quebec,R03BA,Glucocorticoids,Total,F,"20,791.31",1.0,8.8,"146,240",27
6,Quebec,N02AA,Natural opium alkaloids,Total,F,"19,864.81",1.0,10.0,"166,147",28
6,Quebec,N06BA,Centrally acting sympathomimetics,Total,F,"19,713.90",1.0,2.4,"39,786",29
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"19,142.55",0.9,1.6,"26,994",30
6,Quebec,N05BA,Benzodiazepine derivatives,Total,F,"18,339.27",0.9,15.4,"254,561",31
6,Quebec,L04AC,Interleukin inhibitors,Total,F,"17,682.19",0.9,0.1,"1,119",32
6,Quebec,M05BA,Bisphosphonates,Total,F,"17,606.51",0.9,7.6,"125,568",33
6,Quebec,B03XA,Other antianemic preparations,Total,F,"17,245.19",0.9,0.3,"4,180",34
6,Quebec,L03AA,Colony-stimulating factors,Total,F,"17,188.90",0.9,0.2,"3,114",35
6,Quebec,B01AB,Heparin group,Total,F,"15,008.68",0.7,1.0,"17,061",36
6,Quebec,A12AA,Calcium,Total,F,"14,396.46",0.7,11.3,"187,172",37
6,Quebec,A10BA,Biguanides,Total,F,"13,913.98",0.7,7.9,"130,953",38
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"13,889.61",0.7,1.1,"18,155",39
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"13,854.03",0.7,13.3,"220,385",40
6,Quebec,N02BE,Anilides,Total,F,"13,173.59",0.7,14.7,"243,688",41
6,Quebec,C09DA,Angiotensin II antagonists and diuretics,Total,F,"12,648.61",0.6,5.9,"97,224",42
6,Quebec,N06DA,Anticholinesterases,Total,F,"12,605.39",0.6,1.6,"26,799",43
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"12,003.05",0.6,0.1,983,44
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"11,878.04",0.6,8.2,"135,334",45
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"11,821.55",0.6,0.1,"1,591",46
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,Total,F,"11,593.52",0.6,2.7,"45,295",47
6,Quebec,C03CA,"Sulfonamides, plain",Total,F,"10,346.23",0.5,4.7,"77,273",48
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"10,323.58",0.5,2.4,"39,077",49
6,Quebec,H01CB,Somatostatin and analogues,Total,F,"10,132.11",0.5,0.1,889,50
6,Quebec,C08DB,Benzothiazepine derivatives,Total,F,"9,838.22",0.5,2.3,"38,250",51
6,Quebec,S01XA,Other ophthalmologicals,Total,F,"9,516.53",0.5,1.6,"25,711",52
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"9,510.26",0.5,1.3,"21,895",53
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"9,490.77",0.5,0.9,"14,930",54
6,Quebec,L03AB,Interferons,Total,F,"9,134.34",0.5,0.0,654,55
6,Quebec,R01AD,Corticosteroids,Total,F,"8,951.50",0.4,11.7,"192,704",56
6,Quebec,S01EE,Prostaglandin analogues,Total,F,"8,916.71",0.4,2.5,"42,135",57
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"8,801.56",0.4,7.2,"118,771",58
6,Quebec,S01ED,Beta-blocking agents,Total,F,"8,707.67",0.4,2.5,"40,556",59
6,Quebec,A06AA,"Softeners, emollients",Total,F,"8,540.27",0.4,5.7,"93,991",60
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,Total,F,"7,871.69",0.4,1.8,"30,118",61
6,Quebec,A10BB,Sulfonylureas,Total,F,"6,999.43",0.3,3.3,"54,878",62
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"6,888.33",0.3,0.2,"3,380",63
6,Quebec,N03AE,Benzodiazepine derivatives,Total,F,"6,785.14",0.3,4.6,"75,934",64
6,Quebec,L04AD,Calcineurin inhibitors,Total,F,"6,433.09",0.3,0.1,"2,032",65
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"6,431.91",0.3,4.2,"69,260",66
6,Quebec,C09BA,ACE inhibitors and diuretics,Total,F,"6,414.42",0.3,1.9,"32,152",67
6,Quebec,N07BA,Drugs used in nicotine dependence,Total,F,"6,391.52",0.3,2.6,"43,078",68
6,Quebec,A07EC,Aminosalicylic acid and similar agents,Total,F,"6,338.51",0.3,0.6,"10,305",69
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,Total,F,"6,298.29",0.3,0.3,"4,208",70
6,Quebec,A16AB,Enzymes,Total,F,"6,024.38",0.3,0.0,8,71
6,Quebec,L02BG,Aromatase inhibitors,Total,F,"5,972.89",0.3,1.1,"18,808",72
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),Total,F,"5,939.38",0.3,3.8,"62,599",73
6,Quebec,B01AE,Direct thrombin inhibitors,Total,F,"5,836.06",0.3,0.4,"6,151",74
6,Quebec,C01DA,Organic nitrates,Total,F,"5,832.94",0.3,3.2,"53,019",75
6,Quebec,N07XX,Other nervous system drugs,Total,F,"5,813.45",0.3,0.1,941,76
6,Quebec,C03AA,"Thiazides, plain",Total,F,"5,798.47",0.3,5.5,"91,564",77
6,Quebec,V06C,Infant formulas,Total,F,"5,791.91",0.3,0.3,"5,252",78
6,Quebec,C10AX,Other lipid-modifying agents,Total,F,"5,720.03",0.3,1.8,"30,343",79
6,Quebec,L01XC,Monoclonal antibodies,Total,F,"5,710.24",0.3,0.0,560,80
6,Quebec,B03AA,"Iron bivalent, oral preparations",Total,F,"5,618.13",0.3,5.3,"87,386",81
6,Quebec,N02AB,Phenylpiperidine derivatives,Total,F,"5,566.47",0.3,0.7,"11,558",82
6,Quebec,L03AX,Other immunostimulants,Total,F,"5,562.33",0.3,0.0,528,83
6,Quebec,M03BX,Other centrally acting agents,Total,F,"5,265.34",0.3,5.0,"82,297",84
6,Quebec,A06AB,Contact laxatives,Total,F,"5,043.64",0.2,3.2,"53,157",85
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"4,979.71",0.2,0.0,215,86
6,Quebec,H05AA,Parathyroid hormones and analogues,Total,F,"4,964.82",0.2,0.0,789,87
6,Quebec,N04BA,Dopa and dopa derivatives,Total,F,"4,898.69",0.2,0.4,"6,837",88
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"4,886.81",0.2,4.5,"74,393",89
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,"4,805.10",0.2,0.3,"4,324",90
6,Quebec,R03DC,Leukotriene receptor antagonists,Total,F,"4,681.94",0.2,1.2,"20,229",91
6,Quebec,B01AA,Vitamin K antagonists,Total,F,"4,482.26",0.2,1.7,"28,085",92
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,"4,412.38",0.2,1.0,"16,478",93
6,Quebec,H02AB,Glucocorticoids,Total,F,"4,362.26",0.2,8.9,"147,503",94
6,Quebec,G02BA,Intrauterine contraceptives,Total,F,"4,258.94",0.2,0.9,"14,375",95
6,Quebec,L01BA,Folic acid analogues,Total,F,"4,208.37",0.2,1.1,"17,828",96
6,Quebec,M01AH,Coxibs,Total,F,"4,191.41",0.2,6.2,"102,799",97
6,Quebec,G03DA,Pregnen (4) derivatives,Total,F,"4,180.41",0.2,2.6,"43,751",98
6,Quebec,M01AE,Propionic acid derivatives,Total,F,"4,170.06",0.2,12.4,"204,400",99
6,Quebec,A12BA,Potassium,Total,F,"4,143.91",0.2,2.1,"34,092",100
6,Quebec,S01LA,Antineovascularization agents,65+,Total,"149,881.80",6.4,1.2,"15,708",1
6,Quebec,C10AA,HMG-CoA reductase inhibitors,65+,Total,"100,865.10",4.3,52.7,"707,247",2
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"96,501.94",4.1,0.4,"5,100",3
6,Quebec,L01XE,Protein kinase inhibitors,65+,Total,"82,517.66",3.5,0.2,"2,667",4
6,Quebec,A02BC,Proton pump inhibitors,65+,Total,"77,271.17",3.3,41.4,"555,875",5
6,Quebec,B01AF,Direct factor Xa inhibitors,65+,Total,"68,044.19",2.9,7.0,"93,730",6
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"55,101.40",2.3,6.7,"89,812",7
6,Quebec,L04AX,Other immunosuppressants,65+,Total,"53,638.48",2.3,0.3,"3,353",8
6,Quebec,C08CA,Dihydropyridine derivatives,65+,Total,"50,730.26",2.2,25.2,"337,865",9
6,Quebec,C09AA,"ACE inhibitors, plain",65+,Total,"45,824.06",2.0,19.1,"255,691",10
6,Quebec,R03BB,Anticholinergics,65+,Total,"39,261.73",1.7,8.0,"107,335",11
6,Quebec,C07AB,"Beta-blocking agents, selective",65+,Total,"37,640.80",1.6,25.0,"334,972",12
6,Quebec,N02BA,Salicylic acid and derivatives,65+,Total,"36,469.18",1.6,31.1,"417,758",13
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"36,147.19",1.5,3.9,"52,723",14
6,Quebec,L04AA,Selective immunosuppressants,65+,Total,"36,006.03",1.5,0.4,"5,050",15
6,Quebec,N03AX,Other antiepileptics,65+,Total,"35,985.94",1.5,10.7,"142,905",16
6,Quebec,A11CC,Vitamin D and analogues,65+,Total,"32,790.03",1.4,30.3,"405,891",17
6,Quebec,C09CA,"Angiotensin II antagonists, plain",65+,Total,"31,998.67",1.4,17.8,"239,158",18
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"31,626.84",1.3,3.3,"44,497",19
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"30,643.98",1.3,3.3,"44,376",20
6,Quebec,B03XA,Other antianemic preparations,65+,Total,"29,753.65",1.3,0.5,"7,300",21
6,Quebec,H03AA,Thyroid hormones,65+,Total,"27,713.64",1.2,21.6,"289,597",22
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,Total,"27,318.23",1.2,20.1,"270,093",23
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"27,214.30",1.2,0.7,"8,787",24
6,Quebec,N06AX,Other antidepressants,65+,Total,"24,550.17",1.0,10.8,"144,525",25
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"23,115.49",1.0,10.6,"141,823",26
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"20,985.10",0.9,2.0,"26,178",27
6,Quebec,A10BA,Biguanides,65+,Total,"20,852.22",0.9,15.1,"202,305",28
6,Quebec,L03AA,Colony-stimulating factors,65+,Total,"20,793.96",0.9,0.3,"3,592",29
6,Quebec,B01AB,Heparin group,65+,Total,"20,049.24",0.9,1.6,"21,654",30
6,Quebec,M05BA,Bisphosphonates,65+,Total,"19,469.37",0.8,10.1,"135,089",31
6,Quebec,N06DA,Anticholinesterases,65+,Total,"19,242.94",0.8,3.1,"41,598",32
6,Quebec,N05BA,Benzodiazepine derivatives,65+,Total,"19,158.98",0.8,19.9,"266,285",33
6,Quebec,R03BA,Glucocorticoids,65+,Total,"18,129.60",0.8,8.3,"111,074",34
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"17,542.28",0.7,4.9,"65,581",35
6,Quebec,C09DA,Angiotensin II antagonists and diuretics,65+,Total,"17,346.36",0.7,10.2,"136,311",36
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"17,249.13",0.7,5.8,"77,525",37
6,Quebec,N02AA,Natural opium alkaloids,65+,Total,"17,145.89",0.7,12.3,"164,780",38
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"16,581.44",0.7,10.6,"142,836",39
6,Quebec,C03CA,"Sulfonamides, plain",65+,Total,"16,363.46",0.7,9.2,"123,565",40
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"15,974.48",0.7,14.5,"194,191",41
6,Quebec,A12AA,Calcium,65+,Total,"15,330.44",0.7,13.8,"184,722",42
6,Quebec,L02BX,Other hormone antagonists and related agents,65+,Total,"15,280.82",0.7,0.1,"1,078",43
6,Quebec,N02BE,Anilides,65+,Total,"14,520.72",0.6,19.3,"258,615",44
6,Quebec,J05AP,Antivirals for treatment of HCV infections,65+,Total,"14,381.87",0.6,0.0,259,45
6,Quebec,H01CB,Somatostatin and analogues,65+,Total,"14,324.99",0.6,0.1,"1,203",46
6,Quebec,N05AX,Other antipsychotics,65+,Total,"14,197.31",0.6,2.1,"28,793",47
6,Quebec,C08DB,Benzothiazepine derivatives,65+,Total,"13,854.80",0.6,4.1,"54,555",48
6,Quebec,S01ED,Beta-blocking agents,65+,Total,"13,807.38",0.6,4.9,"65,253",49
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"13,728.41",0.6,2.2,"29,063",50
6,Quebec,S01EE,Prostaglandin analogues,65+,Total,"13,555.39",0.6,4.9,"65,733",51
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"13,529.97",0.6,1.6,"21,087",52
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"13,289.86",0.6,4.0,"53,451",53
6,Quebec,L02BB,Antiandrogens,65+,Total,"12,829.88",0.5,0.4,"5,365",54
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"12,329.06",0.5,5.8,"77,727",55
6,Quebec,B01AE,Direct thrombin inhibitors,65+,Total,"12,040.59",0.5,1.0,"13,446",56
6,Quebec,L04AC,Interleukin inhibitors,65+,Total,"11,481.45",0.5,0.1,782,57
6,Quebec,A10BB,Sulfonylureas,65+,Total,"11,292.64",0.5,6.8,"91,315",58
6,Quebec,C01DA,Organic nitrates,65+,Total,"10,272.80",0.4,7.5,"100,798",59
6,Quebec,C09BA,ACE inhibitors and diuretics,65+,Total,"9,964.47",0.4,3.8,"50,328",60
6,Quebec,A06AA,"Softeners, emollients",65+,Total,"9,725.72",0.4,8.3,"110,893",61
6,Quebec,S01XA,Other ophthalmologicals,65+,Total,"9,698.36",0.4,2.1,"27,874",62
6,Quebec,N04BA,Dopa and dopa derivatives,65+,Total,"9,483.11",0.4,1.0,"13,743",63
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"9,431.21",0.4,0.1,882,64
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,"9,154.44",0.4,0.1,"1,072",65
6,Quebec,C10AX,Other lipid-modifying agents,65+,Total,"9,090.48",0.4,3.9,"52,948",66
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,"8,637.26",0.4,6.7,"89,739",67
6,Quebec,R01AD,Corticosteroids,65+,Total,"8,325.18",0.4,11.4,"153,446",68
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,"8,237.93",0.4,0.6,"8,046",69
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,Total,"8,022.40",0.3,0.4,"5,168",70
6,Quebec,B01AA,Vitamin K antagonists,65+,Total,"7,440.63",0.3,3.8,"50,709",71
6,Quebec,C03AA,"Thiazides, plain",65+,Total,"7,403.36",0.3,8.8,"117,805",72
6,Quebec,A07EC,Aminosalicylic acid and similar agents,65+,Total,"7,216.73",0.3,0.8,"10,467",73
6,Quebec,B03AA,"Iron bivalent, oral preparations",65+,Total,"7,206.23",0.3,6.8,"90,575",74
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"6,878.86",0.3,5.9,"79,054",75
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"6,665.53",0.3,1.1,"14,233",76
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"6,519.75",0.3,1.8,"23,656",77
6,Quebec,M04AA,Preparations inhibiting uric acid production,65+,Total,"6,448.45",0.3,4.2,"56,581",78
6,Quebec,L04AD,Calcineurin inhibitors,65+,Total,"6,118.56",0.3,0.2,"2,213",79
6,Quebec,A06AB,Contact laxatives,65+,Total,"5,718.81",0.2,4.8,"64,874",80
6,Quebec,A12BA,Potassium,65+,Total,"5,654.67",0.2,3.5,"47,029",81
6,Quebec,L01XC,Monoclonal antibodies,65+,Total,"5,022.51",0.2,0.0,566,82
6,Quebec,H02AB,Glucocorticoids,65+,Total,"5,017.82",0.2,11.4,"153,099",83
6,Quebec,N02AB,Phenylpiperidine derivatives,65+,Total,"4,978.55",0.2,0.9,"11,647",84
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"4,898.05",0.2,3.7,"49,861",85
6,Quebec,H05AA,Parathyroid hormones and analogues,65+,Total,"4,872.68",0.2,0.1,773,86
6,Quebec,L02BG,Aromatase inhibitors,65+,Total,"4,785.83",0.2,1.0,"13,547",87
6,Quebec,N03AE,Benzodiazepine derivatives,65+,Total,"4,723.26",0.2,4.4,"58,551",88
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"4,638.16",0.2,0.2,"2,455",89
6,Quebec,L01XX,Other antineoplastic agents,65+,Total,"4,603.72",0.2,0.2,"3,283",90
6,Quebec,L01BA,Folic acid analogues,65+,Total,"4,377.31",0.2,1.4,"18,370",91
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"4,313.68",0.2,0.0,181,92
6,Quebec,A06AD,Osmotically acting laxatives,65+,Total,"4,302.90",0.2,6.1,"82,392",93
6,Quebec,C03DA,Aldosterone antagonists,65+,Total,"3,997.71",0.2,2.2,"30,002",94
6,Quebec,M01AH,Coxibs,65+,Total,"3,984.91",0.2,7.5,"101,189",95
6,Quebec,D07AC,"Corticosteroids, potent (group III)",65+,Total,"3,982.15",0.2,9.1,"122,616",96
6,Quebec,R03DC,Leukotriene receptor antagonists,65+,Total,"3,875.48",0.2,1.1,"14,616",97
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,65+,Total,"3,774.20",0.2,0.6,"7,484",98
6,Quebec,A03FA,Propulsives,65+,Total,"3,739.22",0.2,3.4,"45,244",99
6,Quebec,J05AX,Other antivirals,65+,Total,"3,736.34",0.2,0.0,488,100
6,Quebec,S01LA,Antineovascularization agents,65+,M,"60,126.44",5.6,1.1,"6,387",1
6,Quebec,C10AA,HMG-CoA reductase inhibitors,65+,M,"50,187.72",4.6,62.5,"370,149",2
6,Quebec,L01XE,Protein kinase inhibitors,65+,M,"44,171.34",4.1,0.2,"1,401",3
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"42,319.65",3.9,0.3,"2,061",4
6,Quebec,B01AF,Direct factor Xa inhibitors,65+,M,"33,891.57",3.1,8.0,"47,300",5
6,Quebec,L04AX,Other immunosuppressants,65+,M,"31,124.75",2.9,0.3,"1,621",6
6,Quebec,A02BC,Proton pump inhibitors,65+,M,"30,401.52",2.8,38.9,"230,069",7
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"27,178.18",2.5,1.5,"8,776",8
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"24,465.14",2.3,6.5,"38,458",9
6,Quebec,C09AA,"ACE inhibitors, plain",65+,M,"24,188.86",2.2,23.6,"139,864",10
6,Quebec,C08CA,Dihydropyridine derivatives,65+,M,"21,426.13",2.0,25.5,"151,049",11
6,Quebec,R03BB,Anticholinergics,65+,M,"19,060.39",1.8,8.8,"52,263",12
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"18,585.80",1.7,4.5,"26,615",13
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"18,441.50",1.7,4.7,"27,570",14
6,Quebec,N02BA,Salicylic acid and derivatives,65+,M,"18,103.03",1.7,37.6,"222,348",15
6,Quebec,C07AB,"Beta-blocking agents, selective",65+,M,"17,241.66",1.6,27.6,"163,586",16
6,Quebec,B03XA,Other antianemic preparations,65+,M,"16,038.45",1.5,0.6,"3,838",17
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"15,836.80",1.5,23.2,"137,396",18
6,Quebec,L02BX,Other hormone antagonists and related agents,65+,M,"15,280.82",1.4,0.2,"1,078",19
6,Quebec,L04AA,Selective immunosuppressants,65+,M,"14,912.58",1.4,0.4,"2,229",20
6,Quebec,N03AX,Other antiepileptics,65+,M,"13,654.73",1.3,9.0,"53,489",21
6,Quebec,L02BB,Antiandrogens,65+,M,"12,828.43",1.2,0.9,"5,360",22
6,Quebec,C09CA,"Angiotensin II antagonists, plain",65+,M,"12,343.71",1.1,16.9,"100,213",23
6,Quebec,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"12,309.71",1.1,13.1,"77,511",24
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"12,071.03",1.1,2.4,"14,366",25
6,Quebec,A10BA,Biguanides,65+,M,"10,740.02",1.0,18.6,"109,796",26
6,Quebec,B01AB,Heparin group,65+,M,"10,028.88",0.9,1.7,"9,908",27
6,Quebec,A11CC,Vitamin D and analogues,65+,M,"9,959.96",0.9,19.5,"115,704",28
6,Quebec,L03AA,Colony-stimulating factors,65+,M,"9,887.94",0.9,0.3,"1,610",29
6,Quebec,J05AP,Antivirals for treatment of HCV infections,65+,M,"9,059.44",0.8,0.0,164,30
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"8,839.16",0.8,7.4,"43,751",31
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"8,178.04",0.8,2.2,"12,848",32
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"8,101.33",0.8,2.7,"15,987",33
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,"8,033.46",0.7,0.2,946,34
6,Quebec,N06AX,Other antidepressants,65+,M,"7,517.07",0.7,8.0,"47,248",35
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"7,271.37",0.7,13.6,"80,450",36
6,Quebec,H03AA,Thyroid hormones,65+,M,"7,206.86",0.7,13.0,"77,222",37
6,Quebec,R03BA,Glucocorticoids,65+,M,"7,122.84",0.7,7.0,"41,608",38
6,Quebec,C03CA,"Sulfonamides, plain",65+,M,"7,089.03",0.7,9.3,"54,794",39
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"6,987.08",0.6,4.3,"25,514",40
6,Quebec,H01CB,Somatostatin and analogues,65+,M,"6,942.70",0.6,0.1,544,41
6,Quebec,C09DA,Angiotensin II antagonists and diuretics,65+,M,"6,916.09",0.6,9.7,"57,583",42
6,Quebec,N02AA,Natural opium alkaloids,65+,M,"6,830.34",0.6,12.0,"71,235",43
6,Quebec,N06DA,Anticholinesterases,65+,M,"6,777.47",0.6,2.6,"15,112",44
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,65+,M,"6,583.55",0.6,7.1,"41,821",45
6,Quebec,B01AE,Direct thrombin inhibitors,65+,M,"6,431.55",0.6,1.3,"7,570",46
6,Quebec,A10BB,Sulfonylureas,65+,M,"6,038.85",0.6,8.8,"51,802",47
6,Quebec,N05BA,Benzodiazepine derivatives,65+,M,"5,951.46",0.6,14.6,"86,415",48
6,Quebec,S01ED,Beta-blocking agents,65+,M,"5,913.07",0.5,4.9,"29,184",49
6,Quebec,S01EE,Prostaglandin analogues,65+,M,"5,479.94",0.5,4.7,"28,049",50
6,Quebec,C08DB,Benzothiazepine derivatives,65+,M,"5,294.51",0.5,3.7,"21,614",51
6,Quebec,N04BA,Dopa and dopa derivatives,65+,M,"5,215.78",0.5,1.3,"7,556",52
6,Quebec,N05AX,Other antipsychotics,65+,M,"5,171.96",0.5,1.7,"10,026",53
6,Quebec,C09BA,ACE inhibitors and diuretics,65+,M,"5,110.49",0.5,4.4,"26,171",54
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,M,"4,915.83",0.5,8.0,"47,310",55
6,Quebec,C01DA,Organic nitrates,65+,M,"4,906.09",0.5,9.2,"54,471",56
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,65+,M,"4,892.79",0.5,0.4,"2,140",57
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,"4,889.13",0.5,0.8,"4,627",58
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,M,"4,719.24",0.4,0.5,"3,010",59
6,Quebec,L04AC,Interleukin inhibitors,65+,M,"4,537.79",0.4,0.1,297,60
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,65+,M,"4,521.02",0.4,3.3,"19,236",61
6,Quebec,C10AX,Other lipid-modifying agents,65+,M,"4,506.01",0.4,4.9,"29,167",62
6,Quebec,N02BE,Anilides,65+,M,"4,453.46",0.4,16.0,"94,627",63
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"4,312.46",0.4,0.1,402,64
6,Quebec,M04AA,Preparations inhibiting uric acid production,65+,M,"4,209.16",0.4,6.7,"39,426",65
6,Quebec,M05BA,Bisphosphonates,65+,M,"3,963.80",0.4,4.3,"25,343",66
6,Quebec,L04AD,Calcineurin inhibitors,65+,M,"3,763.61",0.3,0.2,"1,370",67
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,65+,M,"3,753.75",0.3,1.2,"7,274",68
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,"3,613.29",0.3,6.5,"38,511",69
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,"3,598.83",0.3,2.2,"13,022",70
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"3,591.31",0.3,1.3,"7,515",71
6,Quebec,A07EC,Aminosalicylic acid and similar agents,65+,M,"3,575.80",0.3,0.8,"4,944",72
6,Quebec,R01AD,Corticosteroids,65+,M,"3,536.46",0.3,10.4,"61,332",73
6,Quebec,A12AA,Calcium,65+,M,"3,454.22",0.3,6.5,"38,531",74
6,Quebec,A06AA,"Softeners, emollients",65+,M,"3,391.60",0.3,6.9,"40,893",75
6,Quebec,B01AA,Vitamin K antagonists,65+,M,"3,389.86",0.3,4.4,"25,896",76
6,Quebec,J05AX,Other antivirals,65+,M,"3,264.09",0.3,0.1,424,77
6,Quebec,B03AA,"Iron bivalent, oral preparations",65+,M,"2,902.44",0.3,6.5,"38,680",78
6,Quebec,C03AA,"Thiazides, plain",65+,M,"2,609.22",0.2,7.5,"44,357",79
6,Quebec,C09DX,"Angiotensin II antagonists, other combinations",65+,M,"2,497.07",0.2,0.4,"2,088",80
6,Quebec,C03DA,Aldosterone antagonists,65+,M,"2,265.00",0.2,2.6,"15,298",81
6,Quebec,J01DH,Carbapenems,65+,M,"2,188.71",0.2,0.2,"1,222",82
6,Quebec,J05AE,Protease inhibitors,65+,M,"2,098.42",0.2,0.0,279,83
6,Quebec,H02AB,Glucocorticoids,65+,M,"2,056.94",0.2,10.7,"63,614",84
6,Quebec,A06AB,Contact laxatives,65+,M,"2,053.00",0.2,4.1,"24,408",85
6,Quebec,A12BA,Potassium,65+,M,"2,022.00",0.2,3.0,"17,765",86
6,Quebec,L01XX,Other antineoplastic agents,65+,M,"1,984.98",0.2,0.2,"1,318",87
6,Quebec,D07AC,"Corticosteroids, potent (group III)",65+,M,"1,922.42",0.2,9.2,"54,474",88
6,Quebec,S01XA,Other ophthalmologicals,65+,M,"1,911.47",0.2,1.3,"7,450",89
6,Quebec,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,"1,842.71",0.2,0.1,584,90
6,Quebec,L01XC,Monoclonal antibodies,65+,M,"1,824.88",0.2,0.0,204,91
6,Quebec,V03AC,Iron-chelating agents,65+,M,"1,788.91",0.2,0.0,89,92
6,Quebec,A06AD,Osmotically acting laxatives,65+,M,"1,653.33",0.2,5.3,"31,597",93
6,Quebec,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,"1,598.03",0.1,0.5,"3,003",94
6,Quebec,B02BX,Other systemic hemostatics,65+,M,"1,588.01",0.1,0.0,42,95
6,Quebec,J01MA,Fluoroquinolones,65+,M,"1,569.44",0.1,11.7,"69,357",96
6,Quebec,N03AE,Benzodiazepine derivatives,65+,M,"1,567.65",0.1,3.3,"19,817",97
6,Quebec,N02AB,Phenylpiperidine derivatives,65+,M,"1,556.59",0.1,0.7,"3,849",98
6,Quebec,N07BA,Drugs used in nicotine dependence,65+,M,"1,524.60",0.1,1.8,"10,654",99
6,Quebec,C10AB,Fibrates,65+,M,"1,518.01",0.1,1.7,"10,138",100
6,Quebec,S01LA,Antineovascularization agents,65+,F,"89,755.37",7.1,1.2,"9,321",1
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"54,182.29",4.3,0.4,"3,039",2
6,Quebec,C10AA,HMG-CoA reductase inhibitors,65+,F,"50,677.33",4.0,45.0,"337,098",3
6,Quebec,A02BC,Proton pump inhibitors,65+,F,"46,869.65",3.7,43.5,"325,806",4
6,Quebec,L01XE,Protein kinase inhibitors,65+,F,"38,346.32",3.0,0.2,"1,266",5
6,Quebec,B01AF,Direct factor Xa inhibitors,65+,F,"34,152.63",2.7,6.2,"46,430",6
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"30,636.25",2.4,6.9,"51,354",7
6,Quebec,C08CA,Dihydropyridine derivatives,65+,F,"29,304.13",2.3,24.9,"186,816",8
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"25,751.20",2.0,5.6,"42,236",9
6,Quebec,A11CC,Vitamin D and analogues,65+,F,"22,830.07",1.8,38.7,"290,187",10
6,Quebec,L04AX,Other immunosuppressants,65+,F,"22,513.73",1.8,0.2,"1,732",11
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,F,"22,402.40",1.8,29.7,"222,783",12
6,Quebec,N03AX,Other antiepileptics,65+,F,"22,331.21",1.8,11.9,"89,416",13
6,Quebec,C09AA,"ACE inhibitors, plain",65+,F,"21,635.20",1.7,15.5,"115,827",14
6,Quebec,L04AA,Selective immunosuppressants,65+,F,"21,093.45",1.7,0.4,"2,821",15
6,Quebec,H03AA,Thyroid hormones,65+,F,"20,506.78",1.6,28.3,"212,375",16
6,Quebec,C07AB,"Beta-blocking agents, selective",65+,F,"20,399.14",1.6,22.9,"171,386",17
6,Quebec,R03BB,Anticholinergics,65+,F,"20,201.34",1.6,7.3,"55,072",18
6,Quebec,C09CA,"Angiotensin II antagonists, plain",65+,F,"19,654.96",1.5,18.5,"138,945",19
6,Quebec,N02BA,Salicylic acid and derivatives,65+,F,"18,366.15",1.4,26.1,"195,410",20
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"17,705.68",1.4,3.4,"25,153",21
6,Quebec,N06AX,Other antidepressants,65+,F,"17,033.10",1.3,13.0,"97,277",22
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,65+,F,"16,531.94",1.3,13.3,"100,002",23
6,Quebec,M05BA,Bisphosphonates,65+,F,"15,505.58",1.2,14.6,"109,746",24
6,Quebec,B03XA,Other antianemic preparations,65+,F,"13,715.20",1.1,0.5,"3,462",25
6,Quebec,N05BA,Benzodiazepine derivatives,65+,F,"13,207.51",1.0,24.0,"179,870",26
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"13,041.04",1.0,2.4,"17,882",27
6,Quebec,N06DA,Anticholinesterases,65+,F,"12,465.47",1.0,3.5,"26,486",28
6,Quebec,A12AA,Calcium,65+,F,"11,876.22",0.9,19.5,"146,191",29
6,Quebec,R03BA,Glucocorticoids,65+,F,"11,006.76",0.9,9.3,"69,466",30
6,Quebec,L03AA,Colony-stimulating factors,65+,F,"10,906.02",0.9,0.3,"1,982",31
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"10,555.20",0.8,5.3,"40,067",32
6,Quebec,C09DA,Angiotensin II antagonists and diuretics,65+,F,"10,430.27",0.8,10.5,"78,728",33
6,Quebec,N02AA,Natural opium alkaloids,65+,F,"10,315.55",0.8,12.5,"93,545",34
6,Quebec,A10BA,Biguanides,65+,F,"10,112.20",0.8,12.3,"92,509",35
6,Quebec,N02BE,Anilides,65+,F,"10,067.27",0.8,21.9,"163,988",36
6,Quebec,B01AB,Heparin group,65+,F,"10,020.36",0.8,1.6,"11,746",37
6,Quebec,C03CA,"Sulfonamides, plain",65+,F,"9,274.43",0.7,9.2,"68,771",38
6,Quebec,N05AX,Other antipsychotics,65+,F,"9,025.36",0.7,2.5,"18,767",39
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"8,914.07",0.7,1.6,"11,812",40
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,65+,F,"8,768.84",0.7,4.6,"34,215",41
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"8,703.12",0.7,15.2,"113,741",42
6,Quebec,C08DB,Benzothiazepine derivatives,65+,F,"8,560.28",0.7,4.4,"32,941",43
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"8,409.97",0.7,4.5,"33,774",44
6,Quebec,S01EE,Prostaglandin analogues,65+,F,"8,075.45",0.6,5.0,"37,684",45
6,Quebec,S01ED,Beta-blocking agents,65+,F,"7,894.31",0.6,4.8,"36,069",46
6,Quebec,S01XA,Other ophthalmologicals,65+,F,"7,786.89",0.6,2.7,"20,424",47
6,Quebec,H01CB,Somatostatin and analogues,65+,F,"7,382.29",0.6,0.1,659,48
6,Quebec,L04AC,Interleukin inhibitors,65+,F,"6,943.66",0.5,0.1,485,49
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"6,871.91",0.5,10.5,"78,999",50
6,Quebec,A06AA,"Softeners, emollients",65+,F,"6,334.13",0.5,9.3,"70,000",51
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"5,627.07",0.4,1.7,"13,076",52
6,Quebec,B01AE,Direct thrombin inhibitors,65+,F,"5,609.04",0.4,0.8,"5,876",53
6,Quebec,C01DA,Organic nitrates,65+,F,"5,366.72",0.4,6.2,"46,327",54
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"5,351.93",0.4,1.1,"8,239",55
6,Quebec,J05AP,Antivirals for treatment of HCV infections,65+,F,"5,322.43",0.4,0.0,95,56
6,Quebec,A10BB,Sulfonylureas,65+,F,"5,253.79",0.4,5.3,"39,513",57
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"5,118.75",0.4,0.1,480,58
6,Quebec,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,"5,023.96",0.4,6.8,"51,228",59
6,Quebec,C09BA,ACE inhibitors and diuretics,65+,F,"4,853.99",0.4,3.2,"24,157",60
6,Quebec,C03AA,"Thiazides, plain",65+,F,"4,794.13",0.4,9.8,"73,448",61
6,Quebec,R01AD,Corticosteroids,65+,F,"4,788.72",0.4,12.3,"92,114",62
6,Quebec,L02BG,Aromatase inhibitors,65+,F,"4,765.74",0.4,1.8,"13,484",63
6,Quebec,C10AX,Other lipid-modifying agents,65+,F,"4,584.47",0.4,3.2,"23,781",64
6,Quebec,H05AA,Parathyroid hormones and analogues,65+,F,"4,438.79",0.3,0.1,700,65
6,Quebec,B03AA,"Iron bivalent, oral preparations",65+,F,"4,303.79",0.3,6.9,"51,895",66
6,Quebec,N04BA,Dopa and dopa derivatives,65+,F,"4,267.32",0.3,0.8,"6,187",67
6,Quebec,B01AA,Vitamin K antagonists,65+,F,"4,050.77",0.3,3.3,"24,813",68
6,Quebec,A06AB,Contact laxatives,65+,F,"3,665.81",0.3,5.4,"40,466",69
6,Quebec,A07EC,Aminosalicylic acid and similar agents,65+,F,"3,640.92",0.3,0.7,"5,523",70
6,Quebec,A12BA,Potassium,65+,F,"3,632.67",0.3,3.9,"29,264",71
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"3,570.98",0.3,4.8,"36,194",72
6,Quebec,N02AB,Phenylpiperidine derivatives,65+,F,"3,421.96",0.3,1.0,"7,798",73
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,"3,348.80",0.3,0.5,"3,419",74
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"3,342.48",0.3,0.2,"1,814",75
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,65+,F,"3,303.16",0.3,0.3,"2,158",76
6,Quebec,L01XC,Monoclonal antibodies,65+,F,"3,197.63",0.3,0.0,362,77
6,Quebec,N03AE,Benzodiazepine derivatives,65+,F,"3,155.61",0.2,5.2,"38,734",78
6,Quebec,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"3,074.23",0.2,0.9,"6,718",79
6,Quebec,H02AB,Glucocorticoids,65+,F,"2,960.88",0.2,11.9,"89,485",80
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,"2,920.92",0.2,1.4,"10,634",81
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"2,918.02",0.2,0.0,119,82
6,Quebec,L01BA,Folic acid analogues,65+,F,"2,881.55",0.2,1.6,"11,850",83
6,Quebec,A06AD,Osmotically acting laxatives,65+,F,"2,649.57",0.2,6.8,"50,795",84
6,Quebec,L01XX,Other antineoplastic agents,65+,F,"2,618.74",0.2,0.3,"1,965",85
6,Quebec,R03DC,Leukotriene receptor antagonists,65+,F,"2,602.73",0.2,1.3,"9,572",86
6,Quebec,A03FA,Propulsives,65+,F,"2,589.26",0.2,4.0,"30,130",87
6,Quebec,M01AH,Coxibs,65+,F,"2,570.10",0.2,8.5,"63,700",88
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,65+,F,"2,390.78",0.2,0.9,"7,015",89
6,Quebec,L04AD,Calcineurin inhibitors,65+,F,"2,354.96",0.2,0.1,843,90
6,Quebec,L03AB,Interferons,65+,F,"2,257.90",0.2,0.0,165,91
6,Quebec,C07AA,"Beta-blocking agents, non-selective",65+,F,"2,255.57",0.2,2.2,"16,120",92
6,Quebec,M04AA,Preparations inhibiting uric acid production,65+,F,"2,239.29",0.2,2.3,"17,155",93
6,Quebec,N04BC,Dopamine agonists,65+,F,"2,175.17",0.2,1.3,"9,629",94
6,Quebec,D07AC,"Corticosteroids, potent (group III)",65+,F,"2,059.73",0.2,9.1,"68,142",95
6,Quebec,J01MA,Fluoroquinolones,65+,F,"2,058.23",0.2,13.6,"101,868",96
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,"1,988.71",0.2,4.0,"30,034",97
6,Quebec,M03BX,Other centrally acting agents,65+,F,"1,921.70",0.2,3.9,"29,244",98
6,Quebec,N05CD,Benzodiazepine derivatives,65+,F,"1,878.90",0.1,2.3,"17,034",99
6,Quebec,L02BA,Anti-estrogens,65+,F,"1,848.76",0.1,0.6,"4,698",100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"161,285.40",10.6,0.5,"7,788",1
6,Quebec,N05AX,Other antipsychotics,<65,Total,"75,270.93",5.0,3.1,"48,616",2
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"63,615.98",4.2,6.9,"108,010",3
6,Quebec,L04AA,Selective immunosuppressants,<65,Total,"63,396.40",4.2,0.4,"6,003",4
6,Quebec,J05AP,Antivirals for treatment of HCV infections,<65,Total,"58,349.97",3.8,0.1,"1,084",5
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"51,908.88",3.4,0.5,"7,075",6
6,Quebec,N06BA,Centrally acting sympathomimetics,<65,Total,"50,485.53",3.3,5.6,"88,143",7
6,Quebec,N03AX,Other antiepileptics,<65,Total,"33,270.17",2.2,5.9,"93,444",8
6,Quebec,A02BC,Proton pump inhibitors,<65,Total,"30,801.64",2.0,18.4,"288,992",9
6,Quebec,C10AA,HMG-CoA reductase inhibitors,<65,Total,"28,201.75",1.9,14.0,"219,685",10
6,Quebec,N06AX,Other antidepressants,<65,Total,"27,255.92",1.8,10.3,"162,156",11
6,Quebec,L01XE,Protein kinase inhibitors,<65,Total,"27,194.82",1.8,0.1,878,12
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"24,362.21",1.6,3.1,"49,317",13
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"21,972.69",1.4,9.6,"150,488",14
6,Quebec,N02AA,Natural opium alkaloids,<65,Total,"20,194.97",1.3,8.5,"133,798",15
6,Quebec,L04AC,Interleukin inhibitors,<65,Total,"18,536.90",1.2,0.1,"1,101",16
6,Quebec,R03BA,Glucocorticoids,<65,Total,"16,886.28",1.1,8.3,"130,388",17
6,Quebec,C09AA,"ACE inhibitors, plain",<65,Total,"15,242.53",1.0,5.5,"86,783",18
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"14,321.46",0.9,1.4,"21,942",19
6,Quebec,J05AX,Other antivirals,<65,Total,"13,429.58",0.9,0.2,"2,533",20
6,Quebec,R03BB,Anticholinergics,<65,Total,"11,604.73",0.8,2.1,"32,678",21
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"11,425.86",0.8,0.0,775,22
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"11,345.35",0.7,0.9,"14,032",23
6,Quebec,L04AX,Other immunosuppressants,<65,Total,"11,078.27",0.7,0.2,"3,145",24
6,Quebec,A11CC,Vitamin D and analogues,<65,Total,"10,558.51",0.7,11.1,"174,251",25
6,Quebec,C08CA,Dihydropyridine derivatives,<65,Total,"10,420.36",0.7,5.3,"82,723",26
6,Quebec,S01LA,Antineovascularization agents,<65,Total,"10,390.96",0.7,0.1,"1,184",27
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"10,358.22",0.7,1.1,"16,569",28
6,Quebec,L04AD,Calcineurin inhibitors,<65,Total,"10,092.76",0.7,0.2,"2,936",29
6,Quebec,A16AB,Enzymes,<65,Total,"10,070.10",0.7,0.0,15,30
6,Quebec,V06C,Infant formulas,<65,Total,"9,838.33",0.6,0.5,"8,255",31
6,Quebec,L03AA,Colony-stimulating factors,<65,Total,"9,741.80",0.6,0.1,"1,707",32
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"9,584.11",0.6,1.0,"15,537",33
6,Quebec,N07BA,Drugs used in nicotine dependence,<65,Total,"9,437.46",0.6,4.0,"62,294",34
6,Quebec,N05BA,Benzodiazepine derivatives,<65,Total,"9,398.87",0.6,7.7,"121,702",35
6,Quebec,L03AB,Interferons,<65,Total,"9,313.29",0.6,0.0,666,36
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"9,292.60",0.6,11.8,"185,268",37
6,Quebec,J05AE,Protease inhibitors,<65,Total,"9,169.65",0.6,0.1,"1,402",38
6,Quebec,N07BC,Drugs used in opioid dependence,<65,Total,"9,037.03",0.6,0.3,"5,269",39
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"8,920.47",0.6,1.2,"18,884",40
6,Quebec,H03AA,Thyroid hormones,<65,Total,"8,874.63",0.6,7.5,"118,390",41
6,Quebec,B01AB,Heparin group,<65,Total,"8,858.81",0.6,0.6,"9,112",42
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"8,799.52",0.6,7.6,"118,760",43
6,Quebec,N02BA,Salicylic acid and derivatives,<65,Total,"8,297.48",0.5,6.4,"99,854",44
6,Quebec,A10BA,Biguanides,<65,Total,"7,939.70",0.5,5.3,"82,569",45
6,Quebec,C09CA,"Angiotensin II antagonists, plain",<65,Total,"7,463.72",0.5,4.2,"65,552",46
6,Quebec,C07AB,"Beta-blocking agents, selective",<65,Total,"7,302.19",0.5,4.5,"71,162",47
6,Quebec,B03XA,Other antianemic preparations,<65,Total,"7,287.16",0.5,0.1,"1,620",48
6,Quebec,N07XX,Other nervous system drugs,<65,Total,"7,116.10",0.5,0.1,991,49
6,Quebec,B01AF,Direct factor Xa inhibitors,<65,Total,"7,089.96",0.5,0.8,"12,581",50
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,<65,Total,"6,931.08",0.5,1.8,"27,746",51
6,Quebec,R01AD,Corticosteroids,<65,Total,"6,903.94",0.5,10.3,"161,806",52
6,Quebec,N03AE,Benzodiazepine derivatives,<65,Total,"6,612.09",0.4,3.8,"60,267",53
6,Quebec,N03AG,Fatty acid derivatives,<65,Total,"6,571.98",0.4,1.2,"18,410",54
6,Quebec,L03AX,Other immunostimulants,<65,Total,"6,407.92",0.4,0.0,612,55
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",<65,Total,"5,832.88",0.4,4.3,"67,704",56
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,"5,793.98",0.4,0.3,"3,973",57
6,Quebec,C02AC,Imidazoline receptor agonists,<65,Total,"5,578.72",0.4,0.8,"11,833",58
6,Quebec,M03BX,Other centrally acting agents,<65,Total,"5,527.05",0.4,5.6,"87,662",59
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"5,451.97",0.4,1.0,"15,724",60
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"5,405.04",0.4,0.1,"2,224",61
6,Quebec,N02BE,Anilides,<65,Total,"5,399.75",0.4,8.9,"139,758",62
6,Quebec,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"5,205.40",0.3,0.1,"1,509",63
6,Quebec,H01CB,Somatostatin and analogues,<65,Total,"5,107.47",0.3,0.0,395,64
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,"5,104.57",0.3,3.6,"56,759",65
6,Quebec,A07EC,Aminosalicylic acid and similar agents,<65,Total,"5,077.78",0.3,0.5,"8,413",66
6,Quebec,M01AE,Propionic acid derivatives,<65,Total,"4,872.21",0.3,16.4,"258,027",67
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"4,455.96",0.3,3.0,"47,022",68
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"4,429.97",0.3,3.9,"61,038",69
6,Quebec,J01FA,Macrolides,<65,Total,"4,315.30",0.3,10.9,"170,736",70
6,Quebec,C09DA,Angiotensin II antagonists and diuretics,<65,Total,"4,265.20",0.3,2.3,"36,670",71
6,Quebec,G02BA,Intrauterine contraceptives,<65,Total,"4,249.51",0.3,0.9,"14,346",72
6,Quebec,R07AX,Other respiratory system products,<65,Total,"4,012.77",0.3,0.0,24,73
6,Quebec,A10BB,Sulfonylureas,<65,Total,"3,998.21",0.3,2.4,"37,005",74
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,"3,992.76",0.3,0.1,"2,354",75
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,<65,Total,"3,961.01",0.3,1.0,"15,550",76
6,Quebec,A06AA,"Softeners, emollients",<65,Total,"3,951.11",0.3,2.5,"39,078",77
6,Quebec,N05AE,Indole derivatives,<65,Total,"3,876.04",0.3,0.2,"3,198",78
6,Quebec,N02AB,Phenylpiperidine derivatives,<65,Total,"3,737.98",0.2,0.4,"6,102",79
6,Quebec,C09BA,ACE inhibitors and diuretics,<65,Total,"3,729.64",0.2,1.2,"19,082",80
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,<65,Total,"3,700.60",0.2,0.3,"4,969",81
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,"3,699.78",0.2,0.1,"1,838",82
6,Quebec,J01CA,Penicillins with extended spectrum,<65,Total,"3,657.15",0.2,11.0,"172,319",83
6,Quebec,A04AD,Other antiemetics,<65,Total,"3,653.12",0.2,0.3,"4,854",84
6,Quebec,C01CA,Adrenergic and dopaminergic agents,<65,Total,"3,642.55",0.2,1.6,"24,773",85
6,Quebec,L01XC,Monoclonal antibodies,<65,Total,"3,582.42",0.2,0.0,295,86
6,Quebec,J01DH,Carbapenems,<65,Total,"3,505.64",0.2,0.1,"1,748",87
6,Quebec,A12AA,Calcium,<65,Total,"3,386.85",0.2,3.2,"49,617",88
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"3,310.74",0.2,0.0,158,89
6,Quebec,R03DC,Leukotriene receptor antagonists,<65,Total,"3,254.68",0.2,1.1,"17,488",90
6,Quebec,N03AF,Carboxamide derivatives,<65,Total,"3,223.24",0.2,0.6,"9,038",91
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,"3,215.57",0.2,0.8,"11,877",92
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,<65,Total,"3,127.96",0.2,0.5,"7,148",93
6,Quebec,C10AX,Other lipid-modifying agents,<65,Total,"3,013.01",0.2,1.0,"15,976",94
6,Quebec,M05BA,Bisphosphonates,<65,Total,"2,869.91",0.2,1.3,"19,992",95
6,Quebec,D07AC,"Corticosteroids, potent (group III)",<65,Total,"2,831.51",0.2,5.7,"89,871",96
6,Quebec,G03GA,Gonadotropins,<65,Total,"2,722.20",0.2,0.1,"1,539",97
6,Quebec,M01AH,Coxibs,<65,Total,"2,662.45",0.2,4.0,"62,734",98
6,Quebec,V03AC,Iron-chelating agents,<65,Total,"2,610.41",0.2,0.0,106,99
6,Quebec,A09AA,Enzyme preparations,<65,Total,"2,583.03",0.2,0.2,"3,570",100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"82,422.03",10.7,0.6,"3,736",1
6,Quebec,N05AX,Other antipsychotics,<65,M,"48,541.67",6.3,4.0,"26,929",2
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"41,208.31",5.4,0.8,"5,610",3
6,Quebec,J05AP,Antivirals for treatment of HCV infections,<65,M,"40,840.96",5.3,0.1,760,4
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"40,588.36",5.3,8.2,"54,530",5
6,Quebec,N06BA,Centrally acting sympathomimetics,<65,M,"31,217.20",4.1,7.5,"49,914",6
6,Quebec,L04AA,Selective immunosuppressants,<65,M,"21,795.43",2.8,0.4,"2,383",7
6,Quebec,C10AA,HMG-CoA reductase inhibitors,<65,M,"15,461.46",2.0,18.6,"124,405",8
6,Quebec,N03AX,Other antiepileptics,<65,M,"14,910.93",1.9,5.8,"38,963",9
6,Quebec,L01XE,Protein kinase inhibitors,<65,M,"13,448.75",1.7,0.1,428,10
6,Quebec,A02BC,Proton pump inhibitors,<65,M,"13,402.84",1.7,18.4,"122,935",11
6,Quebec,N02AA,Natural opium alkaloids,<65,M,"10,645.71",1.4,9.2,"61,196",12
6,Quebec,J05AX,Other antivirals,<65,M,"10,258.22",1.3,0.3,"1,880",13
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"10,119.91",1.3,3.0,"19,860",14
6,Quebec,N06AX,Other antidepressants,<65,M,"10,063.65",1.3,8.9,"59,549",15
6,Quebec,C09AA,"ACE inhibitors, plain",<65,M,"9,119.83",1.2,7.7,"51,647",16
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,<65,M,"8,532.21",1.1,7.9,"52,904",17
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"8,219.94",1.1,1.9,"12,830",18
6,Quebec,L04AC,Interleukin inhibitors,<65,M,"7,798.36",1.0,0.1,467,19
6,Quebec,J05AE,Protease inhibitors,<65,M,"7,144.06",0.9,0.2,"1,061",20
6,Quebec,R03BA,Glucocorticoids,<65,M,"7,101.74",0.9,8.0,"53,614",21
6,Quebec,L04AX,Other immunosuppressants,<65,M,"6,781.20",0.9,0.2,"1,370",22
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"6,369.81",0.8,1.2,"7,689",23
6,Quebec,L04AD,Calcineurin inhibitors,<65,M,"6,014.63",0.8,0.3,"1,747",24
6,Quebec,N07BC,Drugs used in opioid dependence,<65,M,"5,825.20",0.8,0.5,"3,267",25
6,Quebec,S01LA,Antineovascularization agents,<65,M,"5,781.08",0.8,0.1,657,26
6,Quebec,C08CA,Dihydropyridine derivatives,<65,M,"5,738.45",0.7,6.8,"45,177",27
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"5,445.27",0.7,1.3,"8,846",28
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,"5,433.28",0.7,1.3,"8,932",29
6,Quebec,R03BB,Anticholinergics,<65,M,"5,116.45",0.7,2.1,"14,248",30
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"5,037.28",0.7,1.5,"10,065",31
6,Quebec,N02BA,Salicylic acid and derivatives,<65,M,"4,865.83",0.6,8.8,"58,639",32
6,Quebec,V06C,Infant formulas,<65,M,"4,776.32",0.6,0.5,"3,658",33
6,Quebec,N07BA,Drugs used in nicotine dependence,<65,M,"4,773.14",0.6,4.6,"30,856",34
6,Quebec,A16AB,Enzymes,<65,M,"4,662.17",0.6,0.0,8,35
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"4,541.56",0.6,0.0,272,36
6,Quebec,B01AF,Direct factor Xa inhibitors,<65,M,"4,309.77",0.6,1.1,"7,265",37
6,Quebec,N05BA,Benzodiazepine derivatives,<65,M,"4,267.11",0.6,7.0,"47,011",38
6,Quebec,C07AB,"Beta-blocking agents, selective",<65,M,"4,238.02",0.6,6.0,"39,941",39
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"4,141.69",0.5,11.8,"78,624",40
6,Quebec,A10BA,Biguanides,<65,M,"4,137.92",0.5,6.6,"44,125",41
6,Quebec,C02AC,Imidazoline receptor agonists,<65,M,"4,127.25",0.5,0.9,"6,299",42
6,Quebec,B01AB,Heparin group,<65,M,"3,870.49",0.5,0.6,"3,797",43
6,Quebec,N03AG,Fatty acid derivatives,<65,M,"3,771.98",0.5,1.5,"10,121",44
6,Quebec,B03XA,Other antianemic preparations,<65,M,"3,757.18",0.5,0.1,902,45
6,Quebec,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"3,636.38",0.5,0.2,"1,027",46
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"3,538.35",0.5,1.6,"10,421",47
6,Quebec,C09CA,"Angiotensin II antagonists, plain",<65,M,"3,524.98",0.5,4.8,"31,738",48
6,Quebec,A11CC,Vitamin D and analogues,<65,M,"3,468.07",0.5,6.6,"43,718",49
6,Quebec,L03AA,Colony-stimulating factors,<65,M,"3,458.92",0.4,0.1,575,50
6,Quebec,G03BA,3-oxoandrosten (4) derivatives,<65,M,"3,076.71",0.4,1.0,"6,643",51
6,Quebec,N03AE,Benzodiazepine derivatives,<65,M,"2,982.56",0.4,3.5,"23,067",52
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,"2,798.84",0.4,0.3,"1,923",53
6,Quebec,R01AD,Corticosteroids,<65,M,"2,741.16",0.4,9.2,"61,216",54
6,Quebec,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,"2,536.46",0.3,0.2,"1,449",55
6,Quebec,N07XX,Other nervous system drugs,<65,M,"2,476.53",0.3,0.1,405,56
6,Quebec,H03AA,Thyroid hormones,<65,M,"2,462.97",0.3,4.0,"26,568",57
6,Quebec,L03AB,Interferons,<65,M,"2,436.85",0.3,0.0,177,58
6,Quebec,A07EC,Aminosalicylic acid and similar agents,<65,M,"2,380.19",0.3,0.5,"3,631",59
6,Quebec,H01CB,Somatostatin and analogues,<65,M,"2,357.65",0.3,0.0,165,60
6,Quebec,N02BE,Anilides,<65,M,"2,293.43",0.3,9.0,"60,058",61
6,Quebec,A10BB,Sulfonylureas,<65,M,"2,252.57",0.3,3.2,"21,640",62
6,Quebec,R07AX,Other respiratory system products,<65,M,"2,230.98",0.3,0.0,12,63
6,Quebec,J01DH,Carbapenems,<65,M,"2,185.03",0.3,0.2,"1,011",64
6,Quebec,M03BX,Other centrally acting agents,<65,M,"2,183.41",0.3,5.2,"34,609",65
6,Quebec,C09BA,ACE inhibitors and diuretics,<65,M,"2,169.21",0.3,1.7,"11,087",66
6,Quebec,G04CA,Alpha-adrenoreceptor antagonists,<65,M,"2,103.42",0.3,3.2,"21,613",67
6,Quebec,C09DA,Angiotensin II antagonists and diuretics,<65,M,"2,046.86",0.3,2.7,"18,174",68
6,Quebec,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,"1,969.94",0.3,0.1,530,69
6,Quebec,M01AE,Propionic acid derivatives,<65,M,"1,959.64",0.3,15.9,"106,042",70
6,Quebec,J01FA,Macrolides,<65,M,"1,886.25",0.2,10.9,"72,963",71
6,Quebec,C10AX,Other lipid-modifying agents,<65,M,"1,877.45",0.2,1.4,"9,414",72
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"1,859.19",0.2,0.1,658,73
6,Quebec,N05AE,Indole derivatives,<65,M,"1,783.41",0.2,0.2,"1,386",74
6,Quebec,A06AA,"Softeners, emollients",<65,M,"1,744.97",0.2,2.3,"15,087",75
6,Quebec,N03AF,Carboxamide derivatives,<65,M,"1,726.80",0.2,0.7,"4,753",76
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,"1,724.10",0.2,0.9,"6,033",77
6,Quebec,J01CA,Penicillins with extended spectrum,<65,M,"1,716.19",0.2,11.3,"75,261",78
6,Quebec,L03AX,Other immunostimulants,<65,M,"1,699.88",0.2,0.0,156,79
6,Quebec,C01CA,Adrenergic and dopaminergic agents,<65,M,"1,688.05",0.2,1.5,"10,233",80
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,<65,M,"1,639.90",0.2,0.1,553,81
6,Quebec,A04AD,Other antiemetics,<65,M,"1,605.34",0.2,0.3,"1,939",82
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"1,595.03",0.2,2.1,"13,956",83
6,Quebec,N02AB,Phenylpiperidine derivatives,<65,M,"1,593.47",0.2,0.4,"2,342",84
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,"1,531.88",0.2,2.5,"16,679",85
6,Quebec,A09AA,Enzyme preparations,<65,M,"1,530.22",0.2,0.2,"1,488",86
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,<65,M,"1,450.17",0.2,0.7,"4,643",87
6,Quebec,J01GB,Other aminoglycosides,<65,M,"1,387.76",0.2,0.0,269,88
6,Quebec,V03AC,Iron-chelating agents,<65,M,"1,277.61",0.2,0.0,50,89
6,Quebec,D07AC,"Corticosteroids, potent (group III)",<65,M,"1,260.67",0.2,5.5,"36,443",90
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,"1,249.06",0.2,0.0,62,91
6,Quebec,L02BX,Other hormone antagonists and related agents,<65,M,"1,207.25",0.2,0.0,95,92
6,Quebec,C03CA,"Sulfonamides, plain",<65,M,"1,193.15",0.2,1.3,"8,581",93
6,Quebec,R03DC,Leukotriene receptor antagonists,<65,M,"1,175.46",0.2,1.0,"6,831",94
6,Quebec,C10AB,Fibrates,<65,M,"1,156.66",0.2,1.1,"7,344",95
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,<65,M,"1,136.33",0.1,0.7,"4,470",96
6,Quebec,R05CB,Mucolytics,<65,M,"1,130.32",0.1,0.1,398,97
6,Quebec,A06AB,Contact laxatives,<65,M,"1,120.83",0.1,1.3,"8,953",98
6,Quebec,C08DB,Benzothiazepine derivatives,<65,M,"1,099.54",0.1,0.7,"4,554",99
6,Quebec,L01XC,Monoclonal antibodies,<65,M,"1,069.81",0.1,0.0,97,100
6,Quebec,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"78,863.35",10.5,0.4,"4,052",1
6,Quebec,L04AA,Selective immunosuppressants,<65,F,"41,600.97",5.5,0.4,"3,620",2
6,Quebec,N05AX,Other antipsychotics,<65,F,"26,729.26",3.6,2.4,"21,687",3
6,Quebec,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"23,027.62",3.1,5.9,"53,480",4
6,Quebec,N06BA,Centrally acting sympathomimetics,<65,F,"19,268.33",2.6,4.2,"38,229",5
6,Quebec,N03AX,Other antiepileptics,<65,F,"18,359.25",2.4,6.0,"54,481",6
6,Quebec,J05AP,Antivirals for treatment of HCV infections,<65,F,"17,509.00",2.3,0.0,324,7
6,Quebec,A02BC,Proton pump inhibitors,<65,F,"17,398.80",2.3,18.4,"166,057",8
6,Quebec,N06AX,Other antidepressants,<65,F,"17,192.26",2.3,11.3,"102,607",9
6,Quebec,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"14,242.30",1.9,3.3,"29,457",10
6,Quebec,L01XE,Protein kinase inhibitors,<65,F,"13,746.06",1.8,0.0,450,11
6,Quebec,N06AB,Selective serotonin reuptake inhibitors,<65,F,"13,440.48",1.8,10.8,"97,584",12
6,Quebec,C10AA,HMG-CoA reductase inhibitors,<65,F,"12,740.29",1.7,10.5,"95,280",13
6,Quebec,L04AC,Interleukin inhibitors,<65,F,"10,738.54",1.4,0.1,634,14
6,Quebec,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"10,700.57",1.4,0.2,"1,465",15
6,Quebec,R03BA,Glucocorticoids,<65,F,"9,784.55",1.3,8.5,"76,774",16
6,Quebec,N02AA,Natural opium alkaloids,<65,F,"9,549.26",1.3,8.0,"72,602",17
6,Quebec,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"8,797.53",1.2,13.1,"118,741",18
6,Quebec,A11CC,Vitamin D and analogues,<65,F,"7,090.44",0.9,14.4,"130,533",19
6,Quebec,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"6,884.30",0.9,0.1,503,20
6,Quebec,L03AB,Interferons,<65,F,"6,876.44",0.9,0.1,489,21
6,Quebec,R03BB,Anticholinergics,<65,F,"6,488.28",0.9,2.0,"18,430",22
6,Quebec,H03AA,Thyroid hormones,<65,F,"6,411.66",0.9,10.2,"91,822",23
6,Quebec,L03AA,Colony-stimulating factors,<65,F,"6,282.88",0.8,0.1,"1,132",24
6,Quebec,C09AA,"ACE inhibitors, plain",<65,F,"6,122.70",0.8,3.9,"35,136",25
6,Quebec,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"6,101.52",0.8,1.0,"9,112",26
6,Quebec,N02CC,Selective serotonin (5HT1) agonists,<65,F,"5,480.91",0.7,2.6,"23,103",27
6,Quebec,A16AB,Enzymes,<65,F,"5,407.93",0.7,0.0,7,28
6,Quebec,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"5,150.91",0.7,11.8,"106,644",29
6,Quebec,N05BA,Benzodiazepine derivatives,<65,F,"5,131.76",0.7,8.3,"74,691",30
6,Quebec,V06C,Infant formulas,<65,F,"5,062.01",0.7,0.5,"4,597",31
6,Quebec,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,"5,006.13",0.7,6.2,"56,335",32
6,Quebec,B01AB,Heparin group,<65,F,"4,988.32",0.7,0.6,"5,315",33
6,Quebec,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"4,975.54",0.7,0.7,"6,343",34
6,Quebec,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,"4,924.94",0.7,0.8,"7,637",35
6,Quebec,A12AX,"Calcium, combinations with vitamin D and/or other drugs",<65,F,"4,795.64",0.6,6.5,"58,742",36
6,Quebec,L03AX,Other immunostimulants,<65,F,"4,708.04",0.6,0.1,456,37
6,Quebec,C08CA,Dihydropyridine derivatives,<65,F,"4,681.92",0.6,4.2,"37,546",38
6,Quebec,N07BA,Drugs used in nicotine dependence,<65,F,"4,664.32",0.6,3.5,"31,438",39
6,Quebec,N07XX,Other nervous system drugs,<65,F,"4,639.57",0.6,0.1,586,40
6,Quebec,S01LA,Antineovascularization agents,<65,F,"4,609.89",0.6,0.1,527,41
6,Quebec,L04AX,Other immunosuppressants,<65,F,"4,297.07",0.6,0.2,"1,775",42
6,Quebec,G02BA,Intrauterine contraceptives,<65,F,"4,248.80",0.6,1.6,"14,344",43
6,Quebec,R01AD,Corticosteroids,<65,F,"4,162.78",0.6,11.1,"100,590",44
6,Quebec,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"4,138.84",0.6,0.7,"6,691",45
6,Quebec,L04AD,Calcineurin inhibitors,<65,F,"4,078.13",0.5,0.1,"1,189",46
6,Quebec,C09CA,"Angiotensin II antagonists, plain",<65,F,"3,938.75",0.5,3.7,"33,814",47
6,Quebec,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"3,883.19",0.5,1.0,"8,819",48
6,Quebec,A10BA,Biguanides,<65,F,"3,801.78",0.5,4.3,"38,444",49
6,Quebec,N03AE,Benzodiazepine derivatives,<65,F,"3,629.53",0.5,4.1,"37,200",50
6,Quebec,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"3,545.85",0.5,0.2,"1,566",51
6,Quebec,B03XA,Other antianemic preparations,<65,F,"3,529.99",0.5,0.1,718,52
6,Quebec,N02BA,Salicylic acid and derivatives,<65,F,"3,431.65",0.5,4.6,"41,215",53
6,Quebec,M03BX,Other centrally acting agents,<65,F,"3,343.64",0.4,5.9,"53,053",54
6,Quebec,M05BX,Other drugs affecting bone structure and mineralization,<65,F,"3,233.65",0.4,0.5,"4,720",55
6,Quebec,N07BC,Drugs used in opioid dependence,<65,F,"3,211.83",0.4,0.2,"2,002",56
6,Quebec,J05AX,Other antivirals,<65,F,"3,171.36",0.4,0.1,653,57
6,Quebec,N02BE,Anilides,<65,F,"3,106.33",0.4,8.8,"79,700",58
6,Quebec,C07AB,"Beta-blocking agents, selective",<65,F,"3,064.17",0.4,3.5,"31,221",59
6,Quebec,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,F,"2,995.13",0.4,0.2,"2,050",60
6,Quebec,M01AE,Propionic acid derivatives,<65,F,"2,912.57",0.4,16.8,"151,985",61
6,Quebec,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"2,898.09",0.4,4.9,"44,359",62
6,Quebec,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"2,860.93",0.4,3.7,"33,066",63
6,Quebec,G04BD,Drugs for urinary frequency and incontinence,<65,F,"2,824.68",0.4,1.2,"11,080",64
6,Quebec,N03AG,Fatty acid derivatives,<65,F,"2,800.00",0.4,0.9,"8,289",65
6,Quebec,B01AF,Direct factor Xa inhibitors,<65,F,"2,780.19",0.4,0.6,"5,316",66
6,Quebec,H01CB,Somatostatin and analogues,<65,F,"2,749.82",0.4,0.0,230,67
6,Quebec,A07EC,Aminosalicylic acid and similar agents,<65,F,"2,697.59",0.4,0.5,"4,782",68
6,Quebec,G03GA,Gonadotropins,<65,F,"2,685.58",0.4,0.2,"1,525",69
6,Quebec,A12AA,Calcium,<65,F,"2,520.24",0.3,4.5,"40,981",70
6,Quebec,L01XC,Monoclonal antibodies,<65,F,"2,512.61",0.3,0.0,198,71
6,Quebec,G03DA,Pregnen (4) derivatives,<65,F,"2,431.30",0.3,2.9,"26,670",72
6,Quebec,J01FA,Macrolides,<65,F,"2,429.04",0.3,10.8,"97,773",73
6,Quebec,G03XB,Progesterone receptor modulators,<65,F,"2,276.86",0.3,0.2,"2,181",74
6,Quebec,C09DA,Angiotensin II antagonists and diuretics,<65,F,"2,218.34",0.3,2.0,"18,496",75
6,Quebec,A06AA,"Softeners, emollients",<65,F,"2,206.14",0.3,2.7,"23,991",76
6,Quebec,N02AB,Phenylpiperidine derivatives,<65,F,"2,144.52",0.3,0.4,"3,760",77
6,Quebec,M05BA,Bisphosphonates,<65,F,"2,100.93",0.3,1.7,"15,822",78
6,Quebec,N05AE,Indole derivatives,<65,F,"2,092.63",0.3,0.2,"1,812",79
6,Quebec,R03DC,Leukotriene receptor antagonists,<65,F,"2,079.21",0.3,1.2,"10,657",80
6,Quebec,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"2,061.69",0.3,0.0,96,81
6,Quebec,L02AE,Gonadotropin-releasing hormone analogues,<65,F,"2,059.88",0.3,0.1,"1,285",82
6,Quebec,A04AD,Other antiemetics,<65,F,"2,047.78",0.3,0.3,"2,915",83
6,Quebec,J05AE,Protease inhibitors,<65,F,"2,025.60",0.3,0.0,341,84
6,Quebec,C01CA,Adrenergic and dopaminergic agents,<65,F,"1,954.50",0.3,1.6,"14,540",85
6,Quebec,J01CA,Penicillins with extended spectrum,<65,F,"1,940.96",0.3,10.7,"97,058",86
6,Quebec,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"1,913.62",0.3,0.6,"5,303",87
6,Quebec,R06AA,Aminoalkyl ethers,<65,F,"1,830.94",0.2,1.4,"12,993",88
6,Quebec,R07AX,Other respiratory system products,<65,F,"1,781.78",0.2,0.0,12,89
6,Quebec,A10BB,Sulfonylureas,<65,F,"1,745.64",0.2,1.7,"15,365",90
6,Quebec,S01XA,Other ophthalmologicals,<65,F,"1,729.64",0.2,0.6,"5,287",91
6,Quebec,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,"1,641.25",0.2,2.2,"19,550",92
6,Quebec,M01AH,Coxibs,<65,F,"1,621.30",0.2,4.3,"39,099",93
6,Quebec,D07AC,"Corticosteroids, potent (group III)",<65,F,"1,570.84",0.2,5.9,"53,428",94
6,Quebec,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,"1,569.02",0.2,0.1,482,95
6,Quebec,G03AC,Progestogens,<65,F,"1,566.67",0.2,2.7,"24,810",96
6,Quebec,C09BA,ACE inhibitors and diuretics,<65,F,"1,560.43",0.2,0.9,"7,995",97
6,Quebec,N03AF,Carboxamide derivatives,<65,F,"1,496.44",0.2,0.5,"4,285",98
6,Quebec,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,"1,491.46",0.2,0.6,"5,844",99
6,Quebec,J02AC,Triazole derivatives,<65,F,"1,470.37",0.2,4.4,"39,361",100
7,Ontario,S01LA,Antineovascularization agents,Total,Total,"422,667.70",7.4,1.4,"43,947",1
7,Ontario,J05AP,Antivirals for treatment of HCV infections,Total,Total,"318,985.00",5.6,0.2,"5,523",2
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"272,133.00",4.7,0.5,"14,787",3
7,Ontario,C10AA,HMG-CoA reductase inhibitors,Total,Total,"157,843.60",2.8,41.7,"1,327,910",4
7,Ontario,L01XE,Protein kinase inhibitors,Total,Total,"156,335.20",2.7,0.2,"5,001",5
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"147,524.00",2.6,7.8,"248,848",6
7,Ontario,L04AX,Other immunosuppressants,Total,Total,"146,379.20",2.6,0.3,"10,604",7
7,Ontario,B01AF,Direct factor Xa inhibitors,Total,Total,"145,404.10",2.5,5.5,"176,231",8
7,Ontario,N05AX,Other antipsychotics,Total,Total,"145,297.80",2.5,3.2,"101,914",9
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"128,576.10",2.2,4.5,"144,273",10
7,Ontario,C09AA,"ACE inhibitors, plain",Total,Total,"117,206.50",2.0,20.9,"664,759",11
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"113,930.60",2.0,3.9,"122,901",12
7,Ontario,A02BC,Proton pump inhibitors,Total,Total,"108,184.40",1.9,28.3,"900,311",13
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"105,801.30",1.8,3.9,"125,531",14
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"102,382.30",1.8,0.3,"10,156",15
7,Ontario,L04AA,Selective immunosuppressants,Total,Total,"102,182.90",1.8,0.6,"18,504",16
7,Ontario,N06AX,Other antidepressants,Total,Total,"86,963.90",1.5,12.9,"410,314",17
7,Ontario,N03AX,Other antiepileptics,Total,Total,"86,021.88",1.5,9.3,"294,849",18
7,Ontario,N02AA,Natural opium alkaloids,Total,Total,"85,517.73",1.5,7.2,"229,194",19
7,Ontario,N07BC,Drugs used in opioid dependence,Total,Total,"79,478.52",1.4,1.3,"39,816",20
7,Ontario,C08CA,Dihydropyridine derivatives,Total,Total,"74,763.78",1.3,17.7,"564,161",21
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"74,498.66",1.3,12.2,"386,955",22
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"68,979.09",1.2,2.9,"92,961",23
7,Ontario,R03BB,Anticholinergics,Total,Total,"64,877.84",1.1,5.5,"175,160",24
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"56,689.00",1.0,4.8,"152,420",25
7,Ontario,C09CA,"Angiotensin II antagonists, plain",Total,Total,"56,563.64",1.0,13.6,"433,773",26
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"54,992.65",1.0,2.5,"79,479",27
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,"54,232.20",0.9,0.5,"16,972",28
7,Ontario,M05BA,Bisphosphonates,Total,Total,"51,599.19",0.9,6.6,"210,173",29
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"40,977.78",0.7,2.3,"74,590",30
7,Ontario,L04AC,Interleukin inhibitors,Total,Total,"40,549.51",0.7,0.1,"2,698",31
7,Ontario,C07AB,"Beta-blocking agents, selective",Total,Total,"38,612.93",0.7,18.0,"572,669",32
7,Ontario,L02BX,Other hormone antagonists and related agents,Total,Total,"37,138.43",0.6,0.1,"2,358",33
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"35,584.95",0.6,4.6,"145,082",34
7,Ontario,R03BA,Glucocorticoids,Total,Total,"34,670.30",0.6,5.8,"184,778",35
7,Ontario,L03AA,Colony-stimulating factors,Total,Total,"34,276.22",0.6,0.2,"6,504",36
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"33,300.05",0.6,3.5,"111,408",37
7,Ontario,B01AB,Heparin group,Total,Total,"33,095.01",0.6,0.6,"19,662",38
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,Total,"31,933.46",0.6,0.7,"20,808",39
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"31,444.98",0.5,7.2,"228,489",40
7,Ontario,L04AD,Calcineurin inhibitors,Total,Total,"30,919.45",0.5,0.3,"9,531",41
7,Ontario,S01EE,Prostaglandin analogues,Total,Total,"30,250.90",0.5,3.9,"125,570",42
7,Ontario,B01AE,Direct thrombin inhibitors,Total,Total,"29,496.59",0.5,0.9,"28,238",43
7,Ontario,C09BA,ACE inhibitors and diuretics,Total,Total,"29,125.41",0.5,3.7,"116,761",44
7,Ontario,H01CB,Somatostatin and analogues,Total,Total,"28,948.38",0.5,0.1,"1,767",45
7,Ontario,N06DA,Anticholinesterases,Total,Total,"27,727.99",0.5,2.2,"70,919",46
7,Ontario,N06BA,Centrally acting sympathomimetics,Total,Total,"27,467.63",0.5,1.5,"47,231",47
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"27,421.84",0.5,14.8,"470,152",48
7,Ontario,H03AA,Thyroid hormones,Total,Total,"27,306.66",0.5,13.7,"435,889",49
7,Ontario,S01ED,Beta-blocking agents,Total,Total,"26,478.04",0.5,3.6,"113,597",50
7,Ontario,C08DB,Benzothiazepine derivatives,Total,Total,"26,045.93",0.5,2.9,"92,868",51
7,Ontario,A10BA,Biguanides,Total,Total,"25,860.08",0.5,12.1,"383,716",52
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"25,502.02",0.4,0.3,"9,675",53
7,Ontario,L02BB,Antiandrogens,Total,Total,"25,332.69",0.4,0.3,"9,085",54
7,Ontario,B03XA,Other antianemic preparations,Total,Total,"23,235.30",0.4,0.1,"3,213",55
7,Ontario,N04BA,Dopa and dopa derivatives,Total,Total,"22,865.32",0.4,1.0,"32,878",56
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,"20,998.86",0.4,0.2,"5,164",57
7,Ontario,C09DA,Angiotensin II antagonists and diuretics,Total,Total,"20,936.21",0.4,4.8,"152,575",58
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"20,913.50",0.4,0.9,"28,241",59
7,Ontario,A16AB,Enzymes,Total,Total,"19,535.87",0.3,0.0,36,60
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"18,825.27",0.3,14.8,"471,819",61
7,Ontario,N05BA,Benzodiazepine derivatives,Total,Total,"18,248.57",0.3,9.6,"306,572",62
7,Ontario,C03CA,"Sulfonamides, plain",Total,Total,"17,670.00",0.3,7.7,"246,558",63
7,Ontario,J05AX,Other antivirals,Total,Total,"17,569.85",0.3,0.1,"2,545",64
7,Ontario,A07EC,Aminosalicylic acid and similar agents,Total,Total,"17,549.79",0.3,0.7,"23,411",65
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"16,189.22",0.3,1.0,"33,390",66
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"16,042.57",0.3,3.3,"104,767",67
7,Ontario,A04AD,Other antiemetics,Total,Total,"16,042.24",0.3,0.8,"25,146",68
7,Ontario,R01AD,Corticosteroids,Total,Total,"15,739.21",0.3,8.5,"270,467",69
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"15,583.49",0.3,4.1,"130,584",70
7,Ontario,J05AE,Protease inhibitors,Total,Total,"15,364.96",0.3,0.1,"2,186",71
7,Ontario,A10BB,Sulfonylureas,Total,Total,"15,214.93",0.3,5.3,"170,139",72
7,Ontario,C10AX,Other lipid-modifying agents,Total,Total,"14,892.65",0.3,4.0,"125,782",73
7,Ontario,L03AB,Interferons,Total,Total,"14,830.79",0.3,0.0,929,74
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"13,970.25",0.2,0.0,785,75
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"13,408.30",0.2,2.7,"86,902",76
7,Ontario,A02BA,H2-receptor antagonists,Total,Total,"12,420.77",0.2,4.4,"140,920",77
7,Ontario,N03AE,Benzodiazepine derivatives,Total,Total,"12,004.70",0.2,3.4,"108,650",78
7,Ontario,D07AC,"Corticosteroids, potent (group III)",Total,Total,"11,915.06",0.2,10.5,"333,499",79
7,Ontario,N03AG,Fatty acid derivatives,Total,Total,"11,756.83",0.2,1.1,"34,670",80
7,Ontario,N02AB,Phenylpiperidine derivatives,Total,Total,"11,540.58",0.2,0.4,"13,028",81
7,Ontario,N05AE,Indole derivatives,Total,Total,"11,256.09",0.2,0.3,"9,353",82
7,Ontario,N07XX,Other nervous system drugs,Total,Total,"11,213.35",0.2,0.0,"1,027",83
7,Ontario,H01AC,Somatropin and somatropin agonists,Total,Total,"11,157.47",0.2,0.0,942,84
7,Ontario,A06AB,Contact laxatives,Total,Total,"10,439.04",0.2,8.4,"267,446",85
7,Ontario,N02BE,Anilides,Total,Total,"10,193.96",0.2,9.4,"297,666",86
7,Ontario,B03AA,"Iron bivalent, oral preparations",Total,Total,"9,846.96",0.2,5.3,"167,884",87
7,Ontario,L01XC,Monoclonal antibodies,Total,Total,"9,844.74",0.2,0.0,819,88
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"9,552.43",0.2,0.0,446,89
7,Ontario,L03AX,Other immunostimulants,Total,Total,"9,495.13",0.2,0.0,780,90
7,Ontario,D05AX,Other antipsoriatics for topical use,Total,Total,"9,438.32",0.2,0.8,"25,945",91
7,Ontario,H02AB,Glucocorticoids,Total,Total,"9,305.52",0.2,9.9,"315,806",92
7,Ontario,C01DA,Organic nitrates,Total,Total,"9,034.96",0.2,4.2,"134,667",93
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,Total,Total,"9,005.94",0.2,0.6,"17,994",94
7,Ontario,V03AC,Iron-chelating agents,Total,Total,"9,005.67",0.2,0.0,413,95
7,Ontario,D06AX,Other antibiotics for topical use,Total,Total,"8,731.62",0.2,6.6,"211,063",96
7,Ontario,M01AE,Propionic acid derivatives,Total,Total,"8,685.11",0.2,8.5,"271,184",97
7,Ontario,A06AD,Osmotically acting laxatives,Total,Total,"8,652.40",0.2,4.7,"148,161",98
7,Ontario,M01AH,Coxibs,Total,Total,"8,600.64",0.2,3.2,"101,538",99
7,Ontario,J01CA,Penicillins with extended spectrum,Total,Total,"8,442.73",0.1,15.9,"505,127",100
7,Ontario,J05AP,Antivirals for treatment of HCV infections,Total,M,"199,932.80",7.0,0.2,"3,458",1
7,Ontario,S01LA,Antineovascularization agents,Total,M,"180,536.70",6.3,1.3,"19,201",2
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"127,748.80",4.5,0.5,"6,505",3
7,Ontario,L01XE,Protein kinase inhibitors,Total,M,"91,346.48",3.2,0.2,"2,752",4
7,Ontario,L04AX,Other immunosuppressants,Total,M,"86,194.76",3.0,0.3,"4,869",5
7,Ontario,N05AX,Other antipsychotics,Total,M,"83,325.89",2.9,3.4,"48,764",6
7,Ontario,C10AA,HMG-CoA reductase inhibitors,Total,M,"79,876.10",2.8,47.5,"686,181",7
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"78,127.24",2.7,0.5,"7,719",8
7,Ontario,B01AF,Direct factor Xa inhibitors,Total,M,"73,251.00",2.6,6.1,"87,540",9
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"66,192.74",2.3,5.2,"74,588",10
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"65,077.79",2.3,7.3,"104,671",11
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"64,503.95",2.3,4.8,"69,122",12
7,Ontario,C09AA,"ACE inhibitors, plain",Total,M,"60,989.59",2.1,24.8,"357,649",13
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"57,714.11",2.0,4.6,"66,882",14
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,Total,M,"51,442.65",1.8,1.1,"15,724",15
7,Ontario,N07BC,Drugs used in opioid dependence,Total,M,"45,430.80",1.6,1.6,"22,847",16
7,Ontario,A02BC,Proton pump inhibitors,Total,M,"43,041.11",1.5,25.9,"374,620",17
7,Ontario,N02AA,Natural opium alkaloids,Total,M,"40,106.07",1.4,6.6,"95,288",18
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"39,656.38",1.4,3.7,"52,883",19
7,Ontario,L02BX,Other hormone antagonists and related agents,Total,M,"37,133.25",1.3,0.2,"2,356",20
7,Ontario,N03AX,Other antiepileptics,Total,M,"37,117.33",1.3,8.2,"117,911",21
7,Ontario,L04AA,Selective immunosuppressants,Total,M,"33,394.03",1.2,0.5,"7,734",22
7,Ontario,C08CA,Dihydropyridine derivatives,Total,M,"32,542.60",1.1,17.7,"255,169",23
7,Ontario,R03BB,Anticholinergics,Total,M,"32,188.57",1.1,5.9,"85,454",24
7,Ontario,N06AX,Other antidepressants,Total,M,"30,901.11",1.1,10.5,"151,307",25
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"30,569.67",1.1,5.0,"71,508",26
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"30,205.81",1.1,15.0,"217,244",27
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,Total,M,"27,001.15",0.9,9.4,"135,737",28
7,Ontario,L02BB,Antiandrogens,Total,M,"25,315.31",0.9,0.6,"9,062",29
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"22,685.46",0.8,2.7,"39,133",30
7,Ontario,C09CA,"Angiotensin II antagonists, plain",Total,M,"22,634.57",0.8,12.8,"184,184",31
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"19,718.67",0.7,5.9,"84,742",32
7,Ontario,L04AD,Calcineurin inhibitors,Total,M,"19,225.08",0.7,0.4,"5,923",33
7,Ontario,L04AC,Interleukin inhibitors,Total,M,"18,663.95",0.7,0.1,"1,151",34
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,M,"18,544.37",0.6,0.8,"11,587",35
7,Ontario,C07AB,"Beta-blocking agents, selective",Total,M,"17,542.76",0.6,20.0,"288,762",36
7,Ontario,N06BA,Centrally acting sympathomimetics,Total,M,"17,117.49",0.6,2.0,"28,689",37
7,Ontario,B01AE,Direct thrombin inhibitors,Total,M,"16,839.79",0.6,1.1,"16,201",38
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"16,026.16",0.6,7.2,"104,624",39
7,Ontario,B01AB,Heparin group,Total,M,"15,815.30",0.6,0.6,"8,764",40
7,Ontario,C09BA,ACE inhibitors and diuretics,Total,M,"14,971.85",0.5,4.1,"59,505",41
7,Ontario,H01CB,Somatostatin and analogues,Total,M,"14,967.63",0.5,0.1,804,42
7,Ontario,R03BA,Glucocorticoids,Total,M,"13,893.92",0.5,5.1,"73,188",43
7,Ontario,J05AX,Other antivirals,Total,M,"13,872.67",0.5,0.1,"1,933",44
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"13,740.23",0.5,0.2,"3,384",45
7,Ontario,A16AB,Enzymes,Total,M,"13,489.58",0.5,0.0,23,46
7,Ontario,N04BA,Dopa and dopa derivatives,Total,M,"13,213.81",0.5,1.3,"18,164",47
7,Ontario,S01EE,Prostaglandin analogues,Total,M,"13,154.96",0.5,3.8,"55,289",48
7,Ontario,A10BA,Biguanides,Total,M,"12,905.70",0.5,13.8,"199,530",49
7,Ontario,B03XA,Other antianemic preparations,Total,M,"12,334.09",0.4,0.1,"1,478",50
7,Ontario,J05AE,Protease inhibitors,Total,M,"12,294.12",0.4,0.1,"1,687",51
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"12,284.49",0.4,14.7,"212,367",52
7,Ontario,S01ED,Beta-blocking agents,Total,M,"12,122.87",0.4,3.6,"52,256",53
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,Total,M,"12,023.12",0.4,2.7,"38,656",54
7,Ontario,L03AA,Colony-stimulating factors,Total,M,"11,939.72",0.4,0.2,"2,351",55
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,"10,763.57",0.4,1.0,"14,043",56
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"10,757.08",0.4,0.3,"3,720",57
7,Ontario,C08DB,Benzothiazepine derivatives,Total,M,"10,664.00",0.4,2.6,"38,213",58
7,Ontario,M05BA,Bisphosphonates,Total,M,"10,544.27",0.4,2.7,"38,847",59
7,Ontario,N06DA,Anticholinesterases,Total,M,"10,079.03",0.4,1.9,"27,506",60
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"8,976.02",0.3,1.2,"17,899",61
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,Total,M,"8,940.74",0.3,1.2,"17,570",62
7,Ontario,C09DA,Angiotensin II antagonists and diuretics,Total,M,"8,689.82",0.3,4.5,"64,779",63
7,Ontario,A07EC,Aminosalicylic acid and similar agents,Total,M,"8,591.75",0.3,0.7,"10,402",64
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"8,280.09",0.3,13.5,"195,348",65
7,Ontario,A10BB,Sulfonylureas,Total,M,"7,983.29",0.3,6.5,"93,467",66
7,Ontario,C10AX,Other lipid-modifying agents,Total,M,"7,932.85",0.3,4.7,"68,546",67
7,Ontario,H01AC,Somatropin and somatropin agonists,Total,M,"7,446.45",0.3,0.0,586,68
7,Ontario,A04AD,Other antiemetics,Total,M,"7,370.68",0.3,0.7,"10,494",69
7,Ontario,N05BA,Benzodiazepine derivatives,Total,M,"7,149.74",0.2,7.4,"107,351",70
7,Ontario,R01AD,Corticosteroids,Total,M,"7,123.51",0.2,8.0,"115,147",71
7,Ontario,C03CA,"Sulfonamides, plain",Total,M,"6,975.29",0.2,7.6,"109,041",72
7,Ontario,N03AG,Fatty acid derivatives,Total,M,"6,527.06",0.2,1.2,"17,878",73
7,Ontario,H03AA,Thyroid hormones,Total,M,"6,328.24",0.2,7.3,"105,784",74
7,Ontario,D07AC,"Corticosteroids, potent (group III)",Total,M,"5,868.57",0.2,10.5,"151,053",75
7,Ontario,M04AA,Preparations inhibiting uric acid production,Total,M,"5,613.71",0.2,5.6,"81,003",76
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,"5,542.44",0.2,3.0,"42,799",77
7,Ontario,D05AX,Other antipsoriatics for topical use,Total,M,"5,362.98",0.2,0.9,"13,712",78
7,Ontario,N03AE,Benzodiazepine derivatives,Total,M,"5,308.81",0.2,2.9,"42,139",79
7,Ontario,J05AG,Non-nucleoside reverse transcriptase inhibitors,Total,M,"5,204.90",0.2,0.1,"1,304",80
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"5,169.22",0.2,0.0,261,81
7,Ontario,A02BA,H2-receptor antagonists,Total,M,"5,005.20",0.2,3.8,"55,187",82
7,Ontario,C09DX,"Angiotensin II antagonists, other combinations",Total,M,"4,768.00",0.2,0.2,"3,602",83
7,Ontario,N05AE,Indole derivatives,Total,M,"4,624.25",0.2,0.3,"3,701",84
7,Ontario,V03AC,Iron-chelating agents,Total,M,"4,548.61",0.2,0.0,205,85
7,Ontario,A06AB,Contact laxatives,Total,M,"4,436.21",0.2,8.3,"119,340",86
7,Ontario,N02AB,Phenylpiperidine derivatives,Total,M,"4,427.84",0.2,0.3,"4,763",87
7,Ontario,C01DA,Organic nitrates,Total,M,"4,250.48",0.1,5.0,"72,392",88
7,Ontario,C10AB,Fibrates,Total,M,"4,111.69",0.1,1.3,"18,919",89
7,Ontario,L03AB,Interferons,Total,M,"4,104.47",0.1,0.0,270,90
7,Ontario,N07XX,Other nervous system drugs,Total,M,"4,066.19",0.1,0.0,422,91
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,Total,M,"3,999.77",0.1,0.1,"1,957",92
7,Ontario,B01AA,Vitamin K antagonists,Total,M,"3,923.16",0.1,3.0,"43,891",93
7,Ontario,D06AX,Other antibiotics for topical use,Total,M,"3,892.54",0.1,6.4,"93,061",94
7,Ontario,L01XX,Other antineoplastic agents,Total,M,"3,872.11",0.1,0.1,"2,127",95
7,Ontario,C10AC,Bile acid sequestrants,Total,M,"3,866.83",0.1,0.5,"7,495",96
7,Ontario,C07AG,Alpha- and beta-blocking agents,Total,M,"3,774.11",0.1,1.0,"13,853",97
7,Ontario,H02AB,Glucocorticoids,Total,M,"3,748.11",0.1,9.1,"131,937",98
7,Ontario,J01CA,Penicillins with extended spectrum,Total,M,"3,692.44",0.1,15.4,"221,925",99
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,M,"3,690.79",0.1,0.5,"7,505",100
7,Ontario,S01LA,Antineovascularization agents,Total,F,"242,083.20",8.5,1.4,"24,741",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"144,327.30",5.1,0.5,"8,278",2
7,Ontario,J05AP,Antivirals for treatment of HCV infections,Total,F,"118,379.60",4.1,0.1,"2,054",3
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"82,325.02",2.9,8.3,"143,878",4
7,Ontario,C10AA,HMG-CoA reductase inhibitors,Total,F,"77,789.27",2.7,37.1,"640,042",5
7,Ontario,B01AF,Direct factor Xa inhibitors,Total,F,"72,109.04",2.5,5.1,"88,622",6
7,Ontario,L04AA,Selective immunosuppressants,Total,F,"68,743.51",2.4,0.6,"10,745",7
7,Ontario,A02BC,Proton pump inhibitors,Total,F,"64,998.36",2.3,30.4,"523,391",8
7,Ontario,L01XE,Protein kinase inhibitors,Total,F,"64,974.67",2.3,0.1,"2,246",9
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"62,229.71",2.2,4.0,"69,469",10
7,Ontario,N05AX,Other antipsychotics,Total,F,"61,697.67",2.2,3.1,"52,907",11
7,Ontario,L04AX,Other immunosuppressants,Total,F,"60,183.24",2.1,0.3,"5,723",12
7,Ontario,C09AA,"ACE inhibitors, plain",Total,F,"56,082.82",2.0,17.8,"306,173",13
7,Ontario,N06AX,Other antidepressants,Total,F,"55,958.12",2.0,15.0,"258,098",14
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"50,978.39",1.8,4.5,"77,500",15
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"49,174.91",1.7,3.1,"53,423",16
7,Ontario,N03AX,Other antiepileptics,Total,F,"48,786.96",1.7,10.2,"176,350",17
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"47,962.86",1.7,3.4,"58,414",18
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,Total,F,"47,379.55",1.7,14.5,"250,073",19
7,Ontario,N02AA,Natural opium alkaloids,Total,F,"45,379.92",1.6,7.8,"133,598",20
7,Ontario,C08CA,Dihydropyridine derivatives,Total,F,"42,113.39",1.5,17.9,"308,024",21
7,Ontario,M05BA,Bisphosphonates,Total,F,"41,020.77",1.4,9.9,"171,165",22
7,Ontario,N07BC,Drugs used in opioid dependence,Total,F,"33,941.94",1.2,1.0,"16,870",23
7,Ontario,C09CA,"Angiotensin II antagonists, plain",Total,F,"33,862.20",1.2,14.5,"249,022",24
7,Ontario,R03BB,Anticholinergics,Total,F,"32,658.93",1.1,5.2,"89,582",25
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"29,222.30",1.0,2.3,"39,904",26
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"26,037.00",0.9,4.7,"80,522",27
7,Ontario,L03AA,Colony-stimulating factors,Total,F,"22,308.70",0.8,0.2,"4,150",28
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"22,199.68",0.8,0.1,"2,218",29
7,Ontario,L04AC,Interleukin inhibitors,Total,F,"21,885.57",0.8,0.1,"1,547",30
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,Total,F,"21,261.90",0.7,4.2,"72,662",31
7,Ontario,C07AB,"Beta-blocking agents, selective",Total,F,"21,018.14",0.7,16.4,"283,173",32
7,Ontario,H03AA,Thyroid hormones,Total,F,"20,943.70",0.7,19.1,"329,522",33
7,Ontario,R03BA,Glucocorticoids,Total,F,"20,678.25",0.7,6.4,"110,702",34
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"18,233.78",0.6,2.0,"35,295",35
7,Ontario,N06DA,Anticholinesterases,Total,F,"17,640.84",0.6,2.5,"43,382",36
7,Ontario,B01AB,Heparin group,Total,F,"17,236.73",0.6,0.6,"10,874",37
7,Ontario,S01EE,Prostaglandin analogues,Total,F,"17,079.43",0.6,4.1,"70,212",38
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"15,833.14",0.6,3.5,"60,191",39
7,Ontario,C08DB,Benzothiazepine derivatives,Total,F,"15,373.68",0.5,3.2,"54,614",40
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"15,105.77",0.5,14.9,"256,569",41
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"14,732.97",0.5,0.3,"5,948",42
7,Ontario,S01ED,Beta-blocking agents,Total,F,"14,339.67",0.5,3.6,"61,251",43
7,Ontario,C09BA,ACE inhibitors and diuretics,Total,F,"14,102.21",0.5,3.3,"57,005",44
7,Ontario,H01CB,Somatostatin and analogues,Total,F,"13,980.75",0.5,0.1,963,45
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,F,"13,326.15",0.5,0.5,"9,180",46
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"13,287.16",0.5,5.0,"86,425",47
7,Ontario,A10BA,Biguanides,Total,F,"12,896.98",0.5,10.6,"183,281",48
7,Ontario,B01AE,Direct thrombin inhibitors,Total,F,"12,650.99",0.4,0.7,"12,031",49
7,Ontario,C09DA,Angiotensin II antagonists and diuretics,Total,F,"12,212.87",0.4,5.1,"87,573",50
7,Ontario,L04AD,Calcineurin inhibitors,Total,F,"11,678.79",0.4,0.2,"3,598",51
7,Ontario,N05BA,Benzodiazepine derivatives,Total,F,"11,079.75",0.4,11.5,"198,709",52
7,Ontario,B03XA,Other antianemic preparations,Total,F,"10,897.93",0.4,0.1,"1,732",53
7,Ontario,L03AB,Interferons,Total,F,"10,726.32",0.4,0.0,659,54
7,Ontario,C03CA,"Sulfonamides, plain",Total,F,"10,683.36",0.4,8.0,"137,319",55
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"10,503.55",0.4,15.9,"274,830",56
7,Ontario,N06BA,Centrally acting sympathomimetics,Total,F,"10,293.86",0.4,1.1,"18,394",57
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,"10,117.79",0.4,0.8,"14,126",58
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"10,022.09",0.4,5.1,"87,417",59
7,Ontario,N04BA,Dopa and dopa derivatives,Total,F,"9,642.32",0.3,0.9,"14,692",60
7,Ontario,A07EC,Aminosalicylic acid and similar agents,Total,F,"8,950.09",0.3,0.8,"12,988",61
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"8,801.03",0.3,0.0,524,62
7,Ontario,A04AD,Other antiemetics,Total,F,"8,658.98",0.3,0.8,"14,630",63
7,Ontario,R01AD,Corticosteroids,Total,F,"8,562.82",0.3,8.9,"154,078",64
7,Ontario,A02BA,H2-receptor antagonists,Total,F,"7,388.15",0.3,4.9,"85,118",65
7,Ontario,L02BG,Aromatase inhibitors,Total,F,"7,297.35",0.3,1.1,"18,721",66
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"7,208.03",0.3,0.9,"15,476",67
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,F,"7,197.38",0.3,0.1,"1,761",68
7,Ontario,A10BB,Sulfonylureas,Total,F,"7,197.21",0.3,4.4,"76,273",69
7,Ontario,L01XC,Monoclonal antibodies,Total,F,"7,180.80",0.3,0.0,592,70
7,Ontario,N07XX,Other nervous system drugs,Total,F,"7,147.16",0.3,0.0,605,71
7,Ontario,N02AB,Phenylpiperidine derivatives,Total,F,"7,107.91",0.2,0.5,"8,259",72
7,Ontario,C10AX,Other lipid-modifying agents,Total,F,"6,953.10",0.2,3.3,"57,176",73
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"6,763.12",0.2,0.0,297,74
7,Ontario,N02BE,Anilides,Total,F,"6,750.01",0.2,10.7,"184,299",75
7,Ontario,N03AE,Benzodiazepine derivatives,Total,F,"6,680.49",0.2,3.8,"66,250",76
7,Ontario,N05AE,Indole derivatives,Total,F,"6,611.52",0.2,0.3,"5,628",77
7,Ontario,L03AX,Other immunostimulants,Total,F,"6,600.97",0.2,0.0,565,78
7,Ontario,B03AA,"Iron bivalent, oral preparations",Total,F,"6,194.46",0.2,6.0,"103,130",79
7,Ontario,A16AB,Enzymes,Total,F,"6,046.29",0.2,0.0,13,80
7,Ontario,D07AC,"Corticosteroids, potent (group III)",Total,F,"6,009.55",0.2,10.5,"181,168",81
7,Ontario,A06AB,Contact laxatives,Total,F,"5,987.86",0.2,8.6,"147,645",82
7,Ontario,H02AB,Glucocorticoids,Total,F,"5,544.42",0.2,10.6,"183,227",83
7,Ontario,M01AH,Coxibs,Total,F,"5,487.28",0.2,3.7,"63,822",84
7,Ontario,N03AG,Fatty acid derivatives,Total,F,"5,215.51",0.2,1.0,"16,703",85
7,Ontario,M01AE,Propionic acid derivatives,Total,F,"4,997.07",0.2,8.9,"153,371",86
7,Ontario,A06AD,Osmotically acting laxatives,Total,F,"4,983.37",0.2,4.8,"82,813",87
7,Ontario,A06AA,"Softeners, emollients",Total,F,"4,937.06",0.2,6.0,"103,762",88
7,Ontario,D06AX,Other antibiotics for topical use,Total,F,"4,810.00",0.2,6.8,"117,197",89
7,Ontario,C01DA,Organic nitrates,Total,F,"4,775.87",0.2,3.6,"62,120",90
7,Ontario,J01CA,Penicillins with extended spectrum,Total,F,"4,664.30",0.2,16.2,"279,113",91
7,Ontario,V03AC,Iron-chelating agents,Total,F,"4,457.06",0.2,0.0,208,92
7,Ontario,C10AC,Bile acid sequestrants,Total,F,"4,285.19",0.2,0.7,"12,546",93
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",Total,F,"4,214.52",0.1,0.7,"11,268",94
7,Ontario,C03AA,"Thiazides, plain",Total,F,"4,202.54",0.1,9.2,"159,159",95
7,Ontario,N04BC,Dopamine agonists,Total,F,"4,169.57",0.1,0.9,"15,339",96
7,Ontario,B01AA,Vitamin K antagonists,Total,F,"4,146.73",0.1,2.2,"37,108",97
7,Ontario,M03BX,Other centrally acting agents,Total,F,"4,063.94",0.1,2.7,"47,081",98
7,Ontario,D05AX,Other antipsoriatics for topical use,Total,F,"4,053.19",0.1,0.7,"12,164",99
7,Ontario,A04AA,Serotonin (5HT3) antagonists,Total,F,"4,043.06",0.1,0.8,"14,598",100
7,Ontario,S01LA,Antineovascularization agents,65+,Total,"401,922.50",10.9,1.8,"41,571",1
7,Ontario,B01AF,Direct factor Xa inhibitors,65+,Total,"139,452.70",3.8,7.4,"166,257",2
7,Ontario,C10AA,HMG-CoA reductase inhibitors,65+,Total,"137,333.50",3.7,51.8,"1,169,751",3
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"116,361.10",3.1,8.5,"191,842",4
7,Ontario,L04AX,Other immunosuppressants,65+,Total,"116,141.90",3.1,0.3,"6,967",5
7,Ontario,L01XE,Protein kinase inhibitors,65+,Total,"115,907.50",3.1,0.2,"3,712",6
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"109,661.40",3.0,5.4,"120,942",7
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"109,009.70",2.9,0.3,"5,967",8
7,Ontario,C09AA,"ACE inhibitors, plain",65+,Total,"101,767.90",2.8,25.7,"580,092",9
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"90,721.08",2.5,4.2,"94,886",10
7,Ontario,A02BC,Proton pump inhibitors,65+,Total,"84,205.17",2.3,31.4,"709,831",11
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"76,391.95",2.1,4.1,"92,257",12
7,Ontario,C08CA,Dihydropyridine derivatives,65+,Total,"67,001.40",1.8,22.4,"506,391",13
7,Ontario,J05AP,Antivirals for treatment of HCV infections,65+,Total,"60,459.88",1.6,0.0,"1,024",14
7,Ontario,R03BB,Anticholinergics,65+,Total,"54,181.21",1.5,6.4,"144,425",15
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"53,547.22",1.4,3.4,"77,397",16
7,Ontario,C09CA,"Angiotensin II antagonists, plain",65+,Total,"51,191.91",1.4,17.4,"392,937",17
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"50,786.23",1.4,3.0,"66,995",18
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,"49,068.39",1.3,0.7,"14,954",19
7,Ontario,M05BA,Bisphosphonates,65+,Total,"47,945.26",1.3,8.7,"196,308",20
7,Ontario,N06AX,Other antidepressants,65+,Total,"46,136.32",1.2,11.3,"255,726",21
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"42,406.34",1.1,10.5,"236,064",22
7,Ontario,N03AX,Other antiepileptics,65+,Total,"41,187.74",1.1,8.4,"188,776",23
7,Ontario,L04AA,Selective immunosuppressants,65+,Total,"38,586.68",1.0,0.5,"10,700",24
7,Ontario,N02AA,Natural opium alkaloids,65+,Total,"38,237.42",1.0,7.2,"163,501",25
7,Ontario,L02BX,Other hormone antagonists and related agents,65+,Total,"35,463.83",1.0,0.1,"2,228",26
7,Ontario,C07AB,"Beta-blocking agents, selective",65+,Total,"33,911.93",0.9,22.8,"514,403",27
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"29,638.51",0.8,5.8,"130,330",28
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"29,415.59",0.8,9.4,"212,520",29
7,Ontario,S01EE,Prostaglandin analogues,65+,Total,"28,877.76",0.8,5.3,"119,875",30
7,Ontario,B01AE,Direct thrombin inhibitors,65+,Total,"28,823.20",0.8,1.2,"27,479",31
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"28,318.07",0.8,4.1,"92,840",32
7,Ontario,N06DA,Anticholinesterases,65+,Total,"27,217.58",0.7,3.1,"69,701",33
7,Ontario,N05AX,Other antipsychotics,65+,Total,"26,994.68",0.7,1.7,"37,992",34
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"26,990.39",0.7,2.2,"50,430",35
7,Ontario,S01ED,Beta-blocking agents,65+,Total,"25,170.59",0.7,4.8,"107,908",36
7,Ontario,C09BA,ACE inhibitors and diuretics,65+,Total,"25,084.07",0.7,4.5,"100,921",37
7,Ontario,C08DB,Benzothiazepine derivatives,65+,Total,"24,121.34",0.7,3.8,"85,553",38
7,Ontario,L02BB,Antiandrogens,65+,Total,"23,839.50",0.6,0.4,"8,834",39
7,Ontario,B01AB,Heparin group,65+,Total,"22,670.39",0.6,0.7,"14,830",40
7,Ontario,H03AA,Thyroid hormones,65+,Total,"22,234.62",0.6,16.4,"371,136",41
7,Ontario,R03BA,Glucocorticoids,65+,Total,"21,807.78",0.6,4.9,"110,562",42
7,Ontario,B03XA,Other antianemic preparations,65+,Total,"21,499.13",0.6,0.1,"2,773",43
7,Ontario,N04BA,Dopa and dopa derivatives,65+,Total,"21,383.26",0.6,1.4,"30,568",44
7,Ontario,H01CB,Somatostatin and analogues,65+,Total,"21,170.65",0.6,0.1,"1,195",45
7,Ontario,L04AC,Interleukin inhibitors,65+,Total,"20,904.80",0.6,0.1,"1,334",46
7,Ontario,A10BA,Biguanides,65+,Total,"20,295.29",0.5,13.9,"313,439",47
7,Ontario,C09DA,Angiotensin II antagonists and diuretics,65+,Total,"18,762.69",0.5,6.1,"137,653",48
7,Ontario,L03AA,Colony-stimulating factors,65+,Total,"17,373.72",0.5,0.2,"3,485",49
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"17,309.58",0.5,1.0,"23,647",50
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"15,965.06",0.4,2.9,"65,425",51
7,Ontario,C03CA,"Sulfonamides, plain",65+,Total,"15,797.29",0.4,9.8,"221,717",52
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"15,584.76",0.4,4.5,"101,825",53
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"15,003.12",0.4,0.3,"6,407",54
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"14,021.72",0.4,1.3,"28,557",55
7,Ontario,A07EC,Aminosalicylic acid and similar agents,65+,Total,"13,764.03",0.4,0.8,"17,694",56
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"13,316.21",0.4,14.2,"321,640",57
7,Ontario,C10AX,Other lipid-modifying agents,65+,Total,"13,148.86",0.4,5.0,"112,749",58
7,Ontario,A10BB,Sulfonylureas,65+,Total,"12,125.34",0.3,6.2,"139,199",59
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,"12,055.95",0.3,0.1,"1,215",60
7,Ontario,L04AD,Calcineurin inhibitors,65+,Total,"11,838.54",0.3,0.2,"4,002",61
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"11,704.15",0.3,3.4,"75,779",62
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"11,422.10",0.3,13.5,"304,773",63
7,Ontario,R01AD,Corticosteroids,65+,Total,"10,913.76",0.3,8.5,"191,117",64
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,Total,"10,202.66",0.3,0.5,"10,403",65
7,Ontario,N05BA,Benzodiazepine derivatives,65+,Total,"9,078.50",0.2,9.6,"215,734",66
7,Ontario,D07AC,"Corticosteroids, potent (group III)",65+,Total,"8,903.10",0.2,11.3,"255,033",67
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,Total,"8,817.47",0.2,0.1,"2,059",68
7,Ontario,A02BA,H2-receptor antagonists,65+,Total,"8,781.41",0.2,4.5,"101,421",69
7,Ontario,C01DA,Organic nitrates,65+,Total,"8,338.55",0.2,5.4,"122,284",70
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"8,328.40",0.2,3.7,"83,395",71
7,Ontario,N02BE,Anilides,65+,Total,"7,679.41",0.2,9.9,"224,513",72
7,Ontario,M04AA,Preparations inhibiting uric acid production,65+,Total,"7,438.65",0.2,4.6,"104,736",73
7,Ontario,A06AB,Contact laxatives,65+,Total,"7,427.51",0.2,9.5,"214,109",74
7,Ontario,B03AA,"Iron bivalent, oral preparations",65+,Total,"7,376.96",0.2,5.6,"126,822",75
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"7,304.38",0.2,0.0,402,76
7,Ontario,B01AA,Vitamin K antagonists,65+,Total,"7,196.43",0.2,3.3,"73,948",77
7,Ontario,C10AC,Bile acid sequestrants,65+,Total,"6,897.98",0.2,0.7,"16,755",78
7,Ontario,H02AB,Glucocorticoids,65+,Total,"6,867.07",0.2,10.6,"240,424",79
7,Ontario,A06AD,Osmotically acting laxatives,65+,Total,"6,792.93",0.2,5.3,"119,479",80
7,Ontario,L02BG,Aromatase inhibitors,65+,Total,"6,662.55",0.2,0.7,"16,506",81
7,Ontario,M01AH,Coxibs,65+,Total,"6,510.01",0.2,3.6,"80,990",82
7,Ontario,L01XC,Monoclonal antibodies,65+,Total,"6,266.24",0.2,0.0,491,83
7,Ontario,N02AB,Phenylpiperidine derivatives,65+,Total,"6,258.38",0.2,0.4,"8,354",84
7,Ontario,D05AX,Other antipsoriatics for topical use,65+,Total,"6,202.63",0.2,0.9,"19,576",85
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"6,056.80",0.2,0.0,272,86
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,65+,Total,"5,875.28",0.2,0.4,"10,046",87
7,Ontario,D06AX,Other antibiotics for topical use,65+,Total,"5,835.66",0.2,6.6,"149,895",88
7,Ontario,J01MA,Fluoroquinolones,65+,Total,"5,825.83",0.2,10.4,"234,714",89
7,Ontario,A06AA,"Softeners, emollients",65+,Total,"5,746.77",0.2,6.3,"142,854",90
7,Ontario,C09DX,"Angiotensin II antagonists, other combinations",65+,Total,"5,606.06",0.2,0.2,"4,173",91
7,Ontario,C10AB,Fibrates,65+,Total,"5,574.46",0.2,1.2,"26,064",92
7,Ontario,C07AG,Alpha- and beta-blocking agents,65+,Total,"5,574.42",0.2,0.9,"20,246",93
7,Ontario,N04BC,Dopamine agonists,65+,Total,"5,549.55",0.2,0.9,"19,457",94
7,Ontario,S01EC,Carbonic anhydrase inhibitors,65+,Total,"5,346.56",0.1,1.3,"29,527",95
7,Ontario,C03AA,"Thiazides, plain",65+,Total,"5,311.85",0.1,10.2,"230,405",96
7,Ontario,C10BX,"HMG-CoA reductase inhibitors, other combinations",65+,Total,"5,179.71",0.1,1.0,"21,843",97
7,Ontario,L01XX,Other antineoplastic agents,65+,Total,"5,163.51",0.1,0.2,"4,137",98
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",65+,Total,"5,063.93",0.1,0.6,"13,256",99
7,Ontario,M01AB,Acetic acid derivatives and related substances,65+,Total,"4,925.53",0.1,3.5,"79,682",100
7,Ontario,S01LA,Antineovascularization agents,65+,M,"169,276.90",9.5,1.8,"17,894",1
7,Ontario,B01AF,Direct factor Xa inhibitors,65+,M,"69,756.74",3.9,8.1,"82,177",2
7,Ontario,L04AX,Other immunosuppressants,65+,M,"69,413.89",3.9,0.3,"3,312",3
7,Ontario,C10AA,HMG-CoA reductase inhibitors,65+,M,"68,979.36",3.9,59.2,"602,657",4
7,Ontario,L01XE,Protein kinase inhibitors,65+,M,"66,183.89",3.7,0.2,"2,022",5
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"57,012.24",3.2,6.2,"63,113",6
7,Ontario,C09AA,"ACE inhibitors, plain",65+,M,"52,395.94",2.9,30.5,"310,570",7
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"52,388.89",2.9,5.3,"54,429",8
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"52,150.48",2.9,8.1,"82,535",9
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,65+,M,"49,049.73",2.7,1.5,"14,946",10
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"42,907.01",2.4,4.9,"50,048",11
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"42,905.57",2.4,0.2,"2,208",12
7,Ontario,J05AP,Antivirals for treatment of HCV infections,65+,M,"37,332.44",2.1,0.1,631,13
7,Ontario,L02BX,Other hormone antagonists and related agents,65+,M,"35,460.07",2.0,0.2,"2,227",14
7,Ontario,A02BC,Proton pump inhibitors,65+,M,"32,567.13",1.8,28.9,"293,887",15
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"30,517.49",1.7,3.9,"39,786",16
7,Ontario,C08CA,Dihydropyridine derivatives,65+,M,"28,556.40",1.6,22.2,"225,812",17
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"28,339.72",1.6,20.0,"203,266",18
7,Ontario,R03BB,Anticholinergics,65+,M,"26,973.00",1.5,7.0,"70,976",19
7,Ontario,L02BB,Antiandrogens,65+,M,"23,827.32",1.3,0.9,"8,821",20
7,Ontario,C09CA,"Angiotensin II antagonists, plain",65+,M,"20,209.07",1.1,16.3,"165,739",21
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"16,732.47",0.9,7.4,"75,198",22
7,Ontario,N03AX,Other antiepileptics,65+,M,"16,470.76",0.9,7.2,"73,165",23
7,Ontario,B01AE,Direct thrombin inhibitors,65+,M,"16,404.56",0.9,1.5,"15,721",24
7,Ontario,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"15,574.39",0.9,10.0,"101,741",25
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"15,407.88",0.9,2.6,"26,955",26
7,Ontario,N02AA,Natural opium alkaloids,65+,M,"15,344.25",0.9,6.5,"65,790",27
7,Ontario,C07AB,"Beta-blocking agents, selective",65+,M,"14,856.27",0.8,25.1,"255,818",28
7,Ontario,N06AX,Other antidepressants,65+,M,"14,520.90",0.8,8.7,"88,370",29
7,Ontario,L04AA,Selective immunosuppressants,65+,M,"14,232.20",0.8,0.4,"4,448",30
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,65+,M,"13,255.33",0.7,7.5,"75,959",31
7,Ontario,C09BA,ACE inhibitors and diuretics,65+,M,"12,832.73",0.7,5.0,"51,300",32
7,Ontario,S01EE,Prostaglandin analogues,65+,M,"12,496.27",0.7,5.2,"52,641",33
7,Ontario,N04BA,Dopa and dopa derivatives,65+,M,"12,429.69",0.7,1.7,"17,021",34
7,Ontario,B03XA,Other antianemic preparations,65+,M,"11,467.38",0.6,0.1,"1,261",35
7,Ontario,B01AB,Heparin group,65+,M,"11,394.29",0.6,0.7,"6,667",36
7,Ontario,S01ED,Beta-blocking agents,65+,M,"11,391.78",0.6,4.8,"49,264",37
7,Ontario,H01CB,Somatostatin and analogues,65+,M,"10,956.13",0.6,0.1,559,38
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,65+,M,"10,695.38",0.6,3.3,"33,354",39
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,"10,615.06",0.6,0.1,"1,054",40
7,Ontario,A10BA,Biguanides,65+,M,"10,180.76",0.6,16.3,"165,627",41
7,Ontario,N05AX,Other antipsychotics,65+,M,"10,022.66",0.6,1.3,"13,665",42
7,Ontario,N06DA,Anticholinesterases,65+,M,"9,827.84",0.6,2.6,"26,895",43
7,Ontario,L04AC,Interleukin inhibitors,65+,M,"9,772.41",0.5,0.1,565,44
7,Ontario,C08DB,Benzothiazepine derivatives,65+,M,"9,714.04",0.5,3.4,"34,696",45
7,Ontario,M05BA,Bisphosphonates,65+,M,"9,487.08",0.5,3.5,"35,252",46
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,"8,923.34",0.5,1.2,"11,708",47
7,Ontario,R03BA,Glucocorticoids,65+,M,"8,507.05",0.5,4.1,"42,150",48
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"7,750.20",0.4,1.5,"15,301",49
7,Ontario,C09DA,Angiotensin II antagonists and diuretics,65+,M,"7,714.48",0.4,5.7,"58,243",50
7,Ontario,L04AD,Calcineurin inhibitors,65+,M,"7,559.22",0.4,0.3,"2,563",51
7,Ontario,L03AA,Colony-stimulating factors,65+,M,"7,486.71",0.4,0.1,"1,497",52
7,Ontario,C10AX,Other lipid-modifying agents,65+,M,"6,999.73",0.4,6.0,"61,466",53
7,Ontario,A07EC,Aminosalicylic acid and similar agents,65+,M,"6,734.73",0.4,0.8,"7,973",54
7,Ontario,A10BB,Sulfonylureas,65+,M,"6,401.57",0.4,7.6,"77,380",55
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"6,254.54",0.4,2.6,"25,987",56
7,Ontario,C03CA,"Sulfonamides, plain",65+,M,"6,052.91",0.3,9.6,"97,177",57
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,M,"5,896.82",0.3,0.6,"5,598",58
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,65+,M,"5,871.55",0.3,1.0,"9,999",59
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,"5,820.41",0.3,0.2,"2,247",60
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,"5,735.19",0.3,0.1,"1,342",61
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"5,649.85",0.3,14.4,"146,980",62
7,Ontario,R01AD,Corticosteroids,65+,M,"5,100.13",0.3,8.3,"83,976",63
7,Ontario,M04AA,Preparations inhibiting uric acid production,65+,M,"5,034.00",0.3,7.3,"74,453",64
7,Ontario,H03AA,Thyroid hormones,65+,M,"5,007.41",0.3,8.9,"90,361",65
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"4,978.13",0.3,12.3,"125,320",66
7,Ontario,D07AC,"Corticosteroids, potent (group III)",65+,M,"4,531.37",0.3,11.7,"118,821",67
7,Ontario,C09DX,"Angiotensin II antagonists, other combinations",65+,M,"4,227.82",0.2,0.3,"3,142",68
7,Ontario,C01DA,Organic nitrates,65+,M,"3,826.24",0.2,6.4,"64,972",69
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,65+,M,"3,754.63",0.2,0.2,"1,852",70
7,Ontario,D05AX,Other antipsoriatics for topical use,65+,M,"3,632.39",0.2,1.0,"10,498",71
7,Ontario,B01AA,Vitamin K antagonists,65+,M,"3,432.72",0.2,3.9,"39,823",72
7,Ontario,A02BA,H2-receptor antagonists,65+,M,"3,398.23",0.2,3.9,"39,618",73
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,"3,397.19",0.2,0.0,163,74
7,Ontario,C10AC,Bile acid sequestrants,65+,M,"3,272.19",0.2,0.6,"6,189",75
7,Ontario,C07AG,Alpha- and beta-blocking agents,65+,M,"3,168.34",0.2,1.2,"11,820",76
7,Ontario,A06AB,Contact laxatives,65+,M,"3,123.96",0.2,9.5,"96,695",77
7,Ontario,L01XX,Other antineoplastic agents,65+,M,"3,067.31",0.2,0.2,"1,794",78
7,Ontario,C10AB,Fibrates,65+,M,"3,042.36",0.2,1.4,"14,312",79
7,Ontario,J05AX,Other antivirals,65+,M,"2,928.79",0.2,0.0,357,80
7,Ontario,B03AA,"Iron bivalent, oral preparations",65+,M,"2,881.38",0.2,5.3,"53,799",81
7,Ontario,C10BX,"HMG-CoA reductase inhibitors, other combinations",65+,M,"2,773.05",0.2,1.2,"11,894",82
7,Ontario,N05BA,Benzodiazepine derivatives,65+,M,"2,753.44",0.2,6.9,"69,973",83
7,Ontario,J01MA,Fluoroquinolones,65+,M,"2,743.61",0.2,10.3,"104,290",84
7,Ontario,A06AD,Osmotically acting laxatives,65+,M,"2,723.75",0.2,5.1,"51,915",85
7,Ontario,H02AB,Glucocorticoids,65+,M,"2,717.08",0.2,10.0,"101,538",86
7,Ontario,D06AX,Other antibiotics for topical use,65+,M,"2,626.86",0.1,6.6,"66,904",87
7,Ontario,J05AE,Protease inhibitors,65+,M,"2,576.42",0.1,0.0,319,88
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",65+,M,"2,476.02",0.1,0.5,"5,337",89
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,"2,467.39",0.1,2.5,"25,455",90
7,Ontario,C03DA,Aldosterone antagonists,65+,M,"2,415.79",0.1,2.4,"24,871",91
7,Ontario,S01EC,Carbonic anhydrase inhibitors,65+,M,"2,409.64",0.1,1.3,"13,485",92
7,Ontario,N02BE,Anilides,65+,M,"2,350.98",0.1,8.0,"81,288",93
7,Ontario,M01AH,Coxibs,65+,M,"2,312.65",0.1,2.9,"29,894",94
7,Ontario,N04BC,Dopamine agonists,65+,M,"2,285.74",0.1,0.7,"7,507",95
7,Ontario,M01AB,Acetic acid derivatives and related substances,65+,M,"2,281.33",0.1,4.1,"41,851",96
7,Ontario,A06AA,"Softeners, emollients",65+,M,"2,247.57",0.1,6.1,"62,472",97
7,Ontario,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,"2,212.58",0.1,0.5,"5,211",98
7,Ontario,N02AB,Phenylpiperidine derivatives,65+,M,"2,062.42",0.1,0.3,"2,752",99
7,Ontario,J01CA,Penicillins with extended spectrum,65+,M,"1,988.91",0.1,14.0,"142,824",100
7,Ontario,S01LA,Antineovascularization agents,65+,F,"232,643.90",12.2,1.9,"23,676",1
7,Ontario,B01AF,Direct factor Xa inhibitors,65+,F,"69,679.78",3.6,6.8,"84,058",2
7,Ontario,C10AA,HMG-CoA reductase inhibitors,65+,F,"68,316.33",3.6,45.7,"566,828",3
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"66,104.12",3.5,0.3,"3,759",4
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"64,190.76",3.4,8.8,"109,268",5
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"52,616.91",2.8,4.7,"57,794",6
7,Ontario,A02BC,Proton pump inhibitors,65+,F,"51,615.82",2.7,33.5,"415,755",7
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"49,785.77",2.6,6.1,"75,535",8
7,Ontario,L01XE,Protein kinase inhibitors,65+,F,"49,711.41",2.6,0.1,"1,688",9
7,Ontario,C09AA,"ACE inhibitors, plain",65+,F,"49,345.00",2.6,21.7,"269,395",10
7,Ontario,L04AX,Other immunosuppressants,65+,F,"46,727.70",2.4,0.3,"3,654",11
7,Ontario,M05BA,Bisphosphonates,65+,F,"38,443.30",2.0,13.0,"160,996",12
7,Ontario,C08CA,Dihydropyridine derivatives,65+,F,"38,417.20",2.0,22.6,"280,423",13
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"38,283.26",2.0,3.3,"40,406",14
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"33,469.61",1.8,3.4,"42,181",15
7,Ontario,N06AX,Other antidepressants,65+,F,"31,609.96",1.7,13.5,"167,316",16
7,Ontario,C09CA,"Angiotensin II antagonists, plain",65+,F,"30,966.12",1.6,18.3,"227,099",17
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,65+,F,"29,142.79",1.5,12.9,"160,062",18
7,Ontario,R03BB,Anticholinergics,65+,F,"27,203.99",1.4,5.9,"73,433",19
7,Ontario,N03AX,Other antiepileptics,65+,F,"24,710.39",1.3,9.3,"115,563",20
7,Ontario,L04AA,Selective immunosuppressants,65+,F,"24,354.48",1.3,0.5,"6,252",21
7,Ontario,J05AP,Antivirals for treatment of HCV infections,65+,F,"23,001.10",1.2,0.0,391,22
7,Ontario,N02AA,Natural opium alkaloids,65+,F,"22,892.66",1.2,7.9,"97,691",23
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"20,255.07",1.1,2.2,"27,187",24
7,Ontario,C07AB,"Beta-blocking agents, selective",65+,F,"19,043.60",1.0,20.8,"258,460",25
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,65+,F,"17,618.37",0.9,4.8,"59,468",26
7,Ontario,N06DA,Anticholinesterases,65+,F,"17,384.94",0.9,3.5,"42,792",27
7,Ontario,H03AA,Thyroid hormones,65+,F,"17,221.03",0.9,22.6,"280,714",28
7,Ontario,N05AX,Other antipsychotics,65+,F,"16,969.10",0.9,2.0,"24,320",29
7,Ontario,S01EE,Prostaglandin analogues,65+,F,"16,376.88",0.9,5.4,"67,219",30
7,Ontario,C08DB,Benzothiazepine derivatives,65+,F,"14,405.41",0.8,4.1,"50,850",31
7,Ontario,S01ED,Beta-blocking agents,65+,F,"13,774.16",0.7,4.7,"58,624",32
7,Ontario,R03BA,Glucocorticoids,65+,F,"13,293.98",0.7,5.5,"68,382",33
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"12,899.99",0.7,4.4,"55,106",34
7,Ontario,B01AE,Direct thrombin inhibitors,65+,F,"12,414.19",0.6,0.9,"11,754",35
7,Ontario,C09BA,ACE inhibitors and diuretics,65+,F,"12,240.71",0.6,4.0,"49,587",36
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"11,696.66",0.6,6.1,"75,731",37
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"11,577.87",0.6,1.9,"23,462",38
7,Ontario,B01AB,Heparin group,65+,F,"11,274.49",0.6,0.7,"8,161",39
7,Ontario,L04AC,Interleukin inhibitors,65+,F,"11,132.39",0.6,0.1,769,40
7,Ontario,C09DA,Angiotensin II antagonists and diuretics,65+,F,"11,040.87",0.6,6.4,"79,375",41
7,Ontario,H01CB,Somatostatin and analogues,65+,F,"10,214.52",0.5,0.1,636,42
7,Ontario,A10BA,Biguanides,65+,F,"10,103.84",0.5,11.9,"147,706",43
7,Ontario,B03XA,Other antianemic preparations,65+,F,"10,030.04",0.5,0.1,"1,511",44
7,Ontario,L03AA,Colony-stimulating factors,65+,F,"9,887.01",0.5,0.2,"1,988",45
7,Ontario,C03CA,"Sulfonamides, plain",65+,F,"9,741.18",0.5,10.0,"124,493",46
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"9,707.53",0.5,3.2,"39,425",47
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"9,182.71",0.5,0.3,"4,160",48
7,Ontario,N04BA,Dopa and dopa derivatives,65+,F,"8,949.62",0.5,1.1,"13,544",49
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,"8,379.84",0.4,1.0,"11,929",50
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"7,665.05",0.4,14.1,"174,607",51
7,Ontario,A07EC,Aminosalicylic acid and similar agents,65+,F,"7,027.50",0.4,0.8,"9,719",52
7,Ontario,L02BG,Aromatase inhibitors,65+,F,"6,653.43",0.3,1.3,"16,451",53
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"6,440.78",0.3,14.5,"179,384",54
7,Ontario,N05BA,Benzodiazepine derivatives,65+,F,"6,323.84",0.3,11.8,"145,739",55
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"6,271.00",0.3,1.1,"13,253",56
7,Ontario,C10AX,Other lipid-modifying agents,65+,F,"6,148.12",0.3,4.1,"51,278",57
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"5,858.59",0.3,4.7,"57,922",58
7,Ontario,R01AD,Corticosteroids,65+,F,"5,810.93",0.3,8.6,"107,087",59
7,Ontario,A10BB,Sulfonylureas,65+,F,"5,715.83",0.3,5.0,"61,755",60
7,Ontario,A02BA,H2-receptor antagonists,65+,F,"5,379.28",0.3,5.0,"61,773",61
7,Ontario,N02BE,Anilides,65+,F,"5,323.33",0.3,11.5,"143,079",62
7,Ontario,C01DA,Organic nitrates,65+,F,"4,509.56",0.2,4.6,"57,283",63
7,Ontario,B03AA,"Iron bivalent, oral preparations",65+,F,"4,491.39",0.2,5.9,"72,976",64
7,Ontario,L01XC,Monoclonal antibodies,65+,F,"4,461.27",0.2,0.0,349,65
7,Ontario,D07AC,"Corticosteroids, potent (group III)",65+,F,"4,369.94",0.2,11.0,"136,168",66
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"4,359.08",0.2,0.0,182,67
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",65+,F,"4,300.86",0.2,0.4,"4,800",68
7,Ontario,A06AB,Contact laxatives,65+,F,"4,299.36",0.2,9.5,"117,351",69
7,Ontario,L04AD,Calcineurin inhibitors,65+,F,"4,279.31",0.2,0.1,"1,439",70
7,Ontario,N02AB,Phenylpiperidine derivatives,65+,F,"4,195.96",0.2,0.5,"5,602",71
7,Ontario,M01AH,Coxibs,65+,F,"4,195.46",0.2,4.1,"51,076",72
7,Ontario,H02AB,Glucocorticoids,65+,F,"4,149.02",0.2,11.2,"138,849",73
7,Ontario,A06AD,Osmotically acting laxatives,65+,F,"4,068.40",0.2,5.4,"67,543",74
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"3,907.19",0.2,0.0,239,75
7,Ontario,B01AA,Vitamin K antagonists,65+,F,"3,762.28",0.2,2.8,"34,115",76
7,Ontario,C10AC,Bile acid sequestrants,65+,F,"3,624.41",0.2,0.9,"10,564",77
7,Ontario,C03AA,"Thiazides, plain",65+,F,"3,543.56",0.2,11.6,"143,593",78
7,Ontario,A06AA,"Softeners, emollients",65+,F,"3,496.76",0.2,6.5,"80,337",79
7,Ontario,N04BC,Dopamine agonists,65+,F,"3,262.42",0.2,1.0,"11,946",80
7,Ontario,M05BB,"Bisphosphonates, combinations",65+,F,"3,210.57",0.2,3.0,"36,851",81
7,Ontario,D06AX,Other antibiotics for topical use,65+,F,"3,207.19",0.2,6.7,"82,961",82
7,Ontario,L01BA,Folic acid analogues,65+,F,"3,110.91",0.2,1.3,"16,501",83
7,Ontario,J01MA,Fluoroquinolones,65+,F,"3,081.10",0.2,10.5,"130,383",84
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,F,"3,080.21",0.2,0.1,716,85
7,Ontario,J01XE,Nitrofuran derivatives,65+,F,"3,003.09",0.2,9.1,"113,386",86
7,Ontario,S01EC,Carbonic anhydrase inhibitors,65+,F,"2,933.55",0.2,1.3,"16,036",87
7,Ontario,A04AD,Other antiemetics,65+,F,"2,660.26",0.1,0.5,"6,193",88
7,Ontario,M01AB,Acetic acid derivatives and related substances,65+,F,"2,642.39",0.1,3.0,"37,799",89
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",65+,F,"2,587.67",0.1,0.6,"7,917",90
7,Ontario,D05AX,Other antipsoriatics for topical use,65+,F,"2,569.39",0.1,0.7,"9,075",91
7,Ontario,C10AB,Fibrates,65+,F,"2,530.16",0.1,0.9,"11,745",92
7,Ontario,J01FA,Macrolides,65+,F,"2,476.95",0.1,9.8,"121,284",93
7,Ontario,A03FA,Propulsives,65+,F,"2,457.38",0.1,3.0,"37,471",94
7,Ontario,J01CA,Penicillins with extended spectrum,65+,F,"2,439.34",0.1,14.1,"174,941",95
7,Ontario,C10BX,"HMG-CoA reductase inhibitors, other combinations",65+,F,"2,405.76",0.1,0.8,"9,946",96
7,Ontario,C07AG,Alpha- and beta-blocking agents,65+,F,"2,403.30",0.1,0.7,"8,417",97
7,Ontario,M04AA,Preparations inhibiting uric acid production,65+,F,"2,403.23",0.1,2.4,"30,268",98
7,Ontario,C01AA,Digitalis glycosides,65+,F,"2,338.91",0.1,1.6,"19,476",99
7,Ontario,S01BA,"Corticosteroids, plain",65+,F,"2,320.65",0.1,5.2,"63,998",100
7,Ontario,J05AP,Antivirals for treatment of HCV infections,<65,Total,"258,113.60",12.7,0.5,"4,492",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"163,100.90",8.0,1.0,"8,819",2
7,Ontario,N05AX,Other antipsychotics,<65,Total,"118,205.40",5.8,7.0,"63,769",3
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"89,336.66",4.4,1.0,"8,816",4
7,Ontario,N07BC,Drugs used in opioid dependence,<65,Total,"77,312.46",3.8,4.2,"37,921",5
7,Ontario,L04AA,Selective immunosuppressants,<65,Total,"63,570.78",3.1,0.9,"7,786",6
7,Ontario,N02AA,Natural opium alkaloids,<65,Total,"47,258.08",2.3,7.2,"65,487",7
7,Ontario,N03AX,Other antiepileptics,<65,Total,"44,774.85",2.2,11.6,"105,704",8
7,Ontario,N06AX,Other antidepressants,<65,Total,"40,774.29",2.0,16.9,"154,004",9
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"40,696.80",2.0,9.5,"86,758",10
7,Ontario,L01XE,Protein kinase inhibitors,<65,Total,"40,425.86",2.0,0.1,"1,288",11
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"32,030.36",1.6,16.5,"150,122",12
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"31,107.68",1.5,6.2,"56,842",13
7,Ontario,L04AX,Other immunosuppressants,<65,Total,"30,236.93",1.5,0.4,"3,631",14
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"29,345.00",1.4,3.6,"33,130",15
7,Ontario,N06BA,Centrally acting sympathomimetics,<65,Total,"25,795.08",1.3,4.7,"42,462",16
7,Ontario,A02BC,Proton pump inhibitors,<65,Total,"23,904.22",1.2,20.7,"188,950",17
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"23,079.35",1.1,3.0,"27,795",18
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,Total,"21,686.62",1.1,1.1,"10,376",19
7,Ontario,S01LA,Antineovascularization agents,<65,Total,"20,699.03",1.0,0.3,"2,372",20
7,Ontario,C10AA,HMG-CoA reductase inhibitors,<65,Total,"20,423.13",1.0,17.2,"157,149",21
7,Ontario,L04AC,Interleukin inhibitors,<65,Total,"19,644.71",1.0,0.1,"1,364",22
7,Ontario,L04AD,Calcineurin inhibitors,<65,Total,"19,069.88",0.9,0.6,"5,521",23
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"18,843.34",0.9,2.5,"23,212",24
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"18,146.75",0.9,2.8,"25,866",25
7,Ontario,L03AA,Colony-stimulating factors,<65,Total,"16,882.07",0.8,0.3,"3,017",26
7,Ontario,A16AB,Enzymes,<65,Total,"16,305.51",0.8,0.0,30,27
7,Ontario,C09AA,"ACE inhibitors, plain",<65,Total,"15,370.64",0.8,9.2,"84,092",28
7,Ontario,J05AX,Other antivirals,<65,Total,"14,100.79",0.7,0.2,"2,108",29
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"14,090.83",0.7,16.2,"147,672",30
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"13,952.32",0.7,2.6,"24,051",31
7,Ontario,R03BA,Glucocorticoids,<65,Total,"12,801.77",0.6,8.1,"73,580",32
7,Ontario,L03AB,Interferons,<65,Total,"12,670.10",0.6,0.1,797,33
7,Ontario,J05AE,Protease inhibitors,<65,Total,"12,474.96",0.6,0.2,"1,815",34
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"12,164.13",0.6,0.3,"3,096",35
7,Ontario,A04AD,Other antiemetics,<65,Total,"11,417.02",0.6,1.6,"14,580",36
7,Ontario,H01AC,Somatropin and somatropin agonists,<65,Total,"11,116.13",0.5,0.1,930,37
7,Ontario,R03BB,Anticholinergics,<65,Total,"10,680.49",0.5,3.4,"30,665",38
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"10,492.86",0.5,0.4,"3,265",39
7,Ontario,B01AB,Heparin group,<65,Total,"10,405.44",0.5,0.5,"4,819",40
7,Ontario,N05AE,Indole derivatives,<65,Total,"9,855.21",0.5,0.9,"8,133",41
7,Ontario,N07XX,Other nervous system drugs,<65,Total,"9,775.81",0.5,0.1,695,42
7,Ontario,N05BA,Benzodiazepine derivatives,<65,Total,"9,161.27",0.5,9.9,"90,510",43
7,Ontario,N03AG,Fatty acid derivatives,<65,Total,"9,006.70",0.4,2.7,"24,303",44
7,Ontario,N03AE,Benzodiazepine derivatives,<65,Total,"8,612.44",0.4,5.9,"54,170",45
7,Ontario,L03AX,Other immunostimulants,<65,Total,"8,537.71",0.4,0.1,703,46
7,Ontario,H01CB,Somatostatin and analogues,<65,Total,"7,777.73",0.4,0.1,572,47
7,Ontario,C08CA,Dihydropyridine derivatives,<65,Total,"7,714.19",0.4,6.3,"57,183",48
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"7,376.52",0.4,18.2,"165,878",49
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"7,246.14",0.4,5.1,"46,960",50
7,Ontario,V03AC,Iron-chelating agents,<65,Total,"6,979.17",0.3,0.0,290,51
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"6,665.87",0.3,0.0,383,52
7,Ontario,R07AX,Other respiratory system products,<65,Total,"6,015.94",0.3,0.0,22,53
7,Ontario,B01AF,Direct factor Xa inhibitors,<65,Total,"5,932.24",0.3,1.1,"9,940",54
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"5,927.08",0.3,1.6,"14,664",55
7,Ontario,V06,General nutrients,<65,Total,"5,772.59",0.3,0.0,190,56
7,Ontario,A10BA,Biguanides,<65,Total,"5,534.21",0.3,7.6,"69,684",57
7,Ontario,C09CA,"Angiotensin II antagonists, plain",<65,Total,"5,337.90",0.3,4.4,"40,486",58
7,Ontario,N02AB,Phenylpiperidine derivatives,<65,Total,"5,281.67",0.3,0.5,"4,671",59
7,Ontario,M01AE,Propionic acid derivatives,<65,Total,"5,170.64",0.3,15.0,"136,868",60
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,"5,155.55",0.3,0.2,"2,011",61
7,Ontario,H03AA,Thyroid hormones,<65,Total,"5,052.72",0.2,7.1,"64,361",62
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,<65,Total,"4,977.65",0.2,2.0,"18,527",63
7,Ontario,N03AF,Carboxamide derivatives,<65,Total,"4,895.06",0.2,1.3,"11,916",64
7,Ontario,M03BX,Other centrally acting agents,<65,Total,"4,864.44",0.2,4.6,"42,222",65
7,Ontario,R01AD,Corticosteroids,<65,Total,"4,793.08",0.2,8.6,"78,491",66
7,Ontario,C07AB,"Beta-blocking agents, selective",<65,Total,"4,676.37",0.2,6.3,"57,828",67
7,Ontario,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,Total,"4,486.42",0.2,0.1,"1,170",68
7,Ontario,C09BA,ACE inhibitors and diuretics,<65,Total,"4,017.52",0.2,1.7,"15,692",69
7,Ontario,J01CA,Penicillins with extended spectrum,<65,Total,"3,946.62",0.2,20.2,"184,093",70
7,Ontario,A07EC,Aminosalicylic acid and similar agents,<65,Total,"3,781.92",0.2,0.6,"5,703",71
7,Ontario,M05BA,Bisphosphonates,<65,Total,"3,642.19",0.2,1.5,"13,792",72
7,Ontario,A02BA,H2-receptor antagonists,<65,Total,"3,623.52",0.2,4.3,"39,068",73
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,"3,585.99",0.2,0.5,"4,546",74
7,Ontario,L01XC,Monoclonal antibodies,<65,Total,"3,578.50",0.2,0.0,328,75
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"3,495.63",0.2,0.0,174,76
7,Ontario,J02AC,Triazole derivatives,<65,Total,"3,426.46",0.2,1.4,"12,324",77
7,Ontario,A09AA,Enzyme preparations,<65,Total,"3,257.10",0.2,0.3,"2,480",78
7,Ontario,D05AX,Other antipsoriatics for topical use,<65,Total,"3,225.63",0.2,0.7,"6,325",79
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,<65,Total,"3,126.52",0.2,0.9,"7,936",80
7,Ontario,A10BB,Sulfonylureas,<65,Total,"3,072.08",0.2,3.4,"30,696",81
7,Ontario,A06AB,Contact laxatives,<65,Total,"3,005.69",0.1,5.8,"53,045",82
7,Ontario,D07AC,"Corticosteroids, potent (group III)",<65,Total,"2,988.34",0.1,8.5,"77,537",83
7,Ontario,N07BA,Drugs used in nicotine dependence,<65,Total,"2,920.38",0.1,1.4,"12,386",84
7,Ontario,D06AX,Other antibiotics for topical use,<65,Total,"2,876.34",0.1,6.6,"60,581",85
7,Ontario,A04AA,Serotonin (5HT3) antagonists,<65,Total,"2,865.52",0.1,0.9,"8,628",86
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,Total,"2,844.30",0.1,0.6,"5,537",87
7,Ontario,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"2,700.64",0.1,2.9,"26,605",88
7,Ontario,J01FA,Macrolides,<65,Total,"2,596.80",0.1,10.7,"97,694",89
7,Ontario,A06AA,"Softeners, emollients",<65,Total,"2,596.33",0.1,4.4,"40,038",90
7,Ontario,N05AF,Thioxanthene derivatives,<65,Total,"2,558.78",0.1,0.4,"3,588",91
7,Ontario,N02BE,Anilides,<65,Total,"2,492.97",0.1,7.9,"71,922",92
7,Ontario,B03AA,"Iron bivalent, oral preparations",<65,Total,"2,453.51",0.1,4.4,"40,468",93
7,Ontario,H02AB,Glucocorticoids,<65,Total,"2,429.97",0.1,8.2,"74,932",94
7,Ontario,J01GB,Other aminoglycosides,<65,Total,"2,419.08",0.1,0.1,524,95
7,Ontario,J01DB,First-generation cephalosporins,<65,Total,"2,393.66",0.1,7.1,"65,197",96
7,Ontario,C01CA,Adrenergic and dopaminergic agents,<65,Total,"2,389.21",0.1,1.2,"11,219",97
7,Ontario,L01AX,Other alkylating agents,<65,Total,"2,378.83",0.1,0.0,337,98
7,Ontario,M01AB,Acetic acid derivatives and related substances,<65,Total,"2,312.96",0.1,3.4,"31,106",99
7,Ontario,G02BA,Intrauterine contraceptives,<65,Total,"2,281.10",0.1,0.7,"5,956",100
7,Ontario,J05AP,Antivirals for treatment of HCV infections,<65,M,"162,600.40",15.0,0.7,"2,827",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"84,843.19",7.9,1.0,"4,297",2
7,Ontario,N05AX,Other antipsychotics,<65,M,"73,303.23",6.8,8.2,"35,099",3
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"67,512.17",6.2,1.6,"6,665",4
7,Ontario,N07BC,Drugs used in opioid dependence,<65,M,"43,997.90",4.1,5.1,"21,729",5
7,Ontario,L01XE,Protein kinase inhibitors,<65,M,"25,162.59",2.3,0.2,730,6
7,Ontario,N02AA,Natural opium alkaloids,<65,M,"24,761.81",2.3,6.9,"29,498",7
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"24,315.13",2.3,10.7,"45,521",8
7,Ontario,N03AX,Other antiepileptics,<65,M,"20,646.57",1.9,10.5,"44,746",9
7,Ontario,L04AA,Selective immunosuppressants,<65,M,"19,161.83",1.8,0.8,"3,286",10
7,Ontario,L04AX,Other immunosuppressants,<65,M,"16,780.87",1.6,0.4,"1,557",11
7,Ontario,N06AX,Other antidepressants,<65,M,"16,380.20",1.5,14.8,"62,937",12
7,Ontario,N06BA,Centrally acting sympathomimetics,<65,M,"16,295.03",1.5,6.2,"26,395",13
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"14,807.09",1.4,3.9,"16,834",14
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,<65,M,"13,745.82",1.3,14.0,"59,778",15
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"12,927.31",1.2,5.2,"22,136",16
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,M,"12,647.54",1.2,1.4,"5,989",17
7,Ontario,A16AB,Enzymes,<65,M,"12,115.56",1.1,0.0,20,18
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"12,115.06",1.1,3.4,"14,693",19
7,Ontario,L04AD,Calcineurin inhibitors,<65,M,"11,665.86",1.1,0.8,"3,360",20
7,Ontario,S01LA,Antineovascularization agents,<65,M,"11,259.76",1.0,0.3,"1,307",21
7,Ontario,J05AX,Other antivirals,<65,M,"10,943.87",1.0,0.4,"1,576",22
7,Ontario,C10AA,HMG-CoA reductase inhibitors,<65,M,"10,896.74",1.0,19.6,"83,524",23
7,Ontario,A02BC,Proton pump inhibitors,<65,M,"10,473.98",1.0,18.9,"80,733",24
7,Ontario,J05AE,Protease inhibitors,<65,M,"9,717.70",0.9,0.3,"1,368",25
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,"9,180.51",0.8,2.7,"11,475",26
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"9,138.90",0.8,3.1,"13,097",27
7,Ontario,L04AC,Interleukin inhibitors,<65,M,"8,891.54",0.8,0.1,586,28
7,Ontario,C09AA,"ACE inhibitors, plain",<65,M,"8,593.65",0.8,11.0,"47,079",29
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"8,005.04",0.7,0.5,"2,042",30
7,Ontario,H01AC,Somatropin and somatropin agonists,<65,M,"7,430.75",0.7,0.1,581,31
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"7,277.59",0.7,2.9,"12,178",32
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"6,634.64",0.6,15.3,"65,387",33
7,Ontario,A04AD,Other antiemetics,<65,M,"5,410.20",0.5,1.4,"6,134",34
7,Ontario,R03BA,Glucocorticoids,<65,M,"5,386.88",0.5,7.3,"31,038",35
7,Ontario,N03AG,Fatty acid derivatives,<65,M,"5,263.09",0.5,3.1,"13,342",36
7,Ontario,R03BB,Anticholinergics,<65,M,"5,215.57",0.5,3.4,"14,478",37
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"4,936.67",0.5,0.3,"1,473",38
7,Ontario,L03AA,Colony-stimulating factors,<65,M,"4,453.01",0.4,0.2,854,39
7,Ontario,B01AB,Heparin group,<65,M,"4,421.01",0.4,0.5,"2,097",40
7,Ontario,N05BA,Benzodiazepine derivatives,<65,M,"4,396.29",0.4,8.8,"37,378",41
7,Ontario,N03AE,Benzodiazepine derivatives,<65,M,"4,182.41",0.4,5.4,"22,943",42
7,Ontario,N05AE,Indole derivatives,<65,M,"4,168.94",0.4,0.8,"3,295",43
7,Ontario,H01CB,Somatostatin and analogues,<65,M,"4,011.50",0.4,0.1,245,44
7,Ontario,C08CA,Dihydropyridine derivatives,<65,M,"3,986.20",0.4,6.9,"29,357",45
7,Ontario,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,"3,767.65",0.3,0.2,952,46
7,Ontario,L03AB,Interferons,<65,M,"3,577.52",0.3,0.1,236,47
7,Ontario,B01AF,Direct factor Xa inhibitors,<65,M,"3,494.26",0.3,1.3,"5,363",48
7,Ontario,N07XX,Other nervous system drugs,<65,M,"3,435.09",0.3,0.1,255,49
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"3,301.96",0.3,16.4,"70,028",50
7,Ontario,V03AC,Iron-chelating agents,<65,M,"3,259.46",0.3,0.0,133,51
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"3,075.05",0.3,4.1,"17,344",52
7,Ontario,G03BA,3-oxoandrosten (4) derivatives,<65,M,"3,069.19",0.3,1.8,"7,571",53
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"2,986.20",0.3,2.2,"9,544",54
7,Ontario,A10BA,Biguanides,<65,M,"2,724.94",0.3,8.0,"33,903",55
7,Ontario,C07AB,"Beta-blocking agents, selective",<65,M,"2,686.49",0.2,7.7,"32,944",56
7,Ontario,R07AX,Other respiratory system products,<65,M,"2,671.92",0.2,0.0,9,57
7,Ontario,N03AF,Carboxamide derivatives,<65,M,"2,662.96",0.2,1.4,"6,117",58
7,Ontario,L03AX,Other immunostimulants,<65,M,"2,546.68",0.2,0.0,191,59
7,Ontario,V06,General nutrients,<65,M,"2,431.95",0.2,0.0,74,60
7,Ontario,C09CA,"Angiotensin II antagonists, plain",<65,M,"2,425.50",0.2,4.3,"18,445",61
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,<65,M,"2,392.92",0.2,0.2,778,62
7,Ontario,N02AB,Phenylpiperidine derivatives,<65,M,"2,365.42",0.2,0.5,"2,011",63
7,Ontario,M03BX,Other centrally acting agents,<65,M,"2,163.80",0.2,4.1,"17,286",64
7,Ontario,M01AE,Propionic acid derivatives,<65,M,"2,161.89",0.2,13.2,"56,108",65
7,Ontario,C09BA,ACE inhibitors and diuretics,<65,M,"2,139.11",0.2,1.9,"8,205",66
7,Ontario,R01AD,Corticosteroids,<65,M,"2,023.38",0.2,7.3,"31,171",67
7,Ontario,J02AC,Triazole derivatives,<65,M,"1,963.66",0.2,0.3,"1,339",68
7,Ontario,G04CA,Alpha-adrenoreceptor antagonists,<65,M,"1,866.09",0.2,3.3,"13,978",69
7,Ontario,A07EC,Aminosalicylic acid and similar agents,<65,M,"1,857.02",0.2,0.6,"2,429",70
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,"1,840.24",0.2,0.5,"2,335",71
7,Ontario,A09AA,Enzyme preparations,<65,M,"1,812.55",0.2,0.3,"1,267",72
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,"1,772.03",0.2,0.0,98,73
7,Ontario,D05AX,Other antipsoriatics for topical use,<65,M,"1,730.59",0.2,0.8,"3,214",74
7,Ontario,J01CA,Penicillins with extended spectrum,<65,M,"1,703.52",0.2,18.6,"79,101",75
7,Ontario,N05AF,Thioxanthene derivatives,<65,M,"1,683.49",0.2,0.5,"2,280",76
7,Ontario,L02BX,Other hormone antagonists and related agents,<65,M,"1,673.18",0.2,0.0,129,77
7,Ontario,L01AX,Other alkylating agents,<65,M,"1,613.54",0.1,0.0,209,78
7,Ontario,A02BA,H2-receptor antagonists,<65,M,"1,606.97",0.1,3.7,"15,569",79
7,Ontario,A10BB,Sulfonylureas,<65,M,"1,581.72",0.1,3.8,"16,087",80
7,Ontario,L02BB,Antiandrogens,<65,M,"1,487.99",0.1,0.1,241,81
7,Ontario,N07BA,Drugs used in nicotine dependence,<65,M,"1,396.04",0.1,1.4,"5,910",82
7,Ontario,J01GB,Other aminoglycosides,<65,M,"1,349.06",0.1,0.1,281,83
7,Ontario,D07AC,"Corticosteroids, potent (group III)",<65,M,"1,337.20",0.1,7.6,"32,232",84
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,<65,M,"1,327.74",0.1,1.2,"5,302",85
7,Ontario,H03AA,Thyroid hormones,<65,M,"1,320.82",0.1,3.6,"15,423",86
7,Ontario,A06AB,Contact laxatives,<65,M,"1,312.25",0.1,5.3,"22,645",87
7,Ontario,D06AX,Other antibiotics for topical use,<65,M,"1,265.68",0.1,6.1,"26,157",88
7,Ontario,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,"1,225.82",0.1,0.6,"2,598",89
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,M,"1,214.77",0.1,0.5,"2,168",90
7,Ontario,N03AB,Hydantoin derivatives,<65,M,"1,178.75",0.1,1.1,"4,787",91
7,Ontario,N04AC,Ethers of tropine or tropine derivatives,<65,M,"1,158.82",0.1,1.4,"6,059",92
7,Ontario,A06AA,"Softeners, emollients",<65,M,"1,151.71",0.1,3.9,"16,516",93
7,Ontario,J01DB,First-generation cephalosporins,<65,M,"1,140.01",0.1,7.0,"29,735",94
7,Ontario,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,"1,098.91",0.1,0.9,"3,647",95
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,"1,091.59",0.1,0.0,59,96
7,Ontario,M01AB,Acetic acid derivatives and related substances,<65,M,"1,074.93",0.1,3.3,"14,049",97
7,Ontario,A04AA,Serotonin (5HT3) antagonists,<65,M,"1,074.18",0.1,0.8,"3,328",98
7,Ontario,C10AB,Fibrates,<65,M,"1,069.33",0.1,1.1,"4,607",99
7,Ontario,J01FA,Macrolides,<65,M,"1,069.14",0.1,9.0,"38,177",100
7,Ontario,J05AP,Antivirals for treatment of HCV infections,<65,F,"95,378.53",10.1,0.3,"1,663",1
7,Ontario,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"78,223.15",8.3,0.9,"4,519",2
7,Ontario,N05AX,Other antipsychotics,<65,F,"44,728.57",4.7,5.9,"28,587",3
7,Ontario,L04AA,Selective immunosuppressants,<65,F,"44,389.03",4.7,0.9,"4,493",4
7,Ontario,N07BC,Drugs used in opioid dependence,<65,F,"33,281.72",3.5,3.3,"16,170",5
7,Ontario,N06AX,Other antidepressants,<65,F,"24,348.16",2.6,18.8,"90,782",6
7,Ontario,N03AX,Other antiepileptics,<65,F,"24,076.57",2.6,12.6,"60,787",7
7,Ontario,N02AA,Natural opium alkaloids,<65,F,"22,487.26",2.4,7.4,"35,907",8
7,Ontario,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"20,782.58",2.2,0.4,"2,060",9
7,Ontario,N06AB,Selective serotonin reuptake inhibitors,<65,F,"18,236.76",1.9,18.6,"90,011",10
7,Ontario,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"18,134.26",1.9,7.2,"34,610",11
7,Ontario,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"16,329.47",1.7,8.5,"41,097",12
7,Ontario,L01XE,Protein kinase inhibitors,<65,F,"15,263.26",1.6,0.1,558,13
7,Ontario,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"14,493.25",1.5,3.4,"16,233",14
7,Ontario,L04AX,Other immunosuppressants,<65,F,"13,455.54",1.4,0.4,"2,069",15
7,Ontario,A02BC,Proton pump inhibitors,<65,F,"13,382.54",1.4,22.3,"107,636",16
7,Ontario,L03AA,Colony-stimulating factors,<65,F,"12,421.69",1.3,0.4,"2,162",17
7,Ontario,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"10,891.65",1.2,2.7,"13,017",18
7,Ontario,L04AC,Interleukin inhibitors,<65,F,"10,753.17",1.1,0.2,778,19
7,Ontario,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,"9,612.80",1.0,2.4,"11,675",20
7,Ontario,N06BA,Centrally acting sympathomimetics,<65,F,"9,484.41",1.0,3.3,"16,031",21
7,Ontario,C10AA,HMG-CoA reductase inhibitors,<65,F,"9,472.94",1.0,15.2,"73,214",22
7,Ontario,S01LA,Antineovascularization agents,<65,F,"9,439.27",1.0,0.2,"1,065",23
7,Ontario,L03AB,Interferons,<65,F,"9,092.57",1.0,0.1,561,24
7,Ontario,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,F,"9,025.28",1.0,0.9,"4,380",25
7,Ontario,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"8,967.23",1.0,2.6,"12,717",26
7,Ontario,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"7,440.71",0.8,17.0,"81,962",27
7,Ontario,L04AD,Calcineurin inhibitors,<65,F,"7,399.48",0.8,0.4,"2,159",28
7,Ontario,R03BA,Glucocorticoids,<65,F,"7,384.26",0.8,8.8,"42,320",29
7,Ontario,C09AA,"ACE inhibitors, plain",<65,F,"6,737.81",0.7,7.6,"36,778",30
7,Ontario,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"6,655.91",0.7,2.5,"11,833",31
7,Ontario,N07XX,Other nervous system drugs,<65,F,"6,340.72",0.7,0.1,440,32
7,Ontario,A04AD,Other antiemetics,<65,F,"5,998.72",0.6,1.7,"8,437",33
7,Ontario,L03AX,Other immunostimulants,<65,F,"5,991.03",0.6,0.1,512,34
7,Ontario,B01AB,Heparin group,<65,F,"5,962.24",0.6,0.6,"2,713",35
7,Ontario,N05AE,Indole derivatives,<65,F,"5,674.03",0.6,1.0,"4,828",36
7,Ontario,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"5,550.25",0.6,0.4,"1,788",37
7,Ontario,R03BB,Anticholinergics,<65,F,"5,454.94",0.6,3.3,"16,149",38
7,Ontario,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"4,893.84",0.5,0.1,285,39
7,Ontario,N05BA,Benzodiazepine derivatives,<65,F,"4,755.91",0.5,11.0,"52,970",40
7,Ontario,N03AE,Benzodiazepine derivatives,<65,F,"4,422.25",0.5,6.4,"31,149",41
7,Ontario,A16AB,Enzymes,<65,F,"4,189.95",0.4,0.0,10,42
7,Ontario,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"4,163.51",0.4,6.1,"29,495",43
7,Ontario,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,"4,117.17",0.4,0.2,"1,045",44
7,Ontario,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"4,062.77",0.4,19.8,"95,446",45
7,Ontario,H01CB,Somatostatin and analogues,<65,F,"3,766.23",0.4,0.1,327,46
7,Ontario,N03AG,Fatty acid derivatives,<65,F,"3,736.65",0.4,2.3,"10,932",47
7,Ontario,H03AA,Thyroid hormones,<65,F,"3,722.68",0.4,10.1,"48,808",48
7,Ontario,V03AC,Iron-chelating agents,<65,F,"3,719.72",0.4,0.0,157,49
7,Ontario,C08CA,Dihydropyridine derivatives,<65,F,"3,696.19",0.4,5.7,"27,601",50
7,Ontario,H01AC,Somatropin and somatropin agonists,<65,F,"3,685.38",0.4,0.1,349,51
7,Ontario,G04BD,Drugs for urinary frequency and incontinence,<65,F,"3,643.53",0.4,2.7,"13,194",52
7,Ontario,R07AX,Other respiratory system products,<65,F,"3,344.02",0.4,0.0,13,53
7,Ontario,V06,General nutrients,<65,F,"3,340.65",0.4,0.0,116,54
7,Ontario,J05AX,Other antivirals,<65,F,"3,046.34",0.3,0.1,521,55
7,Ontario,M01AE,Propionic acid derivatives,<65,F,"2,993.42",0.3,16.6,"80,138",56
7,Ontario,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"2,933.15",0.3,1.1,"5,085",57
7,Ontario,N02AB,Phenylpiperidine derivatives,<65,F,"2,911.94",0.3,0.6,"2,657",58
7,Ontario,C09CA,"Angiotensin II antagonists, plain",<65,F,"2,896.08",0.3,4.5,"21,923",59
7,Ontario,A10BA,Biguanides,<65,F,"2,793.14",0.3,7.4,"35,575",60
7,Ontario,L02AE,Gonadotropin-releasing hormone analogues,<65,F,"2,756.25",0.3,0.3,"1,229",61
7,Ontario,R01AD,Corticosteroids,<65,F,"2,751.89",0.3,9.7,"46,991",62
7,Ontario,L01XC,Monoclonal antibodies,<65,F,"2,719.53",0.3,0.1,243,63
7,Ontario,M03BX,Other centrally acting agents,<65,F,"2,694.39",0.3,5.1,"24,793",64
7,Ontario,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"2,692.89",0.3,5.5,"26,499",65
7,Ontario,J05AE,Protease inhibitors,<65,F,"2,668.55",0.3,0.1,432,66
7,Ontario,M05BA,Bisphosphonates,<65,F,"2,577.47",0.3,2.1,"10,169",67
7,Ontario,B01AF,Direct factor Xa inhibitors,<65,F,"2,429.26",0.3,0.9,"4,564",68
7,Ontario,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"2,404.04",0.3,0.0,115,69
7,Ontario,G02BA,Intrauterine contraceptives,<65,F,"2,273.45",0.2,1.2,"5,936",70
7,Ontario,N03AF,Carboxamide derivatives,<65,F,"2,227.19",0.2,1.2,"5,779",71
7,Ontario,J01CA,Penicillins with extended spectrum,<65,F,"2,224.96",0.2,21.6,"104,172",72
7,Ontario,A02BA,H2-receptor antagonists,<65,F,"2,008.87",0.2,4.8,"23,345",73
7,Ontario,C07AB,"Beta-blocking agents, selective",<65,F,"1,974.53",0.2,5.1,"24,713",74
7,Ontario,A07EC,Aminosalicylic acid and similar agents,<65,F,"1,922.59",0.2,0.7,"3,269",75
7,Ontario,C09BA,ACE inhibitors and diuretics,<65,F,"1,861.50",0.2,1.5,"7,418",76
7,Ontario,A04AA,Serotonin (5HT3) antagonists,<65,F,"1,790.62",0.2,1.1,"5,295",77
7,Ontario,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,"1,737.95",0.2,0.5,"2,197",78
7,Ontario,B03AA,"Iron bivalent, oral preparations",<65,F,"1,703.07",0.2,6.2,"30,154",79
7,Ontario,A06AB,Contact laxatives,<65,F,"1,688.50",0.2,6.3,"30,294",80
7,Ontario,D07AC,"Corticosteroids, potent (group III)",<65,F,"1,639.61",0.2,9.3,"45,000",81
7,Ontario,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,F,"1,626.84",0.2,0.7,"3,351",82
7,Ontario,D06AX,Other antibiotics for topical use,<65,F,"1,602.81",0.2,7.1,"34,236",83
7,Ontario,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,"1,590.50",0.2,2.2,"10,694",84
7,Ontario,N07BA,Drugs used in nicotine dependence,<65,F,"1,521.42",0.2,1.3,"6,461",85
7,Ontario,J01FA,Macrolides,<65,F,"1,515.81",0.2,12.2,"59,150",86
7,Ontario,D05AX,Other antipsoriatics for topical use,<65,F,"1,483.79",0.2,0.6,"3,089",87
7,Ontario,A10BB,Sulfonylureas,<65,F,"1,481.38",0.2,3.0,"14,518",88
7,Ontario,J02AC,Triazole derivatives,<65,F,"1,460.45",0.2,2.3,"10,949",89
7,Ontario,A09AA,Enzyme preparations,<65,F,"1,441.60",0.2,0.3,"1,211",90
7,Ontario,A06AA,"Softeners, emollients",<65,F,"1,440.30",0.2,4.9,"23,425",91
7,Ontario,N02BE,Anilides,<65,F,"1,426.68",0.2,8.5,"41,220",92
7,Ontario,H02AB,Glucocorticoids,<65,F,"1,395.40",0.1,9.2,"44,378",93
7,Ontario,C01CA,Adrenergic and dopaminergic agents,<65,F,"1,323.51",0.1,1.4,"6,558",94
7,Ontario,M01AH,Coxibs,<65,F,"1,291.82",0.1,2.6,"12,746",95
7,Ontario,J01DB,First-generation cephalosporins,<65,F,"1,247.02",0.1,7.3,"35,292",96
7,Ontario,M01AB,Acetic acid derivatives and related substances,<65,F,"1,229.96",0.1,3.5,"16,917",97
7,Ontario,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,"1,218.56",0.1,1.8,"8,769",98
7,Ontario,M05BX,Other drugs affecting bone structure and mineralization,<65,F,"1,192.62",0.1,0.4,"1,965",99
7,Ontario,R06AA,Aminoalkyl ethers,<65,F,"1,174.38",0.1,1.2,"5,936",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"71,805.45",20.5,0.4,"3,009",1
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,Total,Total,"16,952.58",4.8,0.0,298,2
8,Manitoba,L01XE,Protein kinase inhibitors,Total,Total,"15,468.94",4.4,0.1,553,3
8,Manitoba,L04AX,Other immunosuppressants,Total,Total,"11,894.39",3.4,0.3,"2,248",4
8,Manitoba,L04AA,Selective immunosuppressants,Total,Total,"8,207.58",2.3,0.2,"1,779",5
8,Manitoba,N05AX,Other antipsychotics,Total,Total,"7,639.33",2.2,1.4,"11,468",6
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"7,353.59",2.1,4.0,"33,429",7
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"7,157.14",2.0,2.3,"19,334",8
8,Manitoba,N02AA,Natural opium alkaloids,Total,Total,"6,392.97",1.8,2.1,"17,717",9
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"6,306.09",1.8,0.1,900,10
8,Manitoba,A02BC,Proton pump inhibitors,Total,Total,"5,850.64",1.7,14.6,"122,604",11
8,Manitoba,N03AX,Other antiepileptics,Total,Total,"5,646.86",1.6,4.4,"37,200",12
8,Manitoba,L04AC,Interleukin inhibitors,Total,Total,"5,299.10",1.5,0.0,405,13
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,Total,Total,"5,128.25",1.5,16.7,"140,087",14
8,Manitoba,N06AX,Other antidepressants,Total,Total,"5,058.01",1.4,6.8,"56,758",15
8,Manitoba,L03AB,Interferons,Total,Total,"4,843.85",1.4,0.0,308,16
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"4,606.19",1.3,9.8,"81,854",17
8,Manitoba,C09AA,"ACE inhibitors, plain",Total,Total,"4,192.98",1.2,9.9,"82,546",18
8,Manitoba,C08CA,Dihydropyridine derivatives,Total,Total,"3,444.33",1.0,8.3,"69,063",19
8,Manitoba,B01AF,Direct factor Xa inhibitors,Total,Total,"3,260.56",0.9,1.4,"11,358",20
8,Manitoba,H01CB,Somatostatin and analogues,Total,Total,"3,164.98",0.9,0.0,149,21
8,Manitoba,A16AB,Enzymes,Total,Total,"3,115.03",0.9,0.0,8,22
8,Manitoba,L03AX,Other immunostimulants,Total,Total,"2,874.62",0.8,0.0,300,23
8,Manitoba,N06BA,Centrally acting sympathomimetics,Total,Total,"2,840.25",0.8,1.8,"15,317",24
8,Manitoba,B02AB,Proteinase inhibitors,Total,Total,"2,650.55",0.8,0.0,21,25
8,Manitoba,L02BX,Other hormone antagonists and related agents,Total,Total,"2,592.57",0.7,0.0,91,26
8,Manitoba,J05AE,Protease inhibitors,Total,Total,"2,420.21",0.7,0.0,399,27
8,Manitoba,L02BB,Antiandrogens,Total,Total,"2,410.15",0.7,0.1,"1,005",28
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"2,408.05",0.7,13.3,"111,346",29
8,Manitoba,C07AB,"Beta-blocking agents, selective",Total,Total,"2,389.65",0.7,7.6,"63,857",30
8,Manitoba,L04AD,Calcineurin inhibitors,Total,Total,"2,305.78",0.7,0.1,739,31
8,Manitoba,B01AB,Heparin group,Total,Total,"2,274.56",0.6,0.2,"2,053",32
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"2,262.59",0.6,1.2,"10,224",33
8,Manitoba,N07BC,Drugs used in opioid dependence,Total,Total,"2,240.51",0.6,0.2,"1,694",34
8,Manitoba,R03BB,Anticholinergics,Total,Total,"2,124.90",0.6,1.8,"15,036",35
8,Manitoba,H03AA,Thyroid hormones,Total,Total,"2,091.34",0.6,9.7,"81,084",36
8,Manitoba,A10BA,Biguanides,Total,Total,"2,031.33",0.6,7.5,"62,430",37
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"2,004.18",0.6,0.5,"4,595",38
8,Manitoba,N07XX,Other nervous system drugs,Total,Total,"1,973.93",0.6,0.0,238,39
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"1,934.42",0.6,0.0,141,40
8,Manitoba,A04AD,Other antiemetics,Total,Total,"1,911.72",0.5,0.4,"3,037",41
8,Manitoba,N05BA,Benzodiazepine derivatives,Total,Total,"1,880.95",0.5,6.7,"56,473",42
8,Manitoba,N05CF,Benzodiazepine-related drugs,Total,Total,"1,851.41",0.5,5.7,"47,977",43
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"1,594.79",0.5,0.5,"4,139",44
8,Manitoba,C03CA,"Sulfonamides, plain",Total,Total,"1,562.88",0.4,3.6,"30,130",45
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"1,549.85",0.4,2.3,"18,841",46
8,Manitoba,L01XC,Monoclonal antibodies,Total,Total,"1,525.51",0.4,0.0,149,47
8,Manitoba,R03BA,Glucocorticoids,Total,Total,"1,512.05",0.4,3.5,"29,496",48
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,Total,Total,"1,502.05",0.4,0.7,"5,491",49
8,Manitoba,N03AE,Benzodiazepine derivatives,Total,Total,"1,453.87",0.4,2.3,"18,895",50
8,Manitoba,C09CA,"Angiotensin II antagonists, plain",Total,Total,"1,449.91",0.4,5.7,"47,391",51
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,417.11",0.4,11.2,"94,110",52
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,407.13",0.4,3.1,"26,316",53
8,Manitoba,A10BB,Sulfonylureas,Total,Total,"1,393.22",0.4,3.7,"30,667",54
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"1,375.72",0.4,1.0,"8,155",55
8,Manitoba,L02BG,Aromatase inhibitors,Total,Total,"1,258.59",0.4,0.5,"4,144",56
8,Manitoba,N03AG,Fatty acid derivatives,Total,Total,"1,061.42",0.3,0.5,"3,894",57
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,057.63",0.3,0.6,"5,126",58
8,Manitoba,J05AX,Other antivirals,Total,Total,"1,057.09",0.3,0.0,157,59
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,028.47",0.3,1.0,"7,959",60
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"1,027.42",0.3,0.4,"3,446",61
8,Manitoba,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,"1,007.88",0.3,0.0,333,62
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,973.68,0.3,0.1,990,63
8,Manitoba,N02AB,Phenylpiperidine derivatives,Total,Total,922.71,0.3,0.2,"1,643",64
8,Manitoba,A02BA,H2-receptor antagonists,Total,Total,907.10,0.3,3.1,"25,748",65
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,852.61,0.2,0.5,"3,965",66
8,Manitoba,C08DB,Benzothiazepine derivatives,Total,Total,823.57,0.2,1.0,"8,413",67
8,Manitoba,N04BA,Dopa and dopa derivatives,Total,Total,819.91,0.2,0.4,"3,619",68
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,808.15,0.2,2.9,"24,263",69
8,Manitoba,C09BA,ACE inhibitors and diuretics,Total,Total,806.50,0.2,1.9,"16,106",70
8,Manitoba,S01EE,Prostaglandin analogues,Total,Total,787.16,0.2,1.5,"12,862",71
8,Manitoba,H02AB,Glucocorticoids,Total,Total,784.81,0.2,6.5,"54,345",72
8,Manitoba,M03BX,Other centrally acting agents,Total,Total,764.59,0.2,3.1,"25,531",73
8,Manitoba,B01AA,Vitamin K antagonists,Total,Total,728.60,0.2,1.3,"11,180",74
8,Manitoba,R01AD,Corticosteroids,Total,Total,714.22,0.2,8.2,"68,934",75
8,Manitoba,S01ED,Beta-blocking agents,Total,Total,703.56,0.2,1.3,"10,681",76
8,Manitoba,A12BA,Potassium,Total,Total,692.69,0.2,1.2,"10,190",77
8,Manitoba,N03AF,Carboxamide derivatives,Total,Total,681.83,0.2,0.4,"3,442",78
8,Manitoba,L01AX,Other alkylating agents,Total,Total,669.74,0.2,0.0,89,79
8,Manitoba,B01AE,Direct thrombin inhibitors,Total,Total,658.90,0.2,0.2,"1,448",80
8,Manitoba,C03AA,"Thiazides, plain",Total,Total,658.71,0.2,5.0,"41,668",81
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,Total,Total,638.17,0.2,1.1,"8,795",82
8,Manitoba,M01AB,Acetic acid derivatives and related substances,Total,Total,636.13,0.2,3.8,"31,876",83
8,Manitoba,N02BE,Anilides,Total,Total,599.39,0.2,1.8,"14,959",84
8,Manitoba,H01AC,Somatropin and somatropin agonists,Total,Total,597.63,0.2,0.0,88,85
8,Manitoba,C10AB,Fibrates,Total,Total,586.25,0.2,0.8,"6,602",86
8,Manitoba,R07AX,Other respiratory system products,Total,Total,**,**,**,*,87
8,Manitoba,C01DA,Organic nitrates,Total,Total,568.20,0.2,1.5,"12,305",88
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,562.10,0.2,0.0,73,89
8,Manitoba,M01AE,Propionic acid derivatives,Total,Total,559.49,0.2,7.7,"64,656",90
8,Manitoba,L01XX,Other antineoplastic agents,Total,Total,556.22,0.2,0.1,618,91
8,Manitoba,C09DA,Angiotensin II antagonists and diuretics,Total,Total,555.80,0.2,3.0,"25,096",92
8,Manitoba,A09AA,Enzyme preparations,Total,Total,555.80,0.2,0.1,"1,019",93
8,Manitoba,M04AA,Preparations inhibiting uric acid production,Total,Total,543.50,0.2,2.3,"18,946",94
8,Manitoba,R03DC,Leukotriene receptor antagonists,Total,Total,531.25,0.2,1.4,"11,368",95
8,Manitoba,C02AC,Imidazoline receptor agonists,Total,Total,522.77,0.1,0.6,"4,664",96
8,Manitoba,J01CA,Penicillins with extended spectrum,Total,Total,505.63,0.1,18.8,"157,762",97
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,494.71,0.1,2.5,"20,852",98
8,Manitoba,M05BA,Bisphosphonates,Total,Total,493.26,0.1,0.9,"7,243",99
8,Manitoba,J01MA,Fluoroquinolones,Total,Total,489.23,0.1,6.5,"54,573",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"34,654.39",20.2,0.4,"1,377",1
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,Total,M,"11,406.09",6.6,0.1,197,2
8,Manitoba,L01XE,Protein kinase inhibitors,Total,M,"9,524.16",5.5,0.1,328,3
8,Manitoba,L04AX,Other immunosuppressants,Total,M,"7,019.67",4.1,0.3,956,4
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"4,431.06",2.6,0.1,561,5
8,Manitoba,N05AX,Other antipsychotics,Total,M,"4,400.14",2.6,1.5,"5,650",6
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"4,378.88",2.5,2.4,"8,928",7
8,Manitoba,N02AA,Natural opium alkaloids,Total,M,"3,103.01",1.8,2.0,"7,427",8
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,993.12",1.7,3.9,"14,687",9
8,Manitoba,L04AA,Selective immunosuppressants,Total,M,"2,856.34",1.7,0.2,728,10
8,Manitoba,A16AB,Enzymes,Total,M,**,**,**,**,11
8,Manitoba,L02BX,Other hormone antagonists and related agents,Total,M,"2,592.57",1.5,0.0,91,12
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,Total,M,"2,467.88",1.4,20.8,"78,730",13
8,Manitoba,L02BB,Antiandrogens,Total,M,"2,410.15",1.4,0.3,"1,005",14
8,Manitoba,N03AX,Other antiepileptics,Total,M,"2,380.39",1.4,3.9,"14,586",15
8,Manitoba,L04AC,Interleukin inhibitors,Total,M,"2,376.20",1.4,0.0,176,16
8,Manitoba,A02BC,Proton pump inhibitors,Total,M,"2,243.57",1.3,14.0,"52,990",17
8,Manitoba,C09AA,"ACE inhibitors, plain",Total,M,"1,997.66",1.2,12.2,"46,272",18
8,Manitoba,N06BA,Centrally acting sympathomimetics,Total,M,"1,851.83",1.1,2.6,"9,898",19
8,Manitoba,N06AX,Other antidepressants,Total,M,"1,828.38",1.1,5.1,"19,372",20
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,720.28",1.0,7.0,"26,634",21
8,Manitoba,J05AE,Protease inhibitors,Total,M,"1,688.94",1.0,0.1,263,22
8,Manitoba,B02AB,Proteinase inhibitors,Total,M,"1,640.35",1.0,0.0,12,23
8,Manitoba,H01CB,Somatostatin and analogues,Total,M,"1,573.19",0.9,0.0,64,24
8,Manitoba,C08CA,Dihydropyridine derivatives,Total,M,"1,428.54",0.8,8.9,"33,859",25
8,Manitoba,L04AD,Calcineurin inhibitors,Total,M,"1,410.39",0.8,0.1,457,26
8,Manitoba,B01AF,Direct factor Xa inhibitors,Total,M,"1,392.94",0.8,1.5,"5,548",27
8,Manitoba,N07BC,Drugs used in opioid dependence,Total,M,"1,205.63",0.7,0.2,929,28
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"1,200.30",0.7,1.4,"5,368",29
8,Manitoba,C07AB,"Beta-blocking agents, selective",Total,M,"1,114.21",0.6,9.1,"34,523",30
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"1,068.45",0.6,13.9,"52,612",31
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"1,043.68",0.6,0.6,"2,406",32
8,Manitoba,B01AB,Heparin group,Total,M,"1,040.72",0.6,0.2,859,33
8,Manitoba,L03AB,Interferons,Total,M,997.67,0.6,0.0,66,34
8,Manitoba,A10BA,Biguanides,Total,M,986.60,0.6,9.0,"33,922",35
8,Manitoba,R03BB,Anticholinergics,Total,M,966.54,0.6,1.9,"7,077",36
8,Manitoba,L03AX,Other immunostimulants,Total,M,857.71,0.5,0.0,84,37
8,Manitoba,J05AX,Other antivirals,Total,M,840.74,0.5,0.0,119,38
8,Manitoba,N05BA,Benzodiazepine derivatives,Total,M,809.17,0.5,5.0,"19,058",39
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,Total,M,750.82,0.4,6.1,"22,916",40
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,736.62,0.4,0.6,"2,139",41
8,Manitoba,N05CF,Benzodiazepine-related drugs,Total,M,733.97,0.4,4.7,"17,782",42
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,711.40,0.4,1.2,"4,383",43
8,Manitoba,A10BB,Sulfonylureas,Total,M,700.08,0.4,4.7,"17,702",44
8,Manitoba,A04AD,Other antiemetics,Total,M,696.12,0.4,0.3,"1,052",45
8,Manitoba,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,693.92,0.4,0.1,242,46
8,Manitoba,N07XX,Other nervous system drugs,Total,M,690.29,0.4,0.0,92,47
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,662.91,0.4,2.8,"10,746",48
8,Manitoba,C03CA,"Sulfonamides, plain",Total,M,633.37,0.4,3.5,"13,213",49
8,Manitoba,R03BA,Glucocorticoids,Total,M,619.64,0.4,3.7,"13,839",50
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,610.46,0.4,11.1,"42,187",51
8,Manitoba,N03AG,Fatty acid derivatives,Total,M,605.45,0.4,0.5,"2,024",52
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,601.55,0.4,0.0,43,53
8,Manitoba,N03AE,Benzodiazepine derivatives,Total,M,584.91,0.3,1.9,"7,064",54
8,Manitoba,H03AA,Thyroid hormones,Total,M,538.19,0.3,5.0,"19,037",55
8,Manitoba,C09CA,"Angiotensin II antagonists, plain",Total,M,522.92,0.3,5.6,"21,187",56
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,517.07,0.3,2.2,"8,309",57
8,Manitoba,N04BA,Dopa and dopa derivatives,Total,M,506.04,0.3,0.5,"1,909",58
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,483.84,0.3,0.5,"1,772",59
8,Manitoba,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,473.34,0.3,2.8,"10,637",60
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,Total,M,470.72,0.3,0.6,"2,304",61
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,Total,M,458.44,0.3,0.5,"1,898",62
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,433.82,0.3,0.6,"2,254",63
8,Manitoba,L01AX,Other alkylating agents,Total,M,417.43,0.2,0.0,48,64
8,Manitoba,C09BA,ACE inhibitors and diuretics,Total,M,393.65,0.2,2.4,"9,038",65
8,Manitoba,A02BA,H2-receptor antagonists,Total,M,392.51,0.2,2.7,"10,136",66
8,Manitoba,H01AC,Somatropin and somatropin agonists,Total,M,388.31,0.2,0.0,49,67
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,370.76,0.2,0.1,345,68
8,Manitoba,B01AA,Vitamin K antagonists,Total,M,359.65,0.2,1.7,"6,484",69
8,Manitoba,N03AF,Carboxamide derivatives,Total,M,356.60,0.2,0.4,"1,626",70
8,Manitoba,M03BX,Other centrally acting agents,Total,M,352.94,0.2,3.0,"11,483",71
8,Manitoba,H02AB,Glucocorticoids,Total,M,348.25,0.2,6.4,"24,359",72
8,Manitoba,R07AX,Other respiratory system products,Total,M,**,**,**,*,73
8,Manitoba,A09AA,Enzyme preparations,Total,M,323.87,0.2,0.1,448,74
8,Manitoba,C10AB,Fibrates,Total,M,322.55,0.2,1.1,"4,134",75
8,Manitoba,L01XC,Monoclonal antibodies,Total,M,320.23,0.2,0.0,34,76
8,Manitoba,N02AB,Phenylpiperidine derivatives,Total,M,317.17,0.2,0.2,627,77
8,Manitoba,C08DB,Benzothiazepine derivatives,Total,M,315.37,0.2,1.0,"3,824",78
8,Manitoba,M04AA,Preparations inhibiting uric acid production,Total,M,301.91,0.2,3.6,"13,696",79
8,Manitoba,B01AE,Direct thrombin inhibitors,Total,M,300.75,0.2,0.2,753,80
8,Manitoba,J05AG,Non-nucleoside reverse transcriptase inhibitors,Total,M,292.87,0.2,0.0,91,81
8,Manitoba,R01AD,Corticosteroids,Total,M,291.32,0.2,7.6,"28,644",82
8,Manitoba,S01EE,Prostaglandin analogues,Total,M,278.24,0.2,1.5,"5,545",83
8,Manitoba,M01AB,Acetic acid derivatives and related substances,Total,M,273.30,0.2,4.6,"17,479",84
8,Manitoba,C03AA,"Thiazides, plain",Total,M,257.53,0.2,4.6,"17,311",85
8,Manitoba,S01ED,Beta-blocking agents,Total,M,256.71,0.1,1.3,"4,782",86
8,Manitoba,L01XX,Other antineoplastic agents,Total,M,249.87,0.1,0.1,243,87
8,Manitoba,C01DA,Organic nitrates,Total,M,247.32,0.1,1.8,"6,841",88
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,Total,M,244.67,0.1,0.5,"1,812",89
8,Manitoba,C02AC,Imidazoline receptor agonists,Total,M,242.13,0.1,0.4,"1,694",90
8,Manitoba,R05CB,Mucolytics,Total,M,235.26,0.1,0.0,28,91
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,227.39,0.1,0.0,26,92
8,Manitoba,M01AE,Propionic acid derivatives,Total,M,225.62,0.1,7.4,"28,091",93
8,Manitoba,J01CA,Penicillins with extended spectrum,Total,M,216.31,0.1,18.8,"71,072",94
8,Manitoba,C09DA,Angiotensin II antagonists and diuretics,Total,M,214.56,0.1,3.1,"11,877",95
8,Manitoba,A12BA,Potassium,Total,M,213.78,0.1,1.0,"3,674",96
8,Manitoba,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,213.34,0.1,0.2,738,97
8,Manitoba,N02BE,Anilides,Total,M,213.21,0.1,1.5,"5,623",98
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",Total,M,210.48,0.1,7.8,"29,607",99
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,199.22,0.1,1.8,"6,860",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"37,151.06",20.8,0.4,"1,632",1
8,Manitoba,L01XE,Protein kinase inhibitors,Total,F,"5,944.78",3.3,0.0,225,2
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,Total,F,"5,546.49",3.1,0.0,101,3
8,Manitoba,L04AA,Selective immunosuppressants,Total,F,"5,351.24",3.0,0.2,"1,051",4
8,Manitoba,L04AX,Other immunosuppressants,Total,F,"4,874.72",2.7,0.3,"1,292",5
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"4,360.48",2.4,4.1,"18,742",6
8,Manitoba,L03AB,Interferons,Total,F,"3,846.17",2.2,0.1,242,7
8,Manitoba,A02BC,Proton pump inhibitors,Total,F,"3,607.07",2.0,15.2,"69,614",8
8,Manitoba,N02AA,Natural opium alkaloids,Total,F,"3,289.96",1.8,2.2,"10,290",9
8,Manitoba,N03AX,Other antiepileptics,Total,F,"3,266.47",1.8,4.9,"22,614",10
8,Manitoba,N05AX,Other antipsychotics,Total,F,"3,239.19",1.8,1.3,"5,818",11
8,Manitoba,N06AX,Other antidepressants,Total,F,"3,229.63",1.8,8.2,"37,386",12
8,Manitoba,L04AC,Interleukin inhibitors,Total,F,"2,922.90",1.6,0.0,229,13
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,885.91",1.6,12.0,"55,220",14
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"2,778.26",1.6,2.3,"10,406",15
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,660.37",1.5,13.4,"61,357",16
8,Manitoba,C09AA,"ACE inhibitors, plain",Total,F,"2,195.32",1.2,7.9,"36,274",17
8,Manitoba,L03AX,Other immunostimulants,Total,F,"2,016.90",1.1,0.0,216,18
8,Manitoba,C08CA,Dihydropyridine derivatives,Total,F,"2,015.79",1.1,7.7,"35,204",19
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"1,875.03",1.0,0.1,339,20
8,Manitoba,B01AF,Direct factor Xa inhibitors,Total,F,"1,867.63",1.0,1.3,"5,810",21
8,Manitoba,H01CB,Somatostatin and analogues,Total,F,"1,591.78",0.9,0.0,85,22
8,Manitoba,H03AA,Thyroid hormones,Total,F,"1,553.15",0.9,13.5,"62,047",23
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"1,339.60",0.8,12.8,"58,734",24
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"1,332.87",0.7,0.0,98,25
8,Manitoba,N07XX,Other nervous system drugs,Total,F,"1,283.64",0.7,0.0,146,26
8,Manitoba,C07AB,"Beta-blocking agents, selective",Total,F,"1,275.45",0.7,6.4,"29,334",27
8,Manitoba,L02BG,Aromatase inhibitors,Total,F,"1,256.17",0.7,0.9,"4,130",28
8,Manitoba,B01AB,Heparin group,Total,F,"1,233.84",0.7,0.3,"1,194",29
8,Manitoba,A04AD,Other antiemetics,Total,F,"1,215.60",0.7,0.4,"1,985",30
8,Manitoba,L01XC,Monoclonal antibodies,Total,F,"1,205.28",0.7,0.0,115,31
8,Manitoba,R03BB,Anticholinergics,Total,F,"1,158.36",0.6,1.7,"7,959",32
8,Manitoba,N05CF,Benzodiazepine-related drugs,Total,F,"1,117.44",0.6,6.6,"30,195",33
8,Manitoba,N05BA,Benzodiazepine derivatives,Total,F,"1,071.79",0.6,8.2,"37,415",34
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,062.29",0.6,1.1,"4,856",35
8,Manitoba,A10BA,Biguanides,Total,F,"1,044.73",0.6,6.2,"28,508",36
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,Total,F,"1,043.61",0.6,0.8,"3,593",37
8,Manitoba,N07BC,Drugs used in opioid dependence,Total,F,"1,034.89",0.6,0.2,765,38
8,Manitoba,B02AB,Proteinase inhibitors,Total,F,"1,010.19",0.6,0.0,9,39
8,Manitoba,N06BA,Centrally acting sympathomimetics,Total,F,988.42,0.6,1.2,"5,419",40
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",Total,F,960.51,0.5,0.5,"2,189",41
8,Manitoba,C03CA,"Sulfonamides, plain",Total,F,929.50,0.5,3.7,"16,917",42
8,Manitoba,C09CA,"Angiotensin II antagonists, plain",Total,F,926.98,0.5,5.7,"26,204",43
8,Manitoba,L04AD,Calcineurin inhibitors,Total,F,895.39,0.5,0.1,282,44
8,Manitoba,R03BA,Glucocorticoids,Total,F,892.42,0.5,3.4,"15,657",45
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,890.06,0.5,3.9,"18,007",46
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,886.94,0.5,1.8,"8,095",47
8,Manitoba,N03AE,Benzodiazepine derivatives,Total,F,868.96,0.5,2.6,"11,831",48
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,858.17,0.5,0.4,"2,000",49
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,806.65,0.5,11.3,"51,923",50
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,Total,F,783.80,0.4,1.3,"6,147",51
8,Manitoba,J05AE,Protease inhibitors,Total,F,731.27,0.4,0.0,136,52
8,Manitoba,A10BB,Sulfonylureas,Total,F,693.14,0.4,2.8,"12,965",53
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,664.32,0.4,0.8,"3,772",54
8,Manitoba,N02AB,Phenylpiperidine derivatives,Total,F,605.55,0.3,0.2,"1,016",55
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,602.92,0.3,0.1,645,56
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,Total,F,586.91,0.3,0.6,"2,822",57
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,543.58,0.3,0.4,"1,674",58
8,Manitoba,A02BA,H2-receptor antagonists,Total,F,514.59,0.3,3.4,"15,612",59
8,Manitoba,S01EE,Prostaglandin analogues,Total,F,508.93,0.3,1.6,"7,317",60
8,Manitoba,C08DB,Benzothiazepine derivatives,Total,F,508.19,0.3,1.0,"4,589",61
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,Total,F,495.09,0.3,1.6,"7,272",62
8,Manitoba,A12BA,Potassium,Total,F,478.91,0.3,1.4,"6,516",63
8,Manitoba,N03AG,Fatty acid derivatives,Total,F,455.97,0.3,0.4,"1,870",64
8,Manitoba,S01ED,Beta-blocking agents,Total,F,446.85,0.3,1.3,"5,899",65
8,Manitoba,A16AB,Enzymes,Total,F,**,**,**,*,66
8,Manitoba,H02AB,Glucocorticoids,Total,F,436.56,0.2,6.5,"29,986",67
8,Manitoba,M05BA,Bisphosphonates,Total,F,424.73,0.2,1.4,"6,413",68
8,Manitoba,R01AD,Corticosteroids,Total,F,422.90,0.2,8.8,"40,290",69
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,418.79,0.2,0.4,"1,711",70
8,Manitoba,C09BA,ACE inhibitors and diuretics,Total,F,412.85,0.2,1.5,"7,068",71
8,Manitoba,M03BX,Other centrally acting agents,Total,F,411.65,0.2,3.1,"14,048",72
8,Manitoba,C03AA,"Thiazides, plain",Total,F,401.19,0.2,5.3,"24,357",73
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,394.17,0.2,3.8,"17,341",74
8,Manitoba,N02BE,Anilides,Total,F,386.18,0.2,2.0,"9,336",75
8,Manitoba,B01AA,Vitamin K antagonists,Total,F,368.95,0.2,1.0,"4,696",76
8,Manitoba,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,367.44,0.2,7.9,"36,053",77
8,Manitoba,M01AB,Acetic acid derivatives and related substances,Total,F,362.84,0.2,3.1,"14,397",78
8,Manitoba,B01AE,Direct thrombin inhibitors,Total,F,358.15,0.2,0.2,695,79
8,Manitoba,R03DC,Leukotriene receptor antagonists,Total,F,350.23,0.2,1.4,"6,588",80
8,Manitoba,C09DA,Angiotensin II antagonists and diuretics,Total,F,341.24,0.2,2.9,"13,219",81
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,334.71,0.2,0.0,47,82
8,Manitoba,M01AE,Propionic acid derivatives,Total,F,333.87,0.2,8.0,"36,565",83
8,Manitoba,N03AF,Carboxamide derivatives,Total,F,325.23,0.2,0.4,"1,816",84
8,Manitoba,C01DA,Organic nitrates,Total,F,320.88,0.2,1.2,"5,464",85
8,Manitoba,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,F,313.95,0.2,0.0,91,86
8,Manitoba,N04BA,Dopa and dopa derivatives,Total,F,313.87,0.2,0.4,"1,710",87
8,Manitoba,A03FA,Propulsives,Total,F,307.47,0.2,2.1,"9,632",88
8,Manitoba,L01XX,Other antineoplastic agents,Total,F,306.36,0.2,0.1,375,89
8,Manitoba,J01MA,Fluoroquinolones,Total,F,297.91,0.2,7.5,"34,311",90
8,Manitoba,B06AC,Drugs used in hereditary angioedema,Total,F,297.63,0.2,0.0,6,91
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,295.49,0.2,3.1,"13,992",92
8,Manitoba,J01CA,Penicillins with extended spectrum,Total,F,289.32,0.2,18.9,"86,690",93
8,Manitoba,C02AC,Imidazoline receptor agonists,Total,F,280.64,0.2,0.6,"2,970",94
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",Total,F,271.03,0.2,8.3,"38,074",95
8,Manitoba,N05AE,Indole derivatives,Total,F,269.30,0.2,0.1,306,96
8,Manitoba,C10AB,Fibrates,Total,F,263.70,0.1,0.5,"2,468",97
8,Manitoba,L01AX,Other alkylating agents,Total,F,252.31,0.1,0.0,41,98
8,Manitoba,J01FA,Macrolides,Total,F,252.27,0.1,11.8,"54,009",99
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",Total,F,252.25,0.1,1.2,"5,325",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"14,197.72",11.3,0.3,654,1
8,Manitoba,L01XE,Protein kinase inhibitors,65+,Total,"9,022.42",7.2,0.2,335,2
8,Manitoba,L04AX,Other immunosuppressants,65+,Total,"7,581.40",6.0,0.4,695,3
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"4,301.24",3.4,6.7,"12,676",4
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,65+,Total,"3,337.00",2.7,41.4,"78,722",5
8,Manitoba,A02BC,Proton pump inhibitors,65+,Total,"3,240.25",2.6,27.3,"51,902",6
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,65+,Total,"3,215.44",2.6,0.0,55,7
8,Manitoba,B01AF,Direct factor Xa inhibitors,65+,Total,"2,800.02",2.2,4.5,"8,647",8
8,Manitoba,C09AA,"ACE inhibitors, plain",65+,Total,"2,693.92",2.1,23.2,"44,222",9
8,Manitoba,C08CA,Dihydropyridine derivatives,65+,Total,"2,457.72",2.0,21.6,"41,042",10
8,Manitoba,L02BX,Other hormone antagonists and related agents,65+,Total,"2,279.77",1.8,0.0,79,11
8,Manitoba,L02BB,Antiandrogens,65+,Total,"2,097.77",1.7,0.5,895,12
8,Manitoba,N02AA,Natural opium alkaloids,65+,Total,"2,002.15",1.6,4.6,"8,772",13
8,Manitoba,H01CB,Somatostatin and analogues,65+,Total,"1,769.34",1.4,0.0,78,14
8,Manitoba,C07AB,"Beta-blocking agents, selective",65+,Total,"1,766.86",1.4,22.5,"42,831",15
8,Manitoba,N06AX,Other antidepressants,65+,Total,"1,635.38",1.3,8.0,"15,170",16
8,Manitoba,R03BB,Anticholinergics,65+,Total,"1,548.29",1.2,5.2,"9,951",17
8,Manitoba,N03AX,Other antiepileptics,65+,Total,"1,431.56",1.1,7.3,"13,939",18
8,Manitoba,L04AA,Selective immunosuppressants,65+,Total,"1,383.86",1.1,0.3,520,19
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,371.29",1.1,10.0,"19,057",20
8,Manitoba,C03CA,"Sulfonamides, plain",65+,Total,"1,257.09",1.0,12.3,"23,360",21
8,Manitoba,H03AA,Thyroid hormones,65+,Total,"1,229.74",1.0,19.9,"37,959",22
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"1,193.00",0.9,7.5,"14,321",23
8,Manitoba,B02AB,Proteinase inhibitors,65+,Total,"1,144.00",0.9,0.0,9,24
8,Manitoba,A10BA,Biguanides,65+,Total,"1,138.63",0.9,15.4,"29,218",25
8,Manitoba,B01AB,Heparin group,65+,Total,"1,119.34",0.9,0.6,"1,166",26
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"1,105.31",0.9,2.6,"4,958",27
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"1,068.88",0.9,0.0,84,28
8,Manitoba,L04AC,Interleukin inhibitors,65+,Total,"1,026.11",0.8,0.0,88,29
8,Manitoba,C09CA,"Angiotensin II antagonists, plain",65+,Total,"1,024.16",0.8,14.1,"26,771",30
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,952.87,0.8,1.2,"2,206",31
8,Manitoba,N05AX,Other antipsychotics,65+,Total,932.51,0.7,1.5,"2,847",32
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,909.16,0.7,1.0,"1,896",33
8,Manitoba,N05CF,Benzodiazepine-related drugs,65+,Total,838.40,0.7,10.4,"19,706",34
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,833.46,0.7,1.8,"3,458",35
8,Manitoba,A10BB,Sulfonylureas,65+,Total,831.36,0.7,8.1,"15,328",36
8,Manitoba,L02BG,Aromatase inhibitors,65+,Total,805.52,0.6,0.9,"1,786",37
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,743.54,0.6,14.1,"26,797",38
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,700.16,0.6,2.1,"3,922",39
8,Manitoba,S01EE,Prostaglandin analogues,65+,Total,682.60,0.5,5.3,"10,012",40
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,671.74,0.5,11.4,"21,769",41
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,667.27,0.5,1.1,"2,121",42
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,648.30,0.5,9.1,"17,296",43
8,Manitoba,C08DB,Benzothiazepine derivatives,65+,Total,629.93,0.5,3.1,"5,822",44
8,Manitoba,S01ED,Beta-blocking agents,65+,Total,605.78,0.5,4.4,"8,313",45
8,Manitoba,B01AE,Direct thrombin inhibitors,65+,Total,591.74,0.5,0.7,"1,256",46
8,Manitoba,N05BA,Benzodiazepine derivatives,65+,Total,581.62,0.5,9.7,"18,459",47
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,65+,Total,571.93,0.5,2.4,"4,578",48
8,Manitoba,B01AA,Vitamin K antagonists,65+,Total,566.28,0.5,4.4,"8,387",49
8,Manitoba,A12BA,Potassium,65+,Total,553.52,0.4,4.1,"7,858",50
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,65+,Total,544.78,0.4,0.9,"1,701",51
8,Manitoba,L01XC,Monoclonal antibodies,65+,Total,533.93,0.4,0.0,49,52
8,Manitoba,N04BA,Dopa and dopa derivatives,65+,Total,529.88,0.4,1.5,"2,801",53
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,506.15,0.4,4.6,"8,732",54
8,Manitoba,C01DA,Organic nitrates,65+,Total,493.00,0.4,4.8,"9,120",55
8,Manitoba,R03BA,Glucocorticoids,65+,Total,478.52,0.4,2.4,"4,656",56
8,Manitoba,L04AD,Calcineurin inhibitors,65+,Total,475.81,0.4,0.1,183,57
8,Manitoba,C09BA,ACE inhibitors and diuretics,65+,Total,441.95,0.4,3.7,"7,123",58
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,65+,Total,433.73,0.3,0.8,"1,616",59
8,Manitoba,L03AB,Interferons,65+,Total,430.85,0.3,0.0,27,60
8,Manitoba,C03AA,"Thiazides, plain",65+,Total,429.92,0.3,12.5,"23,702",61
8,Manitoba,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,419.72,0.3,4.4,"8,365",62
8,Manitoba,N02AB,Phenylpiperidine derivatives,65+,Total,408.36,0.3,0.5,904,63
8,Manitoba,A02BA,H2-receptor antagonists,65+,Total,406.12,0.3,4.4,"8,439",64
8,Manitoba,M05BA,Bisphosphonates,65+,Total,404.80,0.3,3.2,"6,123",65
8,Manitoba,A04AD,Other antiemetics,65+,Total,399.53,0.3,0.5,934,66
8,Manitoba,M04AA,Preparations inhibiting uric acid production,65+,Total,391.63,0.3,5.8,"10,965",67
8,Manitoba,L01XX,Other antineoplastic agents,65+,Total,381.88,0.3,0.2,440,68
8,Manitoba,H02AB,Glucocorticoids,65+,Total,378.49,0.3,7.9,"14,995",69
8,Manitoba,C09DA,Angiotensin II antagonists and diuretics,65+,Total,367.06,0.3,7.2,"13,766",70
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,344.43,0.3,0.0,47,71
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,343.66,0.3,0.7,"1,411",72
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,337.66,0.3,0.2,311,73
8,Manitoba,C01AA,Digitalis glycosides,65+,Total,322.17,0.3,2.0,"3,830",74
8,Manitoba,N06DA,Anticholinesterases,65+,Total,321.23,0.3,1.0,"1,917",75
8,Manitoba,N03AE,Benzodiazepine derivatives,65+,Total,301.88,0.2,2.3,"4,380",76
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,296.79,0.2,0.9,"1,668",77
8,Manitoba,C10AB,Fibrates,65+,Total,294.32,0.2,1.5,"2,913",78
8,Manitoba,J01MA,Fluoroquinolones,65+,Total,285.12,0.2,12.2,"23,134",79
8,Manitoba,R01AD,Corticosteroids,65+,Total,278.69,0.2,7.9,"14,940",80
8,Manitoba,N02BE,Anilides,65+,Total,272.98,0.2,3.3,"6,270",81
8,Manitoba,B03XA,Other antianemic preparations,65+,Total,259.54,0.2,0.0,28,82
8,Manitoba,A03FA,Propulsives,65+,Total,258.53,0.2,2.8,"5,293",83
8,Manitoba,C07AG,Alpha- and beta-blocking agents,65+,Total,235.03,0.2,0.8,"1,588",84
8,Manitoba,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,Total,229.17,0.2,0.0,64,85
8,Manitoba,M01AH,Coxibs,65+,Total,226.85,0.2,1.6,"2,994",86
8,Manitoba,M01AB,Acetic acid derivatives and related substances,65+,Total,224.34,0.2,4.5,"8,555",87
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",65+,Total,217.10,0.2,1.8,"3,509",88
8,Manitoba,C03DA,Aldosterone antagonists,65+,Total,215.44,0.2,2.2,"4,236",89
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",65+,Total,201.30,0.2,9.5,"18,151",90
8,Manitoba,L01AX,Other alkylating agents,65+,Total,199.02,0.2,0.0,28,91
8,Manitoba,R03DC,Leukotriene receptor antagonists,65+,Total,197.68,0.2,1.0,"1,894",92
8,Manitoba,V03AC,Iron-chelating agents,65+,Total,190.11,0.2,0.0,15,93
8,Manitoba,J05AE,Protease inhibitors,65+,Total,189.12,0.2,0.0,23,94
8,Manitoba,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,189.03,0.2,0.4,762,95
8,Manitoba,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,182.33,0.1,0.4,694,96
8,Manitoba,N04BC,Dopamine agonists,65+,Total,178.58,0.1,0.8,"1,480",97
8,Manitoba,M03BX,Other centrally acting agents,65+,Total,160.39,0.1,2.2,"4,269",98
8,Manitoba,L02AB,Progestogens,65+,Total,157.83,0.1,0.1,161,99
8,Manitoba,L01BA,Folic acid analogues,65+,Total,155.46,0.1,1.1,"1,999",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"6,468.58",11.2,0.3,251,1
8,Manitoba,L01XE,Protein kinase inhibitors,65+,M,"5,733.58",9.9,0.2,203,2
8,Manitoba,L04AX,Other immunosuppressants,65+,M,"4,612.79",8.0,0.4,302,3
8,Manitoba,L02BX,Other hormone antagonists and related agents,65+,M,"2,279.77",3.9,0.1,79,4
8,Manitoba,L02BB,Antiandrogens,65+,M,"2,097.77",3.6,1.1,895,5
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,65+,M,"2,092.67",3.6,0.0,36,6
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"1,729.31",3.0,6.4,"5,446",7
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,65+,M,"1,483.81",2.6,48.4,"41,134",8
8,Manitoba,C09AA,"ACE inhibitors, plain",65+,M,"1,154.95",2.0,27.3,"23,254",9
8,Manitoba,B01AF,Direct factor Xa inhibitors,65+,M,"1,142.12",2.0,4.8,"4,090",10
8,Manitoba,A02BC,Proton pump inhibitors,65+,M,"1,124.55",1.9,24.6,"20,965",11
8,Manitoba,H01CB,Somatostatin and analogues,65+,M,909.74,1.6,0.0,32,12
8,Manitoba,C08CA,Dihydropyridine derivatives,65+,M,883.93,1.5,21.3,"18,092",13
8,Manitoba,C07AB,"Beta-blocking agents, selective",65+,M,743.12,1.3,25.7,"21,845",14
8,Manitoba,B02AB,Proteinase inhibitors,65+,M,**,**,**,**,15
8,Manitoba,R03BB,Anticholinergics,65+,M,680.66,1.2,5.5,"4,682",16
8,Manitoba,N02AA,Natural opium alkaloids,65+,M,669.49,1.2,3.8,"3,263",17
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,65+,M,604.76,1.0,19.6,"16,694",18
8,Manitoba,B01AB,Heparin group,65+,M,556.61,1.0,0.6,527,19
8,Manitoba,A10BA,Biguanides,65+,M,528.06,0.9,18.7,"15,900",20
8,Manitoba,N03AX,Other antiepileptics,65+,M,518.61,0.9,6.3,"5,330",21
8,Manitoba,N06AX,Other antidepressants,65+,M,508.27,0.9,5.9,"5,020",22
8,Manitoba,C03CA,"Sulfonamides, plain",65+,M,489.30,0.8,11.9,"10,126",23
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,472.36,0.8,2.3,"1,999",24
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",65+,M,457.10,0.8,1.2,980,25
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,454.04,0.8,8.8,"7,484",26
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,436.71,0.8,2.2,"1,856",27
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,429.04,0.7,1.3,"1,104",28
8,Manitoba,L04AA,Selective immunosuppressants,65+,M,422.01,0.7,0.2,206,29
8,Manitoba,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,419.72,0.7,9.8,"8,359",30
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,407.61,0.7,0.0,26,31
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,65+,M,400.23,0.7,6.8,"5,771",32
8,Manitoba,A10BB,Sulfonylureas,65+,M,398.98,0.7,10.2,"8,697",33
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,363.50,0.6,2.5,"2,161",34
8,Manitoba,N05AX,Other antipsychotics,65+,M,335.87,0.6,1.2,"1,033",35
8,Manitoba,C09CA,"Angiotensin II antagonists, plain",65+,M,323.92,0.6,12.6,"10,731",36
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,300.14,0.5,0.0,38,37
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,296.82,0.5,1.2,"1,060",38
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,296.10,0.5,14.5,"12,373",39
8,Manitoba,N05CF,Benzodiazepine-related drugs,65+,M,293.83,0.5,8.3,"7,060",40
8,Manitoba,H03AA,Thyroid hormones,65+,M,293.61,0.5,11.7,"9,912",41
8,Manitoba,L04AD,Calcineurin inhibitors,65+,M,283.23,0.5,0.1,112,42
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,282.37,0.5,10.4,"8,866",43
8,Manitoba,N04BA,Dopa and dopa derivatives,65+,M,269.62,0.5,1.8,"1,504",44
8,Manitoba,B01AA,Vitamin K antagonists,65+,M,267.64,0.5,5.6,"4,749",45
8,Manitoba,B01AE,Direct thrombin inhibitors,65+,M,252.92,0.4,0.7,620,46
8,Manitoba,L04AC,Interleukin inhibitors,65+,M,245.56,0.4,0.0,24,47
8,Manitoba,S01EE,Prostaglandin analogues,65+,M,223.79,0.4,4.8,"4,085",48
8,Manitoba,C08DB,Benzothiazepine derivatives,65+,M,213.72,0.4,2.8,"2,419",49
8,Manitoba,C01DA,Organic nitrates,65+,M,202.74,0.4,5.6,"4,768",50
8,Manitoba,S01ED,Beta-blocking agents,65+,M,201.48,0.3,4.1,"3,482",51
8,Manitoba,M04AA,Preparations inhibiting uric acid production,65+,M,196.86,0.3,8.3,"7,093",52
8,Manitoba,C09BA,ACE inhibitors and diuretics,65+,M,192.83,0.3,4.3,"3,664",53
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,65+,M,189.71,0.3,0.8,656,54
8,Manitoba,N05BA,Benzodiazepine derivatives,65+,M,187.08,0.3,6.7,"5,692",55
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,181.77,0.3,1.0,825,56
8,Manitoba,H02AB,Glucocorticoids,65+,M,175.09,0.3,7.8,"6,658",57
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,65+,M,167.47,0.3,0.8,687,58
8,Manitoba,A12BA,Potassium,65+,M,162.92,0.3,3.2,"2,722",59
8,Manitoba,R03BA,Glucocorticoids,65+,M,159.03,0.3,2.0,"1,702",60
8,Manitoba,A02BA,H2-receptor antagonists,65+,M,158.21,0.3,4.1,"3,447",61
8,Manitoba,L01XX,Other antineoplastic agents,65+,M,157.37,0.3,0.2,168,62
8,Manitoba,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,154.00,0.3,0.1,44,63
8,Manitoba,J05AE,Protease inhibitors,65+,M,151.26,0.3,0.0,18,64
8,Manitoba,C03AA,"Thiazides, plain",65+,M,149.12,0.3,10.8,"9,190",65
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,144.76,0.2,0.9,782,66
8,Manitoba,L01AX,Other alkylating agents,65+,M,143.71,0.2,0.0,17,67
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,143.18,0.2,2.9,"2,494",68
8,Manitoba,C10AB,Fibrates,65+,M,139.53,0.2,1.8,"1,550",69
8,Manitoba,C01AA,Digitalis glycosides,65+,M,132.76,0.2,2.1,"1,776",70
8,Manitoba,C09DA,Angiotensin II antagonists and diuretics,65+,M,127.74,0.2,7.0,"5,946",71
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,65+,M,123.72,0.2,1.3,"1,073",72
8,Manitoba,N02AB,Phenylpiperidine derivatives,65+,M,123.23,0.2,0.4,324,73
8,Manitoba,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,122.24,0.2,0.5,458,74
8,Manitoba,A04AD,Other antiemetics,65+,M,121.53,0.2,0.4,339,75
8,Manitoba,C07AG,Alpha- and beta-blocking agents,65+,M,114.43,0.2,1.0,865,76
8,Manitoba,J05AX,Other antivirals,65+,M,112.41,0.2,0.0,15,77
8,Manitoba,J01MA,Fluoroquinolones,65+,M,111.65,0.2,11.0,"9,345",78
8,Manitoba,R01AD,Corticosteroids,65+,M,110.73,0.2,7.2,"6,156",79
8,Manitoba,N06DA,Anticholinesterases,65+,M,100.45,0.2,0.8,721,80
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,99.12,0.2,0.1,96,81
8,Manitoba,C03DA,Aldosterone antagonists,65+,M,93.66,0.2,2.3,"1,959",82
8,Manitoba,N03AE,Benzodiazepine derivatives,65+,M,93.33,0.2,1.8,"1,502",83
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",65+,M,88.69,0.2,9.5,"8,088",84
8,Manitoba,A03FA,Propulsives,65+,M,88.49,0.2,2.3,"1,936",85
8,Manitoba,B03XA,Other antianemic preparations,65+,M,86.67,0.1,0.0,11,86
8,Manitoba,C01BD,"Antiarrhythmics, class III",65+,M,85.96,0.1,0.8,657,87
8,Manitoba,M01AB,Acetic acid derivatives and related substances,65+,M,85.12,0.1,5.2,"4,424",88
8,Manitoba,J05AG,Non-nucleoside reverse transcriptase inhibitors,65+,M,82.14,0.1,0.0,20,89
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",65+,M,80.45,0.1,1.7,"1,442",90
8,Manitoba,M01AH,Coxibs,65+,M,74.45,0.1,1.1,912,91
8,Manitoba,N02BE,Anilides,65+,M,73.36,0.1,2.1,"1,792",92
8,Manitoba,V03AC,Iron-chelating agents,65+,M,73.29,0.1,0.0,7,93
8,Manitoba,N04BC,Dopamine agonists,65+,M,73.04,0.1,0.7,564,94
8,Manitoba,L01XC,Monoclonal antibodies,65+,M,71.15,0.1,0.0,10,95
8,Manitoba,A09AA,Enzyme preparations,65+,M,70.27,0.1,0.2,170,96
8,Manitoba,M03BX,Other centrally acting agents,65+,M,69.20,0.1,2.2,"1,846",97
8,Manitoba,N03AB,Hydantoin derivatives,65+,M,63.89,0.1,0.9,795,98
8,Manitoba,N03AG,Fatty acid derivatives,65+,M,59.72,0.1,0.3,261,99
8,Manitoba,L02AE,Gonadotropin-releasing hormone analogues,65+,M,57.38,0.1,0.0,18,100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"7,729.14",11.4,0.4,403,1
8,Manitoba,L01XE,Protein kinase inhibitors,65+,F,"3,288.84",4.9,0.1,132,2
8,Manitoba,L04AX,Other immunosuppressants,65+,F,"2,968.62",4.4,0.4,393,3
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,571.93",3.8,6.9,"7,230",4
8,Manitoba,A02BC,Proton pump inhibitors,65+,F,"2,115.70",3.1,29.4,"30,937",5
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,65+,F,"1,853.19",2.7,35.7,"37,588",6
8,Manitoba,B01AF,Direct factor Xa inhibitors,65+,F,"1,657.90",2.4,4.3,"4,557",7
8,Manitoba,C08CA,Dihydropyridine derivatives,65+,F,"1,573.80",2.3,21.8,"22,950",8
8,Manitoba,C09AA,"ACE inhibitors, plain",65+,F,"1,538.97",2.3,19.9,"20,968",9
8,Manitoba,N02AA,Natural opium alkaloids,65+,F,"1,332.66",2.0,5.2,"5,509",10
8,Manitoba,N06AX,Other antidepressants,65+,F,"1,127.10",1.7,9.6,"10,150",11
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,65+,F,"1,122.77",1.7,0.0,19,12
8,Manitoba,C07AB,"Beta-blocking agents, selective",65+,F,"1,023.74",1.5,19.9,"20,986",13
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,65+,F,971.06,1.4,12.6,"13,286",14
8,Manitoba,L04AA,Selective immunosuppressants,65+,F,961.84,1.4,0.3,314,15
8,Manitoba,H03AA,Thyroid hormones,65+,F,936.12,1.4,26.7,"28,047",16
8,Manitoba,N03AX,Other antiepileptics,65+,F,912.96,1.3,8.2,"8,609",17
8,Manitoba,R03BB,Anticholinergics,65+,F,867.64,1.3,5.0,"5,269",18
8,Manitoba,H01CB,Somatostatin and analogues,65+,F,859.59,1.3,0.0,46,19
8,Manitoba,L02BG,Aromatase inhibitors,65+,F,803.82,1.2,1.7,"1,780",20
8,Manitoba,L04AC,Interleukin inhibitors,65+,F,780.54,1.2,0.1,64,21
8,Manitoba,C03CA,"Sulfonamides, plain",65+,F,767.79,1.1,12.6,"13,234",22
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,738.95,1.1,6.5,"6,837",23
8,Manitoba,C09CA,"Angiotensin II antagonists, plain",65+,F,700.24,1.0,15.2,"16,040",24
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,661.27,1.0,0.1,58,25
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,632.95,0.9,2.8,"2,959",26
8,Manitoba,A10BA,Biguanides,65+,F,610.57,0.9,12.7,"13,318",27
8,Manitoba,N05AX,Other antipsychotics,65+,F,596.64,0.9,1.7,"1,814",28
8,Manitoba,B01AB,Heparin group,65+,F,562.72,0.8,0.6,639,29
8,Manitoba,N05CF,Benzodiazepine-related drugs,65+,F,544.57,0.8,12.0,"12,646",30
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,523.83,0.8,1.0,"1,102",31
8,Manitoba,L01XC,Monoclonal antibodies,65+,F,462.78,0.7,0.0,39,32
8,Manitoba,S01EE,Prostaglandin analogues,65+,F,458.81,0.7,5.6,"5,927",33
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",65+,F,452.07,0.7,0.9,916,34
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,65+,F,448.21,0.7,3.3,"3,505",35
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,447.45,0.7,13.7,"14,424",36
8,Manitoba,B02AB,Proteinase inhibitors,65+,F,**,**,**,*,37
8,Manitoba,A10BB,Sulfonylureas,65+,F,432.38,0.6,6.3,"6,631",38
8,Manitoba,C08DB,Benzothiazepine derivatives,65+,F,416.20,0.6,3.2,"3,403",39
8,Manitoba,S01ED,Beta-blocking agents,65+,F,404.30,0.6,4.6,"4,831",40
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,396.75,0.6,1.5,"1,602",41
8,Manitoba,N05BA,Benzodiazepine derivatives,65+,F,394.55,0.6,12.1,"12,767",42
8,Manitoba,L03AB,Interferons,65+,F,392.55,0.6,0.0,21,43
8,Manitoba,A12BA,Potassium,65+,F,390.60,0.6,4.9,"5,136",44
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,389.37,0.6,12.3,"12,903",45
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,370.44,0.5,1.0,"1,061",46
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,362.97,0.5,5.9,"6,238",47
8,Manitoba,M05BA,Bisphosphonates,65+,F,360.41,0.5,5.2,"5,494",48
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,65+,F,355.07,0.5,1.0,"1,045",49
8,Manitoba,B01AE,Direct thrombin inhibitors,65+,F,338.82,0.5,0.6,636,50
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,336.66,0.5,1.7,"1,761",51
8,Manitoba,R03BA,Glucocorticoids,65+,F,319.50,0.5,2.8,"2,954",52
8,Manitoba,B01AA,Vitamin K antagonists,65+,F,298.64,0.4,3.5,"3,638",53
8,Manitoba,C01DA,Organic nitrates,65+,F,290.26,0.4,4.1,"4,352",54
8,Manitoba,N02AB,Phenylpiperidine derivatives,65+,F,285.13,0.4,0.6,580,55
8,Manitoba,C03AA,"Thiazides, plain",65+,F,280.80,0.4,13.8,"14,512",56
8,Manitoba,A04AD,Other antiemetics,65+,F,278.01,0.4,0.6,595,57
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,65+,F,266.26,0.4,0.9,929,58
8,Manitoba,N04BA,Dopa and dopa derivatives,65+,F,260.26,0.4,1.2,"1,297",59
8,Manitoba,C09BA,ACE inhibitors and diuretics,65+,F,249.12,0.4,3.3,"3,459",60
8,Manitoba,A02BA,H2-receptor antagonists,65+,F,247.90,0.4,4.7,"4,992",61
8,Manitoba,C09DA,Angiotensin II antagonists and diuretics,65+,F,239.32,0.4,7.4,"7,820",62
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,238.54,0.4,0.2,215,63
8,Manitoba,L01XX,Other antineoplastic agents,65+,F,224.51,0.3,0.3,272,64
8,Manitoba,N06DA,Anticholinesterases,65+,F,220.78,0.3,1.1,"1,196",65
8,Manitoba,N03AE,Benzodiazepine derivatives,65+,F,208.55,0.3,2.7,"2,878",66
8,Manitoba,H02AB,Glucocorticoids,65+,F,203.40,0.3,7.9,"8,337",67
8,Manitoba,N02BE,Anilides,65+,F,199.61,0.3,4.3,"4,478",68
8,Manitoba,M04AA,Preparations inhibiting uric acid production,65+,F,194.78,0.3,3.7,"3,872",69
8,Manitoba,L04AD,Calcineurin inhibitors,65+,F,192.59,0.3,0.1,71,70
8,Manitoba,C01AA,Digitalis glycosides,65+,F,189.41,0.3,2.0,"2,054",71
8,Manitoba,M05BX,Other drugs affecting bone structure and mineralization,65+,F,178.58,0.3,0.6,681,72
8,Manitoba,J01MA,Fluoroquinolones,65+,F,173.47,0.3,13.1,"13,789",73
8,Manitoba,B03XA,Other antianemic preparations,65+,F,172.88,0.3,0.0,17,74
8,Manitoba,A03FA,Propulsives,65+,F,170.04,0.3,3.2,"3,357",75
8,Manitoba,R01AD,Corticosteroids,65+,F,167.96,0.2,8.3,"8,784",76
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,161.89,0.2,0.6,586,77
8,Manitoba,C10AB,Fibrates,65+,F,154.79,0.2,1.3,"1,363",78
8,Manitoba,B06AC,Drugs used in hereditary angioedema,65+,F,**,**,**,*,79
8,Manitoba,M01AH,Coxibs,65+,F,152.40,0.2,2.0,"2,082",80
8,Manitoba,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,152.03,0.2,0.8,886,81
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,150.45,0.2,5.5,"5,755",82
8,Manitoba,L02AB,Progestogens,65+,F,144.44,0.2,0.1,133,83
8,Manitoba,R03DC,Leukotriene receptor antagonists,65+,F,142.38,0.2,1.2,"1,281",84
8,Manitoba,M01AB,Acetic acid derivatives and related substances,65+,F,139.22,0.2,3.9,"4,131",85
8,Manitoba,C07AA,"Beta-blocking agents, non-selective",65+,F,136.65,0.2,2.0,"2,067",86
8,Manitoba,C03DA,Aldosterone antagonists,65+,F,121.78,0.2,2.2,"2,277",87
8,Manitoba,C07AG,Alpha- and beta-blocking agents,65+,F,120.60,0.2,0.7,723,88
8,Manitoba,V03AC,Iron-chelating agents,65+,F,116.82,0.2,0.0,8,89
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",65+,F,112.61,0.2,9.6,"10,063",90
8,Manitoba,L01BA,Folic acid analogues,65+,F,111.54,0.2,1.3,"1,387",91
8,Manitoba,N07CA,Antivertigo preparations,65+,F,111.32,0.2,3.6,"3,772",92
8,Manitoba,N04BC,Dopamine agonists,65+,F,105.54,0.2,0.9,916,93
8,Manitoba,G04BE,Drugs used in erectile dysfunction,65+,F,104.93,0.2,0.0,24,94
8,Manitoba,J01XE,Nitrofuran derivatives,65+,F,99.63,0.1,7.9,"8,332",95
8,Manitoba,A11CC,Vitamin D and analogues,65+,F,95.62,0.1,4.4,"4,664",96
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,65+,F,94.60,0.1,0.6,637,97
8,Manitoba,S01EC,Carbonic anhydrase inhibitors,65+,F,93.34,0.1,1.5,"1,563",98
8,Manitoba,M03BX,Other centrally acting agents,65+,F,91.19,0.1,2.3,"2,423",99
8,Manitoba,N03AG,Fatty acid derivatives,65+,F,87.26,0.1,0.3,348,100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"57,607.73",25.6,0.4,"2,355",1
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,<65,Total,"13,737.13",6.1,0.0,243,2
8,Manitoba,L04AA,Selective immunosuppressants,<65,Total,"6,823.72",3.0,0.2,"1,259",3
8,Manitoba,N05AX,Other antipsychotics,<65,Total,"6,706.81",3.0,1.3,"8,621",4
8,Manitoba,L01XE,Protein kinase inhibitors,<65,Total,"6,446.52",2.9,0.0,218,5
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"6,051.83",2.7,2.2,"14,376",6
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"5,961.66",2.7,0.1,853,7
8,Manitoba,L03AB,Interferons,<65,Total,"4,412.99",2.0,0.0,281,8
8,Manitoba,N02AA,Natural opium alkaloids,<65,Total,"4,390.83",2.0,1.4,"8,945",9
8,Manitoba,L04AX,Other immunosuppressants,<65,Total,"4,312.99",1.9,0.2,"1,553",10
8,Manitoba,L04AC,Interleukin inhibitors,<65,Total,"4,273.00",1.9,0.0,317,11
8,Manitoba,N03AX,Other antiepileptics,<65,Total,"4,215.30",1.9,3.6,"23,261",12
8,Manitoba,N06AX,Other antidepressants,<65,Total,"3,422.63",1.5,6.4,"41,588",13
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"3,234.90",1.4,9.7,"62,797",14
8,Manitoba,A16AB,Enzymes,<65,Total,"3,115.03",1.4,0.0,8,15
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"3,052.35",1.4,3.2,"20,753",16
8,Manitoba,N06BA,Centrally acting sympathomimetics,<65,Total,"2,799.39",1.2,2.3,"15,053",17
8,Manitoba,L03AX,Other immunostimulants,<65,Total,"2,760.14",1.2,0.0,286,18
8,Manitoba,A02BC,Proton pump inhibitors,<65,Total,"2,610.40",1.2,10.9,"70,702",19
8,Manitoba,J05AE,Protease inhibitors,<65,Total,"2,231.09",1.0,0.1,376,20
8,Manitoba,N07BC,Drugs used in opioid dependence,<65,Total,"2,160.74",1.0,0.2,"1,597",21
8,Manitoba,N07XX,Other nervous system drugs,<65,Total,"1,915.42",0.9,0.0,189,22
8,Manitoba,L04AD,Calcineurin inhibitors,<65,Total,"1,829.97",0.8,0.1,556,23
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,791.24",0.8,9.5,"61,365",24
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"1,664.51",0.7,13.1,"84,549",25
8,Manitoba,A04AD,Other antiemetics,<65,Total,"1,512.18",0.7,0.3,"2,103",26
8,Manitoba,B02AB,Proteinase inhibitors,<65,Total,"1,506.54",0.7,0.0,12,27
8,Manitoba,C09AA,"ACE inhibitors, plain",<65,Total,"1,499.06",0.7,5.9,"38,324",28
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,429.12",0.6,1.0,"6,766",29
8,Manitoba,H01CB,Somatostatin and analogues,<65,Total,"1,395.64",0.6,0.0,71,30
8,Manitoba,N05BA,Benzodiazepine derivatives,<65,Total,"1,299.33",0.6,5.9,"38,014",31
8,Manitoba,B01AB,Heparin group,<65,Total,"1,155.22",0.5,0.1,887,32
8,Manitoba,N03AE,Benzodiazepine derivatives,<65,Total,"1,151.99",0.5,2.2,"14,515",33
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"1,095.02",0.5,0.4,"2,699",34
8,Manitoba,R03BA,Glucocorticoids,<65,Total,"1,033.53",0.5,3.8,"24,840",35
8,Manitoba,N05CF,Benzodiazepine-related drugs,<65,Total,"1,013.01",0.5,4.4,"28,271",36
8,Manitoba,L01XC,Monoclonal antibodies,<65,Total,991.58,0.4,0.0,100,37
8,Manitoba,C08CA,Dihydropyridine derivatives,<65,Total,986.60,0.4,4.3,"28,021",38
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,<65,Total,957.27,0.4,0.6,"3,790",39
8,Manitoba,J05AX,Other antivirals,<65,Total,925.78,0.4,0.0,138,40
8,Manitoba,N03AG,Fatty acid derivatives,<65,Total,914.44,0.4,0.5,"3,285",41
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,900.99,0.4,2.7,"17,584",42
8,Manitoba,A10BA,Biguanides,<65,Total,892.70,0.4,5.1,"33,212",43
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,865.54,0.4,0.0,57,44
8,Manitoba,H03AA,Thyroid hormones,<65,Total,861.60,0.4,6.7,"43,125",45
8,Manitoba,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,778.71,0.3,0.0,269,46
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,745.37,0.3,11.2,"72,341",47
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,675.56,0.3,0.7,"4,233",48
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,641.92,0.3,0.3,"1,933",49
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,636.02,0.3,0.1,679,50
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,<65,Total,623.89,0.3,0.5,"3,510",51
8,Manitoba,C07AB,"Beta-blocking agents, selective",<65,Total,622.80,0.3,3.3,"21,026",52
8,Manitoba,M03BX,Other centrally acting agents,<65,Total,604.20,0.3,3.3,"21,262",53
8,Manitoba,H01AC,Somatropin and somatropin agonists,<65,Total,584.22,0.3,0.0,85,54
8,Manitoba,R03BB,Anticholinergics,<65,Total,576.61,0.3,0.8,"5,085",55
8,Manitoba,R07AX,Other respiratory system products,<65,Total,**,**,**,*,56
8,Manitoba,A10BB,Sulfonylureas,<65,Total,561.86,0.3,2.4,"15,339",57
8,Manitoba,N03AF,Carboxamide derivatives,<65,Total,560.67,0.2,0.4,"2,410",58
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,<65,Total,517.19,0.2,1.2,"8,006",59
8,Manitoba,N02AB,Phenylpiperidine derivatives,<65,Total,514.35,0.2,0.1,739,60
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,508.95,0.2,0.4,"2,554",61
8,Manitoba,A02BA,H2-receptor antagonists,<65,Total,500.99,0.2,2.7,"17,309",62
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,485.71,0.2,0.0,63,63
8,Manitoba,L01AX,Other alkylating agents,<65,Total,470.72,0.2,0.0,61,64
8,Manitoba,B01AF,Direct factor Xa inhibitors,<65,Total,460.55,0.2,0.4,"2,711",65
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,<65,Total,456.55,0.2,0.5,"3,381",66
8,Manitoba,L02BG,Aromatase inhibitors,<65,Total,453.07,0.2,0.4,"2,358",67
8,Manitoba,M01AE,Propionic acid derivatives,<65,Total,447.54,0.2,8.9,"57,259",68
8,Manitoba,C02AC,Imidazoline receptor agonists,<65,Total,438.72,0.2,0.6,"3,558",69
8,Manitoba,R01AD,Corticosteroids,<65,Total,435.53,0.2,8.3,"53,994",70
8,Manitoba,C09CA,"Angiotensin II antagonists, plain",<65,Total,425.75,0.2,3.2,"20,620",71
8,Manitoba,J01CA,Penicillins with extended spectrum,<65,Total,424.30,0.2,21.3,"138,060",72
8,Manitoba,A09AA,Enzyme preparations,<65,Total,411.90,0.2,0.1,645,73
8,Manitoba,M01AB,Acetic acid derivatives and related substances,<65,Total,411.79,0.2,3.6,"23,321",74
8,Manitoba,H02AB,Glucocorticoids,<65,Total,406.32,0.2,6.1,"39,350",75
8,Manitoba,N05AE,Indole derivatives,<65,Total,394.88,0.2,0.1,448,76
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,377.54,0.2,2.6,"16,750",77
8,Manitoba,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,367.71,0.2,5.6,"36,068",78
8,Manitoba,C09BA,ACE inhibitors and diuretics,<65,Total,364.55,0.2,1.4,"8,983",79
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,360.16,0.2,0.2,"1,325",80
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,356.85,0.2,0.7,"4,520",81
8,Manitoba,R05CB,Mucolytics,<65,Total,339.00,0.2,0.0,42,82
8,Manitoba,R03DC,Leukotriene receptor antagonists,<65,Total,333.57,0.1,1.5,"9,474",83
8,Manitoba,N02BE,Anilides,<65,Total,326.42,0.1,1.3,"8,689",84
8,Manitoba,J01DB,First-generation cephalosporins,<65,Total,319.56,0.1,7.4,"47,723",85
8,Manitoba,C01CA,Adrenergic and dopaminergic agents,<65,Total,313.30,0.1,1.9,"12,269",86
8,Manitoba,L02BX,Other hormone antagonists and related agents,<65,Total,312.79,0.1,0.0,12,87
8,Manitoba,L02BB,Antiandrogens,<65,Total,312.38,0.1,0.0,110,88
8,Manitoba,C03CA,"Sulfonamides, plain",<65,Total,305.79,0.1,1.0,"6,770",89
8,Manitoba,J01FA,Macrolides,<65,Total,296.46,0.1,11.6,"75,056",90
8,Manitoba,B06AC,Drugs used in hereditary angioedema,<65,Total,295.96,0.1,0.0,7,91
8,Manitoba,C10AB,Fibrates,<65,Total,291.94,0.1,0.6,"3,689",92
8,Manitoba,N04BA,Dopa and dopa derivatives,<65,Total,290.03,0.1,0.1,818,93
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",<65,Total,280.21,0.1,7.7,"49,530",94
8,Manitoba,N07BA,Drugs used in nicotine dependence,<65,Total,278.76,0.1,0.8,"5,276",95
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,259.71,0.1,1.8,"11,793",96
8,Manitoba,A16AX,Various alimentary tract and metabolism products,<65,Total,259.14,0.1,0.0,5,97
8,Manitoba,J02AC,Triazole derivatives,<65,Total,257.34,0.1,1.1,"7,294",98
8,Manitoba,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,Total,247.90,0.1,0.0,92,99
8,Manitoba,G02BA,Intrauterine contraceptives,<65,Total,235.99,0.1,0.7,"4,843",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"28,185.81",24.8,0.4,"1,126",1
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,<65,M,"9,313.42",8.2,0.1,161,2
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"4,130.92",3.6,0.2,523,3
8,Manitoba,N05AX,Other antipsychotics,<65,M,"4,064.27",3.6,1.6,"4,617",4
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"3,906.52",3.4,2.4,"6,929",5
8,Manitoba,L01XE,Protein kinase inhibitors,<65,M,"3,790.58",3.3,0.0,125,6
8,Manitoba,A16AB,Enzymes,<65,M,**,**,**,**,7
8,Manitoba,L04AA,Selective immunosuppressants,<65,M,"2,434.32",2.1,0.2,522,8
8,Manitoba,N02AA,Natural opium alkaloids,<65,M,"2,433.52",2.1,1.4,"4,164",9
8,Manitoba,L04AX,Other immunosuppressants,<65,M,"2,406.88",2.1,0.2,654,10
8,Manitoba,L04AC,Interleukin inhibitors,<65,M,"2,130.63",1.9,0.1,152,11
8,Manitoba,N03AX,Other antiepileptics,<65,M,"1,861.78",1.6,3.2,"9,256",12
8,Manitoba,N06BA,Centrally acting sympathomimetics,<65,M,"1,826.90",1.6,3.3,"9,767",13
8,Manitoba,J05AE,Protease inhibitors,<65,M,"1,537.67",1.4,0.1,245,14
8,Manitoba,N06AX,Other antidepressants,<65,M,"1,320.10",1.2,4.9,"14,352",15
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,<65,M,"1,320.05",1.2,7.1,"20,863",16
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"1,263.81",1.1,3.2,"9,241",17
8,Manitoba,N07BC,Drugs used in opioid dependence,<65,M,"1,169.18",1.0,0.3,882,18
8,Manitoba,L04AD,Calcineurin inhibitors,<65,M,"1,127.17",1.0,0.1,345,19
8,Manitoba,A02BC,Proton pump inhibitors,<65,M,"1,119.02",1.0,10.9,"32,025",20
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,<65,M,984.07,0.9,12.8,"37,596",21
8,Manitoba,L03AB,Interferons,<65,M,959.37,0.8,0.0,60,22
8,Manitoba,B02AB,Proteinase inhibitors,<65,M,938.07,0.8,0.0,7,23
8,Manitoba,C09AA,"ACE inhibitors, plain",<65,M,842.71,0.7,7.8,"23,018",24
8,Manitoba,L03AX,Other immunostimulants,<65,M,822.49,0.7,0.0,80,25
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,772.36,0.7,13.7,"40,239",26
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,763.59,0.7,1.2,"3,512",27
8,Manitoba,J05AX,Other antivirals,<65,M,728.34,0.6,0.0,104,28
8,Manitoba,N07XX,Other nervous system drugs,<65,M,672.56,0.6,0.0,77,29
8,Manitoba,H01CB,Somatostatin and analogues,<65,M,663.45,0.6,0.0,32,30
8,Manitoba,N05BA,Benzodiazepine derivatives,<65,M,622.09,0.5,4.6,"13,366",31
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",<65,M,586.58,0.5,0.5,"1,426",32
8,Manitoba,A04AD,Other antiemetics,<65,M,574.59,0.5,0.2,713,33
8,Manitoba,N03AG,Fatty acid derivatives,<65,M,545.73,0.5,0.6,"1,763",34
8,Manitoba,C08CA,Dihydropyridine derivatives,<65,M,544.61,0.5,5.4,"15,767",35
8,Manitoba,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,539.92,0.5,0.1,198,36
8,Manitoba,N03AE,Benzodiazepine derivatives,<65,M,491.58,0.4,1.9,"5,562",37
8,Manitoba,B01AB,Heparin group,<65,M,484.10,0.4,0.1,332,38
8,Manitoba,R03BA,Glucocorticoids,<65,M,460.61,0.4,4.1,"12,137",39
8,Manitoba,A10BA,Biguanides,<65,M,458.53,0.4,6.1,"18,022",40
8,Manitoba,N05CF,Benzodiazepine-related drugs,<65,M,440.14,0.4,3.7,"10,722",41
8,Manitoba,H01AC,Somatropin and somatropin agonists,<65,M,388.31,0.3,0.0,49,42
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,373.89,0.3,2.0,"5,815",43
8,Manitoba,C07AB,"Beta-blocking agents, selective",<65,M,371.08,0.3,4.3,"12,678",44
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,347.90,0.3,0.8,"2,222",45
8,Manitoba,R07AX,Other respiratory system products,<65,M,**,**,**,*,46
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,328.10,0.3,11.4,"33,321",47
8,Manitoba,L02BX,Other hormone antagonists and related agents,<65,M,312.79,0.3,0.0,12,48
8,Manitoba,L02BB,Antiandrogens,<65,M,312.38,0.3,0.0,110,49
8,Manitoba,N03AF,Carboxamide derivatives,<65,M,310.43,0.3,0.4,"1,192",50
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,307.59,0.3,0.4,"1,035",51
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,<65,M,303.25,0.3,0.6,"1,617",52
8,Manitoba,A10BB,Sulfonylureas,<65,M,301.10,0.3,3.1,"9,005",53
8,Manitoba,R03BB,Anticholinergics,<65,M,285.88,0.3,0.8,"2,395",54
8,Manitoba,M03BX,Other centrally acting agents,<65,M,283.74,0.2,3.3,"9,637",55
8,Manitoba,L01AX,Other alkylating agents,<65,M,273.73,0.2,0.0,31,56
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,271.64,0.2,0.1,249,57
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,<65,M,268.72,0.2,0.4,"1,242",58
8,Manitoba,A09AA,Enzyme preparations,<65,M,253.60,0.2,0.1,278,59
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,252.05,0.2,0.5,"1,429",60
8,Manitoba,B01AF,Direct factor Xa inhibitors,<65,M,250.82,0.2,0.5,"1,458",61
8,Manitoba,L01XC,Monoclonal antibodies,<65,M,249.08,0.2,0.0,24,62
8,Manitoba,H03AA,Thyroid hormones,<65,M,244.58,0.2,3.1,"9,125",63
8,Manitoba,N04BA,Dopa and dopa derivatives,<65,M,236.42,0.2,0.1,405,64
8,Manitoba,A02BA,H2-receptor antagonists,<65,M,234.30,0.2,2.3,"6,689",65
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,223.86,0.2,0.0,25,66
8,Manitoba,C02AC,Imidazoline receptor agonists,<65,M,220.24,0.2,0.5,"1,384",67
8,Manitoba,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,210.73,0.2,0.0,71,68
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,208.87,0.2,1.1,"3,262",69
8,Manitoba,R05CB,Mucolytics,<65,M,206.51,0.2,0.0,23,70
8,Manitoba,C09BA,ACE inhibitors and diuretics,<65,M,200.82,0.2,1.8,"5,374",71
8,Manitoba,C09CA,"Angiotensin II antagonists, plain",<65,M,199.00,0.2,3.6,"10,456",72
8,Manitoba,H01AX,Other anterior pituitary lobe hormones and analogues,<65,M,**,**,**,*,73
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,193.94,0.2,0.0,17,74
8,Manitoba,N02AB,Phenylpiperidine derivatives,<65,M,193.93,0.2,0.1,303,75
8,Manitoba,M01AB,Acetic acid derivatives and related substances,<65,M,188.18,0.2,4.5,"13,055",76
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,187.02,0.2,0.2,712,77
8,Manitoba,J01CA,Penicillins with extended spectrum,<65,M,184.80,0.2,21.3,"62,372",78
8,Manitoba,M01AE,Propionic acid derivatives,<65,M,184.12,0.2,8.5,"24,822",79
8,Manitoba,C10AB,Fibrates,<65,M,183.02,0.2,0.9,"2,584",80
8,Manitoba,R01AD,Corticosteroids,<65,M,180.59,0.2,7.7,"22,488",81
8,Manitoba,H02AB,Glucocorticoids,<65,M,173.16,0.2,6.0,"17,701",82
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,153.13,0.1,1.8,"5,325",83
8,Manitoba,B06AC,Drugs used in hereditary angioedema,<65,M,**,**,**,*,84
8,Manitoba,G04CA,Alpha-adrenoreceptor antagonists,<65,M,146.06,0.1,2.1,"6,222",85
8,Manitoba,C03CA,"Sulfonamides, plain",<65,M,144.07,0.1,1.1,"3,087",86
8,Manitoba,J01DB,First-generation cephalosporins,<65,M,142.91,0.1,7.6,"22,293",87
8,Manitoba,N05AE,Indole derivatives,<65,M,140.29,0.1,0.1,164,88
8,Manitoba,N02BE,Anilides,<65,M,139.85,0.1,1.3,"3,831",89
8,Manitoba,C01CA,Adrenergic and dopaminergic agents,<65,M,139.44,0.1,1.9,"5,536",90
8,Manitoba,N05AA,Phenothiazines with aliphatic side-chain,<65,M,134.72,0.1,0.2,514,91
8,Manitoba,J01GB,Other aminoglycosides,<65,M,130.00,0.1,0.0,19,92
8,Manitoba,R03DC,Leukotriene receptor antagonists,<65,M,125.73,0.1,1.4,"4,167",93
8,Manitoba,J02AC,Triazole derivatives,<65,M,121.98,0.1,0.4,"1,070",94
8,Manitoba,J01FA,Macrolides,<65,M,121.89,0.1,10.9,"31,868",95
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",<65,M,121.79,0.1,7.3,"21,519",96
8,Manitoba,N05CD,Benzodiazepine derivatives,<65,M,121.77,0.1,0.6,"1,867",97
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,<65,M,120.96,0.1,0.3,739,98
8,Manitoba,N07BA,Drugs used in nicotine dependence,<65,M,120.87,0.1,0.9,"2,744",99
8,Manitoba,N03AB,Hydantoin derivatives,<65,M,117.14,0.1,0.4,"1,173",100
8,Manitoba,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"29,421.92",26.5,0.3,"1,229",1
8,Manitoba,J05AP,Antivirals for treatment of HCV infections,<65,F,"4,423.71",4.0,0.0,82,2
8,Manitoba,L04AA,Selective immunosuppressants,<65,F,"4,389.39",4.0,0.2,737,3
8,Manitoba,L03AB,Interferons,<65,F,"3,453.63",3.1,0.1,221,4
8,Manitoba,L01XE,Protein kinase inhibitors,<65,F,"2,655.94",2.4,0.0,93,5
8,Manitoba,N05AX,Other antipsychotics,<65,F,"2,642.54",2.4,1.1,"4,004",6
8,Manitoba,N03AX,Other antiepileptics,<65,F,"2,353.52",2.1,4.0,"14,005",7
8,Manitoba,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"2,145.31",1.9,2.1,"7,447",8
8,Manitoba,L04AC,Interleukin inhibitors,<65,F,"2,142.36",1.9,0.0,165,9
8,Manitoba,N06AX,Other antidepressants,<65,F,"2,102.52",1.9,7.7,"27,236",10
8,Manitoba,N02AA,Natural opium alkaloids,<65,F,"1,957.30",1.8,1.4,"4,781",11
8,Manitoba,L03AX,Other immunostimulants,<65,F,"1,937.66",1.7,0.1,206,12
8,Manitoba,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,914.85",1.7,11.9,"41,934",13
8,Manitoba,L04AX,Other immunosuppressants,<65,F,"1,906.11",1.7,0.3,899,14
8,Manitoba,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"1,830.74",1.7,0.1,330,15
8,Manitoba,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"1,788.54",1.6,3.3,"11,512",16
8,Manitoba,A02BC,Proton pump inhibitors,<65,F,"1,491.38",1.3,10.9,"38,677",17
8,Manitoba,N07XX,Other nervous system drugs,<65,F,"1,242.86",1.1,0.0,112,18
8,Manitoba,N07BC,Drugs used in opioid dependence,<65,F,991.56,0.9,0.2,715,19
8,Manitoba,N06BA,Centrally acting sympathomimetics,<65,F,972.48,0.9,1.5,"5,286",20
8,Manitoba,A04AD,Other antiemetics,<65,F,937.59,0.8,0.4,"1,390",21
8,Manitoba,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,892.15,0.8,12.5,"44,310",22
8,Manitoba,C10AA,HMG-CoA reductase inhibitors,<65,F,807.17,0.7,6.7,"23,769",23
8,Manitoba,L01XC,Monoclonal antibodies,<65,F,742.50,0.7,0.0,76,24
8,Manitoba,H01CB,Somatostatin and analogues,<65,F,732.19,0.7,0.0,39,25
8,Manitoba,L04AD,Calcineurin inhibitors,<65,F,702.80,0.6,0.1,211,26
8,Manitoba,J05AE,Protease inhibitors,<65,F,693.41,0.6,0.0,131,27
8,Manitoba,A04AA,Serotonin (5HT3) antagonists,<65,F,688.54,0.6,0.7,"2,548",28
8,Manitoba,N05BA,Benzodiazepine derivatives,<65,F,677.24,0.6,7.0,"24,648",29
8,Manitoba,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,671.60,0.6,0.0,40,30
8,Manitoba,B01AB,Heparin group,<65,F,671.12,0.6,0.2,555,31
8,Manitoba,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,665.53,0.6,0.9,"3,254",32
8,Manitoba,N03AE,Benzodiazepine derivatives,<65,F,660.41,0.6,2.5,"8,953",33
8,Manitoba,C09AA,"ACE inhibitors, plain",<65,F,656.35,0.6,4.3,"15,306",34
8,Manitoba,H03AA,Thyroid hormones,<65,F,617.03,0.6,9.6,"34,000",35
8,Manitoba,R03BA,Glucocorticoids,<65,F,572.92,0.5,3.6,"12,703",36
8,Manitoba,N05CF,Benzodiazepine-related drugs,<65,F,572.87,0.5,5.0,"17,549",37
8,Manitoba,B02AB,Proteinase inhibitors,<65,F,568.48,0.5,0.0,5,38
8,Manitoba,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,527.10,0.5,3.3,"11,769",39
8,Manitoba,A10AE,"Insulins and analogues for injection, long-acting",<65,F,508.44,0.5,0.4,"1,273",40
8,Manitoba,L02BG,Aromatase inhibitors,<65,F,452.35,0.4,0.7,"2,350",41
8,Manitoba,A16AB,Enzymes,<65,F,**,**,**,*,42
8,Manitoba,C08CA,Dihydropyridine derivatives,<65,F,441.99,0.4,3.5,"12,254",43
8,Manitoba,A10BA,Biguanides,<65,F,434.16,0.4,4.3,"15,190",44
8,Manitoba,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,417.28,0.4,11.0,"39,020",45
8,Manitoba,N02CC,Selective serotonin (5HT1) agonists,<65,F,400.49,0.4,1.9,"6,635",46
8,Manitoba,N03AG,Fatty acid derivatives,<65,F,368.71,0.3,0.4,"1,522",47
8,Manitoba,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,367.44,0.3,10.2,"36,049",48
8,Manitoba,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,364.38,0.3,0.1,430,49
8,Manitoba,G04BD,Drugs for urinary frequency and incontinence,<65,F,335.59,0.3,0.7,"2,642",50
8,Manitoba,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,334.33,0.3,0.3,898,51
8,Manitoba,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,327.66,0.3,0.6,"2,011",52
8,Manitoba,A07EC,Aminosalicylic acid and similar agents,<65,F,320.64,0.3,0.5,"1,893",53
8,Manitoba,M03BX,Other centrally acting agents,<65,F,320.46,0.3,3.3,"11,625",54
8,Manitoba,N02AB,Phenylpiperidine derivatives,<65,F,320.42,0.3,0.1,436,55
8,Manitoba,R03BB,Anticholinergics,<65,F,290.73,0.3,0.8,"2,690",56
8,Manitoba,A02BA,H2-receptor antagonists,<65,F,266.69,0.2,3.0,"10,620",57
8,Manitoba,M01AE,Propionic acid derivatives,<65,F,263.41,0.2,9.2,"32,437",58
8,Manitoba,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,261.85,0.2,0.0,38,59
8,Manitoba,A10BB,Sulfonylureas,<65,F,260.76,0.2,1.8,"6,334",60
8,Manitoba,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,256.89,0.2,0.3,"1,125",61
8,Manitoba,R01AD,Corticosteroids,<65,F,254.94,0.2,8.9,"31,506",62
8,Manitoba,N05AE,Indole derivatives,<65,F,254.59,0.2,0.1,284,63
8,Manitoba,C07AB,"Beta-blocking agents, selective",<65,F,251.71,0.2,2.4,"8,348",64
8,Manitoba,N03AF,Carboxamide derivatives,<65,F,250.24,0.2,0.3,"1,218",65
8,Manitoba,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,243.73,0.2,3.3,"11,586",66
8,Manitoba,A16AX,Various alimentary tract and metabolism products,<65,F,**,**,**,*,67
8,Manitoba,J01CA,Penicillins with extended spectrum,<65,F,239.50,0.2,21.4,"75,688",68
8,Manitoba,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,238.79,0.2,0.0,71,69
8,Manitoba,G02BA,Intrauterine contraceptives,<65,F,235.44,0.2,1.4,"4,839",70
8,Manitoba,H02AB,Glucocorticoids,<65,F,233.17,0.2,6.1,"21,649",71
8,Manitoba,C09CA,"Angiotensin II antagonists, plain",<65,F,226.74,0.2,2.9,"10,164",72
8,Manitoba,R07AX,Other respiratory system products,<65,F,**,**,**,*,73
8,Manitoba,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,224.42,0.2,3.2,"11,425",74
8,Manitoba,M01AB,Acetic acid derivatives and related substances,<65,F,223.61,0.2,2.9,"10,266",75
8,Manitoba,C02AC,Imidazoline receptor agonists,<65,F,218.47,0.2,0.6,"2,174",76
8,Manitoba,B01AF,Direct factor Xa inhibitors,<65,F,209.73,0.2,0.4,"1,253",77
8,Manitoba,R03DC,Leukotriene receptor antagonists,<65,F,207.85,0.2,1.5,"5,307",78
8,Manitoba,J05AX,Other antivirals,<65,F,197.44,0.2,0.0,34,79
8,Manitoba,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,197.20,0.2,4.3,"15,285",80
8,Manitoba,L01AX,Other alkylating agents,<65,F,196.99,0.2,0.0,30,81
8,Manitoba,H01AC,Somatropin and somatropin agonists,<65,F,195.91,0.2,0.0,36,82
8,Manitoba,N02BE,Anilides,<65,F,186.57,0.2,1.4,"4,858",83
8,Manitoba,J01DB,First-generation cephalosporins,<65,F,176.65,0.2,7.2,"25,430",84
8,Manitoba,J01FA,Macrolides,<65,F,174.57,0.2,12.2,"43,188",85
8,Manitoba,C01CA,Adrenergic and dopaminergic agents,<65,F,173.85,0.2,1.9,"6,733",86
8,Manitoba,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,173.13,0.2,0.2,613,87
8,Manitoba,C09BA,ACE inhibitors and diuretics,<65,F,163.72,0.1,1.0,"3,609",88
8,Manitoba,C03CA,"Sulfonamides, plain",<65,F,161.72,0.1,1.0,"3,683",89
8,Manitoba,D07AC,"Corticosteroids, potent (group III)",<65,F,158.42,0.1,7.9,"28,011",90
8,Manitoba,A09AA,Enzyme preparations,<65,F,158.30,0.1,0.1,367,91
8,Manitoba,N07BA,Drugs used in nicotine dependence,<65,F,157.89,0.1,0.7,"2,532",92
8,Manitoba,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,147.98,0.1,0.4,"1,258",93
8,Manitoba,R06AA,Aminoalkyl ethers,<65,F,146.42,0.1,1.5,"5,176",94
8,Manitoba,G03AC,Progestogens,<65,F,143.43,0.1,2.4,"8,465",95
8,Manitoba,B06AC,Drugs used in hereditary angioedema,<65,F,**,**,**,**,96
8,Manitoba,A03FA,Propulsives,<65,F,137.43,0.1,1.8,"6,275",97
8,Manitoba,J02AC,Triazole derivatives,<65,F,135.36,0.1,1.8,"6,224",98
8,Manitoba,P03AC,"Pyrethrins, including synthetic compounds",<65,F,133.23,0.1,0.6,"2,209",99
8,Manitoba,R05CB,Mucolytics,<65,F,132.49,0.1,0.0,19,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"67,870.31",19.5,0.4,"3,175",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,Total,Total,"20,457.29",5.9,0.1,391,2
9,Saskatchewan,L04AA,Selective immunosuppressants,Total,Total,"10,964.48",3.1,0.3,"1,929",3
9,Saskatchewan,N02AA,Natural opium alkaloids,Total,Total,"7,819.09",2.2,5.8,"43,355",4
9,Saskatchewan,N05AX,Other antipsychotics,Total,Total,"7,802.46",2.2,1.4,"10,024",5
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"7,476.39",2.1,2.0,"15,011",6
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"7,076.49",2.0,1.8,"13,170",7
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,Total,Total,"6,835.92",2.0,1.7,"12,888",8
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"6,289.94",1.8,2.6,"19,297",9
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,Total,Total,"6,108.14",1.8,16.0,"118,542",10
9,Saskatchewan,N03AX,Other antiepileptics,Total,Total,"5,925.73",1.7,5.1,"38,124",11
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,Total,Total,"5,885.40",1.7,1.3,"9,713",12
9,Saskatchewan,C09AA,"ACE inhibitors, plain",Total,Total,"5,804.57",1.7,10.0,"73,975",13
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"5,555.49",1.6,0.1,758,14
9,Saskatchewan,N07XX,Other nervous system drugs,Total,Total,"5,343.09",1.5,0.1,389,15
9,Saskatchewan,A02BC,Proton pump inhibitors,Total,Total,"5,337.67",1.5,15.6,"115,524",16
9,Saskatchewan,S01LA,Antineovascularization agents,Total,Total,"5,103.36",1.5,0.4,"3,015",17
9,Saskatchewan,L04AC,Interleukin inhibitors,Total,Total,"5,057.55",1.5,0.1,379,18
9,Saskatchewan,C08CA,Dihydropyridine derivatives,Total,Total,"4,628.34",1.3,7.0,"51,591",19
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"4,005.30",1.2,9.6,"70,792",20
9,Saskatchewan,N06AX,Other antidepressants,Total,Total,"3,727.52",1.1,7.5,"55,648",21
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"3,521.71",1.0,1.6,"11,798",22
9,Saskatchewan,R03BA,Glucocorticoids,Total,Total,"3,504.71",1.0,5.8,"42,955",23
9,Saskatchewan,L03AB,Interferons,Total,Total,"3,452.51",1.0,0.0,229,24
9,Saskatchewan,R03BB,Anticholinergics,Total,Total,"3,387.24",1.0,2.0,"14,656",25
9,Saskatchewan,B01AB,Heparin group,Total,Total,"2,865.47",0.8,0.2,"1,528",26
9,Saskatchewan,L03AX,Other immunostimulants,Total,Total,"2,806.41",0.8,0.0,280,27
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"2,805.16",0.8,0.6,"4,689",28
9,Saskatchewan,B03XA,Other antianemic preparations,Total,Total,"2,730.01",0.8,0.1,"1,012",29
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,Total,Total,"2,629.10",0.8,3.4,"25,396",30
9,Saskatchewan,C09CA,"Angiotensin II antagonists, plain",Total,Total,"2,468.83",0.7,6.0,"44,825",31
9,Saskatchewan,L04AD,Calcineurin inhibitors,Total,Total,"2,404.82",0.7,0.1,700,32
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",Total,Total,"2,374.49",0.7,7.5,"55,367",33
9,Saskatchewan,N07BC,Drugs used in opioid dependence,Total,Total,"1,815.48",0.5,0.3,"2,312",34
9,Saskatchewan,A10BA,Biguanides,Total,Total,"1,737.16",0.5,6.9,"51,229",35
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,735.66",0.5,0.6,"4,369",36
9,Saskatchewan,C09DA,Angiotensin II antagonists and diuretics,Total,Total,"1,697.70",0.5,4.2,"30,922",37
9,Saskatchewan,H03AA,Thyroid hormones,Total,Total,"1,486.04",0.4,9.3,"68,729",38
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"1,401.52",0.4,3.6,"26,348",39
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"1,391.64",0.4,1.0,"7,749",40
9,Saskatchewan,L01XC,Monoclonal antibodies,Total,Total,"1,365.91",0.4,0.0,155,41
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"1,345.08",0.4,11.5,"84,956",42
9,Saskatchewan,J01DB,First-generation cephalosporins,Total,Total,"1,339.94",0.4,8.6,"63,496",43
9,Saskatchewan,C03CA,"Sulfonamides, plain",Total,Total,"1,302.71",0.4,3.9,"28,821",44
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"1,254.56",0.4,1.3,"9,963",45
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,Total,Total,"1,221.59",0.4,0.2,"1,523",46
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,214.47",0.3,1.3,"9,590",47
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"1,187.53",0.3,0.4,"3,176",48
9,Saskatchewan,S01ED,Beta-blocking agents,Total,Total,"1,184.37",0.3,1.0,"7,710",49
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"1,120.08",0.3,0.2,"1,671",50
9,Saskatchewan,A02BA,H2-receptor antagonists,Total,Total,"1,025.91",0.3,3.8,"28,005",51
9,Saskatchewan,S01EE,Prostaglandin analogues,Total,Total,"1,001.90",0.3,1.0,"7,412",52
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,Total,Total,981.86,0.3,1.4,"10,073",53
9,Saskatchewan,J05AE,Protease inhibitors,Total,Total,973.21,0.3,0.0,180,54
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,945.29,0.3,0.2,"1,728",55
9,Saskatchewan,B01AE,Direct thrombin inhibitors,Total,Total,938.55,0.3,0.1,"1,098",56
9,Saskatchewan,C08DB,Benzothiazepine derivatives,Total,Total,890.45,0.3,0.8,"6,133",57
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,871.38,0.3,3.1,"22,788",58
9,Saskatchewan,A12BA,Potassium,Total,Total,858.56,0.2,1.9,"13,761",59
9,Saskatchewan,N04BA,Dopa and dopa derivatives,Total,Total,857.36,0.2,0.4,"2,659",60
9,Saskatchewan,J05AX,Other antivirals,Total,Total,835.81,0.2,0.0,208,61
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,811.85,0.2,0.0,51,62
9,Saskatchewan,L04AX,Other immunosuppressants,Total,Total,810.78,0.2,0.3,"1,958",63
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,792.03,0.2,2.1,"15,791",64
9,Saskatchewan,A10BB,Sulfonylureas,Total,Total,784.75,0.2,2.6,"18,959",65
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,Total,Total,779.03,0.2,0.7,"5,359",66
9,Saskatchewan,J01CA,Penicillins with extended spectrum,Total,Total,776.26,0.2,18.4,"136,717",67
9,Saskatchewan,R01AD,Corticosteroids,Total,Total,771.63,0.2,7.8,"57,570",68
9,Saskatchewan,N03AG,Fatty acid derivatives,Total,Total,763.49,0.2,0.6,"4,323",69
9,Saskatchewan,B01AA,Vitamin K antagonists,Total,Total,763.44,0.2,1.8,"13,393",70
9,Saskatchewan,N05BA,Benzodiazepine derivatives,Total,Total,756.63,0.2,3.7,"27,174",71
9,Saskatchewan,A09AA,Enzyme preparations,Total,Total,742.98,0.2,0.1,866,72
9,Saskatchewan,C01DA,Organic nitrates,Total,Total,726.31,0.2,1.5,"11,124",73
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,718.58,0.2,0.1,837,74
9,Saskatchewan,M05BA,Bisphosphonates,Total,Total,710.88,0.2,0.9,"7,033",75
9,Saskatchewan,R05CB,Mucolytics,Total,Total,695.51,0.2,0.0,121,76
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,691.77,0.2,3.5,"25,890",77
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,680.00,0.2,0.4,"3,027",78
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,663.23,0.2,5.8,"43,092",79
9,Saskatchewan,H02AB,Glucocorticoids,Total,Total,662.58,0.2,7.8,"57,506",80
9,Saskatchewan,A16AB,Enzymes,Total,Total,658.65,0.2,0.0,6,81
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",Total,Total,655.74,0.2,1.3,"9,516",82
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,Total,Total,653.48,0.2,4.0,"29,366",83
9,Saskatchewan,J01FA,Macrolides,Total,Total,628.99,0.2,11.0,"81,407",84
9,Saskatchewan,V03AC,Iron-chelating agents,Total,Total,604.90,0.2,0.0,38,85
9,Saskatchewan,H01CB,Somatostatin and analogues,Total,Total,604.63,0.2,0.0,39,86
9,Saskatchewan,M03BX,Other centrally acting agents,Total,Total,593.84,0.2,1.9,"14,075",87
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,Total,Total,579.51,0.2,2.1,"15,212",88
9,Saskatchewan,R07AX,Other respiratory system products,Total,Total,**, ** , ** ,*,89
9,Saskatchewan,C10AX,Other lipid-modifying agents,Total,Total,536.90,0.2,1.1,"7,859",90
9,Saskatchewan,M01AE,Propionic acid derivatives,Total,Total,534.96,0.2,8.9,"65,739",91
9,Saskatchewan,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,521.67,0.1,1.0,"7,745",92
9,Saskatchewan,J02AC,Triazole derivatives,Total,Total,509.06,0.1,1.5,"10,936",93
9,Saskatchewan,C03DA,Aldosterone antagonists,Total,Total,500.55,0.1,1.4,"10,281",94
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,Total,Total,477.02,0.1,0.0,41,95
9,Saskatchewan,N05AF,Thioxanthene derivatives,Total,Total,475.61,0.1,0.1,"1,096",96
9,Saskatchewan,M01AH,Coxibs,Total,Total,464.55,0.1,1.3,"9,350",97
9,Saskatchewan,J01DF,Monobactams,Total,Total,454.13,0.1,0.0,29,98
9,Saskatchewan,N03AF,Carboxamide derivatives,Total,Total,451.78,0.1,0.4,"2,808",99
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,446.76,0.1,0.0,54,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"32,381.36",19.1,0.4,"1,399",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,Total,M,"13,193.57",7.8,0.1,256,2
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,Total,M,"4,772.05",2.8,2.4,"8,283",3
9,Saskatchewan,N05AX,Other antipsychotics,Total,M,"4,765.81",2.8,1.5,"5,194",4
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"4,336.28",2.6,2.5,"8,617",5
9,Saskatchewan,L04AA,Selective immunosuppressants,Total,M,"3,944.83",2.3,0.2,761,6
9,Saskatchewan,N02AA,Natural opium alkaloids,Total,M,"3,746.95",2.2,5.7,"19,345",7
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"3,721.08",2.2,0.2,514,8
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"3,562.49",2.1,2.4,"8,312",9
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"3,215.79",1.9,1.8,"6,011",10
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,Total,M,"3,125.18",1.8,20.0,"68,144",11
9,Saskatchewan,C09AA,"ACE inhibitors, plain",Total,M,"2,928.72",1.7,12.3,"41,984",12
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,Total,M,"2,836.47",1.7,1.4,"4,793",13
9,Saskatchewan,N03AX,Other antiepileptics,Total,M,"2,503.34",1.5,4.4,"15,092",14
9,Saskatchewan,L04AC,Interleukin inhibitors,Total,M,"2,242.98",1.3,0.0,151,15
9,Saskatchewan,A02BC,Proton pump inhibitors,Total,M,"2,162.07",1.3,15.2,"51,917",16
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"2,081.29",1.2,1.9,"6,582",17
9,Saskatchewan,C08CA,Dihydropyridine derivatives,Total,M,"2,040.28",1.2,7.6,"25,923",18
9,Saskatchewan,S01LA,Antineovascularization agents,Total,M,"1,923.92",1.1,0.4,"1,248",19
9,Saskatchewan,R03BA,Glucocorticoids,Total,M,"1,684.17",1.0,6.1,"20,696",20
9,Saskatchewan,R03BB,Anticholinergics,Total,M,"1,667.10",1.0,2.1,"7,123",21
9,Saskatchewan,B03XA,Other antianemic preparations,Total,M,"1,538.26",0.9,0.2,575,22
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"1,525.86",0.9,0.8,"2,690",23
9,Saskatchewan,L04AD,Calcineurin inhibitors,Total,M,"1,477.50",0.9,0.1,430,24
9,Saskatchewan,B01AB,Heparin group,Total,M,"1,444.28",0.9,0.2,621,25
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,Total,M,"1,427.94",0.8,6.8,"23,135",26
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,Total,M,"1,375.04",0.8,4.2,"14,475",27
9,Saskatchewan,N07XX,Other nervous system drugs,Total,M,"1,358.16",0.8,0.0,106,28
9,Saskatchewan,N06AX,Other antidepressants,Total,M,"1,297.35",0.8,5.7,"19,539",29
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",Total,M,"1,113.42",0.7,8.6,"29,191",30
9,Saskatchewan,C09CA,"Angiotensin II antagonists, plain",Total,M,975.98,0.6,6.1,"20,917",31
9,Saskatchewan,N07BC,Drugs used in opioid dependence,Total,M,947.68,0.6,0.4,"1,325",32
9,Saskatchewan,A10BA,Biguanides,Total,M,895.85,0.5,8.4,"28,615",33
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,Total,M,867.80,0.5,0.6,"2,072",34
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,Total,M,853.98,0.5,6.4,"21,674",35
9,Saskatchewan,L03AB,Interferons,Total,M,848.21,0.5,0.0,56,36
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,735.10,0.4,1.8,"6,039",37
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,711.17,0.4,1.1,"3,658",38
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,695.33,0.4,0.6,"1,943",39
9,Saskatchewan,C09DA,Angiotensin II antagonists and diuretics,Total,M,689.22,0.4,4.4,"14,928",40
9,Saskatchewan,A16AB,Enzymes,Total,M,**, ** , ** ,*,41
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,654.95,0.4,0.3,"1,010",42
9,Saskatchewan,J01DB,First-generation cephalosporins,Total,M,642.89,0.4,8.9,"30,275",43
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,631.79,0.4,0.3,"1,040",44
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,623.98,0.4,11.8,"40,375",45
9,Saskatchewan,J05AE,Protease inhibitors,Total,M,598.16,0.4,0.0,114,46
9,Saskatchewan,J05AX,Other antivirals,Total,M,583.59,0.3,0.0,136,47
9,Saskatchewan,C03CA,"Sulfonamides, plain",Total,M,555.23,0.3,3.7,"12,684",48
9,Saskatchewan,L03AX,Other immunostimulants,Total,M,550.14,0.3,0.0,60,49
9,Saskatchewan,R07AX,Other respiratory system products,Total,M,**, ** , ** ,*,50
9,Saskatchewan,L04AX,Other immunosuppressants,Total,M,540.57,0.3,0.3,902,51
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,Total,M,528.60,0.3,1.3,"4,394",52
9,Saskatchewan,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,519.12,0.3,2.2,"7,648",53
9,Saskatchewan,L01XC,Monoclonal antibodies,Total,M,516.58,0.3,0.0,61,54
9,Saskatchewan,A09AA,Enzyme preparations,Total,M,515.18,0.3,0.1,439,55
9,Saskatchewan,N04BA,Dopa and dopa derivatives,Total,M,503.27,0.3,0.4,"1,445",56
9,Saskatchewan,B01AE,Direct thrombin inhibitors,Total,M,489.31,0.3,0.2,604,57
9,Saskatchewan,S01ED,Beta-blocking agents,Total,M,480.10,0.3,1.0,"3,414",58
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,Total,M,476.84,0.3,0.8,"2,861",59
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,Total,M,474.48,0.3,0.2,528,60
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,457.15,0.3,2.4,"8,066",61
9,Saskatchewan,N03AG,Fatty acid derivatives,Total,M,431.88,0.3,0.7,"2,233",62
9,Saskatchewan,A02BA,H2-receptor antagonists,Total,M,421.47,0.2,3.2,"10,893",63
9,Saskatchewan,A10BB,Sulfonylureas,Total,M,416.91,0.2,3.3,"11,410",64
9,Saskatchewan,R05CB,Mucolytics,Total,M,398.88,0.2,0.0,68,65
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,385.82,0.2,0.5,"1,643",66
9,Saskatchewan,B01AA,Vitamin K antagonists,Total,M,384.07,0.2,2.2,"7,491",67
9,Saskatchewan,H03AA,Thyroid hormones,Total,M,377.62,0.2,4.7,"16,023",68
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,Total,M,372.18,0.2,3.4,"11,575",69
9,Saskatchewan,V03AC,Iron-chelating agents,Total,M,370.62,0.2,0.0,21,70
9,Saskatchewan,S01EE,Prostaglandin analogues,Total,M,365.98,0.2,0.9,"3,075",71
9,Saskatchewan,J01CA,Penicillins with extended spectrum,Total,M,358.84,0.2,18.5,"63,247",72
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,Total,M,357.68,0.2,0.0,29,73
9,Saskatchewan,C08DB,Benzothiazepine derivatives,Total,M,353.63,0.2,0.8,"2,653",74
9,Saskatchewan,R01AD,Corticosteroids,Total,M,345.05,0.2,7.1,"24,332",75
9,Saskatchewan,C01DA,Organic nitrates,Total,M,318.16,0.2,1.8,"6,220",76
9,Saskatchewan,N05BA,Benzodiazepine derivatives,Total,M,305.12,0.2,2.8,"9,616",77
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,Total,M,304.85,0.2,4.8,"16,238",78
9,Saskatchewan,H02AB,Glucocorticoids,Total,M,299.37,0.2,7.7,"26,240",79
9,Saskatchewan,H01CB,Somatostatin and analogues,Total,M,292.26,0.2,0.0,17,80
9,Saskatchewan,A12BA,Potassium,Total,M,291.72,0.2,1.5,"5,071",81
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,Total,M,284.83,0.2,0.7,"2,470",82
9,Saskatchewan,J01FA,Macrolides,Total,M,283.83,0.2,10.5,"35,966",83
9,Saskatchewan,L01XE,Protein kinase inhibitors,Total,M,283.48,0.2,0.0,16,84
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,278.99,0.2,2.5,"8,385",85
9,Saskatchewan,N05AF,Thioxanthene derivatives,Total,M,278.42,0.2,0.2,620,86
9,Saskatchewan,C10AX,Other lipid-modifying agents,Total,M,274.28,0.2,1.4,"4,637",87
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,269.92,0.2,6.0,"20,461",88
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",Total,M,267.11,0.2,1.1,"3,911",89
9,Saskatchewan,M03BX,Other centrally acting agents,Total,M,251.50,0.1,1.9,"6,468",90
9,Saskatchewan,N03AF,Carboxamide derivatives,Total,M,246.26,0.1,0.4,"1,374",91
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,240.47,0.1,0.0,20,92
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,234.00,0.1,0.1,250,93
9,Saskatchewan,C03DA,Aldosterone antagonists,Total,M,233.22,0.1,1.3,"4,524",94
9,Saskatchewan,M01AE,Propionic acid derivatives,Total,M,230.04,0.1,8.9,"30,326",95
9,Saskatchewan,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,226.45,0.1,0.2,556,96
9,Saskatchewan,C10AB,Fibrates,Total,M,225.21,0.1,1.0,"3,377",97
9,Saskatchewan,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,224.84,0.1,0.0,94,98
9,Saskatchewan,J01DF,Monobactams,Total,M,212.00,0.1,0.0,15,99
9,Saskatchewan,C02AC,Imidazoline receptor agonists,Total,M,209.75,0.1,0.6,"2,162",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"35,488.95",19.8,0.4,"1,776",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,Total,F,"7,263.73",4.1,0.0,135,2
9,Saskatchewan,L04AA,Selective immunosuppressants,Total,F,"7,019.66",3.9,0.3,"1,168",3
9,Saskatchewan,N02AA,Natural opium alkaloids,Total,F,"4,072.13",2.3,6.0,"24,010",4
9,Saskatchewan,N07XX,Other nervous system drugs,Total,F,"3,984.93",2.2,0.1,283,5
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"3,860.70",2.2,1.8,"7,159",6
9,Saskatchewan,N03AX,Other antiepileptics,Total,F,"3,422.39",1.9,5.8,"23,032",7
9,Saskatchewan,S01LA,Antineovascularization agents,Total,F,"3,179.44",1.8,0.4,"1,767",8
9,Saskatchewan,A02BC,Proton pump inhibitors,Total,F,"3,175.59",1.8,15.9,"63,607",9
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"3,140.11",1.8,1.6,"6,394",10
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,Total,F,"3,048.93",1.7,1.2,"4,920",11
9,Saskatchewan,N05AX,Other antipsychotics,Total,F,"3,036.65",1.7,1.2,"4,830",12
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,Total,F,"2,982.96",1.7,12.6,"50,398",13
9,Saskatchewan,C09AA,"ACE inhibitors, plain",Total,F,"2,875.85",1.6,8.0,"31,991",14
9,Saskatchewan,L04AC,Interleukin inhibitors,Total,F,"2,814.57",1.6,0.1,228,15
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"2,727.45",1.5,2.7,"10,985",16
9,Saskatchewan,L03AB,Interferons,Total,F,"2,604.30",1.5,0.0,173,17
9,Saskatchewan,C08CA,Dihydropyridine derivatives,Total,F,"2,588.06",1.4,6.4,"25,668",18
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,Total,F,"2,577.35",1.4,11.9,"47,657",19
9,Saskatchewan,N06AX,Other antidepressants,Total,F,"2,430.18",1.4,9.0,"36,109",20
9,Saskatchewan,L03AX,Other immunostimulants,Total,F,"2,256.27",1.3,0.1,220,21
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,Total,F,"2,063.87",1.2,1.2,"4,605",22
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"1,834.41",1.0,0.1,244,23
9,Saskatchewan,R03BA,Glucocorticoids,Total,F,"1,820.54",1.0,5.6,"22,259",24
9,Saskatchewan,R03BB,Anticholinergics,Total,F,"1,720.14",1.0,1.9,"7,533",25
9,Saskatchewan,C09CA,"Angiotensin II antagonists, plain",Total,F,"1,492.85",0.8,6.0,"23,908",26
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"1,440.41",0.8,1.3,"5,216",27
9,Saskatchewan,B01AB,Heparin group,Total,F,"1,421.20",0.8,0.2,907,28
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"1,279.30",0.7,0.5,"1,999",29
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",Total,F,"1,261.08",0.7,6.5,"26,176",30
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,Total,F,"1,254.05",0.7,2.7,"10,921",31
9,Saskatchewan,B03XA,Other antianemic preparations,Total,F,"1,191.75",0.7,0.1,437,32
9,Saskatchewan,H03AA,Thyroid hormones,Total,F,"1,108.42",0.6,13.2,"52,706",33
9,Saskatchewan,C09DA,Angiotensin II antagonists and diuretics,Total,F,"1,008.48",0.6,4.0,"15,994",34
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,944.38,0.5,4.6,"18,282",35
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,Total,F,929.64,0.5,1.8,"7,120",36
9,Saskatchewan,L04AD,Calcineurin inhibitors,Total,F,927.32,0.5,0.1,270,37
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,Total,F,867.86,0.5,0.6,"2,297",38
9,Saskatchewan,N07BC,Drugs used in opioid dependence,Total,F,867.80,0.5,0.2,987,39
9,Saskatchewan,L01XC,Monoclonal antibodies,Total,F,849.32,0.5,0.0,94,40
9,Saskatchewan,A10BA,Biguanides,Total,F,841.31,0.5,5.7,"22,614",41
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,781.00,0.4,3.9,"15,687",42
9,Saskatchewan,C03CA,"Sulfonamides, plain",Total,F,747.48,0.4,4.0,"16,137",43
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,Total,F,747.11,0.4,0.2,995,44
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,721.11,0.4,11.1,"44,581",45
9,Saskatchewan,S01ED,Beta-blocking agents,Total,F,704.26,0.4,1.1,"4,296",46
9,Saskatchewan,J01DB,First-generation cephalosporins,Total,F,697.05,0.4,8.3,"33,221",47
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,680.47,0.4,1.0,"4,091",48
9,Saskatchewan,S01EE,Prostaglandin analogues,Total,F,635.92,0.4,1.1,"4,337",49
9,Saskatchewan,M05BA,Bisphosphonates,Total,F,608.92,0.3,1.6,"6,233",50
9,Saskatchewan,A02BA,H2-receptor antagonists,Total,F,604.44,0.3,4.3,"17,112",51
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,571.37,0.3,0.0,31,52
9,Saskatchewan,A12BA,Potassium,Total,F,566.84,0.3,2.2,"8,690",53
9,Saskatchewan,C08DB,Benzothiazepine derivatives,Total,F,536.82,0.3,0.9,"3,480",54
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,519.47,0.3,1.0,"3,924",55
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,492.20,0.3,0.3,"1,233",56
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,484.58,0.3,0.1,587,57
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,465.14,0.3,0.2,661,58
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,Total,F,453.26,0.3,1.4,"5,679",59
9,Saskatchewan,N05BA,Benzodiazepine derivatives,Total,F,451.52,0.3,4.4,"17,558",60
9,Saskatchewan,B01AE,Direct thrombin inhibitors,Total,F,449.24,0.3,0.1,494,61
9,Saskatchewan,R01AD,Corticosteroids,Total,F,426.58,0.2,8.3,"33,238",62
9,Saskatchewan,J01CA,Penicillins with extended spectrum,Total,F,417.42,0.2,18.4,"73,470",63
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,412.79,0.2,4.4,"17,505",64
9,Saskatchewan,C01DA,Organic nitrates,Total,F,408.15,0.2,1.2,"4,904",65
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,393.30,0.2,5.7,"22,631",66
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,Total,F,391.73,0.2,0.2,701,67
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",Total,F,388.63,0.2,1.4,"5,605",68
9,Saskatchewan,B01AA,Vitamin K antagonists,Total,F,379.37,0.2,1.5,"5,902",69
9,Saskatchewan,J05AE,Protease inhibitors,Total,F,375.05,0.2,0.0,66,70
9,Saskatchewan,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,370.07,0.2,8.6,"34,435",71
9,Saskatchewan,A10BB,Sulfonylureas,Total,F,367.83,0.2,1.9,"7,549",72
9,Saskatchewan,H02AB,Glucocorticoids,Total,F,363.21,0.2,7.8,"31,266",73
9,Saskatchewan,N04BA,Dopa and dopa derivatives,Total,F,354.09,0.2,0.3,"1,214",74
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,Total,F,348.63,0.2,3.3,"13,128",75
9,Saskatchewan,J01FA,Macrolides,Total,F,345.16,0.2,11.4,"45,441",76
9,Saskatchewan,M03BX,Other centrally acting agents,Total,F,342.34,0.2,1.9,"7,607",77
9,Saskatchewan,N03AG,Fatty acid derivatives,Total,F,331.62,0.2,0.5,"2,090",78
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,314.12,0.2,0.0,38,79
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,313.50,0.2,0.2,688,80
9,Saskatchewan,H01CB,Somatostatin and analogues,Total,F,312.37,0.2,0.0,22,81
9,Saskatchewan,M01AH,Coxibs,Total,F,309.14,0.2,1.5,"5,866",82
9,Saskatchewan,J02AC,Triazole derivatives,Total,F,308.69,0.2,2.3,"9,154",83
9,Saskatchewan,M01AE,Propionic acid derivatives,Total,F,304.92,0.2,8.9,"35,413",84
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,Total,F,302.19,0.2,0.6,"2,498",85
9,Saskatchewan,R05CB,Mucolytics,Total,F,296.63,0.2,0.0,53,86
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,294.18,0.2,0.3,"1,384",87
9,Saskatchewan,L01BA,Folic acid analogues,Total,F,280.04,0.2,0.7,"2,851",88
9,Saskatchewan,J01XE,Nitrofuran derivatives,Total,F,270.85,0.2,7.6,"30,346",89
9,Saskatchewan,L04AX,Other immunosuppressants,Total,F,270.21,0.2,0.3,"1,056",90
9,Saskatchewan,C03DA,Aldosterone antagonists,Total,F,267.33,0.1,1.4,"5,757",91
9,Saskatchewan,G02BA,Intrauterine contraceptives,Total,F,265.47,0.1,1.2,"4,858",92
9,Saskatchewan,C10AX,Other lipid-modifying agents,Total,F,262.62,0.1,0.8,"3,222",93
9,Saskatchewan,J05AX,Other antivirals,Total,F,252.23,0.1,0.0,72,94
9,Saskatchewan,N03AE,Benzodiazepine derivatives,Total,F,246.80,0.1,1.4,"5,665",95
9,Saskatchewan,J01DF,Monobactams,Total,F,242.13,0.1,0.0,14,96
9,Saskatchewan,C03AA,"Thiazides, plain",Total,F,240.61,0.1,4.5,"17,837",97
9,Saskatchewan,V03AC,Iron-chelating agents,Total,F,234.28,0.1,0.0,17,98
9,Saskatchewan,A03FA,Propulsives,Total,F,229.57,0.1,2.5,"9,890",99
9,Saskatchewan,A09AA,Enzyme preparations,Total,F,227.80,0.1,0.1,427,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"14,466.37",10.3,0.4,739,1
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,65+,Total,"5,491.06",3.9,4.8,"8,020",2
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"5,330.18",3.8,4.6,"7,554",3
9,Saskatchewan,S01LA,Antineovascularization agents,65+,Total,"4,728.69",3.4,1.5,"2,567",4
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"4,491.20",3.2,4.3,"7,111",5
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,65+,Total,"4,353.73",3.1,39.7,"65,785",6
9,Saskatchewan,C09AA,"ACE inhibitors, plain",65+,Total,"4,322.77",3.1,24.4,"40,489",7
9,Saskatchewan,C08CA,Dihydropyridine derivatives,65+,Total,"3,730.71",2.7,19.9,"32,901",8
9,Saskatchewan,A02BC,Proton pump inhibitors,65+,Total,"3,345.63",2.4,29.7,"49,198",9
9,Saskatchewan,N02AA,Natural opium alkaloids,65+,Total,"2,925.02",2.1,8.7,"14,472",10
9,Saskatchewan,R03BB,Anticholinergics,65+,Total,"2,789.81",2.0,6.0,"9,914",11
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"2,113.71",1.5,1.7,"2,775",12
9,Saskatchewan,N03AX,Other antiepileptics,65+,Total,"2,108.33",1.5,8.5,"14,096",13
9,Saskatchewan,L04AA,Selective immunosuppressants,65+,Total,"2,010.81",1.4,0.4,597,14
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,65+,Total,"1,988.92",1.4,0.0,36,15
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,65+,Total,"1,973.61",1.4,7.3,"12,157",16
9,Saskatchewan,C09CA,"Angiotensin II antagonists, plain",65+,Total,"1,935.50",1.4,16.1,"26,732",17
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",65+,Total,"1,852.59",1.3,22.9,"38,033",18
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"1,784.78",1.3,3.1,"5,055",19
9,Saskatchewan,B03XA,Other antianemic preparations,65+,Total,"1,751.83",1.2,0.4,643,20
9,Saskatchewan,B01AB,Heparin group,65+,Total,"1,737.28",1.2,0.6,917,21
9,Saskatchewan,R03BA,Glucocorticoids,65+,Total,"1,650.94",1.2,5.2,"8,664",22
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,496.89",1.1,9.8,"16,174",23
9,Saskatchewan,N06AX,Other antidepressants,65+,Total,"1,445.61",1.0,8.9,"14,780",24
9,Saskatchewan,C09DA,Angiotensin II antagonists and diuretics,65+,Total,"1,303.38",0.9,10.6,"17,608",25
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"1,236.50",0.9,3.4,"5,675",26
9,Saskatchewan,N05AX,Other antipsychotics,65+,Total,"1,228.04",0.9,1.9,"3,182",27
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"1,146.23",0.8,3.1,"5,097",28
9,Saskatchewan,A10BA,Biguanides,65+,Total,"1,082.54",0.8,15.4,"25,549",29
9,Saskatchewan,S01ED,Beta-blocking agents,65+,Total,"1,068.95",0.8,3.6,"5,898",30
9,Saskatchewan,C03CA,"Sulfonamides, plain",65+,Total,"1,061.43",0.8,13.6,"22,505",31
9,Saskatchewan,L04AC,Interleukin inhibitors,65+,Total,"1,033.21",0.7,0.0,81,32
9,Saskatchewan,H03AA,Thyroid hormones,65+,Total,"1,001.51",0.7,20.1,"33,277",33
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,949.00,0.7,4.0,"6,629",34
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,65+,Total,940.89,0.7,0.8,"1,244",35
9,Saskatchewan,S01EE,Prostaglandin analogues,65+,Total,927.65,0.7,3.5,"5,768",36
9,Saskatchewan,B01AE,Direct thrombin inhibitors,65+,Total,894.59,0.6,0.6,970,37
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,65+,Total,856.16,0.6,3.5,"5,772",38
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,797.20,0.6,0.6,945,39
9,Saskatchewan,N04BA,Dopa and dopa derivatives,65+,Total,756.57,0.5,1.3,"2,171",40
9,Saskatchewan,C08DB,Benzothiazepine derivatives,65+,Total,747.35,0.5,2.6,"4,368",41
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,723.28,0.5,9.6,"15,849",42
9,Saskatchewan,A12BA,Potassium,65+,Total,703.46,0.5,6.4,"10,656",43
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,700.79,0.5,0.7,"1,205",44
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,65+,Total,692.77,0.5,0.6,958,45
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,679.14,0.5,11.7,"19,403",46
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,676.76,0.5,5.1,"8,410",47
9,Saskatchewan,C01DA,Organic nitrates,65+,Total,647.27,0.5,5.0,"8,230",48
9,Saskatchewan,B01AA,Vitamin K antagonists,65+,Total,629.26,0.4,6.4,"10,530",49
9,Saskatchewan,M05BA,Bisphosphonates,65+,Total,618.02,0.4,3.6,"5,983",50
9,Saskatchewan,L04AX,Other immunosuppressants,65+,Total,602.22,0.4,0.3,509,51
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,568.94,0.4,3.7,"6,178",52
9,Saskatchewan,L01XC,Monoclonal antibodies,65+,Total,566.27,0.4,0.0,54,53
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,65+,Total,564.43,0.4,1.8,"2,908",54
9,Saskatchewan,A02BA,H2-receptor antagonists,65+,Total,546.18,0.4,5.7,"9,380",55
9,Saskatchewan,L04AD,Calcineurin inhibitors,65+,Total,536.77,0.4,0.1,179,56
9,Saskatchewan,A10BB,Sulfonylureas,65+,Total,498.64,0.4,5.9,"9,780",57
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,487.30,0.3,0.7,"1,167",58
9,Saskatchewan,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,477.63,0.3,3.5,"5,737",59
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,65+,Total,448.54,0.3,5.5,"9,070",60
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",65+,Total,425.43,0.3,2.5,"4,174",61
9,Saskatchewan,L03AB,Interferons,65+,Total,414.62,0.3,0.0,22,62
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,406.66,0.3,0.9,"1,455",63
9,Saskatchewan,C10AX,Other lipid-modifying agents,65+,Total,405.49,0.3,3.2,"5,307",64
9,Saskatchewan,R01AD,Corticosteroids,65+,Total,395.48,0.3,8.0,"13,260",65
9,Saskatchewan,V03AC,Iron-chelating agents,65+,Total,391.96,0.3,0.0,21,66
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,384.23,0.3,0.4,641,67
9,Saskatchewan,C03DA,Aldosterone antagonists,65+,Total,358.56,0.3,3.9,"6,493",68
9,Saskatchewan,L01XE,Protein kinase inhibitors,65+,Total,350.29,0.2,0.0,21,69
9,Saskatchewan,C01AA,Digitalis glycosides,65+,Total,337.95,0.2,2.3,"3,883",70
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,65+,Total,335.16,0.2,4.9,"8,201",71
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,332.71,0.2,2.8,"4,698",72
9,Saskatchewan,H02AB,Glucocorticoids,65+,Total,325.81,0.2,10.2,"16,844",73
9,Saskatchewan,M01AH,Coxibs,65+,Total,325.79,0.2,3.5,"5,845",74
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,319.44,0.2,0.0,35,75
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,317.91,0.2,0.2,269,76
9,Saskatchewan,C10AC,Bile acid sequestrants,65+,Total,304.50,0.2,0.6,"1,077",77
9,Saskatchewan,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,303.75,0.2,0.4,698,78
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,302.36,0.2,6.8,"11,320",79
9,Saskatchewan,N05BA,Benzodiazepine derivatives,65+,Total,294.20,0.2,5.5,"9,109",80
9,Saskatchewan,H01CB,Somatostatin and analogues,65+,Total,285.74,0.2,0.0,16,81
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,274.80,0.2,0.0,17,82
9,Saskatchewan,C03AA,"Thiazides, plain",65+,Total,274.19,0.2,10.4,"17,229",83
9,Saskatchewan,C10AB,Fibrates,65+,Total,256.92,0.2,1.4,"2,366",84
9,Saskatchewan,L01BA,Folic acid analogues,65+,Total,229.68,0.2,1.1,"1,864",85
9,Saskatchewan,J01DB,First-generation cephalosporins,65+,Total,229.58,0.2,9.1,"15,003",86
9,Saskatchewan,N04BC,Dopamine agonists,65+,Total,219.00,0.2,1.0,"1,599",87
9,Saskatchewan,C02DB,Hydrazinophthalazine derivatives,65+,Total,210.83,0.1,0.8,"1,292",88
9,Saskatchewan,L03AX,Other immunostimulants,65+,Total,207.55,0.1,0.0,17,89
9,Saskatchewan,A03FA,Propulsives,65+,Total,203.25,0.1,3.1,"5,206",90
9,Saskatchewan,J01XE,Nitrofuran derivatives,65+,Total,199.91,0.1,6.9,"11,363",91
9,Saskatchewan,D01AC,Imidazole and triazole derivatives,65+,Total,199.42,0.1,3.3,"5,423",92
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,65+,Total,187.02,0.1,0.7,"1,083",93
9,Saskatchewan,N07XX,Other nervous system drugs,65+,Total,184.70,0.1,0.0,28,94
9,Saskatchewan,J01FA,Macrolides,65+,Total,180.04,0.1,8.7,"14,346",95
9,Saskatchewan,B03BB,Folic acid and derivatives,65+,Total,179.95,0.1,2.8,"4,612",96
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",65+,Total,177.23,0.1,6.5,"10,849",97
9,Saskatchewan,S01EC,Carbonic anhydrase inhibitors,65+,Total,175.89,0.1,0.9,"1,518",98
9,Saskatchewan,M03BX,Other centrally acting agents,65+,Total,169.71,0.1,1.6,"2,711",99
9,Saskatchewan,A05AA,Bile acids and derivatives,65+,Total,165.95,0.1,0.1,241,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"5,782.73",9.0,0.4,275,1
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"2,689.38",4.2,5.4,"4,104",2
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,65+,M,"2,612.33",4.1,5.1,"3,856",3
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"2,424.12",3.8,4.6,"3,467",4
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,65+,M,"2,163.93",3.4,46.8,"35,280",5
9,Saskatchewan,C09AA,"ACE inhibitors, plain",65+,M,"2,098.34",3.3,28.6,"21,538",6
9,Saskatchewan,S01LA,Antineovascularization agents,65+,M,"1,729.45",2.7,1.3,981,7
9,Saskatchewan,C08CA,Dihydropyridine derivatives,65+,M,"1,533.87",2.4,19.4,"14,618",8
9,Saskatchewan,R03BB,Anticholinergics,65+,M,"1,358.98",2.1,6.5,"4,891",9
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,65+,M,"1,356.52",2.1,0.0,24,10
9,Saskatchewan,N02AA,Natural opium alkaloids,65+,M,"1,279.95",2.0,7.9,"5,970",11
9,Saskatchewan,A02BC,Proton pump inhibitors,65+,M,"1,267.40",2.0,27.6,"20,819",12
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"1,161.02",1.8,2.1,"1,579",13
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"1,111.75",1.7,3.9,"2,911",14
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,65+,M,"1,001.85",1.6,8.5,"6,429",15
9,Saskatchewan,B03XA,Other antianemic preparations,65+,M,964.40,1.5,0.5,361,16
9,Saskatchewan,B01AB,Heparin group,65+,M,913.24,1.4,0.5,375,17
9,Saskatchewan,N03AX,Other antiepileptics,65+,M,848.16,1.3,7.4,"5,585",18
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",65+,M,811.57,1.3,25.0,"18,861",19
9,Saskatchewan,C09CA,"Angiotensin II antagonists, plain",65+,M,722.09,1.1,15.1,"11,353",20
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,65+,M,712.83,1.1,20.6,"15,570",21
9,Saskatchewan,R03BA,Glucocorticoids,65+,M,702.23,1.1,4.9,"3,666",22
9,Saskatchewan,L04AA,Selective immunosuppressants,65+,M,698.97,1.1,0.3,221,23
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,579.77,0.9,3.2,"2,434",24
9,Saskatchewan,A10BA,Biguanides,65+,M,567.99,0.9,19.2,"14,491",25
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,550.34,0.9,5.0,"3,764",26
9,Saskatchewan,N05AX,Other antipsychotics,65+,M,526.76,0.8,1.6,"1,240",27
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,505.43,0.8,2.9,"2,210",28
9,Saskatchewan,C09DA,Angiotensin II antagonists and diuretics,65+,M,497.47,0.8,10.0,"7,521",29
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,484.78,0.8,0.8,588,30
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,65+,M,480.95,0.8,0.8,612,31
9,Saskatchewan,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,477.11,0.7,7.6,"5,713",32
9,Saskatchewan,N06AX,Other antidepressants,65+,M,465.23,0.7,6.7,"5,077",33
9,Saskatchewan,B01AE,Direct thrombin inhibitors,65+,M,462.44,0.7,0.7,508,34
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,65+,M,450.25,0.7,6.7,"5,034",35
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,446.32,0.7,1.0,770,36
9,Saskatchewan,N04BA,Dopa and dopa derivatives,65+,M,439.13,0.7,1.6,"1,195",37
9,Saskatchewan,C03CA,"Sulfonamides, plain",65+,M,436.95,0.7,13.0,"9,802",38
9,Saskatchewan,S01ED,Beta-blocking agents,65+,M,419.42,0.7,3.2,"2,411",39
9,Saskatchewan,L04AX,Other immunosuppressants,65+,M,395.88,0.6,0.3,225,40
9,Saskatchewan,L04AD,Calcineurin inhibitors,65+,M,361.59,0.6,0.2,124,41
9,Saskatchewan,L04AC,Interleukin inhibitors,65+,M,343.22,0.5,0.0,27,42
9,Saskatchewan,S01EE,Prostaglandin analogues,65+,M,332.26,0.5,3.0,"2,248",43
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,65+,M,329.89,0.5,2.4,"1,788",44
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,322.35,0.5,0.9,691,45
9,Saskatchewan,B01AA,Vitamin K antagonists,65+,M,310.03,0.5,7.5,"5,668",46
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,303.42,0.5,11.4,"8,576",47
9,Saskatchewan,L01XE,Protein kinase inhibitors,65+,M,283.48,0.4,0.0,16,48
9,Saskatchewan,C08DB,Benzothiazepine derivatives,65+,M,277.95,0.4,2.3,"1,717",49
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,65+,M,273.45,0.4,8.2,"6,178",50
9,Saskatchewan,C01DA,Organic nitrates,65+,M,271.35,0.4,5.7,"4,296",51
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,270.67,0.4,0.0,31,52
9,Saskatchewan,A10BB,Sulfonylureas,65+,M,265.56,0.4,7.6,"5,745",53
9,Saskatchewan,L01XC,Monoclonal antibodies,65+,M,259.46,0.4,0.0,25,54
9,Saskatchewan,V03AC,Iron-chelating agents,65+,M,248.94,0.4,0.0,13,55
9,Saskatchewan,H03AA,Thyroid hormones,65+,M,244.56,0.4,11.4,"8,610",56
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,240.45,0.4,1.1,837,57
9,Saskatchewan,A12BA,Potassium,65+,M,229.53,0.4,5.0,"3,808",58
9,Saskatchewan,A02BA,H2-receptor antagonists,65+,M,208.58,0.3,5.0,"3,755",59
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,65+,M,200.75,0.3,0.4,276,60
9,Saskatchewan,C10AX,Other lipid-modifying agents,65+,M,198.29,0.3,3.9,"2,906",61
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,65+,M,188.09,0.3,2.0,"1,535",62
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,186.74,0.3,3.3,"2,485",63
9,Saskatchewan,R01AD,Corticosteroids,65+,M,177.45,0.3,7.6,"5,708",64
9,Saskatchewan,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,174.67,0.3,0.5,381,65
9,Saskatchewan,C03DA,Aldosterone antagonists,65+,M,167.80,0.3,4.1,"3,077",66
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",65+,M,167.56,0.3,2.4,"1,798",67
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,65+,M,153.20,0.2,5.8,"4,356",68
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,150.95,0.2,2.3,"1,766",69
9,Saskatchewan,C01AA,Digitalis glycosides,65+,M,144.34,0.2,2.4,"1,810",70
9,Saskatchewan,H02AB,Glucocorticoids,65+,M,140.51,0.2,10.0,"7,563",71
9,Saskatchewan,C10AC,Bile acid sequestrants,65+,M,139.84,0.2,0.6,415,72
9,Saskatchewan,C09DX,"Angiotensin II antagonists, other combinations",65+,M,139.15,0.2,0.1,94,73
9,Saskatchewan,C10AB,Fibrates,65+,M,134.24,0.2,1.7,"1,261",74
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,127.13,0.2,0.0,7,75
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,117.96,0.2,6.8,"5,113",76
9,Saskatchewan,C02DB,Hydrazinophthalazine derivatives,65+,M,110.91,0.2,0.9,671,77
9,Saskatchewan,M01AH,Coxibs,65+,M,105.67,0.2,2.8,"2,112",78
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,65+,M,102.19,0.2,0.7,553,79
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,98.07,0.2,0.1,81,80
9,Saskatchewan,J01DB,First-generation cephalosporins,65+,M,96.48,0.2,9.3,"7,052",81
9,Saskatchewan,H01CB,Somatostatin and analogues,65+,M,**, ** , ** ,*,82
9,Saskatchewan,C03AA,"Thiazides, plain",65+,M,94.86,0.1,8.7,"6,583",83
9,Saskatchewan,N04BC,Dopamine agonists,65+,M,91.50,0.1,0.8,618,84
9,Saskatchewan,J05AX,Other antivirals,65+,M,88.68,0.1,0.0,14,85
9,Saskatchewan,A09AA,Enzyme preparations,65+,M,88.12,0.1,0.2,160,86
9,Saskatchewan,N05BA,Benzodiazepine derivatives,65+,M,87.79,0.1,3.8,"2,852",87
9,Saskatchewan,C01BD,"Antiarrhythmics, class III",65+,M,85.64,0.1,1.0,771,88
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",65+,M,85.37,0.1,6.6,"4,976",89
9,Saskatchewan,D01AC,Imidazole and triazole derivatives,65+,M,82.87,0.1,3.2,"2,382",90
9,Saskatchewan,C10BX,"HMG-CoA reductase inhibitors, other combinations",65+,M,81.75,0.1,0.7,540,91
9,Saskatchewan,G03BA,3-oxoandrosten (4) derivatives,65+,M,78.14,0.1,0.8,576,92
9,Saskatchewan,J02AC,Triazole derivatives,65+,M,76.17,0.1,0.8,578,93
9,Saskatchewan,J01AA,Tetracyclines,65+,M,75.62,0.1,6.0,"4,550",94
9,Saskatchewan,L01BA,Folic acid analogues,65+,M,75.59,0.1,0.9,672,95
9,Saskatchewan,B03BB,Folic acid and derivatives,65+,M,74.65,0.1,2.8,"2,141",96
9,Saskatchewan,J01FA,Macrolides,65+,M,73.75,0.1,8.1,"6,086",97
9,Saskatchewan,N07XX,Other nervous system drugs,65+,M,72.85,0.1,0.0,8,98
9,Saskatchewan,M05BA,Bisphosphonates,65+,M,72.76,0.1,0.8,601,99
9,Saskatchewan,A10BG,Thiazolidinediones,65+,M,71.51,0.1,0.4,291,100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"8,683.64",11.3,0.5,464,1
9,Saskatchewan,S01LA,Antineovascularization agents,65+,F,"2,999.24",3.9,1.8,"1,586",2
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"2,906.06",3.8,4.5,"4,087",3
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,65+,F,"2,878.73",3.7,4.6,"4,164",4
9,Saskatchewan,C09AA,"ACE inhibitors, plain",65+,F,"2,224.43",2.9,21.0,"18,951",5
9,Saskatchewan,C08CA,Dihydropyridine derivatives,65+,F,"2,196.85",2.9,20.2,"18,283",6
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,65+,F,"2,189.80",2.9,33.8,"30,505",7
9,Saskatchewan,A02BC,Proton pump inhibitors,65+,F,"2,078.23",2.7,31.4,"28,379",8
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"1,801.82",2.3,3.3,"3,007",9
9,Saskatchewan,N02AA,Natural opium alkaloids,65+,F,"1,645.07",2.1,9.4,"8,502",10
9,Saskatchewan,R03BB,Anticholinergics,65+,F,"1,430.83",1.9,5.6,"5,023",11
9,Saskatchewan,L04AA,Selective immunosuppressants,65+,F,"1,311.84",1.7,0.4,376,12
9,Saskatchewan,N03AX,Other antiepileptics,65+,F,"1,260.17",1.6,9.4,"8,511",13
9,Saskatchewan,C09CA,"Angiotensin II antagonists, plain",65+,F,"1,213.41",1.6,17.0,"15,379",14
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,65+,F,"1,046.64",1.4,12.3,"11,140",15
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",65+,F,"1,041.02",1.4,21.2,"19,172",16
9,Saskatchewan,N06AX,Other antidepressants,65+,F,980.38,1.3,10.7,"9,703",17
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,65+,F,971.76,1.3,6.3,"5,728",18
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,952.69,1.2,1.3,"1,196",19
9,Saskatchewan,R03BA,Glucocorticoids,65+,F,948.71,1.2,5.5,"4,998",20
9,Saskatchewan,B01AB,Heparin group,65+,F,824.04,1.1,0.6,542,21
9,Saskatchewan,C09DA,Angiotensin II antagonists and diuretics,65+,F,805.91,1.0,11.2,"10,087",22
9,Saskatchewan,B03XA,Other antianemic preparations,65+,F,787.43,1.0,0.3,282,23
9,Saskatchewan,H03AA,Thyroid hormones,65+,F,756.95,1.0,27.3,"24,667",24
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,731.07,1.0,3.8,"3,465",25
9,Saskatchewan,N05AX,Other antipsychotics,65+,F,701.27,0.9,2.2,"1,942",26
9,Saskatchewan,L04AC,Interleukin inhibitors,65+,F,689.98,0.9,0.1,54,27
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,673.03,0.9,2.4,"2,144",28
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,65+,F,668.07,0.9,4.7,"4,237",29
9,Saskatchewan,S01ED,Beta-blocking agents,65+,F,649.53,0.8,3.9,"3,487",30
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,65+,F,632.40,0.8,0.0,12,31
9,Saskatchewan,C03CA,"Sulfonamides, plain",65+,F,624.48,0.8,14.1,"12,703",32
9,Saskatchewan,S01EE,Prostaglandin analogues,65+,F,595.39,0.8,3.9,"3,520",33
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,567.88,0.7,6.8,"6,165",34
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,566.46,0.7,2.9,"2,663",35
9,Saskatchewan,M05BA,Bisphosphonates,65+,F,545.26,0.7,6.0,"5,382",36
9,Saskatchewan,A10BA,Biguanides,65+,F,514.55,0.7,12.2,"11,058",37
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,65+,F,492.01,0.6,0.8,682,38
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,490.01,0.6,6.6,"5,925",39
9,Saskatchewan,A12BA,Potassium,65+,F,473.93,0.6,7.6,"6,848",40
9,Saskatchewan,C08DB,Benzothiazepine derivatives,65+,F,469.40,0.6,2.9,"2,651",41
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,65+,F,459.94,0.6,0.7,632,42
9,Saskatchewan,B01AE,Direct thrombin inhibitors,65+,F,432.16,0.6,0.5,462,43
9,Saskatchewan,L03AB,Interferons,65+,F,412.82,0.5,0.0,21,44
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,398.66,0.5,3.2,"2,865",45
9,Saskatchewan,M05BX,Other drugs affecting bone structure and mineralization,65+,F,379.14,0.5,0.7,630,46
9,Saskatchewan,C01DA,Organic nitrates,65+,F,375.92,0.5,4.4,"3,934",47
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,375.71,0.5,12.0,"10,827",48
9,Saskatchewan,A02BA,H2-receptor antagonists,65+,F,337.60,0.4,6.2,"5,625",49
9,Saskatchewan,B01AA,Vitamin K antagonists,65+,F,319.23,0.4,5.4,"4,862",50
9,Saskatchewan,N04BA,Dopa and dopa derivatives,65+,F,317.44,0.4,1.1,976,51
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,312.42,0.4,0.4,357,52
9,Saskatchewan,L01XC,Monoclonal antibodies,65+,F,306.81,0.4,0.0,29,53
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",65+,F,257.86,0.3,2.6,"2,376",54
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,254.47,0.3,0.5,435,55
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,65+,F,234.54,0.3,1.2,"1,120",56
9,Saskatchewan,A10BB,Sulfonylureas,65+,F,233.08,0.3,4.5,"4,035",57
9,Saskatchewan,M01AH,Coxibs,65+,F,220.12,0.3,4.1,"3,733",58
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,219.84,0.3,0.2,188,59
9,Saskatchewan,R01AD,Corticosteroids,65+,F,218.03,0.3,8.4,"7,552",60
9,Saskatchewan,C10AX,Other lipid-modifying agents,65+,F,207.20,0.3,2.7,"2,401",61
9,Saskatchewan,N05BA,Benzodiazepine derivatives,65+,F,206.41,0.3,6.9,"6,257",62
9,Saskatchewan,L04AX,Other immunosuppressants,65+,F,206.35,0.3,0.3,284,63
9,Saskatchewan,L03AX,Other immunostimulants,65+,F,200.25,0.3,0.0,15,64
9,Saskatchewan,C01AA,Digitalis glycosides,65+,F,193.61,0.3,2.3,"2,073",65
9,Saskatchewan,C03DA,Aldosterone antagonists,65+,F,190.76,0.2,3.8,"3,416",66
9,Saskatchewan,H01CB,Somatostatin and analogues,65+,F,**, ** , ** ,**,67
9,Saskatchewan,H02AB,Glucocorticoids,65+,F,185.30,0.2,10.3,"9,281",68
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,184.40,0.2,6.9,"6,207",69
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,65+,F,181.96,0.2,4.3,"3,845",70
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,181.76,0.2,3.2,"2,932",71
9,Saskatchewan,C03AA,"Thiazides, plain",65+,F,179.33,0.2,11.8,"10,646",72
9,Saskatchewan,L04AD,Calcineurin inhibitors,65+,F,175.18,0.2,0.1,55,73
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,65+,F,175.09,0.2,3.2,"2,892",74
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,166.20,0.2,0.7,618,75
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,164.95,0.2,0.5,476,76
9,Saskatchewan,C10AC,Bile acid sequestrants,65+,F,164.66,0.2,0.7,662,77
9,Saskatchewan,J01XE,Nitrofuran derivatives,65+,F,156.18,0.2,10.2,"9,238",78
9,Saskatchewan,L01BA,Folic acid analogues,65+,F,154.09,0.2,1.3,"1,192",79
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,147.67,0.2,0.0,10,80
9,Saskatchewan,V03AC,Iron-chelating agents,65+,F,143.03,0.2,0.0,8,81
9,Saskatchewan,A05AA,Bile acids and derivatives,65+,F,138.77,0.2,0.2,188,82
9,Saskatchewan,J01DB,First-generation cephalosporins,65+,F,133.09,0.2,8.8,"7,951",83
9,Saskatchewan,A03FA,Propulsives,65+,F,132.01,0.2,3.5,"3,202",84
9,Saskatchewan,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,129.08,0.2,0.4,317,85
9,Saskatchewan,N04BC,Dopamine agonists,65+,F,127.50,0.2,1.1,981,86
9,Saskatchewan,C10AB,Fibrates,65+,F,122.67,0.2,1.2,"1,105",87
9,Saskatchewan,D01AC,Imidazole and triazole derivatives,65+,F,116.55,0.2,3.4,"3,041",88
9,Saskatchewan,N07XX,Other nervous system drugs,65+,F,111.85,0.1,0.0,20,89
9,Saskatchewan,S01EC,Carbonic anhydrase inhibitors,65+,F,109.80,0.1,1.0,886,90
9,Saskatchewan,C08DA,Phenylalkylamine derivatives,65+,F,107.84,0.1,0.7,667,91
9,Saskatchewan,J01FA,Macrolides,65+,F,106.29,0.1,9.1,"8,260",92
9,Saskatchewan,N07CA,Antivertigo preparations,65+,F,105.86,0.1,3.6,"3,287",93
9,Saskatchewan,J05AH,Neuraminidase inhibitors,65+,F,105.52,0.1,2.4,"2,134",94
9,Saskatchewan,B03BB,Folic acid and derivatives,65+,F,105.30,0.1,2.7,"2,471",95
9,Saskatchewan,M03BX,Other centrally acting agents,65+,F,103.12,0.1,1.7,"1,558",96
9,Saskatchewan,C02DB,Hydrazinophthalazine derivatives,65+,F,99.91,0.1,0.7,621,97
9,Saskatchewan,M05BB,"Bisphosphonates, combinations",65+,F,98.99,0.1,2.5,"2,243",98
9,Saskatchewan,C01BC,"Antiarrhythmics, class Ic",65+,F,97.79,0.1,0.5,418,99
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",65+,F,91.85,0.1,6.5,"5,873",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"53,403.94",25.7,0.4,"2,436",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,<65,Total,"18,468.37",8.9,0.1,355,2
9,Saskatchewan,L04AA,Selective immunosuppressants,<65,Total,"8,953.67",4.3,0.2,"1,332",3
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,<65,Total,"6,750.32",3.3,2.2,"12,646",4
9,Saskatchewan,N05AX,Other antipsychotics,<65,Total,"6,574.42",3.2,1.2,"6,842",5
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"5,236.06",2.5,0.1,723,6
9,Saskatchewan,N07XX,Other nervous system drugs,<65,Total,"5,158.39",2.5,0.1,361,7
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"5,053.44",2.4,2.4,"13,622",8
9,Saskatchewan,N02AA,Natural opium alkaloids,<65,Total,"4,894.07",2.4,5.0,"28,883",9
9,Saskatchewan,L04AC,Interleukin inhibitors,<65,Total,"4,024.35",1.9,0.1,298,10
9,Saskatchewan,N03AX,Other antiepileptics,<65,Total,"3,817.40",1.8,4.2,"24,028",11
9,Saskatchewan,L03AB,Interferons,<65,Total,"3,037.89",1.5,0.0,207,12
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"2,985.19",1.4,1.4,"7,900",13
9,Saskatchewan,L03AX,Other immunostimulants,<65,Total,"2,598.86",1.3,0.0,263,14
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"2,508.41",1.2,9.5,"54,618",15
9,Saskatchewan,N06AX,Other antidepressants,<65,Total,"2,281.91",1.1,7.1,"40,868",16
9,Saskatchewan,A02BC,Proton pump inhibitors,<65,Total,"1,992.03",1.0,11.5,"66,326",17
9,Saskatchewan,L04AD,Calcineurin inhibitors,<65,Total,"1,868.05",0.9,0.1,521,18
9,Saskatchewan,R03BA,Glucocorticoids,<65,Total,"1,853.77",0.9,6.0,"34,291",19
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,<65,Total,"1,754.40",0.8,9.2,"52,757",20
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"1,746.31",0.8,1.0,"5,616",21
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,736.93",0.8,1.2,"6,743",22
9,Saskatchewan,N07BC,Drugs used in opioid dependence,<65,Total,"1,724.83",0.8,0.4,"2,043",23
9,Saskatchewan,C09AA,"ACE inhibitors, plain",<65,Total,"1,481.81",0.7,5.8,"33,486",24
9,Saskatchewan,B01AB,Heparin group,<65,Total,"1,128.19",0.5,0.1,611,25
9,Saskatchewan,J01DB,First-generation cephalosporins,<65,Total,"1,110.36",0.5,8.4,"48,493",26
9,Saskatchewan,B03XA,Other antianemic preparations,<65,Total,978.18,0.5,0.1,369,27
9,Saskatchewan,J05AE,Protease inhibitors,<65,Total,959.63,0.5,0.0,179,28
9,Saskatchewan,C08CA,Dihydropyridine derivatives,<65,Total,897.62,0.4,3.2,"18,690",29
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,<65,Total,846.89,0.4,1.5,"8,890",30
9,Saskatchewan,L01XC,Monoclonal antibodies,<65,Total,799.64,0.4,0.0,101,31
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,<65,Total,794.77,0.4,0.5,"3,125",32
9,Saskatchewan,J05AX,Other antivirals,<65,Total,738.43,0.4,0.0,192,33
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,724.77,0.3,3.1,"17,938",34
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,691.45,0.3,0.3,"1,914",35
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,665.95,0.3,11.4,"65,553",36
9,Saskatchewan,R05CB,Mucolytics,<65,Total,664.51,0.3,0.0,78,37
9,Saskatchewan,A16AB,Enzymes,<65,Total,**, ** , ** ,**,38
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,<65,Total,655.49,0.3,2.3,"13,239",39
9,Saskatchewan,A10BA,Biguanides,<65,Total,654.62,0.3,4.5,"25,680",40
9,Saskatchewan,J01CA,Penicillins with extended spectrum,<65,Total,652.20,0.3,20.8,"119,620",41
9,Saskatchewan,N03AG,Fatty acid derivatives,<65,Total,629.91,0.3,0.6,"3,578",42
9,Saskatchewan,R03BB,Anticholinergics,<65,Total,597.43,0.3,0.8,"4,742",43
9,Saskatchewan,A09AA,Enzyme preparations,<65,Total,586.01,0.3,0.1,504,44
9,Saskatchewan,R07AX,Other respiratory system products,<65,Total,**, ** , ** ,*,45
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,537.05,0.3,0.0,34,46
9,Saskatchewan,C09CA,"Angiotensin II antagonists, plain",<65,Total,533.33,0.3,3.1,"18,093",47
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,<65,Total,528.83,0.3,0.1,565,48
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",<65,Total,521.90,0.3,3.0,"17,334",49
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,486.74,0.2,0.3,"1,971",50
9,Saskatchewan,H03AA,Thyroid hormones,<65,Total,484.53,0.2,6.2,"35,452",51
9,Saskatchewan,A02BA,H2-receptor antagonists,<65,Total,479.72,0.2,3.2,"18,625",52
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,<65,Total,477.02,0.2,0.0,41,53
9,Saskatchewan,N05BA,Benzodiazepine derivatives,<65,Total,462.44,0.2,3.1,"18,065",54
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,458.00,0.2,0.1,561,55
9,Saskatchewan,J01DF,Monobactams,<65,Total,454.13,0.2,0.0,29,56
9,Saskatchewan,J01FA,Macrolides,<65,Total,448.95,0.2,11.7,"67,061",57
9,Saskatchewan,M03BX,Other centrally acting agents,<65,Total,424.13,0.2,2.0,"11,364",58
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,402.06,0.2,0.0,49,59
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,400.67,0.2,0.1,568,60
9,Saskatchewan,M01AE,Propionic acid derivatives,<65,Total,399.47,0.2,10.0,"57,411",61
9,Saskatchewan,N05AF,Thioxanthene derivatives,<65,Total,395.92,0.2,0.2,903,62
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,<65,Total,394.34,0.2,0.3,"1,693",63
9,Saskatchewan,C09DA,Angiotensin II antagonists and diuretics,<65,Total,394.32,0.2,2.3,"13,314",64
9,Saskatchewan,R01AD,Corticosteroids,<65,Total,376.15,0.2,7.7,"44,310",65
9,Saskatchewan,S01LA,Antineovascularization agents,<65,Total,374.67,0.2,0.1,448,66
9,Saskatchewan,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,369.37,0.2,6.0,"34,435",67
9,Saskatchewan,J02AC,Triazole derivatives,<65,Total,364.22,0.2,1.5,"8,787",68
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,360.87,0.2,5.5,"31,772",69
9,Saskatchewan,N03AF,Carboxamide derivatives,<65,Total,360.39,0.2,0.3,"2,006",70
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,359.06,0.2,3.7,"21,192",71
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,<65,Total,358.31,0.2,0.7,"3,818",72
9,Saskatchewan,H02AB,Glucocorticoids,<65,Total,336.78,0.2,7.1,"40,662",73
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,322.89,0.2,0.1,726,74
9,Saskatchewan,H01CB,Somatostatin and analogues,<65,Total,318.89,0.2,0.0,23,75
9,Saskatchewan,J01GB,Other aminoglycosides,<65,Total,318.45,0.2,0.0,53,76
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,<65,Total,318.32,0.2,3.7,"21,165",77
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,305.57,0.1,0.6,"3,334",78
9,Saskatchewan,N03AE,Benzodiazepine derivatives,<65,Total,298.85,0.1,1.1,"6,319",79
9,Saskatchewan,A10BB,Sulfonylureas,<65,Total,286.11,0.1,1.6,"9,179",80
9,Saskatchewan,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,280.99,0.1,0.0,128,81
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,273.34,0.1,0.3,"1,572",82
9,Saskatchewan,G02BA,Intrauterine contraceptives,<65,Total,264.08,0.1,0.8,"4,854",83
9,Saskatchewan,S02CA,Corticosteroids and antiinfectives in combination,<65,Total,252.12,0.1,3.0,"17,067",84
9,Saskatchewan,C02AC,Imidazoline receptor agonists,<65,Total,250.48,0.1,0.5,"3,145",85
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,245.41,0.1,0.5,"2,652",86
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,241.69,0.1,4.6,"26,181",87
9,Saskatchewan,C03CA,"Sulfonamides, plain",<65,Total,241.28,0.1,1.1,"6,316",88
9,Saskatchewan,D06AX,Other antibiotics for topical use,<65,Total,234.75,0.1,3.5,"20,386",89
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",<65,Total,230.31,0.1,0.9,"5,342",90
9,Saskatchewan,N07BA,Drugs used in nicotine dependence,<65,Total,228.28,0.1,1.0,"5,808",91
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,223.09,0.1,1.7,"9,613",92
9,Saskatchewan,G03AC,Progestogens,<65,Total,218.12,0.1,1.5,"8,647",93
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,<65,Total,214.60,0.1,0.4,"2,451",94
9,Saskatchewan,V03AC,Iron-chelating agents,<65,Total,212.94,0.1,0.0,17,95
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",<65,Total,210.19,0.1,5.3,"30,604",96
9,Saskatchewan,L04AX,Other immunosuppressants,<65,Total,208.56,0.1,0.3,"1,449",97
9,Saskatchewan,L01BA,Folic acid analogues,<65,Total,203.50,0.1,0.5,"2,753",98
9,Saskatchewan,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,201.30,0.1,0.0,120,99
9,Saskatchewan,J01AA,Tetracyclines,<65,Total,196.32,0.1,4.4,"25,222",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"26,598.63",25.3,0.4,"1,124",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,<65,M,"11,837.05",11.2,0.1,232,2
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,<65,M,"4,733.05",4.5,3.1,"8,161",3
9,Saskatchewan,N05AX,Other antipsychotics,<65,M,"4,239.05",4.0,1.5,"3,954",4
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"3,450.41",3.3,0.2,483,5
9,Saskatchewan,L04AA,Selective immunosuppressants,<65,M,"3,245.85",3.1,0.2,540,6
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"3,057.06",2.9,2.3,"6,102",7
9,Saskatchewan,N02AA,Natural opium alkaloids,<65,M,"2,467.01",2.3,5.0,"13,375",8
9,Saskatchewan,L04AC,Interleukin inhibitors,<65,M,"1,899.76",1.8,0.0,124,9
9,Saskatchewan,N03AX,Other antiepileptics,<65,M,"1,655.18",1.6,3.6,"9,507",10
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"1,646.91",1.6,1.7,"4,513",11
9,Saskatchewan,N07XX,Other nervous system drugs,<65,M,"1,285.32",1.2,0.0,98,12
9,Saskatchewan,L04AD,Calcineurin inhibitors,<65,M,"1,115.91",1.1,0.1,306,13
9,Saskatchewan,R03BA,Glucocorticoids,<65,M,981.94,0.9,6.4,"17,030",14
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,<65,M,977.70,0.9,6.8,"18,101",15
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,969.54,0.9,1.4,"3,671",16
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,<65,M,961.25,0.9,12.4,"32,864",17
9,Saskatchewan,A02BC,Proton pump inhibitors,<65,M,894.67,0.8,11.7,"31,098",18
9,Saskatchewan,N07BC,Drugs used in opioid dependence,<65,M,891.07,0.8,0.4,"1,185",19
9,Saskatchewan,L03AB,Interferons,<65,M,846.41,0.8,0.0,55,20
9,Saskatchewan,N06AX,Other antidepressants,<65,M,832.12,0.8,5.4,"14,462",21
9,Saskatchewan,C09AA,"ACE inhibitors, plain",<65,M,830.39,0.8,7.7,"20,446",22
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,791.67,0.8,1.0,"2,544",23
9,Saskatchewan,A16AB,Enzymes,<65,M,**, ** , ** ,*,24
9,Saskatchewan,J05AE,Protease inhibitors,<65,M,584.58,0.6,0.0,113,25
9,Saskatchewan,B03XA,Other antianemic preparations,<65,M,573.86,0.5,0.1,214,26
9,Saskatchewan,J01DB,First-generation cephalosporins,<65,M,546.41,0.5,8.7,"23,223",27
9,Saskatchewan,L03AX,Other immunostimulants,<65,M,542.85,0.5,0.0,58,28
9,Saskatchewan,R07AX,Other respiratory system products,<65,M,**, ** , ** ,*,29
9,Saskatchewan,B01AB,Heparin group,<65,M,531.04,0.5,0.1,246,30
9,Saskatchewan,C08CA,Dihydropyridine derivatives,<65,M,506.41,0.5,4.3,"11,305",31
9,Saskatchewan,J05AX,Other antivirals,<65,M,494.91,0.5,0.0,122,32
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,<65,M,466.66,0.4,1.5,"3,917",33
9,Saskatchewan,A09AA,Enzyme preparations,<65,M,427.06,0.4,0.1,279,34
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,<65,M,386.85,0.4,0.5,"1,460",35
9,Saskatchewan,R05CB,Mucolytics,<65,M,380.50,0.4,0.0,44,36
9,Saskatchewan,N03AG,Fatty acid derivatives,<65,M,374.25,0.4,0.7,"1,916",37
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,<65,M,373.19,0.4,3.0,"8,046",38
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,364.84,0.3,0.4,"1,111",39
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,<65,M,357.68,0.3,0.0,29,40
9,Saskatchewan,A10BA,Biguanides,<65,M,327.86,0.3,5.3,"14,124",41
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,320.55,0.3,12.0,"31,799",42
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,309.44,0.3,0.1,349,43
9,Saskatchewan,R03BB,Anticholinergics,<65,M,308.12,0.3,0.8,"2,232",44
9,Saskatchewan,J01CA,Penicillins with extended spectrum,<65,M,305.50,0.3,20.8,"55,319",45
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",<65,M,301.84,0.3,3.9,"10,330",46
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,<65,M,273.73,0.3,0.1,252,47
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,270.40,0.3,2.1,"5,581",48
9,Saskatchewan,L01XC,Monoclonal antibodies,<65,M,257.12,0.2,0.0,36,49
9,Saskatchewan,C09CA,"Angiotensin II antagonists, plain",<65,M,253.88,0.2,3.6,"9,564",50
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,249.01,0.2,0.4,"1,173",51
9,Saskatchewan,N05AF,Thioxanthene derivatives,<65,M,244.91,0.2,0.2,537,52
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,<65,M,224.14,0.2,0.4,937,53
9,Saskatchewan,N05BA,Benzodiazepine derivatives,<65,M,217.33,0.2,2.5,"6,764",54
9,Saskatchewan,A02BA,H2-receptor antagonists,<65,M,212.89,0.2,2.7,"7,138",55
9,Saskatchewan,J01DF,Monobactams,<65,M,212.00,0.2,0.0,15,56
9,Saskatchewan,J01FA,Macrolides,<65,M,210.08,0.2,11.2,"29,880",57
9,Saskatchewan,N03AF,Carboxamide derivatives,<65,M,203.71,0.2,0.4,"1,017",58
9,Saskatchewan,H01CB,Somatostatin and analogues,<65,M,**, ** , ** ,**,59
9,Saskatchewan,S01LA,Antineovascularization agents,<65,M,194.47,0.2,0.1,267,60
9,Saskatchewan,C09DA,Angiotensin II antagonists and diuretics,<65,M,191.75,0.2,2.8,"7,407",61
9,Saskatchewan,M03BX,Other centrally acting agents,<65,M,184.90,0.2,2.0,"5,315",62
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,184.76,0.2,0.9,"2,275",63
9,Saskatchewan,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,182.11,0.2,0.0,80,64
9,Saskatchewan,J01GB,Other aminoglycosides,<65,M,179.89,0.2,0.0,32,65
9,Saskatchewan,M01AE,Propionic acid derivatives,<65,M,172.60,0.2,9.9,"26,368",66
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,170.16,0.2,0.2,422,67
9,Saskatchewan,R01AD,Corticosteroids,<65,M,167.61,0.2,7.0,"18,624",68
9,Saskatchewan,H02AB,Glucocorticoids,<65,M,158.87,0.2,7.0,"18,677",69
9,Saskatchewan,C02AC,Imidazoline receptor agonists,<65,M,156.70,0.1,0.6,"1,614",70
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,151.96,0.1,5.8,"15,348",71
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,<65,M,151.66,0.1,4.5,"11,882",72
9,Saskatchewan,A10BB,Sulfonylureas,<65,M,151.36,0.1,2.1,"5,665",73
9,Saskatchewan,C07AG,Alpha- and beta-blocking agents,<65,M,146.95,0.1,0.4,"1,073",74
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,145.37,0.1,0.3,806,75
9,Saskatchewan,L04AX,Other immunosuppressants,<65,M,144.70,0.1,0.3,677,76
9,Saskatchewan,N03AE,Benzodiazepine derivatives,<65,M,141.84,0.1,0.9,"2,460",77
9,Saskatchewan,G04CA,Alpha-adrenoreceptor antagonists,<65,M,141.16,0.1,2.3,"6,104",78
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,135.92,0.1,0.1,169,79
9,Saskatchewan,H03AA,Thyroid hormones,<65,M,133.06,0.1,2.8,"7,413",80
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,131.40,0.1,0.5,"1,224",81
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,128.04,0.1,2.5,"6,619",82
9,Saskatchewan,J02AC,Triazole derivatives,<65,M,124.20,0.1,0.5,"1,204",83
9,Saskatchewan,V03AC,Iron-chelating agents,<65,M,121.69,0.1,0.0,8,84
9,Saskatchewan,S02CA,Corticosteroids and antiinfectives in combination,<65,M,121.20,0.1,3.0,"7,870",85
9,Saskatchewan,C03CA,"Sulfonamides, plain",<65,M,118.28,0.1,1.1,"2,882",86
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,117.59,0.1,4.5,"11,971",87
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,113.34,0.1,0.0,13,88
9,Saskatchewan,D06AX,Other antibiotics for topical use,<65,M,112.29,0.1,3.6,"9,598",89
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,110.97,0.1,0.0,14,90
9,Saskatchewan,N07BA,Drugs used in nicotine dependence,<65,M,107.66,0.1,1.2,"3,162",91
9,Saskatchewan,A16AA,Amino acids and derivatives,<65,M,106.62,0.1,0.0,17,92
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",<65,M,99.55,0.1,0.8,"2,113",93
9,Saskatchewan,M04AA,Preparations inhibiting uric acid production,<65,M,98.73,0.1,2.0,"5,397",94
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,<65,M,96.74,0.1,0.4,935,95
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",<65,M,91.88,0.1,4.8,"12,868",96
9,Saskatchewan,J01AA,Tetracyclines,<65,M,91.75,0.1,4.0,"10,635",97
9,Saskatchewan,C10AB,Fibrates,<65,M,90.97,0.1,0.8,"2,116",98
9,Saskatchewan,D05AX,Other antipsoriatics for topical use,<65,M,83.37,0.1,0.6,"1,498",99
9,Saskatchewan,L01BA,Folic acid analogues,<65,M,77.55,0.1,0.4,"1,094",100
9,Saskatchewan,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"26,805.31",26.2,0.4,"1,312",1
9,Saskatchewan,J05AP,Antivirals for treatment of HCV infections,<65,F,"6,631.32",6.5,0.0,123,2
9,Saskatchewan,L04AA,Selective immunosuppressants,<65,F,"5,707.82",5.6,0.3,792,3
9,Saskatchewan,N07XX,Other nervous system drugs,<65,F,"3,873.08",3.8,0.1,263,4
9,Saskatchewan,N02AA,Natural opium alkaloids,<65,F,"2,427.06",2.4,5.0,"15,508",5
9,Saskatchewan,N05AX,Other antipsychotics,<65,F,"2,335.38",2.3,0.9,"2,888",6
9,Saskatchewan,L03AB,Interferons,<65,F,"2,191.47",2.1,0.0,152,7
9,Saskatchewan,N03AX,Other antiepileptics,<65,F,"2,162.22",2.1,4.7,"14,521",8
9,Saskatchewan,L04AC,Interleukin inhibitors,<65,F,"2,124.59",2.1,0.1,174,9
9,Saskatchewan,L03AX,Other immunostimulants,<65,F,"2,056.01",2.0,0.1,205,10
9,Saskatchewan,N06BA,Centrally acting sympathomimetics,<65,F,"2,017.27",2.0,1.4,"4,485",11
9,Saskatchewan,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"1,996.38",2.0,2.4,"7,520",12
9,Saskatchewan,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"1,785.64",1.7,0.1,240,13
9,Saskatchewan,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,530.71",1.5,11.8,"36,517",14
9,Saskatchewan,N06AX,Other antidepressants,<65,F,"1,449.80",1.4,8.5,"26,406",15
9,Saskatchewan,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"1,338.29",1.3,1.1,"3,387",16
9,Saskatchewan,A02BC,Proton pump inhibitors,<65,F,"1,097.36",1.1,11.4,"35,228",17
9,Saskatchewan,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,954.64,0.9,1.0,"3,072",18
9,Saskatchewan,R03BA,Glucocorticoids,<65,F,871.83,0.9,5.6,"17,261",19
9,Saskatchewan,N07BC,Drugs used in opioid dependence,<65,F,833.76,0.8,0.3,858,20
9,Saskatchewan,C10AA,HMG-CoA reductase inhibitors,<65,F,793.15,0.8,6.4,"19,893",21
9,Saskatchewan,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,767.39,0.8,1.0,"3,072",22
9,Saskatchewan,L04AD,Calcineurin inhibitors,<65,F,752.14,0.7,0.1,215,23
9,Saskatchewan,C09AA,"ACE inhibitors, plain",<65,F,651.42,0.6,4.2,"13,040",24
9,Saskatchewan,B01AB,Heparin group,<65,F,597.16,0.6,0.1,365,25
9,Saskatchewan,J01DB,First-generation cephalosporins,<65,F,563.96,0.6,8.2,"25,270",26
9,Saskatchewan,L01XC,Monoclonal antibodies,<65,F,542.52,0.5,0.0,65,27
9,Saskatchewan,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,454.37,0.4,4.0,"12,357",28
9,Saskatchewan,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,423.71,0.4,0.0,21,29
9,Saskatchewan,A07EC,Aminosalicylic acid and similar agents,<65,F,407.92,0.4,0.5,"1,665",30
9,Saskatchewan,B03XA,Other antianemic preparations,<65,F,404.32,0.4,0.1,155,31
9,Saskatchewan,C08CA,Dihydropyridine derivatives,<65,F,391.21,0.4,2.4,"7,385",32
9,Saskatchewan,C01CA,Adrenergic and dopaminergic agents,<65,F,380.23,0.4,1.6,"4,973",33
9,Saskatchewan,J05AE,Protease inhibitors,<65,F,375.05,0.4,0.0,66,34
9,Saskatchewan,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,369.37,0.4,11.1,"34,431",35
9,Saskatchewan,H03AA,Thyroid hormones,<65,F,351.47,0.3,9.1,"28,039",36
9,Saskatchewan,J01CA,Penicillins with extended spectrum,<65,F,346.70,0.3,20.8,"64,301",37
9,Saskatchewan,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,345.39,0.3,10.9,"33,754",38
9,Saskatchewan,A10BA,Biguanides,<65,F,326.76,0.3,3.7,"11,556",39
9,Saskatchewan,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,326.61,0.3,0.3,803,40
9,Saskatchewan,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,291.09,0.3,0.0,35,41
9,Saskatchewan,R03BB,Anticholinergics,<65,F,289.31,0.3,0.8,"2,510",42
9,Saskatchewan,R05CB,Mucolytics,<65,F,284.01,0.3,0.0,34,43
9,Saskatchewan,C09BA,ACE inhibitors and diuretics,<65,F,282.29,0.3,1.7,"5,193",44
9,Saskatchewan,C09CA,"Angiotensin II antagonists, plain",<65,F,279.45,0.3,2.8,"8,529",45
9,Saskatchewan,A02BA,H2-receptor antagonists,<65,F,266.84,0.3,3.7,"11,487",46
9,Saskatchewan,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,264.75,0.3,0.1,399,47
9,Saskatchewan,G02BA,Intrauterine contraceptives,<65,F,264.08,0.3,1.6,"4,853",48
9,Saskatchewan,G04BD,Drugs for urinary frequency and incontinence,<65,F,261.57,0.3,0.9,"2,883",49
9,Saskatchewan,N03AG,Fatty acid derivatives,<65,F,255.66,0.3,0.5,"1,662",50
9,Saskatchewan,N02AB,Phenylpiperidine derivatives,<65,F,255.10,0.2,0.1,313,51
9,Saskatchewan,N05BA,Benzodiazepine derivatives,<65,F,245.11,0.2,3.6,"11,301",52
9,Saskatchewan,J05AX,Other antivirals,<65,F,243.52,0.2,0.0,70,53
9,Saskatchewan,J01DF,Monobactams,<65,F,242.13,0.2,0.0,14,54
9,Saskatchewan,J02AC,Triazole derivatives,<65,F,240.02,0.2,2.4,"7,583",55
9,Saskatchewan,M03BX,Other centrally acting agents,<65,F,239.22,0.2,2.0,"6,049",56
9,Saskatchewan,J01FA,Macrolides,<65,F,238.88,0.2,12.0,"37,181",57
9,Saskatchewan,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,237.72,0.2,0.3,798,58
9,Saskatchewan,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,231.03,0.2,4.7,"14,573",59
9,Saskatchewan,M01AE,Propionic acid derivatives,<65,F,226.87,0.2,10.0,"31,043",60
9,Saskatchewan,C07AB,"Beta-blocking agents, selective",<65,F,220.06,0.2,2.3,"7,004",61
9,Saskatchewan,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,213.12,0.2,3.1,"9,522",62
9,Saskatchewan,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,208.91,0.2,5.3,"16,424",63
9,Saskatchewan,R01AD,Corticosteroids,<65,F,208.54,0.2,8.3,"25,686",64
9,Saskatchewan,C09DA,Angiotensin II antagonists and diuretics,<65,F,202.57,0.2,1.9,"5,907",65
9,Saskatchewan,G03AC,Progestogens,<65,F,183.71,0.2,2.8,"8,600",66
9,Saskatchewan,S01LA,Antineovascularization agents,<65,F,180.20,0.2,0.1,181,67
9,Saskatchewan,H02AB,Glucocorticoids,<65,F,177.91,0.2,7.1,"21,985",68
9,Saskatchewan,L02AE,Gonadotropin-releasing hormone analogues,<65,F,177.63,0.2,0.0,114,69
9,Saskatchewan,B01AF,Direct factor Xa inhibitors,<65,F,170.20,0.2,0.2,756,70
9,Saskatchewan,M01AB,Acetic acid derivatives and related substances,<65,F,166.67,0.2,3.0,"9,283",71
9,Saskatchewan,R06AA,Aminoalkyl ethers,<65,F,162.89,0.2,1.9,"5,807",72
9,Saskatchewan,A09AA,Enzyme preparations,<65,F,158.95,0.2,0.1,225,73
9,Saskatchewan,N03AE,Benzodiazepine derivatives,<65,F,157.01,0.2,1.2,"3,859",74
9,Saskatchewan,N03AF,Carboxamide derivatives,<65,F,156.68,0.2,0.3,989,75
9,Saskatchewan,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,152.77,0.1,3.2,"9,914",76
9,Saskatchewan,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,152.72,0.1,0.1,304,77
9,Saskatchewan,N05AF,Thioxanthene derivatives,<65,F,151.01,0.1,0.1,366,78
9,Saskatchewan,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,148.55,0.1,0.1,212,79
9,Saskatchewan,J01GB,Other aminoglycosides,<65,F,138.56,0.1,0.0,21,80
9,Saskatchewan,A10BB,Sulfonylureas,<65,F,134.75,0.1,1.1,"3,514",81
9,Saskatchewan,L03AA,Colony-stimulating factors,<65,F,133.62,0.1,0.0,8,82
9,Saskatchewan,S02CA,Corticosteroids and antiinfectives in combination,<65,F,130.92,0.1,3.0,"9,197",83
9,Saskatchewan,C07AA,"Beta-blocking agents, non-selective",<65,F,130.76,0.1,1.0,"3,229",84
9,Saskatchewan,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,127.97,0.1,0.2,766,85
9,Saskatchewan,L01BA,Folic acid analogues,<65,F,125.95,0.1,0.5,"1,659",86
9,Saskatchewan,D10AD,Retinoids for topical use in acne,<65,F,125.20,0.1,1.4,"4,347",87
9,Saskatchewan,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,124.10,0.1,4.6,"14,210",88
9,Saskatchewan,C03CA,"Sulfonamides, plain",<65,F,123.00,0.1,1.1,"3,434",89
9,Saskatchewan,H01CB,Somatostatin and analogues,<65,F,**, ** , ** ,**,90
9,Saskatchewan,D06AX,Other antibiotics for topical use,<65,F,122.46,0.1,3.5,"10,788",91
9,Saskatchewan,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,120.81,0.1,0.3,"1,059",92
9,Saskatchewan,N07BA,Drugs used in nicotine dependence,<65,F,120.62,0.1,0.9,"2,646",93
9,Saskatchewan,H01AC,Somatropin and somatropin agonists,<65,F,119.34,0.1,0.0,12,94
9,Saskatchewan,D07AC,"Corticosteroids, potent (group III)",<65,F,118.31,0.1,5.7,"17,736",95
9,Saskatchewan,J01XE,Nitrofuran derivatives,<65,F,114.66,0.1,6.8,"21,108",96
9,Saskatchewan,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,114.01,0.1,0.5,"1,428",97
9,Saskatchewan,J01AA,Tetracyclines,<65,F,104.57,0.1,4.7,"14,587",98
9,Saskatchewan,N02CC,Selective serotonin (5HT1) agonists,<65,F,103.17,0.1,0.6,"1,827",99
9,Saskatchewan,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,98.88,0.1,0.0,48,100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"149,443.50",18.1,1.2,"7,230",1
10,Alberta,J05AP,Antivirals for treatment of HCV infections,Total,Total,"32,598.75",3.9,0.1,563,2
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"29,774.64",3.6,7.5,"44,743",3
10,Alberta,L04AA,Selective immunosuppressants,Total,Total,"28,390.03",3.4,0.5,"2,696",4
10,Alberta,C10AA,HMG-CoA reductase inhibitors,Total,Total,"27,756.74",3.4,40.7,"243,199",5
10,Alberta,C09AA,"ACE inhibitors, plain",Total,Total,"22,248.67",2.7,22.0,"131,232",6
10,Alberta,B01AF,Direct factor Xa inhibitors,Total,Total,"21,503.15",2.6,4.6,"27,554",7
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"19,507.47",2.4,4.0,"24,047",8
10,Alberta,A02BC,Proton pump inhibitors,Total,Total,"16,213.83",2.0,30.5,"182,019",9
10,Alberta,L04AC,Interleukin inhibitors,Total,Total,"15,407.85",1.9,0.2,"1,024",10
10,Alberta,C08CA,Dihydropyridine derivatives,Total,Total,"14,429.17",1.7,17.8,"106,658",11
10,Alberta,N02AA,Natural opium alkaloids,Total,Total,"13,826.06",1.7,4.4,"26,521",12
10,Alberta,R03BB,Anticholinergics,Total,Total,"13,008.12",1.6,6.4,"38,058",13
10,Alberta,S01LA,Antineovascularization agents,Total,Total,"12,396.84",1.5,0.2,"1,253",14
10,Alberta,C09CA,"Angiotensin II antagonists, plain",Total,Total,"11,938.97",1.4,16.3,"97,484",15
10,Alberta,N06AX,Other antidepressants,Total,Total,"10,699.03",1.3,11.1,"66,124",16
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"10,078.65",1.2,2.1,"12,410",17
10,Alberta,B01AB,Heparin group,Total,Total,"9,645.59",1.2,1.4,"8,495",18
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"9,617.84",1.2,10.8,"64,678",19
10,Alberta,H03AA,Thyroid hormones,Total,Total,"9,554.29",1.2,21.5,"128,802",20
10,Alberta,L03AX,Other immunostimulants,Total,Total,"9,182.54",1.1,0.1,803,21
10,Alberta,C07AB,"Beta-blocking agents, selective",Total,Total,"8,716.92",1.1,18.5,"110,546",22
10,Alberta,B03XA,Other antianemic preparations,Total,Total,"8,560.06",1.0,0.4,"2,158",23
10,Alberta,N03AX,Other antiepileptics,Total,Total,"8,411.30",1.0,7.6,"45,491",24
10,Alberta,N07XX,Other nervous system drugs,Total,Total,"8,042.33",1.0,0.1,552,25
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"6,461.81",0.8,2.4,"14,601",26
10,Alberta,L03AB,Interferons,Total,Total,"6,348.44",0.8,0.1,401,27
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"6,348.37",0.8,6.2,"36,809",28
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"6,260.53",0.8,1.3,"7,640",29
10,Alberta,C09BA,ACE inhibitors and diuretics,Total,Total,"6,220.46",0.8,4.2,"25,098",30
10,Alberta,A10BA,Biguanides,Total,Total,"6,106.21",0.7,14.4,"86,053",31
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"6,041.25",0.7,1.6,"9,290",32
10,Alberta,N05CF,Benzodiazepine-related drugs,Total,Total,"5,933.92",0.7,12.5,"74,520",33
10,Alberta,C09DA,Angiotensin II antagonists and diuretics,Total,Total,"5,915.19",0.7,8.0,"47,872",34
10,Alberta,H01CB,Somatostatin and analogues,Total,Total,"5,430.67",0.7,0.1,308,35
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"5,425.45",0.7,3.8,"22,824",36
10,Alberta,M05BA,Bisphosphonates,Total,Total,"5,412.18",0.7,7.0,"41,606",37
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"5,269.21",0.6,0.5,"3,198",38
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",Total,Total,"5,266.20",0.6,13.4,"80,081",39
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,"4,982.35",0.6,0.2,"1,166",40
10,Alberta,B01AE,Direct thrombin inhibitors,Total,Total,"4,668.68",0.6,0.8,"4,628",41
10,Alberta,C08DB,Benzothiazepine derivatives,Total,Total,"4,603.89",0.6,2.7,"16,393",42
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"4,564.07",0.6,9.1,"54,542",43
10,Alberta,L04AX,Other immunosuppressants,Total,Total,"4,443.89",0.5,0.4,"2,499",44
10,Alberta,A07EC,Aminosalicylic acid and similar agents,Total,Total,"4,405.11",0.5,0.9,"5,462",45
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"4,388.56",0.5,0.0,191,46
10,Alberta,L03AA,Colony-stimulating factors,Total,Total,"4,375.38",0.5,0.1,679,47
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"4,131.61",0.5,13.2,"78,839",48
10,Alberta,R03BA,Glucocorticoids,Total,Total,"4,126.09",0.5,3.8,"22,749",49
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"4,079.98",0.5,2.9,"17,050",50
10,Alberta,N05AX,Other antipsychotics,Total,Total,"3,924.86",0.5,1.1,"6,460",51
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"3,766.55",0.5,2.8,"16,480",52
10,Alberta,C03CA,"Sulfonamides, plain",Total,Total,"3,493.51",0.4,8.0,"47,662",53
10,Alberta,S01ED,Beta-blocking agents,Total,Total,"3,444.43",0.4,2.8,"16,480",54
10,Alberta,L01XC,Monoclonal antibodies,Total,Total,"3,372.84",0.4,0.0,280,55
10,Alberta,S01EE,Prostaglandin analogues,Total,Total,"3,367.83",0.4,3.4,"20,386",56
10,Alberta,R07AX,Other respiratory system products,Total,Total,"3,209.30",0.4,0.0,12,57
10,Alberta,A04AA,Serotonin (5HT3) antagonists,Total,Total,"3,068.51",0.4,1.9,"11,442",58
10,Alberta,N04BA,Dopa and dopa derivatives,Total,Total,"3,055.48",0.4,1.0,"5,894",59
10,Alberta,L01XE,Protein kinase inhibitors,Total,Total,"2,969.06",0.4,0.0,142,60
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,"2,926.45",0.4,3.6,"21,564",61
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"2,892.00",0.3,11.5,"68,683",62
10,Alberta,B01AA,Vitamin K antagonists,Total,Total,"2,552.84",0.3,3.6,"21,680",63
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"2,520.62",0.3,0.9,"5,268",64
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"2,420.59",0.3,3.8,"22,526",65
10,Alberta,C07AG,Alpha- and beta-blocking agents,Total,Total,"2,398.50",0.3,1.7,"9,867",66
10,Alberta,M01AB,Acetic acid derivatives and related substances,Total,Total,"2,383.31",0.3,7.4,"44,205",67
10,Alberta,C01DA,Organic nitrates,Total,Total,"2,359.94",0.3,4.6,"27,684",68
10,Alberta,N06DA,Anticholinesterases,Total,Total,"2,238.09",0.3,1.2,"6,927",69
10,Alberta,A10BB,Sulfonylureas,Total,Total,"2,173.99",0.3,4.5,"27,034",70
10,Alberta,N06BA,Centrally acting sympathomimetics,Total,Total,"2,051.49",0.2,0.6,"3,694",71
10,Alberta,C03AA,"Thiazides, plain",Total,Total,"2,041.05",0.2,8.4,"50,406",72
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"2,028.68",0.2,3.7,"22,179",73
10,Alberta,N05BA,Benzodiazepine derivatives,Total,Total,"2,008.59",0.2,7.4,"44,257",74
10,Alberta,M04AA,Preparations inhibiting uric acid production,Total,Total,"1,992.10",0.2,4.1,"24,689",75
10,Alberta,H02AB,Glucocorticoids,Total,Total,"1,878.10",0.2,10.3,"61,730",76
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,Total,Total,"1,869.99",0.2,0.8,"4,881",77
10,Alberta,D07AC,"Corticosteroids, potent (group III)",Total,Total,"1,785.54",0.2,9.3,"55,726",78
10,Alberta,L01BA,Folic acid analogues,Total,Total,"1,718.48",0.2,1.6,"9,551",79
10,Alberta,V03AC,Iron-chelating agents,Total,Total,"1,651.39",0.2,0.0,113,80
10,Alberta,J01MA,Fluoroquinolones,Total,Total,"1,620.38",0.2,10.8,"64,480",81
10,Alberta,A04AD,Other antiemetics,Total,Total,"1,582.85",0.2,0.5,"2,943",82
10,Alberta,A09AA,Enzyme preparations,Total,Total,"1,556.73",0.2,0.3,"1,859",83
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"1,533.10",0.2,0.4,"2,507",84
10,Alberta,G03DA,Pregnen (4) derivatives,Total,Total,"1,503.93",0.2,0.9,"5,335",85
10,Alberta,J01CA,Penicillins with extended spectrum,Total,Total,"1,473.43",0.2,12.7,"75,937",86
10,Alberta,J01FA,Macrolides,Total,Total,"1,473.16",0.2,8.8,"52,683",87
10,Alberta,N07BC,Drugs used in opioid dependence,Total,Total,"1,395.76",0.2,0.2,"1,106",88
10,Alberta,C03DA,Aldosterone antagonists,Total,Total,"1,288.78",0.2,2.5,"14,987",89
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"1,244.72",0.2,0.3,"2,053",90
10,Alberta,J01DB,First-generation cephalosporins,Total,Total,"1,243.57",0.2,7.4,"44,505",91
10,Alberta,A12BA,Potassium,Total,Total,"1,222.94",0.1,2.7,"16,290",92
10,Alberta,M01AE,Propionic acid derivatives,Total,Total,"1,212.39",0.1,6.5,"38,764",93
10,Alberta,M05BB,"Bisphosphonates, combinations",Total,Total,"1,170.76",0.1,2.3,"13,829",94
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"1,160.19",0.1,0.6,"3,362",95
10,Alberta,C10AX,Other lipid-modifying agents,Total,Total,"1,148.36",0.1,1.7,"10,047",96
10,Alberta,N02AB,Phenylpiperidine derivatives,Total,Total,"1,146.10",0.1,0.3,"1,659",97
10,Alberta,M03BX,Other centrally acting agents,Total,Total,"1,114.66",0.1,4.1,"24,619",98
10,Alberta,C10AC,Bile acid sequestrants,Total,Total,"1,086.29",0.1,0.6,"3,452",99
10,Alberta,A02BA,H2-receptor antagonists,Total,Total,"1,084.30",0.1,2.3,"13,750",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"78,647.07",20.1,1.3,"3,510",1
10,Alberta,J05AP,Antivirals for treatment of HCV infections,Total,M,"22,047.00",5.6,0.1,378,2
10,Alberta,C10AA,HMG-CoA reductase inhibitors,Total,M,"14,848.22",3.8,49.4,"130,053",3
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"13,631.21",3.5,7.5,"19,812",4
10,Alberta,C09AA,"ACE inhibitors, plain",Total,M,"11,787.31",3.0,27.0,"71,035",5
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"11,553.51",3.0,5.1,"13,548",6
10,Alberta,B01AF,Direct factor Xa inhibitors,Total,M,"11,376.03",2.9,5.4,"14,228",7
10,Alberta,L04AA,Selective immunosuppressants,Total,M,"9,227.59",2.4,0.3,794,8
10,Alberta,L04AC,Interleukin inhibitors,Total,M,"7,566.40",1.9,0.2,476,9
10,Alberta,A02BC,Proton pump inhibitors,Total,M,"6,545.59",1.7,29.0,"76,310",10
10,Alberta,C08CA,Dihydropyridine derivatives,Total,M,"6,477.13",1.7,18.7,"49,274",11
10,Alberta,R03BB,Anticholinergics,Total,M,"6,460.22",1.7,7.1,"18,716",12
10,Alberta,N02AA,Natural opium alkaloids,Total,M,"6,323.65",1.6,4.1,"10,708",13
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"5,572.35",1.4,2.6,"6,790",14
10,Alberta,S01LA,Antineovascularization agents,Total,M,"4,989.98",1.3,0.2,516,15
10,Alberta,B03XA,Other antianemic preparations,Total,M,"4,881.29",1.2,0.5,"1,224",16
10,Alberta,C09CA,"Angiotensin II antagonists, plain",Total,M,"4,805.72",1.2,15.5,"40,934",17
10,Alberta,B01AB,Heparin group,Total,M,"4,677.07",1.2,1.4,"3,656",18
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"4,482.77",1.1,20.1,"53,054",19
10,Alberta,C07AB,"Beta-blocking agents, selective",Total,M,"4,354.16",1.1,22.4,"59,056",20
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"3,930.22",1.0,3.1,"8,189",21
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"3,720.04",1.0,1.7,"4,509",22
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"3,589.69",0.9,2.1,"5,479",23
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"3,493.58",0.9,5.4,"14,214",24
10,Alberta,A10BA,Biguanides,Total,M,"3,291.23",0.8,17.8,"46,787",25
10,Alberta,C09BA,ACE inhibitors and diuretics,Total,M,"3,286.43",0.8,5.0,"13,058",26
10,Alberta,N03AX,Other antiepileptics,Total,M,"3,172.13",0.8,6.5,"17,113",27
10,Alberta,N06AX,Other antidepressants,Total,M,"3,126.04",0.8,8.0,"21,016",28
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"3,091.74",0.8,0.3,741,29
10,Alberta,L04AX,Other immunosuppressants,Total,M,"3,070.79",0.8,0.4,"1,174",30
10,Alberta,H01CB,Somatostatin and analogues,Total,M,"2,963.11",0.8,0.1,153,31
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,"2,890.53",0.7,8.0,"21,088",32
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,Total,M,"2,885.03",0.7,7.5,"19,823",33
10,Alberta,N07XX,Other nervous system drugs,Total,M,"2,788.16",0.7,0.1,198,34
10,Alberta,L03AX,Other immunostimulants,Total,M,"2,687.20",0.7,0.1,229,35
10,Alberta,B01AE,Direct thrombin inhibitors,Total,M,"2,658.33",0.7,1.0,"2,640",36
10,Alberta,C09DA,Angiotensin II antagonists and diuretics,Total,M,"2,485.82",0.6,7.8,"20,421",37
10,Alberta,H03AA,Thyroid hormones,Total,M,"2,419.54",0.6,13.2,"34,838",38
10,Alberta,A07EC,Aminosalicylic acid and similar agents,Total,M,"2,123.08",0.5,0.9,"2,399",39
10,Alberta,N05CF,Benzodiazepine-related drugs,Total,M,"2,092.53",0.5,10.1,"26,549",40
10,Alberta,R07AX,Other respiratory system products,Total,M,"2,017.97",0.5,0.0,7,41
10,Alberta,C08DB,Benzothiazepine derivatives,Total,M,"1,981.87",0.5,2.6,"6,939",42
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"1,941.60",0.5,0.0,83,43
10,Alberta,L01XE,Protein kinase inhibitors,Total,M,"1,909.08",0.5,0.0,95,44
10,Alberta,N04BA,Dopa and dopa derivatives,Total,M,"1,861.71",0.5,1.2,"3,285",45
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",Total,M,"1,750.05",0.4,10.6,"28,022",46
10,Alberta,R03BA,Glucocorticoids,Total,M,"1,741.89",0.4,3.5,"9,281",47
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"1,733.06",0.4,13.6,"35,793",48
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"1,649.08",0.4,2.4,"6,428",49
10,Alberta,N05AX,Other antipsychotics,Total,M,"1,636.85",0.4,0.9,"2,467",50
10,Alberta,S01ED,Beta-blocking agents,Total,M,"1,560.97",0.4,2.9,"7,653",51
10,Alberta,L03AB,Interferons,Total,M,"1,535.03",0.4,0.0,99,52
10,Alberta,C03CA,"Sulfonamides, plain",Total,M,"1,472.14",0.4,8.2,"21,490",53
10,Alberta,S01EE,Prostaglandin analogues,Total,M,"1,453.25",0.4,3.4,"8,919",54
10,Alberta,C07AG,Alpha- and beta-blocking agents,Total,M,"1,418.81",0.4,2.2,"5,810",55
10,Alberta,M04AA,Preparations inhibiting uric acid production,Total,M,"1,389.83",0.4,6.7,"17,686",56
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"1,317.58",0.3,1.0,"2,697",57
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"1,280.51",0.3,10.8,"28,430",58
10,Alberta,B01AA,Vitamin K antagonists,Total,M,"1,258.67",0.3,4.5,"11,758",59
10,Alberta,A10BB,Sulfonylureas,Total,M,"1,235.72",0.3,5.9,"15,549",60
10,Alberta,L03AA,Colony-stimulating factors,Total,M,"1,227.02",0.3,0.1,207,61
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,Total,M,"1,188.77",0.3,1.8,"4,851",62
10,Alberta,C01DA,Organic nitrates,Total,M,"1,184.97",0.3,5.9,"15,616",63
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"1,163.22",0.3,0.3,735,64
10,Alberta,M01AB,Acetic acid derivatives and related substances,Total,M,"1,158.13",0.3,8.3,"21,861",65
10,Alberta,V03AC,Iron-chelating agents,Total,M,"1,039.04",0.3,0.0,59,66
10,Alberta,N06BA,Centrally acting sympathomimetics,Total,M,"1,022.82",0.3,0.7,"1,806",67
10,Alberta,A04AA,Serotonin (5HT3) antagonists,Total,M,988.68,0.3,1.5,"3,878",68
10,Alberta,L01XC,Monoclonal antibodies,Total,M,974.68,0.2,0.0,80,69
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,882.76,0.2,0.5,"1,353",70
10,Alberta,D07AC,"Corticosteroids, potent (group III)",Total,M,877.35,0.2,9.5,"25,126",71
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,818.10,0.2,2.8,"7,312",72
10,Alberta,H02AB,Glucocorticoids,Total,M,814.10,0.2,10.2,"26,909",73
10,Alberta,N06DA,Anticholinesterases,Total,M,803.52,0.2,1.0,"2,653",74
10,Alberta,A09AA,Enzyme preparations,Total,M,772.88,0.2,0.3,790,75
10,Alberta,C03AA,"Thiazides, plain",Total,M,735.53,0.2,7.2,"19,063",76
10,Alberta,N07BC,Drugs used in opioid dependence,Total,M,730.84,0.2,0.2,571,77
10,Alberta,J01MA,Fluoroquinolones,Total,M,728.34,0.2,10.3,"27,104",78
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,663.15,0.2,0.7,"1,892",79
10,Alberta,J01CA,Penicillins with extended spectrum,Total,M,662.08,0.2,12.7,"33,369",80
10,Alberta,M05BA,Bisphosphonates,Total,M,656.23,0.2,2.0,"5,167",81
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,655.22,0.2,2.4,"6,411",82
10,Alberta,C10AX,Other lipid-modifying agents,Total,M,651.66,0.2,2.2,"5,732",83
10,Alberta,C03DA,Aldosterone antagonists,Total,M,642.72,0.2,2.8,"7,364",84
10,Alberta,J01FA,Macrolides,Total,M,622.41,0.2,8.0,"21,198",85
10,Alberta,N05BA,Benzodiazepine derivatives,Total,M,606.37,0.2,5.1,"13,350",86
10,Alberta,A04AD,Other antiemetics,Total,M,599.91,0.2,0.4,"1,112",87
10,Alberta,J01DB,First-generation cephalosporins,Total,M,596.78,0.2,7.9,"20,879",88
10,Alberta,L01BA,Folic acid analogues,Total,M,575.25,0.1,1.2,"3,262",89
10,Alberta,C10AB,Fibrates,Total,M,561.96,0.1,1.6,"4,291",90
10,Alberta,J01GB,Other aminoglycosides,Total,M,517.73,0.1,0.0,88,91
10,Alberta,D05AX,Other antipsoriatics for topical use,Total,M,513.51,0.1,0.9,"2,278",92
10,Alberta,G03BA,3-oxoandrosten (4) derivatives,Total,M,504.66,0.1,1.1,"2,893",93
10,Alberta,M01AE,Propionic acid derivatives,Total,M,500.94,0.1,6.2,"16,312",94
10,Alberta,C10AC,Bile acid sequestrants,Total,M,488.59,0.1,0.4,"1,181",95
10,Alberta,A10BX,"Other blood glucose–lowering drugs, excluding insulins",Total,M,473.00,0.1,1.7,"4,348",96
10,Alberta,A07AA,Antibiotics,Total,M,457.54,0.1,1.0,"2,723",97
10,Alberta,M03BX,Other centrally acting agents,Total,M,419.98,0.1,3.6,"9,511",98
10,Alberta,A02BA,H2-receptor antagonists,Total,M,404.95,0.1,1.9,"5,056",99
10,Alberta,A10BG,Thiazolidinediones,Total,M,401.04,0.1,0.6,"1,657",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"70,796.48",16.2,1.1,"3,720",1
10,Alberta,L04AA,Selective immunosuppressants,Total,F,"19,162.44",4.4,0.6,"1,902",2
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"16,143.43",3.7,7.5,"24,931",3
10,Alberta,C10AA,HMG-CoA reductase inhibitors,Total,F,"12,908.52",3.0,33.8,"113,146",4
10,Alberta,J05AP,Antivirals for treatment of HCV infections,Total,F,"10,551.75",2.4,0.1,185,5
10,Alberta,C09AA,"ACE inhibitors, plain",Total,F,"10,461.35",2.4,18.0,"60,197",6
10,Alberta,B01AF,Direct factor Xa inhibitors,Total,F,"10,127.12",2.3,4.0,"13,326",7
10,Alberta,A02BC,Proton pump inhibitors,Total,F,"9,668.24",2.2,31.6,"105,709",8
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"7,953.96",1.8,3.1,"10,499",9
10,Alberta,C08CA,Dihydropyridine derivatives,Total,F,"7,952.04",1.8,17.2,"57,384",10
10,Alberta,L04AC,Interleukin inhibitors,Total,F,"7,841.45",1.8,0.2,548,11
10,Alberta,N06AX,Other antidepressants,Total,F,"7,572.99",1.7,13.5,"45,108",12
10,Alberta,N02AA,Natural opium alkaloids,Total,F,"7,502.41",1.7,4.7,"15,813",13
10,Alberta,S01LA,Antineovascularization agents,Total,F,"7,406.86",1.7,0.2,737,14
10,Alberta,H03AA,Thyroid hormones,Total,F,"7,134.75",1.6,28.1,"93,964",15
10,Alberta,C09CA,"Angiotensin II antagonists, plain",Total,F,"7,133.24",1.6,16.9,"56,550",16
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,Total,F,"6,732.80",1.5,13.4,"44,855",17
10,Alberta,R03BB,Anticholinergics,Total,F,"6,547.90",1.5,5.8,"19,342",18
10,Alberta,L03AX,Other immunostimulants,Total,F,"6,495.33",1.5,0.2,574,19
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"6,311.06",1.4,10.9,"36,551",20
10,Alberta,N07XX,Other nervous system drugs,Total,F,"5,254.18",1.2,0.1,354,21
10,Alberta,N03AX,Other antiepileptics,Total,F,"5,239.18",1.2,8.5,"28,378",22
10,Alberta,B01AB,Heparin group,Total,F,"4,968.52",1.1,1.4,"4,839",23
10,Alberta,L03AB,Interferons,Total,F,"4,813.41",1.1,0.1,302,24
10,Alberta,M05BA,Bisphosphonates,Total,F,"4,755.95",1.1,10.9,"36,439",25
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"4,506.30",1.0,1.7,"5,620",26
10,Alberta,C07AB,"Beta-blocking agents, selective",Total,F,"4,362.75",1.0,15.4,"51,490",27
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"4,105.99",0.9,0.7,"2,463",28
10,Alberta,N05CF,Benzodiazepine-related drugs,Total,F,"3,841.39",0.9,14.4,"47,971",29
10,Alberta,B03XA,Other antianemic preparations,Total,F,"3,678.77",0.8,0.3,934,30
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",Total,F,"3,516.15",0.8,15.6,"52,059",31
10,Alberta,C09DA,Angiotensin II antagonists and diuretics,Total,F,"3,429.36",0.8,8.2,"27,451",32
10,Alberta,L03AA,Colony-stimulating factors,Total,F,"3,148.36",0.7,0.1,472,33
10,Alberta,C09BA,ACE inhibitors and diuretics,Total,F,"2,934.03",0.7,3.6,"12,040",34
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,Total,F,"2,891.21",0.7,3.6,"12,199",35
10,Alberta,A10BA,Biguanides,Total,F,"2,814.98",0.6,11.7,"39,266",36
10,Alberta,C08DB,Benzothiazepine derivatives,Total,F,"2,622.01",0.6,2.8,"9,454",37
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"2,540.49",0.6,0.9,"3,131",38
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"2,531.60",0.6,1.9,"6,412",39
10,Alberta,H01CB,Somatostatin and analogues,Total,F,"2,467.56",0.6,0.0,155,40
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"2,451.57",0.6,1.1,"3,811",41
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"2,446.97",0.6,0.0,108,42
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"2,398.55",0.5,12.9,"43,046",43
10,Alberta,L01XC,Monoclonal antibodies,Total,F,"2,398.16",0.5,0.1,200,44
10,Alberta,R03BA,Glucocorticoids,Total,F,"2,384.20",0.5,4.0,"13,468",45
10,Alberta,N05AX,Other antipsychotics,Total,F,"2,288.01",0.5,1.2,"3,993",46
10,Alberta,A07EC,Aminosalicylic acid and similar agents,Total,F,"2,282.02",0.5,0.9,"3,063",47
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"2,117.47",0.5,3.0,"10,052",48
10,Alberta,A04AA,Serotonin (5HT3) antagonists,Total,F,"2,079.84",0.5,2.3,"7,564",49
10,Alberta,C03CA,"Sulfonamides, plain",Total,F,"2,021.37",0.5,7.8,"26,172",50
10,Alberta,B01AE,Direct thrombin inhibitors,Total,F,"2,010.35",0.5,0.6,"1,988",51
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"1,931.87",0.4,2.6,"8,610",52
10,Alberta,S01EE,Prostaglandin analogues,Total,F,"1,914.59",0.4,3.4,"11,467",53
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,F,"1,890.61",0.4,0.1,425,54
10,Alberta,S01ED,Beta-blocking agents,Total,F,"1,883.46",0.4,2.6,"8,827",55
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"1,765.37",0.4,4.8,"16,115",56
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"1,611.49",0.4,12.0,"40,253",57
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,Total,F,"1,524.16",0.3,1.2,"4,161",58
10,Alberta,G03DA,Pregnen (4) derivatives,Total,F,"1,491.32",0.3,1.6,"5,281",59
10,Alberta,N06DA,Anticholinesterases,Total,F,"1,434.57",0.3,1.3,"4,274",60
10,Alberta,N05BA,Benzodiazepine derivatives,Total,F,"1,402.22",0.3,9.2,"30,907",61
10,Alberta,L04AX,Other immunosuppressants,Total,F,"1,373.09",0.3,0.4,"1,325",62
10,Alberta,C03AA,"Thiazides, plain",Total,F,"1,305.53",0.3,9.4,"31,343",63
10,Alberta,B01AA,Vitamin K antagonists,Total,F,"1,294.18",0.3,3.0,"9,922",64
10,Alberta,M01AB,Acetic acid derivatives and related substances,Total,F,"1,225.19",0.3,6.7,"22,344",65
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"1,210.57",0.3,4.4,"14,867",66
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"1,203.04",0.3,0.8,"2,571",67
10,Alberta,N04BA,Dopa and dopa derivatives,Total,F,"1,193.77",0.3,0.8,"2,609",68
10,Alberta,R07AX,Other respiratory system products,Total,F,"1,191.33",0.3,0.0,5,69
10,Alberta,C01DA,Organic nitrates,Total,F,"1,174.97",0.3,3.6,"12,068",70
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"1,146.09",0.3,0.6,"1,875",71
10,Alberta,L01BA,Folic acid analogues,Total,F,"1,143.22",0.3,1.9,"6,289",72
10,Alberta,H02AB,Glucocorticoids,Total,F,"1,064.00",0.2,10.4,"34,821",73
10,Alberta,L01XE,Protein kinase inhibitors,Total,F,"1,059.99",0.2,0.0,47,74
10,Alberta,N06BA,Centrally acting sympathomimetics,Total,F,"1,028.67",0.2,0.6,"1,888",75
10,Alberta,M05BB,"Bisphosphonates, combinations",Total,F,"1,018.03",0.2,3.6,"11,969",76
10,Alberta,A04AD,Other antiemetics,Total,F,982.94,0.2,0.5,"1,831",77
10,Alberta,C07AG,Alpha- and beta-blocking agents,Total,F,979.69,0.2,1.2,"4,057",78
10,Alberta,A10BB,Sulfonylureas,Total,F,938.27,0.2,3.4,"11,485",79
10,Alberta,D07AC,"Corticosteroids, potent (group III)",Total,F,908.19,0.2,9.2,"30,600",80
10,Alberta,J01MA,Fluoroquinolones,Total,F,892.04,0.2,11.2,"37,376",81
10,Alberta,J01FA,Macrolides,Total,F,850.75,0.2,9.4,"31,485",82
10,Alberta,A12BA,Potassium,Total,F,834.21,0.2,3.2,"10,646",83
10,Alberta,J01CA,Penicillins with extended spectrum,Total,F,811.35,0.2,12.7,"42,568",84
10,Alberta,A09AA,Enzyme preparations,Total,F,783.84,0.2,0.3,"1,069",85
10,Alberta,N02AB,Phenylpiperidine derivatives,Total,F,747.11,0.2,0.3,"1,099",86
10,Alberta,M01AE,Propionic acid derivatives,Total,F,711.45,0.2,6.7,"22,452",87
10,Alberta,N03AE,Benzodiazepine derivatives,Total,F,699.80,0.2,2.8,"9,442",88
10,Alberta,M03BX,Other centrally acting agents,Total,F,694.68,0.2,4.5,"15,108",89
10,Alberta,A02BA,H2-receptor antagonists,Total,F,679.35,0.2,2.6,"8,694",90
10,Alberta,A05AA,Bile acids and derivatives,Total,F,674.59,0.2,0.2,818,91
10,Alberta,P01BA,Aminoquinolines,Total,F,673.61,0.2,1.7,"5,632",92
10,Alberta,N07BC,Drugs used in opioid dependence,Total,F,664.92,0.2,0.2,535,93
10,Alberta,J01XE,Nitrofuran derivatives,Total,F,656.46,0.2,7.0,"23,239",94
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,650.33,0.1,0.3,"1,154",95
10,Alberta,J01DB,First-generation cephalosporins,Total,F,646.78,0.1,7.1,"23,626",96
10,Alberta,C03DA,Aldosterone antagonists,Total,F,646.06,0.1,2.3,"7,623",97
10,Alberta,A03FA,Propulsives,Total,F,629.36,0.1,3.4,"11,460",98
10,Alberta,V03AC,Iron-chelating agents,Total,F,612.35,0.1,0.0,54,99
10,Alberta,M04AA,Preparations inhibiting uric acid production,Total,F,602.27,0.1,2.1,"7,003",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"39,706.74",7.3,0.4,"2,013",1
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"26,468.72",4.8,7.9,"38,632",2
10,Alberta,C10AA,HMG-CoA reductase inhibitors,65+,Total,"25,285.73",4.6,44.6,"217,363",3
10,Alberta,B01AF,Direct factor Xa inhibitors,65+,Total,"20,703.37",3.8,5.4,"26,207",4
10,Alberta,C09AA,"ACE inhibitors, plain",65+,Total,"20,126.88",3.7,24.1,"117,648",5
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"15,360.90",2.8,4.0,"19,390",6
10,Alberta,A02BC,Proton pump inhibitors,65+,Total,"14,405.37",2.6,32.1,"156,543",7
10,Alberta,C08CA,Dihydropyridine derivatives,65+,Total,"13,311.16",2.4,20.0,"97,317",8
10,Alberta,J05AP,Antivirals for treatment of HCV infections,65+,Total,"13,258.85",2.4,0.0,224,9
10,Alberta,R03BB,Anticholinergics,65+,Total,"12,234.09",2.2,7.2,"35,281",10
10,Alberta,S01LA,Antineovascularization agents,65+,Total,"12,212.41",2.2,0.3,"1,231",11
10,Alberta,C09CA,"Angiotensin II antagonists, plain",65+,Total,"10,901.42",2.0,18.0,"87,662",12
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"8,883.73",1.6,2.2,"10,849",13
10,Alberta,N02AA,Natural opium alkaloids,65+,Total,"8,746.45",1.6,4.4,"21,522",14
10,Alberta,H03AA,Thyroid hormones,65+,Total,"8,406.39",1.5,22.9,"111,489",15
10,Alberta,C07AB,"Beta-blocking agents, selective",65+,Total,"8,200.05",1.5,21.0,"102,259",16
10,Alberta,N06AX,Other antidepressants,65+,Total,"8,174.92",1.5,10.5,"51,172",17
10,Alberta,B01AB,Heparin group,65+,Total,"7,722.70",1.4,1.5,"7,273",18
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"7,625.16",1.4,10.3,"50,116",19
10,Alberta,B03XA,Other antianemic preparations,65+,Total,"7,138.70",1.3,0.4,"1,754",20
10,Alberta,N03AX,Other antiepileptics,65+,Total,"6,368.77",1.2,7.6,"37,252",21
10,Alberta,L04AA,Selective immunosuppressants,65+,Total,"6,367.19",1.2,0.3,"1,354",22
10,Alberta,A10BA,Biguanides,65+,Total,"5,445.10",1.0,15.4,"75,079",23
10,Alberta,C09BA,ACE inhibitors and diuretics,65+,Total,"5,400.54",1.0,4.4,"21,657",24
10,Alberta,C09DA,Angiotensin II antagonists and diuretics,65+,Total,"5,243.26",1.0,8.7,"42,173",25
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"5,155.40",0.9,1.3,"6,217",26
10,Alberta,N05CF,Benzodiazepine-related drugs,65+,Total,"5,117.48",0.9,13.0,"63,234",27
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"5,049.09",0.9,4.4,"21,325",28
10,Alberta,M05BA,Bisphosphonates,65+,Total,"5,045.37",0.9,7.9,"38,622",29
10,Alberta,L04AC,Interleukin inhibitors,65+,Total,"5,039.34",0.9,0.1,330,30
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,"4,993.17",0.9,5.9,"28,790",31
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"4,810.00",0.9,2.3,"11,134",32
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",65+,Total,"4,754.28",0.9,14.3,"69,745",33
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,"4,674.80",0.9,1.5,"7,104",34
10,Alberta,B01AE,Direct thrombin inhibitors,65+,Total,"4,521.45",0.8,0.9,"4,454",35
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"4,407.40",0.8,10.7,"51,939",36
10,Alberta,C08DB,Benzothiazepine derivatives,65+,Total,"4,237.02",0.8,3.1,"14,989",37
10,Alberta,L04AX,Other immunosuppressants,65+,Total,"3,974.50",0.7,0.3,"1,318",38
10,Alberta,H01CB,Somatostatin and analogues,65+,Total,"3,794.45",0.7,0.0,204,39
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,65+,Total,"3,683.94",0.7,3.1,"15,325",40
10,Alberta,R03BA,Glucocorticoids,65+,Total,"3,401.71",0.6,3.7,"17,840",41
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"3,377.24",0.6,13.3,"65,067",42
10,Alberta,C03CA,"Sulfonamides, plain",65+,Total,"3,361.56",0.6,9.2,"44,797",43
10,Alberta,S01ED,Beta-blocking agents,65+,Total,"3,300.06",0.6,3.2,"15,657",44
10,Alberta,S01EE,Prostaglandin analogues,65+,Total,"3,222.87",0.6,4.0,"19,336",45
10,Alberta,A07EC,Aminosalicylic acid and similar agents,65+,Total,"3,062.76",0.6,0.8,"3,721",46
10,Alberta,L03AA,Colony-stimulating factors,65+,Total,"2,969.35",0.5,0.1,481,47
10,Alberta,L01XE,Protein kinase inhibitors,65+,Total,"2,908.56",0.5,0.0,137,48
10,Alberta,N04BA,Dopa and dopa derivatives,65+,Total,"2,873.60",0.5,1.1,"5,572",49
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,"2,838.84",0.5,4.2,"20,670",50
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"2,610.37",0.5,0.4,"1,741",51
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"2,540.36",0.5,2.5,"12,353",52
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"2,462.50",0.5,11.5,"56,104",53
10,Alberta,B01AA,Vitamin K antagonists,65+,Total,"2,450.96",0.4,4.2,"20,569",54
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"2,360.43",0.4,1.0,"4,884",55
10,Alberta,N05AX,Other antipsychotics,65+,Total,"2,343.70",0.4,1.0,"4,632",56
10,Alberta,C01DA,Organic nitrates,65+,Total,"2,285.20",0.4,5.4,"26,115",57
10,Alberta,N06DA,Anticholinesterases,65+,Total,"2,224.39",0.4,1.4,"6,885",58
10,Alberta,L01XC,Monoclonal antibodies,65+,Total,"2,223.47",0.4,0.0,184,59
10,Alberta,C07AG,Alpha- and beta-blocking agents,65+,Total,"2,187.84",0.4,1.8,"8,923",60
10,Alberta,A04AA,Serotonin (5HT3) antagonists,65+,Total,"2,159.53",0.4,1.8,"8,720",61
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,"1,995.40",0.4,0.0,76,62
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,Total,"1,966.72",0.4,0.1,480,63
10,Alberta,M01AB,Acetic acid derivatives and related substances,65+,Total,"1,934.58",0.4,7.2,"35,125",64
10,Alberta,A10BB,Sulfonylureas,65+,Total,"1,932.64",0.4,4.8,"23,620",65
10,Alberta,C03AA,"Thiazides, plain",65+,Total,"1,876.19",0.3,9.3,"45,308",66
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"1,873.15",0.3,3.6,"17,679",67
10,Alberta,M04AA,Preparations inhibiting uric acid production,65+,Total,"1,855.63",0.3,4.6,"22,583",68
10,Alberta,N05BA,Benzodiazepine derivatives,65+,Total,"1,625.41",0.3,7.3,"35,478",69
10,Alberta,D07AC,"Corticosteroids, potent (group III)",65+,Total,"1,559.79",0.3,9.8,"47,577",70
10,Alberta,H02AB,Glucocorticoids,65+,Total,"1,540.96",0.3,10.4,"50,545",71
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,"1,431.49",0.3,3.4,"16,643",72
10,Alberta,J01MA,Fluoroquinolones,65+,Total,"1,411.01",0.3,11.4,"55,788",73
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"1,401.53",0.3,0.5,"2,305",74
10,Alberta,L01BA,Folic acid analogues,65+,Total,"1,313.55",0.2,1.4,"6,911",75
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"1,205.87",0.2,0.4,"1,984",76
10,Alberta,J01CA,Penicillins with extended spectrum,65+,Total,"1,189.63",0.2,12.5,"60,743",77
10,Alberta,C03DA,Aldosterone antagonists,65+,Total,"1,164.52",0.2,2.8,"13,416",78
10,Alberta,A12BA,Potassium,65+,Total,"1,159.99",0.2,3.1,"15,061",79
10,Alberta,J01FA,Macrolides,65+,Total,"1,158.95",0.2,8.5,"41,503",80
10,Alberta,M05BB,"Bisphosphonates, combinations",65+,Total,"1,094.33",0.2,2.6,"12,809",81
10,Alberta,J01DB,First-generation cephalosporins,65+,Total,"1,051.57",0.2,7.7,"37,604",82
10,Alberta,V03AC,Iron-chelating agents,65+,Total,"1,050.47",0.2,0.0,71,83
10,Alberta,C10AX,Other lipid-modifying agents,65+,Total,"1,045.12",0.2,1.9,"9,060",84
10,Alberta,A09AA,Enzyme preparations,65+,Total,"1,004.68",0.2,0.3,"1,459",85
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,961.90,0.2,0.6,"2,807",86
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,65+,Total,958.00,0.2,0.4,"2,050",87
10,Alberta,A02BA,H2-receptor antagonists,65+,Total,942.52,0.2,2.4,"11,542",88
10,Alberta,M01AE,Propionic acid derivatives,65+,Total,930.96,0.2,6.1,"29,498",89
10,Alberta,A04AD,Other antiemetics,65+,Total,922.12,0.2,0.4,"2,048",90
10,Alberta,C10AC,Bile acid sequestrants,65+,Total,911.80,0.2,0.6,"2,801",91
10,Alberta,C10AB,Fibrates,65+,Total,904.16,0.2,1.4,"6,742",92
10,Alberta,G03DA,Pregnen (4) derivatives,65+,Total,861.11,0.2,0.6,"3,031",93
10,Alberta,A03FA,Propulsives,65+,Total,795.08,0.1,3.0,"14,448",94
10,Alberta,A10BX,"Other blood glucose–lowering drugs, excluding insulins",65+,Total,793.79,0.1,1.4,"7,048",95
10,Alberta,N03AE,Benzodiazepine derivatives,65+,Total,781.41,0.1,2.2,"10,623",96
10,Alberta,C01AA,Digitalis glycosides,65+,Total,771.31,0.1,1.2,"6,017",97
10,Alberta,C03BA,"Sulfonamides, plain",65+,Total,769.60,0.1,2.8,"13,775",98
10,Alberta,S01BA,"Corticosteroids, plain",65+,Total,756.30,0.1,3.9,"18,935",99
10,Alberta,A07AA,Antibiotics,65+,Total,755.31,0.1,1.3,"6,293",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"17,866.31",6.9,0.4,850,1
10,Alberta,C10AA,HMG-CoA reductase inhibitors,65+,M,"13,718.67",5.3,52.7,"118,657",2
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"12,400.18",4.8,7.9,"17,686",3
10,Alberta,B01AF,Direct factor Xa inhibitors,65+,M,"10,924.55",4.2,6.0,"13,559",4
10,Alberta,C09AA,"ACE inhibitors, plain",65+,M,"10,794.57",4.2,28.7,"64,690",5
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"9,282.86",3.6,5.0,"11,179",6
10,Alberta,J05AP,Antivirals for treatment of HCV infections,65+,M,"8,869.93",3.4,0.1,149,7
10,Alberta,R03BB,Anticholinergics,65+,M,"6,147.73",2.4,7.8,"17,636",8
10,Alberta,C08CA,Dihydropyridine derivatives,65+,M,"5,971.70",2.3,20.1,"45,144",9
10,Alberta,A02BC,Proton pump inhibitors,65+,M,"5,941.46",2.3,30.2,"67,981",10
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"5,005.33",1.9,2.7,"6,063",11
10,Alberta,S01LA,Antineovascularization agents,65+,M,"4,864.95",1.9,0.2,501,12
10,Alberta,C09CA,"Angiotensin II antagonists, plain",65+,M,"4,439.97",1.7,16.7,"37,531",13
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"4,337.46",1.7,22.6,"50,793",14
10,Alberta,B03XA,Other antianemic preparations,65+,M,"4,120.63",1.6,0.4,996,15
10,Alberta,C07AB,"Beta-blocking agents, selective",65+,M,"4,089.61",1.6,24.4,"54,939",16
10,Alberta,B01AB,Heparin group,65+,M,"3,933.97",1.5,1.4,"3,237",17
10,Alberta,N02AA,Natural opium alkaloids,65+,M,"3,887.00",1.5,3.9,"8,822",18
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"3,249.98",1.3,5.9,"13,276",19
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,"3,154.09",1.2,1.7,"3,784",20
10,Alberta,A10BA,Biguanides,65+,M,"2,995.22",1.2,18.7,"42,075",21
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"2,980.35",1.2,2.8,"6,384",22
10,Alberta,C09BA,ACE inhibitors and diuretics,65+,M,"2,912.49",1.1,5.1,"11,527",23
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,"2,889.01",1.1,1.9,"4,357",24
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,"2,810.94",1.1,9.0,"20,313",25
10,Alberta,L04AX,Other immunosuppressants,65+,M,"2,730.98",1.1,0.3,617,26
10,Alberta,B01AE,Direct thrombin inhibitors,65+,M,"2,576.36",1.0,1.1,"2,542",27
10,Alberta,N03AX,Other antiepileptics,65+,M,"2,535.02",1.0,6.5,"14,650",28
10,Alberta,N06AX,Other antidepressants,65+,M,"2,512.17",1.0,7.6,"17,219",29
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,65+,M,"2,359.95",0.9,7.1,"15,975",30
10,Alberta,L04AC,Interleukin inhibitors,65+,M,"2,355.60",0.9,0.1,142,31
10,Alberta,H03AA,Thyroid hormones,65+,M,"2,252.37",0.9,14.3,"32,159",32
10,Alberta,C09DA,Angiotensin II antagonists and diuretics,65+,M,"2,243.06",0.9,8.2,"18,393",33
10,Alberta,L04AA,Selective immunosuppressants,65+,M,"2,176.22",0.8,0.2,446,34
10,Alberta,H01CB,Somatostatin and analogues,65+,M,"2,028.32",0.8,0.0,101,35
10,Alberta,L01XE,Protein kinase inhibitors,65+,M,"1,872.96",0.7,0.0,92,36
10,Alberta,N05CF,Benzodiazepine-related drugs,65+,M,"1,857.00",0.7,10.4,"23,519",37
10,Alberta,C08DB,Benzothiazepine derivatives,65+,M,"1,824.59",0.7,2.8,"6,358",38
10,Alberta,N04BA,Dopa and dopa derivatives,65+,M,"1,758.27",0.7,1.4,"3,142",39
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",65+,M,"1,624.15",0.6,11.3,"25,476",40
10,Alberta,A07EC,Aminosalicylic acid and similar agents,65+,M,"1,519.86",0.6,0.8,"1,696",41
10,Alberta,S01ED,Beta-blocking agents,65+,M,"1,508.26",0.6,3.3,"7,332",42
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"1,476.99",0.6,13.8,"31,052",43
10,Alberta,R03BA,Glucocorticoids,65+,M,"1,470.86",0.6,3.3,"7,507",44
10,Alberta,C03CA,"Sulfonamides, plain",65+,M,"1,413.25",0.5,9.0,"20,368",45
10,Alberta,S01EE,Prostaglandin analogues,65+,M,"1,408.60",0.5,3.8,"8,580",46
10,Alberta,M04AA,Preparations inhibiting uric acid production,65+,M,"1,294.44",0.5,7.2,"16,241",47
10,Alberta,C07AG,Alpha- and beta-blocking agents,65+,M,"1,294.36",0.5,2.4,"5,302",48
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,"1,247.93",0.5,1.1,"2,538",49
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,"1,214.56",0.5,0.1,305,50
10,Alberta,B01AA,Vitamin K antagonists,65+,M,"1,206.48",0.5,5.0,"11,218",51
10,Alberta,C01DA,Organic nitrates,65+,M,"1,141.02",0.4,6.6,"14,752",52
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,65+,M,"1,126.33",0.4,2.0,"4,566",53
10,Alberta,A10BB,Sulfonylureas,65+,M,"1,115.89",0.4,6.2,"13,921",54
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"1,115.28",0.4,10.7,"24,042",55
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"1,043.67",0.4,2.2,"4,952",56
10,Alberta,L03AA,Colony-stimulating factors,65+,M,"1,015.19",0.4,0.1,176,57
10,Alberta,M01AB,Acetic acid derivatives and related substances,65+,M,"1,002.16",0.4,8.3,"18,690",58
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,984.88,0.4,0.0,38,59
10,Alberta,N05AX,Other antipsychotics,65+,M,887.38,0.3,0.8,"1,697",60
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,814.18,0.3,0.6,"1,246",61
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,812.21,0.3,0.2,532,62
10,Alberta,D07AC,"Corticosteroids, potent (group III)",65+,M,799.19,0.3,10.1,"22,631",63
10,Alberta,N06DA,Anticholinesterases,65+,M,798.51,0.3,1.2,"2,639",64
10,Alberta,A04AA,Serotonin (5HT3) antagonists,65+,M,761.79,0.3,1.4,"3,151",65
10,Alberta,C03AA,"Thiazides, plain",65+,M,687.36,0.3,7.8,"17,578",66
10,Alberta,H02AB,Glucocorticoids,65+,M,685.15,0.3,10.2,"22,943",67
10,Alberta,V03AC,Iron-chelating agents,65+,M,669.12,0.3,0.0,40,68
10,Alberta,L01XC,Monoclonal antibodies,65+,M,663.98,0.3,0.0,56,69
10,Alberta,J01MA,Fluoroquinolones,65+,M,658.74,0.3,11.0,"24,671",70
10,Alberta,M05BA,Bisphosphonates,65+,M,628.16,0.2,2.2,"4,941",71
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,598.39,0.2,2.7,"6,080",72
10,Alberta,C10AX,Other lipid-modifying agents,65+,M,596.25,0.2,2.3,"5,201",73
10,Alberta,C03DA,Aldosterone antagonists,65+,M,590.63,0.2,3.0,"6,791",74
10,Alberta,J01CA,Penicillins with extended spectrum,65+,M,563.86,0.2,12.6,"28,266",75
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,563.37,0.2,0.7,"1,602",76
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,523.49,0.2,2.4,"5,346",77
10,Alberta,J01DB,First-generation cephalosporins,65+,M,521.24,0.2,8.2,"18,367",78
10,Alberta,J01FA,Macrolides,65+,M,517.02,0.2,7.9,"17,793",79
10,Alberta,N05BA,Benzodiazepine derivatives,65+,M,493.28,0.2,5.0,"11,150",80
10,Alberta,C10AB,Fibrates,65+,M,478.12,0.2,1.6,"3,633",81
10,Alberta,A09AA,Enzyme preparations,65+,M,458.78,0.2,0.3,622,82
10,Alberta,L01BA,Folic acid analogues,65+,M,447.08,0.2,1.1,"2,417",83
10,Alberta,A10BX,"Other blood glucose–lowering drugs, excluding insulins",65+,M,435.38,0.2,1.8,"3,940",84
10,Alberta,M01AE,Propionic acid derivatives,65+,M,414.77,0.2,6.0,"13,525",85
10,Alberta,C10AC,Bile acid sequestrants,65+,M,412.18,0.2,0.4,938,86
10,Alberta,D05AX,Other antipsoriatics for topical use,65+,M,411.57,0.2,0.8,"1,903",87
10,Alberta,A04AD,Other antiemetics,65+,M,376.11,0.1,0.4,827,88
10,Alberta,G03BA,3-oxoandrosten (4) derivatives,65+,M,371.29,0.1,1.0,"2,179",89
10,Alberta,A12BA,Potassium,65+,M,370.55,0.1,2.3,"5,290",90
10,Alberta,A10BG,Thiazolidinediones,65+,M,367.92,0.1,0.7,"1,487",91
10,Alberta,A02BA,H2-receptor antagonists,65+,M,360.83,0.1,2.0,"4,404",92
10,Alberta,A07AA,Antibiotics,65+,M,358.58,0.1,1.0,"2,337",93
10,Alberta,M04AC,Preparations with no effect on uric acid metabolism,65+,M,349.41,0.1,3.7,"8,338",94
10,Alberta,C01AA,Digitalis glycosides,65+,M,345.82,0.1,1.3,"2,894",95
10,Alberta,R01AD,Corticosteroids,65+,M,339.02,0.1,3.3,"7,423",96
10,Alberta,S01BA,"Corticosteroids, plain",65+,M,327.79,0.1,3.7,"8,277",97
10,Alberta,C03BA,"Sulfonamides, plain",65+,M,325.01,0.1,2.7,"6,150",98
10,Alberta,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,315.28,0.1,0.5,"1,140",99
10,Alberta,J01AA,Tetracyclines,65+,M,311.11,0.1,4.5,"10,132",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"21,840.43",7.6,0.4,"1,163",1
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"14,068.55",4.9,8.0,"20,946",2
10,Alberta,C10AA,HMG-CoA reductase inhibitors,65+,F,"11,567.06",4.0,37.6,"98,706",3
10,Alberta,B01AF,Direct factor Xa inhibitors,65+,F,"9,778.81",3.4,4.8,"12,648",4
10,Alberta,C09AA,"ACE inhibitors, plain",65+,F,"9,332.31",3.2,20.2,"52,958",5
10,Alberta,A02BC,Proton pump inhibitors,65+,F,"8,463.91",2.9,33.8,"88,562",6
10,Alberta,S01LA,Antineovascularization agents,65+,F,"7,347.46",2.6,0.3,730,7
10,Alberta,C08CA,Dihydropyridine derivatives,65+,F,"7,339.47",2.6,19.9,"52,173",8
10,Alberta,C09CA,"Angiotensin II antagonists, plain",65+,F,"6,461.45",2.2,19.1,"50,131",9
10,Alberta,H03AA,Thyroid hormones,65+,F,"6,154.02",2.1,30.2,"79,330",10
10,Alberta,R03BB,Anticholinergics,65+,F,"6,086.36",2.1,6.7,"17,645",11
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"6,078.04",2.1,3.1,"8,211",12
10,Alberta,N06AX,Other antidepressants,65+,F,"5,662.75",2.0,12.9,"33,953",13
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,65+,F,"5,265.21",1.8,13.0,"34,141",14
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,"4,962.60",1.7,10.9,"28,583",15
10,Alberta,N02AA,Natural opium alkaloids,65+,F,"4,859.45",1.7,4.8,"12,700",16
10,Alberta,M05BA,Bisphosphonates,65+,F,"4,417.21",1.5,12.8,"33,681",17
10,Alberta,J05AP,Antivirals for treatment of HCV infections,65+,F,"4,388.93",1.5,0.0,75,18
10,Alberta,L04AA,Selective immunosuppressants,65+,F,"4,190.97",1.5,0.3,908,19
10,Alberta,C07AB,"Beta-blocking agents, selective",65+,F,"4,110.44",1.4,18.0,"47,320",20
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"3,878.40",1.3,1.8,"4,786",21
10,Alberta,N03AX,Other antiepileptics,65+,F,"3,833.75",1.3,8.6,"22,602",22
10,Alberta,B01AB,Heparin group,65+,F,"3,788.73",1.3,1.5,"4,036",23
10,Alberta,N05CF,Benzodiazepine-related drugs,65+,F,"3,260.47",1.1,15.1,"39,715",24
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",65+,F,"3,130.13",1.1,16.9,"44,269",25
10,Alberta,B03XA,Other antianemic preparations,65+,F,"3,018.07",1.0,0.3,758,26
10,Alberta,C09DA,Angiotensin II antagonists and diuretics,65+,F,"3,000.20",1.0,9.1,"23,780",27
10,Alberta,L04AC,Interleukin inhibitors,65+,F,"2,683.75",0.9,0.1,188,28
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,65+,F,"2,557.60",0.9,4.1,"10,759",29
10,Alberta,C09BA,ACE inhibitors and diuretics,65+,F,"2,488.04",0.9,3.9,"10,130",30
10,Alberta,A10BA,Biguanides,65+,F,"2,449.88",0.9,12.6,"33,004",31
10,Alberta,C08DB,Benzothiazepine derivatives,65+,F,"2,412.43",0.8,3.3,"8,631",32
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,"2,001.32",0.7,0.9,"2,433",33
10,Alberta,L03AA,Colony-stimulating factors,65+,F,"1,954.16",0.7,0.1,305,34
10,Alberta,C03CA,"Sulfonamides, plain",65+,F,"1,948.31",0.7,9.3,"24,429",35
10,Alberta,B01AE,Direct thrombin inhibitors,65+,F,"1,945.09",0.7,0.7,"1,912",36
10,Alberta,R03BA,Glucocorticoids,65+,F,"1,930.85",0.7,3.9,"10,333",37
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"1,900.25",0.7,13.0,"34,015",38
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,"1,829.64",0.6,1.8,"4,750",39
10,Alberta,S01EE,Prostaglandin analogues,65+,F,"1,814.28",0.6,4.1,"10,756",40
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"1,799.10",0.6,3.1,"8,049",41
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,"1,798.17",0.6,0.5,"1,209",42
10,Alberta,S01ED,Beta-blocking agents,65+,F,"1,791.81",0.6,3.2,"8,325",43
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,"1,785.79",0.6,1.0,"2,747",44
10,Alberta,H01CB,Somatostatin and analogues,65+,F,"1,766.13",0.6,0.0,103,45
10,Alberta,L01XC,Monoclonal antibodies,65+,F,"1,559.50",0.5,0.0,128,46
10,Alberta,A07EC,Aminosalicylic acid and similar agents,65+,F,"1,542.91",0.5,0.8,"2,025",47
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"1,496.69",0.5,2.8,"7,401",48
10,Alberta,N05AX,Other antipsychotics,65+,F,"1,456.32",0.5,1.1,"2,935",49
10,Alberta,N06DA,Anticholinesterases,65+,F,"1,425.88",0.5,1.6,"4,246",50
10,Alberta,A04AA,Serotonin (5HT3) antagonists,65+,F,"1,397.73",0.5,2.1,"5,569",51
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"1,349.66",0.5,4.7,"12,333",52
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"1,347.21",0.5,12.2,"32,062",53
10,Alberta,B01AA,Vitamin K antagonists,65+,F,"1,244.48",0.4,3.6,"9,351",54
10,Alberta,L04AX,Other immunosuppressants,65+,F,"1,243.52",0.4,0.3,701,55
10,Alberta,C03AA,"Thiazides, plain",65+,F,"1,188.83",0.4,10.6,"27,730",56
10,Alberta,C01DA,Organic nitrates,65+,F,"1,144.18",0.4,4.3,"11,363",57
10,Alberta,N05BA,Benzodiazepine derivatives,65+,F,"1,132.13",0.4,9.3,"24,328",58
10,Alberta,N04BA,Dopa and dopa derivatives,65+,F,"1,115.33",0.4,0.9,"2,430",59
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,"1,112.50",0.4,0.9,"2,346",60
10,Alberta,M05BX,Other drugs affecting bone structure and mineralization,65+,F,"1,110.65",0.4,0.7,"1,814",61
10,Alberta,L01XE,Protein kinase inhibitors,65+,F,"1,035.60",0.4,0.0,45,62
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,"1,010.52",0.4,0.0,38,63
10,Alberta,M05BB,"Bisphosphonates, combinations",65+,F,947.35,0.3,4.2,"11,017",64
10,Alberta,M01AB,Acetic acid derivatives and related substances,65+,F,932.42,0.3,6.3,"16,435",65
10,Alberta,C07AG,Alpha- and beta-blocking agents,65+,F,893.48,0.3,1.4,"3,621",66
10,Alberta,L01BA,Folic acid analogues,65+,F,866.47,0.3,1.7,"4,494",67
10,Alberta,H02AB,Glucocorticoids,65+,F,855.81,0.3,10.5,"27,602",68
10,Alberta,G03DA,Pregnen (4) derivatives,65+,F,851.86,0.3,1.1,"2,995",69
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,833.10,0.3,4.0,"10,563",70
10,Alberta,A10BB,Sulfonylureas,65+,F,816.75,0.3,3.7,"9,699",71
10,Alberta,A12BA,Potassium,65+,F,789.44,0.3,3.7,"9,771",72
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,65+,F,773.26,0.3,0.6,"1,700",73
10,Alberta,D07AC,"Corticosteroids, potent (group III)",65+,F,760.60,0.3,9.5,"24,946",74
10,Alberta,J01MA,Fluoroquinolones,65+,F,752.27,0.3,11.9,"31,117",75
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,F,752.16,0.3,0.1,175,76
10,Alberta,J01FA,Macrolides,65+,F,641.93,0.2,9.0,"23,710",77
10,Alberta,J01CA,Penicillins with extended spectrum,65+,F,625.78,0.2,12.4,"32,477",78
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,587.35,0.2,0.4,"1,059",79
10,Alberta,A02BA,H2-receptor antagonists,65+,F,581.69,0.2,2.7,"7,138",80
10,Alberta,C03DA,Aldosterone antagonists,65+,F,573.89,0.2,2.5,"6,625",81
10,Alberta,M04AA,Preparations inhibiting uric acid production,65+,F,561.19,0.2,2.4,"6,342",82
10,Alberta,J01XE,Nitrofuran derivatives,65+,F,557.73,0.2,7.3,"19,234",83
10,Alberta,A04AD,Other antiemetics,65+,F,546.02,0.2,0.5,"1,221",84
10,Alberta,A09AA,Enzyme preparations,65+,F,545.90,0.2,0.3,837,85
10,Alberta,J01DB,First-generation cephalosporins,65+,F,530.33,0.2,7.3,"19,237",86
10,Alberta,A05AA,Bile acids and derivatives,65+,F,530.06,0.2,0.2,611,87
10,Alberta,N03AE,Benzodiazepine derivatives,65+,F,528.76,0.2,2.7,"7,007",88
10,Alberta,M01AE,Propionic acid derivatives,65+,F,516.18,0.2,6.1,"15,973",89
10,Alberta,A03FA,Propulsives,65+,F,510.88,0.2,3.5,"9,110",90
10,Alberta,N02AB,Phenylpiperidine derivatives,65+,F,506.30,0.2,0.3,793,91
10,Alberta,P01BA,Aminoquinolines,65+,F,503.95,0.2,1.5,"4,008",92
10,Alberta,C10AC,Bile acid sequestrants,65+,F,499.62,0.2,0.7,"1,863",93
10,Alberta,L03AX,Other immunostimulants,65+,F,492.14,0.2,0.0,37,94
10,Alberta,L03AB,Interferons,65+,F,463.15,0.2,0.0,25,95
10,Alberta,N04BC,Dopamine agonists,65+,F,451.64,0.2,1.0,"2,572",96
10,Alberta,C10AX,Other lipid-modifying agents,65+,F,448.87,0.2,1.5,"3,859",97
10,Alberta,C03BA,"Sulfonamides, plain",65+,F,444.59,0.2,2.9,"7,625",98
10,Alberta,R03DC,Leukotriene receptor antagonists,65+,F,432.76,0.2,0.7,"1,746",99
10,Alberta,S01BA,"Corticosteroids, plain",65+,F,428.51,0.1,4.1,"10,658",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"109,736.80",39.0,4.7,"5,217",1
10,Alberta,L04AA,Selective immunosuppressants,<65,Total,"22,022.84",7.8,1.2,"1,342",2
10,Alberta,J05AP,Antivirals for treatment of HCV infections,<65,Total,"19,339.89",6.9,0.3,339,3
10,Alberta,L04AC,Interleukin inhibitors,<65,Total,"10,368.51",3.7,0.6,694,4
10,Alberta,L03AX,Other immunostimulants,<65,Total,"8,458.96",3.0,0.7,748,5
10,Alberta,N07XX,Other nervous system drugs,<65,Total,"7,648.41",2.7,0.4,459,6
10,Alberta,L03AB,Interferons,<65,Total,"5,724.79",2.0,0.3,369,7
10,Alberta,N02AA,Natural opium alkaloids,<65,Total,"5,079.61",1.8,4.5,"4,999",8
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"4,146.57",1.5,4.2,"4,657",9
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"3,305.92",1.2,5.5,"6,111",10
10,Alberta,R07AX,Other respiratory system products,<65,Total,"3,209.30",1.1,0.0,12,11
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"3,015.63",1.1,0.6,686,12
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"2,658.84",0.9,1.3,"1,457",13
10,Alberta,N06AX,Other antidepressants,<65,Total,"2,524.11",0.9,13.6,"14,952",14
10,Alberta,C10AA,HMG-CoA reductase inhibitors,<65,Total,"2,471.00",0.9,23.4,"25,836",15
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"2,393.17",0.9,0.1,115,16
10,Alberta,C09AA,"ACE inhibitors, plain",<65,Total,"2,121.79",0.8,12.3,"13,584",17
10,Alberta,N03AX,Other antiepileptics,<65,Total,"2,042.54",0.7,7.5,"8,239",18
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"1,992.67",0.7,13.2,"14,562",19
10,Alberta,B01AB,Heparin group,<65,Total,"1,922.89",0.7,1.1,"1,222",20
10,Alberta,A02BC,Proton pump inhibitors,<65,Total,"1,808.46",0.6,23.1,"25,476",21
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"1,651.82",0.6,3.1,"3,467",22
10,Alberta,H01CB,Somatostatin and analogues,<65,Total,"1,636.22",0.6,0.1,104,23
10,Alberta,N05AX,Other antipsychotics,<65,Total,"1,581.15",0.6,1.7,"1,828",24
10,Alberta,N06BA,Centrally acting sympathomimetics,<65,Total,"1,550.54",0.6,2.3,"2,537",25
10,Alberta,B03XA,Other antianemic preparations,<65,Total,"1,421.36",0.5,0.4,404,26
10,Alberta,L03AA,Colony-stimulating factors,<65,Total,"1,406.03",0.5,0.2,198,27
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"1,366.46",0.5,2.0,"2,186",28
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,"1,355.20",0.5,7.3,"8,019",29
10,Alberta,A07EC,Aminosalicylic acid and similar agents,<65,Total,"1,342.35",0.5,1.6,"1,741",30
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"1,226.19",0.4,3.7,"4,127",31
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"1,194.91",0.4,1.4,"1,561",32
10,Alberta,L01XC,Monoclonal antibodies,<65,Total,"1,149.36",0.4,0.1,96,33
10,Alberta,H03AA,Thyroid hormones,<65,Total,"1,147.91",0.4,15.7,"17,313",34
10,Alberta,C08CA,Dihydropyridine derivatives,<65,Total,"1,118.01",0.4,8.5,"9,341",35
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"1,105.12",0.4,1.3,"1,423",36
10,Alberta,C09CA,"Angiotensin II antagonists, plain",<65,Total,"1,037.55",0.4,8.9,"9,822",37
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,<65,Total,911.99,0.3,2.6,"2,831",38
10,Alberta,A04AA,Serotonin (5HT3) antagonists,<65,Total,908.99,0.3,2.5,"2,722",39
10,Alberta,N07BC,Drugs used in opioid dependence,<65,Total,824.21,0.3,0.5,570,40
10,Alberta,C09BA,ACE inhibitors and diuretics,<65,Total,819.92,0.3,3.1,"3,441",41
10,Alberta,N05CF,Benzodiazepine-related drugs,<65,Total,816.44,0.3,10.2,"11,286",42
10,Alberta,B01AF,Direct factor Xa inhibitors,<65,Total,799.79,0.3,1.2,"1,347",43
10,Alberta,R03BB,Anticholinergics,<65,Total,774.03,0.3,2.5,"2,777",44
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,754.38,0.3,12.5,"13,772",45
10,Alberta,R03BA,Glucocorticoids,<65,Total,724.38,0.3,4.5,"4,909",46
10,Alberta,C09DA,Angiotensin II antagonists and diuretics,<65,Total,671.93,0.2,5.2,"5,699",47
10,Alberta,A10BA,Biguanides,<65,Total,661.11,0.2,10.0,"10,974",48
10,Alberta,A04AD,Other antiemetics,<65,Total,660.73,0.2,0.8,895,49
10,Alberta,G03DA,Pregnen (4) derivatives,<65,Total,642.82,0.2,2.1,"2,304",50
10,Alberta,J01GB,Other aminoglycosides,<65,Total,602.89,0.2,0.1,90,51
10,Alberta,V03AC,Iron-chelating agents,<65,Total,600.92,0.2,0.0,42,52
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,597.18,0.2,5.0,"5,536",53
10,Alberta,A09AA,Enzyme preparations,<65,Total,552.04,0.2,0.4,400,54
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,547.44,0.2,4.4,"4,847",55
10,Alberta,J01DF,Monobactams,<65,Total,539.47,0.2,0.0,29,56
10,Alberta,C07AB,"Beta-blocking agents, selective",<65,Total,516.86,0.2,7.5,"8,287",57
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",<65,Total,511.92,0.2,9.4,"10,336",58
10,Alberta,N05AE,Indole derivatives,<65,Total,474.82,0.2,0.4,422,59
10,Alberta,L04AX,Other immunosuppressants,<65,Total,469.39,0.2,1.1,"1,181",60
10,Alberta,M01AB,Acetic acid derivatives and related substances,<65,Total,448.73,0.2,8.2,"9,080",61
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,429.50,0.2,11.4,"12,579",62
10,Alberta,M03BX,Other centrally acting agents,<65,Total,410.77,0.1,6.0,"6,560",63
10,Alberta,L01BA,Folic acid analogues,<65,Total,404.93,0.1,2.4,"2,640",64
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,<65,Total,396.05,0.1,1.6,"1,725",65
10,Alberta,N02AB,Phenylpiperidine derivatives,<65,Total,395.77,0.1,0.4,472,66
10,Alberta,N05BA,Benzodiazepine derivatives,<65,Total,383.18,0.1,8.0,"8,779",67
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,376.37,0.1,1.4,"1,499",68
10,Alberta,C08DB,Benzothiazepine derivatives,<65,Total,366.87,0.1,1.3,"1,404",69
10,Alberta,M05BA,Bisphosphonates,<65,Total,366.81,0.1,2.7,"2,984",70
10,Alberta,H02AB,Glucocorticoids,<65,Total,337.14,0.1,10.1,"11,185",71
10,Alberta,J01FA,Macrolides,<65,Total,314.21,0.1,10.1,"11,180",72
10,Alberta,C01CA,Adrenergic and dopaminergic agents,<65,Total,304.98,0.1,1.9,"2,146",73
10,Alberta,J01CA,Penicillins with extended spectrum,<65,Total,283.79,0.1,13.8,"15,194",74
10,Alberta,M01AE,Propionic acid derivatives,<65,Total,281.43,0.1,8.4,"9,266",75
10,Alberta,H01AC,Somatropin and somatropin agonists,<65,Total,278.73,0.1,0.0,47,76
10,Alberta,A10BB,Sulfonylureas,<65,Total,241.35,0.1,3.1,"3,414",77
10,Alberta,N03AE,Benzodiazepine derivatives,<65,Total,240.04,0.1,3.1,"3,379",78
10,Alberta,D07AC,"Corticosteroids, potent (group III)",<65,Total,225.75,0.1,7.4,"8,149",79
10,Alberta,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,223.34,0.1,2.5,"2,709",80
10,Alberta,P01BA,Aminoquinolines,<65,Total,213.67,0.1,1.8,"2,000",81
10,Alberta,J02AC,Triazole derivatives,<65,Total,211.81,0.1,2.3,"2,579",82
10,Alberta,C07AG,Alpha- and beta-blocking agents,<65,Total,210.66,0.1,0.9,944,83
10,Alberta,J01MA,Fluoroquinolones,<65,Total,209.37,0.1,7.9,"8,692",84
10,Alberta,A07AA,Antibiotics,<65,Total,209.32,0.1,1.2,"1,291",85
10,Alberta,R03DC,Leukotriene receptor antagonists,<65,Total,199.43,0.1,1.1,"1,191",86
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,198.29,0.1,0.5,555,87
10,Alberta,A05AA,Bile acids and derivatives,<65,Total,194.42,0.1,0.3,289,88
10,Alberta,J01DB,First-generation cephalosporins,<65,Total,192.00,0.1,6.3,"6,901",89
10,Alberta,D05AX,Other antipsoriatics for topical use,<65,Total,187.69,0.1,0.8,928,90
10,Alberta,S01LA,Antineovascularization agents,<65,Total,184.43,0.1,0.0,22,91
10,Alberta,N04BA,Dopa and dopa derivatives,<65,Total,181.88,0.1,0.3,322,92
10,Alberta,N03AG,Fatty acid derivatives,<65,Total,180.31,0.1,0.8,841,93
10,Alberta,J01AA,Tetracyclines,<65,Total,175.83,0.1,4.4,"4,825",94
10,Alberta,C10AC,Bile acid sequestrants,<65,Total,174.49,0.1,0.6,651,95
10,Alberta,P01AX,Other agents against amebiasis and other protozoal diseases,<65,Total,171.42,0.1,0.0,38,96
10,Alberta,V04CJ,Tests for thyroid function,<65,Total,171.39,0.1,0.1,89,97
10,Alberta,G02BA,Intrauterine contraceptives,<65,Total,169.19,0.1,0.5,527,98
10,Alberta,A03FA,Propulsives,<65,Total,165.26,0.1,2.9,"3,180",99
10,Alberta,C03AA,"Thiazides, plain",<65,Total,164.86,0.1,4.6,"5,098",100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"60,780.75",45.9,6.9,"2,660",1
10,Alberta,J05AP,Antivirals for treatment of HCV infections,<65,M,"13,177.07",10.0,0.6,229,2
10,Alberta,L04AA,Selective immunosuppressants,<65,M,"7,051.37",5.3,0.9,348,3
10,Alberta,L04AC,Interleukin inhibitors,<65,M,"5,210.80",3.9,0.9,334,4
10,Alberta,N07XX,Other nervous system drugs,<65,M,"2,557.66",1.9,0.4,154,5
10,Alberta,L03AX,Other immunostimulants,<65,M,"2,455.77",1.9,0.6,211,6
10,Alberta,N02AA,Natural opium alkaloids,<65,M,"2,436.65",1.8,4.9,"1,886",7
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"2,270.65",1.7,6.2,"2,369",8
10,Alberta,R07AX,Other respiratory system products,<65,M,"2,017.97",1.5,0.0,7,9
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"1,877.18",1.4,1.1,436,10
10,Alberta,L03AB,Interferons,<65,M,"1,374.53",1.0,0.2,92,11
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"1,231.03",0.9,5.5,"2,126",12
10,Alberta,C10AA,HMG-CoA reductase inhibitors,<65,M,"1,129.55",0.9,29.7,"11,396",13
10,Alberta,C09AA,"ACE inhibitors, plain",<65,M,992.74,0.8,16.6,"6,345",14
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,956.72,0.7,0.1,45,15
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,949.86,0.7,4.7,"1,805",16
10,Alberta,H01CB,Somatostatin and analogues,<65,M,934.79,0.7,0.1,52,17
10,Alberta,N06BA,Centrally acting sympathomimetics,<65,M,784.38,0.6,3.3,"1,269",18
10,Alberta,B03XA,Other antianemic preparations,<65,M,760.66,0.6,0.6,228,19
10,Alberta,N05AX,Other antipsychotics,<65,M,749.47,0.6,2.0,770,20
10,Alberta,B01AB,Heparin group,<65,M,743.10,0.6,1.1,419,21
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,700.68,0.5,2.9,"1,122",22
10,Alberta,N03AX,Other antiepileptics,<65,M,637.11,0.5,6.4,"2,463",23
10,Alberta,N06AX,Other antidepressants,<65,M,613.87,0.5,9.9,"3,797",24
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,605.41,0.5,3.9,"1,476",25
10,Alberta,A02BC,Proton pump inhibitors,<65,M,604.13,0.5,21.7,"8,329",26
10,Alberta,A07EC,Aminosalicylic acid and similar agents,<65,M,603.23,0.5,1.8,703,27
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,567.02,0.4,1.9,727,28
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,565.95,0.4,1.9,725,29
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,<65,M,525.08,0.4,10.0,"3,848",30
10,Alberta,C08CA,Dihydropyridine derivatives,<65,M,505.44,0.4,10.8,"4,130",31
10,Alberta,B01AF,Direct factor Xa inhibitors,<65,M,451.48,0.3,1.7,669,32
10,Alberta,N07BC,Drugs used in opioid dependence,<65,M,422.01,0.3,0.8,295,33
10,Alberta,J01GB,Other aminoglycosides,<65,M,404.33,0.3,0.1,52,34
10,Alberta,C09BA,ACE inhibitors and diuretics,<65,M,373.94,0.3,4.0,"1,531",35
10,Alberta,V03AC,Iron-chelating agents,<65,M,369.91,0.3,0.0,19,36
10,Alberta,C09CA,"Angiotensin II antagonists, plain",<65,M,365.75,0.3,8.9,"3,403",37
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,351.01,0.3,0.5,203,38
10,Alberta,L04AX,Other immunosuppressants,<65,M,339.82,0.3,1.5,557,39
10,Alberta,A09AA,Enzyme preparations,<65,M,314.10,0.2,0.4,168,40
10,Alberta,R03BB,Anticholinergics,<65,M,312.50,0.2,2.8,"1,080",41
10,Alberta,L01XC,Monoclonal antibodies,<65,M,310.70,0.2,0.1,24,42
10,Alberta,A10BA,Biguanides,<65,M,296.01,0.2,12.3,"4,712",43
10,Alberta,R03BA,Glucocorticoids,<65,M,271.03,0.2,4.6,"1,774",44
10,Alberta,C07AB,"Beta-blocking agents, selective",<65,M,264.55,0.2,10.7,"4,117",45
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,256.07,0.2,12.4,"4,741",46
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,243.60,0.2,2.4,938,47
10,Alberta,C09DA,Angiotensin II antagonists and diuretics,<65,M,242.76,0.2,5.3,"2,028",48
10,Alberta,N05CF,Benzodiazepine-related drugs,<65,M,235.53,0.2,7.9,"3,030",49
10,Alberta,J01DF,Monobactams,<65,M,232.71,0.2,0.0,11,50
10,Alberta,A04AA,Serotonin (5HT3) antagonists,<65,M,226.88,0.2,1.9,727,51
10,Alberta,A04AD,Other antiemetics,<65,M,223.81,0.2,0.7,285,52
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,219.71,0.2,3.2,"1,232",53
10,Alberta,L03AA,Colony-stimulating factors,<65,M,211.83,0.2,0.1,31,54
10,Alberta,H03AA,Thyroid hormones,<65,M,167.18,0.1,7.0,"2,679",55
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,165.22,0.1,11.4,"4,388",56
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,<65,M,161.08,0.1,1.0,370,57
10,Alberta,C08DB,Benzothiazepine derivatives,<65,M,157.29,0.1,1.5,581,58
10,Alberta,M01AB,Acetic acid derivatives and related substances,<65,M,155.97,0.1,8.3,"3,171",59
10,Alberta,N02AB,Phenylpiperidine derivatives,<65,M,154.96,0.1,0.4,166,60
10,Alberta,N05AE,Indole derivatives,<65,M,147.77,0.1,0.3,122,61
10,Alberta,G04CA,Alpha-adrenoreceptor antagonists,<65,M,145.31,0.1,5.9,"2,261",62
10,Alberta,H01AC,Somatropin and somatropin agonists,<65,M,136.95,0.1,0.0,18,63
10,Alberta,G03BA,3-oxoandrosten (4) derivatives,<65,M,133.37,0.1,1.9,714,64
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,131.73,0.1,2.8,"1,065",65
10,Alberta,H02AB,Glucocorticoids,<65,M,128.96,0.1,10.3,"3,966",66
10,Alberta,L01BA,Folic acid analogues,<65,M,128.18,0.1,2.2,845,67
10,Alberta,M03BX,Other centrally acting agents,<65,M,127.85,0.1,4.9,"1,889",68
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",<65,M,125.90,0.1,6.6,"2,546",69
10,Alberta,S01LA,Antineovascularization agents,<65,M,125.03,0.1,0.0,15,70
10,Alberta,C07AG,Alpha- and beta-blocking agents,<65,M,124.46,0.1,1.3,508,71
10,Alberta,A10BB,Sulfonylureas,<65,M,119.83,0.1,4.2,"1,628",72
10,Alberta,N05BA,Benzodiazepine derivatives,<65,M,113.08,0.1,5.7,"2,200",73
10,Alberta,C01CA,Adrenergic and dopaminergic agents,<65,M,109.19,0.1,1.8,694,74
10,Alberta,J01FA,Macrolides,<65,M,105.39,0.1,8.9,"3,405",75
10,Alberta,N04BA,Dopa and dopa derivatives,<65,M,103.44,0.1,0.4,143,76
10,Alberta,D05AX,Other antipsoriatics for topical use,<65,M,101.94,0.1,1.0,375,77
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,99.78,0.1,0.8,290,78
10,Alberta,A07AA,Antibiotics,<65,M,98.96,0.1,1.0,386,79
10,Alberta,J01CA,Penicillins with extended spectrum,<65,M,98.22,0.1,13.3,"5,103",80
10,Alberta,M04AA,Preparations inhibiting uric acid production,<65,M,95.40,0.1,3.8,"1,445",81
10,Alberta,N03AG,Fatty acid derivatives,<65,M,90.08,0.1,1.0,369,82
10,Alberta,M01AE,Propionic acid derivatives,<65,M,86.16,0.1,7.3,"2,787",83
10,Alberta,C10AB,Fibrates,<65,M,83.84,0.1,1.7,658,84
10,Alberta,B01AE,Direct thrombin inhibitors,<65,M,81.97,0.1,0.3,98,85
10,Alberta,G04CB,Testosterone-5-alpha reductase inhibitors,<65,M,79.59,0.1,2.0,775,86
10,Alberta,A07EA,Corticosteroids acting locally,<65,M,79.31,0.1,0.3,113,87
10,Alberta,D07AC,"Corticosteroids, potent (group III)",<65,M,78.16,0.1,6.5,"2,495",88
10,Alberta,C10AC,Bile acid sequestrants,<65,M,76.41,0.1,0.6,243,89
10,Alberta,J01DB,First-generation cephalosporins,<65,M,75.54,0.1,6.6,"2,512",90
10,Alberta,N03AF,Carboxamide derivatives,<65,M,73.37,0.1,0.8,305,91
10,Alberta,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,69.65,0.1,0.4,159,92
10,Alberta,J01MA,Fluoroquinolones,<65,M,69.60,0.1,6.3,"2,433",93
10,Alberta,N03AE,Benzodiazepine derivatives,<65,M,69.00,0.1,2.5,944,94
10,Alberta,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,68.59,0.1,0.3,107,95
10,Alberta,J02AC,Triazole derivatives,<65,M,65.74,0.0,0.8,308,96
10,Alberta,H01BA,Vasopressin and analogues,<65,M,63.42,0.0,0.1,55,97
10,Alberta,L04AD,Calcineurin inhibitors,<65,M,63.10,0.0,0.1,24,98
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,<65,M,62.44,0.0,0.7,285,99
10,Alberta,N07BA,Drugs used in nicotine dependence,<65,M,60.39,0.0,0.9,354,100
10,Alberta,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"48,956.05",32.9,3.6,"2,557",1
10,Alberta,L04AA,Selective immunosuppressants,<65,F,"14,971.47",10.1,1.4,994,2
10,Alberta,J05AP,Antivirals for treatment of HCV infections,<65,F,"6,162.82",4.1,0.2,110,3
10,Alberta,L03AX,Other immunostimulants,<65,F,"6,003.19",4.0,0.7,537,4
10,Alberta,L04AC,Interleukin inhibitors,<65,F,"5,157.71",3.5,0.5,360,5
10,Alberta,N07XX,Other nervous system drugs,<65,F,"5,090.76",3.4,0.4,305,6
10,Alberta,L03AB,Interferons,<65,F,"4,350.26",2.9,0.4,277,7
10,Alberta,N02AA,Natural opium alkaloids,<65,F,"2,642.96",1.8,4.3,"3,113",8
10,Alberta,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"2,307.82",1.6,1.7,"1,254",9
10,Alberta,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"2,074.88",1.4,5.5,"3,985",10
10,Alberta,N06AX,Other antidepressants,<65,F,"1,910.24",1.3,15.5,"11,155",11
10,Alberta,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"1,875.92",1.3,3.2,"2,288",12
10,Alberta,N06AB,Selective serotonin reuptake inhibitors,<65,F,"1,467.59",1.0,14.9,"10,714",13
10,Alberta,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"1,436.45",1.0,0.1,70,14
10,Alberta,N03AX,Other antiepileptics,<65,F,"1,405.43",0.9,8.0,"5,776",15
10,Alberta,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,"1,348.46",0.9,11.1,"7,968",16
10,Alberta,C10AA,HMG-CoA reductase inhibitors,<65,F,"1,341.46",0.9,20.1,"14,440",17
10,Alberta,A02BC,Proton pump inhibitors,<65,F,"1,204.33",0.8,23.8,"17,147",18
10,Alberta,L03AA,Colony-stimulating factors,<65,F,"1,194.20",0.8,0.2,167,19
10,Alberta,R07AX,Other respiratory system products,<65,F,"1,191.33",0.8,0.0,5,20
10,Alberta,B01AB,Heparin group,<65,F,"1,179.79",0.8,1.1,803,21
10,Alberta,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,"1,138.45",0.8,0.3,250,22
10,Alberta,C09AA,"ACE inhibitors, plain",<65,F,"1,129.05",0.8,10.1,"7,239",23
10,Alberta,H03AA,Thyroid hormones,<65,F,980.73,0.7,20.4,"14,634",24
10,Alberta,L01XC,Monoclonal antibodies,<65,F,838.66,0.6,0.1,72,25
10,Alberta,N05AX,Other antipsychotics,<65,F,831.69,0.6,1.5,"1,058",26
10,Alberta,N06BA,Centrally acting sympathomimetics,<65,F,766.15,0.5,1.8,"1,268",27
10,Alberta,N02CC,Selective serotonin (5HT1) agonists,<65,F,750.91,0.5,3.4,"2,461",28
10,Alberta,A07EC,Aminosalicylic acid and similar agents,<65,F,739.12,0.5,1.4,"1,038",29
10,Alberta,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,701.95,0.5,2.3,"1,662",30
10,Alberta,H01CB,Somatostatin and analogues,<65,F,701.43,0.5,0.1,52,31
10,Alberta,A04AA,Serotonin (5HT3) antagonists,<65,F,682.11,0.5,2.8,"1,995",32
10,Alberta,C09CA,"Angiotensin II antagonists, plain",<65,F,671.80,0.5,8.9,"6,419",33
10,Alberta,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,665.78,0.4,1.5,"1,064",34
10,Alberta,B03XA,Other antianemic preparations,<65,F,660.70,0.4,0.2,176,35
10,Alberta,G03DA,Pregnen (4) derivatives,<65,F,639.46,0.4,3.2,"2,286",36
10,Alberta,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,627.90,0.4,1.2,834,37
10,Alberta,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,620.78,0.4,3.7,"2,651",38
10,Alberta,C08CA,Dihydropyridine derivatives,<65,F,612.57,0.4,7.2,"5,211",39
10,Alberta,N05CF,Benzodiazepine-related drugs,<65,F,580.91,0.4,11.5,"8,256",40
10,Alberta,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,539.17,0.4,1.0,698,41
10,Alberta,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,498.30,0.3,12.6,"9,031",42
10,Alberta,R03BB,Anticholinergics,<65,F,461.54,0.3,2.4,"1,697",43
10,Alberta,R03BA,Glucocorticoids,<65,F,453.35,0.3,4.4,"3,135",44
10,Alberta,C09BA,ACE inhibitors and diuretics,<65,F,445.99,0.3,2.7,"1,910",45
10,Alberta,A04AD,Other antiemetics,<65,F,436.92,0.3,0.8,610,46
10,Alberta,C09DA,Angiotensin II antagonists and diuretics,<65,F,429.16,0.3,5.1,"3,671",47
10,Alberta,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,415.71,0.3,5.3,"3,782",48
10,Alberta,N07BC,Drugs used in opioid dependence,<65,F,402.20,0.3,0.4,275,49
10,Alberta,M02AA,"Antiinflammatory preparations, non-steroids for topical use",<65,F,386.02,0.3,10.8,"7,790",50
10,Alberta,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,377.47,0.3,6.0,"4,304",51
10,Alberta,A10BA,Biguanides,<65,F,365.09,0.2,8.7,"6,262",52
10,Alberta,B01AF,Direct factor Xa inhibitors,<65,F,348.31,0.2,0.9,678,53
10,Alberta,M05BA,Bisphosphonates,<65,F,338.74,0.2,3.8,"2,758",54
10,Alberta,G04BD,Drugs for urinary frequency and incontinence,<65,F,333.61,0.2,2.0,"1,440",55
10,Alberta,N05AE,Indole derivatives,<65,F,327.05,0.2,0.4,300,56
10,Alberta,J01DF,Monobactams,<65,F,306.76,0.2,0.0,18,57
10,Alberta,M01AB,Acetic acid derivatives and related substances,<65,F,292.76,0.2,8.2,"5,909",58
10,Alberta,M03BX,Other centrally acting agents,<65,F,282.93,0.2,6.5,"4,671",59
10,Alberta,L01BA,Folic acid analogues,<65,F,276.76,0.2,2.5,"1,795",60
10,Alberta,N05BA,Benzodiazepine derivatives,<65,F,270.09,0.2,9.2,"6,579",61
10,Alberta,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,264.28,0.2,11.4,"8,191",62
10,Alberta,C07AB,"Beta-blocking agents, selective",<65,F,252.31,0.2,5.8,"4,170",63
10,Alberta,N02AB,Phenylpiperidine derivatives,<65,F,240.81,0.2,0.4,306,64
10,Alberta,A09AA,Enzyme preparations,<65,F,237.94,0.2,0.3,232,65
10,Alberta,V03AC,Iron-chelating agents,<65,F,231.01,0.2,0.0,23,66
10,Alberta,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,222.61,0.1,3.7,"2,695",67
10,Alberta,C08DB,Benzothiazepine derivatives,<65,F,209.58,0.1,1.1,823,68
10,Alberta,J01FA,Macrolides,<65,F,208.82,0.1,10.8,"7,775",69
10,Alberta,H02AB,Glucocorticoids,<65,F,208.19,0.1,10.0,"7,219",70
10,Alberta,J01GB,Other aminoglycosides,<65,F,198.56,0.1,0.1,38,71
10,Alberta,C01CA,Adrenergic and dopaminergic agents,<65,F,195.79,0.1,2.0,"1,452",72
10,Alberta,M01AE,Propionic acid derivatives,<65,F,195.27,0.1,9.0,"6,479",73
10,Alberta,J01CA,Penicillins with extended spectrum,<65,F,185.57,0.1,14.0,"10,091",74
10,Alberta,N03AE,Benzodiazepine derivatives,<65,F,171.04,0.1,3.4,"2,435",75
10,Alberta,P01BA,Aminoquinolines,<65,F,169.66,0.1,2.3,"1,624",76
10,Alberta,G02BA,Intrauterine contraceptives,<65,F,168.45,0.1,0.7,525,77
10,Alberta,D07AC,"Corticosteroids, potent (group III)",<65,F,147.59,0.1,7.9,"5,654",78
10,Alberta,J02AC,Triazole derivatives,<65,F,146.06,0.1,3.2,"2,271",79
10,Alberta,A05AA,Bile acids and derivatives,<65,F,144.53,0.1,0.3,207,80
10,Alberta,H01AC,Somatropin and somatropin agonists,<65,F,141.78,0.1,0.0,29,81
10,Alberta,R03DC,Leukotriene receptor antagonists,<65,F,139.85,0.1,1.0,736,82
10,Alberta,J01MA,Fluoroquinolones,<65,F,139.77,0.1,8.7,"6,259",83
10,Alberta,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,132.77,0.1,0.8,561,84
10,Alberta,V04CJ,Tests for thyroid function,<65,F,130.44,0.1,0.1,68,85
10,Alberta,L04AX,Other immunosuppressants,<65,F,129.58,0.1,0.9,624,86
10,Alberta,L02AE,Gonadotropin-releasing hormone analogues,<65,F,124.63,0.1,0.1,57,87
10,Alberta,A10BB,Sulfonylureas,<65,F,121.52,0.1,2.5,"1,786",88
10,Alberta,J01AA,Tetracyclines,<65,F,119.14,0.1,4.7,"3,347",89
10,Alberta,C02AC,Imidazoline receptor agonists,<65,F,118.72,0.1,1.2,864,90
10,Alberta,A03FA,Propulsives,<65,F,118.48,0.1,3.3,"2,350",91
10,Alberta,C03AA,"Thiazides, plain",<65,F,116.70,0.1,5.0,"3,613",92
10,Alberta,J01DB,First-generation cephalosporins,<65,F,116.46,0.1,6.1,"4,389",93
10,Alberta,P01AX,Other agents against amebiasis and other protozoal diseases,<65,F,112.23,0.1,0.0,21,94
10,Alberta,A07AA,Antibiotics,<65,F,110.37,0.1,1.3,905,95
10,Alberta,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,107.42,0.1,1.2,827,96
10,Alberta,S01EE,Prostaglandin analogues,<65,F,100.31,0.1,1.0,711,97
10,Alberta,N07BA,Drugs used in nicotine dependence,<65,F,100.00,0.1,0.8,583,98
10,Alberta,J01XE,Nitrofuran derivatives,<65,F,98.72,0.1,5.6,"4,005",99
10,Alberta,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,98.52,0.1,0.4,265,100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"197,849.10",17.4,0.4,"11,159",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,Total,Total,"142,626.60",12.5,0.1,"2,579",2
11,British Columbia,N05AX,Other antipsychotics,Total,Total,"49,111.65",4.3,1.3,"37,481",3
11,British Columbia,N07BC,Drugs used in opioid dependence,Total,Total,"40,826.55",3.6,0.9,"25,632",4
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"39,639.00",3.5,3.3,"96,813",5
11,British Columbia,L04AA,Selective immunosuppressants,Total,Total,"30,463.39",2.7,0.2,"4,845",6
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,Total,Total,"22,517.92",2.0,16.2,"475,789",7
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"22,252.76",2.0,10.5,"307,534",8
11,British Columbia,N03AX,Other antiepileptics,Total,Total,"20,718.11",1.8,4.7,"137,230",9
11,British Columbia,N06AX,Other antidepressants,Total,Total,"20,337.29",1.8,7.3,"215,091",10
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"18,695.27",1.6,1.7,"50,054",11
11,British Columbia,N02AA,Natural opium alkaloids,Total,Total,"18,364.58",1.6,3.6,"104,842",12
11,British Columbia,C09AA,"ACE inhibitors, plain",Total,Total,"14,360.40",1.3,11.9,"348,726",13
11,British Columbia,N07BA,Drugs used in nicotine dependence,Total,Total,"14,320.81",1.3,3.0,"89,301",14
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"13,966.62",1.2,0.9,"25,558",15
11,British Columbia,A02BC,Proton pump inhibitors,Total,Total,"13,810.13",1.2,5.5,"160,328",16
11,British Columbia,L04AC,Interleukin inhibitors,Total,Total,"12,994.97",1.1,0.0,"1,001",17
11,British Columbia,B01AF,Direct factor Xa inhibitors,Total,Total,"12,752.39",1.1,1.0,"28,753",18
11,British Columbia,C08CA,Dihydropyridine derivatives,Total,Total,"12,466.11",1.1,7.5,"219,155",19
11,British Columbia,C07AB,"Beta-blocking agents, selective",Total,Total,"9,942.98",0.9,7.7,"225,080",20
11,British Columbia,H03AA,Thyroid hormones,Total,Total,"8,961.50",0.8,9.4,"276,501",21
11,British Columbia,N06BA,Centrally acting sympathomimetics,Total,Total,"8,956.42",0.8,1.1,"32,812",22
11,British Columbia,L01XC,Monoclonal antibodies,Total,Total,"8,139.91",0.7,0.0,718,23
11,British Columbia,B02AB,Proteinase inhibitors,Total,Total,"7,777.50",0.7,0.0,79,24
11,British Columbia,R03BB,Anticholinergics,Total,Total,"7,634.38",0.7,1.7,"50,703",25
11,British Columbia,N07XX,Other nervous system drugs,Total,Total,"7,534.75",0.7,0.0,757,26
11,British Columbia,B01AB,Heparin group,Total,Total,"7,478.17",0.7,0.4,"10,298",27
11,British Columbia,A10BA,Biguanides,Total,Total,"7,195.74",0.6,6.5,"190,714",28
11,British Columbia,R03BA,Glucocorticoids,Total,Total,"6,977.12",0.6,4.2,"122,767",29
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,"6,929.01",0.6,0.1,"3,245",30
11,British Columbia,C09CA,"Angiotensin II antagonists, plain",Total,Total,"6,378.45",0.6,2.7,"80,885",31
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"6,243.06",0.5,11.5,"337,356",32
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"5,809.72",0.5,0.4,"11,964",33
11,British Columbia,N05BA,Benzodiazepine derivatives,Total,Total,"5,780.96",0.5,7.5,"219,717",34
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"5,774.03",0.5,1.0,"28,695",35
11,British Columbia,N03AG,Fatty acid derivatives,Total,Total,"5,368.28",0.5,0.6,"17,890",36
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"5,066.16",0.4,1.1,"33,462",37
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"5,028.69",0.4,10.3,"301,576",38
11,British Columbia,L03AB,Interferons,Total,Total,"5,008.54",0.4,0.0,371,39
11,British Columbia,A02BA,H2-receptor antagonists,Total,Total,"4,988.13",0.4,3.3,"96,691",40
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"4,966.04",0.4,0.0,176,41
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,Total,Total,"4,835.96",0.4,0.7,"20,935",42
11,British Columbia,C03CA,"Sulfonamides, plain",Total,Total,"4,572.58",0.4,2.9,"84,752",43
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"4,482.09",0.4,2.7,"79,954",44
11,British Columbia,L03AX,Other immunostimulants,Total,Total,"4,371.18",0.4,0.0,515,45
11,British Columbia,A04AD,Other antiemetics,Total,Total,"4,323.01",0.4,0.3,"9,721",46
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"4,260.56",0.4,0.1,"3,844",47
11,British Columbia,L03AA,Colony-stimulating factors,Total,Total,"4,049.82",0.4,0.1,"1,724",48
11,British Columbia,N03AE,Benzodiazepine derivatives,Total,Total,"3,907.28",0.3,1.7,"49,587",49
11,British Columbia,M03BX,Other centrally acting agents,Total,Total,"3,897.13",0.3,4.3,"127,179",50
11,British Columbia,N06DA,Anticholinesterases,Total,Total,"3,723.74",0.3,0.4,"11,557",51
11,British Columbia,N04BA,Dopa and dopa derivatives,Total,Total,"3,681.81",0.3,0.5,"13,462",52
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,Total,Total,"3,652.90",0.3,1.3,"38,960",53
11,British Columbia,M01AE,Propionic acid derivatives,Total,Total,"3,639.53",0.3,7.2,"212,595",54
11,British Columbia,N05CF,Benzodiazepine-related drugs,Total,Total,"3,548.45",0.3,1.1,"31,364",55
11,British Columbia,A09AA,Enzyme preparations,Total,Total,"3,498.41",0.3,0.2,"5,675",56
11,British Columbia,V03AC,Iron-chelating agents,Total,Total,"3,322.97",0.3,0.0,161,57
11,British Columbia,C08DB,Benzothiazepine derivatives,Total,Total,"3,261.57",0.3,1.2,"34,440",58
11,British Columbia,S01EE,Prostaglandin analogues,Total,Total,"3,209.30",0.3,1.4,"42,372",59
11,British Columbia,S01ED,Beta-blocking agents,Total,Total,"3,201.13",0.3,1.4,"40,070",60
11,British Columbia,B03AA,"Iron bivalent, oral preparations",Total,Total,"3,151.51",0.3,1.6,"46,338",61
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"3,129.40",0.3,3.0,"89,235",62
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"3,124.17",0.3,0.5,"15,784",63
11,British Columbia,A10BB,Sulfonylureas,Total,Total,"3,011.17",0.3,1.4,"40,045",64
11,British Columbia,C03AA,"Thiazides, plain",Total,Total,"2,877.32",0.3,5.8,"171,382",65
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,"2,852.69",0.3,0.0,121,66
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"2,737.03",0.2,0.2,"6,255",67
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"2,684.96",0.2,0.3,"7,896",68
11,British Columbia,H02AB,Glucocorticoids,Total,Total,"2,592.00",0.2,7.6,"224,349",69
11,British Columbia,N03AF,Carboxamide derivatives,Total,Total,"2,507.31",0.2,0.4,"12,711",70
11,British Columbia,C01DA,Organic nitrates,Total,Total,"2,459.43",0.2,1.7,"50,588",71
11,British Columbia,H01AC,Somatropin and somatropin agonists,Total,Total,"2,326.75",0.2,0.0,230,72
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,"2,250.68",0.2,0.4,"11,064",73
11,British Columbia,B01AE,Direct thrombin inhibitors,Total,Total,"2,218.67",0.2,0.1,"3,335",74
11,British Columbia,B01AA,Vitamin K antagonists,Total,Total,"2,214.39",0.2,1.5,"45,451",75
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"2,200.58",0.2,4.2,"122,703",76
11,British Columbia,N02AB,Phenylpiperidine derivatives,Total,Total,"2,162.90",0.2,0.1,"4,229",77
11,British Columbia,R05CB,Mucolytics,Total,Total,"2,075.07",0.2,0.0,561,78
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",Total,Total,"2,055.96",0.2,8.9,"261,319",79
11,British Columbia,M04AA,Preparations inhibiting uric acid production,Total,Total,"1,950.28",0.2,2.0,"57,599",80
11,British Columbia,A03FA,Propulsives,Total,Total,"1,881.36",0.2,1.8,"52,112",81
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",Total,Total,"1,764.43",0.2,1.1,"32,883",82
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,"1,738.31",0.2,0.1,"1,987",83
11,British Columbia,J01CA,Penicillins with extended spectrum,Total,Total,"1,722.67",0.2,16.9,"498,050",84
11,British Columbia,N05AN,Lithium,Total,Total,"1,632.54",0.1,0.3,"9,729",85
11,British Columbia,J01DB,First-generation cephalosporins,Total,Total,"1,589.48",0.1,7.1,"207,607",86
11,British Columbia,C03DA,Aldosterone antagonists,Total,Total,"1,583.36",0.1,1.3,"37,518",87
11,British Columbia,L01BA,Folic acid analogues,Total,Total,"1,496.21",0.1,0.8,"22,812",88
11,British Columbia,N05AF,Thioxanthene derivatives,Total,Total,"1,432.86",0.1,0.1,"2,387",89
11,British Columbia,G04BE,Drugs used in erectile dysfunction,Total,Total,"1,387.35",0.1,0.0,391,90
11,British Columbia,C07AG,Alpha- and beta-blocking agents,Total,Total,"1,385.98",0.1,0.3,"9,512",91
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"1,367.61",0.1,1.9,"55,626",92
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,Total,Total,"1,347.91",0.1,0.3,"9,221",93
11,British Columbia,N05AE,Indole derivatives,Total,Total,"1,333.57",0.1,0.0,887,94
11,British Columbia,J01MA,Fluoroquinolones,Total,Total,"1,307.09",0.1,6.1,"180,129",95
11,British Columbia,C02AC,Imidazoline receptor agonists,Total,Total,"1,304.10",0.1,0.5,"13,884",96
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,"1,288.41",0.1,4.2,"122,459",97
11,British Columbia,J01FA,Macrolides,Total,Total,"1,250.93",0.1,7.8,"230,289",98
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,Total,Total,"1,248.93",0.1,1.4,"41,777",99
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,"1,247.02",0.1,0.2,"5,401",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"99,808.70",17.6,0.4,"5,221",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,Total,M,"93,556.55",16.5,0.1,"1,681",2
11,British Columbia,N05AX,Other antipsychotics,Total,M,"29,390.06",5.2,1.5,"19,380",3
11,British Columbia,N07BC,Drugs used in opioid dependence,Total,M,"26,525.99",4.7,1.3,"16,814",4
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"23,807.50",4.2,3.5,"45,905",5
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,Total,M,"10,825.12",1.9,21.1,"278,646",6
11,British Columbia,N03AX,Other antiepileptics,Total,M,"9,224.06",1.6,4.2,"54,996",7
11,British Columbia,N02AA,Natural opium alkaloids,Total,M,"9,012.85",1.6,3.6,"47,239",8
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,Total,M,"8,664.27",1.5,7.9,"104,244",9
11,British Columbia,N06AX,Other antidepressants,Total,M,"8,518.54",1.5,6.1,"80,813",10
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"8,134.29",1.4,1.7,"21,996",11
11,British Columbia,N07BA,Drugs used in nicotine dependence,Total,M,"7,878.13",1.4,3.7,"49,435",12
11,British Columbia,L04AA,Selective immunosuppressants,Total,M,"7,491.46",1.3,0.1,"1,282",13
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"7,397.08",1.3,1.1,"14,086",14
11,British Columbia,C09AA,"ACE inhibitors, plain",Total,M,"7,014.07",1.2,15.1,"199,680",15
11,British Columbia,L04AC,Interleukin inhibitors,Total,M,"6,134.72",1.1,0.0,413,16
11,British Columbia,B01AF,Direct factor Xa inhibitors,Total,M,"5,667.80",1.0,1.1,"14,419",17
11,British Columbia,B02AB,Proteinase inhibitors,Total,M,"5,358.87",0.9,0.0,49,18
11,British Columbia,A02BC,Proton pump inhibitors,Total,M,"5,344.68",0.9,5.0,"66,565",19
11,British Columbia,N06BA,Centrally acting sympathomimetics,Total,M,"5,343.54",0.9,1.5,"19,433",20
11,British Columbia,C08CA,Dihydropyridine derivatives,Total,M,"4,961.28",0.9,8.4,"111,666",21
11,British Columbia,C07AB,"Beta-blocking agents, selective",Total,M,"4,500.17",0.8,9.3,"123,523",22
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,"4,346.55",0.8,0.1,"1,978",23
11,British Columbia,R03BB,Anticholinergics,Total,M,"3,736.22",0.7,1.9,"25,095",24
11,British Columbia,B01AB,Heparin group,Total,M,"3,649.68",0.6,0.4,"4,749",25
11,British Columbia,A10BA,Biguanides,Total,M,"3,418.37",0.6,8.0,"106,201",26
11,British Columbia,N03AG,Fatty acid derivatives,Total,M,"3,064.24",0.5,0.7,"9,462",27
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,Total,M,"2,994.60",0.5,6.4,"84,965",28
11,British Columbia,R03BA,Glucocorticoids,Total,M,"2,874.01",0.5,4.2,"54,967",29
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"2,853.35",0.5,12.4,"163,675",30
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"2,843.89",0.5,1.4,"18,569",31
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"2,695.53",0.5,0.5,"6,080",32
11,British Columbia,A02BA,H2-receptor antagonists,Total,M,"2,432.32",0.4,3.0,"39,806",33
11,British Columbia,N07XX,Other nervous system drugs,Total,M,"2,376.77",0.4,0.0,290,34
11,British Columbia,N05BA,Benzodiazepine derivatives,Total,M,"2,324.83",0.4,5.6,"73,457",35
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"2,279.36",0.4,10.1,"134,034",36
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,Total,M,"2,183.89",0.4,0.7,"9,476",37
11,British Columbia,H03AA,Thyroid hormones,Total,M,"2,156.30",0.4,4.6,"60,561",38
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"2,066.47",0.4,1.4,"17,994",39
11,British Columbia,N04BA,Dopa and dopa derivatives,Total,M,"2,055.51",0.4,0.6,"7,453",40
11,British Columbia,C09CA,"Angiotensin II antagonists, plain",Total,M,"2,024.95",0.4,2.4,"32,078",41
11,British Columbia,M01AE,Propionic acid derivatives,Total,M,"2,005.40",0.4,7.6,"100,127",42
11,British Columbia,A04AD,Other antiemetics,Total,M,"1,978.45",0.3,0.3,"3,933",43
11,British Columbia,L01XC,Monoclonal antibodies,Total,M,"1,974.01",0.3,0.0,183,44
11,British Columbia,C03CA,"Sulfonamides, plain",Total,M,"1,896.05",0.3,3.0,"39,383",45
11,British Columbia,A09AA,Enzyme preparations,Total,M,"1,880.00",0.3,0.2,"2,465",46
11,British Columbia,N03AE,Benzodiazepine derivatives,Total,M,"1,761.12",0.3,1.4,"18,621",47
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,"1,758.60",0.3,1.9,"25,665",48
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,"1,742.02",0.3,0.1,"1,286",49
11,British Columbia,M03BX,Other centrally acting agents,Total,M,"1,687.23",0.3,4.3,"56,327",50
11,British Columbia,V03AC,Iron-chelating agents,Total,M,"1,676.20",0.3,0.0,78,51
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,"1,624.89",0.3,0.6,"7,926",52
11,British Columbia,N05CF,Benzodiazepine-related drugs,Total,M,"1,472.53",0.3,0.8,"11,119",53
11,British Columbia,H01AC,Somatropin and somatropin agonists,Total,M,"1,452.64",0.3,0.0,136,54
11,British Columbia,A10BB,Sulfonylureas,Total,M,"1,433.50",0.3,1.7,"22,451",55
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,"1,425.26",0.3,0.0,57,56
11,British Columbia,N03AF,Carboxamide derivatives,Total,M,"1,377.91",0.2,0.5,"6,122",57
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,"1,359.40",0.2,0.3,"4,377",58
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"1,354.21",0.2,0.3,"3,453",59
11,British Columbia,L03AA,Colony-stimulating factors,Total,M,"1,351.47",0.2,0.0,496,60
11,British Columbia,L03AB,Interferons,Total,M,"1,336.64",0.2,0.0,102,61
11,British Columbia,S01ED,Beta-blocking agents,Total,M,"1,303.52",0.2,1.5,"19,563",62
11,British Columbia,N06DA,Anticholinesterases,Total,M,"1,297.83",0.2,0.4,"4,678",63
11,British Columbia,S01EE,Prostaglandin analogues,Total,M,"1,226.25",0.2,1.5,"19,673",64
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,"1,214.65",0.2,0.4,"5,882",65
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,M,"1,197.21",0.2,0.0,46,66
11,British Columbia,C08DB,Benzothiazepine derivatives,Total,M,"1,178.94",0.2,1.2,"15,833",67
11,British Columbia,B03AA,"Iron bivalent, oral preparations",Total,M,"1,174.84",0.2,1.2,"16,016",68
11,British Columbia,M04AA,Preparations inhibiting uric acid production,Total,M,"1,165.86",0.2,3.4,"44,821",69
11,British Columbia,R05CB,Mucolytics,Total,M,"1,098.66",0.2,0.0,306,70
11,British Columbia,B01AA,Vitamin K antagonists,Total,M,"1,081.66",0.2,2.0,"26,493",71
11,British Columbia,C03AA,"Thiazides, plain",Total,M,"1,061.39",0.2,5.6,"73,465",72
11,British Columbia,L03AX,Other immunostimulants,Total,M,"1,057.08",0.2,0.0,116,73
11,British Columbia,H02AB,Glucocorticoids,Total,M,"1,055.05",0.2,7.6,"100,270",74
11,British Columbia,C01DA,Organic nitrates,Total,M,"1,044.49",0.2,2.2,"28,538",75
11,British Columbia,B01AE,Direct thrombin inhibitors,Total,M,"1,028.25",0.2,0.1,"1,796",76
11,British Columbia,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,970.99,0.2,0.6,"8,396",77
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",Total,M,968.90,0.2,8.8,"116,182",78
11,British Columbia,N05AF,Thioxanthene derivatives,Total,M,917.19,0.2,0.1,"1,466",79
11,British Columbia,N02AB,Phenylpiperidine derivatives,Total,M,871.41,0.2,0.1,"1,670",80
11,British Columbia,N05AN,Lithium,Total,M,855.07,0.2,0.3,"4,622",81
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,Total,M,846.73,0.1,0.6,"7,670",82
11,British Columbia,C07AG,Alpha- and beta-blocking agents,Total,M,809.91,0.1,0.4,"4,920",83
11,British Columbia,J01DB,First-generation cephalosporins,Total,M,765.76,0.1,7.6,"100,521",84
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,764.80,0.1,3.2,"42,117",85
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,763.78,0.1,0.3,"3,379",86
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",Total,M,753.86,0.1,1.0,"13,800",87
11,British Columbia,J01CA,Penicillins with extended spectrum,Total,M,744.64,0.1,17.5,"231,120",88
11,British Columbia,C03DA,Aldosterone antagonists,Total,M,730.89,0.1,1.2,"16,432",89
11,British Columbia,A03FA,Propulsives,Total,M,693.61,0.1,1.2,"15,793",90
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,Total,M,651.98,0.1,0.2,"3,152",91
11,British Columbia,C02AC,Imidazoline receptor agonists,Total,M,636.44,0.1,0.4,"5,489",92
11,British Columbia,J02AC,Triazole derivatives,Total,M,636.07,0.1,0.1,715,93
11,British Columbia,A16AX,Various alimentary tract and metabolism products,Total,M,629.54,0.1,0.0,26,94
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,Total,M,600.84,0.1,0.0,320,95
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,Total,M,561.45,0.1,0.3,"4,450",96
11,British Columbia,N03AB,Hydantoin derivatives,Total,M,560.91,0.1,0.4,"5,081",97
11,British Columbia,J01MA,Fluoroquinolones,Total,M,560.45,0.1,5.7,"75,282",98
11,British Columbia,J01AA,Tetracyclines,Total,M,556.75,0.1,4.7,"62,413",99
11,British Columbia,N05AE,Indole derivatives,Total,M,551.28,0.1,0.0,339,100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"98,040.37",17.1,0.4,"5,938",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,Total,F,"49,070.07",8.6,0.1,898,2
11,British Columbia,L04AA,Selective immunosuppressants,Total,F,"22,971.93",4.0,0.2,"3,563",3
11,British Columbia,N05AX,Other antipsychotics,Total,F,"19,721.59",3.4,1.1,"18,101",4
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"15,831.50",2.8,3.1,"50,907",5
11,British Columbia,N07BC,Drugs used in opioid dependence,Total,F,"14,300.56",2.5,0.5,"8,818",6
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,Total,F,"13,588.49",2.4,12.6,"203,290",7
11,British Columbia,N06AX,Other antidepressants,Total,F,"11,818.75",2.1,8.3,"134,278",8
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,Total,F,"11,692.69",2.0,12.2,"197,141",9
11,British Columbia,N03AX,Other antiepileptics,Total,F,"11,494.05",2.0,5.1,"82,234",10
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"10,560.98",1.8,1.7,"28,058",11
11,British Columbia,N02AA,Natural opium alkaloids,Total,F,"9,351.70",1.6,3.6,"57,602",12
11,British Columbia,A02BC,Proton pump inhibitors,Total,F,"8,465.25",1.5,5.8,"93,762",13
11,British Columbia,C08CA,Dihydropyridine derivatives,Total,F,"7,504.70",1.3,6.6,"107,487",14
11,British Columbia,C09AA,"ACE inhibitors, plain",Total,F,"7,346.14",1.3,9.2,"149,040",15
11,British Columbia,B01AF,Direct factor Xa inhibitors,Total,F,"7,084.60",1.2,0.9,"14,334",16
11,British Columbia,L04AC,Interleukin inhibitors,Total,F,"6,860.24",1.2,0.0,588,17
11,British Columbia,H03AA,Thyroid hormones,Total,F,"6,805.18",1.2,13.3,"215,939",18
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"6,569.54",1.1,0.7,"11,472",19
11,British Columbia,N07BA,Drugs used in nicotine dependence,Total,F,"6,442.60",1.1,2.5,"39,864",20
11,British Columbia,L01XC,Monoclonal antibodies,Total,F,"6,165.90",1.1,0.0,535,21
11,British Columbia,C07AB,"Beta-blocking agents, selective",Total,F,"5,442.81",1.0,6.3,"101,556",22
11,British Columbia,N07XX,Other nervous system drugs,Total,F,"5,157.97",0.9,0.0,467,23
11,British Columbia,C09CA,"Angiotensin II antagonists, plain",Total,F,"4,353.48",0.8,3.0,"48,806",24
11,British Columbia,R03BA,Glucocorticoids,Total,F,"4,103.11",0.7,4.2,"67,800",25
11,British Columbia,R03BB,Anticholinergics,Total,F,"3,898.16",0.7,1.6,"25,608",26
11,British Columbia,B01AB,Heparin group,Total,F,"3,828.49",0.7,0.3,"5,549",27
11,British Columbia,A10BA,Biguanides,Total,F,"3,777.37",0.7,5.2,"84,512",28
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"3,768.83",0.7,0.0,130,29
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"3,707.57",0.6,0.7,"10,701",30
11,British Columbia,L03AB,Interferons,Total,F,"3,671.90",0.6,0.0,269,31
11,British Columbia,N06BA,Centrally acting sympathomimetics,Total,F,"3,612.88",0.6,0.8,"13,379",32
11,British Columbia,N05BA,Benzodiazepine derivatives,Total,F,"3,456.12",0.6,9.0,"146,260",33
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"3,389.70",0.6,10.7,"173,680",34
11,British Columbia,L03AX,Other immunostimulants,Total,F,"3,314.10",0.6,0.0,399,35
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"3,114.20",0.5,0.4,"5,884",36
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,Total,F,"2,806.17",0.5,1.9,"31,290",37
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"2,749.26",0.5,10.3,"167,539",38
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"2,723.39",0.5,3.4,"54,288",39
11,British Columbia,L03AA,Colony-stimulating factors,Total,F,"2,698.36",0.5,0.1,"1,228",40
11,British Columbia,C03CA,"Sulfonamides, plain",Total,F,"2,676.53",0.5,2.8,"45,368",41
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,Total,F,"2,652.08",0.5,0.7,"11,459",42
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,F,"2,582.46",0.5,0.1,"1,267",43
11,British Columbia,A02BA,H2-receptor antagonists,Total,F,"2,555.81",0.4,3.5,"56,885",44
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,"2,518.54",0.4,0.2,"2,558",45
11,British Columbia,N06DA,Anticholinesterases,Total,F,"2,425.92",0.4,0.4,"6,879",46
11,British Columbia,B02AB,Proteinase inhibitors,Total,F,"2,418.63",0.4,0.0,30,47
11,British Columbia,A04AD,Other antiemetics,Total,F,"2,344.56",0.4,0.4,"5,788",48
11,British Columbia,N03AG,Fatty acid derivatives,Total,F,"2,304.04",0.4,0.5,"8,428",49
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"2,222.27",0.4,0.9,"14,893",50
11,British Columbia,M03BX,Other centrally acting agents,Total,F,"2,209.91",0.4,4.4,"70,852",51
11,British Columbia,N03AE,Benzodiazepine derivatives,Total,F,"2,146.16",0.4,1.9,"30,966",52
11,British Columbia,C08DB,Benzothiazepine derivatives,Total,F,"2,082.45",0.4,1.1,"18,606",53
11,British Columbia,N05CF,Benzodiazepine-related drugs,Total,F,"2,075.92",0.4,1.2,"20,245",54
11,British Columbia,S01EE,Prostaglandin analogues,Total,F,"1,983.05",0.3,1.4,"22,699",55
11,British Columbia,B03AA,"Iron bivalent, oral preparations",Total,F,"1,976.67",0.3,1.9,"30,322",56
11,British Columbia,S01ED,Beta-blocking agents,Total,F,"1,897.14",0.3,1.3,"20,506",57
11,British Columbia,C03AA,"Thiazides, plain",Total,F,"1,815.86",0.3,6.0,"97,915",58
11,British Columbia,V03AC,Iron-chelating agents,Total,F,"1,646.77",0.3,0.0,83,59
11,British Columbia,M01AE,Propionic acid derivatives,Total,F,"1,634.13",0.3,6.9,"112,468",60
11,British Columbia,N04BA,Dopa and dopa derivatives,Total,F,"1,626.30",0.3,0.4,"6,009",61
11,British Columbia,A09AA,Enzyme preparations,Total,F,"1,618.41",0.3,0.2,"3,210",62
11,British Columbia,A10BB,Sulfonylureas,Total,F,"1,577.68",0.3,1.1,"17,594",63
11,British Columbia,H02AB,Glucocorticoids,Total,F,"1,536.94",0.3,7.7,"124,079",64
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,"1,499.28",0.3,0.5,"7,858",65
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"1,435.78",0.3,5.0,"80,586",66
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,Total,F,"1,427.43",0.2,0.0,64,67
11,British Columbia,C01DA,Organic nitrates,Total,F,"1,414.94",0.2,1.4,"22,050",68
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"1,382.82",0.2,0.2,"2,802",69
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,"1,325.57",0.2,0.2,"3,519",70
11,British Columbia,N02AB,Phenylpiperidine derivatives,Total,F,"1,291.49",0.2,0.2,"2,559",71
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"1,287.93",0.2,7.6,"122,403",72
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"1,240.98",0.2,3.4,"54,785",73
11,British Columbia,B01AE,Direct thrombin inhibitors,Total,F,"1,190.42",0.2,0.1,"1,539",74
11,British Columbia,A03FA,Propulsives,Total,F,"1,187.75",0.2,2.2,"36,319",75
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,Total,F,"1,137.47",0.2,0.1,"1,667",76
11,British Columbia,B01AA,Vitamin K antagonists,Total,F,"1,132.73",0.2,1.2,"18,958",77
11,British Columbia,N03AF,Carboxamide derivatives,Total,F,"1,129.39",0.2,0.4,"6,589",78
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",Total,F,"1,087.05",0.2,9.0,"145,134",79
11,British Columbia,G04BE,Drugs used in erectile dysfunction,Total,F,"1,069.53",0.2,0.0,219,80
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,F,"1,036.03",0.2,0.3,"5,182",81
11,British Columbia,L01BA,Folic acid analogues,Total,F,"1,031.16",0.2,0.9,"14,749",82
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",Total,F,"1,010.47",0.2,1.2,"19,082",83
11,British Columbia,G02BA,Intrauterine contraceptives,Total,F,997.99,0.2,1.3,"20,799",84
11,British Columbia,J01CA,Penicillins with extended spectrum,Total,F,978.02,0.2,16.5,"266,927",85
11,British Columbia,R05CB,Mucolytics,Total,F,976.41,0.2,0.0,255,86
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,Total,F,912.90,0.2,0.3,"5,349",87
11,British Columbia,M05BA,Bisphosphonates,Total,F,890.21,0.2,0.5,"7,764",88
11,British Columbia,C05BA,Heparins or heparinoids for topical use,Total,F,883.94,0.2,0.1,"1,270",89
11,British Columbia,H01AC,Somatropin and somatropin agonists,Total,F,874.11,0.2,0.0,94,90
11,British Columbia,C03DA,Aldosterone antagonists,Total,F,852.45,0.1,1.3,"21,085",91
11,British Columbia,M05BB,"Bisphosphonates, combinations",Total,F,834.31,0.1,0.6,"9,786",92
11,British Columbia,J01XE,Nitrofuran derivatives,Total,F,833.45,0.1,7.8,"126,267",93
11,British Columbia,J01DB,First-generation cephalosporins,Total,F,823.72,0.1,6.6,"107,085",94
11,British Columbia,M04AA,Preparations inhibiting uric acid production,Total,F,784.42,0.1,0.8,"12,778",95
11,British Columbia,N05AE,Indole derivatives,Total,F,782.29,0.1,0.0,548,96
11,British Columbia,N05AN,Lithium,Total,F,777.47,0.1,0.3,"5,107",97
11,British Columbia,J01MA,Fluoroquinolones,Total,F,746.62,0.1,6.5,"104,846",98
11,British Columbia,J01FA,Macrolides,Total,F,731.10,0.1,8.0,"129,797",99
11,British Columbia,C09DA,Angiotensin II antagonists and diuretics,Total,F,726.45,0.1,0.7,"11,357",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"40,417.04",10.1,0.3,"2,405",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,65+,Total,"32,153.33",8.0,0.1,579,2
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,65+,Total,"16,876.98",4.2,38.4,"300,062",3
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"12,826.43",3.2,3.6,"28,300",4
11,British Columbia,B01AF,Direct factor Xa inhibitors,65+,Total,"11,470.12",2.9,3.0,"23,561",5
11,British Columbia,C09AA,"ACE inhibitors, plain",65+,Total,"10,314.89",2.6,26.7,"208,935",6
11,British Columbia,C08CA,Dihydropyridine derivatives,65+,Total,"10,169.45",2.5,18.8,"146,853",7
11,British Columbia,A02BC,Proton pump inhibitors,65+,Total,"8,268.93",2.1,12.2,"95,282",8
11,British Columbia,C07AB,"Beta-blocking agents, selective",65+,Total,"7,988.03",2.0,20.3,"159,058",9
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"7,618.64",1.9,1.6,"12,235",10
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"6,692.89",1.7,9.9,"77,147",11
11,British Columbia,N02AA,Natural opium alkaloids,65+,Total,"6,617.18",1.7,6.1,"47,743",12
11,British Columbia,L04AA,Selective immunosuppressants,65+,Total,"6,294.70",1.6,0.2,"1,644",13
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,"6,095.07",1.5,3.8,"29,355",14
11,British Columbia,N03AX,Other antiepileptics,65+,Total,"5,895.80",1.5,6.9,"54,012",15
11,British Columbia,N06AX,Other antidepressants,65+,Total,"5,723.36",1.4,9.0,"70,720",16
11,British Columbia,R03BB,Anticholinergics,65+,Total,"5,680.45",1.4,4.4,"34,542",17
11,British Columbia,N05AX,Other antipsychotics,65+,Total,"5,668.91",1.4,1.3,"10,204",18
11,British Columbia,H03AA,Thyroid hormones,65+,Total,"5,560.74",1.4,17.2,"134,718",19
11,British Columbia,C09CA,"Angiotensin II antagonists, plain",65+,Total,"5,502.76",1.4,8.0,"62,270",20
11,British Columbia,A10BA,Biguanides,65+,Total,"4,713.11",1.2,13.2,"103,372",21
11,British Columbia,B01AB,Heparin group,65+,Total,"4,231.96",1.1,0.8,"6,211",22
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"4,189.51",1.0,1.0,"8,058",23
11,British Columbia,C03CA,"Sulfonamides, plain",65+,Total,"3,831.06",1.0,8.8,"68,498",24
11,British Columbia,L01XC,Monoclonal antibodies,65+,Total,"3,655.89",0.9,0.0,317,25
11,British Columbia,N06DA,Anticholinesterases,65+,Total,"3,615.69",0.9,1.4,"11,198",26
11,British Columbia,B02AB,Proteinase inhibitors,65+,Total,"3,477.39",0.9,0.0,32,27
11,British Columbia,R03BA,Glucocorticoids,65+,Total,"3,292.56",0.8,3.5,"27,584",28
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"3,211.94",0.8,2.7,"21,452",29
11,British Columbia,L04AC,Interleukin inhibitors,65+,Total,"3,190.05",0.8,0.0,257,30
11,British Columbia,N04BA,Dopa and dopa derivatives,65+,Total,"3,106.92",0.8,1.4,"10,777",31
11,British Columbia,S01EE,Prostaglandin analogues,65+,Total,"2,881.17",0.7,4.3,"33,934",32
11,British Columbia,S01ED,Beta-blocking agents,65+,Total,"2,836.45",0.7,3.9,"30,673",33
11,British Columbia,C08DB,Benzothiazepine derivatives,65+,Total,"2,719.17",0.7,3.2,"25,306",34
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,"2,584.31",0.6,8.3,"64,780",35
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,"2,567.72",0.6,10.6,"82,769",36
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"2,385.10",0.6,12.1,"94,382",37
11,British Columbia,N05BA,Benzodiazepine derivatives,65+,Total,"2,271.25",0.6,9.8,"76,832",38
11,British Columbia,C01DA,Organic nitrates,65+,Total,"2,228.05",0.6,4.7,"36,411",39
11,British Columbia,N07BA,Drugs used in nicotine dependence,65+,Total,"2,225.83",0.6,1.7,"13,040",40
11,British Columbia,A02BA,H2-receptor antagonists,65+,Total,"2,166.54",0.5,4.8,"37,705",41
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,Total,"2,139.37",0.5,0.1,948,42
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,Total,"2,103.20",0.5,0.0,79,43
11,British Columbia,B01AE,Direct thrombin inhibitors,65+,Total,"2,063.32",0.5,0.4,"3,066",44
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"2,053.85",0.5,1.6,"12,364",45
11,British Columbia,A10BB,Sulfonylureas,65+,Total,"2,038.55",0.5,3.1,"24,493",46
11,British Columbia,C03AA,"Thiazides, plain",65+,Total,"2,037.62",0.5,13.5,"105,702",47
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,65+,Total,"2,026.44",0.5,0.9,"6,821",48
11,British Columbia,B03AA,"Iron bivalent, oral preparations",65+,Total,"1,944.70",0.5,3.3,"25,914",49
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,"1,941.26",0.5,0.7,"5,532",50
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,"1,858.21",0.5,1.0,"7,827",51
11,British Columbia,B01AA,Vitamin K antagonists,65+,Total,"1,843.79",0.5,4.7,"36,443",52
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,"1,766.55",0.4,0.5,"3,529",53
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,"1,649.95",0.4,1.0,"7,675",54
11,British Columbia,M04AA,Preparations inhibiting uric acid production,65+,Total,"1,583.64",0.4,4.6,"36,335",55
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,"1,563.05",0.4,3.6,"27,846",56
11,British Columbia,H02AB,Glucocorticoids,65+,Total,"1,524.59",0.4,11.0,"85,731",57
11,British Columbia,N07BC,Drugs used in opioid dependence,65+,Total,"1,523.48",0.4,0.2,"1,475",58
11,British Columbia,L03AA,Colony-stimulating factors,65+,Total,"1,521.77",0.4,0.1,613,59
11,British Columbia,V03AC,Iron-chelating agents,65+,Total,"1,431.78",0.4,0.0,87,60
11,British Columbia,N05CF,Benzodiazepine-related drugs,65+,Total,"1,335.89",0.3,2.2,"16,845",61
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,"1,320.27",0.3,0.2,"1,632",62
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",65+,Total,"1,139.02",0.3,10.2,"79,459",63
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,"1,120.09",0.3,0.2,"1,330",64
11,British Columbia,A03FA,Propulsives,65+,Total,"1,094.49",0.3,2.7,"21,158",65
11,British Columbia,N02AB,Phenylpiperidine derivatives,65+,Total,"1,072.08",0.3,0.3,"2,343",66
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,996.45,0.2,0.5,"3,986",67
11,British Columbia,M05BA,Bisphosphonates,65+,Total,987.46,0.2,1.0,"7,778",68
11,British Columbia,C03DA,Aldosterone antagonists,65+,Total,982.10,0.2,2.8,"21,735",69
11,British Columbia,A04AD,Other antiemetics,65+,Total,964.68,0.2,0.4,"3,118",70
11,British Columbia,C02DB,Hydrazinophthalazine derivatives,65+,Total,958.32,0.2,0.8,"6,067",71
11,British Columbia,C07AG,Alpha- and beta-blocking agents,65+,Total,939.59,0.2,0.7,"5,102",72
11,British Columbia,N03AE,Benzodiazepine derivatives,65+,Total,919.68,0.2,1.8,"14,374",73
11,British Columbia,C01AA,Digitalis glycosides,65+,Total,911.58,0.2,1.4,"11,095",74
11,British Columbia,N03AG,Fatty acid derivatives,65+,Total,898.04,0.2,0.4,"3,464",75
11,British Columbia,C09DA,Angiotensin II antagonists and diuretics,65+,Total,893.41,0.2,1.8,"13,824",76
11,British Columbia,A09AA,Enzyme preparations,65+,Total,883.97,0.2,0.4,"2,770",77
11,British Columbia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,878.97,0.2,1.0,"7,514",78
11,British Columbia,M05BB,"Bisphosphonates, combinations",65+,Total,867.50,0.2,1.3,"9,810",79
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,852.97,0.2,0.0,36,80
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",65+,Total,837.00,0.2,1.7,"13,173",81
11,British Columbia,L01BA,Folic acid analogues,65+,Total,795.43,0.2,1.3,"10,137",82
11,British Columbia,J01MA,Fluoroquinolones,65+,Total,794.17,0.2,10.0,"77,838",83
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,65+,Total,793.38,0.2,0.7,"5,119",84
11,British Columbia,C10AC,Bile acid sequestrants,65+,Total,765.00,0.2,0.6,"4,415",85
11,British Columbia,A12BA,Potassium,65+,Total,724.20,0.2,2.2,"17,406",86
11,British Columbia,M03BX,Other centrally acting agents,65+,Total,718.57,0.2,2.9,"22,283",87
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,689.12,0.2,3.2,"24,703",88
11,British Columbia,S01EC,Carbonic anhydrase inhibitors,65+,Total,687.67,0.2,1.2,"9,372",89
11,British Columbia,G04BE,Drugs used in erectile dysfunction,65+,Total,599.57,0.2,0.0,153,90
11,British Columbia,A11CC,Vitamin D and analogues,65+,Total,598.69,0.1,0.7,"5,464",91
11,British Columbia,J01DB,First-generation cephalosporins,65+,Total,585.81,0.1,6.9,"53,699",92
11,British Columbia,J01XE,Nitrofuran derivatives,65+,Total,564.66,0.1,5.6,"44,133",93
11,British Columbia,S01BA,"Corticosteroids, plain",65+,Total,555.90,0.1,5.0,"38,959",94
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,551.00,0.1,3.0,"23,720",95
11,British Columbia,J01CA,Penicillins with extended spectrum,65+,Total,528.22,0.1,11.6,"90,805",96
11,British Columbia,J01FA,Macrolides,65+,Total,516.80,0.1,6.3,"49,596",97
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,65+,Total,504.68,0.1,0.6,"4,343",98
11,British Columbia,M01AE,Propionic acid derivatives,65+,Total,493.43,0.1,4.3,"33,651",99
11,British Columbia,C01BD,"Antiarrhythmics, class III",65+,Total,480.31,0.1,0.7,"5,353",100
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,65+,M,"22,566.60",12.7,0.1,406,1
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,"17,859.07",10.0,0.3,986,2
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,65+,M,"7,626.58",4.3,46.1,"167,171",3
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,"5,492.19",3.1,3.5,"12,571",4
11,British Columbia,B01AF,Direct factor Xa inhibitors,65+,M,"4,856.28",2.7,3.2,"11,438",5
11,British Columbia,C09AA,"ACE inhibitors, plain",65+,M,"4,651.21",2.6,31.6,"114,685",6
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"3,967.95",2.2,1.8,"6,686",7
11,British Columbia,C08CA,Dihydropyridine derivatives,65+,M,"3,696.60",2.1,19.2,"69,535",8
11,British Columbia,C07AB,"Beta-blocking agents, selective",65+,M,"3,314.42",1.9,23.0,"83,425",9
11,British Columbia,A02BC,Proton pump inhibitors,65+,M,"2,774.89",1.6,10.4,"37,848",10
11,British Columbia,N02AA,Natural opium alkaloids,65+,M,"2,765.20",1.6,5.5,"19,955",11
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,"2,744.98",1.5,3.5,"12,824",12
11,British Columbia,R03BB,Anticholinergics,65+,M,"2,690.58",1.5,4.7,"17,091",13
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,65+,M,"2,478.78",1.4,17.4,"63,107",14
11,British Columbia,B02AB,Proteinase inhibitors,65+,M,"2,438.77",1.4,0.0,20,15
11,British Columbia,N05AX,Other antipsychotics,65+,M,"2,261.97",1.3,1.1,"3,951",16
11,British Columbia,N03AX,Other antiepileptics,65+,M,"2,247.74",1.3,5.8,"21,131",17
11,British Columbia,B01AB,Heparin group,65+,M,"2,182.31",1.2,0.8,"2,943",18
11,British Columbia,A10BA,Biguanides,65+,M,"2,140.39",1.2,15.9,"57,796",19
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,65+,M,"2,036.17",1.1,6.8,"24,748",20
11,British Columbia,N06AX,Other antidepressants,65+,M,"1,918.74",1.1,7.1,"25,748",21
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,"1,899.63",1.1,1.1,"4,011",22
11,British Columbia,N04BA,Dopa and dopa derivatives,65+,M,"1,693.23",1.0,1.7,"6,049",23
11,British Columbia,C09CA,"Angiotensin II antagonists, plain",65+,M,"1,655.55",0.9,6.5,"23,678",24
11,British Columbia,C03CA,"Sulfonamides, plain",65+,M,"1,512.92",0.9,8.7,"31,577",25
11,British Columbia,L04AA,Selective immunosuppressants,65+,M,"1,454.32",0.8,0.1,458,26
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"1,377.95",0.8,3.5,"12,564",27
11,British Columbia,R03BA,Glucocorticoids,65+,M,"1,272.68",0.7,3.0,"10,809",28
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,M,"1,270.19",0.7,0.2,568,29
11,British Columbia,H03AA,Thyroid hormones,65+,M,"1,255.44",0.7,9.3,"33,857",30
11,British Columbia,N06DA,Anticholinesterases,65+,M,"1,238.60",0.7,1.2,"4,496",31
11,British Columbia,N07BA,Drugs used in nicotine dependence,65+,M,"1,169.41",0.7,1.9,"6,906",32
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,"1,165.51",0.7,2.0,"7,136",33
11,British Columbia,L04AC,Interleukin inhibitors,65+,M,"1,156.68",0.7,0.0,83,34
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,"1,131.75",0.6,9.8,"35,387",35
11,British Columbia,S01ED,Beta-blocking agents,65+,M,"1,098.37",0.6,4.0,"14,400",36
11,British Columbia,N07BC,Drugs used in opioid dependence,65+,M,"1,085.66",0.6,0.3,944,37
11,British Columbia,S01EE,Prostaglandin analogues,65+,M,"1,067.54",0.6,4.3,"15,408",38
11,British Columbia,L01XC,Monoclonal antibodies,65+,M,"1,044.67",0.6,0.0,93,39
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,"1,003.38",0.6,12.6,"45,635",40
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,976.35,0.5,0.8,"2,990",41
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,976.29,0.5,1.2,"4,420",42
11,British Columbia,A10BB,Sulfonylureas,65+,M,931.93,0.5,3.7,"13,377",43
11,British Columbia,B01AE,Direct thrombin inhibitors,65+,M,908.81,0.5,0.4,"1,578",44
11,British Columbia,C01DA,Organic nitrates,65+,M,905.39,0.5,5.4,"19,643",45
11,British Columbia,C08DB,Benzothiazepine derivatives,65+,M,897.27,0.5,3.0,"10,802",46
11,British Columbia,M04AA,Preparations inhibiting uric acid production,65+,M,893.85,0.5,7.3,"26,335",47
11,British Columbia,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,878.97,0.5,2.1,"7,512",48
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,860.81,0.5,0.5,"1,909",49
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,65+,M,857.82,0.5,0.9,"3,137",50
11,British Columbia,B01AA,Vitamin K antagonists,65+,M,854.62,0.5,5.7,"20,759",51
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,853.80,0.5,1.1,"4,032",52
11,British Columbia,A02BA,H2-receptor antagonists,65+,M,852.80,0.5,4.3,"15,718",53
11,British Columbia,N05BA,Benzodiazepine derivatives,65+,M,753.32,0.4,7.1,"25,645",54
11,British Columbia,V03AC,Iron-chelating agents,65+,M,739.33,0.4,0.0,42,55
11,British Columbia,B03AA,"Iron bivalent, oral preparations",65+,M,730.91,0.4,3.0,"10,935",56
11,British Columbia,C03AA,"Thiazides, plain",65+,M,668.00,0.4,12.1,"43,931",57
11,British Columbia,L03AA,Colony-stimulating factors,65+,M,611.22,0.3,0.1,232,58
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,599.55,0.3,0.7,"2,437",59
11,British Columbia,H02AB,Glucocorticoids,65+,M,589.16,0.3,10.6,"38,504",60
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,537.56,0.3,0.0,20,61
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",65+,M,532.73,0.3,10.3,"37,443",62
11,British Columbia,C07AG,Alpha- and beta-blocking agents,65+,M,523.58,0.3,0.9,"3,130",63
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,65+,M,520.61,0.3,0.1,261,64
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,470.53,0.3,2.3,"8,497",65
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,M,470.03,0.3,0.0,21,66
11,British Columbia,N05CF,Benzodiazepine-related drugs,65+,M,448.34,0.3,1.5,"5,554",67
11,British Columbia,C03DA,Aldosterone antagonists,65+,M,430.18,0.2,3.0,"10,705",68
11,British Columbia,N03AG,Fatty acid derivatives,65+,M,425.75,0.2,0.4,"1,604",69
11,British Columbia,A04AD,Other antiemetics,65+,M,398.70,0.2,0.4,"1,291",70
11,British Columbia,C02DB,Hydrazinophthalazine derivatives,65+,M,386.73,0.2,0.8,"2,895",71
11,British Columbia,A03FA,Propulsives,65+,M,385.06,0.2,2.2,"8,003",72
11,British Columbia,N02AB,Phenylpiperidine derivatives,65+,M,379.89,0.2,0.3,929,73
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,M,379.25,0.2,0.1,416,74
11,British Columbia,A09AA,Enzyme preparations,65+,M,349.86,0.2,0.3,"1,143",75
11,British Columbia,C01AA,Digitalis glycosides,65+,M,337.84,0.2,1.4,"5,208",76
11,British Columbia,J01MA,Fluoroquinolones,65+,M,332.61,0.2,9.8,"35,486",77
11,British Columbia,N03AE,Benzodiazepine derivatives,65+,M,317.55,0.2,1.4,"5,178",78
11,British Columbia,C10AC,Bile acid sequestrants,65+,M,300.15,0.2,0.4,"1,570",79
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",65+,M,299.37,0.2,1.6,"5,827",80
11,British Columbia,M03BX,Other centrally acting agents,65+,M,282.18,0.2,2.6,"9,537",81
11,British Columbia,S01EC,Carbonic anhydrase inhibitors,65+,M,278.03,0.2,1.2,"4,450",82
11,British Columbia,A11CC,Vitamin D and analogues,65+,M,274.36,0.2,0.7,"2,573",83
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,270.30,0.2,2.6,"9,351",84
11,British Columbia,C09DA,Angiotensin II antagonists and diuretics,65+,M,263.59,0.1,1.4,"5,075",85
11,British Columbia,M05BA,Bisphosphonates,65+,M,260.19,0.1,0.3,"1,191",86
11,British Columbia,J01DB,First-generation cephalosporins,65+,M,250.26,0.1,7.2,"25,930",87
11,British Columbia,C01BD,"Antiarrhythmics, class III",65+,M,241.44,0.1,0.9,"3,233",88
11,British Columbia,L01BA,Folic acid analogues,65+,M,232.33,0.1,1.0,"3,570",89
11,British Columbia,M01AE,Propionic acid derivatives,65+,M,217.73,0.1,4.4,"15,955",90
11,British Columbia,J01CA,Penicillins with extended spectrum,65+,M,216.74,0.1,11.8,"42,844",91
11,British Columbia,S01BA,"Corticosteroids, plain",65+,M,214.59,0.1,4.7,"17,022",92
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,65+,M,211.95,0.1,0.7,"2,477",93
11,British Columbia,A12BA,Potassium,65+,M,210.71,0.1,1.7,"6,261",94
11,British Columbia,H01AX,Other anterior pituitary lobe hormones and analogues,65+,M,**, ** , ** ,*,95
11,British Columbia,J01FA,Macrolides,65+,M,206.18,0.1,5.9,"21,306",96
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,65+,M,192.36,0.1,0.6,"2,062",97
11,British Columbia,J02AC,Triazole derivatives,65+,M,192.11,0.1,0.1,256,98
11,British Columbia,N05AD,Butyrophenone derivatives,65+,M,190.22,0.1,0.6,"2,042",99
11,British Columbia,N03AB,Hydantoin derivatives,65+,M,189.19,0.1,0.6,"2,138",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"22,557.97",10.2,0.3,"1,419",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,65+,F,"9,586.73",4.3,0.0,173,2
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,65+,F,"9,250.29",4.2,31.7,"132,889",3
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"7,334.24",3.3,3.8,"15,729",4
11,British Columbia,B01AF,Direct factor Xa inhibitors,65+,F,"6,613.84",3.0,2.9,"12,123",5
11,British Columbia,C08CA,Dihydropyridine derivatives,65+,F,"6,472.72",2.9,18.4,"77,316",6
11,British Columbia,C09AA,"ACE inhibitors, plain",65+,F,"5,663.49",2.6,22.5,"94,244",7
11,British Columbia,A02BC,Proton pump inhibitors,65+,F,"5,493.85",2.5,13.7,"57,433",8
11,British Columbia,L04AA,Selective immunosuppressants,65+,F,"4,840.39",2.2,0.3,"1,186",9
11,British Columbia,C07AB,"Beta-blocking agents, selective",65+,F,"4,673.61",2.1,18.0,"75,632",10
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,65+,F,"4,656.72",2.1,12.5,"52,399",11
11,British Columbia,H03AA,Thyroid hormones,65+,F,"4,305.28",1.9,24.1,"100,860",12
11,British Columbia,N02AA,Natural opium alkaloids,65+,F,"3,851.95",1.7,6.6,"27,787",13
11,British Columbia,C09CA,"Angiotensin II antagonists, plain",65+,F,"3,847.19",1.7,9.2,"38,591",14
11,British Columbia,N06AX,Other antidepressants,65+,F,"3,804.62",1.7,10.7,"44,972",15
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"3,650.69",1.6,1.3,"5,549",16
11,British Columbia,N03AX,Other antiepileptics,65+,F,"3,648.06",1.6,7.8,"32,881",17
11,British Columbia,N05AX,Other antipsychotics,65+,F,"3,406.94",1.5,1.5,"6,253",18
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,"3,350.09",1.5,3.9,"16,530",19
11,British Columbia,R03BB,Anticholinergics,65+,F,"2,989.87",1.3,4.2,"17,451",20
11,British Columbia,L01XC,Monoclonal antibodies,65+,F,"2,611.22",1.2,0.1,224,21
11,British Columbia,A10BA,Biguanides,65+,F,"2,572.72",1.2,10.9,"45,575",22
11,British Columbia,N06DA,Anticholinesterases,65+,F,"2,377.09",1.1,1.6,"6,702",23
11,British Columbia,C03CA,"Sulfonamides, plain",65+,F,"2,318.13",1.0,8.8,"36,920",24
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"2,289.88",1.0,1.0,"4,047",25
11,British Columbia,B01AB,Heparin group,65+,F,"2,049.66",0.9,0.8,"3,268",26
11,British Columbia,L04AC,Interleukin inhibitors,65+,F,"2,033.37",0.9,0.0,174,27
11,British Columbia,R03BA,Glucocorticoids,65+,F,"2,019.88",0.9,4.0,"16,775",28
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"1,833.99",0.8,2.1,"8,888",29
11,British Columbia,C08DB,Benzothiazepine derivatives,65+,F,"1,821.73",0.8,3.5,"14,503",30
11,British Columbia,S01EE,Prostaglandin analogues,65+,F,"1,813.63",0.8,4.4,"18,526",31
11,British Columbia,S01ED,Beta-blocking agents,65+,F,"1,737.61",0.8,3.9,"16,272",32
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,"1,633.17",0.7,0.0,58,33
11,British Columbia,N05BA,Benzodiazepine derivatives,65+,F,"1,517.93",0.7,12.2,"51,187",34
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,"1,435.92",0.6,11.3,"47,380",35
11,British Columbia,N04BA,Dopa and dopa derivatives,65+,F,"1,413.69",0.6,1.1,"4,728",36
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,"1,381.71",0.6,11.6,"48,746",37
11,British Columbia,C03AA,"Thiazides, plain",65+,F,"1,369.55",0.6,14.7,"61,769",38
11,British Columbia,C01DA,Organic nitrates,65+,F,"1,322.66",0.6,4.0,"16,768",39
11,British Columbia,A02BA,H2-receptor antagonists,65+,F,"1,313.74",0.6,5.2,"21,987",40
11,British Columbia,B03AA,"Iron bivalent, oral preparations",65+,F,"1,213.79",0.5,3.6,"14,979",41
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,65+,F,"1,168.63",0.5,0.9,"3,684",42
11,British Columbia,B01AE,Direct thrombin inhibitors,65+,F,"1,154.51",0.5,0.4,"1,488",43
11,British Columbia,A10BB,Sulfonylureas,65+,F,"1,106.62",0.5,2.7,"11,116",44
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,"1,092.42",0.5,4.6,"19,348",45
11,British Columbia,N07BA,Drugs used in nicotine dependence,65+,F,"1,056.33",0.5,1.5,"6,133",46
11,British Columbia,B02AB,Proteinase inhibitors,65+,F,"1,038.62",0.5,0.0,12,47
11,British Columbia,B01AA,Vitamin K antagonists,65+,F,989.18,0.4,3.7,"15,684",48
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,964.91,0.4,0.6,"2,542",49
11,British Columbia,H02AB,Glucocorticoids,65+,F,935.43,0.4,11.3,"47,227",50
11,British Columbia,L03AA,Colony-stimulating factors,65+,F,910.55,0.4,0.1,381,51
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,905.74,0.4,0.4,"1,620",52
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,888.34,0.4,1.2,"5,228",53
11,British Columbia,N05CF,Benzodiazepine-related drugs,65+,F,887.55,0.4,2.7,"11,291",54
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,881.92,0.4,0.8,"3,407",55
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,65+,F,869.18,0.4,0.1,380,56
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,65+,F,799.66,0.4,0.3,"1,371",57
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,796.15,0.4,0.9,"3,643",58
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,740.84,0.3,0.2,914,59
11,British Columbia,M05BB,"Bisphosphonates, combinations",65+,F,738.86,0.3,2.0,"8,326",60
11,British Columbia,M05BA,Bisphosphonates,65+,F,727.26,0.3,1.6,"6,587",61
11,British Columbia,A03FA,Propulsives,65+,F,709.43,0.3,3.1,"13,155",62
11,British Columbia,V03AC,Iron-chelating agents,65+,F,692.46,0.3,0.0,45,63
11,British Columbia,N02AB,Phenylpiperidine derivatives,65+,F,692.19,0.3,0.3,"1,414",64
11,British Columbia,M04AA,Preparations inhibiting uric acid production,65+,F,689.79,0.3,2.4,"10,000",65
11,British Columbia,C09DA,Angiotensin II antagonists and diuretics,65+,F,629.82,0.3,2.1,"8,749",66
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,65+,F,620.22,0.3,1.0,"4,102",67
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",65+,F,606.27,0.3,10.0,"42,013",68
11,British Columbia,N03AE,Benzodiazepine derivatives,65+,F,602.13,0.3,2.2,"9,196",69
11,British Columbia,C01AA,Digitalis glycosides,65+,F,573.74,0.3,1.4,"5,887",70
11,British Columbia,C02DB,Hydrazinophthalazine derivatives,65+,F,571.59,0.3,0.8,"3,172",71
11,British Columbia,A04AD,Other antiemetics,65+,F,565.98,0.3,0.4,"1,827",72
11,British Columbia,L01BA,Folic acid analogues,65+,F,563.10,0.3,1.6,"6,567",73
11,British Columbia,C03DA,Aldosterone antagonists,65+,F,551.90,0.2,2.6,"11,029",74
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,546.95,0.2,5.6,"23,655",75
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",65+,F,537.54,0.2,1.8,"7,345",76
11,British Columbia,A09AA,Enzyme preparations,65+,F,534.11,0.2,0.4,"1,627",77
11,British Columbia,A12BA,Potassium,65+,F,513.49,0.2,2.7,"11,145",78
11,British Columbia,J01XE,Nitrofuran derivatives,65+,F,488.80,0.2,9.1,"37,997",79
11,British Columbia,G04BE,Drugs used in erectile dysfunction,65+,F,479.42,0.2,0.0,91,80
11,British Columbia,N03AG,Fatty acid derivatives,65+,F,472.29,0.2,0.4,"1,860",81
11,British Columbia,C10AC,Bile acid sequestrants,65+,F,464.84,0.2,0.7,"2,845",82
11,British Columbia,J01MA,Fluoroquinolones,65+,F,461.55,0.2,10.1,"42,351",83
11,British Columbia,N07BC,Drugs used in opioid dependence,65+,F,437.82,0.2,0.1,531,84
11,British Columbia,M03BX,Other centrally acting agents,65+,F,436.40,0.2,3.0,"12,746",85
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,418.82,0.2,3.7,"15,352",86
11,British Columbia,C07AG,Alpha- and beta-blocking agents,65+,F,416.01,0.2,0.5,"1,972",87
11,British Columbia,S01EC,Carbonic anhydrase inhibitors,65+,F,409.60,0.2,1.2,"4,921",88
11,British Columbia,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,396.90,0.2,0.4,"1,549",89
11,British Columbia,C05BA,Heparins or heparinoids for topical use,65+,F,364.36,0.2,0.1,392,90
11,British Columbia,S01BA,"Corticosteroids, plain",65+,F,341.31,0.2,5.2,"21,937",91
11,British Columbia,J01DB,First-generation cephalosporins,65+,F,335.55,0.2,6.6,"27,768",92
11,British Columbia,L03AB,Interferons,65+,F,333.00,0.2,0.0,22,93
11,British Columbia,A11CC,Vitamin D and analogues,65+,F,324.33,0.1,0.7,"2,891",94
11,British Columbia,G04BD,Drugs for urinary frequency and incontinence,65+,F,316.26,0.1,1.1,"4,432",95
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,65+,F,315.41,0.1,0.0,16,96
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,65+,F,312.32,0.1,0.5,"2,281",97
11,British Columbia,J01CA,Penicillins with extended spectrum,65+,F,311.47,0.1,11.4,"47,958",98
11,British Columbia,J01FA,Macrolides,65+,F,310.61,0.1,6.7,"28,290",99
11,British Columbia,C08DA,Phenylalkylamine derivatives,65+,F,306.42,0.1,0.6,"2,697",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"157,432.00",21.3,0.4,"8,754",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,<65,Total,"110,473.30",14.9,0.1,"2,000",2
11,British Columbia,N05AX,Other antipsychotics,<65,Total,"43,442.74",5.9,1.3,"27,277",3
11,British Columbia,N07BC,Drugs used in opioid dependence,<65,Total,"39,303.07",5.3,1.1,"24,157",4
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"33,543.93",4.5,3.1,"67,458",5
11,British Columbia,L04AA,Selective immunosuppressants,<65,Total,"24,168.69",3.3,0.1,"3,201",6
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"15,559.87",2.1,10.7,"230,387",7
11,British Columbia,N03AX,Other antiepileptics,<65,Total,"14,822.31",2.0,3.9,"83,218",8
11,British Columbia,N06AX,Other antidepressants,<65,Total,"14,613.93",2.0,6.7,"144,371",9
11,British Columbia,N07BA,Drugs used in nicotine dependence,<65,Total,"12,094.98",1.6,3.5,"76,261",10
11,British Columbia,N02AA,Natural opium alkaloids,<65,Total,"11,747.41",1.6,2.6,"57,099",11
11,British Columbia,L04AC,Interleukin inhibitors,<65,Total,"9,804.91",1.3,0.0,744,12
11,British Columbia,N06BA,Centrally acting sympathomimetics,<65,Total,"8,582.58",1.2,1.4,"31,055",13
11,British Columbia,N07XX,Other nervous system drugs,<65,Total,"7,308.28",1.0,0.0,634,14
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"6,347.98",0.9,0.6,"13,323",15
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"5,868.85",0.8,1.0,"21,754",16
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,<65,Total,"5,640.94",0.8,8.1,"175,727",17
11,British Columbia,A02BC,Proton pump inhibitors,<65,Total,"5,541.19",0.7,3.0,"65,046",18
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,"4,789.64",0.6,0.1,"2,297",19
11,British Columbia,L03AB,Interferons,<65,Total,"4,582.53",0.6,0.0,340,20
11,British Columbia,L01XC,Monoclonal antibodies,<65,Total,"4,484.02",0.6,0.0,401,21
11,British Columbia,N03AG,Fatty acid derivatives,<65,Total,"4,470.24",0.6,0.7,"14,426",22
11,British Columbia,B02AB,Proteinase inhibitors,<65,Total,"4,300.10",0.6,0.0,47,23
11,British Columbia,L03AX,Other immunostimulants,<65,Total,"4,151.42",0.6,0.0,489,24
11,British Columbia,C09AA,"ACE inhibitors, plain",<65,Total,"4,045.51",0.5,6.5,"139,791",25
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"3,857.96",0.5,11.3,"242,974",26
11,British Columbia,R03BA,Glucocorticoids,<65,Total,"3,684.55",0.5,4.4,"95,183",27
11,British Columbia,N05BA,Benzodiazepine derivatives,<65,Total,"3,509.70",0.5,6.6,"142,885",28
11,British Columbia,H03AA,Thyroid hormones,<65,Total,"3,400.76",0.5,6.6,"141,783",29
11,British Columbia,A04AD,Other antiemetics,<65,Total,"3,358.33",0.5,0.3,"6,603",30
11,British Columbia,B01AB,Heparin group,<65,Total,"3,246.21",0.4,0.2,"4,087",31
11,British Columbia,M03BX,Other centrally acting agents,<65,Total,"3,178.56",0.4,4.9,"104,896",32
11,British Columbia,M01AE,Propionic acid derivatives,<65,Total,"3,146.10",0.4,8.3,"178,944",33
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,"3,140.47",0.4,0.1,"2,514",34
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"3,012.31",0.4,1.0,"21,098",35
11,British Columbia,N03AE,Benzodiazepine derivatives,<65,Total,"2,987.61",0.4,1.6,"35,213",36
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"2,919.04",0.4,2.4,"52,108",37
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"2,862.83",0.4,0.0,97,38
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,<65,Total,"2,859.52",0.4,1.6,"33,841",39
11,British Columbia,A02BA,H2-receptor antagonists,<65,Total,"2,821.60",0.4,2.7,"58,986",40
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,<65,Total,"2,809.52",0.4,0.7,"14,114",41
11,British Columbia,A09AA,Enzyme preparations,<65,Total,"2,614.43",0.4,0.1,"2,905",42
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"2,562.10",0.3,0.3,"7,243",43
11,British Columbia,L03AA,Colony-stimulating factors,<65,Total,"2,528.05",0.3,0.1,"1,111",44
11,British Columbia,A10BA,Biguanides,<65,Total,"2,482.63",0.3,4.0,"87,342",45
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"2,460.97",0.3,10.1,"218,807",46
11,British Columbia,H01AC,Somatropin and somatropin agonists,<65,Total,"2,324.26",0.3,0.0,229,47
11,British Columbia,C08CA,Dihydropyridine derivatives,<65,Total,"2,296.66",0.3,3.3,"72,302",48
11,British Columbia,N05CF,Benzodiazepine-related drugs,<65,Total,"2,212.56",0.3,0.7,"14,519",49
11,British Columbia,N03AF,Carboxamide derivatives,<65,Total,"2,153.22",0.3,0.4,"8,961",50
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,"1,999.72",0.3,0.0,85,51
11,British Columbia,R05CB,Mucolytics,<65,Total,"1,982.47",0.3,0.0,313,52
11,British Columbia,C07AB,"Beta-blocking agents, selective",<65,Total,"1,954.95",0.3,3.1,"66,022",53
11,British Columbia,R03BB,Anticholinergics,<65,Total,"1,953.93",0.3,0.7,"16,161",54
11,British Columbia,V03AC,Iron-chelating agents,<65,Total,"1,891.18",0.3,0.0,74,55
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"1,620.21",0.2,0.2,"3,906",56
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"1,511.46",0.2,4.5,"98,000",57
11,British Columbia,N05AN,Lithium,<65,Total,"1,421.07",0.2,0.4,"7,958",58
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"1,287.71",0.2,5.7,"122,445",59
11,British Columbia,B01AF,Direct factor Xa inhibitors,<65,Total,"1,282.27",0.2,0.2,"5,192",60
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,"1,265.96",0.2,0.4,"7,957",61
11,British Columbia,N05AF,Thioxanthene derivatives,<65,Total,"1,258.54",0.2,0.1,"2,000",62
11,British Columbia,B03AA,"Iron bivalent, oral preparations",<65,Total,"1,206.81",0.2,0.9,"20,424",63
11,British Columbia,N05AE,Indole derivatives,<65,Total,"1,198.11",0.2,0.0,791,64
11,British Columbia,J01CA,Penicillins with extended spectrum,<65,Total,"1,194.45",0.2,18.9,"407,245",65
11,British Columbia,C02AC,Imidazoline receptor agonists,<65,Total,"1,119.52",0.2,0.5,"11,304",66
11,British Columbia,N02AB,Phenylpiperidine derivatives,<65,Total,"1,090.82",0.1,0.1,"1,886",67
11,British Columbia,H02AB,Glucocorticoids,<65,Total,"1,067.41",0.1,6.4,"138,618",68
11,British Columbia,A16AX,Various alimentary tract and metabolism products,<65,Total,"1,061.80",0.1,0.0,49,69
11,British Columbia,J01DB,First-generation cephalosporins,<65,Total,"1,003.67",0.1,7.1,"153,908",70
11,British Columbia,G02BA,Intrauterine contraceptives,<65,Total,995.23,0.1,1.0,"20,785",71
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,<65,Total,991.61,0.1,0.2,"4,551",72
11,British Columbia,A10BB,Sulfonylureas,<65,Total,972.63,0.1,0.7,"15,552",73
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,970.48,0.1,0.1,"2,726",74
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,<65,Total,936.05,0.1,1.7,"36,649",75
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",<65,Total,927.43,0.1,0.9,"19,710",76
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",<65,Total,916.94,0.1,8.4,"181,860",77
11,British Columbia,J01DF,Monobactams,<65,Total,893.51,0.1,0.0,70,78
11,British Columbia,C09CA,"Angiotensin II antagonists, plain",<65,Total,875.69,0.1,0.9,"18,615",79
11,British Columbia,J01GB,Other aminoglycosides,<65,Total,852.19,0.1,0.0,205,80
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,<65,Total,843.24,0.1,0.2,"4,878",81
11,British Columbia,C03AA,"Thiazides, plain",<65,Total,839.70,0.1,3.0,"65,680",82
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,816.61,0.1,1.5,"31,906",83
11,British Columbia,J02AC,Triazole derivatives,<65,Total,809.05,0.1,0.0,917,84
11,British Columbia,N05BE,Azaspirodecanedione derivatives,<65,Total,795.20,0.1,0.3,"6,020",85
11,British Columbia,G04BE,Drugs used in erectile dysfunction,<65,Total,787.78,0.1,0.0,238,86
11,British Columbia,A03FA,Propulsives,<65,Total,786.87,0.1,1.4,"30,954",87
11,British Columbia,J01AA,Tetracyclines,<65,Total,767.48,0.1,4.6,"99,969",88
11,British Columbia,N07BB,Drugs used in alcohol dependence,<65,Total,759.53,0.1,0.1,"2,958",89
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,743.70,0.1,0.1,"2,364",90
11,British Columbia,C03CA,"Sulfonamides, plain",<65,Total,741.52,0.1,0.8,"16,254",91
11,British Columbia,J01FA,Macrolides,<65,Total,734.13,0.1,8.4,"180,693",92
11,British Columbia,L01BA,Folic acid analogues,<65,Total,700.78,0.1,0.6,"12,675",93
11,British Columbia,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,653.85,0.1,0.0,456,94
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,<65,Total,646.56,0.1,0.2,"3,914",95
11,British Columbia,C03DA,Aldosterone antagonists,<65,Total,601.26,0.1,0.7,"15,783",96
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,600.74,0.1,0.2,"3,389",97
11,British Columbia,C05BA,Heparins or heparinoids for topical use,<65,Total,581.70,0.1,0.0,962,98
11,British Columbia,N04BA,Dopa and dopa derivatives,<65,Total,574.89,0.1,0.1,"2,685",99
11,British Columbia,N03AB,Hydantoin derivatives,<65,Total,557.39,0.1,0.2,"4,284",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"81,949.62",21.0,0.4,"4,235",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,<65,M,"70,989.95",18.2,0.1,"1,275",2
11,British Columbia,N05AX,Other antipsychotics,<65,M,"27,128.09",7.0,1.6,"15,429",3
11,British Columbia,N07BC,Drugs used in opioid dependence,<65,M,"25,440.33",6.5,1.7,"15,870",4
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"21,062.52",5.4,3.4,"33,081",5
11,British Columbia,N03AX,Other antiepileptics,<65,M,"6,976.32",1.8,3.5,"33,865",6
11,British Columbia,N07BA,Drugs used in nicotine dependence,<65,M,"6,708.72",1.7,4.4,"42,529",7
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,<65,M,"6,628.10",1.7,8.3,"79,496",8
11,British Columbia,N06AX,Other antidepressants,<65,M,"6,599.80",1.7,5.7,"55,065",9
11,British Columbia,N02AA,Natural opium alkaloids,<65,M,"6,247.66",1.6,2.8,"27,284",10
11,British Columbia,L04AA,Selective immunosuppressants,<65,M,"6,037.15",1.5,0.1,824,11
11,British Columbia,N06BA,Centrally acting sympathomimetics,<65,M,"5,171.94",1.3,1.9,"18,611",12
11,British Columbia,L04AC,Interleukin inhibitors,<65,M,"4,978.04",1.3,0.0,330,13
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"3,429.13",0.9,0.8,"7,400",14
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,<65,M,"3,198.54",0.8,11.6,"111,475",15
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,"3,076.36",0.8,0.1,"1,410",16
11,British Columbia,B02AB,Proteinase inhibitors,<65,M,"2,920.09",0.7,0.0,29,17
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"2,642.11",0.7,1.0,"9,425",18
11,British Columbia,N03AG,Fatty acid derivatives,<65,M,"2,638.49",0.7,0.8,"7,858",19
11,British Columbia,A02BC,Proton pump inhibitors,<65,M,"2,569.79",0.7,3.0,"28,717",20
11,British Columbia,C09AA,"ACE inhibitors, plain",<65,M,"2,362.85",0.6,8.9,"84,995",21
11,British Columbia,N07XX,Other nervous system drugs,<65,M,"2,343.14",0.6,0.0,248,22
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"1,849.97",0.5,12.3,"118,040",23
11,British Columbia,M01AE,Propionic acid derivatives,<65,M,"1,787.66",0.5,8.8,"84,172",24
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"1,678.38",0.4,1.2,"11,433",25
11,British Columbia,R03BA,Glucocorticoids,<65,M,"1,601.33",0.4,4.6,"44,158",26
11,British Columbia,A04AD,Other antiemetics,<65,M,"1,579.75",0.4,0.3,"2,642",27
11,British Columbia,A02BA,H2-receptor antagonists,<65,M,"1,579.52",0.4,2.5,"24,088",28
11,British Columbia,N05BA,Benzodiazepine derivatives,<65,M,"1,571.52",0.4,5.0,"47,812",29
11,British Columbia,A09AA,Enzyme preparations,<65,M,"1,530.14",0.4,0.1,"1,322",30
11,British Columbia,B01AB,Heparin group,<65,M,"1,467.38",0.4,0.2,"1,806",31
11,British Columbia,H01AC,Somatropin and somatropin agonists,<65,M,"1,450.15",0.4,0.0,135,32
11,British Columbia,N03AE,Benzodiazepine derivatives,<65,M,"1,443.57",0.4,1.4,"13,443",33
11,British Columbia,M03BX,Other centrally acting agents,<65,M,"1,405.05",0.4,4.9,"46,790",34
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,"1,362.77",0.3,0.1,870,35
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,<65,M,"1,326.07",0.3,0.7,"6,339",36
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,"1,288.07",0.3,1.8,"17,168",37
11,British Columbia,A10BA,Biguanides,<65,M,"1,277.98",0.3,5.0,"48,405",38
11,British Columbia,C08CA,Dihydropyridine derivatives,<65,M,"1,264.68",0.3,4.4,"42,131",39
11,British Columbia,L03AB,Interferons,<65,M,"1,243.63",0.3,0.0,93,40
11,British Columbia,N03AF,Carboxamide derivatives,<65,M,"1,219.41",0.3,0.5,"4,415",41
11,British Columbia,C07AB,"Beta-blocking agents, selective",<65,M,"1,185.74",0.3,4.2,"40,098",42
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"1,147.61",0.3,10.3,"98,647",43
11,British Columbia,R03BB,Anticholinergics,<65,M,"1,045.64",0.3,0.8,"8,004",44
11,British Columbia,R05CB,Mucolytics,<65,M,"1,034.40",0.3,0.0,162,45
11,British Columbia,N05CF,Benzodiazepine-related drugs,<65,M,"1,024.19",0.3,0.6,"5,565",46
11,British Columbia,L03AX,Other immunostimulants,<65,M,988.16,0.3,0.0,107,47
11,British Columbia,V03AC,Iron-chelating agents,<65,M,936.87,0.2,0.0,36,48
11,British Columbia,L01XC,Monoclonal antibodies,<65,M,929.34,0.2,0.0,90,49
11,British Columbia,H03AA,Thyroid hormones,<65,M,900.85,0.2,2.8,"26,704",50
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,887.70,0.2,0.0,37,51
11,British Columbia,N05AF,Thioxanthene derivatives,<65,M,832.65,0.2,0.1,"1,302",52
11,British Columbia,B01AF,Direct factor Xa inhibitors,<65,M,811.52,0.2,0.3,"2,981",53
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,795.90,0.2,0.2,"2,069",54
11,British Columbia,N05AN,Lithium,<65,M,767.50,0.2,0.4,"3,851",55
11,British Columbia,L03AA,Colony-stimulating factors,<65,M,740.25,0.2,0.0,264,56
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,M,727.17,0.2,0.0,25,57
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,688.52,0.2,0.6,"5,430",58
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,<65,M,673.57,0.2,0.7,"6,653",59
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,648.60,0.2,0.4,"3,506",60
11,British Columbia,A16AX,Various alimentary tract and metabolism products,<65,M,625.67,0.2,0.0,17,61
11,British Columbia,C02AC,Imidazoline receptor agonists,<65,M,587.22,0.2,0.5,"4,786",62
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,<65,M,582.36,0.1,0.3,"2,672",63
11,British Columbia,J01CA,Penicillins with extended spectrum,<65,M,527.90,0.1,19.6,"188,276",64
11,British Columbia,J01GB,Other aminoglycosides,<65,M,523.58,0.1,0.0,120,65
11,British Columbia,G04CA,Alpha-adrenoreceptor antagonists,<65,M,515.82,0.1,2.3,"21,858",66
11,British Columbia,J01DB,First-generation cephalosporins,<65,M,515.50,0.1,7.8,"74,591",67
11,British Columbia,N05AE,Indole derivatives,<65,M,502.87,0.1,0.0,307,68
11,British Columbia,A10BB,Sulfonylureas,<65,M,501.57,0.1,0.9,"9,074",69
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,494.50,0.1,3.4,"32,766",70
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,493.40,0.1,0.2,"1,544",71
11,British Columbia,N02AB,Phenylpiperidine derivatives,<65,M,491.52,0.1,0.1,741,72
11,British Columbia,J01DF,Monobactams,<65,M,469.98,0.1,0.0,35,73
11,British Columbia,H02AB,Glucocorticoids,<65,M,465.89,0.1,6.4,"61,766",74
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",<65,M,454.49,0.1,0.8,"7,973",75
11,British Columbia,J02AC,Triazole derivatives,<65,M,443.96,0.1,0.0,459,76
11,British Columbia,B03AA,"Iron bivalent, oral preparations",<65,M,443.93,0.1,0.5,"5,081",77
11,British Columbia,N07BB,Drugs used in alcohol dependence,<65,M,443.73,0.1,0.2,"1,794",78
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",<65,M,436.17,0.1,8.2,"78,739",79
11,British Columbia,C03AA,"Thiazides, plain",<65,M,393.38,0.1,3.1,"29,534",80
11,British Columbia,C03CA,"Sulfonamides, plain",<65,M,383.12,0.1,0.8,"7,806",81
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,383.05,0.1,0.1,"1,387",82
11,British Columbia,N05BE,Azaspirodecanedione derivatives,<65,M,379.09,0.1,0.2,"2,346",83
11,British Columbia,J01AA,Tetracyclines,<65,M,373.86,0.1,4.5,"43,384",84
11,British Columbia,N03AB,Hydantoin derivatives,<65,M,371.72,0.1,0.3,"2,943",85
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,<65,M,371.64,0.1,1.7,"16,168",86
11,British Columbia,C09CA,"Angiotensin II antagonists, plain",<65,M,369.40,0.1,0.9,"8,400",87
11,British Columbia,N04BA,Dopa and dopa derivatives,<65,M,362.28,0.1,0.1,"1,404",88
11,British Columbia,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,360.85,0.1,0.2,"1,850",89
11,British Columbia,N05AA,Phenothiazines with aliphatic side-chain,<65,M,349.50,0.1,0.2,"1,973",90
11,British Columbia,G03BA,3-oxoandrosten (4) derivatives,<65,M,337.69,0.1,0.2,"2,044",91
11,British Columbia,J01FA,Macrolides,<65,M,313.64,0.1,8.3,"79,186",92
11,British Columbia,A03FA,Propulsives,<65,M,308.55,0.1,0.8,"7,790",93
11,British Columbia,C03DA,Aldosterone antagonists,<65,M,300.71,0.1,0.6,"5,727",94
11,British Columbia,C07AG,Alpha- and beta-blocking agents,<65,M,286.32,0.1,0.2,"1,790",95
11,British Columbia,C08DB,Benzothiazepine derivatives,<65,M,281.67,0.1,0.5,"5,031",96
11,British Columbia,D06AX,Other antibiotics for topical use,<65,M,277.89,0.1,2.9,"27,397",97
11,British Columbia,M04AA,Preparations inhibiting uric acid production,<65,M,272.01,0.1,1.9,"18,486",98
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,<65,M,242.66,0.1,0.2,"1,810",99
11,British Columbia,N05AD,Butyrophenone derivatives,<65,M,238.53,0.1,0.1,"1,006",100
11,British Columbia,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"75,482.41",21.6,0.4,"4,519",1
11,British Columbia,J05AP,Antivirals for treatment of HCV infections,<65,F,"39,483.33",11.3,0.1,725,2
11,British Columbia,L04AA,Selective immunosuppressants,<65,F,"18,131.54",5.2,0.2,"2,377",3
11,British Columbia,N05AX,Other antipsychotics,<65,F,"16,314.65",4.7,1.0,"11,848",4
11,British Columbia,N07BC,Drugs used in opioid dependence,<65,F,"13,862.74",4.0,0.7,"8,287",5
11,British Columbia,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"12,481.41",3.6,2.9,"34,377",6
11,British Columbia,N06AB,Selective serotonin reuptake inhibitors,<65,F,"8,931.77",2.6,12.6,"150,891",7
11,British Columbia,N06AX,Other antidepressants,<65,F,"8,014.13",2.3,7.4,"89,306",8
11,British Columbia,N03AX,Other antiepileptics,<65,F,"7,845.99",2.2,4.1,"49,353",9
11,British Columbia,N02AA,Natural opium alkaloids,<65,F,"5,499.75",1.6,2.5,"29,815",10
11,British Columbia,N07BA,Drugs used in nicotine dependence,<65,F,"5,386.26",1.5,2.8,"33,731",11
11,British Columbia,N07XX,Other nervous system drugs,<65,F,"4,965.14",1.4,0.0,386,12
11,British Columbia,L04AC,Interleukin inhibitors,<65,F,"4,826.88",1.4,0.0,414,13
11,British Columbia,L01XC,Monoclonal antibodies,<65,F,"3,554.68",1.0,0.0,311,14
11,British Columbia,N06BA,Centrally acting sympathomimetics,<65,F,"3,410.64",1.0,1.0,"12,444",15
11,British Columbia,L03AB,Interferons,<65,F,"3,338.90",1.0,0.0,247,16
11,British Columbia,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"3,226.74",0.9,1.0,"12,329",17
11,British Columbia,L03AX,Other immunostimulants,<65,F,"3,163.27",0.9,0.0,382,18
11,British Columbia,A02BC,Proton pump inhibitors,<65,F,"2,971.41",0.8,3.0,"36,329",19
11,British Columbia,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"2,918.85",0.8,0.5,"5,923",20
11,British Columbia,H03AA,Thyroid hormones,<65,F,"2,499.91",0.7,9.6,"115,079",21
11,British Columbia,C10AA,HMG-CoA reductase inhibitors,<65,F,"2,442.40",0.7,5.4,"64,252",22
11,British Columbia,N02CC,Selective serotonin (5HT1) agonists,<65,F,"2,185.95",0.6,2.3,"27,188",23
11,British Columbia,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,"2,135.66",0.6,0.0,72,24
11,British Columbia,R03BA,Glucocorticoids,<65,F,"2,083.22",0.6,4.2,"51,025",25
11,British Columbia,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"2,008.00",0.6,10.4,"124,934",26
11,British Columbia,N05BA,Benzodiazepine derivatives,<65,F,"1,938.19",0.6,7.9,"95,073",27
11,British Columbia,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"1,873.58",0.5,0.2,"1,813",28
11,British Columbia,N03AG,Fatty acid derivatives,<65,F,"1,831.75",0.5,0.5,"6,568",29
11,British Columbia,L03AA,Colony-stimulating factors,<65,F,"1,787.80",0.5,0.1,847,30
11,British Columbia,B01AB,Heparin group,<65,F,"1,778.83",0.5,0.2,"2,281",31
11,British Columbia,A04AD,Other antiemetics,<65,F,"1,778.58",0.5,0.3,"3,961",32
11,British Columbia,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,"1,777.70",0.5,0.1,"1,644",33
11,British Columbia,M03BX,Other centrally acting agents,<65,F,"1,773.51",0.5,4.8,"58,106",34
11,British Columbia,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,"1,713.28",0.5,0.1,887,35
11,British Columbia,C09AA,"ACE inhibitors, plain",<65,F,"1,682.66",0.5,4.6,"54,796",36
11,British Columbia,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"1,630.97",0.5,2.9,"34,940",37
11,British Columbia,N03AE,Benzodiazepine derivatives,<65,F,"1,544.03",0.4,1.8,"21,770",38
11,British Columbia,A07EC,Aminosalicylic acid and similar agents,<65,F,"1,483.45",0.4,0.6,"7,775",39
11,British Columbia,B02AB,Proteinase inhibitors,<65,F,"1,380.01",0.4,0.0,18,40
11,British Columbia,M01AE,Propionic acid derivatives,<65,F,"1,358.43",0.4,7.9,"94,772",41
11,British Columbia,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"1,333.93",0.4,0.8,"9,665",42
11,British Columbia,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"1,313.34",0.4,10.0,"120,159",43
11,British Columbia,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"1,287.26",0.4,10.2,"122,390",44
11,British Columbia,A02BA,H2-receptor antagonists,<65,F,"1,242.07",0.4,2.9,"34,898",45
11,British Columbia,A10BA,Biguanides,<65,F,"1,204.65",0.3,3.2,"38,937",46
11,British Columbia,N05CF,Benzodiazepine-related drugs,<65,F,"1,188.37",0.3,0.7,"8,954",47
11,British Columbia,R03DX,Other systemic drugs for obstructive airway diseases,<65,F,"1,112.01",0.3,0.0,48,48
11,British Columbia,A09AA,Enzyme preparations,<65,F,"1,084.30",0.3,0.1,"1,583",49
11,British Columbia,C08CA,Dihydropyridine derivatives,<65,F,"1,031.98",0.3,2.5,"30,171",50
11,British Columbia,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,"1,016.96",0.3,5.4,"65,234",51
11,British Columbia,G02BA,Intrauterine contraceptives,<65,F,995.23,0.3,1.7,"20,782",52
11,British Columbia,V03AC,Iron-chelating agents,<65,F,954.31,0.3,0.0,38,53
11,British Columbia,R05CB,Mucolytics,<65,F,948.07,0.3,0.0,151,54
11,British Columbia,N03AF,Carboxamide derivatives,<65,F,933.81,0.3,0.4,"4,546",55
11,British Columbia,R03BB,Anticholinergics,<65,F,908.29,0.3,0.7,"8,157",56
11,British Columbia,H01AC,Somatropin and somatropin agonists,<65,F,874.11,0.2,0.0,94,57
11,British Columbia,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,824.32,0.2,0.2,"1,837",58
11,British Columbia,C07AB,"Beta-blocking agents, selective",<65,F,769.21,0.2,2.2,"25,924",59
11,British Columbia,B03AA,"Iron bivalent, oral preparations",<65,F,762.88,0.2,1.3,"15,343",60
11,British Columbia,N05AE,Indole derivatives,<65,F,695.24,0.2,0.0,484,61
11,British Columbia,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,694.03,0.2,2.6,"31,130",62
11,British Columbia,J01CA,Penicillins with extended spectrum,<65,F,666.55,0.2,18.2,"218,969",63
11,British Columbia,N05AN,Lithium,<65,F,653.57,0.2,0.3,"4,107",64
11,British Columbia,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,617.36,0.2,0.4,"4,451",65
11,British Columbia,H02AB,Glucocorticoids,<65,F,601.51,0.2,6.4,"76,852",66
11,British Columbia,A04AA,Serotonin (5HT3) antagonists,<65,F,600.58,0.2,0.3,"3,068",67
11,British Columbia,N02AB,Phenylpiperidine derivatives,<65,F,599.30,0.2,0.1,"1,145",68
11,British Columbia,G04BE,Drugs used in erectile dysfunction,<65,F,590.11,0.2,0.0,128,69
11,British Columbia,C01CA,Adrenergic and dopaminergic agents,<65,F,564.30,0.2,1.7,"20,480",70
11,British Columbia,C02AC,Imidazoline receptor agonists,<65,F,532.30,0.2,0.5,"6,518",71
11,British Columbia,C05BA,Heparins or heparinoids for topical use,<65,F,519.58,0.1,0.1,878,72
11,British Columbia,C09CA,"Angiotensin II antagonists, plain",<65,F,506.30,0.1,0.9,"10,215",73
11,British Columbia,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,502.76,0.1,2.8,"33,247",74
11,British Columbia,J01DB,First-generation cephalosporins,<65,F,488.17,0.1,6.6,"79,317",75
11,British Columbia,D07AC,"Corticosteroids, potent (group III)",<65,F,480.77,0.1,8.6,"103,121",76
11,British Columbia,A03FA,Propulsives,<65,F,478.32,0.1,1.9,"23,164",77
11,British Columbia,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,477.08,0.1,0.1,"1,182",78
11,British Columbia,C07AA,"Beta-blocking agents, non-selective",<65,F,472.94,0.1,1.0,"11,737",79
11,British Columbia,A10BB,Sulfonylureas,<65,F,471.06,0.1,0.5,"6,478",80
11,British Columbia,B01AF,Direct factor Xa inhibitors,<65,F,470.75,0.1,0.2,"2,211",81
11,British Columbia,L01BA,Folic acid analogues,<65,F,468.06,0.1,0.7,"8,182",82
11,British Columbia,H01AX,Other anterior pituitary lobe hormones and analogues,<65,F,**, ** , ** ,**,83
11,British Columbia,C03AA,"Thiazides, plain",<65,F,446.32,0.1,3.0,"36,146",84
11,British Columbia,A16AX,Various alimentary tract and metabolism products,<65,F,436.13,0.1,0.0,32,85
11,British Columbia,L02AE,Gonadotropin-releasing hormone analogues,<65,F,428.58,0.1,0.0,365,86
11,British Columbia,N05AF,Thioxanthene derivatives,<65,F,425.89,0.1,0.1,698,87
11,British Columbia,J01DF,Monobactams,<65,F,423.53,0.1,0.0,35,88
11,British Columbia,J01FA,Macrolides,<65,F,420.49,0.1,8.5,"101,507",89
11,British Columbia,G03AC,Progestogens,<65,F,417.06,0.1,1.8,"21,336",90
11,British Columbia,N05BE,Azaspirodecanedione derivatives,<65,F,416.10,0.1,0.3,"3,674",91
11,British Columbia,N04AC,Ethers of tropine or tropine derivatives,<65,F,409.25,0.1,0.2,"1,879",92
11,British Columbia,J01AA,Tetracyclines,<65,F,393.62,0.1,4.7,"56,585",93
11,British Columbia,J02AC,Triazole derivatives,<65,F,365.09,0.1,0.0,458,94
11,British Columbia,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,360.65,0.1,0.1,977,95
11,British Columbia,C03CA,"Sulfonamides, plain",<65,F,358.40,0.1,0.7,"8,448",96
11,British Columbia,R06AA,Aminoalkyl ethers,<65,F,346.70,0.1,1.0,"12,135",97
11,British Columbia,J01XE,Nitrofuran derivatives,<65,F,344.64,0.1,7.4,"88,270",98
11,British Columbia,M05BX,Other drugs affecting bone structure and mineralization,<65,F,337.81,0.1,0.0,296,99
11,British Columbia,G04BD,Drugs for urinary frequency and incontinence,<65,F,334.12,0.1,0.3,"3,354",100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,Total,Total,"1,260.53",10.1,0.4,20,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"1,028.20",8.2,1.3,70,2
12,Yukon,L01XE,Protein kinase inhibitors,Total,Total,342.95,2.7,0.3,15,3
12,Yukon,R07AX,Other respiratory system products,Total,Total,**, ** , ** ,*,4
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,269.19,2.1,0.4,22,5
12,Yukon,C10AA,HMG-CoA reductase inhibitors,Total,Total,243.60,1.9,29.0,"1,560",6
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,239.96,1.9,4.9,262,7
12,Yukon,L04AA,Selective immunosuppressants,Total,Total,204.34,1.6,1.0,53,8
12,Yukon,C09AA,"ACE inhibitors, plain",Total,Total,203.33,1.6,26.4,"1,418",9
12,Yukon,A02BC,Proton pump inhibitors,Total,Total,180.01,1.4,20.2,"1,088",10
12,Yukon,N03AX,Other antiepileptics,Total,Total,170.71,1.4,7.8,418,11
12,Yukon,N07XX,Other nervous system drugs,Total,Total,153.53,1.2,0.2,11,12
12,Yukon,R03BB,Anticholinergics,Total,Total,143.49,1.1,8.3,449,13
12,Yukon,N02AA,Natural opium alkaloids,Total,Total,136.92,1.1,5.7,308,14
12,Yukon,L04AX,Other immunosuppressants,Total,Total,131.62,1.1,0.6,31,15
12,Yukon,B01AB,Heparin group,Total,Total,115.22,0.9,0.9,50,16
12,Yukon,C08CA,Dihydropyridine derivatives,Total,Total,114.63,0.9,14.2,765,17
12,Yukon,R03BA,Glucocorticoids,Total,Total,104.80,0.8,6.2,333,18
12,Yukon,N05AX,Other antipsychotics,Total,Total,104.35,0.8,1.0,52,19
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,Total,Total,102.83,0.8,0.4,24,20
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,Total,Total,100.12,0.8,9.9,535,21
12,Yukon,L04AC,Interleukin inhibitors,Total,Total,95.31,0.8,0.2,12,22
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,91.02,0.7,3.5,187,23
12,Yukon,N06AX,Other antidepressants,Total,Total,86.95,0.7,8.5,456,24
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,80.51,0.6,2.0,105,25
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,77.05,0.6,3.2,174,26
12,Yukon,N04BA,Dopa and dopa derivatives,Total,Total,74.66,0.6,0.7,35,27
12,Yukon,C07AB,"Beta-blocking agents, selective",Total,Total,73.18,0.6,14.7,789,28
12,Yukon,C09CA,"Angiotensin II antagonists, plain",Total,Total,71.94,0.6,9.3,498,29
12,Yukon,A10BA,Biguanides,Total,Total,69.24,0.6,14.5,782,30
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,69.22,0.6,15.1,812,31
12,Yukon,H03AA,Thyroid hormones,Total,Total,68.63,0.5,15.5,833,32
12,Yukon,L02BB,Antiandrogens,Total,Total,65.36,0.5,0.2,12,33
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,61.44,0.5,2.9,158,34
12,Yukon,A16AB,Enzymes,Total,Total,**, ** , ** ,*,35
12,Yukon,L03AB,Interferons,Total,Total,**, ** , ** ,*,36
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,Total,Total,**, ** , ** ,*,37
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,53.90,0.4,19.4,"1,046",38
12,Yukon,A07EC,Aminosalicylic acid and similar agents,Total,Total,53.88,0.4,1.3,70,39
12,Yukon,N06BA,Centrally acting sympathomimetics,Total,Total,50.87,0.4,1.0,56,40
12,Yukon,S01LA,Antineovascularization agents,Total,Total,49.53,0.4,0.2,12,41
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,49.17,0.4,0.9,51,42
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,47.62,0.4,7.9,423,43
12,Yukon,B03XA,Other antianemic preparations,Total,Total,47.57,0.4,0.3,14,44
12,Yukon,L04AD,Calcineurin inhibitors,Total,Total,44.84,0.4,0.4,24,45
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,44.54,0.4,0.3,18,46
12,Yukon,N02AB,Phenylpiperidine derivatives,Total,Total,44.29,0.4,1.0,56,47
12,Yukon,L01XC,Monoclonal antibodies,Total,Total,44.12,0.4,0.3,18,48
12,Yukon,L01BC,Pyrimidine analogues,Total,Total,43.08,0.3,0.6,31,49
12,Yukon,S01ED,Beta-blocking agents,Total,Total,40.44,0.3,2.5,136,50
12,Yukon,R05CB,Mucolytics,Total,Total,**, ** , ** ,*,51
12,Yukon,C01DA,Organic nitrates,Total,Total,39.19,0.3,5.2,277,52
12,Yukon,J05AE,Protease inhibitors,Total,Total,36.90,0.3,0.1,6,53
12,Yukon,N05CF,Benzodiazepine-related drugs,Total,Total,33.64,0.3,7.1,381,54
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,33.57,0.3,4.1,220,55
12,Yukon,A09AA,Enzyme preparations,Total,Total,32.96,0.3,0.4,22,56
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,32.68,0.3,10.9,586,57
12,Yukon,C03CA,"Sulfonamides, plain",Total,Total,31.19,0.2,6.0,323,58
12,Yukon,A10BB,Sulfonylureas,Total,Total,30.55,0.2,5.2,280,59
12,Yukon,R05DA,Opium alkaloids and derivatives,Total,Total,30.33,0.2,2.6,139,60
12,Yukon,B01AF,Direct factor Xa inhibitors,Total,Total,30.16,0.2,0.9,46,61
12,Yukon,C03AA,"Thiazides, plain",Total,Total,30.03,0.2,12.7,681,62
12,Yukon,L02BX,Other hormone antagonists and related agents,Total,Total,**, ** , ** ,*,63
12,Yukon,M05BA,Bisphosphonates,Total,Total,26.86,0.2,3.0,163,64
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,Total,Total,25.90,0.2,0.2,9,65
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,Total,Total,25.01,0.2,2.5,135,66
12,Yukon,L02BG,Aromatase inhibitors,Total,Total,24.16,0.2,0.7,37,67
12,Yukon,C08DB,Benzothiazepine derivatives,Total,Total,23.81,0.2,2.0,108,68
12,Yukon,L03AA,Colony-stimulating factors,Total,Total,23.64,0.2,0.1,8,69
12,Yukon,H02AB,Glucocorticoids,Total,Total,23.34,0.2,10.4,557,70
12,Yukon,S01EE,Prostaglandin analogues,Total,Total,23.22,0.2,2.4,128,71
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,23.11,0.2,3.6,191,72
12,Yukon,B01AA,Vitamin K antagonists,Total,Total,23.10,0.2,3.7,201,73
12,Yukon,B01AD,Enzymes,Total,Total,**, ** , ** ,*,74
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,Total,Total,20.90,0.2,1.6,84,75
12,Yukon,M01AB,Acetic acid derivatives and related substances,Total,Total,19.98,0.2,4.9,263,76
12,Yukon,M04AA,Preparations inhibiting uric acid production,Total,Total,19.92,0.2,3.2,172,77
12,Yukon,R01AD,Corticosteroids,Total,Total,19.48,0.2,5.8,312,78
12,Yukon,C09BA,ACE inhibitors and diuretics,Total,Total,19.05,0.2,1.8,99,79
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,Total,18.54,0.1,0.5,25,80
12,Yukon,S01EC,Carbonic anhydrase inhibitors,Total,Total,18.35,0.1,0.9,51,81
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,18.30,0.1,2.6,138,82
12,Yukon,A11CC,Vitamin D and analogues,Total,Total,17.16,0.1,12.0,645,83
12,Yukon,N03AE,Benzodiazepine derivatives,Total,Total,17.13,0.1,2.2,120,84
12,Yukon,N05BA,Benzodiazepine derivatives,Total,Total,16.67,0.1,5.3,285,85
12,Yukon,D07AC,"Corticosteroids, potent (group III)",Total,Total,16.50,0.1,6.6,353,86
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,Total,Total,**, ** , ** ,*,87
12,Yukon,M01AE,Propionic acid derivatives,Total,Total,15.99,0.1,7.4,400,88
12,Yukon,L03AX,Other immunostimulants,Total,Total,15.65,0.1,0.1,6,89
12,Yukon,C03DA,Aldosterone antagonists,Total,Total,15.46,0.1,2.8,150,90
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,Total,15.09,0.1,0.2,9,91
12,Yukon,C07AA,"Beta-blocking agents, non-selective",Total,Total,14.23,0.1,1.7,94,92
12,Yukon,C09DA,Angiotensin II antagonists and diuretics,Total,Total,14.14,0.1,1.9,101,93
12,Yukon,N03AF,Carboxamide derivatives,Total,Total,13.97,0.1,0.5,29,94
12,Yukon,N07BA,Drugs used in nicotine dependence,Total,Total,13.82,0.1,0.7,39,95
12,Yukon,N07BC,Drugs used in opioid dependence,Total,Total,13.81,0.1,0.1,5,96
12,Yukon,S01BA,"Corticosteroids, plain",Total,Total,13.72,0.1,2.7,146,97
12,Yukon,L01BA,Folic acid analogues,Total,Total,13.56,0.1,1.4,73,98
12,Yukon,C07AG,Alpha- and beta-blocking agents,Total,Total,13.26,0.1,0.7,40,99
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,Total,Total,13.25,0.1,1.0,54,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,Total,M,"1,000.93",14.5,0.5,15,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,509.13,7.4,1.0,27,2
12,Yukon,L01XE,Protein kinase inhibitors,Total,M,267.60,3.9,0.4,10,3
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,**, ** , ** ,**,4
12,Yukon,C10AA,HMG-CoA reductase inhibitors,Total,M,150.81,2.2,34.7,985,5
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,136.93,2.0,5.0,143,6
12,Yukon,C09AA,"ACE inhibitors, plain",Total,M,127.26,1.8,31.6,896,7
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,Total,M,101.53,1.5,0.8,23,8
12,Yukon,L04AX,Other immunosuppressants,Total,M,90.40,1.3,0.6,16,9
12,Yukon,R03BB,Anticholinergics,Total,M,86.75,1.3,8.8,251,10
12,Yukon,A02BC,Proton pump inhibitors,Total,M,83.39,1.2,18.8,532,11
12,Yukon,N05AX,Other antipsychotics,Total,M,79.26,1.1,1.2,33,12
12,Yukon,N03AX,Other antiepileptics,Total,M,74.44,1.1,6.6,186,13
12,Yukon,N04BA,Dopa and dopa derivatives,Total,M,**, ** , ** ,**,14
12,Yukon,L04AC,Interleukin inhibitors,Total,M,**, ** , ** ,**,15
12,Yukon,L02BB,Antiandrogens,Total,M,65.36,0.9,0.4,12,16
12,Yukon,C08CA,Dihydropyridine derivatives,Total,M,62.79,0.9,15.6,443,17
12,Yukon,N07XX,Other nervous system drugs,Total,M,58.53,0.8,0.2,5,18
12,Yukon,A16AB,Enzymes,Total,M,**, ** , ** ,*,19
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,56.19,0.8,3.8,107,20
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,Total,M,**, ** , ** ,*,21
12,Yukon,R03BA,Glucocorticoids,Total,M,52.21,0.8,5.2,147,22
12,Yukon,N02AA,Natural opium alkaloids,Total,M,51.15,0.7,4.4,124,23
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,Total,M,45.74,0.7,14.3,405,24
12,Yukon,C07AB,"Beta-blocking agents, selective",Total,M,44.86,0.7,18.3,519,25
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,44.15,0.6,3.4,96,26
12,Yukon,A10BA,Biguanides,Total,M,41.67,0.6,16.4,465,27
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,38.97,0.6,2.7,77,28
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",Total,M,38.22,0.6,2.1,59,29
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,38.01,0.6,14.5,411,30
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,Total,M,37.71,0.5,7.3,208,31
12,Yukon,S01LA,Antineovascularization agents,Total,M,36.35,0.5,0.2,6,32
12,Yukon,L04AA,Selective immunosuppressants,Total,M,35.22,0.5,0.5,14,33
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,35.01,0.5,23.5,667,34
12,Yukon,J05AE,Protease inhibitors,Total,M,**, ** , ** ,*,35
12,Yukon,N06AX,Other antidepressants,Total,M,32.31,0.5,6.1,174,36
12,Yukon,C09CA,"Angiotensin II antagonists, plain",Total,M,31.85,0.5,8.4,238,37
12,Yukon,B03XA,Other antianemic preparations,Total,M,30.87,0.4,0.3,9,38
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,29.96,0.4,1.0,29,39
12,Yukon,B01AB,Heparin group,Total,M,29.66,0.4,0.6,17,40
12,Yukon,L02BX,Other hormone antagonists and related agents,Total,M,**, ** , ** ,*,41
12,Yukon,N06BA,Centrally acting sympathomimetics,Total,M,29.49,0.4,1.1,30,42
12,Yukon,L04AD,Calcineurin inhibitors,Total,M,28.22,0.4,0.5,13,43
12,Yukon,S01ED,Beta-blocking agents,Total,M,26.28,0.4,2.9,82,44
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,25.01,0.4,4.8,135,45
12,Yukon,A09AA,Enzyme preparations,Total,M,24.30,0.4,0.4,11,46
12,Yukon,N02AB,Phenylpiperidine derivatives,Total,M,22.33,0.3,1.0,27,47
12,Yukon,A07EC,Aminosalicylic acid and similar agents,Total,M,21.72,0.3,0.9,26,48
12,Yukon,L01BC,Pyrimidine analogues,Total,M,21.54,0.3,0.8,24,49
12,Yukon,B01AD,Enzymes,Total,M,**, ** , ** ,*,50
12,Yukon,L03AB,Interferons,Total,M,**, ** , ** ,*,51
12,Yukon,H03AA,Thyroid hormones,Total,M,19.29,0.3,8.6,245,52
12,Yukon,R05CB,Mucolytics,Total,M,**, ** , ** ,*,53
12,Yukon,R05DA,Opium alkaloids and derivatives,Total,M,18.41,0.3,2.3,65,54
12,Yukon,A10BB,Sulfonylureas,Total,M,18.17,0.3,6.4,181,55
12,Yukon,C01DA,Organic nitrates,Total,M,18.14,0.3,6.4,181,56
12,Yukon,C03CA,"Sulfonamides, plain",Total,M,17.55,0.3,6.1,172,57
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,16.34,0.2,11.4,322,58
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,Total,M,**, ** , ** ,*,59
12,Yukon,M04AA,Preparations inhibiting uric acid production,Total,M,15.32,0.2,5.0,143,60
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,15.23,0.2,3.2,90,61
12,Yukon,C03AA,"Thiazides, plain",Total,M,15.15,0.2,12.5,355,62
12,Yukon,B01AA,Vitamin K antagonists,Total,M,14.79,0.2,4.7,132,63
12,Yukon,N05CF,Benzodiazepine-related drugs,Total,M,14.55,0.2,5.9,167,64
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",Total,M,13.68,0.2,0.6,17,65
12,Yukon,B01AF,Direct factor Xa inhibitors,Total,M,13.12,0.2,0.8,22,66
12,Yukon,C08DB,Benzothiazepine derivatives,Total,M,12.81,0.2,2.2,61,67
12,Yukon,M01AB,Acetic acid derivatives and related substances,Total,M,11.95,0.2,5.6,159,68
12,Yukon,S01EC,Carbonic anhydrase inhibitors,Total,M,11.40,0.2,0.9,26,69
12,Yukon,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,**, ** , ** ,**,70
12,Yukon,R01AD,Corticosteroids,Total,M,10.32,0.1,5.4,154,71
12,Yukon,H02AB,Glucocorticoids,Total,M,9.93,0.1,9.3,263,72
12,Yukon,C03DA,Aldosterone antagonists,Total,M,9.82,0.1,3.3,95,73
12,Yukon,C09BA,ACE inhibitors and diuretics,Total,M,9.72,0.1,2.0,57,74
12,Yukon,N07BA,Drugs used in nicotine dependence,Total,M,9.62,0.1,0.9,26,75
12,Yukon,S01EE,Prostaglandin analogues,Total,M,9.45,0.1,2.2,61,76
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,9.29,0.1,0.2,6,77
12,Yukon,G04BE,Drugs used in erectile dysfunction,Total,M,**, ** , ** ,*,78
12,Yukon,L03AX,Other immunostimulants,Total,M,**, ** , ** ,*,79
12,Yukon,C07AG,Alpha- and beta-blocking agents,Total,M,8.63,0.1,0.8,24,80
12,Yukon,C09DA,Angiotensin II antagonists and diuretics,Total,M,8.39,0.1,2.0,56,81
12,Yukon,M01AE,Propionic acid derivatives,Total,M,7.92,0.1,7.2,203,82
12,Yukon,L03AA,Colony-stimulating factors,Total,M,**, ** , ** ,*,83
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,Total,M,7.82,0.1,0.9,26,84
12,Yukon,D07AC,"Corticosteroids, potent (group III)",Total,M,7.68,0.1,6.7,191,85
12,Yukon,A11CC,Vitamin D and analogues,Total,M,7.44,0.1,9.6,271,86
12,Yukon,G03BA,3-oxoandrosten (4) derivatives,Total,M,7.43,0.1,0.8,23,87
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,Total,M,7.38,0.1,0.6,18,88
12,Yukon,L01XC,Monoclonal antibodies,Total,M,7.28,0.1,0.2,7,89
12,Yukon,H01AC,Somatropin and somatropin agonists,Total,M,**, ** , ** ,*,90
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,6.81,0.1,1.7,49,91
12,Yukon,D05AX,Other antipsoriatics for topical use,Total,M,6.80,0.1,0.7,21,92
12,Yukon,C07AA,"Beta-blocking agents, non-selective",Total,M,6.80,0.1,1.6,45,93
12,Yukon,N05BA,Benzodiazepine derivatives,Total,M,6.63,0.1,3.5,98,94
12,Yukon,N03AE,Benzodiazepine derivatives,Total,M,6.52,0.1,1.7,47,95
12,Yukon,A12BA,Potassium,Total,M,6.29,0.1,1.7,49,96
12,Yukon,N03AF,Carboxamide derivatives,Total,M,6.16,0.1,0.7,19,97
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,M,**, ** , ** ,**,98
12,Yukon,N05AE,Indole derivatives,Total,M,**, ** , ** ,*,99
12,Yukon,S01BA,"Corticosteroids, plain",Total,M,5.93,0.1,3.1,88,100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,519.07,9.2,1.7,43,1
12,Yukon,R07AX,Other respiratory system products,Total,F,**, ** , ** ,*,2
12,Yukon,J05AP,Antivirals for treatment of HCV infections,Total,F,259.60,4.6,0.2,5,3
12,Yukon,L04AA,Selective immunosuppressants,Total,F,169.12,3.0,1.5,39,4
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,103.03,1.8,4.7,119,5
12,Yukon,A02BC,Proton pump inhibitors,Total,F,96.61,1.7,21.9,556,6
12,Yukon,N03AX,Other antiepileptics,Total,F,96.28,1.7,9.1,232,7
12,Yukon,N07XX,Other nervous system drugs,Total,F,95.00,1.7,0.2,6,8
12,Yukon,C10AA,HMG-CoA reductase inhibitors,Total,F,92.79,1.6,22.6,575,9
12,Yukon,N02AA,Natural opium alkaloids,Total,F,85.77,1.5,7.2,184,10
12,Yukon,B01AB,Heparin group,Total,F,85.57,1.5,1.3,33,11
12,Yukon,C09AA,"ACE inhibitors, plain",Total,F,76.07,1.4,20.5,522,12
12,Yukon,L01XE,Protein kinase inhibitors,Total,F,75.34,1.3,0.2,5,13
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,Total,F,62.41,1.1,12.9,327,14
12,Yukon,R03BB,Anticholinergics,Total,F,56.74,1.0,7.8,198,15
12,Yukon,N06AX,Other antidepressants,Total,F,54.64,1.0,11.1,282,16
12,Yukon,R03BA,Glucocorticoids,Total,F,52.59,0.9,7.3,186,17
12,Yukon,C08CA,Dihydropyridine derivatives,Total,F,51.84,0.9,12.7,322,18
12,Yukon,H03AA,Thyroid hormones,Total,F,49.34,0.9,23.1,588,19
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",Total,F,42.29,0.8,1.8,46,20
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,**, ** , ** ,*,21
12,Yukon,L04AX,Other immunosuppressants,Total,F,41.22,0.7,0.6,15,22
12,Yukon,C09CA,"Angiotensin II antagonists, plain",Total,F,40.09,0.7,10.2,260,23
12,Yukon,L01XC,Monoclonal antibodies,Total,F,36.84,0.7,0.4,11,24
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,35.25,0.6,0.5,12,25
12,Yukon,L03AB,Interferons,Total,F,**, ** , ** ,*,26
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,34.83,0.6,3.1,80,27
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,32.90,0.6,3.1,78,28
12,Yukon,A07EC,Aminosalicylic acid and similar agents,Total,F,32.16,0.6,1.7,44,29
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,31.22,0.6,15.8,401,30
12,Yukon,C07AB,"Beta-blocking agents, selective",Total,F,28.32,0.5,10.6,270,31
12,Yukon,A10BA,Biguanides,Total,F,27.57,0.5,12.5,317,32
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,Total,F,25.90,0.5,0.4,9,33
12,Yukon,N05AX,Other antipsychotics,Total,F,25.08,0.4,0.7,19,34
12,Yukon,L02BG,Aromatase inhibitors,Total,F,24.16,0.4,1.5,37,35
12,Yukon,L04AC,Interleukin inhibitors,Total,F,**, ** , ** ,*,36
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,23.05,0.4,7.4,189,37
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,22.46,0.4,3.2,81,38
12,Yukon,M05BA,Bisphosphonates,Total,F,22.29,0.4,5.2,131,39
12,Yukon,N02AB,Phenylpiperidine derivatives,Total,F,21.96,0.4,1.1,29,40
12,Yukon,L01BC,Pyrimidine analogues,Total,F,21.53,0.4,0.3,7,41
12,Yukon,N06BA,Centrally acting sympathomimetics,Total,F,21.37,0.4,1.0,26,42
12,Yukon,C01DA,Organic nitrates,Total,F,21.05,0.4,3.8,96,43
12,Yukon,R05CB,Mucolytics,Total,F,**, ** , ** ,*,44
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,19.21,0.3,0.9,22,45
12,Yukon,N05CF,Benzodiazepine-related drugs,Total,F,19.09,0.3,8.4,214,46
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,18.89,0.3,14.9,379,47
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,18.34,0.3,5.1,130,48
12,Yukon,B01AF,Direct factor Xa inhibitors,Total,F,17.04,0.3,0.9,24,49
12,Yukon,B03XA,Other antianemic preparations,Total,F,16.71,0.3,0.2,5,50
12,Yukon,L04AD,Calcineurin inhibitors,Total,F,16.63,0.3,0.4,11,51
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,16.34,0.3,10.4,264,52
12,Yukon,L03AA,Colony-stimulating factors,Total,F,**, ** , ** ,**,53
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,Total,F,15.26,0.3,2.4,60,54
12,Yukon,C03AA,"Thiazides, plain",Total,F,14.88,0.3,12.8,326,55
12,Yukon,S01ED,Beta-blocking agents,Total,F,14.16,0.3,2.1,54,56
12,Yukon,S01EE,Prostaglandin analogues,Total,F,13.77,0.2,2.6,67,57
12,Yukon,C03CA,"Sulfonamides, plain",Total,F,13.64,0.2,5.9,151,58
12,Yukon,H02AB,Glucocorticoids,Total,F,13.40,0.2,11.6,294,59
12,Yukon,S01LA,Antineovascularization agents,Total,F,13.18,0.2,0.2,6,60
12,Yukon,A10BB,Sulfonylureas,Total,F,12.38,0.2,3.9,99,61
12,Yukon,H05AA,Parathyroid hormones and analogues,Total,F,**, ** , ** ,*,62
12,Yukon,R05DA,Opium alkaloids and derivatives,Total,F,11.92,0.2,2.9,74,63
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,11.49,0.2,3.5,89,64
12,Yukon,C08DB,Benzothiazepine derivatives,Total,F,11.00,0.2,1.8,47,65
12,Yukon,N03AE,Benzodiazepine derivatives,Total,F,10.61,0.2,2.9,73,66
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,**, ** , ** ,*,67
12,Yukon,N05BA,Benzodiazepine derivatives,Total,F,10.04,0.2,7.4,187,68
12,Yukon,A04AD,Other antiemetics,Total,F,9.83,0.2,0.5,13,69
12,Yukon,A11CC,Vitamin D and analogues,Total,F,9.72,0.2,14.7,374,70
12,Yukon,L01BA,Folic acid analogues,Total,F,9.45,0.2,2.0,50,71
12,Yukon,C09BA,ACE inhibitors and diuretics,Total,F,9.33,0.2,1.7,42,72
12,Yukon,R01AD,Corticosteroids,Total,F,9.16,0.2,6.2,158,73
12,Yukon,N07BC,Drugs used in opioid dependence,Total,F,**, ** , ** ,*,74
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,Total,F,**, ** , ** ,*,75
12,Yukon,L01AX,Other alkylating agents,Total,F,**, ** , ** ,*,76
12,Yukon,D07AC,"Corticosteroids, potent (group III)",Total,F,8.82,0.2,6.4,162,77
12,Yukon,A09AA,Enzyme preparations,Total,F,8.66,0.2,0.4,11,78
12,Yukon,R03DC,Leukotriene receptor antagonists,Total,F,8.41,0.1,1.5,37,79
12,Yukon,B01AA,Vitamin K antagonists,Total,F,8.30,0.1,2.7,69,80
12,Yukon,M01AE,Propionic acid derivatives,Total,F,8.06,0.1,7.8,197,81
12,Yukon,M01AB,Acetic acid derivatives and related substances,Total,F,8.02,0.1,4.1,104,82
12,Yukon,N03AF,Carboxamide derivatives,Total,F,7.80,0.1,0.4,10,83
12,Yukon,S01BA,"Corticosteroids, plain",Total,F,7.78,0.1,2.3,58,84
12,Yukon,M01AH,Coxibs,Total,F,7.73,0.1,2.8,71,85
12,Yukon,C07AA,"Beta-blocking agents, non-selective",Total,F,7.43,0.1,1.9,49,86
12,Yukon,V03AF,Detoxifying agents for antineoplastic treatment,Total,F,6.97,0.1,0.3,7,87
12,Yukon,S01EC,Carbonic anhydrase inhibitors,Total,F,6.95,0.1,1.0,25,88
12,Yukon,L03AX,Other immunostimulants,Total,F,**, ** , ** ,*,89
12,Yukon,A12BA,Potassium,Total,F,6.86,0.1,2.5,64,90
12,Yukon,M03BX,Other centrally acting agents,Total,F,6.85,0.1,4.1,103,91
12,Yukon,A02BA,H2-receptor antagonists,Total,F,6.65,0.1,3.3,85,92
12,Yukon,J01MA,Fluoroquinolones,Total,F,6.22,0.1,7.5,190,93
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,Total,F,5.77,0.1,0.8,20,94
12,Yukon,C09DA,Angiotensin II antagonists and diuretics,Total,F,5.76,0.1,1.8,45,95
12,Yukon,C03DA,Aldosterone antagonists,Total,F,5.63,0.1,2.2,55,96
12,Yukon,N05AE,Indole derivatives,Total,F,**, ** , ** ,*,97
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,Total,F,5.43,0.1,1.1,28,98
12,Yukon,N05AN,Lithium,Total,F,5.41,0.1,0.6,15,99
12,Yukon,A05AA,Bile acids and derivatives,Total,F,5.22,0.1,0.2,5,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,65+,Total,453.28,6.3,0.2,7,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,292.40,4.0,0.3,10,2
12,Yukon,C10AA,HMG-CoA reductase inhibitors,65+,Total,196.69,2.7,32.7,"1,261",3
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,168.05,2.3,4.5,174,4
12,Yukon,A02BC,Proton pump inhibitors,65+,Total,163.23,2.3,25.1,966,5
12,Yukon,C09AA,"ACE inhibitors, plain",65+,Total,161.00,2.2,29.5,"1,137",6
12,Yukon,L01XE,Protein kinase inhibitors,65+,Total,157.49,2.2,0.2,8,7
12,Yukon,R03BB,Anticholinergics,65+,Total,107.69,1.5,9.2,353,8
12,Yukon,L04AX,Other immunosuppressants,65+,Total,104.64,1.4,0.3,13,9
12,Yukon,C08CA,Dihydropyridine derivatives,65+,Total,97.10,1.3,16.3,627,10
12,Yukon,N02AA,Natural opium alkaloids,65+,Total,89.89,1.2,6.0,230,11
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,84.66,1.2,0.5,19,12
12,Yukon,N03AX,Other antiepileptics,65+,Total,79.73,1.1,6.5,251,13
12,Yukon,L04AA,Selective immunosuppressants,65+,Total,77.94,1.1,0.5,19,14
12,Yukon,N04BA,Dopa and dopa derivatives,65+,Total,**, ** , ** ,**,15
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,Total,71.66,1.0,0.1,5,16
12,Yukon,L02BB,Antiandrogens,65+,Total,63.73,0.9,0.3,10,17
12,Yukon,R03BA,Glucocorticoids,65+,Total,62.48,0.9,5.6,216,18
12,Yukon,C07AB,"Beta-blocking agents, selective",65+,Total,60.04,0.8,16.6,640,19
12,Yukon,C09CA,"Angiotensin II antagonists, plain",65+,Total,58.05,0.8,10.2,391,20
12,Yukon,H03AA,Thyroid hormones,65+,Total,56.26,0.8,17.3,666,21
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,65+,Total,55.59,0.8,8.2,316,22
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,52.93,0.7,2.7,104,23
12,Yukon,A10BA,Biguanides,65+,Total,50.20,0.7,14.4,556,24
12,Yukon,S01LA,Antineovascularization agents,65+,Total,49.53,0.7,0.3,12,25
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,48.67,0.7,26.2,"1,009",26
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,46.10,0.6,10.6,410,27
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,44.97,0.6,14.9,572,28
12,Yukon,N06AX,Other antidepressants,65+,Total,44.73,0.6,6.8,260,29
12,Yukon,L04AC,Interleukin inhibitors,65+,Total,**, ** , ** ,*,30
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,38.04,0.5,0.9,34,31
12,Yukon,S01ED,Beta-blocking agents,65+,Total,37.43,0.5,3.2,124,32
12,Yukon,B01AB,Heparin group,65+,Total,34.80,0.5,0.8,31,33
12,Yukon,L01XC,Monoclonal antibodies,65+,Total,**, ** , ** ,**,34
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,33.60,0.5,1.2,46,35
12,Yukon,C01DA,Organic nitrates,65+,Total,32.16,0.4,6.0,230,36
12,Yukon,N05CF,Benzodiazepine-related drugs,65+,Total,31.14,0.4,9.2,355,37
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,30.03,0.4,1.7,65,38
12,Yukon,A07EC,Aminosalicylic acid and similar agents,65+,Total,29.59,0.4,0.9,34,39
12,Yukon,B01AF,Direct factor Xa inhibitors,65+,Total,28.27,0.4,1.0,39,40
12,Yukon,N02AB,Phenylpiperidine derivatives,65+,Total,28.16,0.4,1.2,45,41
12,Yukon,C03CA,"Sulfonamides, plain",65+,Total,26.95,0.4,7.1,272,42
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,25.98,0.4,13.1,506,43
12,Yukon,L01BC,Pyrimidine analogues,65+,Total,25.01,0.3,0.6,24,44
12,Yukon,C03AA,"Thiazides, plain",65+,Total,24.82,0.3,14.5,560,45
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,24.64,0.3,3.5,133,46
12,Yukon,M05BA,Bisphosphonates,65+,Total,23.89,0.3,3.7,141,47
12,Yukon,A10BB,Sulfonylureas,65+,Total,23.21,0.3,5.2,201,48
12,Yukon,R05DA,Opium alkaloids and derivatives,65+,Total,22.08,0.3,3.0,115,49
12,Yukon,S01EE,Prostaglandin analogues,65+,Total,21.59,0.3,3.0,117,50
12,Yukon,B01AD,Enzymes,65+,Total,**, ** , ** ,*,51
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,65+,Total,**, ** , ** ,*,52
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,20.94,0.3,4.3,165,53
12,Yukon,C08DB,Benzothiazepine derivatives,65+,Total,20.51,0.3,2.4,92,54
12,Yukon,B01AA,Vitamin K antagonists,65+,Total,19.89,0.3,4.4,171,55
12,Yukon,B03XA,Other antianemic preparations,65+,Total,19.27,0.3,0.2,8,56
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,18.73,0.3,4.1,159,57
12,Yukon,M04AA,Preparations inhibiting uric acid production,65+,Total,18.66,0.3,4.1,157,58
12,Yukon,R01AD,Corticosteroids,65+,Total,18.41,0.3,7.3,283,59
12,Yukon,S01EC,Carbonic anhydrase inhibitors,65+,Total,17.20,0.2,1.2,46,60
12,Yukon,H02AB,Glucocorticoids,65+,Total,16.78,0.2,11.0,422,61
12,Yukon,M01AB,Acetic acid derivatives and related substances,65+,Total,16.53,0.2,5.7,218,62
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,65+,Total,16.15,0.2,2.0,77,63
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,65+,Total,**, ** , ** ,**,64
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,15.51,0.2,1.8,68,65
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,15.02,0.2,3.0,117,66
12,Yukon,C09BA,ACE inhibitors and diuretics,65+,Total,14.97,0.2,2.0,78,67
12,Yukon,N05BA,Benzodiazepine derivatives,65+,Total,14.72,0.2,6.8,260,68
12,Yukon,S01BA,"Corticosteroids, plain",65+,Total,13.62,0.2,3.7,144,69
12,Yukon,A11CC,Vitamin D and analogues,65+,Total,13.22,0.2,16.2,624,70
12,Yukon,L02BG,Aromatase inhibitors,65+,Total,13.21,0.2,0.5,21,71
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,65+,Total,13.01,0.2,1.0,37,72
12,Yukon,M01AE,Propionic acid derivatives,65+,Total,12.84,0.2,8.9,341,73
12,Yukon,G04BE,Drugs used in erectile dysfunction,65+,Total,**, ** , ** ,*,74
12,Yukon,D07AC,"Corticosteroids, potent (group III)",65+,Total,12.33,0.2,8.3,321,75
12,Yukon,N07BA,Drugs used in nicotine dependence,65+,Total,11.75,0.2,0.9,35,76
12,Yukon,A12BA,Potassium,65+,Total,11.73,0.2,2.8,106,77
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",65+,Total,11.73,0.2,0.2,8,78
12,Yukon,C03DA,Aldosterone antagonists,65+,Total,11.69,0.2,3.0,115,79
12,Yukon,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,11.55,0.2,0.2,8,80
12,Yukon,L04AD,Calcineurin inhibitors,65+,Total,11.27,0.2,0.2,7,81
12,Yukon,A02BA,H2-receptor antagonists,65+,Total,11.21,0.2,3.7,143,82
12,Yukon,M01AH,Coxibs,65+,Total,11.16,0.2,2.6,101,83
12,Yukon,C07AG,Alpha- and beta-blocking agents,65+,Total,10.94,0.2,0.8,29,84
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,10.65,0.1,0.5,18,85
12,Yukon,C09DA,Angiotensin II antagonists and diuretics,65+,Total,10.55,0.1,1.9,75,86
12,Yukon,C07AA,"Beta-blocking agents, non-selective",65+,Total,10.40,0.1,1.9,72,87
12,Yukon,A04AD,Other antiemetics,65+,Total,**, ** , ** ,**,88
12,Yukon,J01MA,Fluoroquinolones,65+,Total,9.79,0.1,8.1,312,89
12,Yukon,N06DA,Anticholinesterases,65+,Total,9.70,0.1,0.7,26,90
12,Yukon,L03AA,Colony-stimulating factors,65+,Total,**, ** , ** ,*,91
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,65+,Total,**, ** , ** ,*,92
12,Yukon,L01BA,Folic acid analogues,65+,Total,7.65,0.1,1.0,39,93
12,Yukon,J01DB,First-generation cephalosporins,65+,Total,7.31,0.1,5.5,213,94
12,Yukon,N05AX,Other antipsychotics,65+,Total,7.11,0.1,0.4,15,95
12,Yukon,M03BX,Other centrally acting agents,65+,Total,6.72,0.1,3.7,141,96
12,Yukon,J01FA,Macrolides,65+,Total,6.43,0.1,6.5,249,97
12,Yukon,N07XX,Other nervous system drugs,65+,Total,**, ** , ** ,*,98
12,Yukon,C01BD,"Antiarrhythmics, class III",65+,Total,6.36,0.1,0.7,28,99
12,Yukon,S01GX,Other antiallergics,65+,Total,6.26,0.1,1.7,67,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,65+,M,**, ** , ** ,*,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,**, ** , ** ,**,2
12,Yukon,C10AA,HMG-CoA reductase inhibitors,65+,M,123.36,3.0,38.4,807,3
12,Yukon,C09AA,"ACE inhibitors, plain",65+,M,101.83,2.5,34.6,728,4
12,Yukon,L01XE,Protein kinase inhibitors,65+,M,**, ** , ** ,**,5
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,90.72,2.2,4.1,87,6
12,Yukon,L04AX,Other immunosuppressants,65+,M,86.18,2.1,0.4,8,7
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,65+,M,**, ** , ** ,**,8
12,Yukon,A02BC,Proton pump inhibitors,65+,M,77.54,1.9,23.3,491,9
12,Yukon,N04BA,Dopa and dopa derivatives,65+,M,**, ** , ** ,**,10
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,**, ** , ** ,*,11
12,Yukon,R03BB,Anticholinergics,65+,M,65.64,1.6,9.4,197,12
12,Yukon,L02BB,Antiandrogens,65+,M,**, ** , ** ,**,13
12,Yukon,C08CA,Dihydropyridine derivatives,65+,M,51.65,1.3,17.1,359,14
12,Yukon,G04CA,Alpha-adrenoreceptor antagonists,65+,M,44.51,1.1,18.7,394,15
12,Yukon,C07AB,"Beta-blocking agents, selective",65+,M,36.57,0.9,19.9,418,16
12,Yukon,S01LA,Antineovascularization agents,65+,M,36.35,0.9,0.3,6,17
12,Yukon,N03AX,Other antiepileptics,65+,M,36.18,0.9,5.5,116,18
12,Yukon,N02AA,Natural opium alkaloids,65+,M,34.43,0.8,4.7,99,19
12,Yukon,L04AC,Interleukin inhibitors,65+,M,**, ** , ** ,*,20
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,32.67,0.8,30.7,646,21
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,32.66,0.8,2.9,61,22
12,Yukon,R03BA,Glucocorticoids,65+,M,31.40,0.8,4.9,103,23
12,Yukon,A10BA,Biguanides,65+,M,31.15,0.8,16.3,343,24
12,Yukon,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,24.64,0.6,6.3,133,25
12,Yukon,S01ED,Beta-blocking agents,65+,M,24.23,0.6,3.6,75,26
12,Yukon,C09CA,"Angiotensin II antagonists, plain",65+,M,24.19,0.6,8.8,185,27
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,24.14,0.6,1.1,23,28
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,23.93,0.6,14.0,295,29
12,Yukon,B01AD,Enzymes,65+,M,**, ** , ** ,*,30
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,65+,M,**, ** , ** ,*,31
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,65+,M,18.81,0.5,5.8,122,32
12,Yukon,L01BC,Pyrimidine analogues,65+,M,**, ** , ** ,**,33
12,Yukon,N02AB,Phenylpiperidine derivatives,65+,M,**, ** , ** ,**,34
12,Yukon,N06AX,Other antidepressants,65+,M,17.47,0.4,5.2,110,35
12,Yukon,H03AA,Thyroid hormones,65+,M,16.05,0.4,9.7,204,36
12,Yukon,C01DA,Organic nitrates,65+,M,15.59,0.4,7.1,150,37
12,Yukon,C03CA,"Sulfonamides, plain",65+,M,14.80,0.4,6.8,143,38
12,Yukon,A10BB,Sulfonylureas,65+,M,14.15,0.3,6.5,136,39
12,Yukon,R05DA,Opium alkaloids and derivatives,65+,M,14.10,0.3,2.7,57,40
12,Yukon,M04AA,Preparations inhibiting uric acid production,65+,M,14.06,0.3,6.1,128,41
12,Yukon,N05CF,Benzodiazepine-related drugs,65+,M,13.59,0.3,7.6,159,42
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,13.13,0.3,13.9,293,43
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",65+,M,13.11,0.3,1.2,26,44
12,Yukon,B03XA,Other antianemic preparations,65+,M,**, ** , ** ,**,45
12,Yukon,B01AA,Vitamin K antagonists,65+,M,12.92,0.3,5.4,114,46
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,12.89,0.3,1.6,33,47
12,Yukon,B01AF,Direct factor Xa inhibitors,65+,M,12.46,0.3,1.0,20,48
12,Yukon,B01AB,Heparin group,65+,M,12.42,0.3,0.6,12,49
12,Yukon,C03AA,"Thiazides, plain",65+,M,12.07,0.3,13.9,293,50
12,Yukon,L04AA,Selective immunosuppressants,65+,M,**, ** , ** ,*,51
12,Yukon,C08DB,Benzothiazepine derivatives,65+,M,11.11,0.3,2.5,52,52
12,Yukon,M01AB,Acetic acid derivatives and related substances,65+,M,10.83,0.3,6.8,144,53
12,Yukon,S01EC,Carbonic anhydrase inhibitors,65+,M,10.46,0.3,1.1,24,54
12,Yukon,R01AD,Corticosteroids,65+,M,10.09,0.2,7.0,148,55
12,Yukon,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,**, ** , ** ,*,56
12,Yukon,L04AD,Calcineurin inhibitors,65+,M,**, ** , ** ,*,57
12,Yukon,G04BE,Drugs used in erectile dysfunction,65+,M,**, ** , ** ,*,58
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,8.81,0.2,3.2,68,59
12,Yukon,S01EE,Prostaglandin analogues,65+,M,8.51,0.2,2.7,56,60
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,8.28,0.2,1.5,32,61
12,Yukon,N07BA,Drugs used in nicotine dependence,65+,M,**, ** , ** ,**,62
12,Yukon,L03AA,Colony-stimulating factors,65+,M,**, ** , ** ,*,63
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,65+,M,**, ** , ** ,*,64
12,Yukon,A07EC,Aminosalicylic acid and similar agents,65+,M,7.81,0.2,0.6,13,65
12,Yukon,C03DA,Aldosterone antagonists,65+,M,7.52,0.2,3.5,73,66
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,65+,M,7.38,0.2,0.9,18,67
12,Yukon,D07AC,"Corticosteroids, potent (group III)",65+,M,7.31,0.2,8.7,183,68
12,Yukon,L01XC,Monoclonal antibodies,65+,M,**, ** , ** ,**,69
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,**, ** , ** ,**,70
12,Yukon,C09BA,ACE inhibitors and diuretics,65+,M,7.08,0.2,2.1,45,71
12,Yukon,C07AG,Alpha- and beta-blocking agents,65+,M,7.02,0.2,0.8,17,72
12,Yukon,H02AB,Glucocorticoids,65+,M,6.99,0.2,9.5,200,73
12,Yukon,M01AE,Propionic acid derivatives,65+,M,6.73,0.2,9.0,189,74
12,Yukon,A11CC,Vitamin D and analogues,65+,M,6.70,0.2,12.7,267,75
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,6.10,0.2,2.0,43,76
12,Yukon,A12BA,Potassium,65+,M,5.94,0.1,2.2,47,77
12,Yukon,N05BA,Benzodiazepine derivatives,65+,M,5.88,0.1,4.4,92,78
12,Yukon,S01BA,"Corticosteroids, plain",65+,M,5.84,0.1,4.1,86,79
12,Yukon,C09DA,Angiotensin II antagonists and diuretics,65+,M,5.82,0.1,1.9,41,80
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,65+,M,5.48,0.1,1.0,22,81
12,Yukon,N06DA,Anticholinesterases,65+,M,5.18,0.1,0.7,14,82
12,Yukon,L02BX,Other hormone antagonists and related agents,65+,M,**, ** , ** ,*,83
12,Yukon,A02BA,H2-receptor antagonists,65+,M,4.90,0.1,3.2,67,84
12,Yukon,G03BA,3-oxoandrosten (4) derivatives,65+,M,**, ** , ** ,**,85
12,Yukon,N07BC,Drugs used in opioid dependence,65+,M,**, ** , ** ,*,86
12,Yukon,J01DB,First-generation cephalosporins,65+,M,4.65,0.1,6.2,131,87
12,Yukon,C07AA,"Beta-blocking agents, non-selective",65+,M,4.59,0.1,1.7,36,88
12,Yukon,J01MA,Fluoroquinolones,65+,M,4.59,0.1,6.8,143,89
12,Yukon,D05AX,Other antipsoriatics for topical use,65+,M,4.53,0.1,0.8,16,90
12,Yukon,M01AH,Coxibs,65+,M,4.05,0.1,1.7,35,91
12,Yukon,C01BD,"Antiarrhythmics, class III",65+,M,3.96,0.1,0.9,19,92
12,Yukon,M05BA,Bisphosphonates,65+,M,3.87,0.1,1.2,25,93
12,Yukon,J01FA,Macrolides,65+,M,3.65,0.1,5.7,119,94
12,Yukon,D01AE,Other antifungals for topical use,65+,M,3.35,0.1,2.0,42,95
12,Yukon,J01CA,Penicillins with extended spectrum,65+,M,3.30,0.1,7.7,163,96
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,65+,M,3.25,0.1,0.5,11,97
12,Yukon,N03AF,Carboxamide derivatives,65+,M,3.25,0.1,0.4,9,98
12,Yukon,C01AA,Digitalis glycosides,65+,M,3.09,0.1,0.8,16,99
12,Yukon,N05AX,Other antipsychotics,65+,M,3.02,0.1,0.3,7,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,65+,F,**, ** , ** ,*,1
12,Yukon,A02BC,Proton pump inhibitors,65+,F,85.70,2.7,27.2,475,2
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,77.33,2.4,5.0,87,3
12,Yukon,C10AA,HMG-CoA reductase inhibitors,65+,F,73.33,2.3,26.0,454,4
12,Yukon,L04AA,Selective immunosuppressants,65+,F,**, ** , ** ,**,5
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,**, ** , ** ,*,6
12,Yukon,C09AA,"ACE inhibitors, plain",65+,F,59.17,1.9,23.4,409,7
12,Yukon,L01XE,Protein kinase inhibitors,65+,F,**, ** , ** ,*,8
12,Yukon,N02AA,Natural opium alkaloids,65+,F,55.45,1.8,7.5,131,9
12,Yukon,C08CA,Dihydropyridine derivatives,65+,F,45.45,1.4,15.3,268,10
12,Yukon,N03AX,Other antiepileptics,65+,F,43.56,1.4,7.7,135,11
12,Yukon,R03BB,Anticholinergics,65+,F,42.06,1.3,8.9,156,12
12,Yukon,H03AA,Thyroid hormones,65+,F,40.21,1.3,26.4,462,13
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,65+,F,36.78,1.2,11.1,194,14
12,Yukon,C09CA,"Angiotensin II antagonists, plain",65+,F,33.86,1.1,11.8,206,15
12,Yukon,R03BA,Glucocorticoids,65+,F,31.08,1.0,6.5,113,16
12,Yukon,N06AX,Other antidepressants,65+,F,27.26,0.9,8.6,150,17
12,Yukon,L01XC,Monoclonal antibodies,65+,F,**, ** , ** ,**,18
12,Yukon,C07AB,"Beta-blocking agents, selective",65+,F,23.46,0.7,12.7,222,19
12,Yukon,B01AB,Heparin group,65+,F,22.37,0.7,1.1,19,20
12,Yukon,A07EC,Aminosalicylic acid and similar agents,65+,F,21.78,0.7,1.2,21,21
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,21.03,0.7,15.9,277,22
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,20.88,0.7,9.3,163,23
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",65+,F,20.50,0.6,1.1,20,24
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,20.27,0.6,2.5,43,25
12,Yukon,M05BA,Bisphosphonates,65+,F,20.01,0.6,6.6,116,26
12,Yukon,A10BA,Biguanides,65+,F,19.06,0.6,12.2,213,27
12,Yukon,L04AX,Other immunosuppressants,65+,F,18.46,0.6,0.3,5,28
12,Yukon,N05CF,Benzodiazepine-related drugs,65+,F,17.56,0.6,11.2,196,29
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,17.14,0.5,1.8,32,30
12,Yukon,C01DA,Organic nitrates,65+,F,16.57,0.5,4.6,80,31
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,16.00,0.5,20.8,363,32
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,65+,F,**, ** , ** ,**,33
12,Yukon,B01AF,Direct factor Xa inhibitors,65+,F,15.81,0.5,1.1,19,34
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,13.89,0.4,0.6,11,35
12,Yukon,L02BG,Aromatase inhibitors,65+,F,13.21,0.4,1.2,21,36
12,Yukon,S01ED,Beta-blocking agents,65+,F,13.20,0.4,2.8,49,37
12,Yukon,S01LA,Antineovascularization agents,65+,F,13.18,0.4,0.3,6,38
12,Yukon,S01EE,Prostaglandin analogues,65+,F,13.07,0.4,3.5,61,39
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,12.85,0.4,12.2,213,40
12,Yukon,C03AA,"Thiazides, plain",65+,F,12.75,0.4,15.3,267,41
12,Yukon,C03CA,"Sulfonamides, plain",65+,F,12.15,0.4,7.4,129,42
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,65+,F,10.67,0.3,3.1,55,43
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",65+,F,**, ** , ** ,**,44
12,Yukon,N02AB,Phenylpiperidine derivatives,65+,F,**, ** , ** ,**,45
12,Yukon,L04AC,Interleukin inhibitors,65+,F,**, ** , ** ,*,46
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,9.91,0.3,5.2,91,47
12,Yukon,H02AB,Glucocorticoids,65+,F,9.79,0.3,12.7,222,48
12,Yukon,C08DB,Benzothiazepine derivatives,65+,F,9.40,0.3,2.3,40,49
12,Yukon,A10BB,Sulfonylureas,65+,F,9.06,0.3,3.7,65,50
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,F,8.92,0.3,4.2,74,51
12,Yukon,N05BA,Benzodiazepine derivatives,65+,F,8.84,0.3,9.6,168,52
12,Yukon,R01AD,Corticosteroids,65+,F,8.32,0.3,7.7,135,53
12,Yukon,R05DA,Opium alkaloids and derivatives,65+,F,7.97,0.3,3.3,58,54
12,Yukon,C09BA,ACE inhibitors and diuretics,65+,F,7.89,0.2,1.9,33,55
12,Yukon,S01BA,"Corticosteroids, plain",65+,F,7.78,0.2,3.3,58,56
12,Yukon,A04AD,Other antiemetics,65+,F,**, ** , ** ,*,57
12,Yukon,L01BC,Pyrimidine analogues,65+,F,**, ** , ** ,*,58
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,7.24,0.2,2.1,36,59
12,Yukon,M01AH,Coxibs,65+,F,7.11,0.2,3.8,66,60
12,Yukon,B01AA,Vitamin K antagonists,65+,F,6.97,0.2,3.3,57,61
12,Yukon,S01EC,Carbonic anhydrase inhibitors,65+,F,6.75,0.2,1.3,22,62
12,Yukon,A11CC,Vitamin D and analogues,65+,F,6.53,0.2,20.4,357,63
12,Yukon,B03XA,Other antianemic preparations,65+,F,**, ** , ** ,*,64
12,Yukon,A02BA,H2-receptor antagonists,65+,F,6.32,0.2,4.4,76,65
12,Yukon,M01AE,Propionic acid derivatives,65+,F,6.11,0.2,8.7,152,66
12,Yukon,C07AA,"Beta-blocking agents, non-selective",65+,F,5.81,0.2,2.1,36,67
12,Yukon,A12BA,Potassium,65+,F,5.79,0.2,3.4,59,68
12,Yukon,M01AB,Acetic acid derivatives and related substances,65+,F,5.70,0.2,4.2,74,69
12,Yukon,N02CC,Selective serotonin (5HT1) agonists,65+,F,5.63,0.2,1.1,19,70
12,Yukon,V03AF,Detoxifying agents for antineoplastic treatment,65+,F,**, ** , ** ,*,71
12,Yukon,J01MA,Fluoroquinolones,65+,F,5.20,0.2,9.7,169,72
12,Yukon,L01BA,Folic acid analogues,65+,F,5.14,0.2,1.4,25,73
12,Yukon,D07AC,"Corticosteroids, potent (group III)",65+,F,5.02,0.2,7.9,138,74
12,Yukon,R03DC,Leukotriene receptor antagonists,65+,F,4.93,0.2,1.1,19,75
12,Yukon,C09DA,Angiotensin II antagonists and diuretics,65+,F,4.73,0.1,1.9,34,76
12,Yukon,M04AA,Preparations inhibiting uric acid production,65+,F,4.60,0.1,1.7,29,77
12,Yukon,N06DA,Anticholinesterases,65+,F,4.53,0.1,0.7,12,78
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,F,**, ** , ** ,*,79
12,Yukon,S01GX,Other antiallergics,65+,F,4.29,0.1,2.5,44,80
12,Yukon,N07XX,Other nervous system drugs,65+,F,**, ** , ** ,*,81
12,Yukon,C03DA,Aldosterone antagonists,65+,F,4.18,0.1,2.4,42,82
12,Yukon,N04BC,Dopamine agonists,65+,F,4.12,0.1,0.9,16,83
12,Yukon,N05AX,Other antipsychotics,65+,F,4.08,0.1,0.5,8,84
12,Yukon,M03BX,Other centrally acting agents,65+,F,4.02,0.1,4.3,75,85
12,Yukon,C07AG,Alpha- and beta-blocking agents,65+,F,3.92,0.1,0.7,12,86
12,Yukon,G04BE,Drugs used in erectile dysfunction,65+,F,**, ** , ** ,*,87
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,F,**, ** , ** ,**,88
12,Yukon,N07BA,Drugs used in nicotine dependence,65+,F,**, ** , ** ,**,89
12,Yukon,J01XE,Nitrofuran derivatives,65+,F,3.50,0.1,5.4,94,90
12,Yukon,N01AH,Opioid anesthetics,65+,F,**, ** , ** ,*,91
12,Yukon,N04BA,Dopa and dopa derivatives,65+,F,**, ** , ** ,**,92
12,Yukon,J01AA,Tetracyclines,65+,F,3.05,0.1,5.2,90,93
12,Yukon,A07AA,Antibiotics,65+,F,3.02,0.1,1.3,23,94
12,Yukon,H01CB,Somatostatin and analogues,65+,F,**, ** , ** ,*,95
12,Yukon,P01BA,Aminoquinolines,65+,F,2.85,0.1,0.9,16,96
12,Yukon,J01CA,Penicillins with extended spectrum,65+,F,2.79,0.1,7.8,137,97
12,Yukon,J01FA,Macrolides,65+,F,2.78,0.1,7.4,130,98
12,Yukon,C01AA,Digitalis glycosides,65+,F,2.67,0.1,0.7,12,99
12,Yukon,J01DB,First-generation cephalosporins,65+,F,2.67,0.1,4.7,82,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,<65,Total,807.26,15.2,0.9,13,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,735.80,13.9,3.9,60,2
12,Yukon,R07AX,Other respiratory system products,<65,Total,**, ** , ** ,*,3
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,197.53,3.7,1.1,17,4
12,Yukon,L01XE,Protein kinase inhibitors,<65,Total,185.46,3.5,0.5,7,5
12,Yukon,N07XX,Other nervous system drugs,<65,Total,**, ** , ** ,**,6
12,Yukon,L04AA,Selective immunosuppressants,<65,Total,126.39,2.4,2.2,34,7
12,Yukon,N05AX,Other antipsychotics,<65,Total,97.24,1.8,2.4,37,8
12,Yukon,N03AX,Other antiepileptics,<65,Total,90.98,1.7,10.9,167,9
12,Yukon,B01AB,Heparin group,<65,Total,80.43,1.5,1.2,19,10
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,71.91,1.4,5.8,88,11
12,Yukon,A16AB,Enzymes,<65,Total,**, ** , ** ,*,12
12,Yukon,L03AB,Interferons,<65,Total,**, ** , ** ,*,13
12,Yukon,L04AC,Interleukin inhibitors,<65,Total,**, ** , ** ,**,14
12,Yukon,N06BA,Centrally acting sympathomimetics,<65,Total,48.15,0.9,3.3,51,15
12,Yukon,N02AA,Natural opium alkaloids,<65,Total,47.03,0.9,5.1,78,16
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,47.02,0.9,7.1,109,17
12,Yukon,C10AA,HMG-CoA reductase inhibitors,<65,Total,46.91,0.9,19.6,299,18
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,46.90,0.9,3.9,59,19
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,45.92,0.9,5.9,90,20
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,<65,Total,44.53,0.8,14.3,219,21
12,Yukon,C09AA,"ACE inhibitors, plain",<65,Total,42.33,0.8,18.4,281,22
12,Yukon,R03BA,Glucocorticoids,<65,Total,42.32,0.8,7.7,117,23
12,Yukon,N06AX,Other antidepressants,<65,Total,42.22,0.8,12.8,196,24
12,Yukon,R05CB,Mucolytics,<65,Total,**, ** , ** ,*,25
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,38.08,0.7,5.4,83,26
12,Yukon,J05AE,Protease inhibitors,<65,Total,**, ** , ** ,**,27
12,Yukon,R03BB,Anticholinergics,<65,Total,35.80,0.7,6.3,96,28
12,Yukon,L04AD,Calcineurin inhibitors,<65,Total,33.57,0.6,1.1,17,29
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,<65,Total,**, ** , ** ,*,30
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,32.82,0.6,0.7,10,31
12,Yukon,A09AA,Enzyme preparations,<65,Total,30.27,0.6,0.9,14,32
12,Yukon,B03XA,Other antianemic preparations,<65,Total,28.30,0.5,0.4,6,33
12,Yukon,L04AX,Other immunosuppressants,<65,Total,26.99,0.5,1.2,18,34
12,Yukon,L02BX,Other hormone antagonists and related agents,<65,Total,**, ** , ** ,*,35
12,Yukon,A07EC,Aminosalicylic acid and similar agents,<65,Total,24.29,0.5,2.4,36,36
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,24.26,0.5,15.7,240,37
12,Yukon,A10BA,Biguanides,<65,Total,19.03,0.4,14.8,226,38
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,<65,Total,18.17,0.3,0.3,5,39
12,Yukon,L01BC,Pyrimidine analogues,<65,Total,18.07,0.3,0.5,7,40
12,Yukon,C08CA,Dihydropyridine derivatives,<65,Total,17.53,0.3,9.0,138,41
12,Yukon,A02BC,Proton pump inhibitors,<65,Total,16.77,0.3,8.0,122,42
12,Yukon,N02AB,Phenylpiperidine derivatives,<65,Total,16.14,0.3,0.7,11,43
12,Yukon,L03AA,Colony-stimulating factors,<65,Total,**, ** , ** ,**,44
12,Yukon,L03AX,Other immunostimulants,<65,Total,15.65,0.3,0.4,6,45
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,14.84,0.3,4.0,61,46
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,Total,**, ** , ** ,**,47
12,Yukon,C09CA,"Angiotensin II antagonists, plain",<65,Total,13.89,0.3,7.0,107,48
12,Yukon,N03AE,Benzodiazepine derivatives,<65,Total,13.18,0.2,4.5,69,49
12,Yukon,C07AB,"Beta-blocking agents, selective",<65,Total,13.15,0.2,9.8,149,50
12,Yukon,H03AA,Thyroid hormones,<65,Total,12.37,0.2,10.9,167,51
12,Yukon,H05AA,Parathyroid hormones and analogues,<65,Total,**, ** , ** ,*,52
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,11.13,0.2,1.1,17,53
12,Yukon,L02BG,Aromatase inhibitors,<65,Total,10.95,0.2,1.0,16,54
12,Yukon,N05AE,Indole derivatives,<65,Total,10.84,0.2,0.4,6,55
12,Yukon,N03AF,Carboxamide derivatives,<65,Total,10.46,0.2,1.1,17,56
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,**, ** , ** ,*,57
12,Yukon,L01XC,Monoclonal antibodies,<65,Total,**, ** , ** ,*,58
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,<65,Total,**, ** , ** ,*,59
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,<65,Total,9.33,0.2,2.5,38,60
12,Yukon,L01AX,Other alkylating agents,<65,Total,**, ** , ** ,*,61
12,Yukon,N07BC,Drugs used in opioid dependence,<65,Total,**, ** , ** ,*,62
12,Yukon,R05DA,Opium alkaloids and derivatives,<65,Total,8.25,0.2,1.6,24,63
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,Total,**, ** , ** ,*,64
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,Total,7.89,0.1,0.5,7,65
12,Yukon,A10BB,Sulfonylureas,<65,Total,7.34,0.1,5.2,79,66
12,Yukon,H01AC,Somatropin and somatropin agonists,<65,Total,**, ** , ** ,*,67
12,Yukon,C01DA,Organic nitrates,<65,Total,7.03,0.1,3.1,47,68
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,6.71,0.1,5.2,80,69
12,Yukon,H02AB,Glucocorticoids,<65,Total,6.55,0.1,8.8,135,70
12,Yukon,N03AG,Fatty acid derivatives,<65,Total,6.32,0.1,1.5,23,71
12,Yukon,N05AN,Lithium,<65,Total,6.06,0.1,1.4,22,72
12,Yukon,L01BA,Folic acid analogues,<65,Total,5.90,0.1,2.2,34,73
12,Yukon,M03BX,Other centrally acting agents,<65,Total,5.80,0.1,2.9,45,74
12,Yukon,R03DC,Leukotriene receptor antagonists,<65,Total,5.47,0.1,1.6,25,75
12,Yukon,A05AA,Bile acids and derivatives,<65,Total,5.47,0.1,0.4,6,76
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,5.23,0.1,2.4,37,77
12,Yukon,C03AA,"Thiazides, plain",<65,Total,5.21,0.1,7.9,121,78
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,<65,Total,4.75,0.1,0.5,7,79
12,Yukon,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,Total,**, ** , ** ,*,80
12,Yukon,C03CA,"Sulfonamides, plain",<65,Total,4.23,0.1,3.3,51,81
12,Yukon,H01BA,Vasopressin and analogues,<65,Total,4.19,0.1,0.3,5,82
12,Yukon,D07AC,"Corticosteroids, potent (group III)",<65,Total,4.18,0.1,2.1,32,83
12,Yukon,C09BA,ACE inhibitors and diuretics,<65,Total,4.07,0.1,1.4,21,84
12,Yukon,A11CC,Vitamin D and analogues,<65,Total,3.94,0.1,1.4,21,85
12,Yukon,C07AA,"Beta-blocking agents, non-selective",<65,Total,3.83,0.1,1.4,22,86
12,Yukon,C03DA,Aldosterone antagonists,<65,Total,3.76,0.1,2.3,35,87
12,Yukon,C02AC,Imidazoline receptor agonists,<65,Total,3.59,0.1,0.5,8,88
12,Yukon,C09DA,Angiotensin II antagonists and diuretics,<65,Total,3.59,0.1,1.7,26,89
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,Total,**, ** , ** ,*,90
12,Yukon,D05AX,Other antipsoriatics for topical use,<65,Total,3.47,0.1,0.8,12,91
12,Yukon,M01AB,Acetic acid derivatives and related substances,<65,Total,3.44,0.1,2.9,45,92
12,Yukon,C08DB,Benzothiazepine derivatives,<65,Total,3.30,0.1,1.0,16,93
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,3.28,0.1,1.4,21,94
12,Yukon,B01AA,Vitamin K antagonists,<65,Total,3.21,0.1,2.0,30,95
12,Yukon,M01AE,Propionic acid derivatives,<65,Total,3.14,0.1,3.9,59,96
12,Yukon,J05AX,Other antivirals,<65,Total,**, ** , ** ,*,97
12,Yukon,A04AA,Serotonin (5HT3) antagonists,<65,Total,3.05,0.1,0.7,11,98
12,Yukon,S01ED,Beta-blocking agents,<65,Total,3.00,0.1,0.8,12,99
12,Yukon,M05BA,Bisphosphonates,<65,Total,2.98,0.1,1.4,22,100
12,Yukon,J05AP,Antivirals for treatment of HCV infections,<65,M,**, ** , ** ,**,1
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,**, ** , ** ,**,2
12,Yukon,L01XE,Protein kinase inhibitors,<65,M,**, ** , ** ,**,3
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,**, ** , ** ,*,4
12,Yukon,N05AX,Other antipsychotics,<65,M,76.24,2.7,3.5,26,5
12,Yukon,A16AB,Enzymes,<65,M,**, ** , ** ,*,6
12,Yukon,N07XX,Other nervous system drugs,<65,M,**, ** , ** ,*,7
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,46.22,1.6,7.6,56,8
12,Yukon,N03AX,Other antiepileptics,<65,M,38.26,1.3,9.5,70,9
12,Yukon,L04AC,Interleukin inhibitors,<65,M,**, ** , ** ,**,10
12,Yukon,J05AE,Protease inhibitors,<65,M,**, ** , ** ,*,11
12,Yukon,R03DX,Other systemic drugs for obstructive airway diseases,<65,M,**, ** , ** ,*,12
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,31.26,1.1,8.6,63,13
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,30.70,1.1,6.1,45,14
12,Yukon,C10AA,HMG-CoA reductase inhibitors,<65,M,27.45,1.0,24.3,178,15
12,Yukon,N06BA,Centrally acting sympathomimetics,<65,M,27.02,1.0,3.7,27,16
12,Yukon,C09AA,"ACE inhibitors, plain",<65,M,25.43,0.9,22.9,168,17
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",<65,M,25.11,0.9,4.5,33,18
12,Yukon,L02BX,Other hormone antagonists and related agents,<65,M,**, ** , ** ,*,19
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,23.53,0.8,6.3,46,20
12,Yukon,A09AA,Enzyme preparations,<65,M,23.27,0.8,1.0,7,21
12,Yukon,L04AA,Selective immunosuppressants,<65,M,**, ** , ** ,**,22
12,Yukon,R03BB,Anticholinergics,<65,M,21.12,0.7,7.4,54,23
12,Yukon,L03AB,Interferons,<65,M,**, ** , ** ,*,24
12,Yukon,R03BA,Glucocorticoids,<65,M,20.81,0.7,6.0,44,25
12,Yukon,R05CB,Mucolytics,<65,M,**, ** , ** ,*,26
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,<65,M,18.90,0.7,11.7,86,27
12,Yukon,L04AD,Calcineurin inhibitors,<65,M,**, ** , ** ,**,28
12,Yukon,B03XA,Other antianemic preparations,<65,M,**, ** , ** ,*,29
12,Yukon,B01AB,Heparin group,<65,M,17.23,0.6,0.7,5,30
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,<65,M,**, ** , ** ,*,31
12,Yukon,N02AA,Natural opium alkaloids,<65,M,16.72,0.6,3.4,25,32
12,Yukon,N06AX,Other antidepressants,<65,M,14.84,0.5,8.7,64,33
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,14.07,0.5,15.8,116,34
12,Yukon,A07EC,Aminosalicylic acid and similar agents,<65,M,13.91,0.5,1.8,13,35
12,Yukon,C08CA,Dihydropyridine derivatives,<65,M,11.14,0.4,11.5,84,36
12,Yukon,A10BA,Biguanides,<65,M,10.52,0.4,16.6,122,37
12,Yukon,L03AX,Other immunostimulants,<65,M,**, ** , ** ,*,38
12,Yukon,C07AB,"Beta-blocking agents, selective",<65,M,8.29,0.3,13.8,101,39
12,Yukon,J05AG,Non-nucleoside reverse transcriptase inhibitors,<65,M,**, ** , ** ,*,40
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,**, ** , ** ,*,41
12,Yukon,C09CA,"Angiotensin II antagonists, plain",<65,M,7.66,0.3,7.2,53,42
12,Yukon,H01AC,Somatropin and somatropin agonists,<65,M,**, ** , ** ,*,43
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,M,**, ** , ** ,**,44
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,6.41,0.2,3.0,22,45
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,M,**, ** , ** ,**,46
12,Yukon,A02BC,Proton pump inhibitors,<65,M,5.85,0.2,5.6,41,47
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,5.81,0.2,0.8,6,48
12,Yukon,N05AE,Indole derivatives,<65,M,**, ** , ** ,*,49
12,Yukon,N02AB,Phenylpiperidine derivatives,<65,M,**, ** , ** ,*,50
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,<65,M,4.57,0.2,2.0,15,51
12,Yukon,N03AE,Benzodiazepine derivatives,<65,M,4.36,0.2,3.4,25,52
12,Yukon,R05DA,Opium alkaloids and derivatives,<65,M,4.31,0.2,1.1,8,53
12,Yukon,N03AG,Fatty acid derivatives,<65,M,4.24,0.1,2.0,15,54
12,Yukon,L04AX,Other immunosuppressants,<65,M,4.22,0.1,1.1,8,55
12,Yukon,A10BB,Sulfonylureas,<65,M,4.02,0.1,6.1,45,56
12,Yukon,L01BC,Pyrimidine analogues,<65,M,**, ** , ** ,*,57
12,Yukon,A10BJ,Glucagon-like peptide-1 (GLP-1) analogues,<65,M,**, ** , ** ,*,58
12,Yukon,H03AA,Thyroid hormones,<65,M,3.25,0.1,5.6,41,59
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,3.21,0.1,4.0,29,60
12,Yukon,J05AX,Other antivirals,<65,M,**, ** , ** ,*,61
12,Yukon,C03AA,"Thiazides, plain",<65,M,3.08,0.1,8.5,62,62
12,Yukon,M03BX,Other centrally acting agents,<65,M,2.96,0.1,2.3,17,63
12,Yukon,H02AB,Glucocorticoids,<65,M,2.94,0.1,8.6,63,64
12,Yukon,N03AF,Carboxamide derivatives,<65,M,2.92,0.1,1.4,10,65
12,Yukon,C02AC,Imidazoline receptor agonists,<65,M,**, ** , ** ,*,66
12,Yukon,N05AF,Thioxanthene derivatives,<65,M,**, ** , ** ,*,67
12,Yukon,C03CA,"Sulfonamides, plain",<65,M,2.74,0.1,4.0,29,68
12,Yukon,N04BA,Dopa and dopa derivatives,<65,M,**, ** , ** ,*,69
12,Yukon,C09BA,ACE inhibitors and diuretics,<65,M,2.64,0.1,1.6,12,70
12,Yukon,G03BA,3-oxoandrosten (4) derivatives,<65,M,**, ** , ** ,*,71
12,Yukon,C09DA,Angiotensin II antagonists and diuretics,<65,M,2.56,0.1,2.0,15,72
12,Yukon,C01DA,Organic nitrates,<65,M,2.55,0.1,4.2,31,73
12,Yukon,H01BA,Vasopressin and analogues,<65,M,**, ** , ** ,*,74
12,Yukon,J01GB,Other aminoglycosides,<65,M,**, ** , ** ,*,75
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,2.34,0.1,2.9,21,76
12,Yukon,C03DA,Aldosterone antagonists,<65,M,2.31,0.1,3.0,22,77
12,Yukon,D05AX,Other antipsoriatics for topical use,<65,M,2.27,0.1,0.7,5,78
12,Yukon,C07AA,"Beta-blocking agents, non-selective",<65,M,2.21,0.1,1.2,9,79
12,Yukon,S01ED,Beta-blocking agents,<65,M,2.05,0.1,1.0,7,80
12,Yukon,R03DC,Leukotriene receptor antagonists,<65,M,2.00,0.1,1.0,7,81
12,Yukon,N05AD,Butyrophenone derivatives,<65,M,1.89,0.1,1.0,7,82
12,Yukon,B01AA,Vitamin K antagonists,<65,M,1.87,0.1,2.5,18,83
12,Yukon,A05AA,Bile acids and derivatives,<65,M,**, ** , ** ,*,84
12,Yukon,N01AH,Opioid anesthetics,<65,M,**, ** , ** ,*,85
12,Yukon,C08DB,Benzothiazepine derivatives,<65,M,1.69,0.1,1.2,9,86
12,Yukon,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,**, ** , ** ,*,87
12,Yukon,L02BB,Antiandrogens,<65,M,**, ** , ** ,*,88
12,Yukon,N05AB,Phenothiazines with piperazine structure,<65,M,**, ** , ** ,*,89
12,Yukon,C07AG,Alpha- and beta-blocking agents,<65,M,1.61,0.1,1.0,7,90
12,Yukon,H04AA,Glycogenolytic hormones,<65,M,1.60,0.1,1.4,10,91
12,Yukon,L01BA,Folic acid analogues,<65,M,1.59,0.1,1.2,9,92
12,Yukon,N05AN,Lithium,<65,M,1.51,0.1,1.4,10,93
12,Yukon,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,**, ** , ** ,*,94
12,Yukon,N03AB,Hydantoin derivatives,<65,M,1.41,0.0,0.7,5,95
12,Yukon,A04AA,Serotonin (5HT3) antagonists,<65,M,**, ** , ** ,*,96
12,Yukon,N07BA,Drugs used in nicotine dependence,<65,M,**, ** , ** ,*,97
12,Yukon,C01BD,"Antiarrhythmics, class III",<65,M,1.34,0.0,0.7,5,98
12,Yukon,N05BE,Azaspirodecanedione derivatives,<65,M,1.32,0.0,0.8,6,99
12,Yukon,M04AA,Preparations inhibiting uric acid production,<65,M,1.26,0.0,2.0,15,100
12,Yukon,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,**, ** , ** ,**,1
12,Yukon,R07AX,Other respiratory system products,<65,F,**, ** , ** ,*,2
12,Yukon,L04AA,Selective immunosuppressants,<65,F,**, ** , ** ,**,3
12,Yukon,N07XX,Other nervous system drugs,<65,F,**, ** , ** ,**,4
12,Yukon,J05AP,Antivirals for treatment of HCV infections,<65,F,**, ** , ** ,*,5
12,Yukon,B01AB,Heparin group,<65,F,63.19,2.6,1.8,14,6
12,Yukon,N03AX,Other antiepileptics,<65,F,52.72,2.1,12.2,97,7
12,Yukon,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,**, ** , ** ,*,8
12,Yukon,L03AB,Interferons,<65,F,**, ** , ** ,*,9
12,Yukon,N02AA,Natural opium alkaloids,<65,F,30.31,1.2,6.7,53,10
12,Yukon,N06AX,Other antidepressants,<65,F,27.39,1.1,16.6,132,11
12,Yukon,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,25.70,1.0,4.0,32,12
12,Yukon,N06AB,Selective serotonin reuptake inhibitors,<65,F,25.63,1.0,16.8,133,13
12,Yukon,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,**, ** , ** ,**,14
12,Yukon,L04AX,Other immunosuppressants,<65,F,22.76,0.9,1.3,10,15
12,Yukon,A10AE,"Insulins and analogues for injection, long-acting",<65,F,21.79,0.9,3.3,26,16
12,Yukon,R03BA,Glucocorticoids,<65,F,21.51,0.9,9.2,73,17
12,Yukon,N06BA,Centrally acting sympathomimetics,<65,F,21.13,0.9,3.0,24,18
12,Yukon,N05AX,Other antipsychotics,<65,F,21.00,0.9,1.4,11,19
12,Yukon,R05CB,Mucolytics,<65,F,**, ** , ** ,*,20
12,Yukon,C10AA,HMG-CoA reductase inhibitors,<65,F,19.46,0.8,15.2,121,21
12,Yukon,L01XE,Protein kinase inhibitors,<65,F,**, ** , ** ,*,22
12,Yukon,C09AA,"ACE inhibitors, plain",<65,F,16.90,0.7,14.2,113,23
12,Yukon,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,15.76,0.6,5.8,46,24
12,Yukon,L03AA,Colony-stimulating factors,<65,F,**, ** , ** ,**,25
12,Yukon,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,15.22,0.6,5.7,45,26
12,Yukon,L04AD,Calcineurin inhibitors,<65,F,**, ** , ** ,**,27
12,Yukon,R03BB,Anticholinergics,<65,F,14.69,0.6,5.3,42,28
12,Yukon,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,14.56,0.6,4.7,37,29
12,Yukon,L01BC,Pyrimidine analogues,<65,F,**, ** , ** ,*,30
12,Yukon,L04AC,Interleukin inhibitors,<65,F,**, ** , ** ,*,31
12,Yukon,H05AA,Parathyroid hormones and analogues,<65,F,**, ** , ** ,*,32
12,Yukon,N02AB,Phenylpiperidine derivatives,<65,F,**, ** , ** ,**,33
12,Yukon,L02BG,Aromatase inhibitors,<65,F,10.95,0.4,2.0,16,34
12,Yukon,A02BC,Proton pump inhibitors,<65,F,10.92,0.4,10.2,81,35
12,Yukon,A07EC,Aminosalicylic acid and similar agents,<65,F,10.38,0.4,2.9,23,36
12,Yukon,B03XA,Other antianemic preparations,<65,F,**, ** , ** ,*,37
12,Yukon,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,**, ** , ** ,*,38
12,Yukon,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,10.18,0.4,15.6,124,39
12,Yukon,L01XC,Monoclonal antibodies,<65,F,**, ** , ** ,*,40
12,Yukon,M05BX,Other drugs affecting bone structure and mineralization,<65,F,**, ** , ** ,*,41
12,Yukon,H03AA,Thyroid hormones,<65,F,9.12,0.4,15.9,126,42
12,Yukon,L01AX,Other alkylating agents,<65,F,**, ** , ** ,*,43
12,Yukon,N07BC,Drugs used in opioid dependence,<65,F,**, ** , ** ,*,44
12,Yukon,N03AE,Benzodiazepine derivatives,<65,F,8.81,0.4,5.5,44,45
12,Yukon,A10BA,Biguanides,<65,F,8.52,0.3,13.1,104,46
12,Yukon,J05AF,Nucleoside and nucleotide reverse transcriptase inhibitors,<65,F,**, ** , ** ,*,47
12,Yukon,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,8.43,0.3,4.9,39,48
12,Yukon,N03AF,Carboxamide derivatives,<65,F,7.54,0.3,0.9,7,49
12,Yukon,A09AA,Enzyme preparations,<65,F,7.00,0.3,0.9,7,50
12,Yukon,L03AX,Other immunostimulants,<65,F,**, ** , ** ,*,51
12,Yukon,C08CA,Dihydropyridine derivatives,<65,F,6.39,0.3,6.8,54,52
12,Yukon,C09CA,"Angiotensin II antagonists, plain",<65,F,6.23,0.3,6.8,54,53
12,Yukon,N05AE,Indole derivatives,<65,F,**, ** , ** ,*,54
12,Yukon,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,5.32,0.2,1.4,11,55
12,Yukon,C07AB,"Beta-blocking agents, selective",<65,F,4.86,0.2,6.0,48,56
12,Yukon,C02CA,Alpha-adrenoreceptor antagonists,<65,F,4.76,0.2,2.9,23,57
12,Yukon,G04BD,Drugs for urinary frequency and incontinence,<65,F,4.59,0.2,0.6,5,58
12,Yukon,N05AN,Lithium,<65,F,4.55,0.2,1.5,12,59
12,Yukon,C01DA,Organic nitrates,<65,F,4.48,0.2,2.0,16,60
12,Yukon,D11AH,"Agents for dermatitis, excluding corticosteroids",<65,F,**, ** , ** ,*,61
12,Yukon,L01BA,Folic acid analogues,<65,F,4.31,0.2,3.1,25,62
12,Yukon,R05DA,Opium alkaloids and derivatives,<65,F,3.94,0.2,2.0,16,63
12,Yukon,D07AC,"Corticosteroids, potent (group III)",<65,F,3.81,0.2,3.0,24,64
12,Yukon,A05AA,Bile acids and derivatives,<65,F,**, ** , ** ,*,65
12,Yukon,H02AB,Glucocorticoids,<65,F,3.61,0.1,9.1,72,66
12,Yukon,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,3.50,0.1,6.4,51,67
12,Yukon,R03DC,Leukotriene receptor antagonists,<65,F,3.47,0.1,2.3,18,68
12,Yukon,A10BB,Sulfonylureas,<65,F,3.32,0.1,4.3,34,69
12,Yukon,A11CC,Vitamin D and analogues,<65,F,3.20,0.1,2.1,17,70
12,Yukon,J05AE,Protease inhibitors,<65,F,**, ** , ** ,*,71
12,Yukon,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,2.89,0.1,2.0,16,72
12,Yukon,M03BX,Other centrally acting agents,<65,F,2.83,0.1,3.5,28,73
12,Yukon,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,2.57,0.1,1.9,15,74
12,Yukon,A07EA,Corticosteroids acting locally,<65,F,**, ** , ** ,*,75
12,Yukon,M01AB,Acetic acid derivatives and related substances,<65,F,2.32,0.1,3.8,30,76
12,Yukon,M05BA,Bisphosphonates,<65,F,2.27,0.1,1.9,15,77
12,Yukon,A04AD,Other antiemetics,<65,F,**, ** , ** ,**,78
12,Yukon,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,2.17,0.1,3.3,26,79
12,Yukon,C03AA,"Thiazides, plain",<65,F,2.13,0.1,7.4,59,80
12,Yukon,N03AG,Fatty acid derivatives,<65,F,2.08,0.1,1.0,8,81
12,Yukon,P01BA,Aminoquinolines,<65,F,1.96,0.1,2.1,17,82
12,Yukon,M01AE,Propionic acid derivatives,<65,F,1.95,0.1,5.7,45,83
12,Yukon,H01BA,Vasopressin and analogues,<65,F,**, ** , ** ,*,84
12,Yukon,A04AA,Serotonin (5HT3) antagonists,<65,F,**, ** , ** ,**,85
12,Yukon,C07AA,"Beta-blocking agents, non-selective",<65,F,1.62,0.1,1.6,13,86
12,Yukon,C08DB,Benzothiazepine derivatives,<65,F,1.61,0.1,0.9,7,87
12,Yukon,N05CF,Benzodiazepine-related drugs,<65,F,1.54,0.1,2.3,18,88
12,Yukon,C03CA,"Sulfonamides, plain",<65,F,1.49,0.1,2.8,22,89
12,Yukon,V03AF,Detoxifying agents for antineoplastic treatment,<65,F,**, ** , ** ,*,90
12,Yukon,C03DA,Aldosterone antagonists,<65,F,1.46,0.1,1.6,13,91
12,Yukon,C09BA,ACE inhibitors and diuretics,<65,F,1.44,0.1,1.1,9,92
12,Yukon,J02AC,Triazole derivatives,<65,F,1.42,0.1,1.1,9,93
12,Yukon,B01AA,Vitamin K antagonists,<65,F,1.34,0.1,1.5,12,94
12,Yukon,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",<65,F,**, ** , ** ,*,95
12,Yukon,L02AE,Gonadotropin-releasing hormone analogues,<65,F,**, ** , ** ,*,96
12,Yukon,B01AF,Direct factor Xa inhibitors,<65,F,1.23,0.0,0.6,5,97
12,Yukon,D05AX,Other antipsoriatics for topical use,<65,F,1.20,0.0,0.9,7,98
12,Yukon,N05BA,Benzodiazepine derivatives,<65,F,1.20,0.0,2.4,19,99
12,Yukon,N07AA,Anticholinesterases,<65,F,**, ** , ** ,*,100
13,FNIHB,J05AP,Antivirals for treatment of HCV infections,Total,Total,"56,316.22",9.1,0.2,"1,029",1
13,FNIHB,N07BC,Drugs used in opioid dependence,Total,Total,"30,340.90",4.9,2.2,"14,279",2
13,FNIHB,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,Total,"27,472.89",4.5,0.3,"1,813",3
13,FNIHB,N05AX,Other antipsychotics,Total,Total,"15,275.95",2.5,1.6,"10,092",4
13,FNIHB,N03AX,Other antiepileptics,Total,Total,"14,012.95",2.3,6.2,"39,596",5
13,FNIHB,A10AE,"Insulins and analogues for injection, long-acting",Total,Total,"13,644.27",2.2,3.1,"19,768",6
13,FNIHB,A02BC,Proton pump inhibitors,Total,Total,"13,246.10",2.1,16.4,"104,453",7
13,FNIHB,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,Total,"12,806.87",2.1,0.3,"1,857",8
13,FNIHB,C09AA,"ACE inhibitors, plain",Total,Total,"12,219.83",2.0,10.5,"66,834",9
13,FNIHB,C10AA,HMG-CoA reductase inhibitors,Total,Total,"11,795.76",1.9,11.6,"73,872",10
13,FNIHB,N02AJ,Opioids in combination with non-opioid analgesics,Total,Total,"10,910.29",1.8,17.5,"111,759",11
13,FNIHB,N06AB,Selective serotonin reuptake inhibitors,Total,Total,"9,968.36",1.6,9.8,"62,272",12
13,FNIHB,R03BA,Glucocorticoids,Total,Total,"8,816.71",1.4,7.6,"48,675",13
13,FNIHB,N06AX,Other antidepressants,Total,Total,"8,732.84",1.4,7.9,"50,381",14
13,FNIHB,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,Total,"8,608.96",1.4,3.9,"24,913",15
13,FNIHB,N06BA,Centrally acting sympathomimetics,Total,Total,"8,144.48",1.3,2.1,"13,614",16
13,FNIHB,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,Total,"7,893.72",1.3,1.7,"10,617",17
13,FNIHB,L04AA,Selective immunosuppressants,Total,Total,"7,016.25",1.1,0.3,"2,038",18
13,FNIHB,N02AA,Natural opium alkaloids,Total,Total,"6,874.03",1.1,4.0,"25,322",19
13,FNIHB,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,Total,"6,801.95",1.1,1.7,"10,861",20
13,FNIHB,A10BA,Biguanides,Total,Total,"6,372.91",1.0,9.5,"60,223",21
13,FNIHB,C08CA,Dihydropyridine derivatives,Total,Total,"6,185.57",1.0,5.2,"33,232",22
13,FNIHB,A10AB,"Insulins and analogues for injection, fast-acting",Total,Total,"6,003.37",1.0,2.1,"13,582",23
13,FNIHB,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,Total,"5,328.87",0.9,8.2,"52,258",24
13,FNIHB,M01AE,Propionic acid derivatives,Total,Total,"5,072.79",0.8,26.9,"171,528",25
13,FNIHB,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,Total,"4,954.18",0.8,1.2,"7,678",26
13,FNIHB,R03AC,Selective beta-2-adrenoreceptor agonists,Total,Total,"4,918.64",0.8,15.7,"100,165",27
13,FNIHB,A10BD,Combinations of oral blood glucose–lowering drugs,Total,Total,"4,221.73",0.7,0.9,"5,609",28
13,FNIHB,J05AE,Protease inhibitors,Total,Total,"4,182.73",0.7,0.1,661,29
13,FNIHB,J01CA,Penicillins with extended spectrum,Total,Total,"3,923.01",0.6,22.4,"142,740",30
13,FNIHB,N05BA,Benzodiazepine derivatives,Total,Total,"3,865.67",0.6,7.7,"49,053",31
13,FNIHB,N07BA,Drugs used in nicotine dependence,Total,Total,"3,842.46",0.6,3.5,"22,480",32
13,FNIHB,C07AB,"Beta-blocking agents, selective",Total,Total,"3,705.44",0.6,4.9,"31,370",33
13,FNIHB,A10BB,Sulfonylureas,Total,Total,"3,701.15",0.6,4.6,"29,026",34
13,FNIHB,S01LA,Antineovascularization agents,Total,Total,"3,506.32",0.6,0.1,484,35
13,FNIHB,J01DB,First-generation cephalosporins,Total,Total,"3,297.72",0.5,10.7,"68,475",36
13,FNIHB,A11CC,Vitamin D and analogues,Total,Total,"3,268.00",0.5,9.2,"58,317",37
13,FNIHB,B03XA,Other antianemic preparations,Total,Total,"3,159.97",0.5,0.2,988,38
13,FNIHB,C09CA,"Angiotensin II antagonists, plain",Total,Total,"3,109.57",0.5,3.2,"20,209",39
13,FNIHB,H03AA,Thyroid hormones,Total,Total,"3,105.95",0.5,4.8,"30,604",40
13,FNIHB,R06AE,Piperazine derivatives,Total,Total,"3,069.76",0.5,4.9,"31,350",41
13,FNIHB,G03AA,"Progestogens and estrogens, fixed combinations",Total,Total,"3,022.59",0.5,4.2,"26,817",42
13,FNIHB,L04AX,Other immunosuppressants,Total,Total,"2,948.61",0.5,0.2,"1,285",43
13,FNIHB,M03BX,Other centrally acting agents,Total,Total,"2,915.82",0.5,6.0,"38,334",44
13,FNIHB,G02BA,Intrauterine contraceptives,Total,Total,"2,871.07",0.5,1.3,"8,159",45
13,FNIHB,R03BB,Anticholinergics,Total,Total,"2,835.28",0.5,2.0,"13,043",46
13,FNIHB,L01XC,Monoclonal antibodies,Total,Total,"2,825.76",0.5,0.0,284,47
13,FNIHB,N02BE,Anilides,Total,Total,"2,779.75",0.5,20.7,"131,886",48
13,FNIHB,L04AC,Interleukin inhibitors,Total,Total,"2,583.21",0.4,0.0,234,49
13,FNIHB,A02BA,H2-receptor antagonists,Total,Total,"2,520.75",0.4,4.9,"30,929",50
13,FNIHB,A16AB,Enzymes,Total,Total,"2,519.38",0.4,0.0,5,51
13,FNIHB,C09BA,ACE inhibitors and diuretics,Total,Total,"2,495.66",0.4,1.5,"9,511",52
13,FNIHB,B03AA,"Iron bivalent, oral preparations",Total,Total,"2,461.08",0.4,7.3,"46,814",53
13,FNIHB,B01AF,Direct factor Xa inhibitors,Total,Total,"2,446.62",0.4,0.6,"4,020",54
13,FNIHB,N06AA,Non-selective monoamine reuptake inhibitors,Total,Total,"2,375.83",0.4,3.3,"21,141",55
13,FNIHB,L01XE,Protein kinase inhibitors,Total,Total,"2,340.68",0.4,0.0,108,56
13,FNIHB,D07AC,"Corticosteroids, potent (group III)",Total,Total,"2,254.43",0.4,7.9,"50,200",57
13,FNIHB,R01AD,Corticosteroids,Total,Total,"2,251.20",0.4,6.7,"42,550",58
13,FNIHB,J01FA,Macrolides,Total,Total,"2,206.24",0.4,10.5,"66,865",59
13,FNIHB,R06AA,Aminoalkyl ethers,Total,Total,"2,161.12",0.4,7.2,"45,662",60
13,FNIHB,L04AD,Calcineurin inhibitors,Total,Total,"2,159.11",0.3,0.1,682,61
13,FNIHB,J05AX,Other antivirals,Total,Total,"2,118.33",0.3,0.1,496,62
13,FNIHB,C01CA,Adrenergic and dopaminergic agents,Total,Total,"2,018.59",0.3,1.7,"10,647",63
13,FNIHB,D06AX,Other antibiotics for topical use,Total,Total,"1,993.86",0.3,9.0,"57,554",64
13,FNIHB,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,Total,"1,875.46",0.3,0.3,"1,770",65
13,FNIHB,M01AB,Acetic acid derivatives and related substances,Total,Total,"1,805.71",0.3,4.2,"26,482",66
13,FNIHB,G03AC,Progestogens,Total,Total,"1,796.90",0.3,3.0,"19,086",67
13,FNIHB,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,Total,"1,762.49",0.3,0.5,"3,258",68
13,FNIHB,P03AC,"Pyrethrins, including synthetic compounds",Total,Total,"1,750.85",0.3,5.6,"35,831",69
13,FNIHB,N03AE,Benzodiazepine derivatives,Total,Total,"1,750.40",0.3,2.1,"13,083",70
13,FNIHB,N05CD,Benzodiazepine derivatives,Total,Total,"1,708.53",0.3,2.0,"12,970",71
13,FNIHB,A04AA,Serotonin (5HT3) antagonists,Total,Total,"1,701.92",0.3,1.1,"6,706",72
13,FNIHB,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,Total,"1,672.00",0.3,2.5,"16,083",73
13,FNIHB,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,Total,"1,669.98",0.3,0.8,"4,849",74
13,FNIHB,A07EC,Aminosalicylic acid and similar agents,Total,Total,"1,656.09",0.3,0.5,"3,091",75
13,FNIHB,C03AA,"Thiazides, plain",Total,Total,"1,615.03",0.3,3.6,"22,728",76
13,FNIHB,B01AB,Heparin group,Total,Total,"1,512.64",0.2,0.3,"1,886",77
13,FNIHB,A12AA,Calcium,Total,Total,"1,452.80",0.2,4.1,"26,443",78
13,FNIHB,H02AB,Glucocorticoids,Total,Total,"1,421.59",0.2,7.1,"45,132",79
13,FNIHB,G03AB,"Progestogens and estrogens, sequential preparations",Total,Total,"1,369.55",0.2,1.4,"8,813",80
13,FNIHB,C03CA,"Sulfonamides, plain",Total,Total,"1,360.02",0.2,2.1,"13,411",81
13,FNIHB,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,Total,"1,331.45",0.2,6.2,"39,339",82
13,FNIHB,N02CC,Selective serotonin (5HT1) agonists,Total,Total,"1,323.97",0.2,1.1,"6,911",83
13,FNIHB,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,Total,"1,306.53",0.2,0.0,59,84
13,FNIHB,C09DA,Angiotensin II antagonists and diuretics,Total,Total,"1,296.45",0.2,1.2,"7,635",85
13,FNIHB,A06AD,Osmotically acting laxatives,Total,Total,"1,261.08",0.2,4.5,"28,788",86
13,FNIHB,G03CA,"Natural and semisynthetic estrogens, plain",Total,Total,"1,192.15",0.2,1.3,"8,332",87
13,FNIHB,N03AG,Fatty acid derivatives,Total,Total,"1,180.94",0.2,0.6,"3,561",88
13,FNIHB,L01BA,Folic acid analogues,Total,Total,"1,165.52",0.2,0.8,"5,038",89
13,FNIHB,J01MA,Fluoroquinolones,Total,Total,"1,164.30",0.2,5.8,"36,805",90
13,FNIHB,R06AX,Other antihistamines for systemic use,Total,Total,"1,142.45",0.2,2.3,"14,503",91
13,FNIHB,J02AC,Triazole derivatives,Total,Total,"1,128.91",0.2,2.8,"17,872",92
13,FNIHB,S02CA,Corticosteroids and antiinfectives in combination,Total,Total,"1,119.00",0.2,3.4,"21,664",93
13,FNIHB,G04BD,Drugs for urinary frequency and incontinence,Total,Total,"1,092.16",0.2,1.0,"6,282",94
13,FNIHB,G04CA,Alpha-adrenoreceptor antagonists,Total,Total,"1,050.47",0.2,1.4,"9,181",95
13,FNIHB,J01AA,Tetracyclines,Total,Total,"1,041.26",0.2,3.9,"25,097",96
13,FNIHB,C02AC,Imidazoline receptor agonists,Total,Total,"1,041.22",0.2,1.1,"6,949",97
13,FNIHB,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,Total,"1,039.81",0.2,0.1,797,98
13,FNIHB,J01FF,Lincosamides,Total,Total,"1,036.94",0.2,4.3,"27,512",99
13,FNIHB,M03AX,"Other muscle relaxants, peripherally acting agents",Total,Total,"1,031.10",0.2,0.1,525,100
13,FNIHB,J05AP,Antivirals for treatment of HCV infections,Total,M,"30,435.17",11.4,0.2,555,1
13,FNIHB,N07BC,Drugs used in opioid dependence,Total,M,"14,018.93",5.2,2.4,"6,479",2
13,FNIHB,N05AX,Other antipsychotics,Total,M,"10,052.42",3.8,2.1,"5,697",3
13,FNIHB,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,M,"9,585.25",3.6,0.2,596,4
13,FNIHB,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,M,"7,292.72",2.7,0.4,"1,000",5
13,FNIHB,C09AA,"ACE inhibitors, plain",Total,M,"6,058.51",2.3,12.3,"33,338",6
13,FNIHB,C10AA,HMG-CoA reductase inhibitors,Total,M,"5,943.14",2.2,13.8,"37,255",7
13,FNIHB,A10AE,"Insulins and analogues for injection, long-acting",Total,M,"5,905.49",2.2,3.1,"8,465",8
13,FNIHB,N03AX,Other antiepileptics,Total,M,"5,813.06",2.2,5.9,"15,797",9
13,FNIHB,N06BA,Centrally acting sympathomimetics,Total,M,"5,402.35",2.0,3.2,"8,731",10
13,FNIHB,A02BC,Proton pump inhibitors,Total,M,"5,094.98",1.9,15.1,"40,671",11
13,FNIHB,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,M,"4,845.36",1.8,4.1,"11,042",12
13,FNIHB,N02AJ,Opioids in combination with non-opioid analgesics,Total,M,"4,795.46",1.8,18.5,"49,924",13
13,FNIHB,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,M,"3,547.89",1.3,1.7,"4,718",14
13,FNIHB,R03BA,Glucocorticoids,Total,M,"3,466.86",1.3,7.1,"19,293",15
13,FNIHB,N06AB,Selective serotonin reuptake inhibitors,Total,M,"3,051.76",1.1,6.8,"18,466",16
13,FNIHB,A10BA,Biguanides,Total,M,"2,919.84",1.1,10.1,"27,228",17
13,FNIHB,N02AA,Natural opium alkaloids,Total,M,"2,909.41",1.1,3.8,"10,151",18
13,FNIHB,C08CA,Dihydropyridine derivatives,Total,M,"2,890.04",1.1,5.8,"15,531",19
13,FNIHB,N06AX,Other antidepressants,Total,M,"2,747.15",1.0,6.4,"17,150",20
13,FNIHB,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,M,"2,628.05",1.0,9.7,"26,177",21
13,FNIHB,A10AB,"Insulins and analogues for injection, fast-acting",Total,M,"2,549.76",1.0,2.0,"5,430",22
13,FNIHB,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,M,"2,546.96",1.0,1.5,"3,967",23
13,FNIHB,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,M,"2,273.18",0.9,1.3,"3,520",24
13,FNIHB,J05AE,Protease inhibitors,Total,M,"2,199.74",0.8,0.1,349,25
13,FNIHB,M01AE,Propionic acid derivatives,Total,M,"2,064.68",0.8,26.4,"71,312",26
13,FNIHB,L04AA,Selective immunosuppressants,Total,M,"2,039.60",0.8,0.2,529,27
13,FNIHB,A10BD,Combinations of oral blood glucose–lowering drugs,Total,M,"2,005.75",0.8,1.0,"2,675",28
13,FNIHB,R03AC,Selective beta-2-adrenoreceptor agonists,Total,M,"1,973.36",0.7,14.4,"38,966",29
13,FNIHB,C07AB,"Beta-blocking agents, selective",Total,M,"1,950.11",0.7,6.1,"16,517",30
13,FNIHB,A10BB,Sulfonylureas,Total,M,"1,763.19",0.7,5.1,"13,868",31
13,FNIHB,S01LA,Antineovascularization agents,Total,M,"1,748.29",0.7,0.1,240,32
13,FNIHB,N07BA,Drugs used in nicotine dependence,Total,M,"1,645.24",0.6,3.5,"9,413",33
13,FNIHB,L01XE,Protein kinase inhibitors,Total,M,"1,582.76",0.6,0.0,69,34
13,FNIHB,J01CA,Penicillins with extended spectrum,Total,M,"1,564.58",0.6,21.1,"57,040",35
13,FNIHB,J01DB,First-generation cephalosporins,Total,M,"1,468.84",0.5,11.1,"29,911",36
13,FNIHB,N05BA,Benzodiazepine derivatives,Total,M,"1,437.25",0.5,6.2,"16,775",37
13,FNIHB,B03XA,Other antianemic preparations,Total,M,"1,365.70",0.5,0.2,425,38
13,FNIHB,L04AX,Other immunosuppressants,Total,M,"1,352.50",0.5,0.1,374,39
13,FNIHB,B01AF,Direct factor Xa inhibitors,Total,M,"1,350.56",0.5,0.8,"2,075",40
13,FNIHB,C09BA,ACE inhibitors and diuretics,Total,M,"1,283.83",0.5,1.8,"4,803",41
13,FNIHB,A16AB,Enzymes,Total,M,**,**,**,*,42
13,FNIHB,C09CA,"Angiotensin II antagonists, plain",Total,M,"1,239.65",0.5,3.0,"8,129",43
13,FNIHB,M03BX,Other centrally acting agents,Total,M,"1,210.94",0.5,5.8,"15,554",44
13,FNIHB,R03BB,Anticholinergics,Total,M,"1,198.81",0.4,1.9,"5,196",45
13,FNIHB,J05AX,Other antivirals,Total,M,"1,122.09",0.4,0.1,255,46
13,FNIHB,L04AD,Calcineurin inhibitors,Total,M,"1,047.07",0.4,0.1,332,47
13,FNIHB,N02BE,Anilides,Total,M,"1,030.17",0.4,18.8,"50,706",48
13,FNIHB,G04CA,Alpha-adrenoreceptor antagonists,Total,M,975.07,0.4,3.0,"8,152",49
13,FNIHB,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,M,969.08,0.4,0.3,936,50
13,FNIHB,D07AC,"Corticosteroids, potent (group III)",Total,M,960.83,0.4,7.3,"19,667",51
13,FNIHB,A11CC,Vitamin D and analogues,Total,M,960.41,0.4,5.4,"14,715",52
13,FNIHB,A02BA,H2-receptor antagonists,Total,M,918.58,0.3,3.8,"10,382",53
13,FNIHB,R06AE,Piperazine derivatives,Total,M,896.05,0.3,3.7,"9,857",54
13,FNIHB,C01CA,Adrenergic and dopaminergic agents,Total,M,878.36,0.3,1.6,"4,265",55
13,FNIHB,D06AX,Other antibiotics for topical use,Total,M,874.69,0.3,9.2,"24,807",56
13,FNIHB,M01AB,Acetic acid derivatives and related substances,Total,M,834.16,0.3,4.4,"11,896",57
13,FNIHB,J01FA,Macrolides,Total,M,826.17,0.3,9.2,"24,825",58
13,FNIHB,R01AD,Corticosteroids,Total,M,799.06,0.3,5.3,"14,435",59
13,FNIHB,N06AA,Non-selective monoamine reuptake inhibitors,Total,M,798.24,0.3,2.6,"6,985",60
13,FNIHB,N05CD,Benzodiazepine derivatives,Total,M,758.07,0.3,2.1,"5,629",61
13,FNIHB,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,M,731.97,0.3,0.5,"1,352",62
13,FNIHB,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,M,696.07,0.3,0.7,"1,837",63
13,FNIHB,N03AE,Benzodiazepine derivatives,Total,M,691.50,0.3,1.7,"4,619",64
13,FNIHB,H03AA,Thyroid hormones,Total,M,688.01,0.3,2.4,"6,387",65
13,FNIHB,N03AG,Fatty acid derivatives,Total,M,680.22,0.3,0.7,"1,910",66
13,FNIHB,C03AA,"Thiazides, plain",Total,M,679.14,0.3,3.5,"9,404",67
13,FNIHB,A07EC,Aminosalicylic acid and similar agents,Total,M,654.28,0.2,0.4,"1,053",68
13,FNIHB,L04AC,Interleukin inhibitors,Total,M,654.04,0.2,0.0,60,69
13,FNIHB,P03AC,"Pyrethrins, including synthetic compounds",Total,M,599.89,0.2,4.7,"12,658",70
13,FNIHB,C03CA,"Sulfonamides, plain",Total,M,595.63,0.2,2.1,"5,718",71
13,FNIHB,B01AB,Heparin group,Total,M,591.55,0.2,0.3,697,72
13,FNIHB,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,M,587.55,0.2,1.9,"5,042",73
13,FNIHB,B03AA,"Iron bivalent, oral preparations",Total,M,568.71,0.2,3.1,"8,321",74
13,FNIHB,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,M,564.59,0.2,6.0,"16,113",75
13,FNIHB,C09DA,Angiotensin II antagonists and diuretics,Total,M,555.74,0.2,1.2,"3,318",76
13,FNIHB,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",Total,M,552.18,0.2,0.1,400,77
13,FNIHB,D05AX,Other antipsoriatics for topical use,Total,M,523.18,0.2,0.6,"1,668",78
13,FNIHB,H02AB,Glucocorticoids,Total,M,505.82,0.2,6.3,"17,096",79
13,FNIHB,C02AC,Imidazoline receptor agonists,Total,M,475.13,0.2,1.1,"2,886",80
13,FNIHB,A06AD,Osmotically acting laxatives,Total,M,474.20,0.2,3.7,"9,967",81
13,FNIHB,A04AA,Serotonin (5HT3) antagonists,Total,M,469.90,0.2,0.8,"2,073",82
13,FNIHB,J01FF,Lincosamides,Total,M,467.15,0.2,4.3,"11,632",83
13,FNIHB,J01AA,Tetracyclines,Total,M,453.92,0.2,3.6,"9,667",84
13,FNIHB,N03AF,Carboxamide derivatives,Total,M,449.52,0.2,0.5,"1,334",85
13,FNIHB,S02CA,Corticosteroids and antiinfectives in combination,Total,M,441.17,0.2,3.1,"8,348",86
13,FNIHB,N03AB,Hydantoin derivatives,Total,M,432.65,0.2,0.8,"2,084",87
13,FNIHB,M03AX,"Other muscle relaxants, peripherally acting agents",Total,M,422.33,0.2,0.1,188,88
13,FNIHB,L02AE,Gonadotropin-releasing hormone analogues,Total,M,414.67,0.2,0.1,214,89
13,FNIHB,L01XC,Monoclonal antibodies,Total,M,404.13,0.2,0.0,60,90
13,FNIHB,J02AC,Triazole derivatives,Total,M,385.83,0.1,0.6,"1,615",91
13,FNIHB,C08DB,Benzothiazepine derivatives,Total,M,381.79,0.1,0.6,"1,618",92
13,FNIHB,C10AB,Fibrates,Total,M,378.03,0.1,0.6,"1,651",93
13,FNIHB,J01MA,Fluoroquinolones,Total,M,373.57,0.1,4.0,"10,814",94
13,FNIHB,G04CB,Testosterone-5-alpha reductase inhibitors,Total,M,354.14,0.1,0.7,"1,864",95
13,FNIHB,R05DA,Opium alkaloids and derivatives,Total,M,350.58,0.1,0.6,"1,695",96
13,FNIHB,D07AA,"Corticosteroids, weak (group I)",Total,M,350.07,0.1,4.6,"12,423",97
13,FNIHB,A12AA,Calcium,Total,M,339.91,0.1,2.1,"5,654",98
13,FNIHB,R06AX,Other antihistamines for systemic use,Total,M,336.31,0.1,1.8,"4,813",99
13,FNIHB,C07AG,Alpha- and beta-blocking agents,Total,M,335.23,0.1,0.4,"1,142",100
13,FNIHB,J05AP,Antivirals for treatment of HCV infections,Total,F,"25,881.04",7.4,0.1,474,1
13,FNIHB,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,Total,F,"17,887.64",5.1,0.3,"1,217",2
13,FNIHB,N07BC,Drugs used in opioid dependence,Total,F,"16,321.97",4.7,2.2,"7,800",3
13,FNIHB,N03AX,Other antiepileptics,Total,F,"8,197.67",2.4,6.7,"23,775",4
13,FNIHB,A02BC,Proton pump inhibitors,Total,F,"8,136.27",2.3,18.0,"63,640",5
13,FNIHB,A10AE,"Insulins and analogues for injection, long-acting",Total,F,"7,738.78",2.2,3.2,"11,303",6
13,FNIHB,N06AB,Selective serotonin reuptake inhibitors,Total,F,"6,916.60",2.0,12.4,"43,806",7
13,FNIHB,C09AA,"ACE inhibitors, plain",Total,F,"6,160.81",1.8,9.5,"33,489",8
13,FNIHB,N02AJ,Opioids in combination with non-opioid analgesics,Total,F,"6,114.84",1.8,17.5,"61,835",9
13,FNIHB,N06AX,Other antidepressants,Total,F,"5,985.69",1.7,9.4,"33,231",10
13,FNIHB,C10AA,HMG-CoA reductase inhibitors,Total,F,"5,852.62",1.7,10.4,"36,617",11
13,FNIHB,J05AR,"Antivirals for treatment of HIV infections, combinations",Total,F,"5,514.15",1.6,0.2,857,12
13,FNIHB,R03BA,Glucocorticoids,Total,F,"5,297.88",1.5,8.1,"28,513",13
13,FNIHB,N05AX,Other antipsychotics,Total,F,"5,223.53",1.5,1.2,"4,395",14
13,FNIHB,L04AA,Selective immunosuppressants,Total,F,"4,976.65",1.4,0.4,"1,509",15
13,FNIHB,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,Total,F,"4,345.83",1.2,1.7,"5,899",16
13,FNIHB,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",Total,F,"4,254.99",1.2,2.0,"6,894",17
13,FNIHB,N02AA,Natural opium alkaloids,Total,F,"3,963.70",1.1,4.3,"15,128",18
13,FNIHB,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",Total,F,"3,763.59",1.1,3.9,"13,871",19
13,FNIHB,A10AB,"Insulins and analogues for injection, fast-acting",Total,F,"3,453.60",1.0,2.3,"8,152",20
13,FNIHB,A10BA,Biguanides,Total,F,"3,453.07",1.0,9.3,"32,995",21
13,FNIHB,C08CA,Dihydropyridine derivatives,Total,F,"3,295.20",0.9,5.0,"17,696",22
13,FNIHB,G03AA,"Progestogens and estrogens, fixed combinations",Total,F,"3,019.77",0.9,7.6,"26,793",23
13,FNIHB,M01AE,Propionic acid derivatives,Total,F,"2,976.95",0.9,27.9,"98,494",24
13,FNIHB,R03AC,Selective beta-2-adrenoreceptor agonists,Total,F,"2,895.89",0.8,16.7,"59,103",25
13,FNIHB,G02BA,Intrauterine contraceptives,Total,F,"2,871.07",0.8,2.3,"8,159",26
13,FNIHB,N06BA,Centrally acting sympathomimetics,Total,F,"2,742.13",0.8,1.4,"4,883",27
13,FNIHB,B01AC,"Platelet aggregation inhibitors, excluding heparin",Total,F,"2,700.77",0.8,7.4,"26,077",28
13,FNIHB,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,Total,F,"2,681.00",0.8,1.2,"4,158",29
13,FNIHB,N05BA,Benzodiazepine derivatives,Total,F,"2,427.91",0.7,9.1,"32,260",30
13,FNIHB,L01XC,Monoclonal antibodies,Total,F,"2,421.63",0.7,0.1,224,31
13,FNIHB,H03AA,Thyroid hormones,Total,F,"2,417.05",0.7,6.8,"24,196",32
13,FNIHB,J01CA,Penicillins with extended spectrum,Total,F,"2,253.54",0.6,23.1,"81,471",33
13,FNIHB,A11CC,Vitamin D and analogues,Total,F,"2,225.84",0.6,11.3,"39,980",34
13,FNIHB,A10BD,Combinations of oral blood glucose–lowering drugs,Total,F,"2,215.98",0.6,0.8,"2,934",35
13,FNIHB,N07BA,Drugs used in nicotine dependence,Total,F,"2,197.22",0.6,3.7,"13,067",36
13,FNIHB,R06AE,Piperazine derivatives,Total,F,"2,172.90",0.6,6.1,"21,441",37
13,FNIHB,J05AE,Protease inhibitors,Total,F,"1,982.99",0.6,0.1,312,38
13,FNIHB,A10BB,Sulfonylureas,Total,F,"1,937.96",0.6,4.3,"15,158",39
13,FNIHB,L04AC,Interleukin inhibitors,Total,F,"1,929.16",0.6,0.0,174,40
13,FNIHB,B03AA,"Iron bivalent, oral preparations",Total,F,"1,883.28",0.5,10.8,"38,164",41
13,FNIHB,R06AA,Aminoalkyl ethers,Total,F,"1,882.79",0.5,9.1,"32,099",42
13,FNIHB,C09CA,"Angiotensin II antagonists, plain",Total,F,"1,869.92",0.5,3.4,"12,080",43
13,FNIHB,B03XA,Other antianemic preparations,Total,F,"1,794.27",0.5,0.2,563,44
13,FNIHB,G03AC,Progestogens,Total,F,"1,775.10",0.5,5.4,"19,033",45
13,FNIHB,J01DB,First-generation cephalosporins,Total,F,"1,759.88",0.5,10.6,"37,546",46
13,FNIHB,S01LA,Antineovascularization agents,Total,F,"1,758.02",0.5,0.1,244,47
13,FNIHB,C07AB,"Beta-blocking agents, selective",Total,F,"1,755.33",0.5,4.2,"14,853",48
13,FNIHB,M03BX,Other centrally acting agents,Total,F,"1,704.88",0.5,6.4,"22,780",49
13,FNIHB,R03BB,Anticholinergics,Total,F,"1,635.34",0.5,2.2,"7,817",50
13,FNIHB,N02BE,Anilides,Total,F,"1,631.32",0.5,21.6,"76,183",51
13,FNIHB,L04AX,Other immunosuppressants,Total,F,"1,596.11",0.5,0.3,911,52
13,FNIHB,A02BA,H2-receptor antagonists,Total,F,"1,593.60",0.5,5.7,"20,289",53
13,FNIHB,N06AA,Non-selective monoamine reuptake inhibitors,Total,F,"1,577.59",0.5,4.0,"14,156",54
13,FNIHB,R01AD,Corticosteroids,Total,F,"1,451.75",0.4,8.0,"28,104",55
13,FNIHB,G03AB,"Progestogens and estrogens, sequential preparations",Total,F,"1,368.46",0.4,2.5,"8,806",56
13,FNIHB,J01FA,Macrolides,Total,F,"1,352.03",0.4,11.6,"40,945",57
13,FNIHB,D07AC,"Corticosteroids, potent (group III)",Total,F,"1,277.12",0.4,8.5,"30,012",58
13,FNIHB,A16AB,Enzymes,Total,F,**,**,**,*,59
13,FNIHB,A04AA,Serotonin (5HT3) antagonists,Total,F,"1,228.53",0.4,1.3,"4,565",60
13,FNIHB,C09BA,ACE inhibitors and diuretics,Total,F,"1,211.83",0.3,1.3,"4,708",61
13,FNIHB,G03CA,"Natural and semisynthetic estrogens, plain",Total,F,"1,142.72",0.3,2.3,"8,127",62
13,FNIHB,P03AC,"Pyrethrins, including synthetic compounds",Total,F,"1,136.90",0.3,6.5,"22,839",63
13,FNIHB,C01CA,Adrenergic and dopaminergic agents,Total,F,"1,134.48",0.3,1.8,"6,346",64
13,FNIHB,A12AA,Calcium,Total,F,"1,112.66",0.3,5.9,"20,783",65
13,FNIHB,L04AD,Calcineurin inhibitors,Total,F,"1,112.04",0.3,0.1,350,66
13,FNIHB,B01AF,Direct factor Xa inhibitors,Total,F,"1,096.06",0.3,0.6,"1,945",67
13,FNIHB,N02CC,Selective serotonin (5HT1) agonists,Total,F,"1,086.65",0.3,1.6,"5,701",68
13,FNIHB,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",Total,F,"1,074.59",0.3,3.1,"10,986",69
13,FNIHB,C02KX,Antihypertensives for pulmonary arterial hypertension,Total,F,"1,066.38",0.3,0.0,47,70
13,FNIHB,D06AX,Other antibiotics for topical use,Total,F,"1,060.66",0.3,8.8,"31,080",71
13,FNIHB,N03AE,Benzodiazepine derivatives,Total,F,"1,058.34",0.3,2.4,"8,461",72
13,FNIHB,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",Total,F,"1,030.52",0.3,0.5,"1,906",73
13,FNIHB,A07EC,Aminosalicylic acid and similar agents,Total,F,"1,001.82",0.3,0.6,"2,038",74
13,FNIHB,J05AX,Other antivirals,Total,F,996.25,0.3,0.1,241,75
13,FNIHB,A10AC,"Insulins and analogues for injection, intermediate-acting",Total,F,973.91,0.3,0.9,"3,012",76
13,FNIHB,M01AB,Acetic acid derivatives and related substances,Total,F,971.55,0.3,4.1,"14,586",77
13,FNIHB,N05CD,Benzodiazepine derivatives,Total,F,950.45,0.3,2.1,"7,340",78
13,FNIHB,C03AA,"Thiazides, plain",Total,F,935.56,0.3,3.8,"13,313",79
13,FNIHB,B01AB,Heparin group,Total,F,913.14,0.3,0.3,"1,169",80
13,FNIHB,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,Total,F,906.26,0.3,0.2,831,81
13,FNIHB,H02AB,Glucocorticoids,Total,F,903.79,0.3,7.8,"27,444",82
13,FNIHB,L01BA,Folic acid analogues,Total,F,874.29,0.3,1.1,"3,763",83
13,FNIHB,G04BD,Drugs for urinary frequency and incontinence,Total,F,868.80,0.2,1.4,"4,992",84
13,FNIHB,J01XE,Nitrofuran derivatives,Total,F,840.82,0.2,7.7,"27,317",85
13,FNIHB,L03AA,Colony-stimulating factors,Total,F,811.21,0.2,0.0,153,86
13,FNIHB,R06AX,Other antihistamines for systemic use,Total,F,805.17,0.2,2.7,"9,622",87
13,FNIHB,J01MA,Fluoroquinolones,Total,F,790.42,0.2,7.4,"25,987",88
13,FNIHB,A06AD,Osmotically acting laxatives,Total,F,782.38,0.2,5.2,"18,540",89
13,FNIHB,C03CA,"Sulfonamides, plain",Total,F,762.01,0.2,2.2,"7,637",90
13,FNIHB,L01XE,Protein kinase inhibitors,Total,F,757.92,0.2,0.0,39,91
13,FNIHB,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",Total,F,749.62,0.2,6.4,"22,766",92
13,FNIHB,C09DA,Angiotensin II antagonists and diuretics,Total,F,740.71,0.2,1.2,"4,317",93
13,FNIHB,J02AC,Triazole derivatives,Total,F,738.25,0.2,4.6,"16,198",94
13,FNIHB,M05BA,Bisphosphonates,Total,F,714.77,0.2,1.4,"4,775",95
13,FNIHB,S02CA,Corticosteroids and antiinfectives in combination,Total,F,653.23,0.2,3.6,"12,847",96
13,FNIHB,M03AX,"Other muscle relaxants, peripherally acting agents",Total,F,608.77,0.2,0.1,337,97
13,FNIHB,P01BA,Aminoquinolines,Total,F,601.69,0.2,1.2,"4,136",98
13,FNIHB,J01AA,Tetracyclines,Total,F,587.34,0.2,4.4,"15,430",99
13,FNIHB,C02AC,Imidazoline receptor agonists,Total,F,566.03,0.2,1.1,"4,062",100
13,FNIHB,C10AA,HMG-CoA reductase inhibitors,65+,Total,"4,488.49",4.1,48.8,"27,426",1
13,FNIHB,C09AA,"ACE inhibitors, plain",65+,Total,"3,841.86",3.5,37.1,"20,866",2
13,FNIHB,A02BC,Proton pump inhibitors,65+,Total,"3,808.28",3.5,41.7,"23,414",3
13,FNIHB,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,Total,"3,038.64",2.8,0.4,214,4
13,FNIHB,A10AE,"Insulins and analogues for injection, long-acting",65+,Total,"2,866.22",2.6,9.1,"5,133",5
13,FNIHB,C08CA,Dihydropyridine derivatives,65+,Total,"2,539.94",2.3,24.1,"13,516",6
13,FNIHB,J05AP,Antivirals for treatment of HCV infections,65+,Total,"2,506.61",2.3,0.1,48,7
13,FNIHB,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,Total,"2,245.75",2.1,39.8,"22,379",8
13,FNIHB,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,Total,"2,022.88",1.8,5.8,"3,242",9
13,FNIHB,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,Total,"1,895.91",1.7,5.5,"3,078",10
13,FNIHB,A10BA,Biguanides,65+,Total,"1,854.49",1.7,28.0,"15,751",11
13,FNIHB,C07AB,"Beta-blocking agents, selective",65+,Total,"1,771.46",1.6,25.2,"14,170",12
13,FNIHB,N03AX,Other antiepileptics,65+,Total,"1,630.63",1.5,11.4,"6,391",13
13,FNIHB,B01AF,Direct factor Xa inhibitors,65+,Total,"1,409.49",1.3,3.8,"2,113",14
13,FNIHB,N02AJ,Opioids in combination with non-opioid analgesics,65+,Total,"1,407.49",1.3,21.9,"12,300",15
13,FNIHB,R03BB,Anticholinergics,65+,Total,"1,315.98",1.2,10.1,"5,646",16
13,FNIHB,R03BA,Glucocorticoids,65+,Total,"1,270.32",1.2,9.9,"5,562",17
13,FNIHB,L04AX,Other immunosuppressants,65+,Total,"1,237.40",1.1,0.5,253,18
13,FNIHB,C09CA,"Angiotensin II antagonists, plain",65+,Total,"1,215.84",1.1,14.0,"7,884",19
13,FNIHB,A11CC,Vitamin D and analogues,65+,Total,"1,157.98",1.1,27.6,"15,515",20
13,FNIHB,N06AX,Other antidepressants,65+,Total,"1,152.36",1.1,11.1,"6,246",21
13,FNIHB,H03AA,Thyroid hormones,65+,Total,"1,143.57",1.0,18.1,"10,161",22
13,FNIHB,N06AB,Selective serotonin reuptake inhibitors,65+,Total,"1,138.36",1.0,10.7,"6,002",23
13,FNIHB,S01LA,Antineovascularization agents,65+,Total,"1,077.68",1.0,0.3,182,24
13,FNIHB,A10AB,"Insulins and analogues for injection, fast-acting",65+,Total,"1,075.21",1.0,5.5,"3,096",25
13,FNIHB,N02AA,Natural opium alkaloids,65+,Total,"1,032.33",0.9,8.1,"4,576",26
13,FNIHB,A10BB,Sulfonylureas,65+,Total,"1,020.13",0.9,13.5,"7,578",27
13,FNIHB,A10BD,Combinations of oral blood glucose–lowering drugs,65+,Total,961.92,0.9,2.6,"1,479",28
13,FNIHB,R03AC,Selective beta-2-adrenoreceptor agonists,65+,Total,885.02,0.8,23.8,"13,393",29
13,FNIHB,B03XA,Other antianemic preparations,65+,Total,884.71,0.8,0.6,311,30
13,FNIHB,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,Total,870.12,0.8,2.9,"1,602",31
13,FNIHB,L04AA,Selective immunosuppressants,65+,Total,866.13,0.8,0.6,359,32
13,FNIHB,L01XE,Protein kinase inhibitors,65+,Total,806.77,0.7,0.1,37,33
13,FNIHB,C03CA,"Sulfonamides, plain",65+,Total,744.37,0.7,12.3,"6,900",34
13,FNIHB,B03AA,"Iron bivalent, oral preparations",65+,Total,688.34,0.6,14.4,"8,072",35
13,FNIHB,G04CA,Alpha-adrenoreceptor antagonists,65+,Total,658.43,0.6,8.8,"4,931",36
13,FNIHB,A12AA,Calcium,65+,Total,624.13,0.6,16.4,"9,188",37
13,FNIHB,C03AA,"Thiazides, plain",65+,Total,619.89,0.6,14.2,"7,974",38
13,FNIHB,C09BA,ACE inhibitors and diuretics,65+,Total,616.80,0.6,4.5,"2,503",39
13,FNIHB,N02BE,Anilides,65+,Total,576.67,0.5,26.5,"14,905",40
13,FNIHB,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,Total,567.70,0.5,1.9,"1,089",41
13,FNIHB,N05BA,Benzodiazepine derivatives,65+,Total,556.65,0.5,11.6,"6,489",42
13,FNIHB,A02BA,H2-receptor antagonists,65+,Total,533.17,0.5,8.4,"4,717",43
13,FNIHB,M05BA,Bisphosphonates,65+,Total,520.04,0.5,6.1,"3,421",44
13,FNIHB,N06AA,Non-selective monoamine reuptake inhibitors,65+,Total,481.57,0.4,6.4,"3,618",45
13,FNIHB,R06AE,Piperazine derivatives,65+,Total,473.24,0.4,6.3,"3,532",46
13,FNIHB,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,Total,446.41,0.4,3.5,"1,974",47
13,FNIHB,C09DA,Angiotensin II antagonists and diuretics,65+,Total,442.78,0.4,4.7,"2,650",48
13,FNIHB,S01EE,Prostaglandin analogues,65+,Total,429.91,0.4,4.1,"2,316",49
13,FNIHB,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,Total,427.14,0.4,2.1,"1,187",50
13,FNIHB,C01DA,Organic nitrates,65+,Total,400.85,0.4,7.8,"4,387",51
13,FNIHB,C08DB,Benzothiazepine derivatives,65+,Total,389.68,0.4,3.1,"1,749",52
13,FNIHB,B01AB,Heparin group,65+,Total,387.31,0.4,1.0,585,53
13,FNIHB,R01AD,Corticosteroids,65+,Total,379.95,0.3,9.8,"5,499",54
13,FNIHB,G04BD,Drugs for urinary frequency and incontinence,65+,Total,379.90,0.3,3.5,"1,948",55
13,FNIHB,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,Total,368.56,0.3,1.0,536,56
13,FNIHB,N05AX,Other antipsychotics,65+,Total,361.84,0.3,1.2,694,57
13,FNIHB,S01ED,Beta-blocking agents,65+,Total,358.68,0.3,3.2,"1,792",58
13,FNIHB,L01XC,Monoclonal antibodies,65+,Total,351.51,0.3,0.1,46,59
13,FNIHB,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,Total,311.87,0.3,10.0,"5,590",60
13,FNIHB,A06AD,Osmotically acting laxatives,65+,Total,309.79,0.3,11.1,"6,214",61
13,FNIHB,M01AE,Propionic acid derivatives,65+,Total,306.98,0.3,14.4,"8,072",62
13,FNIHB,H02AB,Glucocorticoids,65+,Total,306.62,0.3,14.2,"7,951",63
13,FNIHB,N07BA,Drugs used in nicotine dependence,65+,Total,306.03,0.3,3.2,"1,773",64
13,FNIHB,A06AB,Contact laxatives,65+,Total,295.54,0.3,11.3,"6,350",65
13,FNIHB,D07AC,"Corticosteroids, potent (group III)",65+,Total,288.40,0.3,11.2,"6,313",66
13,FNIHB,A12BA,Potassium,65+,Total,285.53,0.3,4.4,"2,494",67
13,FNIHB,M01AB,Acetic acid derivatives and related substances,65+,Total,283.98,0.3,5.5,"3,095",68
13,FNIHB,N04BA,Dopa and dopa derivatives,65+,Total,278.17,0.3,1.3,734,69
13,FNIHB,G03CA,"Natural and semisynthetic estrogens, plain",65+,Total,275.39,0.3,3.8,"2,145",70
13,FNIHB,G04CB,Testosterone-5-alpha reductase inhibitors,65+,Total,272.91,0.2,2.5,"1,399",71
13,FNIHB,A07EC,Aminosalicylic acid and similar agents,65+,Total,269.21,0.2,0.9,527,72
13,FNIHB,B01AA,Vitamin K antagonists,65+,Total,268.38,0.2,3.2,"1,806",73
13,FNIHB,L04AC,Interleukin inhibitors,65+,Total,267.05,0.2,0.0,24,74
13,FNIHB,A04AA,Serotonin (5HT3) antagonists,65+,Total,266.48,0.2,1.5,848,75
13,FNIHB,J01MA,Fluoroquinolones,65+,Total,262.69,0.2,14.6,"8,216",76
13,FNIHB,L01BA,Folic acid analogues,65+,Total,248.05,0.2,1.8,"1,035",77
13,FNIHB,M03BX,Other centrally acting agents,65+,Total,242.32,0.2,5.9,"3,292",78
13,FNIHB,L02BB,Antiandrogens,65+,Total,240.16,0.2,0.2,121,79
13,FNIHB,N05CD,Benzodiazepine derivatives,65+,Total,232.91,0.2,3.3,"1,844",80
13,FNIHB,L03AA,Colony-stimulating factors,65+,Total,229.63,0.2,0.1,50,81
13,FNIHB,J01FA,Macrolides,65+,Total,228.77,0.2,12.0,"6,732",82
13,FNIHB,L04AD,Calcineurin inhibitors,65+,Total,224.46,0.2,0.2,100,83
13,FNIHB,C10AX,Other lipid-modifying agents,65+,Total,221.68,0.2,2.4,"1,360",84
13,FNIHB,C07AG,Alpha- and beta-blocking agents,65+,Total,218.32,0.2,1.4,784,85
13,FNIHB,N07BC,Drugs used in opioid dependence,65+,Total,209.46,0.2,0.2,123,86
13,FNIHB,L02BX,Other hormone antagonists and related agents,65+,Total,206.61,0.2,0.0,18,87
13,FNIHB,L02AE,Gonadotropin-releasing hormone analogues,65+,Total,200.71,0.2,0.3,145,88
13,FNIHB,B01AE,Direct thrombin inhibitors,65+,Total,198.40,0.2,0.4,240,89
13,FNIHB,R06AX,Other antihistamines for systemic use,65+,Total,192.80,0.2,2.8,"1,583",90
13,FNIHB,J01CA,Penicillins with extended spectrum,65+,Total,187.38,0.2,13.7,"7,671",91
13,FNIHB,C10AB,Fibrates,65+,Total,182.09,0.2,1.4,811,92
13,FNIHB,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,Total,179.08,0.2,1.2,693,93
13,FNIHB,A12CC,Magnesium,65+,Total,172.33,0.2,3.6,"2,032",94
13,FNIHB,J01XE,Nitrofuran derivatives,65+,Total,169.98,0.2,7.8,"4,366",95
13,FNIHB,A03FA,Propulsives,65+,Total,169.56,0.2,4.1,"2,292",96
13,FNIHB,C03DA,Aldosterone antagonists,65+,Total,168.40,0.2,3.0,"1,661",97
13,FNIHB,S01XA,Other ophthalmologicals,65+,Total,164.68,0.2,5.4,"3,051",98
13,FNIHB,N03AE,Benzodiazepine derivatives,65+,Total,163.91,0.1,2.5,"1,420",99
13,FNIHB,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,Total,161.15,0.1,2.7,"1,505",100
13,FNIHB,C10AA,HMG-CoA reductase inhibitors,65+,M,"2,100.06",4.7,55.5,"12,841",1
13,FNIHB,C09AA,"ACE inhibitors, plain",65+,M,"1,731.05",3.8,41.5,"9,603",2
13,FNIHB,J05AP,Antivirals for treatment of HCV infections,65+,M,"1,559.51",3.5,0.1,30,3
13,FNIHB,A02BC,Proton pump inhibitors,65+,M,"1,397.35",3.1,37.7,"8,730",4
13,FNIHB,A10AE,"Insulins and analogues for injection, long-acting",65+,M,"1,288.07",2.9,9.7,"2,239",5
13,FNIHB,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,M,"1,060.98",2.4,45.2,"10,464",6
13,FNIHB,C08CA,Dihydropyridine derivatives,65+,M,"1,012.66",2.2,23.4,"5,418",7
13,FNIHB,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,M,910.33,2.0,6.2,"1,424",8
13,FNIHB,C07AB,"Beta-blocking agents, selective",65+,M,843.64,1.9,29.5,"6,818",9
13,FNIHB,A10BA,Biguanides,65+,M,830.41,1.8,30.7,"7,112",10
13,FNIHB,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,M,829.12,1.8,0.3,61,11
13,FNIHB,B01AF,Direct factor Xa inhibitors,65+,M,716.11,1.6,4.4,"1,022",12
13,FNIHB,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,M,698.25,1.5,4.8,"1,121",13
13,FNIHB,L04AX,Other immunosuppressants,65+,M,656.61,1.5,0.3,76,14
13,FNIHB,G04CA,Alpha-adrenoreceptor antagonists,65+,M,624.54,1.4,20.1,"4,644",15
13,FNIHB,N03AX,Other antiepileptics,65+,M,622.06,1.4,10.2,"2,372",16
13,FNIHB,N02AJ,Opioids in combination with non-opioid analgesics,65+,M,578.75,1.3,22.4,"5,195",17
13,FNIHB,R03BB,Anticholinergics,65+,M,548.77,1.2,10.0,"2,308",18
13,FNIHB,L01XE,Protein kinase inhibitors,65+,M,512.37,1.1,0.1,21,19
13,FNIHB,A10AB,"Insulins and analogues for injection, fast-acting",65+,M,483.93,1.1,5.6,"1,294",20
13,FNIHB,A10BB,Sulfonylureas,65+,M,478.96,1.1,15.5,"3,594",21
13,FNIHB,A10BD,Combinations of oral blood glucose–lowering drugs,65+,M,471.60,1.0,3.2,747,22
13,FNIHB,R03BA,Glucocorticoids,65+,M,453.72,1.0,8.1,"1,877",23
13,FNIHB,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,M,442.74,1.0,3.5,813,24
13,FNIHB,C09CA,"Angiotensin II antagonists, plain",65+,M,422.30,0.9,12.0,"2,785",25
13,FNIHB,S01LA,Antineovascularization agents,65+,M,393.61,0.9,0.3,74,26
13,FNIHB,N02AA,Natural opium alkaloids,65+,M,386.23,0.9,7.3,"1,701",27
13,FNIHB,B03XA,Other antianemic preparations,65+,M,351.44,0.8,0.6,128,28
13,FNIHB,R03AC,Selective beta-2-adrenoreceptor agonists,65+,M,338.66,0.8,20.7,"4,802",29
13,FNIHB,A11CC,Vitamin D and analogues,65+,M,324.90,0.7,17.9,"4,140",30
13,FNIHB,N06AX,Other antidepressants,65+,M,315.48,0.7,8.4,"1,938",31
13,FNIHB,C03CA,"Sulfonamides, plain",65+,M,310.18,0.7,12.4,"2,871",32
13,FNIHB,H03AA,Thyroid hormones,65+,M,288.71,0.6,10.6,"2,461",33
13,FNIHB,N06AB,Selective serotonin reuptake inhibitors,65+,M,285.02,0.6,6.8,"1,571",34
13,FNIHB,C09BA,ACE inhibitors and diuretics,65+,M,279.76,0.6,4.8,"1,102",35
13,FNIHB,G04CB,Testosterone-5-alpha reductase inhibitors,65+,M,272.91,0.6,6.0,"1,399",36
13,FNIHB,C03AA,"Thiazides, plain",65+,M,242.33,0.5,13.3,"3,075",37
13,FNIHB,B03AA,"Iron bivalent, oral preparations",65+,M,240.54,0.5,12.3,"2,850",38
13,FNIHB,L02BB,Antiandrogens,65+,M,240.16,0.5,0.5,121,39
13,FNIHB,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,M,232.34,0.5,1.9,443,40
13,FNIHB,L02BX,Other hormone antagonists and related agents,65+,M,206.61,0.5,0.1,18,41
13,FNIHB,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,M,203.54,0.5,1.2,274,42
13,FNIHB,L02AE,Gonadotropin-releasing hormone analogues,65+,M,200.68,0.4,0.6,144,43
13,FNIHB,N02BE,Anilides,65+,M,196.60,0.4,23.7,"5,487",44
13,FNIHB,A02BA,H2-receptor antagonists,65+,M,195.92,0.4,7.3,"1,694",45
13,FNIHB,C01DA,Organic nitrates,65+,M,188.04,0.4,9.3,"2,153",46
13,FNIHB,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,M,185.17,0.4,2.2,513,47
13,FNIHB,B01AB,Heparin group,65+,M,184.00,0.4,1.0,240,48
13,FNIHB,S01EE,Prostaglandin analogues,65+,M,172.13,0.4,4.0,924,49
13,FNIHB,S01ED,Beta-blocking agents,65+,M,160.24,0.4,3.4,778,50
13,FNIHB,L04AA,Selective immunosuppressants,65+,M,159.58,0.4,0.4,104,51
13,FNIHB,C09DA,Angiotensin II antagonists and diuretics,65+,M,158.19,0.4,4.2,979,52
13,FNIHB,N04BA,Dopa and dopa derivatives,65+,M,154.89,0.3,1.5,349,53
13,FNIHB,N05BA,Benzodiazepine derivatives,65+,M,153.76,0.3,7.7,"1,790",54
13,FNIHB,N05AX,Other antipsychotics,65+,M,152.66,0.3,1.1,254,55
13,FNIHB,C08DB,Benzothiazepine derivatives,65+,M,148.65,0.3,3.0,690,56
13,FNIHB,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,M,146.68,0.3,2.9,681,57
13,FNIHB,B01AA,Vitamin K antagonists,65+,M,139.46,0.3,4.1,953,58
13,FNIHB,D07AC,"Corticosteroids, potent (group III)",65+,M,136.55,0.3,11.7,"2,702",59
13,FNIHB,R01AD,Corticosteroids,65+,M,136.15,0.3,7.9,"1,833",60
13,FNIHB,N06AA,Non-selective monoamine reuptake inhibitors,65+,M,135.13,0.3,4.6,"1,056",61
13,FNIHB,R06AE,Piperazine derivatives,65+,M,132.62,0.3,4.6,"1,075",62
13,FNIHB,A12AA,Calcium,65+,M,129.22,0.3,8.4,"1,950",63
13,FNIHB,M01AB,Acetic acid derivatives and related substances,65+,M,127.22,0.3,6.0,"1,379",64
13,FNIHB,A06AD,Osmotically acting laxatives,65+,M,124.24,0.3,10.5,"2,421",65
13,FNIHB,M01AE,Propionic acid derivatives,65+,M,122.84,0.3,13.7,"3,165",66
13,FNIHB,N07BA,Drugs used in nicotine dependence,65+,M,122.22,0.3,3.1,710,67
13,FNIHB,A06AB,Contact laxatives,65+,M,117.45,0.3,10.8,"2,503",68
13,FNIHB,A07EC,Aminosalicylic acid and similar agents,65+,M,117.11,0.3,0.9,197,69
13,FNIHB,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,M,115.28,0.3,8.5,"1,961",70
13,FNIHB,N07BC,Drugs used in opioid dependence,65+,M,114.50,0.3,0.3,63,71
13,FNIHB,L04AD,Calcineurin inhibitors,65+,M,114.44,0.3,0.2,52,72
13,FNIHB,C10AX,Other lipid-modifying agents,65+,M,112.69,0.2,2.9,673,73
13,FNIHB,C07AG,Alpha- and beta-blocking agents,65+,M,112.36,0.2,1.8,414,74
13,FNIHB,B01AE,Direct thrombin inhibitors,65+,M,107.44,0.2,0.5,126,75
13,FNIHB,H02AB,Glucocorticoids,65+,M,106.10,0.2,12.3,"2,848",76
13,FNIHB,J05AR,"Antivirals for treatment of HIV infections, combinations",65+,M,102.69,0.2,0.1,22,77
13,FNIHB,N05CD,Benzodiazepine derivatives,65+,M,97.74,0.2,3.3,764,78
13,FNIHB,M04AA,Preparations inhibiting uric acid production,65+,M,97.11,0.2,4.1,947,79
13,FNIHB,A12BA,Potassium,65+,M,96.85,0.2,3.7,845,80
13,FNIHB,J01MA,Fluoroquinolones,65+,M,90.18,0.2,11.7,"2,708",81
13,FNIHB,M03BX,Other centrally acting agents,65+,M,89.81,0.2,5.6,"1,297",82
13,FNIHB,L04AC,Interleukin inhibitors,65+,M,88.68,0.2,0.0,7,83
13,FNIHB,A04AA,Serotonin (5HT3) antagonists,65+,M,88.26,0.2,1.3,292,84
13,FNIHB,R03AL,"Adrenergics in combination with anticholinergics, including triple combinations with corticosteroids",65+,M,84.51,0.2,1.3,292,85
13,FNIHB,C10AB,Fibrates,65+,M,83.58,0.2,1.5,357,86
13,FNIHB,C03DA,Aldosterone antagonists,65+,M,77.93,0.2,3.3,759,87
13,FNIHB,D09AA,Medicated dressings with antiinfectives,65+,M,75.80,0.2,0.6,148,88
13,FNIHB,J01FA,Macrolides,65+,M,73.51,0.2,10.0,"2,324",89
13,FNIHB,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",65+,M,72.38,0.2,2.4,560,90
13,FNIHB,J01CA,Penicillins with extended spectrum,65+,M,71.87,0.2,12.5,"2,882",91
13,FNIHB,A10BG,Thiazolidinediones,65+,M,70.08,0.2,0.8,177,92
13,FNIHB,J01DB,First-generation cephalosporins,65+,M,69.71,0.2,9.2,"2,134",93
13,FNIHB,G04BD,Drugs for urinary frequency and incontinence,65+,M,69.41,0.2,1.6,372,94
13,FNIHB,D05AX,Other antipsoriatics for topical use,65+,M,67.83,0.2,1.1,264,95
13,FNIHB,L01XC,Monoclonal antibodies,65+,M,66.96,0.1,0.1,15,96
13,FNIHB,N03AB,Hydantoin derivatives,65+,M,65.66,0.1,1.3,310,97
13,FNIHB,L01BA,Folic acid analogues,65+,M,62.49,0.1,1.1,256,98
13,FNIHB,L03AA,Colony-stimulating factors,65+,M,62.16,0.1,0.1,15,99
13,FNIHB,A11HA,Other plain vitamin preparations,65+,M,60.29,0.1,4.2,974,100
13,FNIHB,A02BC,Proton pump inhibitors,65+,F,"2,410.93",3.7,44.5,"14,684",1
13,FNIHB,C10AA,HMG-CoA reductase inhibitors,65+,F,"2,388.43",3.7,44.2,"14,585",2
13,FNIHB,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,65+,F,"2,209.52",3.4,0.5,153,3
13,FNIHB,C09AA,"ACE inhibitors, plain",65+,F,"2,110.80",3.3,34.1,"11,263",4
13,FNIHB,A10AE,"Insulins and analogues for injection, long-acting",65+,F,"1,578.15",2.4,8.8,"2,894",5
13,FNIHB,C08CA,Dihydropyridine derivatives,65+,F,"1,527.29",2.4,24.5,"8,098",6
13,FNIHB,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",65+,F,"1,197.65",1.9,5.9,"1,957",7
13,FNIHB,B01AC,"Platelet aggregation inhibitors, excluding heparin",65+,F,"1,184.77",1.8,36.1,"11,915",8
13,FNIHB,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,65+,F,"1,112.55",1.7,5.5,"1,818",9
13,FNIHB,A10BA,Biguanides,65+,F,"1,024.08",1.6,26.2,"8,639",10
13,FNIHB,N03AX,Other antiepileptics,65+,F,"1,008.57",1.6,12.2,"4,019",11
13,FNIHB,J05AP,Antivirals for treatment of HCV infections,65+,F,947.10,1.5,0.1,18,12
13,FNIHB,C07AB,"Beta-blocking agents, selective",65+,F,927.82,1.4,22.3,"7,352",13
13,FNIHB,H03AA,Thyroid hormones,65+,F,854.86,1.3,23.3,"7,700",14
13,FNIHB,N06AB,Selective serotonin reuptake inhibitors,65+,F,853.34,1.3,13.4,"4,431",15
13,FNIHB,N06AX,Other antidepressants,65+,F,836.88,1.3,13.0,"4,308",16
13,FNIHB,A11CC,Vitamin D and analogues,65+,F,833.08,1.3,34.4,"11,375",17
13,FNIHB,N02AJ,Opioids in combination with non-opioid analgesics,65+,F,828.74,1.3,21.5,"7,105",18
13,FNIHB,R03BA,Glucocorticoids,65+,F,816.60,1.3,11.2,"3,685",19
13,FNIHB,C09CA,"Angiotensin II antagonists, plain",65+,F,793.54,1.2,15.4,"5,099",20
13,FNIHB,R03BB,Anticholinergics,65+,F,767.21,1.2,10.1,"3,338",21
13,FNIHB,L04AA,Selective immunosuppressants,65+,F,706.55,1.1,0.8,255,22
13,FNIHB,B01AF,Direct factor Xa inhibitors,65+,F,693.38,1.1,3.3,"1,091",23
13,FNIHB,S01LA,Antineovascularization agents,65+,F,684.08,1.1,0.3,108,24
13,FNIHB,N02AA,Natural opium alkaloids,65+,F,646.10,1.0,8.7,"2,875",25
13,FNIHB,A10AB,"Insulins and analogues for injection, fast-acting",65+,F,591.28,0.9,5.5,"1,802",26
13,FNIHB,L04AX,Other immunosuppressants,65+,F,580.79,0.9,0.5,177,27
13,FNIHB,R03AC,Selective beta-2-adrenoreceptor agonists,65+,F,546.35,0.8,26.0,"8,591",28
13,FNIHB,A10BB,Sulfonylureas,65+,F,541.16,0.8,12.1,"3,984",29
13,FNIHB,B03XA,Other antianemic preparations,65+,F,533.27,0.8,0.6,183,30
13,FNIHB,A12AA,Calcium,65+,F,494.92,0.8,21.9,"7,238",31
13,FNIHB,A10BD,Combinations of oral blood glucose–lowering drugs,65+,F,490.31,0.8,2.2,732,32
13,FNIHB,M05BA,Bisphosphonates,65+,F,467.65,0.7,9.3,"3,065",33
13,FNIHB,B03AA,"Iron bivalent, oral preparations",65+,F,447.79,0.7,15.8,"5,222",34
13,FNIHB,C03CA,"Sulfonamides, plain",65+,F,434.19,0.7,12.2,"4,029",35
13,FNIHB,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,65+,F,427.37,0.7,2.4,789,36
13,FNIHB,N05BA,Benzodiazepine derivatives,65+,F,402.89,0.6,14.2,"4,699",37
13,FNIHB,N02BE,Anilides,65+,F,380.07,0.6,28.5,"9,418",38
13,FNIHB,C03AA,"Thiazides, plain",65+,F,377.56,0.6,14.8,"4,899",39
13,FNIHB,N06AA,Non-selective monoamine reuptake inhibitors,65+,F,346.44,0.5,7.8,"2,562",40
13,FNIHB,R06AE,Piperazine derivatives,65+,F,340.62,0.5,7.4,"2,457",41
13,FNIHB,A02BA,H2-receptor antagonists,65+,F,337.25,0.5,9.2,"3,023",42
13,FNIHB,C09BA,ACE inhibitors and diuretics,65+,F,337.04,0.5,4.2,"1,401",43
13,FNIHB,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",65+,F,335.35,0.5,2.0,646,44
13,FNIHB,G04BD,Drugs for urinary frequency and incontinence,65+,F,310.49,0.5,4.8,"1,576",45
13,FNIHB,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",65+,F,299.73,0.5,3.9,"1,293",46
13,FNIHB,L01XE,Protein kinase inhibitors,65+,F,294.40,0.5,0.0,16,47
13,FNIHB,C09DA,Angiotensin II antagonists and diuretics,65+,F,284.59,0.4,5.1,"1,671",48
13,FNIHB,L01XC,Monoclonal antibodies,65+,F,284.55,0.4,0.1,31,49
13,FNIHB,G03CA,"Natural and semisynthetic estrogens, plain",65+,F,274.32,0.4,6.5,"2,139",50
13,FNIHB,S01EE,Prostaglandin analogues,65+,F,257.78,0.4,4.2,"1,392",51
13,FNIHB,R01AD,Corticosteroids,65+,F,243.80,0.4,11.1,"3,666",52
13,FNIHB,A10AC,"Insulins and analogues for injection, intermediate-acting",65+,F,241.97,0.4,2.0,674,53
13,FNIHB,C08DB,Benzothiazepine derivatives,65+,F,241.03,0.4,3.2,"1,059",54
13,FNIHB,C01DA,Organic nitrates,65+,F,212.80,0.3,6.8,"2,234",55
13,FNIHB,N05AX,Other antipsychotics,65+,F,209.18,0.3,1.3,440,56
13,FNIHB,B01AB,Heparin group,65+,F,203.31,0.3,1.0,345,57
13,FNIHB,H02AB,Glucocorticoids,65+,F,200.52,0.3,15.5,"5,103",58
13,FNIHB,S01ED,Beta-blocking agents,65+,F,198.43,0.3,3.1,"1,014",59
13,FNIHB,B03BA,Vitamin B12 (cyanocobalamin and analogues),65+,F,196.59,0.3,11.0,"3,629",60
13,FNIHB,A12BA,Potassium,65+,F,188.68,0.3,5.0,"1,649",61
13,FNIHB,L01BA,Folic acid analogues,65+,F,185.55,0.3,2.4,779,62
13,FNIHB,A06AD,Osmotically acting laxatives,65+,F,185.54,0.3,11.5,"3,793",63
13,FNIHB,M01AE,Propionic acid derivatives,65+,F,184.14,0.3,14.9,"4,907",64
13,FNIHB,N07BA,Drugs used in nicotine dependence,65+,F,183.81,0.3,3.2,"1,063",65
13,FNIHB,L04AC,Interleukin inhibitors,65+,F,178.37,0.3,0.1,17,66
13,FNIHB,A04AA,Serotonin (5HT3) antagonists,65+,F,178.22,0.3,1.7,556,67
13,FNIHB,A06AB,Contact laxatives,65+,F,178.10,0.3,11.6,"3,847",68
13,FNIHB,J01MA,Fluoroquinolones,65+,F,172.50,0.3,16.7,"5,508",69
13,FNIHB,L03AA,Colony-stimulating factors,65+,F,167.46,0.3,0.1,35,70
13,FNIHB,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,65+,F,165.03,0.3,0.8,262,71
13,FNIHB,M01AB,Acetic acid derivatives and related substances,65+,F,156.76,0.2,5.2,"1,716",72
13,FNIHB,J01FA,Macrolides,65+,F,155.26,0.2,13.3,"4,408",73
13,FNIHB,J01XE,Nitrofuran derivatives,65+,F,154.03,0.2,12.0,"3,947",74
13,FNIHB,M03BX,Other centrally acting agents,65+,F,152.51,0.2,6.0,"1,995",75
13,FNIHB,A07EC,Aminosalicylic acid and similar agents,65+,F,152.10,0.2,1.0,330,76
13,FNIHB,D07AC,"Corticosteroids, potent (group III)",65+,F,151.85,0.2,10.9,"3,611",77
13,FNIHB,L02BG,Aromatase inhibitors,65+,F,143.96,0.2,1.0,324,78
13,FNIHB,R06AX,Other antihistamines for systemic use,65+,F,139.48,0.2,3.5,"1,142",79
13,FNIHB,N05CD,Benzodiazepine derivatives,65+,F,135.17,0.2,3.3,"1,080",80
13,FNIHB,B01AA,Vitamin K antagonists,65+,F,128.92,0.2,2.6,853,81
13,FNIHB,N04BA,Dopa and dopa derivatives,65+,F,123.28,0.2,1.2,385,82
13,FNIHB,A12AX,"Calcium, combinations with vitamin D and/or other drugs",65+,F,122.80,0.2,2.4,792,83
13,FNIHB,N03AE,Benzodiazepine derivatives,65+,F,122.42,0.2,3.1,"1,038",84
13,FNIHB,H01CB,Somatostatin and analogues,65+,F,120.14,0.2,0.1,17,85
13,FNIHB,A12CC,Magnesium,65+,F,118.55,0.2,4.2,"1,377",86
13,FNIHB,A03FA,Propulsives,65+,F,115.74,0.2,4.7,"1,566",87
13,FNIHB,J01CA,Penicillins with extended spectrum,65+,F,115.51,0.2,14.5,"4,789",88
13,FNIHB,S01XA,Other ophthalmologicals,65+,F,113.00,0.2,6.2,"2,053",89
13,FNIHB,L04AD,Calcineurin inhibitors,65+,F,110.03,0.2,0.1,48,90
13,FNIHB,P01BA,Aminoquinolines,65+,F,109.96,0.2,2.3,747,91
13,FNIHB,C10AX,Other lipid-modifying agents,65+,F,108.99,0.2,2.1,687,92
13,FNIHB,C07AG,Alpha- and beta-blocking agents,65+,F,105.96,0.2,1.1,370,93
13,FNIHB,N06DA,Anticholinesterases,65+,F,101.22,0.2,0.9,309,94
13,FNIHB,B03BB,Folic acid and derivatives,65+,F,100.96,0.2,4.0,"1,310",95
13,FNIHB,R03DC,Leukotriene receptor antagonists,65+,F,98.67,0.2,0.7,220,96
13,FNIHB,C10AB,Fibrates,65+,F,98.51,0.2,1.4,454,97
13,FNIHB,C02KX,Antihypertensives for pulmonary arterial hypertension,65+,F,98.48,0.2,0.0,6,98
13,FNIHB,A11HA,Other plain vitamin preparations,65+,F,98.04,0.2,5.0,"1,654",99
13,FNIHB,N07BC,Drugs used in opioid dependence,65+,F,94.96,0.1,0.2,60,100
13,FNIHB,J05AP,Antivirals for treatment of HCV infections,<65,Total,"53,809.61",10.6,0.2,981,1
13,FNIHB,N07BC,Drugs used in opioid dependence,<65,Total,"30,131.43",5.9,2.4,"14,156",2
13,FNIHB,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,Total,"24,434.25",4.8,0.3,"1,599",3
13,FNIHB,N05AX,Other antipsychotics,<65,Total,"14,914.11",2.9,1.6,"9,398",4
13,FNIHB,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,Total,"12,681.21",2.5,0.3,"1,823",5
13,FNIHB,N03AX,Other antiepileptics,<65,Total,"12,382.33",2.4,5.7,"33,205",6
13,FNIHB,A10AE,"Insulins and analogues for injection, long-acting",<65,Total,"10,778.05",2.1,2.5,"14,635",7
13,FNIHB,N02AJ,Opioids in combination with non-opioid analgesics,<65,Total,"9,502.80",1.9,17.1,"99,459",8
13,FNIHB,A02BC,Proton pump inhibitors,<65,Total,"9,437.82",1.9,13.9,"81,039",9
13,FNIHB,N06AB,Selective serotonin reuptake inhibitors,<65,Total,"8,830.00",1.7,9.7,"56,270",10
13,FNIHB,C09AA,"ACE inhibitors, plain",<65,Total,"8,377.98",1.7,7.9,"45,968",11
13,FNIHB,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,Total,"8,162.55",1.6,3.9,"22,939",12
13,FNIHB,N06BA,Centrally acting sympathomimetics,<65,Total,"8,122.52",1.6,2.3,"13,551",13
13,FNIHB,N06AX,Other antidepressants,<65,Total,"7,580.48",1.5,7.6,"44,135",14
13,FNIHB,R03BA,Glucocorticoids,<65,Total,"7,546.38",1.5,7.4,"43,113",15
13,FNIHB,C10AA,HMG-CoA reductase inhibitors,<65,Total,"7,307.28",1.4,8.0,"46,446",16
13,FNIHB,L04AA,Selective immunosuppressants,<65,Total,"6,150.12",1.2,0.3,"1,679",17
13,FNIHB,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,Total,"5,870.84",1.2,1.3,"7,375",18
13,FNIHB,N02AA,Natural opium alkaloids,<65,Total,"5,841.70",1.2,3.6,"20,746",19
13,FNIHB,A10AB,"Insulins and analogues for injection, fast-acting",<65,Total,"4,928.16",1.0,1.8,"10,486",20
13,FNIHB,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,Total,"4,906.04",1.0,1.3,"7,783",21
13,FNIHB,M01AE,Propionic acid derivatives,<65,Total,"4,765.81",0.9,28.1,"163,456",22
13,FNIHB,A10BA,Biguanides,<65,Total,"4,518.41",0.9,7.7,"44,472",23
13,FNIHB,J05AE,Protease inhibitors,<65,Total,"4,090.35",0.8,0.1,644,24
13,FNIHB,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,Total,"4,084.07",0.8,1.0,"6,076",25
13,FNIHB,R03AC,Selective beta-2-adrenoreceptor agonists,<65,Total,"4,033.62",0.8,14.9,"86,772",26
13,FNIHB,J01CA,Penicillins with extended spectrum,<65,Total,"3,735.63",0.7,23.2,"135,069",27
13,FNIHB,C08CA,Dihydropyridine derivatives,<65,Total,"3,645.62",0.7,3.4,"19,716",28
13,FNIHB,N07BA,Drugs used in nicotine dependence,<65,Total,"3,536.43",0.7,3.6,"20,707",29
13,FNIHB,N05BA,Benzodiazepine derivatives,<65,Total,"3,309.02",0.7,7.3,"42,564",30
13,FNIHB,A10BD,Combinations of oral blood glucose–lowering drugs,<65,Total,"3,259.81",0.6,0.7,"4,130",31
13,FNIHB,J01DB,First-generation cephalosporins,<65,Total,"3,138.27",0.6,10.9,"63,302",32
13,FNIHB,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,Total,"3,083.12",0.6,5.1,"29,879",33
13,FNIHB,G03AA,"Progestogens and estrogens, fixed combinations",<65,Total,"3,022.59",0.6,4.6,"26,817",34
13,FNIHB,G02BA,Intrauterine contraceptives,<65,Total,"2,869.89",0.6,1.4,"8,155",35
13,FNIHB,A10BB,Sulfonylureas,<65,Total,"2,681.02",0.5,3.7,"21,448",36
13,FNIHB,M03BX,Other centrally acting agents,<65,Total,"2,673.50",0.5,6.0,"35,042",37
13,FNIHB,R06AE,Piperazine derivatives,<65,Total,"2,596.52",0.5,4.8,"27,818",38
13,FNIHB,A16AB,Enzymes,<65,Total,"2,519.38",0.5,0.0,5,39
13,FNIHB,L01XC,Monoclonal antibodies,<65,Total,"2,474.26",0.5,0.0,238,40
13,FNIHB,S01LA,Antineovascularization agents,<65,Total,"2,428.63",0.5,0.1,302,41
13,FNIHB,L04AC,Interleukin inhibitors,<65,Total,"2,316.16",0.5,0.0,210,42
13,FNIHB,B03XA,Other antianemic preparations,<65,Total,"2,275.27",0.4,0.1,677,43
13,FNIHB,N02BE,Anilides,<65,Total,"2,203.07",0.4,20.1,"116,981",44
13,FNIHB,A11CC,Vitamin D and analogues,<65,Total,"2,110.03",0.4,7.4,"42,802",45
13,FNIHB,R06AA,Aminoalkyl ethers,<65,Total,"2,075.39",0.4,7.3,"42,306",46
13,FNIHB,J05AX,Other antivirals,<65,Total,"2,013.43",0.4,0.1,478,47
13,FNIHB,A02BA,H2-receptor antagonists,<65,Total,"1,987.58",0.4,4.5,"26,212",48
13,FNIHB,J01FA,Macrolides,<65,Total,"1,977.47",0.4,10.3,"60,133",49
13,FNIHB,D07AC,"Corticosteroids, potent (group III)",<65,Total,"1,966.04",0.4,7.6,"43,887",50
13,FNIHB,H03AA,Thyroid hormones,<65,Total,"1,962.38",0.4,3.5,"20,443",51
13,FNIHB,L04AD,Calcineurin inhibitors,<65,Total,"1,934.65",0.4,0.1,582,52
13,FNIHB,C07AB,"Beta-blocking agents, selective",<65,Total,"1,933.98",0.4,3.0,"17,200",53
13,FNIHB,C01CA,Adrenergic and dopaminergic agents,<65,Total,"1,924.60",0.4,1.7,"10,053",54
13,FNIHB,N06AA,Non-selective monoamine reuptake inhibitors,<65,Total,"1,894.26",0.4,3.0,"17,523",55
13,FNIHB,C09CA,"Angiotensin II antagonists, plain",<65,Total,"1,893.73",0.4,2.1,"12,325",56
13,FNIHB,C09BA,ACE inhibitors and diuretics,<65,Total,"1,878.87",0.4,1.2,"7,008",57
13,FNIHB,R01AD,Corticosteroids,<65,Total,"1,871.26",0.4,6.4,"37,051",58
13,FNIHB,D06AX,Other antibiotics for topical use,<65,Total,"1,854.33",0.4,9.2,"53,495",59
13,FNIHB,G03AC,Progestogens,<65,Total,"1,796.90",0.4,3.3,"19,086",60
13,FNIHB,B03AA,"Iron bivalent, oral preparations",<65,Total,"1,772.74",0.3,6.7,"38,742",61
13,FNIHB,L04AX,Other immunosuppressants,<65,Total,"1,711.20",0.3,0.2,"1,032",62
13,FNIHB,P03AC,"Pyrethrins, including synthetic compounds",<65,Total,"1,709.73",0.3,6.0,"35,018",63
13,FNIHB,N03AE,Benzodiazepine derivatives,<65,Total,"1,586.49",0.3,2.0,"11,663",64
13,FNIHB,L01XE,Protein kinase inhibitors,<65,Total,"1,533.91",0.3,0.0,71,65
13,FNIHB,M01AB,Acetic acid derivatives and related substances,<65,Total,"1,521.73",0.3,4.0,"23,387",66
13,FNIHB,R03BB,Anticholinergics,<65,Total,"1,519.31",0.3,1.3,"7,397",67
13,FNIHB,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,Total,"1,510.85",0.3,2.5,"14,578",68
13,FNIHB,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,Total,"1,506.90",0.3,0.2,"1,234",69
13,FNIHB,N05CD,Benzodiazepine derivatives,<65,Total,"1,475.62",0.3,1.9,"11,126",70
13,FNIHB,A04AA,Serotonin (5HT3) antagonists,<65,Total,"1,435.44",0.3,1.0,"5,858",71
13,FNIHB,A07EC,Aminosalicylic acid and similar agents,<65,Total,"1,386.88",0.3,0.4,"2,564",72
13,FNIHB,G03AB,"Progestogens and estrogens, sequential preparations",<65,Total,"1,369.55",0.3,1.5,"8,813",73
13,FNIHB,N02CC,Selective serotonin (5HT1) agonists,<65,Total,"1,248.27",0.2,1.1,"6,577",74
13,FNIHB,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,Total,"1,242.83",0.2,0.6,"3,662",75
13,FNIHB,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,Total,"1,203.83",0.2,6.0,"35,037",76
13,FNIHB,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,Total,"1,194.79",0.2,0.4,"2,169",77
13,FNIHB,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,Total,"1,191.63",0.2,0.0,52,78
13,FNIHB,B01AB,Heparin group,<65,Total,"1,125.33",0.2,0.2,"1,301",79
13,FNIHB,N03AG,Fatty acid derivatives,<65,Total,"1,123.79",0.2,0.6,"3,360",80
13,FNIHB,H02AB,Glucocorticoids,<65,Total,"1,114.97",0.2,6.4,"37,181",81
13,FNIHB,J02AC,Triazole derivatives,<65,Total,"1,066.91",0.2,2.9,"16,610",82
13,FNIHB,B01AF,Direct factor Xa inhibitors,<65,Total,"1,037.13",0.2,0.3,"1,907",83
13,FNIHB,S02CA,Corticosteroids and antiinfectives in combination,<65,Total,"1,011.95",0.2,3.4,"19,828",84
13,FNIHB,C03AA,"Thiazides, plain",<65,Total,995.14,0.2,2.5,"14,754",85
13,FNIHB,J01FF,Lincosamides,<65,Total,978.52,0.2,4.4,"25,697",86
13,FNIHB,C02AC,Imidazoline receptor agonists,<65,Total,973.08,0.2,1.1,"6,549",87
13,FNIHB,A06AD,Osmotically acting laxatives,<65,Total,951.29,0.2,3.9,"22,574",88
13,FNIHB,R06AX,Other antihistamines for systemic use,<65,Total,949.65,0.2,2.2,"12,920",89
13,FNIHB,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,Total,937.67,0.2,0.1,597,90
13,FNIHB,L01BA,Folic acid analogues,<65,Total,917.47,0.2,0.7,"4,003",91
13,FNIHB,G03CA,"Natural and semisynthetic estrogens, plain",<65,Total,916.76,0.2,1.1,"6,187",92
13,FNIHB,J01AA,Tetracyclines,<65,Total,911.93,0.2,3.7,"21,369",93
13,FNIHB,J01MA,Fluoroquinolones,<65,Total,901.61,0.2,4.9,"28,589",94
13,FNIHB,M03AX,"Other muscle relaxants, peripherally acting agents",<65,Total,887.71,0.2,0.1,408,95
13,FNIHB,C09DA,Angiotensin II antagonists and diuretics,<65,Total,853.67,0.2,0.9,"4,985",96
13,FNIHB,D05AX,Other antipsoriatics for topical use,<65,Total,833.92,0.2,0.5,"2,932",97
13,FNIHB,A12AA,Calcium,<65,Total,828.67,0.2,3.0,"17,255",98
13,FNIHB,J01EE,"Combinations of sulfonamides and trimethoprim, including derivatives",<65,Total,820.05,0.2,5.5,"31,975",99
13,FNIHB,N03AF,Carboxamide derivatives,<65,Total,803.76,0.2,0.4,"2,503",100
13,FNIHB,J05AP,Antivirals for treatment of HCV infections,<65,M,"28,875.66",13.0,0.2,525,1
13,FNIHB,N07BC,Drugs used in opioid dependence,<65,M,"13,904.43",6.3,2.6,"6,416",2
13,FNIHB,N05AX,Other antipsychotics,<65,M,"9,899.76",4.5,2.2,"5,443",3
13,FNIHB,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,M,"8,756.14",3.9,0.2,535,4
13,FNIHB,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,M,"7,190.03",3.2,0.4,978,5
13,FNIHB,N06BA,Centrally acting sympathomimetics,<65,M,"5,398.13",2.4,3.5,"8,712",6
13,FNIHB,N03AX,Other antiepileptics,<65,M,"5,191.00",2.3,5.4,"13,425",7
13,FNIHB,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,M,"4,698.68",2.1,4.2,"10,361",8
13,FNIHB,A10AE,"Insulins and analogues for injection, long-acting",<65,M,"4,617.42",2.1,2.5,"6,226",9
13,FNIHB,C09AA,"ACE inhibitors, plain",<65,M,"4,327.46",1.9,9.6,"23,735",10
13,FNIHB,N02AJ,Opioids in combination with non-opioid analgesics,<65,M,"4,216.71",1.9,18.1,"44,729",11
13,FNIHB,C10AA,HMG-CoA reductase inhibitors,<65,M,"3,843.09",1.7,9.9,"24,414",12
13,FNIHB,A02BC,Proton pump inhibitors,<65,M,"3,697.63",1.7,12.9,"31,941",13
13,FNIHB,R03BA,Glucocorticoids,<65,M,"3,013.14",1.4,7.1,"17,416",14
13,FNIHB,N06AB,Selective serotonin reuptake inhibitors,<65,M,"2,766.74",1.2,6.8,"16,895",15
13,FNIHB,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,M,"2,637.56",1.2,1.3,"3,294",16
13,FNIHB,N02AA,Natural opium alkaloids,<65,M,"2,523.18",1.1,3.4,"8,450",17
13,FNIHB,N06AX,Other antidepressants,<65,M,"2,431.67",1.1,6.2,"15,212",18
13,FNIHB,J05AE,Protease inhibitors,<65,M,"2,153.84",1.0,0.1,339,19
13,FNIHB,A10BA,Biguanides,<65,M,"2,089.43",0.9,8.1,"20,116",20
13,FNIHB,A10AB,"Insulins and analogues for injection, fast-acting",<65,M,"2,065.84",0.9,1.7,"4,136",21
13,FNIHB,M01AE,Propionic acid derivatives,<65,M,"1,941.84",0.9,27.6,"68,147",22
13,FNIHB,L04AA,Selective immunosuppressants,<65,M,"1,880.02",0.8,0.2,425,23
13,FNIHB,C08CA,Dihydropyridine derivatives,<65,M,"1,877.38",0.8,4.1,"10,113",24
13,FNIHB,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,M,"1,848.70",0.8,1.2,"2,846",25
13,FNIHB,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,M,"1,830.44",0.8,1.1,"2,707",26
13,FNIHB,R03AC,Selective beta-2-adrenoreceptor agonists,<65,M,"1,634.70",0.7,13.8,"34,164",27
13,FNIHB,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,M,"1,567.06",0.7,6.4,"15,713",28
13,FNIHB,A10BD,Combinations of oral blood glucose–lowering drugs,<65,M,"1,534.15",0.7,0.8,"1,928",29
13,FNIHB,N07BA,Drugs used in nicotine dependence,<65,M,"1,523.01",0.7,3.5,"8,703",30
13,FNIHB,J01CA,Penicillins with extended spectrum,<65,M,"1,492.72",0.7,21.9,"54,158",31
13,FNIHB,J01DB,First-generation cephalosporins,<65,M,"1,399.14",0.6,11.3,"27,777",32
13,FNIHB,S01LA,Antineovascularization agents,<65,M,"1,354.69",0.6,0.1,166,33
13,FNIHB,A10BB,Sulfonylureas,<65,M,"1,284.23",0.6,4.2,"10,274",34
13,FNIHB,N05BA,Benzodiazepine derivatives,<65,M,"1,283.49",0.6,6.1,"14,985",35
13,FNIHB,A16AB,Enzymes,<65,M,**,**,**,*,36
13,FNIHB,M03BX,Other centrally acting agents,<65,M,"1,121.13",0.5,5.8,"14,257",37
13,FNIHB,C07AB,"Beta-blocking agents, selective",<65,M,"1,106.47",0.5,3.9,"9,699",38
13,FNIHB,L01XE,Protein kinase inhibitors,<65,M,"1,070.39",0.5,0.0,48,39
13,FNIHB,J05AX,Other antivirals,<65,M,"1,064.45",0.5,0.1,245,40
13,FNIHB,B03XA,Other antianemic preparations,<65,M,"1,014.27",0.5,0.1,297,41
13,FNIHB,C09BA,ACE inhibitors and diuretics,<65,M,"1,004.07",0.5,1.5,"3,701",42
13,FNIHB,L04AD,Calcineurin inhibitors,<65,M,932.64,0.4,0.1,280,43
13,FNIHB,C01CA,Adrenergic and dopaminergic agents,<65,M,844.20,0.4,1.7,"4,089",44
13,FNIHB,N02BE,Anilides,<65,M,833.57,0.4,18.3,"45,219",45
13,FNIHB,D07AC,"Corticosteroids, potent (group III)",<65,M,824.27,0.4,6.9,"16,965",46
13,FNIHB,C09CA,"Angiotensin II antagonists, plain",<65,M,817.35,0.4,2.2,"5,344",47
13,FNIHB,D06AX,Other antibiotics for topical use,<65,M,814.98,0.4,9.4,"23,119",48
13,FNIHB,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,M,765.54,0.3,0.3,662,49
13,FNIHB,R06AE,Piperazine derivatives,<65,M,763.43,0.3,3.6,"8,782",50
13,FNIHB,J01FA,Macrolides,<65,M,752.67,0.3,9.1,"22,501",51
13,FNIHB,A02BA,H2-receptor antagonists,<65,M,722.66,0.3,3.5,"8,688",52
13,FNIHB,M01AB,Acetic acid derivatives and related substances,<65,M,706.94,0.3,4.3,"10,517",53
13,FNIHB,L04AX,Other immunosuppressants,<65,M,695.89,0.3,0.1,298,54
13,FNIHB,N06AA,Non-selective monoamine reuptake inhibitors,<65,M,663.11,0.3,2.4,"5,929",55
13,FNIHB,R01AD,Corticosteroids,<65,M,662.92,0.3,5.1,"12,602",56
13,FNIHB,N05CD,Benzodiazepine derivatives,<65,M,660.32,0.3,2.0,"4,865",57
13,FNIHB,N03AG,Fatty acid derivatives,<65,M,659.45,0.3,0.7,"1,833",58
13,FNIHB,R03BB,Anticholinergics,<65,M,650.04,0.3,1.2,"2,888",59
13,FNIHB,N03AE,Benzodiazepine derivatives,<65,M,650.01,0.3,1.7,"4,237",60
13,FNIHB,A11CC,Vitamin D and analogues,<65,M,635.51,0.3,4.3,"10,575",61
13,FNIHB,B01AF,Direct factor Xa inhibitors,<65,M,634.45,0.3,0.4,"1,053",62
13,FNIHB,P03AC,"Pyrethrins, including synthetic compounds",<65,M,584.58,0.3,5.0,"12,361",63
13,FNIHB,L04AC,Interleukin inhibitors,<65,M,565.36,0.3,0.0,53,64
13,FNIHB,A07EC,Aminosalicylic acid and similar agents,<65,M,537.17,0.2,0.3,856,65
13,FNIHB,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,M,515.17,0.2,1.8,"4,482",66
13,FNIHB,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,M,512.59,0.2,5.8,"14,416",67
13,FNIHB,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,M,510.89,0.2,0.5,"1,324",68
13,FNIHB,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,M,499.63,0.2,0.4,909,69
13,FNIHB,V06DB,"Fats/carbohydrates/proteins/minerals/vitamins, combinations",<65,M,495.22,0.2,0.1,301,70
13,FNIHB,C02AC,Imidazoline receptor agonists,<65,M,456.19,0.2,1.1,"2,780",71
13,FNIHB,D05AX,Other antipsoriatics for topical use,<65,M,455.35,0.2,0.6,"1,404",72
13,FNIHB,J01FF,Lincosamides,<65,M,440.86,0.2,4.4,"10,886",73
13,FNIHB,C03AA,"Thiazides, plain",<65,M,436.81,0.2,2.6,"6,329",74
13,FNIHB,N03AF,Carboxamide derivatives,<65,M,420.76,0.2,0.5,"1,211",75
13,FNIHB,B01AB,Heparin group,<65,M,407.55,0.2,0.2,457,76
13,FNIHB,H02AB,Glucocorticoids,<65,M,399.72,0.2,5.8,"14,248",77
13,FNIHB,H03AA,Thyroid hormones,<65,M,399.30,0.2,1.6,"3,926",78
13,FNIHB,J01AA,Tetracyclines,<65,M,398.84,0.2,3.3,"8,224",79
13,FNIHB,S02CA,Corticosteroids and antiinfectives in combination,<65,M,398.48,0.2,3.1,"7,664",80
13,FNIHB,C09DA,Angiotensin II antagonists and diuretics,<65,M,397.54,0.2,0.9,"2,339",81
13,FNIHB,A04AA,Serotonin (5HT3) antagonists,<65,M,381.63,0.2,0.7,"1,781",82
13,FNIHB,M03AX,"Other muscle relaxants, peripherally acting agents",<65,M,370.01,0.2,0.1,151,83
13,FNIHB,N03AB,Hydantoin derivatives,<65,M,366.99,0.2,0.7,"1,774",84
13,FNIHB,J02AC,Triazole derivatives,<65,M,362.54,0.2,0.6,"1,424",85
13,FNIHB,G04CA,Alpha-adrenoreceptor antagonists,<65,M,350.53,0.2,1.4,"3,508",86
13,FNIHB,A06AD,Osmotically acting laxatives,<65,M,349.96,0.2,3.1,"7,546",87
13,FNIHB,L01XC,Monoclonal antibodies,<65,M,337.18,0.2,0.0,45,88
13,FNIHB,B03AA,"Iron bivalent, oral preparations",<65,M,328.17,0.1,2.2,"5,471",89
13,FNIHB,D07AA,"Corticosteroids, weak (group I)",<65,M,312.22,0.1,4.5,"11,213",90
13,FNIHB,R05DA,Opium alkaloids and derivatives,<65,M,310.05,0.1,0.6,"1,413",91
13,FNIHB,N05AF,Thioxanthene derivatives,<65,M,306.54,0.1,0.2,576,92
13,FNIHB,J01EE,"Combinations of sulfonamides and trimethoprim, including derivatives",<65,M,302.42,0.1,4.0,"9,861",93
13,FNIHB,C10AB,Fibrates,<65,M,294.44,0.1,0.5,"1,294",94
13,FNIHB,C03CA,"Sulfonamides, plain",<65,M,285.45,0.1,1.2,"2,847",95
13,FNIHB,J01MA,Fluoroquinolones,<65,M,283.39,0.1,3.3,"8,106",96
13,FNIHB,R06AX,Other antihistamines for systemic use,<65,M,282.99,0.1,1.8,"4,372",97
13,FNIHB,V06D,Other nutrients,<65,M,277.21,0.1,0.1,133,98
13,FNIHB,L03AB,Interferons,<65,M,272.24,0.1,0.0,17,99
13,FNIHB,N07BB,Drugs used in alcohol dependence,<65,M,265.78,0.1,0.2,536,100
13,FNIHB,J05AP,Antivirals for treatment of HCV infections,<65,F,"24,933.94",8.8,0.1,456,1
13,FNIHB,N07BC,Drugs used in opioid dependence,<65,F,"16,227.00",5.7,2.4,"7,740",2
13,FNIHB,L04AB,Tumour necrosis factor alpha (TNF-a) inhibitors,<65,F,"15,678.12",5.5,0.3,"1,064",3
13,FNIHB,N03AX,Other antiepileptics,<65,F,"7,189.11",2.5,6.2,"19,756",4
13,FNIHB,A10AE,"Insulins and analogues for injection, long-acting",<65,F,"6,160.63",2.2,2.6,"8,409",5
13,FNIHB,N06AB,Selective serotonin reuptake inhibitors,<65,F,"6,063.26",2.1,12.3,"39,375",6
13,FNIHB,A02BC,Proton pump inhibitors,<65,F,"5,725.34",2.0,15.3,"48,956",7
13,FNIHB,J05AR,"Antivirals for treatment of HIV infections, combinations",<65,F,"5,491.18",1.9,0.3,845,8
13,FNIHB,N02AJ,Opioids in combination with non-opioid analgesics,<65,F,"5,286.09",1.9,17.1,"54,730",9
13,FNIHB,N06AX,Other antidepressants,<65,F,"5,148.81",1.8,9.0,"28,923",10
13,FNIHB,N05AX,Other antipsychotics,<65,F,"5,014.35",1.8,1.2,"3,955",11
13,FNIHB,R03BA,Glucocorticoids,<65,F,"4,481.28",1.6,7.8,"24,828",12
13,FNIHB,L04AA,Selective immunosuppressants,<65,F,"4,270.10",1.5,0.4,"1,254",13
13,FNIHB,C09AA,"ACE inhibitors, plain",<65,F,"4,050.00",1.4,6.9,"22,226",14
13,FNIHB,C10AA,HMG-CoA reductase inhibitors,<65,F,"3,464.19",1.2,6.9,"22,032",15
13,FNIHB,N05AH,"Diazepines, oxazepines, thiazepines and oxepines",<65,F,"3,463.86",1.2,3.9,"12,578",16
13,FNIHB,N02AA,Natural opium alkaloids,<65,F,"3,317.60",1.2,3.8,"12,253",17
13,FNIHB,A10BH,Dipeptidyl peptidase-4 (DPP-4) inhibitors,<65,F,"3,233.28",1.1,1.3,"4,081",18
13,FNIHB,R03AK,"Adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics",<65,F,"3,057.34",1.1,1.5,"4,937",19
13,FNIHB,G03AA,"Progestogens and estrogens, fixed combinations",<65,F,"3,019.77",1.1,8.4,"26,793",20
13,FNIHB,G02BA,Intrauterine contraceptives,<65,F,"2,869.89",1.0,2.5,"8,155",21
13,FNIHB,A10AB,"Insulins and analogues for injection, fast-acting",<65,F,"2,862.32",1.0,2.0,"6,350",22
13,FNIHB,M01AE,Propionic acid derivatives,<65,F,"2,792.81",1.0,29.2,"93,587",23
13,FNIHB,N06BA,Centrally acting sympathomimetics,<65,F,"2,724.38",1.0,1.5,"4,839",24
13,FNIHB,A10BA,Biguanides,<65,F,"2,428.98",0.9,7.6,"24,356",25
13,FNIHB,R03AC,Selective beta-2-adrenoreceptor agonists,<65,F,"2,349.54",0.8,15.8,"50,512",26
13,FNIHB,A10BK,Sodium–glucose co-transporter 2 (SGLT2) inhibitors,<65,F,"2,253.63",0.8,1.1,"3,369",27
13,FNIHB,J01CA,Penicillins with extended spectrum,<65,F,"2,138.03",0.8,23.9,"76,682",28
13,FNIHB,L01XC,Monoclonal antibodies,<65,F,"2,137.08",0.8,0.1,193,29
13,FNIHB,N05BA,Benzodiazepine derivatives,<65,F,"2,025.03",0.7,8.6,"27,561",30
13,FNIHB,N07BA,Drugs used in nicotine dependence,<65,F,"2,013.41",0.7,3.7,"12,004",31
13,FNIHB,J05AE,Protease inhibitors,<65,F,"1,936.52",0.7,0.1,305,32
13,FNIHB,R06AE,Piperazine derivatives,<65,F,"1,832.28",0.6,5.9,"18,984",33
13,FNIHB,R06AA,Aminoalkyl ethers,<65,F,"1,820.70",0.6,9.3,"29,681",34
13,FNIHB,G03AC,Progestogens,<65,F,"1,775.10",0.6,5.9,"19,033",35
13,FNIHB,C08CA,Dihydropyridine derivatives,<65,F,"1,767.91",0.6,3.0,"9,598",36
13,FNIHB,L04AC,Interleukin inhibitors,<65,F,"1,750.80",0.6,0.0,157,37
13,FNIHB,A10BD,Combinations of oral blood glucose–lowering drugs,<65,F,"1,725.67",0.6,0.7,"2,202",38
13,FNIHB,J01DB,First-generation cephalosporins,<65,F,"1,670.14",0.6,10.8,"34,507",39
13,FNIHB,H03AA,Thyroid hormones,<65,F,"1,562.19",0.6,5.2,"16,496",40
13,FNIHB,M03BX,Other centrally acting agents,<65,F,"1,552.37",0.5,6.5,"20,785",41
13,FNIHB,B01AC,"Platelet aggregation inhibitors, excluding heparin",<65,F,"1,516.00",0.5,4.4,"14,162",42
13,FNIHB,B03AA,"Iron bivalent, oral preparations",<65,F,"1,435.49",0.5,10.3,"32,942",43
13,FNIHB,A10BB,Sulfonylureas,<65,F,"1,396.80",0.5,3.5,"11,174",44
13,FNIHB,A11CC,Vitamin D and analogues,<65,F,"1,392.76",0.5,8.9,"28,605",45
13,FNIHB,G03AB,"Progestogens and estrogens, sequential preparations",<65,F,"1,368.46",0.5,2.7,"8,806",46
13,FNIHB,B03XA,Other antianemic preparations,<65,F,"1,261.00",0.4,0.1,380,47
13,FNIHB,A02BA,H2-receptor antagonists,<65,F,"1,256.35",0.4,5.4,"17,266",48
13,FNIHB,N02BE,Anilides,<65,F,"1,251.25",0.4,20.8,"66,765",49
13,FNIHB,A16AB,Enzymes,<65,F,**,**,**,*,50
13,FNIHB,N06AA,Non-selective monoamine reuptake inhibitors,<65,F,"1,231.15",0.4,3.6,"11,594",51
13,FNIHB,R01AD,Corticosteroids,<65,F,"1,207.95",0.4,7.6,"24,438",52
13,FNIHB,J01FA,Macrolides,<65,F,"1,196.77",0.4,11.4,"36,537",53
13,FNIHB,D07AC,"Corticosteroids, potent (group III)",<65,F,"1,125.28",0.4,8.2,"26,401",54
13,FNIHB,P03AC,"Pyrethrins, including synthetic compounds",<65,F,"1,111.09",0.4,7.0,"22,323",55
13,FNIHB,C09CA,"Angiotensin II antagonists, plain",<65,F,"1,076.38",0.4,2.2,"6,981",56
13,FNIHB,C01CA,Adrenergic and dopaminergic agents,<65,F,"1,074.65",0.4,1.9,"5,928",57
13,FNIHB,S01LA,Antineovascularization agents,<65,F,"1,073.94",0.4,0.0,136,58
13,FNIHB,A04AA,Serotonin (5HT3) antagonists,<65,F,"1,050.31",0.4,1.3,"4,009",59
13,FNIHB,N02CC,Selective serotonin (5HT1) agonists,<65,F,"1,025.60",0.4,1.7,"5,427",60
13,FNIHB,L04AX,Other immunosuppressants,<65,F,"1,015.31",0.4,0.2,734,61
13,FNIHB,L04AD,Calcineurin inhibitors,<65,F,"1,002.01",0.4,0.1,302,62
13,FNIHB,J05AB,"Nucleosides and nucleotides, excluding reverse transcriptase inhibitors",<65,F,985.82,0.3,3.1,"10,041",63
13,FNIHB,D06AX,Other antibiotics for topical use,<65,F,980.84,0.3,9.0,"28,709",64
13,FNIHB,C02KX,Antihypertensives for pulmonary arterial hypertension,<65,F,967.89,0.3,0.0,41,65
13,FNIHB,J05AX,Other antivirals,<65,F,948.97,0.3,0.1,233,66
13,FNIHB,N03AE,Benzodiazepine derivatives,<65,F,935.92,0.3,2.3,"7,423",67
13,FNIHB,C09BA,ACE inhibitors and diuretics,<65,F,874.79,0.3,1.0,"3,307",68
13,FNIHB,G03CA,"Natural and semisynthetic estrogens, plain",<65,F,868.40,0.3,1.9,"5,988",69
13,FNIHB,R03BB,Anticholinergics,<65,F,868.14,0.3,1.4,"4,479",70
13,FNIHB,A07EC,Aminosalicylic acid and similar agents,<65,F,849.72,0.3,0.5,"1,708",71
13,FNIHB,C07AB,"Beta-blocking agents, selective",<65,F,827.51,0.3,2.3,"7,501",72
13,FNIHB,N05CD,Benzodiazepine derivatives,<65,F,815.27,0.3,2.0,"6,260",73
13,FNIHB,M01AB,Acetic acid derivatives and related substances,<65,F,814.79,0.3,4.0,"12,870",74
13,FNIHB,V03AE,Drugs for treatment of hyperkalemia and hyperphosphatemia,<65,F,741.23,0.3,0.2,569,75
13,FNIHB,A10AC,"Insulins and analogues for injection, intermediate-acting",<65,F,731.94,0.3,0.7,"2,338",76
13,FNIHB,B01AB,Heparin group,<65,F,709.84,0.3,0.3,824,77
13,FNIHB,H02AB,Glucocorticoids,<65,F,703.27,0.2,7.0,"22,341",78
13,FNIHB,J02AC,Triazole derivatives,<65,F,699.53,0.2,4.7,"15,127",79
13,FNIHB,A10AD,"Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting",<65,F,695.16,0.2,0.4,"1,260",80
13,FNIHB,L01BA,Folic acid analogues,<65,F,688.74,0.2,0.9,"2,984",81
13,FNIHB,J01XE,Nitrofuran derivatives,<65,F,686.79,0.2,7.3,"23,370",82
13,FNIHB,J01CR,"Combinations of penicillins, including beta-lactamase inhibitors",<65,F,674.00,0.2,6.3,"20,161",83
13,FNIHB,R06AX,Other antihistamines for systemic use,<65,F,665.69,0.2,2.6,"8,480",84
13,FNIHB,L03AA,Colony-stimulating factors,<65,F,643.74,0.2,0.0,118,85
13,FNIHB,J01MA,Fluoroquinolones,<65,F,617.92,0.2,6.4,"20,479",86
13,FNIHB,A12AA,Calcium,<65,F,617.75,0.2,4.2,"13,545",87
13,FNIHB,A06AD,Osmotically acting laxatives,<65,F,596.84,0.2,4.6,"14,747",88
13,FNIHB,S02CA,Corticosteroids and antiinfectives in combination,<65,F,588.88,0.2,3.7,"11,695",89
13,FNIHB,G04BD,Drugs for urinary frequency and incontinence,<65,F,558.31,0.2,1.1,"3,416",90
13,FNIHB,C03AA,"Thiazides, plain",<65,F,558.00,0.2,2.6,"8,414",91
13,FNIHB,J01FF,Lincosamides,<65,F,531.65,0.2,4.6,"14,674",92
13,FNIHB,M03AX,"Other muscle relaxants, peripherally acting agents",<65,F,517.70,0.2,0.1,257,93
13,FNIHB,C02AC,Imidazoline receptor agonists,<65,F,516.83,0.2,1.2,"3,768",94
13,FNIHB,J01AA,Tetracyclines,<65,F,513.09,0.2,4.1,"13,145",95
13,FNIHB,P01AB,Nitroimidazole derivatives,<65,F,509.75,0.2,6.3,"20,249",96
13,FNIHB,J01EE,"Combinations of sulfonamides and trimethoprim, including derivatives",<65,F,507.96,0.2,6.8,"21,746",97
13,FNIHB,P01BA,Aminoquinolines,<65,F,491.73,0.2,1.1,"3,389",98
13,FNIHB,L03AB,Interferons,<65,F,465.18,0.2,0.0,33,99
13,FNIHB,L01XE,Protein kinase inhibitors,<65,F,463.52,0.2,0.0,23,100